WO2008103949A1 - Modulators of pharmacokinetic properties of therapeutics - Google Patents

Modulators of pharmacokinetic properties of therapeutics Download PDF

Info

Publication number
WO2008103949A1
WO2008103949A1 PCT/US2008/054788 US2008054788W WO2008103949A1 WO 2008103949 A1 WO2008103949 A1 WO 2008103949A1 US 2008054788 W US2008054788 W US 2008054788W WO 2008103949 A1 WO2008103949 A1 WO 2008103949A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
inhibitors
substituted
alkyl
formula
Prior art date
Application number
PCT/US2008/054788
Other languages
French (fr)
Inventor
Manoj C. Desai
Allen Y. Hong
Hon C. Hui
Hongtao Liu
Radall W. Vivian
Lianhong Xu
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39522375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008103949(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP08743531.9A priority Critical patent/EP2118082B1/en
Priority to EP16180589.0A priority patent/EP3150586B1/en
Priority to AP2013007042A priority patent/AP3915A/en
Priority to US12/528,185 priority patent/US9891239B2/en
Priority to AU2008218186A priority patent/AU2008218186C1/en
Priority to PL16180589T priority patent/PL3150586T3/en
Priority to CA2678907A priority patent/CA2678907C/en
Priority to EP24169258.1A priority patent/EP4403221A3/en
Priority to NZ579802A priority patent/NZ579802A/en
Priority to BRPI0807581-6A2A priority patent/BRPI0807581A2/en
Priority to UAA200909677A priority patent/UA101312C2/en
Priority to AP2009004964A priority patent/AP2986A/en
Priority to EP12167589.6A priority patent/EP2487161B2/en
Priority to EA200901155A priority patent/EA019893B1/en
Priority to EP19219599.8A priority patent/EP3689353A1/en
Priority to MX2009008935A priority patent/MX2009008935A/en
Priority to ES08743531.9T priority patent/ES2525454T3/en
Priority to KR1020157011742A priority patent/KR101664154B1/en
Priority to CN2008800132554A priority patent/CN101679325B/en
Priority to JP2009551044A priority patent/JP4881446B2/en
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of WO2008103949A1 publication Critical patent/WO2008103949A1/en
Priority to IL200550A priority patent/IL200550A0/en
Priority to ZA2009/05882A priority patent/ZA200905882B/en
Priority to HK10104142.7A priority patent/HK1137451A1/en
Priority to CY20201100220T priority patent/CY1122761T1/en
Priority to LU00156C priority patent/LUC00156I2/en
Priority to LTPA2020508C priority patent/LTC3150586I2/en
Priority to CY2020011C priority patent/CY2020011I1/en
Priority to NO2020011C priority patent/NO2020011I1/en
Priority to FR20C1021C priority patent/FR20C1021I1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • This application relates generally to compounds and pharmaceutical compositions which modify, e.g., improve, the pharmacokinetics of a coadministered drug, and methods of modifying, e.g., improving, the pharmacokinetics of a drug by co-administration of the compounds with the drug.
  • Oxidative metabolism by cytochrome P450 enzymes is one of the primary mechanisms of drug metabolism. It can be difficult to maintain therapeutically effective blood plasma levels of drugs which are rapidly metabolized by cytochrome P450 enzymes. Accordingly, the blood plasma levels of drugs which are susceptible to cytochrome P450 enzyme degradation can be maintained or enhanced by co-administration of cytochrome P450 inhibitors, thereby improving the pharmacokinetics of the drug.
  • cytochrome P450 monooxygenase inhibitors which do not have appreciable biological activity other than cytochrome P450 inhibition. Such inhibitors can be useful for minimizing undesirable biological activity, e.g., side effects.
  • P450 monooxygenase inhibitors that lack significant or have a reduced level of protease inhibitor activity. Such inhibitors could be useful for enhancing the effectiveness of antiretroviral drugs, while minimizing the possibility of eliciting viral resistance, especially against protease inhibitors.
  • One aspect of the present application is directed to compounds and pharmaceutical compositions which modify, e.g., improve, the pharmacokinetics of a co-administered drug, e.g., by inhibiting cytochrome P450 monooxygenase.
  • the present application provides for compounds having a structure according to Formula IV,
  • G 1 and G 2 are independently CH or N, with the proviso that G 1 and G 2 are different;
  • G 3 is -NR 7 - or -O-;
  • R 1 , R 3 , R 5 , and R 7 are each independently selected from the group consisting of H, alkyl, substituted alkyl, arylatkyl, and substituted arylalkyl;
  • R 2 is independently selected from the group consisting of substituted alkyl, alkoxyalkyl, hydroxyalkyl, trialkylsiloxyalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, amino alkyl, substituted aminoalkyl, -alkylene-N(R B )-C(O)- alkyl, -alkylene-
  • R 8 and R 9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, and -CN; each R a is independently selected from the group consisting of H, alkyl, and substituted alkyl; R b is selected from the group consisting of H, alkyl, substituted alkyl, CN, and -
  • each R c is independently selected from the group consisting of H, alkyl, substituted alkyl, heterocyclyl, substituted heterocyclyl, ⁇ S( ⁇ 2)-alkyl, -S(O2)-aryl / and substituted -S( ⁇ 2)-aryl.
  • the present application provides for a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I, and a pharmaceutically acceptable carrier or excipient.
  • the present application provides for a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I, at least one additional therapeutic agent, and a pharmaceutically acceptable carrier or exipient.
  • the present application provides for a method for improving the pharmacokinetics of a drug, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof,
  • the present application provides for a method for inhibiting cytochrome P450 monooxygenase in a patient comprising administering to a patient in need thereof an amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, effective to inhibit cytochrome P450 monooxygenase.
  • the present application provides for a method for treating a viral infection, e.g., HIV, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents which are metabolized by cytochrome P450 monooxygenase, and are suitable for treating a viral infection, e.g., HIV.
  • a viral infection e.g., HIV
  • the present application provides for a combination pharmaceutical agent comprising: a) a first pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof; and b) a second pharmaceutical composition comprising at least one additional active agent which is metabolized by cytochrome P450 monooxygenase.
  • a compound of the invention or “a compound of formula (I)” means a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester or stereoisomer thereof, or a physiologically functional derivative thereof.
  • a compound of formula (number) means a compound of that formula and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.
  • alkyl is hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms.
  • an alkyl group can have 1 to 20 carbon atoms (i.e, G- C20 alkyl), 1 to 10 carbon atoms (i.e., G-Go alkyl), or 1 to 6 carbon atoms (i.e., G-C& alkyl).
  • alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1-propyl (n-Pr, n-propyl, -CH 2 CHiCH 3 ), 2-propyl G-Pr, i-propyl, -CH(CHa) 2 ), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-l- propyl (i-Bu, i-butyl, -CHiCH(CHs) 2 ), 2-butyl (s-Bu, s-butyl, -CH(CH 3 )CH 2 CH 3 ), 2- methyl-2-propyl (t-Bu, t-butyl, -C(CHs) 3 ), 1- ⁇ entyl (n- pentyl, -CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (--CH(CH 3 ),
  • Alkoxy means a group having the formula -O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom.
  • the alkyl portion of an alkoxy group can have 1 to 20 carbon atoms (Le., Ci-C 2 O alkoxy), 1 to 12 carbon atoms(z.e., Ci-Cn alkoxy), or 1 to 6 carbon atoms(z ' . ⁇ ?., Ci-Ce alkoxy).
  • alkoxy groups include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-OCH 2 CH 3 or -OEt), t-butoxy (-0-C(CHs) 3 or -OtBu) and the like.
  • Haloalkyl is an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halogen atom.
  • the alkyl portion of a haloalkyl group can have 1 to 20 carbon atoms (i.e., Ci-C 2 O haloalkyl), 1 to 12 carbon atoms(z ' .e., Ci-Ci 2 haloalkyl), or 1 to 6 carbon atoms(te,, Ci-Ca alkyl).
  • suitable haloalkyl groups include, but are not limited to, -CF 3 , -CHF2, -CFH 2 , -CH2CF3, and the like.
  • Alkenyl is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp 2 double bond.
  • an alkenyl group can have 2 to 20 carbon atoms (i.e., C2-C20 alkenyl), 2 to 12 carbon atoms (i.e., C2-C12 alkenyl), or 2 to 6 carbon atoms (i.e., C 2 - CO alkenyl).
  • Alkynyl is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond.
  • an alkynyl group can have 2 to 20 carbon atoms (i.e., C 2 -C 2 Q alkynyl), 2 to 12 carbon atoms (i.e., Ci-Cn alkyne,), or 2 to 6 carbon atoms (i.e., C2- Cb alkynyl).
  • Alkylene refers to a saturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
  • an alkylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Typical alkylene radicals include, but are not limited to, methylene (-CH 2 -), 1,1-ethyl (-CH(CH 3 )-), 1,2-ethyl (-CH 2 CH 2 -), 1,1- propyl (-CH(CH 2 CH 3 )-), 1,2-propyl (-CH 2 CH(CH 3 )-), 1,3-propyl (-CH 2 CH 2 CH 2 -), 1,4- butyl (-CH 2 CH 2 CH 2 CH 2 -), and the like.
  • Alkenylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene.
  • alkenylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Alkynylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne.
  • an alkynylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Amino means an -NH 2 or a -NR 2 group in which the "R" groups are independently H, alkyl, haloalkyl, hydroxylalkyl, carbocyclyl (substituted or unsubstituted, including saturated or partially unsaturated cycloalkyl and aryl groups), heterocycly] (substituted or unsubstituted, including saturated or unsaturated heterocycloalkyl and heteroaryl groups), arylalkyl (substituted or unsubstituted) or arylalkyl (substituted or unsubstituted) groups.
  • Non-limiting examples of amino groups include -NH 2 , -NH(alkyl), NH(haloalkyl), -NH(carbocyclyl), -NH(heterocyclyl), -
  • alkyl 2, -N(carbocydyl)2, -N (heterocycly I) 2 , -N(alkyl)(carbocyclyl), -N(alkyl)(hetero cyclyl), -N(carbocyclyl)(heterocyclyl), etc., wherein alkyl, carbocyclyl, and heterocyclyl can be substituted or unsubstituted and as defined and described herein.
  • “Substituted” or “protected” amino means an aminoalkyl as described and defined herein in which a H of the amino group is replaced with e.g., acyl groups, for example conventional amine protecting groups such as 9-Fluorenylmethyl carbamate (“Fmoc”), f-Butyl carbamate (“Boc”), Benzyl carbamate (“Cbz”), acetyl, trifluoracetyl, -C(O)-amino, phthalimidyl, triphenylmethyl, p-ToIuenesulfonyl ("Tosyl”), methylsulfonyl (“mesyl”), etc.
  • acyl groups for example conventional amine protecting groups such as 9-Fluorenylmethyl carbamate (“Fmoc”), f-Butyl carbamate (“Boc”), Benzyl carbamate (“Cbz”), acetyl, trifluorace
  • aminoalkyl means an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with an amino radical as defined and described herein.
  • Non-limiting examples of aminoalkyl include -CH 2 -NH 2 , -CH 2 CH 2 -NH 2 , -CH2CH2CH2- NH 2 , -CH 2 CH 2 CH 2 CH 2 -NH 2 , -CH 2 CH(CHs)-NHi, -CH 2 CH 2 CH(CHa)-NH 2 , -CH 2 - NH(CH 3 ), -CH 2 CH 2 -NH(CH 3 ), -CH 2 CH 2 CH 2 -NH(CH 3 ), -CH 2 CH 2 CH 2 -NH(CH 3 ), -CH 2 CH 2 CH 2 -NH(CH 3 ), -CH 2 CH 2 CH 2 CH 2 -NH(CH 3 ), -CH 2 CH 2 CH 2 CH 2
  • “Substituted” or “protected” aminoalkyl means an aminoalkyl as described and defined herein in which the H of the amino group is replaced with e.g., acyl groups, for example conventional amine protecting groups such as 9-Fluorenylmethyl carbamate (“Fmoc”), t-Butyl carbamate (“Boc”), Benzyl carbamate (“Cbz”), acetyl, -C(O)-amino, trif Iu or acetyl, phthalimidyl, triphenylmethyl, p-Toluenesulfonyl ("Tosyl”), methylsulfonyl ("mesyl”) / etc.
  • acyl groups for example conventional amine protecting groups such as 9-Fluorenylmethyl carbamate (“Fmoc”), t-Butyl carbamate (“Boc”), Benzyl carbamate (“Cbz”), acety
  • Aryl means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
  • an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms.
  • Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like.
  • Arylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with an aryl radical.
  • Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l-yl, naphthylmethyl, 2-naphthylethan-l-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like.
  • the arylalkyl group can comprise 6 to 20 carbon atoms, e.g., the alkyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • Arylalkenyl refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also an sp 2 carbon atom, is replaced with an aryl radical.
  • the aryl portion of the arylalkenyl can include, for example, any of the aryl groups disclosed herein, and the alkenyl portion of the arylalkenyl can include, for example, any of the alkenyl groups disclosed herein.
  • the arylalkenyl group can comprise 6 to 20 carbon atoms, e.g., the alkenyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • Arylalkynyl refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also an sp carbon atom, is replaced with an aryl radical.
  • the aryl portion of the arylalkynyl can include, for example, any of the aryl groups disclosed herein, and the alkynyl portion of the arylalkynyl can include, for example, any of the alkynyl groups disclosed herein.
  • the arylalkynyl group can comprise 6 to 20 carbon atoms, e.g., the alkynyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • substituted in reference to alkyl, alkylene, aryl, arylalkyl, heterocyclyl, heteroaryl, carbocyclyl, etc.
  • substituted alkyl means alkyl, alkylene, aryl, arylalkyl, heterocyclyl, carbocyclyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent.
  • substituents include, but are not limited to, -X, -R, -O, O, -OR, -SR, -S *
  • each X is independently a halogen: F, Cl, Br, or I; and each R is independently H, alkyl, aryl, arylalkyl, a heterocycle, or a protecting group or prodrug moiety.
  • Alkylene, alkenylene, and alkynylene groups may also be similarly substituted. When the number of carbon atoms is designated for a substituted group, the number of carbon atoms refers to the group, not the substituent (unless otherwise indicated).
  • a CM substituted alkyl refers to a CM alkyl, which can be substituted with groups having more the, e.g., 4 carbon atoms.
  • prodrug refers to any compound that when administered to a biological system generates the drug substance, i.e., active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s).
  • a prodrug is thus a covalently modified analog or latent form of a therapeutically active compound.
  • substituents and other moieties of the compounds of Formula I should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition.
  • Compounds of Formula I which have such stability are contemplated as falling within the scope of the present invention.
  • ⁇ eteroalkyl refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S.
  • the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH3, etc.), an amine (e.g., -NHCH3, -N(CIHb) 2 , etc.), or a thioalkyl group (e.g., -SCH3).
  • a heteroatom e.g., O, N, or S
  • the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH3, etc.), an amine (e.g., -NHCH3, -N(CIHb) 2 , etc.), or a thioalkyl group (e.g., -SCH3).
  • the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g., -CHbCH 2 -O-CH 3 , etc.), an alkyl amine (e.g., -CH2NHCH3, -CH 2 N(CHs) 2 , etc.), or a thioalkyl ether (e.g.,-CH2-S-CH3).
  • an alkyl ether e.g., -CHbCH 2 -O-CH 3 , etc.
  • an alkyl amine e.g., -CH2NHCH3, -CH 2 N(CHs) 2 , etc.
  • a thioalkyl ether e.g.,-CH2-S-CH3
  • the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g., -CH 2 CH 2 -OH), an aminoalkyl group (e.g., -CH2NH2), or an alkyl thiol group (e.g., -CH2CH2-SH).
  • a heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • a Ci -CO heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
  • Heterocycle or “heterocyclyl” as used herein includes by way of example and not limitation those heterocycles described in Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and /. Am. Ckem. Soc. (1960) 82:5566.
  • heterocycle includes a "carbocycle” as defined herein, wherein one or more (e.g.
  • heterocycle or “heterocyclyl” includes saturated rings (i.e., heterocycloalkyls), partially unsaturated rings, and aromatic rings [i.e., heteroaromatic rings).
  • Substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups.
  • a non-limiting example of a carbonyl substituted heterocyclyl is:
  • heterocycles include by way of example and not limitation pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-pi ⁇ eridonyl, pyrrolidinyl, 2-py ⁇ roIidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, deca
  • carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a fur an, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6- ⁇ yridyl, 3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, A- pyrimidinyl, 5-py ⁇ imidinyI, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazoIyl, 4-thiazolyl, or 5-thiazolyl.
  • nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3- pyrroline, imidazole, imidazolidme, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, IH-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1 -piper id inyl.
  • Heterocyclylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with a heterocyclyl radical ⁇ i.e., a heterocyclyl-alkylene- moiety).
  • Typical heterocyclyl alkyl groups include, but are not limited to heterocyclyl- CHa-, he terocy CIyI-CH(CHs)-, heterocyclyl-CHkCHa-, 2-(heterocyclyl)ethan-l-yl, and the like, wherein the "heterocyclyl" portion includes any of the heterocyclyl groups described above, including those described in Principles of Modern Heterocyclic Chemistry.
  • the heterocyclyl group can be attached to the alkyl portion of the heterocyclyl alkyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclylalkyl group comprises 2 to 20 carbon atoms, e.g., the alkyl portion of the heterocyclylalkyl group is 1 to 6 carbon atoms and the heterocyclyl moiety is 1 to 14 carbon atoms.
  • heterocyclylalkyls include by way of example and not limitation 5- membered sulfur oxygen, and/or nitrogen containing heterocycles such as thiazolylmethyl, 2-thiazoIylethan-l-yL imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc., 6-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl, pyridizylmethyl, pyrimidylmethyl, pyrazinylmethyl, etc.
  • heterocycles such as thiazolylmethyl, 2-thiazoIylethan-l-yL imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc.
  • 6-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl
  • Heterocyclyl alkenyl refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also a sp 2 carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkenylene- moiety).
  • the heterocyclyl portion of the heterocyclyl alkenyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry, and the alkenyl portion of the heterocyclyl alkenyl group includes any of the alkenyl groups disclosed herein.
  • heterocyclyl group can be attached to the alkenyl portion of the heterocyclyl alkenyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclylalkenyl group comprises 3 to 20 carbon atoms, e.g., the alkenyl portion of the heterocyclyl alkenyl group is 2 to 6 carbon atoms and the heterocyclyl moiety is 1 to 14 carbon atoms.
  • Heterocyclylalkynyl refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also an sp carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkynylene- moiety).
  • the heterocyclyl portion of the heterocyclyl alkynyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry, and the alkynyl portion of the heterocyclyl alkynyl group includes any of the alkynyl groups disclosed herein.
  • heterocyclyl group can be attached to the alkynyl portion of the heterocyclyl alkynyl by means of a carbon-carbon bond or a carbon-heteroatom bond / with the proviso that the resulting group is chemically stable.
  • the heterocyclylalkynyl group comprises 3 to 20 carbon atoms, e.g., the alkynyl portion of the heterocyclylalkynyl group is 2 to 6 carbon atoms and the heterocyclyl moiety is 1 to 14 carbon atoms.
  • Heteroaryl refers to an aromatic heterocyclyl having at least one heteroatom in the ring.
  • suitable heteroatoms which can be included in the aromatic ring include oxygen, sulfur, and nitrogen.
  • Non- limiting examples of heteroaryl rings include all of those listed in the definition of "heterocyclyl", including pyridinyl, pyrrolyl, oxazolyl indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc.
  • Carbocycle or “carbocyclyl” refers to a saturated (i.e., cycloalkyl), partially unsaturated (e.g., cycloakenyl, cycloalkadienyL etc.) or aromatic ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle.
  • Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms.
  • Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system, or spiro-fused rings.
  • Non- limiting examples of monocyclic carbocycles include cyclop ropy 1, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, l-cycIopent-2-enyl, l-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohe ⁇ -2-enyl, l-cyclohe ⁇ -3-enyl, and phenyl.
  • Non-limiting examples of b ⁇ cyclo carbocycles includes naphthyl.
  • Arylheteroalkyl refers to a heteroalkyl as defined herein, in which a hydrogen atom (which may be attached either to a carbon atom or a heteroatom) has been replaced with an aryl group as defined herein.
  • the aryl groups may be bonded to a carbon atom of the heteroalkyl group, or to a heteroatom of the heteroalkyl group, provided that the resulting arylheteroalkyl group provides a chemically stable moiety.
  • an arylheteroalkyl group can have the general formulae -alkylene-
  • any of the alkylene moieties in the general formulae above can be further substituted with any of the substituents defined or exemplified herein.
  • Heteroarylalkyl refers to an alkyl group, as defined herein, in which a hydrogen atom has been replaced with a heteroaryl group as defined herein.
  • Non-limiting examples of heteroaryl alkyl include -CFL-pyridinyl, -CKb-pyrrolyl, -CH'-oxazolyl, -CH2-indolyl, -CH2-isoindol yl, -CH2-purinyl, -CHz-furanyl, -C ⁇ -thienyl, -CFb-benzofuranyl, -CHb-benzothio phenyl, -CHa-carb azolyl, -CHz-imidazolyl, -C ⁇ -thiazolyl, -CHz-isox azolyl, -CH2-p yrazolyl, -CH ⁇ -isothiazolyl, -CJHb-quinolyl, -CH2-iso
  • Ac means acetyl (-C(O)CH 3 ).
  • AC2O means acetic anhydride
  • DCM dichloromethane
  • DIBAL diisobutylaluminum hydride
  • DMAP means dimethylaminopyridine.
  • EDC means l-(3-Dimethylaminopropyl)-3-ethy]carbodiimide.
  • EtOAc means ethylacetate
  • HOBt N-hydroxybenzotriazole
  • Me means methyl (-CH 3 ).
  • MeOH means methanol
  • MeCN means acetonitrile
  • i-Pr means isopropyl (-CH(CHs) 2 ).
  • i-PrOH means isopropanol.
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
  • “Diastereomer” refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may- separate under high resolution analytical procedures such as electrophoresis and chromatography .
  • Enantiomers refer to two stereoisomers of a compound which are non- superimposable mirror images of one another.
  • d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (- ) or 1 meaning that the compound is levorotatory.
  • a compound prefixed with (+) or d is dextrorotatory.
  • these stereoisomers are identical except that they are mirror images of one another.
  • a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
  • a 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
  • racemic mixture and racemate refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
  • protecting groups include prodrug moieties and chemical protecting groups.
  • Protecting groups are available, commonly known and used, and are optionally used to prevent side reactions with the protected group during synthetic procedures, i.e. routes or methods to prepare the compounds of the invention. For the most part the decision as to which groups to protect, when to do so, and the nature of the chemical protecting group "PG" will be dependent upon the chemistry of the reaction to be protected against (e.g., acidic, basic, oxidative, reductive or other conditions) and the intended direction of the synthesis. The PG groups do not need to be, and generally are not, the same if the compound is substituted with multiple PG. In general, PG will be used to protect functional groups such as carboxyl, hydroxyl, thio, or amino groups and to thus prevent side reactions or to otherwise facilitate the synthetic efficiency. The order of deprotection to yield free, deprotected groups is dependent upon the intended direction of the synthesis and the reaction conditions to be encountered, and may occur in any order as determined by the artisan.
  • protecting groups for -OH groups include "ether- or ester- forming groups”.
  • Ether- or ester-forming groups are capable of functioning as chemical protecting groups in the synthetic schemes set forth herein.
  • some hydroxyl and thio protecting groups are neither ether- nor ester-forming groups, as will be understood by those skilled in the art, and are included with amides, discussed below.
  • Ester-forming groups include: (1) phosphonate ester-forming groups, such as phosphonamidate esters, phosphorothioate esters, phosphonate esters, and phosphon-bis-amidates; (2) carboxyl ester-forming groups, and (3) sulphur ester- forming groups, such as sulphonate, sulfate, and sulfinate.
  • phosphonate ester-forming groups such as phosphonamidate esters, phosphorothioate esters, phosphonate esters, and phosphon-bis-amidates
  • carboxyl ester-forming groups such as sulphonate, sulfate, and sulfinate.
  • the invention includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products typically are identified by preparing a radiolabeled (e.g., C 14 or H 3 ) compound of the invention, administering it parenterally in a detectable dose (e.g., greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples.
  • a detectable dose e.g., greater than about 0.5 mg/kg
  • an animal such as rat, mouse, guinea pig, monkey, or to man
  • sufficient time for metabolism to occur typically about 30 seconds to 30 hours
  • isolating its conversion products from the urine, blood or other biological samples typically isolating its conversion products from the urine, blood or other biological samples.
  • the metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis.
  • the present application provides compounds according to Formula I,
  • L 1 is selected from the group consisting of -C(R 6 ) 2 -, -C(O)-, -S(O 2 )-, -N(R 7 )-C(O)-, and -OC(O)-;
  • L 2 is a covalent bond, -C(R 6 )2- or -C(O)-; each L 3 is independently a covalent bond, an alkylene, or substituted alkylene; each L 4 is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O-, and -NH-; each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, and substituted heterocyclyl, with the proviso that when A is H, p is 0; Z 1 and Z 2 are each independently -O- or -N(R 7 )-; Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl; each Ar is independently selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; R 1 , R 3 , and R 5 are each
  • n 1
  • n 0.
  • n is 1 and L 2 is - CH(R 6 )-, wherein R 6 is selected from the group consisting of H, alkyl substituted alkyl, and heteroalkyl.
  • n 1 and L 2 is - CH 2 -.
  • n 1 and L 2 is - C(O)-.
  • n is 1 and Y is heterocyclylalkyl.
  • n is 1 and Y-R 8 is - CH2-(substituted heteroaryl).
  • n 1 and Y-R 8 is
  • R 8 is alkyl, for example 2-propyl.
  • n is 1 and X is heterocyclylalkyl .
  • n is 1 and X is - CH2-heteroaryl.
  • n is 1 and X-R 9 is
  • n 1 and X-R 9 is
  • n is 1 and ZMs - N(R 7 )-.
  • n is 1 and Z 1 is - N(alkyl)- or -Ntcarbocyclyl)-.
  • n is 1 and 2) is - N(CHs)- or -N(cyclopropyl)-.
  • n 1 and Z 1 is - NH-.
  • n is 1 and each A is independently aryl or substituted aryl.
  • n is 1 and each A is phenyl.
  • n is 1 and each A is phenyl and each p is 0.
  • n is 1 and R 2 is H, alkyl, substituted alkyl, or heteroalkyl.
  • n is 1 and R 2 is 2 ⁇ propyl, methyl, -CHi-O-benzyl, -CH(CH 3 ) (O-t-Bu) , or -CH(CH 3 )(OH).
  • L 1 is -C(O)-; each A is independently aryl, substituted aryl, alkyl, or substituted alkyl;
  • R 1 is H or alkyl; each R 2 is independently H, alky L substituted alkyl, or heteroalkyl;
  • R 3 , R 4 , R 5 , and R 6 are each H; each R 7 is independently H, alkyl, or carbocyclyl;
  • R a is H or alkyl
  • R 9 is H
  • X and Y are both heterocydylalkyl
  • Z 2 is -O-; and p is O.
  • each A is phenyl
  • the compounds of Formula I have the following general Formula IA:
  • Z 1 is -N(R 7 )-.
  • R 7 is H.
  • R 7 is alkyl, for example any of the alkyl groups disclosed herein.
  • R 7 is heteroalkyl, for example any of the heteroalkyl groups disclosed herein.
  • R 7 is substituted or unsubstituted carbocyclyl, wherein for example, said carbocyclyl is any of the carbocyclyl groups disclosed herein.
  • R 7 is substituted or unsubstituted heterocyclyl, wherein for example, said heterocyclyl is any of the heterocyclyl groups disclosed herein.
  • Z 1 is -O-.
  • L 2 is -C(R 6 )2-, wherein each R ⁇ is H.
  • L 2 is -C(R 6 )2-, wherein each R 6 is independently H or alkyl, and said alkyl includes any alkyl disclosed herein.
  • L 2 is -C(R 5 )2-, wherein one R 6 is H and the other R 6 is alkyl, wherein said alkyl includes any alkyl disclosed herein.
  • m is 1 and R 2 is H.
  • m is 1 and R 2 is alkyl, wherein said alkyl includes any alkyl disclosed herein.
  • m is 1 and R 2 is i- propyl.
  • m is 1 and R 2 is i- butyl.
  • m is 1 and R 2 is ethyl.
  • m is 1 and R 2 is methyl.
  • m is 2 and each R 2 is independently selected from H and alkyl.
  • m is 2 and each R 2 is H.
  • the compounds of Formula I have the following general Formula IB:
  • Z 1 is -N(R 7 )-.
  • R 7 is H.
  • R 7 is alkyl, for example any of the alkyl groups disclosed herein.
  • R 7 is heteroalkyl, for example any of the heteroalkyl groups disclosed herein.
  • R 7 is substituted or unsubsti tuted carbocyclyl, wherein for example, said carbocyclyl is any of the carbocyclyl groups disclosed herein.
  • R 7 is substituted or unsubsti tuted heterocyclyl, wherein for example, said heterocyclyl is any of the heterocyclyl groups disclosed herein.
  • Z is -O-.
  • L 2 is -C(R ⁇ )2-, wherein each R 6 is H.
  • L 2 is -C(R 6 )2-, wherein each R 6 is independently H or alkyl, and said alkyl includes any alkyl disclosed herein.
  • L 2 is -C(R 6 )z-, wherein one R 6 is H and the other R 6 is alkyl, wherein said alkyl includes any alkyl disclosed herein.
  • R s and R 9 are both H.
  • R 8 and R 9 are independently selected from H and alkyl, wherein said alkyl includes any alkyl disclosed herein.
  • the compounds of Formula I have one of the following structures:
  • stereoisomers or mixtures of stereoisomers thereof include enantiomers, diastereomers, and other stereoisomers.
  • stereoisomers or mixtures of stereoisomers of the compounds of the present application include enantiomers, diastereomers, and other stereoisomers. For example, for:
  • contemplated stereoisomers include at least:
  • L 1 is -C(R 6 )2-, - C(O)-, -S(O 2 )-, -N(IT)-C(O)-, or -O-C(O)-.
  • each R 6 is independently selected from the group consisting of H, alkyl, substituted alkyl, and heteroalkyl, wherein alkyl, substituted alkyl, and heteroalkyl are as defined and exemplified herein.
  • Non-limiting examples of -C(R 6 )2- include - CH 2 -, -CH(alkyl)-, -CH(substituted alkyl)-, -CH(heteroalkyl)-, -C(alkyl)a-, -C(substituted alkyl)2-, -Qheteroalkyl).-, -C(alkyl)(substituted alkyl)-, -C (heteroalkyl) (substituted alkyl)-, and -C(alkyl) (heteroalkyl)-, wherein alkyl, substituted alkyl, and heteroalkyl are as defined and exemplified herein.
  • R 7 is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl are as defined and exemplified herein.
  • L 2 is -C(R 6 J 2 - or -C(O)-.
  • each R 6 is independently selected from H, alkyl, substituted alkyl or heteroalkyl, where each alkyl, substituted alkyl, or heteroalkyl can include any of the alkyl, substituted alkyl, or heteroalkyl groups defined or disclosed herein.
  • Non-limiting examples of -C(R 6 )2- include - CH 2 -, -CH(CH 3 )-, -01(-CH 2 CH 3 )-, -CHt-CH 2 CH 2 CH 3 )-, -CH(-CH(CH 3 ) 2 )-, -CH(- CH2CH2CH2CH3)-, -CH( ⁇ CH 2 CH(CHs) 2 )-, -CH(-CH(CH 3 )CH 2 CH 3 )-, -CH(- C(CHs) 3 )-, -C(CHs) 2 -, -CH(OCHs)-, -CH(CH 2 OH)-, -CH(CH 2 CH 2 OH)-, etc.
  • each L 3 is independently a covalent bond, an alkylene or substituted alkylene.
  • any L 3 is an alkylene
  • non-limiting examples of alkylene includes any of the alkylene s defined or disclosed herein.
  • any L 3 is a substituted alkylene
  • non-limiting examples of substituted alkylene includes any of the substituted alkylenes defined or disclosed herein.
  • substituted alkylenes include alkylenes substituted with one or more -OH group, alkylenes substituted with one or more ether group, e.g., a -O-Bn group, alkylenes substituted with one or more halogen, or alkylenes substituted with combinations of two or more substituents (e.g., -OH and halogen, halogen and ether, etc.).
  • each L 3 is the same, i.e., each L 3 is the same alkylene or substituted alkylene group.
  • each L 3 is different, i.e., one L 3 is an alkylene and the other L 3 is a substituted alkylene, one L 3 is an alkylene and the other L 3 is a different alkylene, or one L 3 is a substituted alkylene, and the other L 3 is a different substituted alkylene.
  • each L 4 is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O-, and -NH-.
  • said alkylene includes any alkylene defined or exemplified herein.
  • said substituent includes any alkylene defined or exemplified herein, substituted by one or more substituents as defined herein.
  • both L 4 groups are the same, i.e. both L 4 groups are a covalent bond, both are -O-, both are -CH2-O-, (wherein the CH2 group is attached to either the "A" moiety or the "Ar” moiety of Formula I), both are a substituted or unsubstiruted alkylene, or both are -NH-.
  • each L 4 is different.
  • one L 4 is a covalent bond and the other L 4 is -O-
  • one L 4 is a covalent bond and the other L 4 is -CH2-O- (wherein the CH2 group is attached to either the "A" moiety or the "Ar” moiety of Formula I)
  • one L 4 is a covalent bond and the other L 4 is -NH-
  • one L 4 is a -O- and the other L 4 is -CH2-O-
  • the CU2 group is attached to either the "A" moiety or the "Ar” moiety of Formula I
  • one L 4 is -O- and the other L 4 is -NH-
  • one L 4 is -CH2-O- (wherein the CH2 group is attached to either the "A" moiety or the "Ar” moiety of Formula I) and the other L 4 is -NH-
  • one L4 is a covalent bond and the other L 4 is a substituted or unsubstit
  • each A is independently H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, or substituted heterocyclyl, with the proviso that when A is H, p is 0.
  • alkyl includes any alkyl defined or exemplified herein.
  • substituted alkyl said alkyl includes any alkyl defined or exemplified herein substituted with one or more of any substituent defined or exemplified herein.
  • said aryl includes any aryl defined or exemplified herein.
  • any A is substituted aryl
  • said aryl includes any aryl defined or exemplified herein substituted with one or more of any substituent defined or exemplified herein.
  • said heterocyclyl includes any heterocyclyl defined or exemplified herein.
  • said heterocyclyl is any heterocyclyl defined or exemplified herein substituted with one or more of any substituent defined or exemplified herein.
  • each A is H and each p is 0.
  • each A is substituted or unsubstituted alkyl, wherein alkyl is any alkyl defined or exemplified herein, and, when present, the substituents on said alkyl include one or more of any substituents defined or exemplified herein.
  • each A is substituted or unsubstituted aryl, wherein aryl is any aryl defined or exemplified herein, and, when present, the substituents on said aryl include one or more of any substituents defined or exemplified herein.
  • A is phenyl.
  • each A is substituted or unsubstituted heterocyclyl, wherein heterocyclyl is any heterocyclyl defined or exemplified herein, and, when present, the substituents on said heterocyclyl include one or more of any substituents defined or exemplified herein.
  • one A is H and the other A is substituted or unsubstituted alkyl, wherein alkyl is any alkyl defined or exemplified herein, and, when present the substituent on said alkyl includes one or more of any substituent defined or exemplified herein.
  • one A is H and the other A is substituted or unsubstituted aryl, wherein aryl is any aryl defined or exemplified herein, and the substituents on said aryl are any substituents defined and exemplified herein.
  • one A is phenyl.
  • one A is H and the other A is substituted or unsubstituted heterocyclyl, wherein heterocyclyl is any heterocyclyl defined or exemplified herein, and, when present, the substituents on said heterocyclyl include one or more of any substituent defined or exemplified herein.
  • one A is substituted or unsubstituted alkyl, and the other A is substituted or unsubstituted aryl, wherein alkyl and aryl are any alkyl or aryl defined or exemplified herein, and, when present the substituents on said alkyl or aryl include one or more of any substituents defined or exemplified herein.
  • one A is substituted or unsubstituted alkyl, and the other A is substituted or unsubstituted heterocyclyl, wherein alkyl and heterocyclyl are any alkyl or heterocyclyl defined or exemplified herein, and, when present, the substituents on said alkyl or heterocyclyl include one or more of any substituents defined or exemplified herein.
  • one A is substituted or unsubstituted aryl, and the other A is substituted or unsubstituted heterocyclyl, wherein aryl and heterocyclyl are any aryl or heterocyclyl defined or exemplified herein, and, when present, the substituents on said aryl or heterocyclyl include one or more of any substituents defined or exemplified herein.
  • Z 1 is -O- or - N(R 7 )-.
  • R 7 is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl are any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl defined or exemplified herein.
  • Z 2 is -O- or - N(R 7 )-.
  • R 7 is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein alkyl, substituted alky I, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl are any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl defined or exemplified herein.
  • Z 1 and Z 2 are the same, e.g., Z 1 and Z 2 are both -O-, or Z 1 and Z 2 are both -N(R 7 )-, where R 7 is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl are any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl defined or exemplified herein.
  • Z 1 and Z 2 are different, e.g. Z 1 is -O- and Z 2 is -N(R 7 )-, Z 1 is -N(R 7 )- and Z 2 is -O-, or Z 1 and Z 2 are both -N(R 7 )- but in Z 1 the R 7 is different from the R 7 in Z 2 .
  • R 7 is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl are any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl defined or exemplified herein.
  • Y is heterocyclyl or heterocyclylalkyl, wherein heterocyclyl and heterocyclylalkyl are any heterocyclyl or heterocyclylalkyl defined or exemplified herein.
  • Y is heterocyclylalkyl, e.g. thiazolylmethyl (-CH2-thiazolyl).
  • X is heterocyclyl or heterocyclylalkyl, wherein heterocyclyl and heterocyclylalkyl are any heterocyclyl or heterocyclylalkyl defined or exemplified herein.
  • X is heterocyclylalkyl, e.g. thiazolylmethyl.
  • X and Y are different e.g., X and Y are different heterocyclyls, X and Y are different heterocyclyl alky Is, X is heterocyclyl and Y is heterocyclylalkyl or X is heterocyclylalkyl and Y is heterocyclyl, wherein heterocyclyl and heterocyclylalkyl are any heterocyclyl or heterocyclylalkyl defined or exemplified herein.
  • X and Y are the same.
  • both X and Y are heterocyclylalkyls, e.g. thiazolylmethyl.
  • each Ar is aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the aryl or heteroaryl are any aryl or heteroaryl defined or exemplified herein, and, when present, the substituents on the aryl or heteroaryl include one or more of any substituents defined or exemplified herein.
  • each Ar is the same, e.g., each Ar is an aryl such as phenyl.
  • each Ar is different, e.g. one Ar is a substituted or unsubstituted aryl and the other Ar is a substituted or unsubstituted heteroaryl, each Ar is a different substituted or unsubstituted aryl, or each Ar is a different substituted or unsubstituted heteroaryl, wherein aryl and heteroaryl are any aryl or heteroaryl defined or exemplified herein, and, when present, the substituents on the aryl or heteroaryl include one or more of any substituents defined or exemplified herein.
  • R 1 , R 3 , and R 5 are each independently H, alkyl, or substituted alky I 7 wherein alkyl and substituted alkyl include any of the alkyl or substituted alkyls defined or disclosed herein.
  • R 1 , R 3 , and R 5 are each the same.
  • R 1 , R 3 , and R 5 are each H.
  • R 1 , R 3 , and R 5 are each alkyl, e.g. one of the alkyl groups defined or disclosed herein.
  • R 1 , R 3 , and R 5 are each different.
  • one of R 1 , R 3 , and R 5 is different from the other two groups.
  • n and m are both I 7 and each R 2 is independently H, alkyl, substituted alkyl, arylheteroalkyl, arylalkyl, or heterocyclylalkyl, wherein alkyl, substituted alkyl, arylheteroalkyl, aryl alkyl, or heterocyclylalkyl is any alkyl, substituted alkyl, arylheteroalkyl, aryl alkyl, or heterocyclylalkyl defined or disclosed herein.
  • n is I 7 m is 2, and R 2 is H.
  • n and m are both 1, and at least one R 2 is alkyl. In a particular embodiment at least one R 2 is methyl. In another particular embodiment at least one R 2 is ethyl. In another particular embodiment at least one R 2 is i-propyl. In another particular embodiment at least one R 2 is t-butyl. In another particular embodiment, one R 2 is H, and the other R 2 is methyl. In another particular embodiment, one R 2 is H, and the other R 2 is ethyl. In another particular embodiment, one R 2 is H, and the other R 2 is i-propyl. In another particular embodiment, one R 2 is H, and the other R 2 is t-butyl.
  • n and m are both 1, and R 2 is substituted alkyl.
  • at least one R 2 is - CH(CH 3 )OH or -CH(CH 3 )O(MSu)
  • n and m are both 1, and at least one R 2 is arylheteroalkyl.
  • at least one R 2 is selected from the group consisting of H, methyl, ethyl, benzyl-O-CHz-, i-propyl, -CH(CH 3 )OBn, -CH 2 CH(CHs)-O- tBu, -CH(CH 3 )OH, -CH2OH, -CH 2 OtBu 7 -CH2CH2NH2, -CH2CH2NH-P (where P is a protecting group such as Boc, Ac, methanesulfonyl, etc.), -CH 2 CH 2 -En or pholine, -CH 2 C(O)OH, -CH 2 C(O)OtBu, and -CH 2 C(O)-NH 2 .
  • n and m are both 1, and at least one R 2 is arylheteroalkyl.
  • one R 2 is H and one R 2 is selected from the group consisting of H, methyl, ethyl, benzyl-O-CHa-, i-propyl, -CH(CH 3 )OBn, -CH 2 CH(CHs)-O- tBu, -CH(CH 3 )OH, -CH2OH, -CH 2 OtBu, -CH 2 CH 2 NH 2 , -CH 2 CH 2 NH-P (where P is a protecting group such as Boc, Ac, methanesulfonyl, etc.), -CH2CH2-morphoIine, -CH 2 C(O)OH, -CH 2 C(O)OtBu, and -CH 2 C(O)-NH 2 .
  • R 4 is H, alkyl, substituted alkyl, and heteroalkyl, wherein alkyl, substituted alkyl, and heteroalkyl are any alkyl, substituted alkyl, or heteroalkyl defined or disclosed herein.
  • R 4 is H.
  • R 6 is H, alkyl, substituted alkyl, and heteroalkyl, wherein alkyl, substituted alkyl, and heteroalkyl are any alkyl, substituted alkyl, or heteroalkyl defined or disclosed herein.
  • R 6 is H.
  • R 8 and R 9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, and -CN, wherein when R 8 or R 9 are alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, or substituted heterocyclyl, said alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, or substituted heterocyclyl are any such groups defined or disclosed herein.
  • R 8 and R 9 are the same. In a particular embodiment R 8 and R 9 are both H.
  • R 8 and R 9 are different.
  • R 8 is alkyl and R 9 is H.
  • R 8 is i-propyl and R 9 is H.
  • At least one of the -L 3 -A-(IAAr)p moieties is an -alkylene-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A- ⁇ L 4 -Ar)p moieties is an -alkylene-aryl-alkylene-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
  • At least one of the ⁇ L 3 -A-(L 4 -Ar)p moieties is an -alkylene-aryl-alkylene-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl, and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar) P moieties is an -alkylene-heteroaryl-alkylene-heteroaryl group, wherein said alkylene and heteroaryl moieties are any alkylene and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -IAA-(L 4 -Ar)p moieties is an -alkylene-heteroaryl-alkylene-aryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl, and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar)p moieties is an -alkylene-aryl-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar)p moieties is an -alkylene-aryl-O-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar)p moieties is an -alkylene-aryl-CHb-O-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 - A- (L 4 - Ar ) P moieties is an -alkylene-aryl-OCFL-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar) P moieties is an -alkylene-aryl-NH-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar) P moieties is an -alkylene-aryl-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -IAA-(L 4 -Ar)p moieties is an -alkylene-aryl-O-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -IA A-(L 4 - Ar) p moieties is an -alkylene-ary!-CH2-O-heterocyc!yl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein / optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substiruents defined or exemplified herein.
  • At least one of the -L 3 - A- (L 4 - Ar )p moieties is an -alkylene-aryl-OClHh-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substiruents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar) P moieties is an -alkylene-aryl-NH-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -IAA-(U- Ar) P moieties is an -alkylene-heterocyclyl-aryl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substiruents defined or exemplified herein.
  • At least one of the -L 3 - A- (L 4 - Ar )p moieties is an -alky] ene-heterocycly 1-0- aryl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 - A- (L 4 - Ar )p moieties is an -alkylene-heterocyclyl-CHb-O-aryl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -IAA-(L 4 - Ar) p moieties is an -alkylene-heterocyclyl-OCft-aryl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 - A- (L 4 - Ar )p moieties is an -alkylene-heterocyclyl-NH-aryl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 - A-(L 4 - Ar) p moieties is an -alkylene-heterocyclyl-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -LAA-(L ⁇ Ar) P moieties is an -alkylene-heterocycIyl-O-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -IAA-(L 4 - Ar)p moieties is an -alkylene-heterocyclyl-CHi-O-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 - A-(L 4 - Ar) p moieties is an -alkylene-heterocyclyl-OCH-j-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkyiene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 - A-(L 4 - Ar )p moieties is an -alkylene-heterocyclyl-NH-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A ⁇ (L 4 -Ar)p moieties is an -alkylene-aryl-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -IAA-(L 4 - Ar) p moieties is an -alkylene-aryl-O-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 - A-(L 4 - Ar) p moieties is an -alkylene- aryl-CHb-O-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar)p moieties is an -alkylene-aryl-OCHi-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar)p moieties is an -alkylene-aryl-NH-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -IAA- (L 4 - Ar) p moieties is an -alkylene-heteroary ⁇ -aryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar) P moieties is an -alkylene-heteroaryl-Oaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 ⁇ Ar)p moieties is an -alkylene-heteroaryl-CHb-O-aryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar)p moieties is an -alkylene-heteroaryl-OQHb-aryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaiyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -IAA-(L 4 - Ar) P moieties is an -alkylene-heteroaryl-NH-aryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 - A- (L 4 - Ar )p moieties is an -alkylene-heterocyclyl-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -IAA-(L 4 - Ar) P moieties is an -alkylene-heterocyclyl-O-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the ⁇ L 3 -A-(L 4 -Ar)p moieties is an -alkylene-heterocyclyl-C ⁇ -O-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the ⁇ L 3 -A-(L 4 -Ar)p moieties is an -alkylene-heteroaryl-OGHk-heteiOaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar)p moieties is an -alkylene-heteroaryl-NH-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryi moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
  • At least one of the -L 3 -A-(L 4 -Ar)p moieties is an alkyl group.
  • both of the -L 3 -A-(L 4 -Ar) P moieties are alkyl groups, wherein the alkyl groups are the same or different.
  • both -LAA- (I ⁇ -Ar)p moieties are -CH2-phenyl and X and Y are both -C ⁇ -heterocyclyl.
  • both -IAA- (L 4 -Ar)p moieties are -ClHb-phenyl and Y is -CH ⁇ -heterocyclyl.
  • both -LAA- (L 4 -Ar)p moieties are -CHi-phenyl and X is -CLL-heterocyclyl.
  • both -LAA- (L 4 - Ar) p moieties are -CH2-phenyl and Y is -CH2-thiazolyl.
  • both -LAA- (L 4 - Ar) p moieties are -CU2 ⁇ phenyl and X is -CH2-thiazolyl.
  • both -L 3 - A- (L 4 -Ar) P moieties are -CHb-phenyl and X and Y are both -CHb-thiazolyl.
  • both -L 3 - A- (L 4 - Ar) p moieties are -Ctfc-phenyl, X and Y are both -Cl-h-thiazolyl, and n and m are both 1.
  • both -IAA- (L 4 -Ar) P moieties are -CFfc-phenyl, X and Y are both -CHz-thiazolyl, n and m are both 1, and at least one R 2 is a Ci-Ce alkyl.
  • both -IAA- (I ⁇ Ar)p moieties are -Ctfe-phenyL X and Y are both -dHfe-thlazolyl, n and m are both 1, and at least one R 2 is a G-G, hydroxyalkyl.
  • both -IAA- (L 4 -Ar) P moieties are -C ⁇ -phenyl
  • X and Y are both -CPfc-thiazolyl
  • n and m are both 1
  • at least one R 2 is a C2-G0 alkoxyalkyl.
  • both -IAA- (LAAr) n moieties are -CFfc-phenyL X and Y are both -GHb-thiazolyl, n and m are both 1, and at least one R 2 is a C7-G4 arylalkyloxy alkyl.
  • both -LAA- (lAAr)p moieties are --CHfe-phenyl
  • X and Y are both -CH2-thiazolyl
  • n and m are both 1
  • at least one R 2 is a G-G aminoalkyl.
  • both -LAA- (lAAr)p moieties are -CFfe-phenyl
  • X and Y are both -CFLa-thiazolyl
  • n and m are both 1
  • at least one R 2 is a G -CO aminoalkyl substituted on the nitrogen with an amine protecting group selected from acyl, alkylsulfonyl, arylsulfonyl, heterocyclylacyl, and benzyl.
  • both -LAA- (IAAr)p moieties are -CE-h-phenyl
  • X and Y are both -CFfc-thiazolyl
  • n and m are both 1
  • at least one R 2 is a substituted or unsubstituted heterocyclylalkyl.
  • both -LAA- (IAAr)p moieties are -CFL-phenyL.
  • X and Y are both -CFfe-thiazolyl, n and m are both ⁇ , and L 2 is -CH 2 -.
  • at least one -IAA-(L 4 -Ar)p moiety is-CHz-phenyl-CFL-phenyl.
  • At least one -L 3 -A-(L 4 -Ar) P moiety is-CHi-phenyl-CI-b-heteroaryl.
  • At least one -L 3 - A-(L 4 - Ar) p moiety is-CH2- heteroaryl-C ⁇ -heteroaryl.
  • X and Y are both heterocyclylalkyl.
  • X and Y are both heteroarylalkyl.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 - A-(L 4 - Ar) P groups are substituted or unsubstituted benzyl.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 -A-(L 4 -Ar)p groups are substituted or unsubstituted benzyl
  • L 2 is -
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 ⁇ A-(L 4 -Ar)p groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 -A-(L 4 -Ar) P groups are substituted or unsubstituted benzyl
  • L 2 is -ClHb-
  • m and n are both 1
  • R 1 is H.
  • L 1 is -C(O) ⁇
  • R 4 is H
  • both -L 3 -A-(L 4 -Ar) P groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(alkyl)-.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 - A- (L 4 - Ar )p groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(CH 3 )-.
  • L 1 is -C(O)-
  • R 4 is H
  • both -1AA-(L 4 -Ar)p groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(alkyl)-
  • Z 2 is -O-.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 -A-(lAAr)p groups are substituted or unsubstituted benzyl
  • L 2 is -CHb-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(CHs)-
  • 71 is -O-.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 -A-(L 4 -Ar)p groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(alkyl)-
  • Z 2 is -O-
  • Y is substituted or unsubstituted ⁇ CH2-4-thiazole.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 - A-(L 4 - Ar) p groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(alkyl)-
  • Z 2 is -O-
  • R 8 -Y is -CH2-(2-a. ⁇ kyl-4- thiazole).
  • L 1 is -C(O)-
  • R 4 is H
  • both -LAA-(L 4 - Ar) P groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(H)-
  • Z 2 is -O-
  • R 8 -Y is -CH 2 -(2-iPr-4- thiazole).
  • ⁇ J is -C(O)-
  • R 4 is H
  • both -L 3 -A-(L 4 -Ar)p groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(alkyl)-
  • Z 2 is -O-
  • Y is substituted or unsubstituted -CH2-4-thiazole
  • X is substituted or unsubstituted -CH>-5- thiazole.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 -A-(L 4 -Ar)p groups are substituted or unsubstituted benzyl
  • L 2 is -CHb-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(alkyl)-
  • Z 2 is -O-
  • Y is substituted or unsubstituted -CH2-4-thiazole
  • X is unsubstituted -CH2-5-thiazole.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 -A-(L 4 -Ar) P groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(H)-
  • Z 2 is -O-
  • R 8 -Y is ⁇ CH2-(2-iPr-4-thiazole)
  • X is unsubstituted -CH ⁇ -S-thiazole.
  • each R 2 is independently H or hydroxyalkyl.
  • each R 2 is independently H or heterocyclylalkyl.
  • each R 2 is independently H or -CHb-heterocydyl, wherein said heterocyclyl is a 5- or 6- membered ring having at least one ring nitrogen atom.
  • each R 2 is independently H or -CHb-heterocyclyl, wherein said heterocyclyl is a 6- membered ring having at least one ring nitrogen atom.
  • each R 2 is independently H or -Cl-fe-heterocycryl, wherein said heterocyclyl is a 6- membered ring having at least one ring nitrogen atom, where the -CH2- moiety thereof is bonded to the ring nitrogen atom.
  • each R 2 is independently H or -CHb-heterocyclyl, wherein said heterocyclyl is selected from the group consisting of piperadyl, piperazyl, and morpholinyl.
  • each R 2 is independently H or -CH2-heterocyclyl / wherein said heterocyclyl is selected from the group consisting of piperadyi, piperazyl, and morpholinyl, and the -CH 2 - moiety thereof is bonded to a ring nitrogen atom of the heterocyclyl.
  • each R 2 is independently H or aminoa ⁇ kyl.
  • each R 2 is independently H or aminoalkyl substituted with an amine protecting group selected from the group consisting of acetyl, alkylsulfonyl, Boc, Cbz, and Fmoc.
  • each R 2 is independently H or ethylacetamide (-CH 2 CH 2 NHC(O)CH 3 ).
  • L 1 is -C(O)-
  • R 4 is H
  • both -L ⁇ A-(L 4 -Ar)p groups are substituted or unsubstituted benzyl
  • L 2 is -CH 2 -
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(H)-
  • Z 2 is -O-
  • R e -Y is -CH 2 -(2-iPr-4-th ⁇ azole)
  • X is unsubstituted -CH2-5-thiazole
  • R 2 is independently H or hydroxyalkyl.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 -A-(L 4 -Ar) P groups are substituted or unsubstituted benzyl
  • L 2 is -CH 2 -
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(H)-
  • Z 2 is -O-
  • R 8 -Y is -CH 2 -(2-iPr-4-thiazole)
  • X is unsubstituted -CH 2 -5-thiazole
  • one R 2 is H and the other R 2 is hydroxyalkyl.
  • L 1 is -C(O)-
  • R 4 is H 7 both -L 3 -A-(L ⁇ Ar)p groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(H)-
  • Z 2 is -O-
  • R s -Y is -CH 2 -(2-iPr-4-thiazole)
  • X is unsubstituted -QHb-S-thiazole
  • one R 2 is H and the other R 2 is hydroxy methyl.
  • L 1 is -C(O)-
  • R 4 is H
  • both ⁇ L 3 -A-(L 4 -Ar)p groups are substituted or unsubstituted benzyl
  • L 2 is -CH 2 -
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(H)-
  • Z 2 is -O-
  • R 8 -Y is -CH2-(2-iPr-4-thiazole)
  • X is unsubstituted -CH 2 -5-thiazole
  • each R 2 is independently H or -CH2- heterocyclyl, wherein said heterocyclyl is a 5- or 6-membered ring having at least one ring nitrogen atom.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 - A- (L 4 - Ar) P groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(H)-
  • Z 2 is -O-
  • R 8 -Y is -CH2 ⁇ (2-iPr-4-thiazole)
  • X is unsubstituted -CH2-5-thiazole
  • one R 2 is H and the other R 2 is -CH2- heterocyclyl, wherein said heterocyclyl is selected from the group consisting of piperadyl, piperazyl, and morpholinyl, and the -CH2- moiety thereof is bonded to a ring nitrogen atom of the heterocyclyl
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 - A- (L 4 - Ar) P groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(H)-
  • Z 2 is -O-
  • R H -Y is -CH 2 -(2-iPr-4-thiazole)
  • X is unsubstituted -CH2-5-thiazole
  • each R 2 is independently H or aminoalkyl substituted with an amine protecting group selected from the group consisting of acetyl, alkylsulfonyL Boc, Cbz, and Fmoc.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 -A-(L 4 -Ar) P groups are substituted or unsubstituted benzyl
  • L 2 is -CH2-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(H)-
  • Z 2 is -O-
  • R 8 - Y is ⁇ -CH2-(2-iPr-4-thiazole)
  • X is unsubstituted -CH2-5-thiazole
  • one R 2 is H and the other R 2 is aminoalkyl substituted with an amine protecting group selected from the group consisting of acetyl, alkylsulf onyl, Boc, Cbz, and Fmoc.
  • L 1 is -C(O)-
  • R 4 is H
  • both -L 3 -A- ⁇ L 4 -Ar)p groups are substituted or unsubstituted benzyl
  • L 2 is -CH 2 -
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(H)-
  • Z 2 is -CK
  • R 8 -Y is -CH2-(2-iPr-4-thiazole)
  • X is unsubstituted -CF ⁇ 2-5-thiazole
  • one R 2 is H and the other R 2 is ethylacetamide (-CH 2 CHiNHC(O)CH 3 ).
  • L 1 is -C(O)-
  • R 4 is H
  • both -IAA-(LZ-A r) P groups are substituted or unsubstituted benzyl
  • L 2 is -CH-.-
  • m and n are both 1
  • R 1 is H
  • Z 1 is -N(alkyl)-
  • Z 2 is -O-
  • Y is substituted or unsubstituted -CH2-thiazole.
  • the compounds of Formula I or pharmaceutically acceptable salts, solvates, esters, or stereoisomers thereof, have the structure shown in Formula HA:
  • R 11 and R 16 are each independently heterocyclyl or substituted heterocyclyl; and R 12 , R 13 , R 14 , and R 15 are each independently H, -Ci -4 alkyl or -C1-4 substituted alkyl.
  • R 13 is - (CH 2 )O-SCR 17 R 18 NR 20 R 2 V -(CH 2 )O-SCR 17 R 18 NR 17 C(O)-NR 20 R 2 V or -(CH 2 )i- 3 -R 23 wherein R 20 and R 21 form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O or R 23 is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O, and the 5-6 membered heterocyclyl ring is optionally substituted with a C1-2 alkyl.
  • R 13 is - (CH2)o-iCR 17 R 18 OR 19 .
  • R 13 is a Ci -2 hydroxyalkyl or a G- 6 alkoxy alkyl group.
  • R 13 is - (CHz)O-SCR 17 R 18 NR 20 R 21 .
  • R 13 is a Cwalkylene-NHz group, G-4alkylene-NHP (wherein P is a protecting group such as Boc, Fmoc, Cbz, Ac, trifluoroacetyl, toluenesulfony group, benzyl, etc.), or Chalky lene-N(alkyl)2 group.
  • R 13 is - (CH 2 )O-SCR 17 R 18 NR 17 C(O)-NR 20 R 21 .
  • R" is a G-4alkylene-C(O)NH2 group or G-4alkylene-C(O)N(alkyl) 2 group.
  • R 1 V R 12 , R 13 , R 14 , R 15 , and R 16 are each independently selected from the groups shown in the Table, below:
  • R 11 is substituted or unsubstituted heterocyclyl
  • R 12 is alkyl
  • R 13 is substituted or unsubstituted heterocyclylalkyl
  • R 14 and R 15 are each independently substituted or unsubstituted arylalkyl
  • R 16 is substituted or unsubstituted heterocyclyl.
  • R 11 is substituted heterocyclyl
  • R 12 is alkyl
  • R 13 is unsubstituted heterocyclylalkyl
  • R 14 and R 15 are both unsubstituted arylalkyl
  • R 16 is unsubstituted heterocyclyl.
  • R 11 is substituted or unsubstituted heterocyclyl
  • R 12 is alkyl
  • R 13 is hydroxyalkyl
  • R 14 and R 15 are each independently substituted or unsubstituted arylalkyl
  • R 16 is substituted or unsubstituted heterocyclyl.
  • R" is substituted heterocyclyl
  • R 12 is alkyl
  • R 13 is hydroxyalkyl
  • R 14 and R 15 are both unsubstituted arylalkyl
  • R 16 is unsubstituted heterocyclyl.
  • R 11 is substituted or unsubstituted heterocyclyl
  • R 12 is alkyl
  • R 13 is protected or unprotected aminoalkyl
  • R 14 and R 15 are each independently substituted or unsubstituted arylalkyl
  • R 16 is substituted or unsubstituted heterocyclyl.
  • R 11 is substituted heterocyclyl
  • R 12 is alkyl
  • R 13 is protected aminoalkyl
  • R 14 and R 15 are both unsubstituted arylalkyl
  • R 16 is unsubstituted heterocyclyl.
  • R 11 is substituted heterocyclyl
  • R 12 is alkyl
  • R 13 is acylated aminoalkyl
  • R 14 and R 15 are both unsubstituted arylalkyl
  • R 16 is unsubstituted heterocyclyl.
  • the compounds of Formula I or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof, have the following structure HB:
  • R 1Oa and R 1Ob are each independently H or -CM alkyl;
  • R 12 is H or -CHa;
  • R 13 is H, -C1-4 alkyl, -(CH 2 )O-I CR 17 R 18 OR 19 , -(CH 2 )O-SCR 17 R 18 NR 20 R 21 , -(CH 2 )o- 3 CR 17 R 18 NR l7 C(O) NR 20 R 21 , -(CH 2 )i-3C(O)R 22 , -(CHz)WS(O) 2 R 22 or -(CHz) 1 -S-R 23 ;
  • R 14 and R 15 are each independently H, -C 1-4 alkyl or arylalkyl;
  • R 17 and R 18 are each independently H or - Ci-3 alkyl;
  • R 19 is H, -Ci-* alkyl or arylalkyl;
  • R 20 and R 21 are each independently H, - C1-3 al
  • R 13 is - (CH 2 )O-SCR 17 R 18 NR 20 R 21 , -(CH 2 )o- 3 CR l7 R 18 NR l7 C(O)-NR 20 R 21 , or -(CH 2 )i- 3 -R 23 wherein R 20 and R 21 form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O or R 23 is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O, and the 5-6 membered heterocyclyl ring is optionally substituted with a Ci -2 alkyl.
  • the compounds of Formula I or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof, have the following structure HC:
  • R 13 is H, -CM alkyl, -(CHI)O-ICR 17 R 18 OR 19 , "(CH 2 )O-SCR 17 R 18 NR 20 R 21 , -(CH 2 )O- 3CR 17 R 38 NR 17 C(O) NR 20 R 21 , -(CH 2 )i- 3 C(O)R 22 or -(CH 2 )H-R 23 ;
  • R 17 and R 1S are each independently H or G -3 alkyl;
  • R 19 is H, -Ci-4 alkyl or arylalkyl;
  • R 20 and R 21 are each independently H, -Ci 3 alkyl, -C(O)R 17 or -S(O) 2 R 17 ; or R 20 and R 21 , taken together with the nitrogen atom to which they are attached, form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O;
  • R 22 is H, -G-
  • R 13 is - (CHiV 3 CR 17 R 18 NR 20 R 21 , -(CH 2 )O-SCR 17 R 18 NR 17 C(O)-NR 20 R 21 , or -(CH 2 )L 3 -R 23 wherein R 20 and R 21 form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O or R 23 is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O, and the 5-6 membered heterocyclyl ring is optionally substituted with a G -2 alkyl.
  • R 13 is -
  • R 13 is a G-4alkylene-NH 2 group, G-4alkylene-NHP (wherein P is a protecting group such as Boc, Fmo ⁇ , Cbz, Ac, trifluoroacetyl, toiuenesulfony group, benzyl, etc.), or G-4alkylene-N(alkyl)2 group.
  • P is a protecting group such as Boc, Fmo ⁇ , Cbz, Ac, trifluoroacetyl, toiuenesulfony group, benzyl, etc.
  • R 13 is - (CH 2 )Q-SCR 17 R 18 NR 17 C(O)-NR 20 R 21 .
  • R 13 is a Ci-4alkylene-C(O)NU2 group or Ci-4alkylene-C(O)N(alkyl)2 group.
  • R 13 is - CHiOH, -CH 2 CH 2 NHC(O)CH 3 or
  • the compounds of of the present invention or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof, have the following structure HD:
  • L 1 is selected from the group consisting of -C(R 6 ) 2 -, -C(O)-, -S(O 2 )-, -N(R 7 )-C(O)-, and -0-C(O)-; each L 3 is independently a covalent bond, an alkylene, or substituted alkylene; each L 4 is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O-, and -NH-; each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, and substituted heterocyclyl, with the proviso that when A is H, p is 0; Z 1 and Z 2 are each independently -O- or -N(R 7 )-; Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl; each Ar
  • R a and R 9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, and -CN; and each p is independently 0 or 1.
  • L 1 is -C(R 6 )2 ⁇ . In another embodiment of the compounds of Formula IID, L 1 is -CH2-. In another embodiment of the compounds of Formula IID, each L 3 is alkylene.
  • each L 3 is -CH2-.
  • each A is aryl or substituted aryl.
  • each A is phenyl or substituted phenyl.
  • X is heterocyclylalkyl
  • X is thiazolylmethyl.
  • Y is thiazolylmethyl
  • Z 1 is -N(R 7 )-.
  • Z 1 is -NH-.
  • Z 1 is -N(alkyl)-.
  • Z 1 is -N(CHs)-.
  • Z 2 is -O- .
  • L 1 is -C(R 6 )2- and X and Y are heterocyclylalkyl.
  • L 1 is -CH2- and X and Y are heterocyclylalkyl.
  • L 1 is -CH2- and X and Y are thiazolylmethyl.
  • L 1 is -C(R 6 )2- and Z 1 is -N(R 7 )-.
  • L 1 is -CH2- and Z 1 is -N(R 7 )-.
  • L 1 is -CH2- and Z 1 is -NH-.
  • L 1 is -CH2- and 7) is -N(alkyl)-.
  • L 1 is -CH2- and Z 1 is -N(CH 3 )-.
  • L 1 is -C(R 6 )2- and Z 2 is -O-.
  • each L 3 is alkylene and each A is aryl or substituted aryl.
  • each L 3 is -CH2- and each A is aryl or substituted aryl.
  • each IAA is benzyl or substituted benzyl.
  • X and Y are heterocydylalkyl and Z 1 is -N(R 7 )-.
  • X and Y are thiazolylmethyl and T) is -N(R 7 )-.
  • X and Y are thiazolylmethyl and Z 1 is -N(alkyl)-.
  • X and Y are thiazolylmethyl and T) is -N(CHs)-.
  • X and Y are thiazolylmethyl and T) is -NH-.
  • X and Y are heterocydylalkyl and Z 2 is -O- .
  • X and Y are thiazoly Im ethyl and Z 2 is -O-.
  • Z 1 is -N(R 7 )- and 2? is -O-.
  • Z 1 is -N(alkyl)- and Z 2 is -O-.
  • Z 1 is -N(CH 3 )- and Z 2 is -O-.
  • Z 1 is -NH- and Z 2 is -O-.
  • L 1 is -C(R 6 )2-
  • X and Y are heterocyclylalkyl
  • Z 1 is -N(R 7 )-.
  • L 1 is -CH2-, X and Y are heterocyclylalkyl, and Z 1 is -N(R 7 )-.
  • L 1 is -CH2-, X and Y are thiazolylmethyl, and Z 1 is -N(R 7 )-.
  • L ! is -CH2-
  • X and Y are thiazolylmethyL
  • Z 3 is -N(alkyl)-.
  • L 1 is -CH2-
  • X and Y are thiazolylmethyl
  • Z 3 is -N(CHs)-.
  • L 1 is -CH2-, X and Y are thiazolylmethyl, and Z ] is -NH-.
  • L 1 is -C(R 6 )2-; X and Y are heterocyclylalkyl; and Z 2 is -O-.
  • L 1 is -CH2-; X and Y are heterocyclylalkyl; and Z 2 is -O- .
  • L 1 is -CH2-; X and Y are thiazolylmethyl; and Z 2 is -O-.
  • L 1 is -C(R 6 )2-; each L 3 is alkylene; each A is aryl or substituted aryl; X and Y are heterocyclylalkyl; Z 1 is -N(R 7 )-; and Z 2 is -O-.
  • L 7 is -CH2-; each IAA is benzyl or substituted benzyl; X and Y are thiazolylmethyl; Z 1 is -N(CHs)-; and Z 2 is -O-.
  • L 1 is -CH2-; each IAA is benzyl or substituted benzyl; Z 1 is -N(CHs)-; Z 2 is -O-; X is
  • the compounds of of the present invention or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof, have the following structure IV:
  • X is heterocyclylalkyl
  • Y is heterocyclylalkyl or alkyl;
  • G 1 and G 2 are independently CH or N, with the proviso that G 1 and G 2 are different;
  • G 3 is -NR 7 - or -O-;
  • R 1 , R 3 , R 5 , and R 7 are each independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyl, and substituted arylalkyl;
  • R 8 and R 9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, and -CN; each R" is independently selected from the group consisting of H, alkyl, and substituted alkyl; R b is selected from the group consisting of H, alkyl, substituted alky I, CN, and -
  • each R c is independently selected from the group consisting of H, alkyl, substituted alkyl, heterocyclyl, and -S( ⁇ 2)-alkyl.
  • each L 3 is alkylene, for example any of those described herein, e.g. -CH2- and each A is phenyl. In a particular embodiment, both -L 3 -A moieties are benzyl.
  • X and Y are both heteroaryl (for example, any heteroaryl described herein). In a particular embodiment, both X and Y are thiazolyl.
  • G 1 is CH, and G 2 is N.
  • G 2 is N and R 1 is H.
  • G 2 is N, R 1 is H, and G 3 is NR 7 .
  • G 2 is N, R 1 is H, and G 3 is NCH 3 .
  • R 2 is substituted or unsubstituted aminoalkyl.
  • R 2 is substituted or unsubstituted aminoalkyl
  • G 2 is N and R 1 is H
  • both X and Y are thiazolyl.
  • R 2 is -CH2CH2-NH- C(O)-alkyl.
  • the compounds of Formula IV have the following structures:
  • the compounds of Formula IV have the following general formula: wherein said
  • Heterocyclyl is substituted or unsubstituted.
  • said “Heterocyclyl” is a substituted or unsubstituted heteroaryl, for example, and of the heteroaryls described herein.
  • said "Heterocyclyl” is a substituted or unsubstituted heterocycloalkyl, including any heterocycloalkyl described herein.
  • the heterocyclyl is unsubstituted morpholinyl.
  • the heterocyclyl is unsubstituted morpholinyl and R 8 is alkyl.
  • the compounds of Formula IV have the following general formula:
  • X and Y are both heteroarylalkyl.
  • the compounds of Formula IV have the following structures:
  • the compounds of Formula IV have the following general formula:
  • Q is -OH or ⁇ N(R a )2.
  • Q is -OH.
  • Q is -N(R a )2.
  • Q is -NH-pyridyl, -NH-pyrrolyl, or -NH-S( ⁇ 2)-alkyl.
  • the compounds of the above general formula have the following structures:
  • the compounds of Formula IV have the following general formula:
  • M is substituted or unsubstituted alkyl.
  • M is a substituted alkyl, for example hydroxyalkyl, substituted hydroxy alkyl, cyanoalkyl, substituted cyanoalkyl, and trialkylsiloxy alkyl.
  • the compounds of the above general formula have the following structures:
  • the compounds of Formula IV have the following general formula:
  • a compound of the above general formula has the following structure:
  • Y is alkyl.
  • such compounds have the following general formula:
  • R 8 -Y- is alkyl, for example any alkyl described herein. In a particular embodiment, R 8 -Y- is methyl. Specific particular embodiments of the above general structure include the following structures:
  • Compounds of general formula II are depicted as a "core" structure (Z) substituted with four moieties Tl, T2, Xl and X2.
  • the core structures Z are depicted in Table 1.
  • the points of attachment of Tl, T2, Xl and X2 are indicated on each of the core structures depicted in Table 1.
  • Tables 2-5 respectively, show the structures of the Tl, T2, Xl and X2 moieties.
  • the point of attachment of the core structure Z is indicated in each of the structures of Tl, T2, Xl and X2.
  • Each core structure Z in Table 1, and each substituent Tl, T2, Xl and X2 and Tables 2-5 is represented by a "code" comprising a letter and a number.
  • Each structure of a compound of Formula II can be designated in tabular form by combining the "code” representing each structural moiety using the following syntax: Z.T1.T2.X1.X2.
  • Z1.T1A.T2B.X1A.X2A represents the following structure:
  • AIk means a substituted or unsubstituted alkyl, cycloalkyl, or alkylene group, wherein the terms “alkyl”, “cycloalkyl”, and “alkylene” are as defined herein.
  • AIk means an alkyl or cycloalkyl group when depicted as monovalent, and an alkylene group when depicted as divalent.
  • Het is a substituted or unsubstituted heterocyclyl or heterocyclylene group, wherein the term “heterocyclyl” is as defined herein, and the term “heterocyclylene” means a heterocyclyl group as defined herein, in which a hydrogen atom has been replaced by an open valence (in analogy to alkylene), thereby defining a divalent heterocyclyl.
  • Het is a heterocyclyl when depicted as monovalent, and heterocyclylene when depicted as divalent.
  • Ar is a substitute or unsubstituted aryl or arylene group, wherein the term “aryl” is as defined herein, and the term “arylene” means an aryl group as defined herein, in which a hydrogen atom has been replaced by an open valence (in analogy to alkylene), thereby defining a divalent aryl.
  • Ar is aryl when depicted as monovalent and arylene when depicted as divalent. When substituted, "AIk”, “Het”, and “Ar” can be substituted with any of the substituents defined or exemplified herein.
  • substituents of "AIk” can include ether, halogen, -OH, amide, amine, etc.
  • substituents of "Het” can include alkyl, aryl, carbonyl, -OH, halogen
  • substituents of "Ar” can include alkyl, aryl, -OH, halogen, etc., with the proviso that the resulting structure is chemically reasonable, and would provide compounds which are sufficiently stable for formulation in a pharmaceutically acceptable composition.
  • substituents of "AIk” can include ether, halogen, -OH, amide, amine, etc.
  • substituents of "Het” can include alkyl, aryl, carbonyl, -OH, halogen
  • substituents of "Ar” can include alkyl, aryl, -OH, halogen, etc.
  • Table 6 List of Compound Structures of Formula II Z1.T1A.T2A.X1A.X2A, Z2.T1A.T2A.X1A.X2A, Z3.T1A.T2A.X1A.X2A, Z4.T1A.T2A.X1A.X2A, Z5.T1A.T2A.X1A.X2A, Z6.T1A.T2A.X1A.X2A, Z1.T1B.T2A.X1A.X2A, Z2.T1B.T2A.X1A.X2A, Z3.T1B.T2A.X1A.X2A, Z4.T1B.T2A.X1A.X2A, Z5.T1B.T2A.X1A.X2A, Z6.T1B.T2A.X1A.X2A, Z1.T1CT2A.X1A.X2A, Z2.T1C.T2
  • selected compounds of Formula I are named below in tabular format (Table 12) as compounds of general Formula III (below):
  • Table 12 List of Compound Structures of Formula II la.2a.3a.4a.5a v lb.2a.3a.4a.5a., lf.2a.3a.4a.5a v lh.2a.3a.4a.5a., lj.2a.3a.4a.5a., lp.2a.3a.4a.5a v la.2b.3a.4a.5a v lb.2b.3a.4a.5a., lf.2b.3a.4a.5a., lh.2b.3a.4a.5a., lj.2b.3a.4a.5a., lp.2b.3a.4a.5a., la.2e.3a.4a.5a., lb.2e.3a.4a.5a., lf.2e.3a.4
  • the compound of the present invention has an inhibition activity against P450 at a level equal to or better than the inhibition activity of a compound as represented by an ICso of less than about 2000 nM, less than about 1500 nM, less than about 1000 nM, less than about 900 nM, less than about 800 nM, less than about 700 nM, less than about 650 nM, less than about 600 nM, less than about 550 nM, less than about 500 nM, less than about 400 nM, less than about 350 nM, less than about 300 nM, less than about 250 nM, less than about 200 nM, less than about 100 nM, or less than about 50 nM.
  • an ICso of less than about 2000 nM, less than about 1500 nM, less than about 1000 nM, less than about 900 nM, less than about 800 nM, less than about 700 nM, less than about 650 nM, less than about 600 nM, less than
  • the compound of the present invention has an inhibition activity against an isozyme of P450, e.g., 3A in a range represented by ICso from about 2000 nM to about 100 nM, from about 1000 nJVI to about 100 nM, from about 900 nM to about 200 nM, from about 800 nM to about 300 nM, from about 700 nM to about 200 nM, from about 600 nM to about 200 nM, from about 500 nM to about 200 nM, from about 700 nM to about 300 nM, from about 600 nM to about 300 nM, from about 700 nM to about 400 nM, from about 600 nM to about 400 nM, from about 400 nM to about 100 nM, from about 300 nM to about 100 nM, or from about 600 nM to about 150 nM.
  • ICso from about 2000 nM to about 100 nM, from about 1000 nJVI to about 100 n
  • the compound of the present invention has an inhibition activity against P450 at a level equal to or better than the inhibition activity of a compound as represented by an ICso of less than about 2000 nM, less than about 1500 nM, less than about 1000 nM, less than about 900 nM, less than about 800 nM, less than about 700 nM, less than about 650 nM, less than about 600 nM, less than about 550 nM, less than about 500 nM, less than about 400 nM, less than about 350 nM, less than about 300 nM, less than about 250 nM, less than about 200 nM, less than about 100 nM, or less than about 50 nM, provided that such compound also does not substantially exhibit biological activities other than its inhibition activity against P450.
  • an ICso of less than about 2000 nM, less than about 1500 nM, less than about 1000 nM, less than about 900 nM, less than about 800 nM, less than about 700 nM
  • the compound of the present invention can have a reduced or not significant activity of protease inhibition, including without any limitation a level of protease inhibition as represented by HIV ECso of greater than about 1000 nM, greater than about 900 nM, greater than about 800 nM, greater than about 700 nM, greater than about 600 nM, greater than about 500 nM, greater than about 400 nM, greater than about 300 nM, greater than about 200 nM, greater than about 100 nM, greater than about 50 nM, greater than about 40 nM, greater than about 30 nM, greater than about 20 nM, greater than about 10 nM, greater than about 5 nM, or greater than about 1 nM.
  • a level of protease inhibition as represented by HIV ECso of greater than about 1000 nM, greater than about 900 nM, greater than about 800 nM, greater than about 700 nM, greater than about 600 nM, greater than about 500 nM, greater than about
  • the compound of the present invention has an inhibition activity specifically against one or more isozymes of P450 including without limitation 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2El, and 3A4, 5, 7, etc.
  • the compound of the present invention has an inhibition activity specifically against an isozyme of P450 that is involved in metabolizing anti-viral drugs, e.g., indinavir, nelfinavir, ritonavir, saquinavir etc.
  • the compound of the present invention has an inhibition activity specifically against one or more isozymes of P450, but not the other(s).
  • the compound of the present invention can have an inhibition activity specifically against P450 3 A, but a reduced, insubstantial, or minimum inhibition activity against another isozyme of P450, e.g., P450 2C9.
  • the compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice.
  • Tablets will contain excipients, glidants, fillers, binders and the like.
  • Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986), herein incorporated by reference in its entirety.
  • Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxy alky lmethylceilulose, stearic acid and the like.
  • the pH of the formulations ranges from about 3 to about 11, but is ordinarily about 7 to 10. While it is possible for the active ingredients to be administered alone it may be preferable to present them as pharmaceutical formulations.
  • the formulations of the invention both for veterinary and for human use, comprise at least one active ingredient, e.g. a compound of the present invention, together with one or more acceptable carriers and optionally other therapeutic ingredients.
  • the carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.
  • the formulations include those suitable for the foregoing administration routes.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.), herein incorporated by reference in its entirety. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in- water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be administered as a bolus, electuary or paste.
  • a tablet is made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient.
  • the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w.
  • the active ingredients may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredients may be formulated in a cream with an oil-in- water cream base.
  • the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
  • the topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogs.
  • the oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.
  • the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax
  • the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
  • Emulgents and emulsion stabilizers suitable for use in the formulation of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
  • the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used.
  • compositions according to the present invention comprise one or more compounds of the invention together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents.
  • Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration.
  • tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation.
  • Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable ex ⁇ pient which are suitable for manufacture of tablets are acceptable.
  • excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc.
  • inert diluents such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate
  • granulating and disintegrating agents such as maize starch, or alginic acid
  • binding agents such as cellulose, microcrystalline cellulose, starch
  • Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl mono stearate or glyceryl distearate alone or with a wax may be employed.
  • Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example calcium phosphate or kaolin
  • an oil medium such as peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate).
  • a suspending agent
  • the aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
  • Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents, such as those set forth herein, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives.
  • a dispersing or wetting agent and suspending agents are exemplified by those disclosed above. Additional exdpients, for example sweetening, flavoring and coloring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
  • Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as poly oxy ethylene sorbitan monooleate.
  • the emulsion may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • sweetening agents such as glycerol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
  • a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned herein.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder.
  • a non-toxic parenterally acceptable diluent or solvent such as a solution in 1,3-butane-diol or prepared as a lyophilized powder.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile fixed oils may conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid may likewise be used in the preparation of injectables.
  • a time-release formulation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight: weight).
  • the pharmaceutical composition can be prepared to provide easily measurable amounts for administration.
  • an aqueous solution intended for intravenous infusion may contain from about 3 to 500 ⁇ g of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
  • Formulations suitable for administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
  • the active ingredient is preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 ⁇ m (including particle sizes in a range between. 0.1 and 500 ⁇ m in increments such as 0.5 ⁇ m, 1 ⁇ m, 30 ⁇ m, 35 ⁇ m, etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs.
  • Suitable formulations include aqueous or oily solutions of the active ingredient.
  • Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of infections as described herein.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
  • sterile liquid carrier for example water for injection
  • Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • the invention further provides veterinary compositions comprising at least one active ingredient, e.g., a compound of the present invention together with a veterinary carrier.
  • Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route. Compounds of the invention can also be formulated to provide controlled release of the active ingredient to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the active ingredient. Accordingly, the invention also provided compositions comprising one or more compounds of the invention formulated for sustained or controlled release.
  • the effective dose of an active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses) or against an active disease or condition, the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies.
  • the effective dose can be expected to be from about 0.0001 to about 100 mg/kg body weight per day. Typically, from about 0.01 to about 10 mg/kg body weight per day. More typically, from about 0.01 to about 5 mg/kg body weight per day. More typically, from about 0.05 to about 0.5 mg/kg body weight per day.
  • the daily candidate dose for an adult human of approximately 70 kg body weight will range from 1 mg to 1000 mg, or between 5 mg and 500 mg, and may take the form of single or multiple doses.
  • the present application discloses pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and a pharmaceutically acceptable carrier or exipient.
  • the present application discloses pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional therapeutic agent, and a pharmaceutically acceptable carrier or exipient.
  • the therapeutic agent used in combination with the compound of the present invention can be any agent having a therapeutic effect when used in combination with the compound of the present invention.
  • the therapeutic agent used in combination with the compound of the present invention can be any agent that is accessible to oxidative metabolism by cytochrome P450 enzymes, especially cytochrome P450 monooxygenase, e.g., 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2El, 3A4,5,7, etc.
  • cytochrome P450 enzymes especially cytochrome P450 monooxygenase, e.g., 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2El, 3A4,5,7, etc.
  • the therapeutic agent used in combination with the compound of the present invention can be any anti- viral agent e.g., anti-HIV, anti- HCV, etc., anti -bacterial agent, anti-fungal agent, immuno-modulator, e.g., immunosuppressant, anti-neoplastic agent, chemotherapeutic agent, agents useful for treating cardiovascular conditions, neurological conditions, etc.
  • anti- viral agent e.g., anti-HIV, anti- HCV, etc.
  • anti-bacterial agent e.g., anti-bacterial agent, anti-fungal agent
  • immuno-modulator e.g., immunosuppressant, anti-neoplastic agent, chemotherapeutic agent, agents useful for treating cardiovascular conditions, neurological conditions, etc.
  • the therapeutic agent used in combination with the compound of the present invention can be any proton pump inhibitor, anti- epileptics, NSAID, oral hypoglycemic agent, angiotensin II, sulfonylureas, beta blocker, antidepressant, antipsychotics, or anesthetics, or a combination thereof.
  • the therapeutic agent used in combination with the compound of the present invention can be any alf entanyl, aprepitant, aripiprazole, buspirone, cafergot, caffeine, TMU, cilostazol, cocaine, codeine- N- demethylation, dapsone, dextromethorphan, docetaxel, domperidone, eplerenone, fentanyl, finasteride, gleevec, haloperidol, irinotecan, LAAM, lidocaine, methadone, nateglinide, ondansetron, pimozide, propranolol, quetiapine, quinine, salmeterol, sildenafil, sirolimus, tamoxifen, taxol, terfenadine, trazodone, vincristine, zaleplon, or Zolpidem or a combination thereof.
  • the present application discloses pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional therapeutic agent selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, non-nucleoside inhibitors of HCV, CCR5 inhibitors, and combinations thereof, and a pharmaceutically acceptable carrier or exipient.
  • HIV protease inhibiting compounds HIV non-nucleoside inhibitors of reverse transcriptase
  • HIV nucleoside inhibitors of reverse transcriptase HIV nucleotide inhibitors of reverse transcriptase
  • HIV integrase inhibitors non-nucleoside inhibitors of HCV, CCR5 inhibitors, and combinations thereof
  • a pharmaceutically acceptable carrier or exipient
  • the present application provides pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional therapeutic agent selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AGl 776), L-756423, RO0334649, KNI-272, DPC- 681, DPC-684, GW640385X, DG17, PPL-100, DG35, AG 1859, capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-
  • the present invention provides pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with two or three additional therapeutic agents.
  • a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof is combined with two or three additional therapeutic agents selected from the classes of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and HIV integrase inhibitors.
  • the two or three additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, or they can be selected from different classes of therapeutic agents.
  • the compounds of the present invention in such ternary or quaternary combinations can include any of the compounds of Formula I disclosed herein, for example a compounds of Formula IIA-D or Formula IV.
  • the pharmaceutical compositions of the present invention comprises a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, combined with two or three additional therapeutic agents selected from the classes of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and HIV integrase inhibitors.
  • the pharmaceutical composition of the present invention comprises Example P, S, or X, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with two or three additional therapeutic agents selected from the classes of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and HIV integrase inhibitors.
  • such combinations can comprise Example P, S, or X, or a pharmaceutically acceptable salt, solvate, and/or ester thereof in combination with two or three additional therapeutic agents selected from the group consisting of tenofovir disoproxil fumarate, GS-9131, emtridtabine, elvitegravir, efavrenz, atazanavir, darunavir, raltegravir, and rilpivirine (or pharmaceutically acceptable salts, solvates, and/or esters thereof).
  • additional therapeutic agents selected from the group consisting of tenofovir disoproxil fumarate, GS-9131, emtridtabine, elvitegravir, efavrenz, atazanavir, darunavir, raltegravir, and rilpivirine (or pharmaceutically acceptable salts, solvates, and/or esters thereof).
  • ternary combinations comprise, for example, Example P/tenofovir disoproxil fumarate/GS-9131, Example P/tenofovir disoproxil fumarate/emtricitabine, Example P/tenofovir disoproxil fumar ate/el vitegravir, Example P/tenofovir disoproxil fumarate/efavrenz, Example P/tenofovir disoproxil fumarate/atazanavir, Example P/tenofovir disoproxil fumarate/darunavir, Example P/tenofovir disoproxil fumarate/raltegravir, Example P/tenofovir disoproxil fumarate/rilpivirine, Example P/GS-9131/emtricitabine, Example P/GS-9131/eIvitegravir, Example P/GS-9131/efavrenz, Example P/GS ⁇ 9131/atazanavir, Example P/GS- 9131/darunavir, Example P/GS-9131/
  • quaternary combinations comprise, for example, Example P/tenofovir disoproxil fumarate/GS-9131/emtricitabine, Example P/tenofovir disoproxil fumarate/GS-9131/elvitegravir, Example P/tenofovir disoproxil fumarate/GS-9131/efavrenz, Example P/tenofovir disoproxil fumarate/GS-9131/atazanavir, Example P/tenofovir disoproxil fumarate/GS- 9131/darunavir, Example P/tenofovir disoproxil fumarate/GS-9131/raltegravir, Example P/tenofovir disoproxil fumarate/GS-9131/rilpivii ⁇ ne, Example P/tenofovir disoproxil fumarate/emtriritabine/elvitegravir, Example P/tenofovir disoproxil fumarate/emtricitabme/efavrenz, Example P/tenofofovir
  • Example P/elvitegravir/efavrenz/rilpivirine Example P/elvitegravir/atazanavir/darunavir, Example P/e lvitegr a vir/atazana vir/r altegra vir, Example P/elvitegravir/atazanavir/rilpivirine, Example
  • Example P/atazanavir/darunavir/raltegravir Example P/atazanavir/darunavir/rilpivirine, Example P/darunavir/raltegravir/rilpivirine, Example S/tenofovir disoproxil fumarate/GS-9131/emtricitabine, Example S/tenofovir disoproxil jfumarate/GS- 9131/elvitegravir, Example S/tenofovir disoproxil f ⁇ imarate/GS-9131/efavrenz, Example S/tenofovir disoproxil fumarate/GS-9131/atazanavir, Example S/tenofovir disoproxil iumarate/GS-9131/darunavir, Example S/tenofovir disoproxil fumarate/GS-9131/raltegravir, Example S/tenofovir disoproxil fumarate/GS-9131/rilpivirine, Example S/tenofovir disoproxil
  • Example S/atazana vir/d aruna vir/rretegra vir Example S/atazana vir/d arunavir/rilpi vir ine, Example S/darunavir/raltegravir/rilpivirine, Example X/tenofovir disoproxil fumarate/GS-9131/emtricitabine, Example X/tenofovir disoproxil fumarate/GS- 9131/elvitegravir, Example X/tenofovir disoproxil fumarate/GS-9131/efavrenz, Example X/tenofovir disoproxil fumarate/GS-9131/atazanavir, Example X/tenofovir disoproxil fumarate/GS-9131/darunavir, Example X/tenofovir disoproxil fumarate/GS-9131/raltegravir, Example X/tenofovir disoproxil fumarate/GS-9131/rilpivirine, Example
  • Example X/elvitegravir/efavrenz/rilpivirine Example X/elvitegravir/atazanavir/darunavir, Example X/elvitegravir/atazanavir/raltegravir, Example X/elvitegravir/atazanavir/rilpivirine, Example X/el vitegr avir/d arunavir /raltegr a vir, Example X/elvitegravir/darunavir/rilpivirine, Example
  • Example X/efavrenz/raltegravir/rilpivirine Example X/atazanavi ⁇ /darunavir/raltegravir, Example X/atazanavir/darunavir/rilpivirine, and Example X/darunavir/raltegravir/rilpivirine (including pharmaceutically acceptable salts, solvates, and/or esters of any of the above).
  • the present application provides a combination pharmaceutical agent comprising: a) a first pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, or ester thereof; and b) a second pharmaceutical composition comprising at least one additional therapeutic agent selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gpl20 inhibitors, CCR5 inhibitors, interferons, ribavirin analogs, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, and combinations thereof.
  • HIV protease inhibiting compounds HIV non-nucleoside inhibitors of reverse transcript
  • One or more compounds of the invention are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient.
  • An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.
  • the compounds of the present invention can be used alone, e.g., for inhibiting cytochrome P450 monooxygenase.
  • the compounds of the present invention are used in combination with other active therapeutic ingredients or agents.
  • the other active therapeutic ingredients or agents are metabolized or accessible to the oxidative metabolism by cytochrome P450 enzymes, e.g., monooxygenase enzymes such as 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2El, 3A4,5,7, etc.
  • Combinations of the compounds of the present invention are typically selected based on the condition to be treated, cross-reactivities of ingredients and pharmaco-properties of the combination. For example, when treating an infection (e.g., HIV or HCV), the compositions of the invention are combined with anti- infective agents (such as those described herein).
  • non-limiting examples of suitable combinations include combinations of one or more compounds of the present invention with one or more anti-viral agents, e.g., anti-HIV, anti-HCV, etc., anti-bacterial agents, anti-fungal agents, immuno-modulators, e.g., immunosuppressant, anti-neoplastic agents, chemo therapeutic agents, agents useful for treating cardiovascular conditions, neurological conditions, etc.
  • anti-viral agents e.g., anti-HIV, anti-HCV, etc.
  • anti-bacterial agents e.g., anti-bacterial agents, anti-fungal agents
  • immuno-modulators e.g., immunosuppressant, anti-neoplastic agents, chemo therapeutic agents, agents useful for treating cardiovascular conditions, neurological conditions, etc.
  • non-limiting examples of suitable combinations include combinations of one or more compounds of the present invention with one or more proton pump inhibitors, anti-epileptics, NSAIDs, oral hypoglycemic agents, angiotensin II, sulfonylureas, beta blockers, antidepressants, antipsychotics, or anesthetics, or a combination thereof.
  • non-limiting examples of suitable combinations include combinations of one or more compounds of the present invention with one or more HIV protease inhibiting compounds, HIV non- nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gpl20 inhibitors, CCR5 inhibitor and other drugs for treating HIV, interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, nucleoside or nucleotide inhibitors of HCV, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.
  • HIV protease inhibiting compounds HIV non- nucleoside inhibitors of reverse transcriptase
  • HIV nucleoside inhibitors of reverse transcriptase HIV nucleotide inhibitors of reverse transcriptase
  • one or more compounds of the present invention may be combined with one or more compounds selected from the group consisting of 1) amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, damnavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, GS-8374, PPL-100, DG35, and AG 1859, 2) a HIV non- rmcleoside inhibitor of reverse transcriptase, e.g., capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC
  • the compounds of the present invention can be used with any other active therapeutic agent or ingredient which is appreciably metabolized by cytochrome P450 monooxygenase enzymes, e.g. cytochrome P450 monooxygenase 3A, thereby reducing the amount or rate at which the other active therapeutic agent or ingredient is metabolized, whereby the pharmacokinetics of the other active therapeutic agent or ingredient is improved.
  • cytochrome P450 monooxygenase enzymes e.g. cytochrome P450 monooxygenase 3A
  • Such improvements can include elevating the blood plasma levels of the other therapeutic agent or ingredient or maintaining a more therapeutically effective blood plasma level of the other therapeutic active agent or ingredient — compared to blood plasma levels of the other therapeutic agent or ingredient administered without the compound of the present invention.
  • any compound of the invention with one or more other active therapeutic agents in a unitary dosage form for simultaneous or sequential administration to a patient.
  • the combination therapy may be administered as a simultaneous or sequential regimen.
  • the combination When administered sequentially, the combination may be administered in two or more administrations.
  • Co-administration of a compound of the invention with one or more other active therapeutic agents generally refers to simultaneous or sequential administration of a compound of the invention and one or more other active therapeutic agents, such that therapeutically effective amounts of the compound of the invention and one or more other active therapeutic agents are both present in the body of the patient.
  • Co-administration includes administration of unit dosages of the compounds of the invention before or after administration of unit dosages of one or more other active therapeutic agents, for example, administration of the compounds of the invention within seconds, minutes, or hours of the administration of one or more other active therapeutic agents.
  • a unit dose of a compound of the invention can be administered first, followed within seconds or minutes by administration of a unit dose of one or more other active therapeutic agents.
  • a unit dose of one or more other therapeutic agents can be administered first, followed by administration of a unit dose of a compound of the invention within seconds or minutes.
  • a unit dose of a compound of the invention may be desirable to administer a unit dose of a compound of the invention first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more other active therapeutic agents. In other cases, it may be desirable to administer a unit dose of one or more other active therapeutic agents first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the invention.
  • the combination therapy may provide "synergy” and "synergistic effect", i.e. the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately.
  • a synergistic effect may be attained when the active ingredients are: (1) co- formulated and administered or delivered simultaneously in a combined formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen.
  • a synergistic effect may be attained when the compounds are administered or delivered sequentially, e.g., in separate tablets, pills or capsules, or by different injections in separate syringes.
  • an effective dosage of each active ingredient is administered sequentially, i.e. serially, whereas in combination therapy, effective dosages of two or more active ingredients are administered together.
  • the present application provides a method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides a method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a combination comprising said drug and a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides a method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase 3A, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides a method for increasing blood plasma levels of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides a method for increasing blood plasma levels of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a combination comprising said drug and a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides a method for increasing blood plasma levels of a drug which is metabolized by cytochrome P450 monooxygenase 3A, comprising administering to a patient treated "with said drug, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides a method for increasing blood plasma levels of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and wherein the amount of the compound of the present invention administered is effective to inhibit cytochrome P450 monooxygenase.
  • the present application provides a method for inhibiting cytochrome P450 monooxygenase in a patient comprising administering to a patient in need thereof an amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, effective to inhibit cytochrome P450 monooxygenase.
  • the present application provides a method for inhibiting cytochrome P450 monooxygenase 3A in a patient comprising administering to a patient in need thereof an amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, effective to inhibit cytochrome P450 monooxygenase 3A.
  • the present application provides a method for inhibiting cytochrome P450 monooxygenase comprising contacting cytochrome P450 monooxygenase with an amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, effective to inhibit cytochrome P450 monooxygenase.
  • the present application provides a method for inhibiting cytochrome P450 monooxygenase 3A comprising contacting cytochrome P450 monooxygenase 3 A with an amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, effective to inhibit cytochrome P450 monooxygenase 3 A.
  • the present application provides a method for treating an HIV infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.
  • additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.
  • the present application provides a method for treating an HIV infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, and GW640385X, DG17, PPL-100, DG35, AG 1859, capravirine, emivirine, delaviridine, efavirenz,
  • the present application provides a method for treating an HCV infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), feron, reaferon, intermax alpha, r-IFN-beta, infergen + actimmune, IFN-omega with DUROS, locteron, albuferon, rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and pegylated IFN-beta, rebetol, copegu
  • the present application provides for the use of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for inhibiting cytochrome P450 monooxygenase in a patient.
  • the present application provides for the use of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for treating an HIV infection.
  • the present application provides for the use of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for increasing blood plasma levels of the drug which is metabolized by cytochrome P450 monooxygenase.
  • the present application provides for the use of a compound of the present invention or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
  • Example B was further purified by trituration with MeOH/hexane to give 83 mg of a white solid, m/z: 719 (M+H) + .
  • Compound 5 was purchased from Aldrich or alternatively prepared according to the procedures of T. Org. Chem. 1994, 59, 1937, herein incorporated by reference in its entirety for all purposes.
  • Compound 6 To a solution of Compound 4 in DCM (3 mL) at room temperature was added 5 (0.1 mL, 0.695 mmol). The resulting clear solution was allowed to stand at room temperature for 2 h.
  • Example C was prepared by the solvent in vacuo and the residue was taken up in MeCN (0.5 mL) and passed through an Acrodisc LC13 PVDF filter (0.45 ⁇ M) prior to purification by preparatory HPLC to afford 0.043 g (71%) of Example C as a fluffy white solid.
  • Example E was prepared following the procedure for Example D (30 mg), except that Compound 13b was used instead of Compound 13a. m/z 677.1 (M+H) + .
  • Example F was prepared following the procedure for Example D (30 mg), except that Compound 13b was used instead of Compound 13a. m/z 677.1 (M+H) + .
  • Example G was prepared following the procedure for Example D (84 mg), except that Compound 13d was used instead of Compound 13a. m/z 783.2 (M+H) ⁇ Example H
  • Example H was prepared following the procedure for Example D (90 mg) 7 except that Compound 13e was used instead of Compound 13a. m/z 763.2 (M+H) + .
  • Example H (24 mg) was dissolved in TFA (2 mL) and the mixture was stirred for 12 hours, then concentrated. Purification by reverse phase HPLC (Phenomenex Synergi® Comb-HTS column, eluent: 25% - 100% CH 3 CN in water) gave Example I (14 mg). m/z 707.2 (M+H) + .
  • Compound 23 was prepared following the procedure for Compound 13, with the exception that methyl 3-isocyanatopropionate was used instead of Compound 11.
  • Example J was prepared following the procedure for Example D (37 mg), except that Compound 23 was used instead of Compound 13a. m/z 677.2 (M+H) + .
  • Example K was prepared following the procedure for Example D (7 mg), except that Compound 3d was used instead of Compound 13a. m/z 705.2 (M+H) + . 1 H-NMR (CDCb) ⁇ 8.8 (1 H, m), 7.86 (1 H, s), 7.26-6.8 (11 H, m), 6.10 (1 H, m), 5.5- 5.10 (4 H, m), 4.46 (2 H, m), 4.2-3.75 (3 H, m), 3.25 (1 H, m), 2.82/2.4 (3 H), 2.8-2.5 (4 H, m), 2.17 (1 H, m), 1.7-1.2 (10 H, m), 0.8 (6 H, m).
  • Compound 25 was prepared following the literature procedure described in T, Org. Chem. 1996, 61, 444 (herein incorporated by reference in its entirety), except that the L-isomer was prepared instead of the D-isomer.
  • Compound 26 was prepared following the literature procedure described in T, Org. Chem. 1996, 61, 444 (herein incorporated by reference in its entirety), except that the L-isomer was prepared instead of the D-isomer.
  • the analogs of Compound 25 can then be transformed, according to the methods outlined in Scheme 12, to form analogs of
  • Compound 28 was prepared using a procedure similar to that used to prepare Compound 6 (described in Scheme 4) except that Compound 9 was used instead of Compound 4.
  • Compound 30 was purchased from Aldrich Chemical Co., and used without further purification.
  • Compound 31 was purchased from Aldrich Chemical Co., and used without further purification.
  • Compound 36 (0.528 g, 1.03 mmol) was diluted in THF (3 mL) and added to liquefied ammonia (approx. 20 mL) at -35 0 C. Small pieces of Na were added until a blue color persisted. After 1.5 h, solid NHO was added in portions until the remaining Na was destroyed and the ammonia was allowed to escape at ambient temperature. Water and EtOAc (20 mL each) were added, and the aqueous layer was extracted with EtOAc.
  • Example N was prepared using procedures similar to those used to prepare Example M, using the following reagents: Compound 40 (0.055 g, 0.152 mmol); Compound 29 (0.92 mL of 0.2 M THF solution, 0.183 mmol); THF (1 mL); DIPEA (0.040 mL, 0.228 mmol); HOBt (0.025 g, 0.182 mmol); EDC (0.032 mL, 0.182 mmol).
  • stereochemical configurations other than those shown i.e v enantiomers or diasteriomers
  • stereochemical configurations other than those shown can be prepared by the selection of analogs of Compound 44 having the appropriate stereochemical configuration at the chiral centers.
  • Compound 47 is commercially available from TCI.
  • Example O To Example O (17 mg) was added TFA (2 mL). The mixture was stirred for 3 hours and concentrated. The mixture was diluted with THF (2 mL) and 1.0 N NaOH solution was added until pH 11. The mixture was stirred for 10 minutes, and extracted with EtOAc. The organic phase was washed with water and brine. Purification by flash column chromatography (EtOAc) gave Example P (12 mg).
  • Compound 50 is commercially available from Chem Impex International, and used without further purification.
  • stereochemical configurations other than those shown i.e., enantiomers or diasteriomers
  • stereochemical configurations other than those shown can be prepared by the selection of analogs of Compound 50 having the appropriate stereochemical configuration at the chiral center.
  • Example Q (3.02 g, 3.74 mmol) was suspended in 4.0 N HCl/dioxane solution (30 mL) and stirred at 25 0 C for 3 hours. Solvent was removed under reduced pressure and Et2 ⁇ was poured into the reaction mixture. The resulting suspension was stirred vigorously for 1.5 hours. The solid was allowed to settle and the ether layer was decanted. Washing of the precipitate with Et2 ⁇ was repeated two more times. The product was dried in vacuo to afford a white solid (3.18 g, quantitative yield). Saturated aqueous Na2CO3 solution was added to above solid (3.18 g) with stirring until solid disappeared. The aqueous solution was extracted with ethyl acetate. The organic phases were dried over Na2SO4, filtered, and evaporated to afford Example R as a yellow foam (2.44g, 81%). The recovered Example R was used without further purification in the next step, m/z: 706.1 (M+H) + .
  • Example R (1.0Og, 1.42 mmol) was dissolved in DMF (20 mL) and bromoethyl ether (196 ⁇ L, 1.56 mmol) was added dropwise, followed by NaHCOs (0.239 g, 2.84 mmol). The reaction mixture was stirred at 25 0 C for 2 hours. The solution was heated to 65°C and stirred for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with EtOAc and washed sequentially with water and brine. The organic phase was dried over Na2$O4 filtered, and evaporated.
  • Compound 54 was prepared following the procedure described in J. Med. Chem, 1993, 36, 1384 (herein incorporated by reference in its entirety for all purposes).
  • Example R To a solution of Example R (70 mg, 0.1 mmol) in CH3CN (5 mL) was added sodium cyanoborohydride (50 mg) in water (5 mL). To the above mixture was added a solution of dialdehyde Compound 54 (0.6 mmol) in CHQ3/H2O) (4 mL/ 1 mL). The mixture was stirred for 12 hours, and basified with saturated Na2CO3 solution. The mixture was extracted with EtOAc, and organic phase was washed with water and brine, and dried over Na2SO4. Purification by reverse-phase HPLC (Phenomenex Synergi® Comb-HTS column) gave Example S (57 mg).
  • Example S (185 mg, 57%) was prepared following the same procedure as for Example Q, except that Compound 57 (160 mg, 0.42 mmol) was used instead of Compound 52. mass m/z: 776.2 (M+H) + .
  • stereochemical configurations other than those shown i.e., enantiomers or diasteriomers
  • stereochemical configurations other than those shown can be prepared by the selection of analogs of Compound 51 having the appropriate stereochemical configuration at the chiral center.
  • Example S Compound 57 was converted to Example S using the procedure described in Method III, above.
  • Example R The hydrochloride salt of Example R (100 mg, 0.13 mmol) was suspended in CH2CI2 (2 mL) and dissolved by addition of iPnNEt (69 uL). Acetyl chloride (11 ⁇ L) was added dropwise and the mixture was allowed to stir at 25°C for 4 hours. The solvent was removed in vacuo. Purification of the residue by flash column chromatography (stationary phase: silica gel; eluent: 8% iPrOH/CH-Ch) gave Example T (39 mg, 40%). m/z: 748.2 (M+H) + .
  • Example R Saturated aqueous NazCOs solution was added to the hydrochloride salt of Example R (3.18 g, 3.46 mmol) while stirring until the solid disappeared. The aqueous solution was extracted with ethyl acetate. The organic phases were dried over Na2SO4, filtered, and evaporated to afford Example R as a yellow foam (2.44g, 81%). This material was used without further purification in the next step, m/z: 706.1 (M+H) ⁇
  • Example R (300 mg, 0.43 mmol) was dissolved in THF (5.5 mL). Acetic acid (37 ⁇ L, 0.64 mmol) was added, followed by HOBt (85 mg, 0.64 mmol), iPr.NEt (304 ⁇ L, 1.70 mmol), and EDC (151 ⁇ L, 0.85 mmol). The reaction mixture was allowed to stir at 25 0 C for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with EtOAc and washed sequentially with saturated aqueous Na2CO3, water, and brine. The organic phase was dried over Na2SO4, filtered, and evaporated. Purification by Combiflash® (stationary phase: silica gel; eluent: 10% MeOH/CIfcCk) gave Example T (249 mg, 77%). m/z: 748.2 (M+H) + .
  • Example U Example U
  • Example R (100 mg, 0.13 mmol) was suspended in OHbCh (2 mL) and dissolved by addition of iPnNEt (69 ⁇ L). Methane sulfonyl chloride (12 ⁇ L) was added dropwise and the mixture was allowed to stir at 25°C for 4 hours. The solvent was removed in vacuo. Purification of the residue by flash column chromatography (stationary phase: silica gel; eluent: 8% iPrOH/CH ⁇ Cb) gave Example U (55 mg, 54%). m/z: 784.2 (M+H) + .
  • Example V (692 mg) was prepared following the same procedure used for preparing Example Q, except that Compound 46 was used instead of Compound 8. m/z: 806.2 (M+H) + .
  • Example W
  • Method II Method II
  • Example X (205 mg, 65%) was prepared following the Method II procedure for Example T except that Example W was used instead of Example R. m/z: 748.2 (M+H) + .
  • Example Y (205 mg, 65%) was prepared following the Method II procedure for Example T except that Example W was used instead of Example R. m/z: 748.2 (M+H) + .
  • Example Y (205 mg, 65%) was prepared following the Method II procedure for Example T except that Example W was used instead of Example R. m/z: 748.2 (M+H) + .
  • Example Y (205 mg, 65%) was prepared following the Method II procedure for Example T except that Example W was used instead of Example R. m/z: 748.2 (M+H) + .
  • Example Y (205 mg, 65%) was prepared following the Method II procedure for Example T except that Example W was used instead of Example R. m/z: 748.2 (M+H) + .
  • Example Y (
  • Example Y (106 mg, 50%) was prepared following the same procedure for Example U, except that Example W was used instead of Example R. m/z: 784.2 (M+H) + .
  • Example Z (54 mg, 38%). m/z: 497.1 (M+H) + .
  • Example AA was prepared following the procedures for steps I-III (Scheme 20) for Example Z 7 with the exception that tert-butyl 3- aminopropylcarbamate was used instead of tert-butyl 2-aminoethykarbamate (Compound 62).
  • Example AB Example AB
  • Example AB was prepared following the procedures for steps HII (Scheme 20) for Example Z, with the exception that tert-butyl 1-piperazinecarboxylate was used instead of tert-butyl 2-aminoethylcarbamate (Compound 62). After Combiflash® purification, 64 mg (45%) of Example AB was obtained, m/z: 523.1 (M+H) + .
  • Example AC was prepared following the procedures for steps I-III (Scheme 20) for Example Z, with the exception that tert-butyl 4-amino-l- piperidinecarboxylate was used instead of tert-butyl 2-aminoethylcarbamate (Compound 62). After Combiflash® purification, 60 mg (44%) of Example AC was obtained, m/z: 537.1 (M+H) + .
  • Compound 65 is commercially available from Chem Impex International, and was used without further purification.
  • Compound 66 is commercially available from Chem Impex International, and was used without further purification.
  • Example AE Purification by flash column chromatography (stationary phase: silica gel; eluent: 8% iPrOH/CH ⁇ CL) gave Example AE (3.02 g). m/z: 777.2 (M+H) + .
  • Example AF Example AE (100 mg, 0.13 mmol) was dissolved in neat TFA (3 mL). The mixture was stirred at 25°C for 2 hours. The solvent was removed under reduced pressure. Purification by reverse-phase HPLC (Phenomenex Synergi® Comb-HTS column, eluent: 5-95% CH3CN/H2O gradient) gave Example AF (20 mg, 21%). m/z: 721.2 (M+H) + .
  • Example AF (70 mg y 0.10 mmol) was dissolved in dioxane (0.5 mL). DMF (83 ⁇ h), pyridine (25 ⁇ L, 0.29 mmol), di-ferf-butyldicarbonate (27 mg, 0.13 mmol), and ammonium bicarbonate (15 mg, 0.19 mmol) were added. The mixture was stirred at 25 0 C for 48 hours, then diluted with ethyl acetate and washed sequentially with water and brine. The organic phase was dried over Na-SO ⁇ filtered, and evaporated.
  • Compound 15 is commercially available from Molekula, and was used without further purification.
  • Compound 68 is commercially available from Molekula, and was used without further purification.
  • Example AH (66 mg, 0.09 mmol) was dissolved in TFA and allowed to stir at 25 0 C for 3 hours. The solvent was removed under reduced pressure and the residue was diluted with THF (3 mL) and 2N aqueous NaOH was added until pH 12. The mixture was allowed to stir for 20 min and extracted with EtOAc. The organic layer was washed sequentially with water and brine, dried over Na2SO4, filtered, and evaporated. Purification by flash chromatography (stationary phase: silica gel; eluent: 0-20% i-PrOH/CftCb gradient) gave Example AI (71 mg, 97%). m/z: 665.2 (M+H) + .
  • Compound 47 is commercially available from TCI America, and was used without further purification.
  • Compound 72 is commercially available from TCI America, and was used without further purification.
  • Example AJ (70 mg) was prepared following the same procedure used to prepare Example AH, with the exception that Compound 73 (41 mg, 0.13 mmol) was used instead of Compound 71. m/z: 707.2 (M+H) + .
  • Example AK (70 mg) was prepared following the same procedure used to prepare Example AH, with the exception that Compound 73 (41 mg, 0.13 mmol) was used instead of Compound 71. m/z: 707.2 (M+H) + .
  • Example AK (70 mg) was prepared following the same procedure used to prepare Example AH, with the exception that Compound 73 (41 mg, 0.13 mmol) was used instead of Compound 71. m/z: 707.2 (M+H) + .
  • Example AK (70 mg) was prepared following the same procedure used to prepare Example AH, with the exception that Compound 73 (41 mg, 0.13 mmol) was used instead of Compound 71. m/z: 707.2 (M+H) + .
  • Example AK (43 mg, 67%) was prepared following the same procedure used to prepare Example AI, with the exception that Example AJ (70 mg, 0.10 mmol) was used instead of Example AH. m/z: 651.2 (M+H) + .
  • Example AL (2.20 g) was prepared following the same procedure used to prepare Example AH, with the exception that Compound 75 (2.00 g, 4.88 mmol) was used instead of Compound 71. m/z: 733.2 (M+H) + .
  • Example AM
  • Example AM (1.88 g, 92%) was prepared following the same procedure used to prepare Example AI, with the exception that Example AL (2.20 g, 3.01 mmol) was used instead of Example AH. m/z: 677.2 (M+H) + .
  • Example AN (68 mg) was prepared following the same procedure used to prepare Example AH, with the exceptions that Compound 49 (68 mg, 0.19 mmol) was used instead of Compound 71, and Compound 79 (50 mg, 0.18 mmol) was used instead of Compound 8. m/z: 625.2 (M+H)- ⁇ Example AO
  • Example AO (66 mg, 76%) was prepared following the same procedure used to prepare Example AI, with the exception that Example AN (43 mg, 0.13 mmol) was used instead of Example AH. m/z: 569.2 (M+H) + .
  • Example AP (87 mg) was prepared following the same procedure used to prepare Example AH, with the exception that Compound 13e (71 mg, 0.19 mmol) was used instead of Compound 71, and Compound 79 (50 mg, 0.18 mmol) was used instead of Compound 8. m/z: 639.2 (M+H) + .
  • Compound AQ Compound AQ
  • Example AQ (61 mg, 76%) was prepared following the same procedure used to prepare Example AI, with the exception that Example AP (87 mg, 0.14 mmol) was used instead of Example AH. m/z: 583.2 (M+H) + .
  • 1 H NMR (CDCl 3 ) ⁇ 8.81 (s, IH); 7.87 (s, IH); 7.01 (s, IH); 6.87 (m, IH); 6.52 (s, IH); 5.28 (m, 2H); 4.47 (m, IH); 4.59, 4.43 (CUB, / 16 HZ, 2H); 4.45 (m, IH); 4.17 (br s, IH); 3.75 (br s, IH); 3.52 (br s, IH); 3.35 (br s, IH); 3.01 (m, 3H); 2.07 (br s, IH); 1.60-1.10 (m, 17H); 1.00- 0.70 (m, 6H).
  • Compound 80 is commercially available from Chem Impex International, and was used without further purification.
  • Compound 81 is commercially available from Chem Impex International, and was used without further purification.
  • Example AR (208 mg, 53%). m/z: 720.2 (M+H) ⁇ .
  • ⁇ NMR (CDCIs) ⁇ 8.80 (s, IH); 7.84 (s, IH); 7.40-7.00 (m, 10H); 6.97 (s, IH); 6.83 (m, IH); 6.65 (br s, IH); 5.99 (m, IH); 5.40-5.10 (m, 4H); 4.52 (m, 3H); 4.06 (m, IH); 3.79 (m, IH); 3.34 (m, IH); 2.97 (s, 3H); 2.90- 2.60 (m, 5H); 2.50-2.40 (br s, IH); 1.80-1.20 (m, 10H).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.

Description

MODULATORS OF PHARMACOKINETIC PROPERTIES OF
THERAPEUTICS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application Ser. No. 60/903,228, entitled "Modulators of Pharmacokinetic Properties of Therapeutics", filed February 23, 2007, and U.S. Provisional Application Ser. No. 60/958,716, entitled "Modulators of Pharmacokinetic Properties of Therapeutics", filed July 6, 2007. The contents of these provisional applications are herein incorporated by reference in their entirety for all purposes.
FIELD OF THE INVENTION
This application relates generally to compounds and pharmaceutical compositions which modify, e.g., improve, the pharmacokinetics of a coadministered drug, and methods of modifying, e.g., improving, the pharmacokinetics of a drug by co-administration of the compounds with the drug.
BACKGROUND OF THE INVENTION
Oxidative metabolism by cytochrome P450 enzymes is one of the primary mechanisms of drug metabolism. It can be difficult to maintain therapeutically effective blood plasma levels of drugs which are rapidly metabolized by cytochrome P450 enzymes. Accordingly, the blood plasma levels of drugs which are susceptible to cytochrome P450 enzyme degradation can be maintained or enhanced by co-administration of cytochrome P450 inhibitors, thereby improving the pharmacokinetics of the drug.
While certain drugs are known to inhibit cytochrome P450 enzymes, more and/or improved inhibitors for cytochrome P450 monooxygenase are desirable. Particularly, it would be desirable to have cytochrome P450 monooxygenase inhibitors which do not have appreciable biological activity other than cytochrome P450 inhibition. Such inhibitors can be useful for minimizing undesirable biological activity, e.g., side effects. In addition, it would be desirable to have P450 monooxygenase inhibitors that lack significant or have a reduced level of protease inhibitor activity. Such inhibitors could be useful for enhancing the effectiveness of antiretroviral drugs, while minimizing the possibility of eliciting viral resistance, especially against protease inhibitors.
SUMMARY OF THE INVENTION
One aspect of the present application is directed to compounds and pharmaceutical compositions which modify, e.g., improve, the pharmacokinetics of a co-administered drug, e.g., by inhibiting cytochrome P450 monooxygenase.
In one embodiment, the present application provides for compounds having a structure according to Formula IV,
Figure imgf000003_0001
Formula IV or a pharmaceutically acceptable salt, solvate, and/or ester thereof, wherein, each L3 is independently an alkylene or substituted alkylene; each A is independently an aryl or substituted aryl; X is heterocyclylalkyl; Y is heterocyclylalkyl or alkyl;
G1 and G2 are independently CH or N, with the proviso that G1 and G2 are different;
G3 is -NR7- or -O-; R1, R3, R5, and R7 are each independently selected from the group consisting of H, alkyl, substituted alkyl, arylatkyl, and substituted arylalkyl; R2 is independently selected from the group consisting of substituted alkyl, alkoxyalkyl, hydroxyalkyl, trialkylsiloxyalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, amino alkyl, substituted aminoalkyl, -alkylene-N(RB)-C(O)- alkyl,
Figure imgf000004_0001
-alkylene-
C(=N~Rb)-N(Ra)2, -alkylene-C(O)-OH, -alkylene-C(O)-Oalkyl, and -alkylene-
C(O)-N(R^)2; R8 and R9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, and -CN; each Ra is independently selected from the group consisting of H, alkyl, and substituted alkyl; Rb is selected from the group consisting of H, alkyl, substituted alkyl, CN, and -
S(θ2)-alkyl; and each Rc is independently selected from the group consisting of H, alkyl, substituted alkyl, heterocyclyl, substituted heterocyclyl, ~S(θ2)-alkyl, -S(O2)-aryl/ and substituted -S(θ2)-aryl.
In another embodiment, the present application provides for a pharmaceutical composition comprising a compound of Formula I, and a pharmaceutically acceptable carrier or excipient.
In another embodiment, the present application provides for a pharmaceutical composition comprising a compound of Formula I, at least one additional therapeutic agent, and a pharmaceutically acceptable carrier or exipient.
In another embodiment the present application provides for a method for improving the pharmacokinetics of a drug, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof,
In another embodiment, the present application provides for a method for inhibiting cytochrome P450 monooxygenase in a patient comprising administering to a patient in need thereof an amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, effective to inhibit cytochrome P450 monooxygenase.
In another embodiment, the present application provides for a method for treating a viral infection, e.g., HIV, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents which are metabolized by cytochrome P450 monooxygenase, and are suitable for treating a viral infection, e.g., HIV.
In another embodiment, the present application provides for a combination pharmaceutical agent comprising: a) a first pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof; and b) a second pharmaceutical composition comprising at least one additional active agent which is metabolized by cytochrome P450 monooxygenase. DETAILED DESCRIPTION
Reference will now be made in detail to certain claims of the invention, examples of which are illustrated in the accompanying structures and formulas. While the invention will be described in conjunction with the enumerated claims, it will be understood that they are not intended to limit the invention to those claims. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims.
All documents cited herein are each incorporated by reference in their entirety for all purposes.
Definitions
Unless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings:
When trade names are used herein, applicants intend to independently include the tradename product and the active pharmaceutical ingredient(s) of the tradename product.
As used herein, "a compound of the invention" or "a compound of formula (I)" means a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester or stereoisomer thereof, or a physiologically functional derivative thereof. Similarly, with respect to isolatable intermediates, the phrase "a compound of formula (number)" means a compound of that formula and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.
"ALkyl" is hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. For example, an alkyl group can have 1 to 20 carbon atoms (i.e, G- C20 alkyl), 1 to 10 carbon atoms (i.e., G-Go alkyl), or 1 to 6 carbon atoms (i.e., G-C& alkyl). Examples of suitable alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CHiCH3), 2-propyl G-Pr, i-propyl, -CH(CHa)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-l- propyl (i-Bu, i-butyl, -CHiCH(CHs)2), 2-butyl (s-Bu, s-butyl, -CH(CH3)CH2CH3), 2- methyl-2-propyl (t-Bu, t-butyl, -C(CHs)3), 1-ρentyl (n- pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (--CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CHs)2), 2-methyl-2-butyl (-C(CHs)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CHs)2), 3-methyI-l-butyl (-CHiCH2CH(CHs)2), 2-methyl-l-butyl (-CH2CH(CH3)CH2CH3), 1-heχyl (-CH2CH2CH2CH2CH2CH3), 2-heχyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2- pentyl (-C(CHs)2CH2CHiCH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CHICH3), 4- methyl-2-penty] (-CH(CH3)CH2CH(CHs)2), 3-methyl-3-pentyl (-C(CH3)(CH2CHs)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CHa)2), 2,3-dimethyl-2-butyl (-C(CHs)2CH(CHs)2), 3,3~dimethyl-2-butyl (-CH(CH3)C(CHa)3, and octyl
Figure imgf000007_0001
"Alkoxy" means a group having the formula -O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom. The alkyl portion of an alkoxy group can have 1 to 20 carbon atoms (Le., Ci-C2O alkoxy), 1 to 12 carbon atoms(z.e., Ci-Cn alkoxy), or 1 to 6 carbon atoms(z'.<?., Ci-Ce alkoxy). Examples of suitable alkoxy groups include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-OCH2CH3 or -OEt), t-butoxy (-0-C(CHs)3 or -OtBu) and the like.
"Haloalkyl" is an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halogen atom. The alkyl portion of a haloalkyl group can have 1 to 20 carbon atoms (i.e., Ci-C2O haloalkyl), 1 to 12 carbon atoms(z'.e., Ci-Ci2 haloalkyl), or 1 to 6 carbon atoms(te,, Ci-Ca alkyl). Examples of suitable haloalkyl groups include, but are not limited to, -CF3, -CHF2, -CFH2, -CH2CF3, and the like.
"Alkenyl" is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp2 double bond. For example, an alkenyl group can have 2 to 20 carbon atoms (i.e., C2-C20 alkenyl), 2 to 12 carbon atoms (i.e., C2-C12 alkenyl), or 2 to 6 carbon atoms (i.e., C2- CO alkenyl). Examples of suitable alkenyl groups include, but are not limited to, ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), cyclopentenyl (-CsH?), and 5- hexenyl (-CH2CH2CH2CH2CH=CH2).
"Alkynyl" is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond. For example, an alkynyl group can have 2 to 20 carbon atoms (i.e., C2-C2Q alkynyl), 2 to 12 carbon atoms (i.e., Ci-Cn alkyne,), or 2 to 6 carbon atoms (i.e., C2- Cb alkynyl). Examples of suitable alkynyl groups include, but are not limited to, acerylenic (-C≡CH), propargyl (-CH2C=CH), and the like.
"Alkylene" refers to a saturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. For example, an alkylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. Typical alkylene radicals include, but are not limited to, methylene (-CH2-), 1,1-ethyl (-CH(CH3)-), 1,2-ethyl (-CH2CH2-), 1,1- propyl (-CH(CH2CH3)-), 1,2-propyl (-CH2CH(CH3)-), 1,3-propyl (-CH2CH2CH2-), 1,4- butyl (-CH2CH2CH2CH2-), and the like.
" Alkenylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. For example, and alkenylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. Typical alkenylene radicals include, but are not limited to, 1,2-ethyIene (-CH=CH-).
"Alkynylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. For example, an alkynylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. Typical alkynylene radicals include, but are not limited to, acetylene (-OC-), propargyl (-CHzC=C-), and 4-pentynyI (-CH2CH2CH2C^CH-).
"Amino" means an -NH2 or a -NR2 group in which the "R" groups are independently H, alkyl, haloalkyl, hydroxylalkyl, carbocyclyl (substituted or unsubstituted, including saturated or partially unsaturated cycloalkyl and aryl groups), heterocycly] (substituted or unsubstituted, including saturated or unsaturated heterocycloalkyl and heteroaryl groups), arylalkyl (substituted or unsubstituted) or arylalkyl (substituted or unsubstituted) groups. Non-limiting examples of amino groups include -NH2, -NH(alkyl), NH(haloalkyl), -NH(carbocyclyl), -NH(heterocyclyl), -
N(alkyl)2, -N(carbocydyl)2, -N (heterocycly I)2, -N(alkyl)(carbocyclyl), -N(alkyl)(hetero cyclyl), -N(carbocyclyl)(heterocyclyl), etc., wherein alkyl, carbocyclyl, and heterocyclyl can be substituted or unsubstituted and as defined and described herein. "Substituted" or "protected" amino means an aminoalkyl as described and defined herein in which a H of the amino group is replaced with e.g., acyl groups, for example conventional amine protecting groups such as 9-Fluorenylmethyl carbamate ("Fmoc"), f-Butyl carbamate ("Boc"), Benzyl carbamate ("Cbz"), acetyl, trifluoracetyl, -C(O)-amino, phthalimidyl, triphenylmethyl, p-ToIuenesulfonyl ("Tosyl"), methylsulfonyl ("mesyl"), etc. "Aminoalkyl" means an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an amino radical as defined and described herein. Non-limiting examples of aminoalkyl include -CH2-NH2, -CH2CH2-NH2, -CH2CH2CH2- NH2, -CH2CH2CH2CH2-NH2, -CH2CH(CHs)-NHi, -CH2CH2CH(CHa)-NH2, -CH2- NH(CH3), -CH2CH2-NH(CH3), -CH2CH2CH2-NH(CH3), -CH2CH2CH2CH2- NH(CH3), -CH2CH(CHs)-NH(CH3), -CH2CH2CH(CHS)-NH(CH3), -CH2- N(CHs)2, -CH2CH2-N(CHs)2, -CH2CH2CHa-N(CHs)3, -CH3CH2CH2CH2- N(CHs)2, -CH2CH(CHs)-N(CHs)2, -CH2CH2CH(CHs)-N(CHa)2, -CH2- NH(CH2CHs), -CH2CH2-NH(CH2CH3), -CH2CH2CH2-
NH(CH2CH3), -CH2CH2CH2CH2-NH(CH2CHS), -CH2CH(CHS)-NH(CH2CHS), -CH2C H2CH(CHS)-NH(CHICH3), -CH2-N(CH2CHS)2, -CH2CH2-N(CH2CHS)2, -CH2CH2CH2- N(CH2CHs)2, -CH2CH2CH2CH2-N(CH2CHS)2, -CH2CH(CHS)-N(CH2CHS)2, -CH2CH2C H(CHs)-N(CH2CHs)2, etc. "Substituted" or "protected" aminoalkyl means an aminoalkyl as described and defined herein in which the H of the amino group is replaced with e.g., acyl groups, for example conventional amine protecting groups such as 9-Fluorenylmethyl carbamate ("Fmoc"), t-Butyl carbamate ("Boc"), Benzyl carbamate ("Cbz"), acetyl, -C(O)-amino, trif Iu or acetyl, phthalimidyl, triphenylmethyl, p-Toluenesulfonyl ("Tosyl"), methylsulfonyl ("mesyl")/ etc.
" Aryl" means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. For example, an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms. Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like.
"Arylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l-yl, naphthylmethyl, 2-naphthylethan-l-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like. The arylalkyl group can comprise 6 to 20 carbon atoms, e.g., the alkyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
"Arylalkenyl" refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, but also an sp2 carbon atom, is replaced with an aryl radical. The aryl portion of the arylalkenyl can include, for example, any of the aryl groups disclosed herein, and the alkenyl portion of the arylalkenyl can include, for example, any of the alkenyl groups disclosed herein. The arylalkenyl group can comprise 6 to 20 carbon atoms, e.g., the alkenyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
" Arylalkynyl" refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, but also an sp carbon atom, is replaced with an aryl radical. The aryl portion of the arylalkynyl can include, for example, any of the aryl groups disclosed herein, and the alkynyl portion of the arylalkynyl can include, for example, any of the alkynyl groups disclosed herein. The arylalkynyl group can comprise 6 to 20 carbon atoms, e.g., the alkynyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
The term "substituted" in reference to alkyl, alkylene, aryl, arylalkyl, heterocyclyl, heteroaryl, carbocyclyl, etc. , for example, "substituted alkyl", "substituted alkylene", "substituted aryl", "substituted arylalkyl", "substituted heterocyclyl", and "substituted carbocyclyl" means alkyl, alkylene, aryl, arylalkyl, heterocyclyl, carbocyclyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent. Typical substituents include, but are not limited to, -X, -R, -O, O, -OR, -SR, -S*
, -NR2, -N+R3, -NR7 -CXs, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, -NO2, =N2, -N3, -
NHC(=O)R, -NHS(O)2R, -C(O)R, -C(O)NRR -S(O)2O", -S(O)2OH, -S(O)2R, -
OS(O)2OR, -S(O)2NR, -S(O)R, -OP(O)(OR)2, -P(O)(OR)2, -P(O)(O
K -P(O)(OH)2, -P(O)(OR)(O
), -C(O)R, -C(O)OR, -C(O)X, -C(S)R, -C(O)OR, -C(O)O
, -C(S)OR, -C(O)SR, -C(S)SR, -C(O)NRR, -C(S)NRR, -Q=NR)NRR, where each X is independently a halogen: F, Cl, Br, or I; and each R is independently H, alkyl, aryl, arylalkyl, a heterocycle, or a protecting group or prodrug moiety. Alkylene, alkenylene, and alkynylene groups may also be similarly substituted. When the number of carbon atoms is designated for a substituted group, the number of carbon atoms refers to the group, not the substituent (unless otherwise indicated). For example, a CM substituted alkyl refers to a CM alkyl, which can be substituted with groups having more the, e.g., 4 carbon atoms.
The term "prodrug" as used herein refers to any compound that when administered to a biological system generates the drug substance, i.e., active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s). A prodrug is thus a covalently modified analog or latent form of a therapeutically active compound.
One skilled in the art will recognize that substituents and other moieties of the compounds of Formula I should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition. Compounds of Formula I which have such stability are contemplated as falling within the scope of the present invention. Ηeteroalkyl" refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S. For example, if the carbon atom of the alkyl group which is attached to the parent molecule is replaced with a heteroatom (e.g., O, N, or S) the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH3, etc.), an amine (e.g., -NHCH3, -N(CIHb)2, etc.), or a thioalkyl group (e.g., -SCH3). If a non-terminal carbon atom of the alkyl group which is not attached to the parent molecule is replaced with a heteroatom (e.g., O, N, or S) the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g., -CHbCH2-O-CH3, etc.), an alkyl amine (e.g., -CH2NHCH3, -CH2N(CHs)2, etc.), or a thioalkyl ether (e.g.,-CH2-S-CH3). If a terminal carbon atom of the alkyl group is replaced with a heteroatom (e.g., O, N, or S), the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g., -CH2CH2-OH), an aminoalkyl group (e.g., -CH2NH2), or an alkyl thiol group (e.g., -CH2CH2-SH). A heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. A Ci -CO heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
"Heterocycle" or "heterocyclyl" as used herein includes by way of example and not limitation those heterocycles described in Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and /. Am. Ckem. Soc. (1960) 82:5566. In one specific embodiment of the invention "heterocycle" includes a "carbocycle" as defined herein, wherein one or more (e.g. I1 2, 3, or 4) carbon atoms have been replaced with a heteroatom {e.g. O, N, or S). The terms "heterocycle" or "heterocyclyl" includes saturated rings (i.e., heterocycloalkyls), partially unsaturated rings, and aromatic rings [i.e., heteroaromatic rings). Substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups. A non-limiting example of a carbonyl substituted heterocyclyl is:
Figure imgf000014_0001
Examples of heterocycles include by way of example and not limitation pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piρeridonyl, pyrrolidinyl, 2-pyτroIidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl, όH-1,2,5- thiadiazinyl, 2H/6H-l,5/2-dithiazinyl/ thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazϊnyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, IH- indazoly, purinyl, 4H-quinolizinyl/ phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, dnnolinyl, pteridinyl, 4aH-carbazolyi carbazolyl, β-carbolinyl, phenanthridinyl, acridinyi pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, isatinoyl, and bis-tetrahydrofuranyl:
Figure imgf000014_0002
By way of example and not limitation, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a fur an, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-ρyridyl, 3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, A- pyrimidinyl, 5-pyτimidinyI, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazoIyl, 4-thiazolyl, or 5-thiazolyl.
By way of example and not limitation, nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3- pyrroline, imidazole, imidazolidme, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, IH-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β-carboline. Still more typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1 -piper id inyl.
"Heterocyclylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heterocyclyl radical {i.e., a heterocyclyl-alkylene- moiety). Typical heterocyclyl alkyl groups include, but are not limited to heterocyclyl- CHa-, he terocy CIyI-CH(CHs)-, heterocyclyl-CHkCHa-, 2-(heterocyclyl)ethan-l-yl, and the like, wherein the "heterocyclyl" portion includes any of the heterocyclyl groups described above, including those described in Principles of Modern Heterocyclic Chemistry. One skilled in the art will also understand that the heterocyclyl group can be attached to the alkyl portion of the heterocyclyl alkyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable. The heterocyclylalkyl group comprises 2 to 20 carbon atoms, e.g., the alkyl portion of the heterocyclylalkyl group is 1 to 6 carbon atoms and the heterocyclyl moiety is 1 to 14 carbon atoms. Examples of heterocyclylalkyls include by way of example and not limitation 5- membered sulfur oxygen, and/or nitrogen containing heterocycles such as thiazolylmethyl, 2-thiazoIylethan-l-yL imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc., 6-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl, pyridizylmethyl, pyrimidylmethyl, pyrazinylmethyl, etc.
"Heterocyclyl alkenyl" refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, but also a sp2 carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkenylene- moiety). The heterocyclyl portion of the heterocyclyl alkenyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry, and the alkenyl portion of the heterocyclyl alkenyl group includes any of the alkenyl groups disclosed herein. One skilled in the art will also understand that the heterocyclyl group can be attached to the alkenyl portion of the heterocyclyl alkenyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable. The heterocyclylalkenyl group comprises 3 to 20 carbon atoms, e.g., the alkenyl portion of the heterocyclyl alkenyl group is 2 to 6 carbon atoms and the heterocyclyl moiety is 1 to 14 carbon atoms.
"Heterocyclylalkynyl" refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, but also an sp carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkynylene- moiety). The heterocyclyl portion of the heterocyclyl alkynyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry, and the alkynyl portion of the heterocyclyl alkynyl group includes any of the alkynyl groups disclosed herein. One skilled in the art will also understand that the heterocyclyl group can be attached to the alkynyl portion of the heterocyclyl alkynyl by means of a carbon-carbon bond or a carbon-heteroatom bond/ with the proviso that the resulting group is chemically stable. The heterocyclylalkynyl group comprises 3 to 20 carbon atoms, e.g., the alkynyl portion of the heterocyclylalkynyl group is 2 to 6 carbon atoms and the heterocyclyl moiety is 1 to 14 carbon atoms.
"Heteroaryl" refers to an aromatic heterocyclyl having at least one heteroatom in the ring. Non-limiting examples of suitable heteroatoms which can be included in the aromatic ring include oxygen, sulfur, and nitrogen. Non- limiting examples of heteroaryl rings include all of those listed in the definition of "heterocyclyl", including pyridinyl, pyrrolyl, oxazolyl indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc.
"Carbocycle" or "carbocyclyl" refers to a saturated (i.e., cycloalkyl), partially unsaturated (e.g., cycloakenyl, cycloalkadienyL etc.) or aromatic ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle. Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system, or spiro-fused rings. Non- limiting examples of monocyclic carbocycles include cyclop ropy 1, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, l-cycIopent-2-enyl, l-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cycloheχ-2-enyl, l-cycloheχ-3-enyl, and phenyl. Non-limiting examples of bϊcyclo carbocycles includes naphthyl.
"Arylheteroalkyl" refers to a heteroalkyl as defined herein, in which a hydrogen atom (which may be attached either to a carbon atom or a heteroatom) has been replaced with an aryl group as defined herein. The aryl groups may be bonded to a carbon atom of the heteroalkyl group, or to a heteroatom of the heteroalkyl group, provided that the resulting arylheteroalkyl group provides a chemically stable moiety. For example, an arylheteroalkyl group can have the general formulae -alkylene-
O-aryl, -alkylene-O-alkylene-aryl, -alkylene-NH-aryl, -alkylene-NH-alkylene-aryl, -alkylene-S-aryl, -alkylene-S-alkylene-aryl, etc. In addition, any of the alkylene moieties in the general formulae above can be further substituted with any of the substituents defined or exemplified herein.
"Heteroarylalkyl" refers to an alkyl group, as defined herein, in which a hydrogen atom has been replaced with a heteroaryl group as defined herein. Non-limiting examples of heteroaryl alkyl include -CFL-pyridinyl, -CKb-pyrrolyl, -CH'-oxazolyl, -CH2-indolyl, -CH2-isoindol yl, -CH2-purinyl, -CHz-furanyl, -Cϋ-thienyl, -CFb-benzofuranyl, -CHb-benzothio phenyl, -CHa-carb azolyl, -CHz-imidazolyl, -Cϋ-thiazolyl, -CHz-isox azolyl, -CH2-p yrazolyl, -CH∑-isothiazolyl, -CJHb-quinolyl, -CH2-isoquinolyl, -CH2-pyridazyl, -CH 2-pyrimidyl, -CHi-pyrazyl, -CH(CHs) -pyridinyl, -CH(CH3)-pyrrolyl, -CH(CH3)-ox azolyl, -CH(CH3)-indolyl, -CH(CH3)-isoindolyl, -CH(CH3)-purinyI, -CH(CH3)-fura nyl, -CH(CH3)-thienyl, -CH(CH3)-benzofuranyl/ -CH(CH3)-benzothiophenyl, -CH( CH3)-carbazolyl, -CH(CH3) -imid azolyl, -CH(CH3)-thiazolyl, -CH(CH3)-isoxazolyl, -CH(CH3)-pyrazolyl, -CH(CH3)-isothiazolyl, -CH(CH3)-quinolyl, -CH(CH3)-isoqui nolyl, -CH(CH3)-pyridazyl, -CH(CH3) -pyrimidyl, -CH(CH3) -pyrazyl, etc. The term "optionally substituted" in reference to a particular moiety of the compound of Formula I (e.gv an optionally substituted aryl group) refers to a moiety having 0, 1, 1, or more substituents.
"Ac" means acetyl (-C(O)CH3).
"AC2O" means acetic anhydride.
"DCM" means dichloromethane (CH2CI2).
"DIBAL" means diisobutylaluminum hydride.
"DMAP" means dimethylaminopyridine.
"EDC" means l-(3-Dimethylaminopropyl)-3-ethy]carbodiimide.
"Et" means ethyl.
"EtOAc" means ethylacetate.
"HOBt" means N-hydroxybenzotriazole.
"Me" means methyl (-CH3).
"MeOH" means methanol.
"MeCN" means acetonitrile.
"Pr" means propyl.
"i-Pr" means isopropyl (-CH(CHs)2).
"i-PrOH" means isopropanol.
"rt" means room temperature.
"TFA" means trifluoroacetic acid.
"THF" means tetrahydrofuran.
The term "crural" refers to molecules which have the property of non- superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.
The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. "Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may- separate under high resolution analytical procedures such as electrophoresis and chromatography .
"Enantiomers" refer to two stereoisomers of a compound which are non- superimposable mirror images of one another.
Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S-, Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (- ) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
Protecting Groups In the context of the present invention, protecting groups include prodrug moieties and chemical protecting groups.
Protecting groups are available, commonly known and used, and are optionally used to prevent side reactions with the protected group during synthetic procedures, i.e. routes or methods to prepare the compounds of the invention. For the most part the decision as to which groups to protect, when to do so, and the nature of the chemical protecting group "PG" will be dependent upon the chemistry of the reaction to be protected against (e.g., acidic, basic, oxidative, reductive or other conditions) and the intended direction of the synthesis. The PG groups do not need to be, and generally are not, the same if the compound is substituted with multiple PG. In general, PG will be used to protect functional groups such as carboxyl, hydroxyl, thio, or amino groups and to thus prevent side reactions or to otherwise facilitate the synthetic efficiency. The order of deprotection to yield free, deprotected groups is dependent upon the intended direction of the synthesis and the reaction conditions to be encountered, and may occur in any order as determined by the artisan.
Various functional groups of the compounds of the invention may be protected. For example, protecting groups for -OH groups (whether hydroxyl, carboxylic acid, phosphonic acid, or other functions) include "ether- or ester- forming groups". Ether- or ester-forming groups are capable of functioning as chemical protecting groups in the synthetic schemes set forth herein. However, some hydroxyl and thio protecting groups are neither ether- nor ester-forming groups, as will be understood by those skilled in the art, and are included with amides, discussed below.
A very large number of hydroxyl protecting groups and amide-forming groups and corresponding chemical cleavage reactions are described in Protective Groups in Organic Synthesis, Theodora W. Greene and Peter G. M. Wuts (John Wiley & Sons, Inc., New York, 1999, ISBN 0-471-16019-9) ("Greene"). See also Kocienski, Philip J.; Protecting Groups (Georg Thieme Verlag Stuttgart, New York, 1994), which is incorporated by reference in its entirety herein. In particular Chapter 1, Protecting Groups: An Overview, pages 1-20, Chapter 2, Hydroxyl Protecting Groups, pages 21-94, Chapter 3, Diol Protecting Groups, pages 95-117, Chapter 4, Carboxyl Protecting Groups, pages 118-154, Chapter 5, Carbonyl Protecting Groups, pages 155-184. For protecting groups for carboxylic acid, phosphonic acid, phosphonate, sulfonic acid and other protecting groups for acids see Greene as set forth below. Such groups include by way of example and not limitation, esters, amides, hydrazides, and the like.
Ether- and Ester-forming protecting groups
Ester-forming groups include: (1) phosphonate ester-forming groups, such as phosphonamidate esters, phosphorothioate esters, phosphonate esters, and phosphon-bis-amidates; (2) carboxyl ester-forming groups, and (3) sulphur ester- forming groups, such as sulphonate, sulfate, and sulfinate.
Metabolites of the Compounds of the Invention
Also falling within the scope of this invention are the in vivo metabolic products of the compounds described herein. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof. Such products typically are identified by preparing a radiolabeled (e.g., C14 or H3) compound of the invention, administering it parenterally in a detectable dose (e.g., greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples. These products are easily isolated since they are labeled (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis. In general, analysis of metabolites is done in the same way as conventional drug metabolism studies well-known to those skilled in the art. The conversion products, so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds of the invention even if they possess no anti-infective activity of their own.
Compounds of Formula I
In one embodiment, the present application provides compounds according to Formula I,
Figure imgf000023_0001
Formula I or a pharmaceutically acceptable salt, solvate, and/or ester thereof, wherein, L1 is selected from the group consisting of -C(R6)2-, -C(O)-, -S(O2)-, -N(R7)-C(O)-, and -OC(O)-;
L2 is a covalent bond, -C(R6)2- or -C(O)-; each L3 is independently a covalent bond, an alkylene, or substituted alkylene; each L4 is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O-, and -NH-; each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, and substituted heterocyclyl, with the proviso that when A is H, p is 0; Z1 and Z2 are each independently -O- or -N(R7)-; Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl; each Ar is independently selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; R1, R3, and R5 are each independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyl, and substituted arylalkyl; each R2 is independently selected from the group consisting of H, alkyl, substituted alkyl, alkoxyalkyl, hydroxyalkyl, arylheteroalkyl, substituted arylheteroalkyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl, substituted aminoalkyl, -alkylene-C{O)-OH, - alkylene-C(O)-Oalkyl, -alkylene-QOJamino, -alkylene-C(O)-alkyl; R4 and R6 are independently selected from the group consisting of H, alkyl, substituted alkyl, and heteroalkyl; each R7 is independently selected from the group consisting of H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, and substituted heterocyclyl; R8 and R9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, and -CN; m is 1 or 2; n is 0 or 1; and each p is independently 0 or 1.
In another embodiment of the compounds of Formula I, n is 1.
In another embodiment of the compounds of Formula I, n is 0.
In another embodiment of the compounds of Formula I, n is 1 and L2 is - CH(R6)-, wherein R6 is selected from the group consisting of H, alkyl substituted alkyl, and heteroalkyl.
In another embodiment of the compounds of Formula I, n is 1 and L2 is - CH2-.
In another embodiment of the compounds of Formula I, n is 1 and L2 is - C(O)-.
In another embodiment of the compounds of Formula I, n is 1 and Y is heterocyclylalkyl.
In another embodiment of the compounds of Formula I, n is 1 and Y-R8 is - CH2-(substituted heteroaryl).
In another embodiment of the compounds of Formula I, n is 1 and Y-R8 is
Figure imgf000025_0001
In another embodiment of the compounds of Formula L n is 1 and Y-R8 is
Figure imgf000025_0002
wherein R8 is alkyl, for example 2-propyl.
In another embodiment of the compounds of Formula I, n is 1 and X is heterocyclylalkyl .
In another embodiment of the compounds of Formula I7 n is 1 and X is - CH2-heteroaryl. In another embodiment of the compounds of Formula I, n is 1 and X-R9 is
Figure imgf000026_0001
In another embodiment of the compounds of Formula I, n is 1 and X-R9 is
Figure imgf000026_0002
In another embodiment of the compounds of Formula I, n is 1 and ZMs - N(R7)-.
In another embodiment of the compounds of Formula I, n is 1 and Z1 is - N(alkyl)- or -Ntcarbocyclyl)-.
In another embodiment of the compounds of Formula I, n is 1 and 2) is - N(CHs)- or -N(cyclopropyl)-.
In another embodiment of the compounds of Formula I, n is 1 and Z1 is - NH-.
In another embodiment of the compounds of Formula I, n is 1 and each A is independently aryl or substituted aryl.
In another embodiment of the compounds of Formula I, n is 1 and each A is phenyl.
In another embodiment of the compounds of Formula I, n is 1 and each A is phenyl and each p is 0.
In another embodiment of the compounds of Formula I, n is 1 and R2 is H, alkyl, substituted alkyl, or heteroalkyl.
In another embodiment of the compounds of Formula I7 n is 1 and R2 is 2~ propyl, methyl, -CHi-O-benzyl, -CH(CH3) (O-t-Bu) , or -CH(CH3)(OH).
In another embodiment of the compounds of Formula I, L1 is -C(O)-; each A is independently aryl, substituted aryl, alkyl, or substituted alkyl;
R1 is H or alkyl; each R2 is independently H, alky L substituted alkyl, or heteroalkyl;
R3, R4, R5, and R6 are each H; each R7 is independently H, alkyl, or carbocyclyl;
Ra is H or alkyl;
R9 is H;
X and Y are both heterocydylalkyl;
Z2 is -O-; and p is O.
In another embodiment of the compounds of Formula I, each A is phenyl;
R1 is H or -CH3; each R2 is H, methyl, ethyl, 2-propyL -CH2-O-benzyI, -CH(CHs)-OH, or -CH(CH3)(CM-Bu); each R7 is H, methyl or cyclopropyl; R8 is H or 2-propyl; X is
Figure imgf000027_0001
Y is
Figure imgf000027_0002
In another embodiment, the compounds of Formula I have the following general Formula IA:
Figure imgf000028_0001
Formula IA.
In another embodiment of the compounds of Formula IA, Z1 is -N(R7)-. In a particular embodiment, R7 is H. In another particular embodiment, R7 is alkyl, for example any of the alkyl groups disclosed herein. In another particular embodiment, R7 is heteroalkyl, for example any of the heteroalkyl groups disclosed herein. In another particular embodiment, R7 is substituted or unsubstituted carbocyclyl, wherein for example, said carbocyclyl is any of the carbocyclyl groups disclosed herein. In another particular embodiment, R7 is substituted or unsubstituted heterocyclyl, wherein for example, said heterocyclyl is any of the heterocyclyl groups disclosed herein.
In another embodiment of the compounds of Formula IA, Z1 is -O-.
In another embodiment of the compounds of Formula IA, L2 is -C(R6)2-, wherein each Rή is H.
In another embodiment of the compounds of Formula IA, L2 is -C(R6)2-, wherein each R6 is independently H or alkyl, and said alkyl includes any alkyl disclosed herein.
In another embodiment of the compounds of Formula IA, L2 is -C(R5)2-, wherein one R6 is H and the other R6 is alkyl, wherein said alkyl includes any alkyl disclosed herein.
In another embodiment of the compounds of Formula IA, m is 1 and R2 is H. In another embodiment of the compounds of Formula IA, m is 1 and R2 is alkyl, wherein said alkyl includes any alkyl disclosed herein.
In another embodiment of the compounds of Formula IA, m is 1 and R2 is i- propyl.
In another embodiment of the compounds of Formula IA, m is 1 and R2 is i- butyl.
In another embodiment of the compounds of Formula IA, m is 1 and R2 is ethyl.
In another embodiment of the compounds of Formula IA, m is 1 and R2 is methyl.
In another embodiment of the compounds of Formula IA, m is 2 and each R2 is independently selected from H and alkyl.
In another embodiment of the compounds of Formula IA, m is 2 and each R2 is H.
In another embodiment, the compounds of Formula I have the following general Formula IB:
Figure imgf000029_0001
Formula IB.
In another embodiment of the compounds of Formula IB, Z1 is -N(R7)-. In a particular embodiment, R7 is H. In another particular embodiment, R7 is alkyl, for example any of the alkyl groups disclosed herein. In another particular embodiment, R7 is heteroalkyl, for example any of the heteroalkyl groups disclosed herein. In another particular embodiment, R7 is substituted or unsubsti tuted carbocyclyl, wherein for example, said carbocyclyl is any of the carbocyclyl groups disclosed herein. In another particular embodiment, R7 is substituted or unsubsti tuted heterocyclyl, wherein for example, said heterocyclyl is any of the heterocyclyl groups disclosed herein.
In another embodiment of the compounds of Formula IB, Z) is -O-.
In another embodiment of the compounds of Formula IB, L2 is -C(Rή)2-, wherein each R6 is H.
In another embodiment of the compounds of Formula IB, L2 is -C(R6)2-, wherein each R6 is independently H or alkyl, and said alkyl includes any alkyl disclosed herein.
In another embodiment of the compounds of Formula IB, L2 is -C(R6)z-, wherein one R6 is H and the other R6 is alkyl, wherein said alkyl includes any alkyl disclosed herein.
In another embodiment of the compounds of Formula IB, Rs and R9 are both H.
In another embodiment of the compounds of Formula IB, R8 and R9 are independently selected from H and alkyl, wherein said alkyl includes any alkyl disclosed herein.
In another embodiment, the compounds of Formula I have one of the following structures:
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001

Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
40
Figure imgf000042_0001
Figure imgf000043_0001
including stereoisomers or mixtures of stereoisomers thereof. One skilled in the art will recognize that stereoisomers or mixtures of stereoisomers of the compounds of the present application include enantiomers, diastereomers, and other stereoisomers. For example, for:
Figure imgf000043_0002
contemplated stereoisomers include at least:
Figure imgf000043_0003
as well as mixtures of two or more of these stereoisomers. In still another embodiment of the compounds of Formula I, L1 is -C(R6)2-, - C(O)-, -S(O2)-, -N(IT)-C(O)-, or -O-C(O)-. When L1 is -C(R6^-, each R6 is independently selected from the group consisting of H, alkyl, substituted alkyl, and heteroalkyl, wherein alkyl, substituted alkyl, and heteroalkyl are as defined and exemplified herein. Non-limiting examples of -C(R6)2- include - CH2-, -CH(alkyl)-, -CH(substituted alkyl)-, -CH(heteroalkyl)-, -C(alkyl)a-, -C(substituted alkyl)2-, -Qheteroalkyl).-, -C(alkyl)(substituted alkyl)-, -C (heteroalkyl) (substituted alkyl)-, and -C(alkyl) (heteroalkyl)-, wherein alkyl, substituted alkyl, and heteroalkyl are as defined and exemplified herein. When L1 is -N(R7)-C(O)-, R7 is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl are as defined and exemplified herein.
In still another embodiment of the compounds of Formula I, L2 is -C(R6J2- or -C(O)-. When L2 is -C(R6Ji-, each R6 is independently selected from H, alkyl, substituted alkyl or heteroalkyl, where each alkyl, substituted alkyl, or heteroalkyl can include any of the alkyl, substituted alkyl, or heteroalkyl groups defined or disclosed herein. Non-limiting examples of -C(R6)2- include - CH2-, -CH(CH3)-, -01(-CH2CH3)-, -CHt-CH2CH2CH3)-, -CH(-CH(CH3)2)-, -CH(- CH2CH2CH2CH3)-, -CH(^CH2CH(CHs)2)-, -CH(-CH(CH3)CH2CH3)-, -CH(- C(CHs)3)-, -C(CHs)2-, -CH(OCHs)-, -CH(CH2OH)-, -CH(CH2CH2OH)-, etc.
In still another embodiment of the compounds of Formula I, each L3 is independently a covalent bond, an alkylene or substituted alkylene. When any L3 is an alkylene, non-limiting examples of alkylene includes any of the alkylene s defined or disclosed herein. When any L3 is a substituted alkylene, non-limiting examples of substituted alkylene includes any of the substituted alkylenes defined or disclosed herein. For example, substituted alkylenes include alkylenes substituted with one or more -OH group, alkylenes substituted with one or more ether group, e.g., a -O-Bn group, alkylenes substituted with one or more halogen, or alkylenes substituted with combinations of two or more substituents (e.g., -OH and halogen, halogen and ether, etc.).
In still another embodiment of the compounds of Formula I, each L3 is the same, i.e., each L3 is the same alkylene or substituted alkylene group.
In still another embodiment of the compounds of Formula I, each L3 is different, i.e., one L3 is an alkylene and the other L3 is a substituted alkylene, one L3 is an alkylene and the other L3 is a different alkylene, or one L3 is a substituted alkylene, and the other L3 is a different substituted alkylene.
In still another embodiment of the compounds of Formula I, each L4 is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O-, and -NH-. When L4 is alkylene, said alkylene includes any alkylene defined or exemplified herein. When L4 is substituted alkylene, said substituent includes any alkylene defined or exemplified herein, substituted by one or more substituents as defined herein.
In still another embodiment of the compounds of Formula I, both L4 groups are the same, i.e. both L4 groups are a covalent bond, both are -O-, both are -CH2-O-, (wherein the CH2 group is attached to either the "A" moiety or the "Ar" moiety of Formula I), both are a substituted or unsubstiruted alkylene, or both are -NH-.
In still another embodiment of the compounds of Formula I, each L4 is different. For example, one L4 is a covalent bond and the other L4 is -O-, one L4 is a covalent bond and the other L4 is -CH2-O- (wherein the CH2 group is attached to either the "A" moiety or the "Ar" moiety of Formula I), one L4 is a covalent bond and the other L4 is -NH-, one L4 is a -O- and the other L4 is -CH2-O- (wherein the CU2 group is attached to either the "A" moiety or the "Ar" moiety of Formula I), one L4 is -O- and the other L4 is -NH-, one L4 is -CH2-O- (wherein the CH2 group is attached to either the "A" moiety or the "Ar" moiety of Formula I) and the other L4 is -NH-, one L4 is a covalent bond and the other L4 is a substituted or unsubstituted alkylene, one L4 is a substituted alkylene and the other L4 is a unsubstituted alkylene, one L4 is a substituted or unsubstituted alkene and the other U is -O-, one L4 is a substituted or unsubstituted alkylene and the other L4 is -CH2-O- (wherein the CH2 group is attached to either the "A" moiety or the "Ar" moiety of Formula I), or one L4 is substituted or unsubstituted alkylene and the other U is -NH-,
In still another embodiment of the compounds of Formula I, each A is independently H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, or substituted heterocyclyl, with the proviso that when A is H, p is 0. When any A is alkyl, said alkyl includes any alkyl defined or exemplified herein. When any A is substituted alkyl, said alkyl includes any alkyl defined or exemplified herein substituted with one or more of any substituent defined or exemplified herein. When any A is aryl, said aryl includes any aryl defined or exemplified herein. When any A is substituted aryl, said aryl includes any aryl defined or exemplified herein substituted with one or more of any substituent defined or exemplified herein. When any A is heterocyclyl, said heterocyclyl includes any heterocyclyl defined or exemplified herein. When any A is substituted heterocyclyl, said heterocyclyl is any heterocyclyl defined or exemplified herein substituted with one or more of any substituent defined or exemplified herein.
In still another embodiment of the compounds of Formula I, each A is H and each p is 0.
In still another embodiment of the compounds of Formula I, each A is substituted or unsubstituted alkyl, wherein alkyl is any alkyl defined or exemplified herein, and, when present, the substituents on said alkyl include one or more of any substituents defined or exemplified herein.
In still another embodiment of the compounds of Formula I, each A is substituted or unsubstituted aryl, wherein aryl is any aryl defined or exemplified herein, and, when present, the substituents on said aryl include one or more of any substituents defined or exemplified herein. In a particular embodiment, A is phenyl.
In still another embodiment of the compounds of Formula I, each A is substituted or unsubstituted heterocyclyl, wherein heterocyclyl is any heterocyclyl defined or exemplified herein, and, when present, the substituents on said heterocyclyl include one or more of any substituents defined or exemplified herein.
In still another embodiment of the compounds of Formula I, one A is H and the other A is substituted or unsubstituted alkyl, wherein alkyl is any alkyl defined or exemplified herein, and, when present the substituent on said alkyl includes one or more of any substituent defined or exemplified herein.
In still another embodiment of the compounds of Formula I, one A is H and the other A is substituted or unsubstituted aryl, wherein aryl is any aryl defined or exemplified herein, and the substituents on said aryl are any substituents defined and exemplified herein. In a particular embodiment, one A is phenyl.
In still another embodiment of the compounds of Formula I, one A is H and the other A is substituted or unsubstituted heterocyclyl, wherein heterocyclyl is any heterocyclyl defined or exemplified herein, and, when present, the substituents on said heterocyclyl include one or more of any substituent defined or exemplified herein. In still another embodiment of the compounds of Formula I, one A is substituted or unsubstituted alkyl, and the other A is substituted or unsubstituted aryl, wherein alkyl and aryl are any alkyl or aryl defined or exemplified herein, and, when present the substituents on said alkyl or aryl include one or more of any substituents defined or exemplified herein.
In still another embodiment of the compounds of Formula I, one A is substituted or unsubstituted alkyl, and the other A is substituted or unsubstituted heterocyclyl, wherein alkyl and heterocyclyl are any alkyl or heterocyclyl defined or exemplified herein, and, when present, the substituents on said alkyl or heterocyclyl include one or more of any substituents defined or exemplified herein.
In still another embodiment of the compounds of Formula I, one A is substituted or unsubstituted aryl, and the other A is substituted or unsubstituted heterocyclyl, wherein aryl and heterocyclyl are any aryl or heterocyclyl defined or exemplified herein, and, when present, the substituents on said aryl or heterocyclyl include one or more of any substituents defined or exemplified herein.
In still another embodiment of the compounds of Formula I, Z1 is -O- or - N(R7)-. When Z1 is -N(R7)-, R7 is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl are any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl defined or exemplified herein.
In still another embodiment of the compounds of Formula I7 Z2 is -O- or - N(R7)-. When Z2 is -N(R7)-, R7 is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein alkyl, substituted alky I, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl are any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl defined or exemplified herein.
In still another embodiment of the compounds of Formula I, Z1 and Z2 are the same, e.g., Z1 and Z2 are both -O-, or Z1 and Z2 are both -N(R7)-, where R7 is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl are any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl defined or exemplified herein.
In still another embodiment of the compounds of Formula I, Z1 and Z2 are different, e.g. Z1 is -O- and Z2 is -N(R7)-, Z1 is -N(R7)- and Z2 is -O-, or Z1 and Z2 are both -N(R7)- but in Z1 the R7 is different from the R7 in Z2. When either Z1 of Z2 is -N(R7)-, R7 is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl are any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl defined or exemplified herein.
In still another embodiment of the compounds of Formula I, Y is heterocyclyl or heterocyclylalkyl, wherein heterocyclyl and heterocyclylalkyl are any heterocyclyl or heterocyclylalkyl defined or exemplified herein. In a particular embodiment, Y is heterocyclylalkyl, e.g. thiazolylmethyl (-CH2-thiazolyl). In still another embodiment of the compounds of Formula I, X is heterocyclyl or heterocyclylalkyl, wherein heterocyclyl and heterocyclylalkyl are any heterocyclyl or heterocyclylalkyl defined or exemplified herein. In a particular embodiment, X is heterocyclylalkyl, e.g. thiazolylmethyl.
In still another embodiment of the compounds of Formula I, X and Y are different e.g., X and Y are different heterocyclyls, X and Y are different heterocyclyl alky Is, X is heterocyclyl and Y is heterocyclylalkyl or X is heterocyclylalkyl and Y is heterocyclyl, wherein heterocyclyl and heterocyclylalkyl are any heterocyclyl or heterocyclylalkyl defined or exemplified herein.
In still another embodiment of the compounds of Formula I, X and Y are the same. In a particular embodiment both X and Y are heterocyclylalkyls, e.g. thiazolylmethyl.
In still another embodiment of the compounds of Formula I, each Ar is aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the aryl or heteroaryl are any aryl or heteroaryl defined or exemplified herein, and, when present, the substituents on the aryl or heteroaryl include one or more of any substituents defined or exemplified herein.
In still another embodiment of the compounds of Formula I, each Ar is the same, e.g., each Ar is an aryl such as phenyl.
In still another embodiment of the compounds of Formula I, each Ar is different, e.g. one Ar is a substituted or unsubstituted aryl and the other Ar is a substituted or unsubstituted heteroaryl, each Ar is a different substituted or unsubstituted aryl, or each Ar is a different substituted or unsubstituted heteroaryl, wherein aryl and heteroaryl are any aryl or heteroaryl defined or exemplified herein, and, when present, the substituents on the aryl or heteroaryl include one or more of any substituents defined or exemplified herein. In still another embodiment of the compounds of Formula I, R1, R3, and R5 are each independently H, alkyl, or substituted alky I7 wherein alkyl and substituted alkyl include any of the alkyl or substituted alkyls defined or disclosed herein.
In still another embodiment of the compounds of Formula I, R1, R3, and R5 are each the same. In a particular embodiment R1, R3, and R5 are each H. in another particular embodiment R1, R3, and R5 are each alkyl, e.g. one of the alkyl groups defined or disclosed herein.
In still another embodiment of the compounds of Formula I, R1, R3, and R5 are each different.
In still another embodiment of the compounds of Formula I, one of R1, R3, and R5 is different from the other two groups.
In still another embodiment of the compounds of Formula I, n and m are both I7 and each R2 is independently H, alkyl, substituted alkyl, arylheteroalkyl, arylalkyl, or heterocyclylalkyl, wherein alkyl, substituted alkyl, arylheteroalkyl, aryl alkyl, or heterocyclylalkyl is any alkyl, substituted alkyl, arylheteroalkyl, aryl alkyl, or heterocyclylalkyl defined or disclosed herein.
In still another embodiment of the compounds of Formula I7 n and m are both 1, and R2 is H.
In still another embodiment of the compounds of Formula I, n is I7 m is 2, and R2 is H.
In still another embodiment of the compounds of Formula I, n and m are both 1, and at least one R2 is alkyl. In a particular embodiment at least one R2 is methyl. In another particular embodiment at least one R2 is ethyl. In another particular embodiment at least one R2 is i-propyl. In another particular embodiment at least one R2 is t-butyl. In another particular embodiment, one R2 is H, and the other R2 is methyl. In another particular embodiment, one R2 is H, and the other R2 is ethyl. In another particular embodiment, one R2 is H, and the other R2 is i-propyl. In another particular embodiment, one R2 is H, and the other R2 is t-butyl.
In still another embodiment of the compounds of Formula I, n and m are both 1, and R2 is substituted alkyl. In a particular embodiment at least one R2 is - CH(CH3)OH or -CH(CH3)O(MSu)
In still another embodiment of the compounds of Formula I, n and m are both 1, and at least one R2 is arylheteroalkyl. In particular embodiment n and m are both 1, and at least one R2 is selected from the group consisting of H, methyl, ethyl, benzyl-O-CHz-, i-propyl, -CH(CH3)OBn, -CH2CH(CHs)-O- tBu, -CH(CH3)OH, -CH2OH, -CH2OtBu7 -CH2CH2NH2, -CH2CH2NH-P (where P is a protecting group such as Boc, Ac, methanesulfonyl, etc.), -CH2CH2-En or pholine, -CH2C(O)OH, -CH2C(O)OtBu, and -CH2C(O)-NH2.
In still another embodiment of the compounds of Formula I, n and m are both 1, and at least one R2 is arylheteroalkyl. In particular embodiment n and m are both 1, one R2 is H and one R2 is selected from the group consisting of H, methyl, ethyl, benzyl-O-CHa-, i-propyl, -CH(CH3)OBn, -CH2CH(CHs)-O- tBu, -CH(CH3)OH, -CH2OH, -CH2OtBu, -CH2CH2NH2, -CH2CH2NH-P (where P is a protecting group such as Boc, Ac, methanesulfonyl, etc.), -CH2CH2-morphoIine, -CH2C(O)OH, -CH2C(O)OtBu, and -CH2C(O)-NH2.
In still another embodiment of the compounds of Formula I, R4 is H, alkyl, substituted alkyl, and heteroalkyl, wherein alkyl, substituted alkyl, and heteroalkyl are any alkyl, substituted alkyl, or heteroalkyl defined or disclosed herein. A particular embodiment, R4 is H.
In still another embodiment of the compounds of Formula I, R6 is H, alkyl, substituted alkyl, and heteroalkyl, wherein alkyl, substituted alkyl, and heteroalkyl are any alkyl, substituted alkyl, or heteroalkyl defined or disclosed herein. A particular embodiment, R6 is H.
In still another embodiment of the compounds of Formula I, R8 and R9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, and -CN, wherein when R8 or R9 are alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, or substituted heterocyclyl, said alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, or substituted heterocyclyl are any such groups defined or disclosed herein.
In still another embodiment of the compounds of Formula I, R8 and R9 are the same. In a particular embodiment R8 and R9 are both H.
In still another embodiment of the compounds of Formula I, R8 and R9 are different. In a particular embodiment R8 is alkyl and R9 is H. in another particular embodiment, R8 is i-propyl and R9 is H.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(IAAr)p moieties is an -alkylene-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-{L4-Ar)p moieties is an -alkylene-aryl-alkylene-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the ~L3-A-(L4-Ar)p moieties is an -alkylene-aryl-alkylene-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl, and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)P moieties is an -alkylene-heteroaryl-alkylene-heteroaryl group, wherein said alkylene and heteroaryl moieties are any alkylene and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -IAA-(L4-Ar)p moieties is an -alkylene-heteroaryl-alkylene-aryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl, and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)p moieties is an -alkylene-aryl-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)p moieties is an -alkylene-aryl-O-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)p moieties is an -alkylene-aryl-CHb-O-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3- A- (L4- Ar )P moieties is an -alkylene-aryl-OCFL-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula L at least one of the -L3-A-(L4-Ar)P moieties is an -alkylene-aryl-NH-aryl group, wherein said alkylene and aryl moieties are any alkylene and aryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)P moieties is an -alkylene-aryl-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -IAA-(L4-Ar)p moieties is an -alkylene-aryl-O-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -IA A-(L4- Ar) p moieties is an -alkylene-ary!-CH2-O-heterocyc!yl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein/ optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substiruents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I7 at least one of the -L3- A- (L4- Ar )p moieties is an -alkylene-aryl-OClHh-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substiruents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)P moieties is an -alkylene-aryl-NH-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -IAA-(U- Ar)P moieties is an -alkylene-heterocyclyl-aryl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substiruents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3- A- (L4- Ar )p moieties is an -alky] ene-heterocycly 1-0- aryl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3- A- (L4- Ar )p moieties is an -alkylene-heterocyclyl-CHb-O-aryl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -IAA-(L4- Ar) p moieties is an -alkylene-heterocyclyl-OCft-aryl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3- A- (L4- Ar )p moieties is an -alkylene-heterocyclyl-NH-aryl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3- A-(L4- Ar) p moieties is an -alkylene-heterocyclyl-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein. In yet another embodiment of the compounds of Formula I, at least one of the -LAA-(LΛAr)P moieties is an -alkylene-heterocycIyl-O-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -IAA-(L4- Ar)p moieties is an -alkylene-heterocyclyl-CHi-O-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3- A-(L4- Ar) p moieties is an -alkylene-heterocyclyl-OCH-j-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkyiene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3- A-(L4- Ar )p moieties is an -alkylene-heterocyclyl-NH-heterocyclyl group, wherein said alkylene, aryl, and heterocyclyl moieties are any alkylene, aryl, and heterocyclyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A~(L4-Ar)p moieties is an -alkylene-aryl-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -IAA-(L4- Ar) p moieties is an -alkylene-aryl-O-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3- A-(L4- Ar) p moieties is an -alkylene- aryl-CHb-O-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula. I, at least one of the -L3-A-(L4-Ar)p moieties is an -alkylene-aryl-OCHi-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)p moieties is an -alkylene-aryl-NH-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein. In yet another embodiment of the compounds of Formula I7 at least one of the -IAA- (L4- Ar) p moieties is an -alkylene-heteroaryϊ-aryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)P moieties is an -alkylene-heteroaryl-Oaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4~Ar)p moieties is an -alkylene-heteroaryl-CHb-O-aryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)p moieties is an -alkylene-heteroaryl-OQHb-aryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaiyl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -IAA-(L4- Ar)P moieties is an -alkylene-heteroaryl-NH-aryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3- A- (L4- Ar )p moieties is an -alkylene-heterocyclyl-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -IAA-(L4- Ar)P moieties is an -alkylene-heterocyclyl-O-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the ~L3-A-(L4-Ar)p moieties is an -alkylene-heterocyclyl-Cϋ-O-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the ~L3-A-(L4-Ar)p moieties is an -alkylene-heteroaryl-OGHk-heteiOaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryl moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein. In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)p moieties is an -alkylene-heteroaryl-NH-heteroaryl group, wherein said alkylene, aryl, and heteroaryl moieties are any alkylene, aryl, and heteroaryi moieties defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.
In yet another embodiment of the compounds of Formula I, at least one of the -L3-A-(L4-Ar)p moieties is an alkyl group.
In yet another embodiment of the compounds of Formula I, both of the -L3-A-(L4-Ar)P moieties are alkyl groups, wherein the alkyl groups are the same or different.
In yet another embodiment of the compounds of Formula I, both -LAA- (IΛ-Ar)p moieties are -CH2-phenyl and X and Y are both -Cϋ-heterocyclyl.
In yet another embodiment of the compounds of Formula I, both -IAA- (L4-Ar)p moieties are -ClHb-phenyl and Y is -CH∑-heterocyclyl.
In yet another embodiment of the compounds of Formula I, both -LAA- (L4-Ar)p moieties are -CHi-phenyl and X is -CLL-heterocyclyl.
In yet another embodiment of the compounds of Formula I7 both -LAA- (L4- Ar) p moieties are -CH2-phenyl and Y is -CH2-thiazolyl.
In yet another embodiment of the compounds of Formula I, both -LAA- (L4- Ar) p moieties are -CU2~phenyl and X is -CH2-thiazolyl.
In yet another embodiment of the compounds of Formula I, both -L3- A- (L4-Ar)P moieties are -CHb-phenyl and X and Y are both -CHb-thiazolyl.
In yet another embodiment of the compounds of Formula I, both -L3- A- (L4- Ar) p moieties are -Ctfc-phenyl, X and Y are both -Cl-h-thiazolyl, and n and m are both 1. In yet another embodiment of the compounds of Formula I, both -IAA- (L4-Ar)P moieties are -CFfc-phenyl, X and Y are both -CHz-thiazolyl, n and m are both 1, and at least one R2 is a Ci-Ce alkyl.
In yet another embodiment of the compounds of Formula I, both -IAA- (IΛAr)p moieties are -Ctfe-phenyL X and Y are both -dHfe-thlazolyl, n and m are both 1, and at least one R2 is a G-G, hydroxyalkyl.
In yet another embodiment of the compounds of Formula I, both -IAA- (L4-Ar)P moieties are -Cϋ-phenyl, X and Y are both -CPfc-thiazolyl, n and m are both 1, and at least one R2 is a C2-G0 alkoxyalkyl.
In yet another embodiment of the compounds of Formula I, both -IAA- (LAAr)n moieties are -CFfc-phenyL X and Y are both -GHb-thiazolyl, n and m are both 1, and at least one R2 is a C7-G4 arylalkyloxy alkyl.
In yet another embodiment of the compounds of Formula I, both -LAA- (lAAr)p moieties are --CHfe-phenyl, X and Y are both -CH2-thiazolyl, n and m are both 1, and at least one R2 is a G-G aminoalkyl.
In yet another embodiment of the compounds of Formula I, both -LAA- (lAAr)p moieties are -CFfe-phenyl, X and Y are both -CFLa-thiazolyl, n and m are both 1, and at least one R2 is a G -CO aminoalkyl substituted on the nitrogen with an amine protecting group selected from acyl, alkylsulfonyl, arylsulfonyl, heterocyclylacyl, and benzyl.
In yet another embodiment of the compounds of Formula I, both -LAA- (IAAr)p moieties are -CE-h-phenyl, X and Y are both -CFfc-thiazolyl, n and m are both 1, and at least one R2 is a substituted or unsubstituted heterocyclylalkyl.
In yet another embodiment of the compounds of Formula I, both -LAA- (IAAr)p moieties are -CFL-phenyL. X and Y are both -CFfe-thiazolyl, n and m are both \, and L2 is -CH2-. In yet another embodiment of the compounds of Formula I, at least one -IAA-(L4-Ar)p moiety is-CHz-phenyl-CFL-phenyl.
In yet another embodiment of the compounds of Formula I, at least one -L3- A-(L4- Ar) p moiety 1S-CH2- heteroaryl-CH2-phenyI.
In yet another embodiment of the compounds of Formula I, at least one -L3-A-(L4-Ar)P moiety is-CHi-phenyl-CI-b-heteroaryl.
In yet another embodiment of the compounds of Formula I, at least one -L3- A-(L4- Ar) p moiety is-CH2- heteroaryl-Cϋ-heteroaryl.
In yet another embodiment of the compounds of Formula I, X and Y are both heterocyclylalkyl.
In yet another embodiment of the compounds of Formula I, X and Y are both heteroarylalkyl.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, and both -L3- A-(L4- Ar) P groups are substituted or unsubstituted benzyl.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3-A-(L4-Ar)p groups are substituted or unsubstituted benzyl, and L2 is -
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3~A-(L4-Ar)p groups are substituted or unsubstituted benzyl, L2 is -CH2-, and m and n are both 1.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3-A-(L4-Ar)P groups are substituted or unsubstituted benzyl, L2 is -ClHb-, m and n are both 1, and R1 is H.
In another embodiment of the compounds of Formula I, L1 is -C(O)~, R4 is H, both -L3-A-(L4-Ar)P groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, and Z1 is -N(alkyl)-. In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3- A- (L4- Ar )p groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, and Z1 is -N(CH3)-.
In another embodiment of the compounds of Formula I7 L1 is -C(O)-, R4 is H, both -1AA-(L4-Ar)p groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(alkyl)-, and Z2 is -O-.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3-A-(lAAr)p groups are substituted or unsubstituted benzyl, L2 is -CHb-, m and n are both 1, R1 is H, Z1 is -N(CHs)-, and 71 is -O-.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3-A-(L4-Ar)p groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(alkyl)-, Z2 is -O-, and Y is substituted or unsubstituted ~CH2-4-thiazole.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3- A-(L4- Ar) p groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(alkyl)-, Z2 is -O-, and R8-Y is -CH2-(2-a.ϊkyl-4- thiazole).
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -LAA-(L4- Ar)P groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -O-, and R8-Y is -CH2-(2-iPr-4- thiazole).
In another embodiment of the compounds of Formula I, ΛJ is -C(O)-, R4 is H, both -L3-A-(L4-Ar)p groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(alkyl)-, Z2 is -O-, Y is substituted or unsubstituted -CH2-4-thiazole, and X is substituted or unsubstituted -CH>-5- thiazole. In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3-A-(L4-Ar)p groups are substituted or unsubstituted benzyl, L2 is -CHb-, m and n are both 1, R1 is H, Z1 is -N(alkyl)-, Z2 is -O-, Y is substituted or unsubstituted -CH2-4-thiazole, and X is unsubstituted -CH2-5-thiazole.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3-A-(L4-Ar)P groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -O-, R8-Y is ~CH2-(2-iPr-4-thiazole), and X is unsubstituted -CH∑-S-thiazole.
In another embodiment of the compounds of Formula I, each R2 is independently H or hydroxyalkyl.
In another embodiment of the compounds of Formula I, each R2 is independently H or heterocyclylalkyl.
In another embodiment of the compounds of Formula I, each R2 is independently H or -CHb-heterocydyl, wherein said heterocyclyl is a 5- or 6- membered ring having at least one ring nitrogen atom.
In another embodiment of the compounds of Formula I, each R2 is independently H or -CHb-heterocyclyl, wherein said heterocyclyl is a 6- membered ring having at least one ring nitrogen atom.
In another embodiment of the compounds of Formula I, each R2 is independently H or -Cl-fe-heterocycryl, wherein said heterocyclyl is a 6- membered ring having at least one ring nitrogen atom, where the -CH2- moiety thereof is bonded to the ring nitrogen atom.
In another embodiment of the compounds of Formula I, each R2 is independently H or -CHb-heterocyclyl, wherein said heterocyclyl is selected from the group consisting of piperadyl, piperazyl, and morpholinyl.
In another embodiment of the compounds of Formula I, each R2 is independently H or -CH2-heterocyclyl/ wherein said heterocyclyl is selected from the group consisting of piperadyi, piperazyl, and morpholinyl, and the -CH2- moiety thereof is bonded to a ring nitrogen atom of the heterocyclyl.
In another embodiment of the compounds of Formula I, each R2 is independently H or aminoaϊkyl.
In another embodiment of the compounds of Formula I, each R2 is independently H or aminoalkyl substituted with an amine protecting group selected from the group consisting of acetyl, alkylsulfonyl, Boc, Cbz, and Fmoc.
In another embodiment of the compounds of Formula I, each R2 is independently H or ethylacetamide (-CH2CH2NHC(O)CH3).
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -LΛA-(L4-Ar)p groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -O-, Re-Y is -CH2-(2-iPr-4-thϊazole), X is unsubstituted -CH2-5-thiazole, and R2 is independently H or hydroxyalkyl.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3-A-(L4-Ar)P groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -O-, R8-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and one R2 is H and the other R2 is hydroxyalkyl.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H7 both -L3-A-(LΛAr)p groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -O-, Rs-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -QHb-S-thiazole, and one R2 is H and the other R2 is hydroxy methyl.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both ~~L3-A-(L4-Ar)p groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -O-, R8-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and each R2 is independently H or -CH2- heterocyclyl, wherein said heterocyclyl is a 5- or 6-membered ring having at least one ring nitrogen atom.
In another embodiment of the compounds of Formula I7 U is -C(O)-, R4 is H, both -LAA- (L4- Ar) p groups are substituted or unsubstituted benzyl, L2 is -CIHb-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -O-, R8-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CFb-S-thiazole, and each R2 is independently H or -CH2- heterocyclyl, wherein said heterocyclyl is selected from the group consisting of piperadyl, piperazyl, and morpholinyl, and the -CHz- moiety thereof is bonded to a ring nitrogen atom of the heterocyclyl
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3- A- (L4- Ar) P groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -O-, R8-Y is -CH2~(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and one R2 is H and the other R2 is -CH2- heterocyclyl, wherein said heterocyclyl is selected from the group consisting of piperadyl, piperazyl, and morpholinyl, and the -CH2- moiety thereof is bonded to a ring nitrogen atom of the heterocyclyl
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3- A- (L4- Ar) P groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -O-, RH-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and each R2 is independently H or aminoalkyl substituted with an amine protecting group selected from the group consisting of acetyl, alkylsulfonyL Boc, Cbz, and Fmoc.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3-A-(L4-Ar)P groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -O-, R8- Y is ~-CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and one R2 is H and the other R2 is aminoalkyl substituted with an amine protecting group selected from the group consisting of acetyl, alkylsulf onyl, Boc, Cbz, and Fmoc.
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -L3-A-{L4-Ar)p groups are substituted or unsubstituted benzyl, L2 is -CH2-, m and n are both 1, R1 is H, Z1 is -N(H)-, Z2 is -CK R8-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CFΪ2-5-thiazole, and one R2 is H and the other R2 is ethylacetamide (-CH2CHiNHC(O)CH3).
In another embodiment of the compounds of Formula I, L1 is -C(O)-, R4 is H, both -IAA-(LZ-A r)P groups are substituted or unsubstituted benzyl, L2 is -CH-.-, m and n are both 1, R1 is H, Z1 is -N(alkyl)-, Z2 is -O-, and Y is substituted or unsubstituted -CH2-thiazole.
In still another embodiment, the compounds of Formula I, or pharmaceutically acceptable salts, solvates, esters, or stereoisomers thereof, have the structure shown in Formula HA:
Figure imgf000069_0001
Formula HA wherein R11 and R16 are each independently heterocyclyl or substituted heterocyclyl; and R12, R13, R14, and R15 are each independently H, -Ci -4 alkyl or -C1-4 substituted alkyl.
In still another embodiment of the compounds of Formula IIA, R13 is H, -Ci- 4 alkyl, -(CH2)o-iCR17R18OR19, -(CH2)o-3CR17R1sNR20R21, -(CH2V3CR17R18NR17C(O)- NR20R21, -(CHi)V3C(O)R22, -(CH2)L3S(O)2R22 or - (CH2) 1-3-R23; R14 and R15 are each independently H, -Ci -4 alkyl or arylalkyl; R17 and R18 are each independently H or - Ci-3 alkyl; R19 is H, -C1-4 alkyl or arylalkyl; R20 and R21 are each independently H, - Ci-3 alkyl, -C(O)R17 or -S(O)2R17; or R20 and R2Ϊ, taken together with the nitrogen atom to which they are attached, form an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; R22 is H, -G-3 alkyl, -OR19 or -NR20R21; and R23 is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O.
In still another embodiment of the compounds of Formula HA, R13 is - (CH2)O-SCR17R18NR20R2V -(CH2)O-SCR17R18NR17C(O)-NR20R2V or -(CH2)i-3-R23 wherein R20 and R21 form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O or R23 is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O, and the 5-6 membered heterocyclyl ring is optionally substituted with a C1-2 alkyl.
In still another embodiment of the compounds of Formula HA, R13 is - (CH2)o-iCR17R18OR19. In a particular embodiment, R13 is a Ci -2 hydroxyalkyl or a G- 6 alkoxy alkyl group.
In still another embodiment of the compounds of Formula IIA, R13 is - (CHz)O-SCR17R18NR20R21. In a particular embodiment, R13 is a Cwalkylene-NHz group, G-4alkylene-NHP (wherein P is a protecting group such as Boc, Fmoc, Cbz, Ac, trifluoroacetyl, toluenesulfony group, benzyl, etc.), or Chalky lene-N(alkyl)2 group.
In still another embodiment of the compounds of Formula IIA, R13 is - (CH2)O-SCR17R18NR17C(O)-NR20R21. In a particular embodiment, R" is a G-4alkylene-C(O)NH2 group or G-4alkylene-C(O)N(alkyl)2 group.
In still another embodiment of the compounds of Formula IIA, R1V R12, R13, R14, R15, and R16 are each independently selected from the groups shown in the Table, below:
R11 R12 R13 RM R15 R16
Figure imgf000071_0001
Figure imgf000071_0002
Figure imgf000071_0003
Figure imgf000071_0004
In still another embodiment of the compounds of Formula HA, R11 is substituted or unsubstituted heterocyclyl, R12 is alkyl, R13 is substituted or unsubstituted heterocyclylalkyl, R14 and R15 are each independently substituted or unsubstituted arylalkyl, and R16 is substituted or unsubstituted heterocyclyl.
In still another embodiment of the compounds of Formula HA, R11 is substituted heterocyclyl, R12 is alkyl, R13 is unsubstituted heterocyclylalkyl, R14 and R15 are both unsubstituted arylalkyl, and R16 is unsubstituted heterocyclyl.
In still another embodiment of the compounds of Formula IIA, R11 is substituted or unsubstituted heterocyclyl, R12 is alkyl, R13 is hydroxyalkyl, R14 and R15 are each independently substituted or unsubstituted arylalkyl, and R16 is substituted or unsubstituted heterocyclyl.
In still another embodiment of the compounds of Formula IIA, R" is substituted heterocyclyl, R12 is alkyl, R13 is hydroxyalkyl, R14 and R15 are both unsubstituted arylalkyl, and R16 is unsubstituted heterocyclyl.
In still another embodiment of the compounds of Formula IIA, R11 is substituted or unsubstituted heterocyclyl, R12 is alkyl, R13 is protected or unprotected aminoalkyl, R14 and R15 are each independently substituted or unsubstituted arylalkyl, and R16 is substituted or unsubstituted heterocyclyl.
In still another embodiment of the compounds of Formula IIA, R11 is substituted heterocyclyl, R12 is alkyl, R13 is protected aminoalkyl, R14 and R15 are both unsubstituted arylalkyl, and R16 is unsubstituted heterocyclyl.
In still another embodiment of the compounds of Formula IIA, R11 is substituted heterocyclyl, R12 is alkyl, R13 is acylated aminoalkyl, R14 and R15 are both unsubstituted arylalkyl, and R16 is unsubstituted heterocyclyl.
In another embodiment, the compounds of Formula I, or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof, have the following structure HB:
Figure imgf000073_0001
Formula IIB
R1Oa and R1Ob are each independently H or -CM alkyl; R12 is H or -CHa; R13 is H, -C1-4 alkyl, -(CH2)O-I CR17R18OR19, -(CH2)O-SCR17R18NR20R21, -(CH2)o-3CR17R18NRl7C(O) NR20R21, -(CH2)i-3C(O)R22, -(CHz)WS(O)2R22 or -(CHz)1-S-R23; R14 and R15 are each independently H, -C 1-4 alkyl or arylalkyl; R17 and R18 are each independently H or - Ci-3 alkyl; R19 is H, -Ci-* alkyl or arylalkyl; R20 and R21 are each independently H, - C1-3 alkyl, -C(O)R17 or -S(O)2R17; or R20 and R21, taken together with the nitrogen atom to which they are attached, form an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; R22 is H, -G-saϊkyl, -OR19 or -NR20R21; and R23 is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O.
In still another embodiment of the compounds of Formula IIB, R13 is - (CH2)O-SCR17R18NR20R21, -(CH2)o-3CRl7R18NRl7C(O)-NR20R21, or -(CH2)i-3-R23 wherein R20 and R21 form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O or R23 is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O, and the 5-6 membered heterocyclyl ring is optionally substituted with a Ci -2 alkyl.
In another embodiment, the compounds of Formula I, or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof, have the following structure HC:
Figure imgf000074_0001
Formula IIC wherein: R13 is H, -CM alkyl, -(CHI)O-ICR17R18OR19, "(CH2)O-SCR17R18NR20R21, -(CH2)O- 3CR17R38NR17C(O) NR20R21, -(CH2)i-3C(O)R22 or -(CH2)H-R23; R17 and R1S are each independently H or G -3 alkyl; R19 is H, -Ci-4 alkyl or arylalkyl; R20 and R21 are each independently H, -Ci 3 alkyl, -C(O)R17 or -S(O)2R17; or R20 and R21, taken together with the nitrogen atom to which they are attached, form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; R22 is H, -G-salkyl, -OR19 or -NR20R21; and R23 is a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O.
In still another embodiment of the compounds of Formula IIC, R13 is - (CHiV3CR17R18NR20R21, -(CH2)O-SCR17R18NR17C(O)-NR20R21, or -(CH2)L3-R23 wherein R20 and R21 form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O or R23 is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O, and the 5-6 membered heterocyclyl ring is optionally substituted with a G -2 alkyl.
In still another embodiment of the compounds of Formula IIC, R13 is -
Figure imgf000074_0002
In a particular embodiment, R13 is a G-4alkylene-NH2 group, G-4alkylene-NHP (wherein P is a protecting group such as Boc, Fmoς, Cbz, Ac, trifluoroacetyl, toiuenesulfony group, benzyl, etc.), or G-4alkylene-N(alkyl)2 group.
In still another embodiment of the compounds of Formula HC, R13 is - (CH2)Q-SCR17R18NR17C(O)-NR20R21. In a particular embodiment, R13 is a Ci-4alkylene-C(O)NU2 group or Ci-4alkylene-C(O)N(alkyl)2 group.
In still another embodiment of the compounds of Formula HC, R13 is - CHiOH, -CH2CH2NHC(O)CH3 or
Figure imgf000075_0001
In another embodiment, the compounds of of the present invention, or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof, have the following structure HD:
Figure imgf000075_0002
Formula IID wherein, L1 is selected from the group consisting of -C(R6)2-, -C(O)-, -S(O2)-, -N(R7)-C(O)-, and -0-C(O)-; each L3 is independently a covalent bond, an alkylene, or substituted alkylene; each L4 is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O-, and -NH-; each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, and substituted heterocyclyl, with the proviso that when A is H, p is 0; Z1 and Z2 are each independently -O- or -N(R7)-; Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl; each Ar is independently selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; R1, R3, and Rs are each independently selected from the group consisting of H, alky I7 substituted alkyl, arylalkyl, and substituted arylalkyl; R2 is independently selected from the group consisting of H, alkyl, substituted alkyl, alkoxy alkyl, hydroxy alkyl, arylheteroalkyl, substituted arylheteroalkyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl, substituted aminoalkyl, -alkylene-C(O)-OH, - alkylene-C(O)-Oalkyl/ -alkylene-C(O)amino/ -alkylene-C(O)-alkyl; R4 and R6 are independently selected from the group consisting of H, alkyl, substituted alkyl, and heteroalkyl; each R7 is independently selected from the group consisting of H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, and substituted heterocyclyl;
Ra and R9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, and -CN; and each p is independently 0 or 1.
In another embodiment of the compounds of Formula IID, L1 is -C(R6)2~. In another embodiment of the compounds of Formula IID, L1 is -CH2-. In another embodiment of the compounds of Formula IID, each L3 is alkylene.
In another embodiment of the compounds of Formula IID, each L3 is -CH2-. In another embodiment of the compounds of Formula HD, each A is aryl or substituted aryl.
In another embodiment of the compounds of Formula DD, each A is phenyl or substituted phenyl.
In another embodiment of the compounds of Formula HD, X is heterocyclylalkyl.
In another embodiment of the compounds of Formula HD, X is thiazolylmethyl.
In another embodiment of the compounds of Formula HD7 Y is heterocyclylalkyl.
In another embodiment of the compounds of Formula IID, Y is thiazolylmethyl.
In another embodiment of the compounds of Formula IID, Z1 is -N(R7)-.
In another embodiment of the compounds of Formula IID, Z1 is -NH-.
In another embodiment of the compounds of Formula IID, Z1 is -N(alkyl)-.
In another embodiment of the compounds of Formula IID, Z1 is -N(CHs)-.
In another embodiment of the compounds of Formula IID, Z2 is -O- .
In another embodiment of the compounds of Formula IID, L1 is -C(R6)2- and X and Y are heterocyclylalkyl.
In another embodiment of the compounds of Formula IID, L1 is -CH2- and X and Y are heterocyclylalkyl.
In another embodiment of the compounds of Formula IID, L1 is -CH2- and X and Y are thiazolylmethyl.
In another embodiment of the compounds of Formula IID, L1 is -C(R6)2- and Z1 is -N(R7)-.
In another embodiment of the compounds of Formula IID, L1 is -CH2- and Z1 is -N(R7)-. In another embodiment of the compounds of Formula HD, L1 is -CH2- and Z1 is -NH-.
In another embodiment of the compounds of Formula HD, L1 is -CH2- and 7) is -N(alkyl)-.
In another embodiment of the compounds of Formula HD, L1 is -CH2- and Z1 is -N(CH3)-.
In another embodiment of the compounds of Formula HD, L1 is -C(R6)2- and Z2 is -O-.
In another embodiment of the compounds of Formula HD, each L3 is alkylene and each A is aryl or substituted aryl.
In another embodiment of the compounds of Formula IID, each L3 is -CH2- and each A is aryl or substituted aryl.
In another embodiment of the compounds of Formula HD, each IAA is benzyl or substituted benzyl.
In another embodiment of the compounds of Formula HD, X and Y are heterocydylalkyl and Z1 is -N(R7)-.
In another embodiment of the compounds of Formula HD, X and Y are thiazolylmethyl and T) is -N(R7)-.
In another embodiment of the compounds of Formula HD, X and Y are thiazolylmethyl and Z1 is -N(alkyl)-.
In another embodiment of the compounds of Formula HD, X and Y are thiazolylmethyl and T) is -N(CHs)-.
In another embodiment of the compounds of Formula HD, X and Y are thiazolylmethyl and T) is -NH-.
In another embodiment of the compounds of Formula EED, X and Y are heterocydylalkyl and Z2 is -O- . In another embodiment of the compounds of Formula HD, X and Y are thiazoly Im ethyl and Z2 is -O-.
In another embodiment of the compounds of Formula IID, Z1 is -N(R7)- and 2? is -O-.
In another embodiment of the compounds of Formula IID, Z1 is -N(alkyl)- and Z2 is -O-.
In another embodiment of the compounds of Formula IID, Z1 is -N(CH3)- and Z2 is -O-.
In another embodiment of the compounds of Formula IID, Z1 is -NH- and Z2 is -O-.
In another embodiment of the compounds of Formula IID, L1 is -C(R6)2-, X and Y are heterocyclylalkyl, and Z1 is -N(R7)-.
In another embodiment of the compounds of Formula IID, L1 is -CH2-, X and Y are heterocyclylalkyl, and Z1 is -N(R7)-.
In another embodiment of the compounds of Formula HD, L1 is -CH2-, X and Y are thiazolylmethyl, and Z1 is -N(R7)-.
In another embodiment of the compounds of Formula IID, L! is -CH2-, X and Y are thiazolylmethyL and Z3 is -N(alkyl)-.
In another embodiment of the compounds of Formula IID, L1 is -CH2-, X and Y are thiazolylmethyl, and Z3 is -N(CHs)-.
In another embodiment of the compounds of Formula IID, L1 is -CH2-, X and Y are thiazolylmethyl, and Z] is -NH-.
In another embodiment of the compounds of Formula. IID, L1 is -C(R6)2-; X and Y are heterocyclylalkyl; and Z2 is -O-.
In another embodiment of the compounds of Formula IID, L1 is -CH2-; X and Y are heterocyclylalkyl; and Z2 is -O- . In another embodiment of the compounds of Formula HD7 L1 is -CH2-; X and Y are thiazolylmethyl; and Z2 is -O-.
In another embodiment of the compounds of Formula HD, L1 is -C(R6)2-; each L3 is alkylene; each A is aryl or substituted aryl; X and Y are heterocyclylalkyl; Z1 is -N(R7)-; and Z2 is -O-.
In another embodiment of the compounds of Formula IID, L7 is -CH2-; each IAA is benzyl or substituted benzyl; X and Y are thiazolylmethyl; Z1 is -N(CHs)-; and Z2 is -O-.
In another embodiment of the compounds of Formula IID, L1 is -CH2-; each IAA is benzyl or substituted benzyl; Z1 is -N(CHs)-; Z2 is -O-; X is
Figure imgf000080_0001
Y is
Figure imgf000080_0002
In another embodiment, the compounds of of the present invention, or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof, have the following structure IV:
Figure imgf000080_0003
wherein, each L3 is independently an alkylene or substituted alkylene; each A is independently an aryl or substituted aryl;
X is heterocyclylalkyl;
Y is heterocyclylalkyl or alkyl; G1 and G2 are independently CH or N, with the proviso that G1 and G2 are different;
G3 is -NR7- or -O-; R1, R3, R5, and R7 are each independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyl, and substituted arylalkyl; R2 is independently selected from the group consisting of substituted alkyl, alkoxyalkyl, hydroxyalkyl, trialkylsiloxyalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl, substituted aminoalkyl, -alkylene-N(Ra)-C(O)- alkyl, -alkylene-NR3-C(O)-N(Ra)2, -alkylene-NRa-C(=N-Rb)-N(Ra)2/ -alkylene-
C(=N-Rb)-N(Ra)2, ~alkylene-C(O)-OH, -alkylene-C(O)-OaIkyl, and -alkylene-
C(O)-N(RC)2; R8 and R9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, and -CN; each R" is independently selected from the group consisting of H, alkyl, and substituted alkyl; Rb is selected from the group consisting of H, alkyl, substituted alky I, CN, and -
S(Oa)-alkyl; and each Rc is independently selected from the group consisting of H, alkyl, substituted alkyl, heterocyclyl, and -S(θ2)-alkyl.
In some embodiments of the compounds of Formula IV, each L3 is alkylene, for example any of those described herein, e.g. -CH2- and each A is phenyl. In a particular embodiment, both -L3-A moieties are benzyl.
In some embodiments of the compounds of Formula IV, X and Y are both heteroaryl (for example, any heteroaryl described herein). In a particular embodiment, both X and Y are thiazolyl.
In some embodiments of the compounds of Formula IV, G1 is CH, and G2 is N. In a particular embodiment, G2 is N and R1 is H. In another particular embodiment, G2 is N, R1 is H, and G3 is NR7. In yet another particular embodiment G2 is N, R1 is H, and G3 is NCH3.
In some embodiments of the compounds of Formula IV, R2 is substituted or unsubstituted aminoalkyl. In a particular embodiment, R2 is substituted or unsubstituted aminoalkyl, G2 is N and R1 is H, and both X and Y are thiazolyl. In another particular embodiment, R2 is -CH2CH2-NHRd, wherein Rd is selected from the group consisting of H, haloalkyl, -C(O)-N(R3K -C(=N-Rb)-N(Ra)2, hydroxyalkyϊ, -C(N(Ra)2)=CHNθ2, -C(O)-alkyl, G2 is N and R1 is H, and both X and Y are thiazolyl. In still another particular embodiment, R2 is -CH2CH2-NH- C(O)-alkyl.
In specific embodiments, the compounds of Formula IV have the following structures:
Figure imgf000082_0001
Figure imgf000083_0001
In other embodiments, the compounds of Formula IV have the following general formula:
Figure imgf000084_0001
wherein said
"Heterocyclyl" is substituted or unsubstituted. In a particular embodiment, said "Heterocyclyl" is a substituted or unsubstituted heteroaryl, for example, and of the heteroaryls described herein. In other embodiments, said "Heterocyclyl" is a substituted or unsubstituted heterocycloalkyl, including any heterocycloalkyl described herein. In a particular embodiment, the heterocyclyl is unsubstituted morpholinyl. In a more specific particular embodiment, the heterocyclyl is unsubstituted morpholinyl and R8 is alkyl.
In other embodiments, the compounds of Formula IV have the following general formula:
Figure imgf000084_0002
In a particular embodiment of the compounds of the above general formula, X and Y are both heteroarylalkyl.
In other specific embodiments, the compounds of Formula IV have the following structures:
Figure imgf000085_0001
84
Figure imgf000086_0001
Figure imgf000087_0001
86
Figure imgf000088_0001
87
Figure imgf000089_0001
Figure imgf000090_0001

Figure imgf000091_0001
Figure imgf000092_0001
In other embodiments, the compounds of Formula IV have the following general formula:
Figure imgf000092_0002
wherein Q is -OH or ~N(Ra)2. In a particular embodiment, Q is -OH. In another particular embodiment, Q is -N(Ra)2. In yet another particular embodiment, Q is -NH-pyridyl, -NH-pyrrolyl, or -NH-S(θ2)-alkyl. In other specific embodiments, the compounds of the above general formula have the following structures:
Figure imgf000093_0001
92
Figure imgf000094_0001
In other embodiments, the compounds of Formula IV have the following general formula:
Figure imgf000094_0002
wherein M is substituted or unsubstituted alkyl. In particular embodiments, M is a substituted alkyl, for example hydroxyalkyl, substituted hydroxy alkyl, cyanoalkyl, substituted cyanoalkyl, and trialkylsiloxy alkyl. In other particular embodiments, the compounds of the above general formula have the following structures:
Figure imgf000095_0001
In still other embodiments, the compounds of Formula IV have the following general formula:
Figure imgf000095_0002
In particular embodiments, a compound of the above general formula has the following structure:
Figure imgf000096_0001
In still other embodiments of the compounds of Formula IV, Y is alkyl. In particular embodiments, such compounds have the following general formula:
Figure imgf000096_0002
In specific embodiments,
R8-Y- is alkyl, for example any alkyl described herein. In a particular embodiment, R8-Y- is methyl. Specific particular embodiments of the above general structure include the following structures:
Figure imgf000096_0003
In still yet another embodiment, the compounds of Formula I are named below in tabular format (Table 6) as compounds of general Formula II:
X2
Ti -T2
X1 Formula II.
Compounds of general formula II are depicted as a "core" structure (Z) substituted with four moieties Tl, T2, Xl and X2. The core structures Z are depicted in Table 1. The points of attachment of Tl, T2, Xl and X2 are indicated on each of the core structures depicted in Table 1. Tables 2-5, respectively, show the structures of the Tl, T2, Xl and X2 moieties. The point of attachment of the core structure Z is indicated in each of the structures of Tl, T2, Xl and X2. Each core structure Z in Table 1, and each substituent Tl, T2, Xl and X2 and Tables 2-5 is represented by a "code" comprising a letter and a number. Each structure of a compound of Formula II can be designated in tabular form by combining the "code" representing each structural moiety using the following syntax: Z.T1.T2.X1.X2. Thus, for example, Z1.T1A.T2B.X1A.X2A represents the following structure:
Figure imgf000097_0001
In the structures depicted in Tables 1-5, the term "AIk" means a substituted or unsubstituted alkyl, cycloalkyl, or alkylene group, wherein the terms "alkyl", "cycloalkyl", and "alkylene" are as defined herein. "AIk" means an alkyl or cycloalkyl group when depicted as monovalent, and an alkylene group when depicted as divalent. "Het" is a substituted or unsubstituted heterocyclyl or heterocyclylene group, wherein the term "heterocyclyl" is as defined herein, and the term "heterocyclylene" means a heterocyclyl group as defined herein, in which a hydrogen atom has been replaced by an open valence (in analogy to alkylene), thereby defining a divalent heterocyclyl. "Het" is a heterocyclyl when depicted as monovalent, and heterocyclylene when depicted as divalent. "Ar" is a substitute or unsubstituted aryl or arylene group, wherein the term "aryl" is as defined herein, and the term "arylene" means an aryl group as defined herein, in which a hydrogen atom has been replaced by an open valence (in analogy to alkylene), thereby defining a divalent aryl. "Ar" is aryl when depicted as monovalent and arylene when depicted as divalent. When substituted, "AIk", "Het", and "Ar" can be substituted with any of the substituents defined or exemplified herein. For example, substituents of "AIk" can include ether, halogen, -OH, amide, amine, etc., substituents of "Het" can include alkyl, aryl, carbonyl, -OH, halogen, and substituents of "Ar" can include alkyl, aryl, -OH, halogen, etc., with the proviso that the resulting structure is chemically reasonable, and would provide compounds which are sufficiently stable for formulation in a pharmaceutically acceptable composition. When a structure or substructure shown in the tables below contains more than one "AIk", "Het" or "Ar" group, these groups are independently selected and can be the same or different. So, for example, each of the "AIk" groups of substructure TlA are independently selected and may be the same or different.
Table 1: Core Structures
Code Core Structure
Figure imgf000098_0001
Code Core Structure
Figure imgf000099_0001
Table 2: Tl Structures
Code Tl Structure
Figure imgf000099_0002
Table 3: T2 Structures
Code T2 Structure
T2A -O-Alk-Het
T2B -NH-Alk-Het
T2C -N(Alk)-Alk-Het
T2D -N(Alk)-Het
Table 4: Xl Structures
Code Xl Structure
XlA -AIk
XlB -AIk-Ar
XlC -Alk-Het
XlD -AIk-Ar-O-AIk-Ar
XlE -AIk-Ar-O-AIk-
Het
Table 5: X2 Structures
Code X2 Structure
X2A -AIk
X2B -AIk-Ar
X2C -Alk-Het
X2D -AIk-Ar-O-AIk-Ar
X2E -AIk-Ar-O-AIk-
Het
Table 6: List of Compound Structures of Formula II Z1.T1A.T2A.X1A.X2A, Z2.T1A.T2A.X1A.X2A, Z3.T1A.T2A.X1A.X2A, Z4.T1A.T2A.X1A.X2A, Z5.T1A.T2A.X1A.X2A, Z6.T1A.T2A.X1A.X2A, Z1.T1B.T2A.X1A.X2A, Z2.T1B.T2A.X1A.X2A, Z3.T1B.T2A.X1A.X2A, Z4.T1B.T2A.X1A.X2A, Z5.T1B.T2A.X1A.X2A, Z6.T1B.T2A.X1A.X2A, Z1.T1CT2A.X1A.X2A, Z2.T1C.T2A.X1A.X2A, Z3.T1C.T2A.X1A.X2A, Z4.T1CT2A.X1A.X2A, Z5.T1C.T2A.X1A.X2A, Z6.T1C.T2A.X1A.X2A, Z1.T1D.T2A.X1A.X2A, Z2.T1D.T2A.X1A.X2A, Z3.T1D.T2A.X1A.X2A, Z4.T1D.T2A.X1A.X2A, Z5.T1D.T2A.X1A.X2A, Z6.T1D.T2A.X1A.X2A, Z1.T1A.T2B.X1A.X2A, Z2.T1A.T2B.X1A.X2A, Z3.T1A.T2B.X1A.X2A, Z4.T1A.T2B.X1A.X2A, Z5.T1A.T2B.X1A.X2A, Z6.T1A.T2B.X1A.X2A, Z1.T1B.T2B.X1A.X2A, Z2.T1B.T2B.X1A.X2A, Z3.T1B.T2B.X1A.X2A, Z4.T1B.T2B.X1A.X2A, Z5.T1B.T2B.X1A.X2A, Z6.T1B.T2B.X1A.X2A, Z1.T1C.T2B.X1A.X2A, Z2.T1C.T2B .Xl A.X2A, Z3.T1CT2B.X1A.X2A, Z4.T1C.T2B.X1A.X2A, Z5.T1C.T2B.X1A.X2A, Z6.T1C.T2B.X1A.X2A, Z1.T1D.T2B.X1A.X2A, Z2.T1D.T2B.X1A.X2A, Z3.T1D.T2B.X1A.X2A, Z4.T1D.T2B.X1A.X2A, Z5.T1D.T2B.X1A.X2A, Z6.T1D.T2B.X1A.X2A, Z1.T1A.T2C.X1A.X2A, Z2.T1A.T2C.X1A.X2A, Z3.T1A.T2C.X1A.X2A, Z4.T1A.T2C.X1A.X2A, Z5.T1A.T2C.X1A.X2A, Z6.T1A.T2C.X1A.X2A, Z1.T1B.T2C.X1A.X2A, Z2.T1B.T2C.X1A.X2A, Z3.T1B.T2C.X1A.X2A, Z4.T1B.T2C.X1A.X2A, Z5.T1B.T2C.X1A.X2A, Z6.T1B.T2C.X1A.X2A, Z1.T1C.T2C.X1A.X2A, Z2.T1C.T2C.X1A.X2A, Z3.T1CT2CX1A.X2A, Z4.T1C.T2C.X1A.X2A, Z5.T1C.T2C.X1A.X2A, Z6.T1C.T2C.X1A.X2A, Z1.T1D.T2C.X1A.X2A, Z2.T1D.T2C.X1A.X2A, Z3.T1D.T2C.X1A.X2A, Z4.T1D.T2C.X1A.X2A, Z5.T1D.T2C-X1A.X2A, Z6.T1D.T2C.X1A.X2A, Z1.T1A.T2D.X1A.X2A, Z2.T1A.T2D.X1A.X2A, Z3.T1A.T2D.X1A.X2A, Z4.T1A.T2D.X1A.X2A, Z5.T1A.T2D.X1A.X2A, Z6.T1A.T2D.X1A.X2A, Z1.T1B.T2D.X1A.X2A, Z2.T1B.T2D.X1A.X2A, Z3.T1B.T2D.X1A.X2A, Z4.T1B.T2D.X1A.X2A, Z5.T1B.T2D.X1A.X2A, Z6.T1B.T2D.X1A.X2A, Z1.T1C.T2D.X1A.X2A, Z2.T1C.T2DXLA.X2A, Z3.T1C.T2D.X1A.X2A, Z4.T1CT2D.X1A.X2A, Z5.T1C.T2D.X1A.X2A, Z6.T1CT2D.X1A.X2A, Z1.T1D.T2D.X1A.X2A, Z2.T1D.T2D.X1A.X2A, Z3.T1D.T2D.X1A.X2A, Z4.T1D.T2D.X1A.X2A, Z5.T1D.T2D.X1A.X2A, Z6.T1D.T2D.X1A.X2A, Z1.T1A.T2A.X1B.X2A, Z2.T1A.T2A.X1B.X2A, Z3.T1A.T2A.X1B.X2A, Z4.T1A.T2A.X1B.X2A, Z5.T1A.T2A.X1B.X2A, Z6.T1A.T2A.X1B.X2A, Z1.T1B.T2A.X1B.X2A, Z2.T1B.T2A.X1B.X2A, Z3.T1B.T2A.X1B.X2A, Z4.T1B.T2A.X1B.X2A, Z5.T1B.T2A.X1B.X2A, Z6.T1B.T2A.X1B.X2A, Z1.T1C.T2A.X1B.X2A, Z2.T1C.T2A.X1B.X2A, Z3.T1C.T2A.X1B.X2A, Z4.T1CT2A.X1B.X2A, Z5.T1C.T2A.X1B.X2A, Z6.T1C.T2A.X1B.X2A, Z1.T1D.T2A.X1B.X2A, Z2.T1D.T2A.X1B.X2A, Z3.T1D.T2A.X1B.X2A, Z4.T1D.T2A.X1B.X2A, Z5.T1D.T2A.X1B.X2A, Z6.T1D.T2A.X1B.X2A, Z1.T1A.T2B.X1B.X2A, Z2.T1A.T2B.X1B.X2A, Z3.T1A.T2B.X1B.X2A, Z4.T1A.T2B.X1B.X2A, Z5.T1A.T2B.X1B.X2A, Z6.T1A.T2B.X1B.X2A, Z1.T1B.T2B.X1B.X2A, Z2.T1B.T2B.X1B.X2A, Z3.T1B.T2B.X1B.X2A, Z4.T1B.T2B.X1B.X2A, Z5.T1B.T2B.X1B.X2A, Z6.T1B.T2B.X1B.X2A, Z1.T1C.T2B.X1B.X2A, Z2.T1C.T2B.X1B.X2A, Z3.T1C.T2B.X1B.X2A, Z4.T1C.T2B.X1B.X2A, Z5.T1C.T2B.X1B.X2A, Z6.T1C.T2B.X1B.X2A, Z1.T1D.T2B.X1B.X2A, Z2.T1D.T2B.X1B.X2A, Z3.T1D.T2B.X1B.X2A, Z4.T1D.T2B.X1B.X2A, Z5.T1D.T2B.X1B.X2A, Z6.T1D.T2B.X1B.X2A, Z1.T1A.T2C.X1B.X2A, Z2.T1A.T2C.X1B.X2A, Z3.T1A.T2C.X1B.X2A, Z4.T1A.T2C.X1B.X2A, Z5.T1A.T2C.X1B.X2A, Z6.T1A.T2C.X1B.X2A, Z1.T1B.T2C.X1B.X2A, Z2.T1B.T2C.X1B.X2A, Z3.T1B.T2C.X1B.X2A, Z4.T1B.T2C.X1B.X2A, Z5.T1B.T2C.X1B.X2A, Z6.T1B.T2C.X1B.X2A, Z1.T1C.T2CX1B.X2A, Z2.T1C.T2C.X1B.X2A, Z3.T1C.T2C.X1B.X2A, Z4.T1C.T2C.X1B.X2A, Z5.T1C.T2C.X1B.X2A, Z6.T1C-T2C.X1B.X2A, Z1.T1D.T2C.X1B.X2A, Z2.T1D.T2C.X1B.X2A, Z3.T1D.T2C.X1B.X2A, Z4.T1D.T2C.X1B.X2A, Z5.T1D.T2CX1B.X2A, Z6.T1D.T2C.X1B.X2A, Z1.T1A.T2D.X1B.X2A, Z2.T1A.T2D.X1B.X2A, Z3.T1A.T2D.X1B.X2A, Z4.T1A.T2D.X1B.X2A, Z5.T1A.T2D.X1B.X2A, Z6.T1A.T2D.X1B.X2A, Z1.T1B.T2D.X1B.X2A, Z2.T1B.T2D.X1B.X2A, Z3.T1B.T2D.X1B.X2A, Z4.T1B.T2D.X1B.X2A, Z5.T1B.T2D.X1B.X2A, Z6.T1B.T2D.X1B.X2A, Z1.T1C.T2D.X1B.X2A, Z2.T1C.T2D.X1B.X2A, Z3.T1C.T2D.X1B.X2A, Z4.T1CT2D.X1B.X2A, Z5.T1C.T2D.X1B.X2A, Z6.T1C.T2D.X1B.X2A, Z1.T1D.T2D.X1B.X2A, Z2.T1D.T2D.X1B.X2A, Z3.T1D.T2D.X1B.X2A, Z4.T1D.T2D.X1B.X2A, Z5.T1D.T2D.X1B.X2A, Z6.T1D.T2D.X1B.X2A, Z1.T1A.T2A.X1C.X2A, Z2.T1A.T2A.X1C.X2A, Z3.T1A.T2A.X1C.X2A, Z4.T1A.T2A.X1C.X2A, Z5.T1A.T2A.X1C.X2A, Z6.T1A.T2A.X1C.X2A, Z1.T1B.T2A.X1CX2A, Z2.T1B.T2A.X1C.X2A, Z3.T1B.T2A.X1CX2A, Z4.T1B.T2A.X1C.X2A, Z5.T1B.T2A.X1C.X2A, Z6.T1B.T2A.X1C.X2A, Z1.T1C.T2A.X1C.X2A, Z2.T1C.T2A.X1C.X2A, Z3.T1C.T2A.X1C.X2A, Z4.T1C.T2A.X1C.X2A, Z5.T1C.T2A.X1C.X2A, Z6.T1C.T2A.X1C.X2A, Z1.T1D.T2A.X1C.X2A, Z2.T1D.T2A.X1C.X2A, Z3.T1D.T2A.X1C.X2A, Z4.T1D.T2A.X1CX2A, Z5.T1D.T2A.X1C.X2A, Z6.T1D.T2A.X1C.X2A, Z1.T1A.T2B.X1C.X2A, Z2.T1A.T2B.X1C.X2A, Z3.T1A.T2B.X1CX2A, Z4.T1A.T2B.X1C.X2A, Z5.T1A.T2B.X1C.X2A, Z6.T1A.T2B.X1C.X2A, Z1.T1B.T2B.X1C.X2A, Z2.T1B.T2B.X1C.X2A, Z3.T1B.T2B.X1C.X2A, Z4.T1B.T2B.X1C.X2A, Z5.T1B.T2B.X1C.X2A, Z6.T1B.T2B.X1C.X2A, Z1.T1C.T2B.X1C.X2A, Z2.T1C.T2B.X1C.X2A, Z3.T1C.T2B.X1C.X2A, Z4.T1C.T2B.X1C.X2A, Z5.T1C.T2B.X1C.X2A, Z6.T1CT2B.X1CX2A, Z1.T1D.T2B.X1CX2A, Z2.T1D.T2B.X1C.X2A, 23.T1D.T2B.X1C.X2A, Z4.T1D.T2B.X1CX2A, Z5.T1D.T2B.X1C.X2A, Z6.T1D.T2B.X1C.X2A, Z1.T1A.T2CX1GX2A, Z2.T1A.T2C.X1C.X2A, Z3.T1A.T2C.X1C.X2A, Z4.T1A.T2CX1CX2A, Z5.T1A.T2C.X1C.X2A, Z6.T1A.T2C.X1C.X2A, Z1.T1B.T2C.X1C.X2A, Z2.T1B.T2C.X1C.X2A, Z3.T1B.T2C.X1C.X2A, Z4.T1B.T2C.X1C.X2A, Z5.T1B.T2CX1C.X2A, Z6.T1B.T2C.X1C.X2A, Z1.T1C.T2C.X1CX2A, Z2.T1C.T2C.X1C.X2A, Z3.T1C.T2C.X1C.X2A, Z4.T1C.T2C.X1C.X2A, Z5.T1C.T2C.X1C.X2A, Z6.T1C.T2C.X1C.X2A, Z1.T1D.T2C.X1C.X2A, Z2.T1D.T2C.X1C.X2A, Z3.T1D.T2C.X1C.X2A, Z4.T1D.T2CX1CX2A, Z5.T1D.T2C.X1C.X2A, Z6.T1D.T2C.X1C.X2A, Z1.T1A.T2D.X1C.X2A, Z2.T1A.T2D.X1C.X2A, Z3.T1A.T2D.X1C.X2A, Z4.T1A.T2D.X1CX2A, Z5.T1A.T2D.X1C.X2A, Z6.T1A.T2D.X1C.X2A, Z1.T1B.T2D.X1C.X2A, Z2.T1B.T2D.X1C.X2A, Z3.T1B.T2D.X1CX2A, Z4.T1B.T2D.X1C.X2A, Z5.T1B.T2D.X1C.X2A, Z6.T1B.T2D.X1C.X2A, Z1.T1CT2D.X1C.X2A, Z2.T1C.T2D.X1C.X2A, Z3.T1C.T2D.X1C.X2A, Z4.T1C.T2D.X1C.X2A, Z5.T1C.T2D.X1C.X2A, Z6.T1C.T2D.X1C.X2A, Z1.T1D.T2D.X1C.X2A, Z2.T1D.T2D.X1C.X2A, Z3.T1D.T2D.X1C.X2A, Z4.T1D.T2D.X1C.X2A, Z5.T1D.T2D.X1CX2A, Z6.T1D.T2D.X1C.X2A, Z1.T1A.T2A.X1D.X2A, Z2.T1A.T2A.X1D.X2A, Z3.T1A.T2A.X1D.X2A, Z4.T1A.T2A.X1D.X2A, Z5.T1A.T2A.X1D.X2A, Z6.T1A.T2A.X1D.X2A, Z1.T1B.T2A.X1D.X2A, Z2.T1B.T2A.X1D.X2A, Z3.T1B.T2A.X1D.X2A, Z4.T1B.T2A.X1D.X2A, Z5.T1B.T2A.X1D.X2A, Z6.T1B.T2A.X1D.X2A, Z1.T1C.T2A.X1D.X2A, Z2.T1C.T2A.X1D.X2A, Z3.T1C.T2A.X1D.X2A, Z4.T1C.T2A.X1D.X2A, Z5.T1C.T2A.X1D.X2A, Z6.T1C.T2A.X1D.X2A, Z1.T1D.T2A.X1D.X2A, Z2.T1D.T2A.X1D.X2A, Z3.T1D.T2A.X1D.X2A, Z4.T1D.T2A.X1D.X2A, Z5.T1D.T2A.X1D.X2A, Z6.T1D.T2A.X1D.X2A, Z1.T1A.T2B.X1D.X2A, Z2.T1A.T2B.X1D.X2A, Z3.T1A.T2B.X1D.X2A, Z4.T1A.T2B.X1D.X2A, Z5.T1A.T2B.X1D.X2A, Z6.T1A.T2B.X1D.X2A, Z1.T1B.T2B.X1D.X2A, Z2.T1B.T2B.X1D.X2A, Z3.T1B.T2B.X1D.X2A, Z4.T1B.T2B.X1D.X2A, Z5.T1B.T2B.X1D.X2A, Z6.T1B.T2B.X1D.X2A, Z1.T1C.T2B.X1D.X2A, Z2.T1C.T2B.X1D.X2A, Z3.T1C.T2B.X1D.X2A, Z4.T1C.T2B.X1D.X2A, Z5.T1C.T2B.X1D.X2A, Z6.T1C.T2B.X1D.X2A, Z1.T1D.T2B.X1D.X2A, Z2.T1D.T2B.X1D.X2A, Z3.T1D.T2B.X1D.X2A, Z4.T1D.T2B.X1D.X2A, Z5.T1D.T2B.X1D.X2A, Z6.T1D.T2B.X1D.X2A, Z1.T1A.T2C.X1D.X2A, Z2.T1A.T2C.X1D.X2A, Z3.T1A.T2C.X1D.X2A, Z4.T1A.T2C.X1D.X2A, Z5.T1A.T2C.X1D.X2A, Z6.T1A.T2C.X1D.X2A, Z1.T1B.T2C.X1D.X2A, Z2.T1B.T2C.X1D.X2A, Z3.T1B.T2C.X1D.X2A, Z4.T1B.T2C.X1D.X2A, Z5.T1B.T2C.X1D.X2A, Z6.T1B.T2C.X1D.X2A, Z1.T1C.T2C.X1D.X2A, Z2.T1C.T2C.X1D.X2A, Z3.T1C.T2C.X1D.X2A, Z4.T1C.T2C.X1D.X2A, Z5.T1C.T2C.X1D.X2A, Z6.T1C.T2C.X1D.X2A, Z1.T1D.T2C.X1D.X2A, Z2.T1D.T2C.X1D.X2A, Z3.T1D.T2C.X1D.X2A, Z4.T1D.T2C.X1D.X2A, Z5.T1D.T2C.X1D.X2A, Z6.T1D.T2C.X1D.X2A, Z1.T1A.T2D.X1D.X2A, Z2.T1A.T2D.X1D.X2A, Z3.T1A.T2D.X1D.X2A, Z4.T1A.T2D.X1D.X2A, Z5.T1A.T2D.X1D.X2A, Z6.T1A.T2D.X1D.X2A, Z1.T1B.T2D.X1D.X2A, Z2.T1B.T2D.X1D.X2A, Z3.T1B.T2D.X1D.X2A, Z4.T1B.T2D.X1D.X2A, Z5.T1B.T2D.X1D.X2A, Z6.T1B.T2D.X1D.X2A, Z1.T1C.T2D.X1D.X2A, Z2.T1C.T2D.X1D.X2A, Z3.T1C.T2D.X1D.X2A, Z4.T1CT2D.X1D.X2A, Z5.T1C.T2D.X1D.X2A, Z6.T1C.T2D.X1D.X2A, Z1.T1D.T2D.X1D.X2A, Z2.T1D.T2D.X1D.X2A, Z3.T1D.T2D.X1D.X2A, Z4.T1D.T2D.X1D.X2A, Z5.T1D.T2D.X1D.X2A, Z6.T1D.T2D.X1D.X2A, Z1.T1A.T2A.X1E.X2A, Z2.T1A.T2A.X1E.X2A, Z3.T1A.T2A.X1E.X2A, Z4.T1A.T2A.X1E.X2A, Z5.T1A.T2A.X1E.X2A, Z6.T1A.T2A.X1E.X2A, Z1.T1B.T2A.X1E.X2A, Z2.T1B.T2A.X1E.X2A, Z3.T1B.T2A.X1E.X2A,
Z4.T1B.T2A.X1E.X2A, Z5.T1B.T2A.X1E.X2A, Z6.T1B.T2A.X1E.X2A, Z1.T1C.T2A.X1E.X2A, Z2.T1C.T2A.X1E.X2A, Z3.T1C.T2A.X1E.X2A, Z4.T1C.T2A.X1E.X2A, Z5.T1C.T2A.X1E.X2A, Z6.T1C.T2A.X1E.X2A, Z1.T1D.T2A.X1E.X2A, Z2.T1D.T2A.X1E.X2A, Z3.T1D.T2A.X1E.X2A, Z4.T1D.T2A.X1E.X2A, Z5.T1D.T2A.X1E.X2A, Z6.T1D.T2A.X1E.X2A, Z1.T1A.T2B.X1E.X2A, Z2.T1A.T2B.X1E.X2A, Z3.T1A.T2B.X1E.X2A, Z4.T1A.T2B.X1E.X2A, Z5.T1A.T2B.X1E.X2A, Z6.T1A.T2B.X1E.X2A, Z1.T1B.T2B.X1E.X2A, Z2.T1B.T2B.X1E.X2A, Z3.T1B.T2B.X1E.X2A, Z4.T1B.T2B.X1E.X2A, Z5.T1B.T2B.X1E.X2A, Z6.T1B.T2B.X1E.X2A, Z1.T1C.T2B.X1E.X2A, Z2.T1C.T2B.X1E.X2A, Z3.T1C.T2B.X1E.X2A, Z4.T1C.T2B.X1E.X2A, Z5.T1C.T2B.X1E.X2A, Z6.T1C.T2B.X1E.X2A, Z1.T1D.T2B.X1E.X2A, Z2.T1D.T2B.X1E.X2A, Z3.T1D.T2B.X1E.X2A, Z4.T1D.T2B.X1E.X2A, Z5.T1D.T2B.X1E.X2A, Z6.T1D.T2B.X1E.X2A, Z1.T1A.T2C.X1E.X2A, Z2.T1A.T2C.X1E.X2A, Z3.T1A.T2C.X1E.X2A, Z4.T1A.T2C.X1E.X2A, Z5.T1A.T2C.X1E.X2A, Z6.T1A.T2C.X1E.X2A, Z1.T1B.T2C.X1E.X2A, Z2.T1B.T2C.X1E.X2A, Z3.T1B.T2C.X1E.X2A, Z4.T1B.T2C.X1E.X2A, Z5.T1B.T2C.X1E.X2A, Z6.T1B.T2C.X1E.X2A, Z1.T1C.T2C.X1E.X2A, Z2.T1C.T2C.X1E.X2A, Z3.T1C.T2C.X1E.X2A, Z4.T1C.T2C.X1E.X2A, Z5.T1C.T2C.X1E.X2A, Z6.T1C.T2C.X1E.X2A, Z1.T1D.T2C.X1E.X2A, Z2.T1D.T2C.X1E.X2A, Z3.T1D.T2C.X1E.X2A, Z4.T1D.T2C.X1E.X2A, Z5.T1D.T2C.X1E.X2A, Z6.T1D.T2C.X1E.X2A, Z1.T1A.T2D.X1E.X2A, Z2.T1A.T2D.X1E.X2A, Z3.T1A.T2D.X1E.X2A, Z4.T1A.T2D.X1E.X2A, Z5.T1A.T2D.X1E.X2A, Z6.T1A.T2D.X1E.X2A, Z1.T1B.T2D.X1E.X2A, Z2.T1B.T2D.X1E.X2A, Z3.T1B.T2D.X1E.X2A, Z4.T1B.T2D.X1E.X2A, Z5.T1B.T2D.X1E.X2A, Z6.T1B.T2D.X1E.X2A, Z1.T1CT2D.X1E.X2A, Z2.T1C.T2D.X1E.X2A, Z3.T1C.T2D.X1E.X2A, Z4.T1C.T2D.X1E.X2A, 25.T1C.T2D.X1E.X2A, Z6.T1C.T2D.X1E.X2A, Z1.T1D.T2D.X1E.X2A, Z2.T1D.T2D.X1E.X2A, Z3.T1D.T2D.X1E.X2A, Z4.T1D.T2D.X1E.X2A, Z5.T1D.T2D.X1E.X2A, Z6.T1D.T2D.X1E.X2A, Z1.T1A.T2A.X1A.X2B, Z2.T1A.T2A.X1A.X2B, Z3.T1A.T2A.X1A.X2B, Z4.T1A.T2A.X1A.X2B, Z5.T1A.T2A.X1A.X2B, Z6.T1A.T2A.X1A.X2B, Z1.T1B.T2A.X1A.X2B, Z2.T1B.T2A.X1A.X2B, Z3.T1B.T2A.X1A.X2B, Z4.T1B.T2A.X1A.X2B, Z5.T1B.T2A.X1A.X2B, Z6.T1B.T2A.X1A.X2B, Z1.T1C.T2A.X1A.X2B, Z2.T1C.T2A.X1A.X2B, Z3.T1C.T2A.X1A.X2B, Z4T1C.T2A.X1A.X2B, Z5.T1C.T2A.X1A.X2B, Z6.T1C.T2A.X1A.X2B, Z1.T1D.T2A.X1A.X2B, Z2.T1D.T2A.X1A.X2B, Z3.T1D.T2A.X1A.X2B, Z4.T1D.T2A.X1A.X2B, Z5.T1D.T2A.X1A.X2B, Z6.T1D.T2A.X1A.X2B, Z1.T1A.T2B.X1A.X2B, Z2.T1A.T2B.X1A.X2B, Z3.T1A.T2B.X1A.X2B, Z4.T1A.T2B.X1A.X2B, Z5.T1A.T2B.X1A.X2B, Z6.T1A.T2B.X1A.X2B, Z1.T1B.T2B.X1A.X2B, Z2.T1B.T2B.X1A.X2B, Z3.T1B.T2B.X1A.X2B, Z4.T1B.T2B.X1A.X2B, Z5.T1B.T2B.X1A.X2B, Z6.T1B.T2B.X1A.X2B, Z1.T1C.T2B.X1A.X2B, Z2.T1C.T2B.X1A.X2B, Z3.T1C.T2B.X1A.X2B, Z4.T1C.T2B.X1A.X2B, Z5.T1C.T2B.X1A.X2B, Z6.T1C.T2B.X1A.X2B, Z1.T1D.T2B.X1A.X2B, Z2.T1D.T2B.X1A.X2B, Z3.T1D.T2B.X1A.X2B, Z4T1D.T2B.X1A.X2B, Z5.T1D.T2B.X1A.X2B, Z6.T1D.T2B.X1A.X2B, Z1.T1A.T2C.X1A.X2B, Z2.T1A.T2C.X1A.X2B, Z3.T1A.T2C.X1A.X2B, Z4.T1A.T2C.X1A.X2B, Z5.T1A.T2C.X1A.X2B, Z6.T1A.T2C.X1A.X2B, Z1.T1B.T2C.X1A.X2B, Z2.T1B.T2C.X1A.X2B, Z3.T1B.T2C.X1A.X2B, Z4.T1B.T2C.X1A.X2B, Z5.T1B.T2C.X1A.X2B, Z6.T1B.T2C.X1A.X2B, Z1.T1C.T2C.X1A.X2B, Z2.T1C.T2C.X1A.X2B, Z3.T1C.T2C.X1A.X2B, Z4.T1C.T2C.X1A.X2B, Z5.T1C.T2C.X1A.X2B, Z6.T1CT2CX1A.X2B, Z1.T1D.T2C.X1A.X2B, Z2.T1D.T2C.X1A.X2B, Z3.T1D.T2CX1A.X2B, Z4.T1D.T2C.X1A.X2B, Z5.T1D.T2CX1A.X2B, Z6.T1D.T2C.X1A.X2B, Z1.T1A.T2D.X1A.X2B, Z2.T1A.T2D.X1A.X2B, Z3.T1A.T2D.X1A.X2B, Z4.T1A.T2D.X1A.X2B, Z5.T1A.T2D.X1A.X2B, Z6.T1A.T2D.X1A.X2B, Z1.T1B.T2D.X1A.X2B, Z2.T1B.T2D.X1A.X2B, Z3.T1B.T2D.X1A.X2B, Z4.T1B.T2D.X1A.X2B, Z5.T1B.T2D.X1A.X2B, Z6.T1B.T2D.X1A.X2B, Z1.T1C.T2D.X1A.X2B, Z2.T1C.T2D.X1A.X2B, Z3.T1C.T2D.X1A.X2B, Z4.T1C.T2D.X1A.X2B, Z5.T1C.T2D.X1A.X2B, Z6.T1C.T2D.X1A.X2B, Z1.T1D.T2D.X1A.X2B, Z2.T1D.T2D.X1A.X2B, Z3.T1D.T2D.X1A.X2B, Z4.T1D.T2D.X1A.X2B, Z5.T1D.T2D.X1A.X2B, Z6.T1D.T2D.X1A.X2B, Z1.T1A.T2A.X1B.X2B, Z2.T1A.T2A.X1B.X2B, Z3.T1A.T2A.X1B.X2B, Z4.T1A.T2A.X1B.X2B, Z5.T1A.T2A.X1B.X2B, Z6.T1A.T2A.X1B.X2B, Z1.T1B.T2A.X1B.X2B, Z2.T1B.T2A.X1B.X2B, Z3.T1B.T2A.X1B.X2B, Z4.T1B.T2A.X1B.X2B, Z5.T1B.T2A.X1B.X2B, Z6.T1B.T2A.X1B.X2B, Z1.T1CT2A.X1B.X2B, Z2.T1C.T2A.X1B.X2B, Z3.T1C.T2A.X1B.X2B, Z4.T1C.T2A.X1B.X2B, Z5.T1C.T2A.X1B.X2B, Z6.T1C.T2A.X1B.X2B, Z1.T1D.T2A.X1B.X2B, Z2.T1D.T2A.X1B.X2B, Z3.T1D.T2A.X1B.X2B, Z4.T1D.T2A.X1B.X2B, Z5.T1D.T2A.X1B.X2B, Z6.T1D.T2A.X1B.X2B, Z1.T1A.T2B.X1B.X2B, Z2.T1A.T2B.X1B.X2B, Z3.T1A.T2B.X1B.X2B, Z4.T1A.T2B.X1B.X2B, Z5.T1A.T2B.X1B.X2B, Z6.T1A.T2B.X1B.X2B, Z1.T1B.T2B.X1B.X2B, Z2.T1B.T2B.X1B.X2B, Z3.T1B.T2B.X1B.X2B, Z4.T1B.T2B.X1B.X2B, Z5.T1B.T2B.X1B.X2B, Z6.T1B.T2B.X1B.X2B, Z1.T1C.T2B.X1B.X2B, Z2.T1C.T2B.X1B.X2B, Z3.T1CT2B.X1B.X2B, Z4.T1C.T2B.X1B.X2B, Z5.T1C.T2B.X1B.X2B, Z6.T1C.T2B.X1B.X2B, Z1.T1D.T2B.X1B.X2B, Z2.T1D.T2B.X1B.X2B, Z3.T1D.T2B.X1B.X2B, Z4.T1D.T2B.X1B.X2B, Z5.T1D.T2B.X1B.X2B, Z6.T1D.T2B.X1B.X2B, Z1.T1A.T2CX1B.X2B, Z2.T1A.T2C.X1B.X2B, Z3.T1A.T2C.X1B.X2B, Z4.T1A.T2C.X1B.X2B, Z5.T1A.T2C.X1B.X2B, Z6.T1A.T2C.X1B.X2B, 21.T1B.T2C.X1B.X2B, Z2.T1B.T2C.X1B.X2B, Z3.T1B.T2C.X1B.X2B, Z4.T1B.T2C.X1B.X2B, Z5.T1B.T2CX1B.X2B, Z6.T1B.T2CX1B.X2B, Z1.T1C.T2CX1B.X2B, Z2.T1C.T2C.X1B.X2B, Z3.T1C.T2C.X1B.X2B, Z4.T1CT2C.X1B.X2B, Z5.T1C.T2C.X1B.X2B, Z6.T1C.T2C.X1B.X2B, Z1.T1D.T2C.X1B.X2B, Z2.T1D.T2C.X1B.X2B, Z3.T1D.T2C.X1B.X2B, Z4.T1D.T2C.X1B.X2B, Z5.T1D.T2C.X1B.X2B, Z6.T1D.T2C.X1B.X2B, Z1.T1A.T2D.X1B.X2B, Z2.T1A.T2D.X1B.X2B, Z3.T1A.T2D.X1B.X2B, Z4.T1A.T2D.X1B.X2B, Z5.T1A.T2D.X1B.X2B, Z6.T1A.T2D.X1B.X2B, Z1.T1B.T2D.X1B.X2B, Z2.T1B.T2D.X1B.X2B, Z3.T1B.T2D.X1B.X2B, Z4.T1B.T2D.X1B.X2B, Z5.T1B.T2D.X1B.X2B, Z6.T1B.T2D.X1B.X2B, Z1.T1C.T2D.X1B.X2B, Z2.T1C.T2D.X1B.X2B, Z3.T1CT2D.X1B.X2B, Z4.T1C.T2D.X1B.X2B, Z5.T1C.T2D.X1B.X2B, Z6.T1C.T2D.X1B.X2B, Z1.T1D.T2D.X1B.X2B, Z2.T1D.T2D.X1B.X2B, Z3.T1D.T2D.X1B.X2B, Z4.T1D.T2D.X1B.X2B, Z5.T1D.T2D.X1B.X2B, Z6.T1D.T2D.X1B.X2B, Z1.T1A.T2A.X1C.X2B, Z2.T1A.T2A.X1C.X2B, Z3.T1A.T2A.X1C.X2B, Z4.T1A.T2A.X1C.X2B, Z5.T1A.T2A.X1C.X2B, Z6.T1A.T2A.X1C.X2B, Z1.T1B.T2A.X1C.X2B, Z2.T1B.T2A.X1C.X2B, Z3.T1B.T2A.X1C.X2B, Z4.T1B.T2A.X1C.X2B, Z5.T1B.T2A.X1C.X2B, Z6.T1B.T2A.X1C.X2B, Z1.T1C.T2A.X1C.X2B, Z2.T1C.T2A.X1C.X2B, Z3.T1C.T2A.X1C.X2B, Z4.T1C.T2A.X1C.X2B, Z5.T1C.T2A.X1C.X2B, Z6.T1C.T2A.X1C.X2B, Z1.T1D.T2A.X1C.X2B, Z2.T1D.T2A.X1C.X2B, Z3.T1D.T2A.X1C.X2B, Z4.T1D.T2A.X1C.X2B, Z5.T1D.T2A.X1C.X2B, Z6.T1D.T2A.X1C.X2B, Z1.T1A.T2B.X1C.X2B, Z2.T1A.T2B.X1C.X2B, Z3.T1A.T2B.X1C.X2B, Z4.T1A.T2B.X1C.X2B, Z5.T1A.T2B.X1C.X2B, Z6.T1A.T2B.X1C.X2B, Z1.T1B.T2B.X1C.X2B, Z2.T1B.T2B.X1CX2B, Z3.T1B.T2B.X1CX2B, Z4.T1B.T2B.X1CX2B, Z5.T1B.T2B.X1C.X2B, Z6.T1B.T2B.X1C.X2B, Z1.T1C.T2B.X1C.X2B, Z2.T1C.T2B.X1C.X2B, Z3.T1C.T2B.X1C.X2B,
Z4.T1C.T2B.X1C.X2B, Z5.T1C.T2B.X1C.X2B, Z6.T1C.T2B.X1C.X2B, Z1.T1D.T2B.X1C.X2B, Z2.T1D.T2B.X1C.X2B, Z3.T1D.T2B.X1C.X2B, Z4.T1D.T2B.X1C.X2B, Z5.T1D.T2B.X1C.X2B, Z6.T1D.T2B.X1C.X2B, Z1.T1A.T2CX1CX2B, Z2.T1A.T2C.X1C.X2B, Z3.T1A.T2C.X1C.X2B, Z4.T1A.T2C.X1C.X2B, Z5.T1A.T2C.X1C.X2B, Z6.T1A.T2C.X1C.X2B, Z1.T1B.T2C.X1C.X2B, Z2.T1B.T2C.X1C.X2B, Z3.T1B.T2C.X1C.X2B, Z4.T1B.T2C.X1C.X2B, Z5.T1B.T2C.X1C.X2B, Z6.T1B.T2C.X1C.X2B, Z1.T1C.T2C.X1C.X2B, Z2.T1C.T2C.X1C.X2B, Z3.T1C.T2C.X1C.X2B, Z4.T1C.T2C.X1C.X2B, Z5.T1C.T2C.X1C.X2B, Z6.T1C.T2C.X1C.X2B, Z1.T1D.T2C.X1C.X2B, Z2.T1D.T2C.X1C.X2B, Z3.T1D.T2C.X1C.X2B, Z4.T1D.T2C.X1C.X2B, Z5.T1D.T2C.X1C.X2B, Z6.T1D.T2C.X1C.X2B, Z1.T1A.T2D.X1C.X2B, Z2.T1A.T2D.X1C.X2B, Z3.T1A.T2D.X1C.X2B, Z4.T1A.T2D.X1C.X2B, Z5.T1A.T2D.X1C.X2B, Z6.T1A.T2D.X1C.X2B, Z1.T1B.T2D.X1C.X2B, Z2.T1B.T2D.X1C.X2B, Z3.T1B.T2D.X1C.X2B, Z4.T1B.T2D.X1C.X2B, Z5.T1B.T2D.X1C.X2B, Z6.T1B.T2D.X1C.X2B, Z1.T1C.T2D.X1C.X2B, Z2.T1C.T2D.X1C.X2B, Z3.T1C.T2D.X1C.X2B, Z4.T1C.T2D.X1C.X2B, Z5.T1C.T2D.X1C.X2B, Z6.T1C.T2D.X1C.X2B, Z1.T1D.T2D.X1C.X2B, Z2.T1D.T2D.X1C.X2B, Z3.T1D.T2D.X1C.X2B, Z4.T1D.T2D.X1CX2B, Z5.T1D.T2D.X1C.X2B, Z6.T1D.T2D.X1C.X2B, Z1.T1A.T2A.X1D.X2B, Z2.T1A.T2A.X1D.X2B, Z3.T1A.T2A.X1D.X2B, Z4.T1A.T2A.X1D.X2B, Z5.T1A.T2A.X1D.X2B, Z6.T1A.T2A.X1D.X2B, Z1.T1B.T2A.X1D.X2B, Z2.T1B.T2A.X1D.X2B, Z3.T1B.T2A.X1D.X2B, Z4.T1B.T2A.X1D.X2B, Z5.T1B.T2A.X1D.X2B, Z6.T1B.T2A.X1D.X2B, Z1.T1CT2A.X1D.X2B, Z2.T1C.T2A.X1D.X2B, Z3.T1C.T2A.X1D.X2B, Z4.T1C.T2A.X1D.X2B, Z5.T1C.T2A.X1D.X2B, Z6.T1C.T2A.X1D.X2B, Z1.T1D.T2A.X1D.X2B, Z2.T1D.T2A.X1D.X2B, Z3.T1D.T2A.X1D.X2B, Z4.T1D.T2A.X1D.X2B, Z5.T1D.T2A.X1D.X2B, Z6.T1D.T2A.X1D.X2B, Z1.T1A.T2B.X1D.X2B, Z2.T1A.T2B.X1D.X2B, Z3.T1A.T2B.X1D.X2B, Z4.T1A.T2B.X1D.X2B, Z5.T1A.T2B.X1D.X2B, Z6.T1A.T2B.X1D.X2B, Z1.T1B.T2B.X1D.X2B, Z2.T1B.T2B.X1D.X2B, Z3.T1B.T2B.X1D.X2B, Z4.T1B.T2B.X1D.X2B, Z5.T1B.T2B.X1D.X2B, Z6.T1B.T2B.X1D.X2B, Z1.T1C.T2B.X1D.X2B, Z2.T1C.T2B.X1D.X2B, Z3.T1C.T2B.X1D.X2B, Z4.T1C.T2B.X1D.X2B, Z5.T1C.T2B.X1D.X2B, Z6.T1C.T2B.X1D.X2B, Z1.T1D.T2B.X1D.X2B, Z2.T1D.T2B.X1D.X2B, Z3.T1D.T2B.X1D.X2B, Z4.T1D.T2B.X1D.X2B, Z5.T1D.T2B.X1D.X2B, Z6.T1D.T2B.X1D.X2B, Z1.T1A.T2CX1D.X2B, Z2.T1A.T2CX1D.X2B, Z3.T1A.T2CX1D.X2B, Z4.T1A.T2C.X1D.X2B, Z5.T1A.T2C.X1D.X2B, Z6.T1A.T2C.X1D.X2B, Z1.T1B.T2C.X1D.X2B, Z2.T1B.T2C.X1D.X2B, Z3.T1B.T2C.X1D.X2B, Z4.T1B.T2C.X1D.X2B, Z5.T1B.T2C.X1D.X2B, Z6.T1B.T2CX1D.X2B, Z1.T1C.T2C.X1D.X2B, Z2.T1C.T2C.X1D.X2B, Z3.T1C.T2C.X1D.X2B, Z4.T1C.T2C.X1D.X2B, Z5.T1CT2CX1D,X2B, Z6.T1C.T2C.X1D.X2B, Z1.T1D.T2C.X1D.X2B, Z2.T1D.T2C.X1D.X2B, Z3.T1D.T2C.X1D.X2B, Z4.T1D.T2C.X1D.X2B, Z5.T1D.T2C.X1D.X2B, Z6.T1D.T2C.X1D.X2B, Z1.T1A.T2D.X1D.X2B, Z2.T1A.T2D.X1D.X2B, Z3.T1A.T2D.X1D.X2B, Z4.T1A.T2D.X1D.X2B, Z5.T1A.T2D.X1D.X2B, Z6.T1A.T2D.X1D.X2B, Z1.T1B.T2D.X1D.X2B, Z2.T1B.T2D.X1D.X2B, Z3.T1B.T2D.X1D.X2B, Z4.T1B.T2D.X1D.X2B, Z5.T1B.T2D.X1D.X2B, Z6.T1B.T2D.X1D.X2B, Z1.T1CT2D.X1D.X2B, Z2.T1C.T2D.X1D.X2B, Z3.T1C.T2D.X1D.X2B, Z4.T1C.T2D.X1D.X2B, Z5.T1C.T2D.X1D.X2B, Z6.T1C.T2D.X1D.X2B, Z1.T1D.T2D.X1D.X2B, Z2.T1D.T2D.X1D.X2B, Z3.T1D.T2D.X1D.X2B, Z4.T1D.T2D.X1D.X2B, Z5.T1D.T2D.X1D.X2B, Z6.T1D.T2D.X1D.X2B, Z1.T1A.T2A.X1E.X2B, Z2.T1A.T2AXLE.X2B, Z3.T1A.T2A.X1E.X2B, Z4.T1A.T2A.X1E.X2B, Z5.T1A.T2A.X1E.X2B, Z6.T1A.T2A.X1E.X2B, Z1.T1B.T2A.X1E.X2B, Z2.T1B.T2A.X1E.X2B, Z3.T1B.T2A.X1E.X2B, Z4.T1B.T2A.X1E.X2B, Z5.T1B.T2A.X1E.X2B, Z6.T1B.T2A.X1E.X2B, Z1.T1C.T2A.X1E.X2B, Z2.T1C.T2A.X1E.X2B, Z3.T1C.T2A.X1E.X2B, Z4.T1C.T2A.X1E.X2B, Z5.T1CT2A.X1E.X2B, Z6.T1C.T2A.X1E.X2B, Zi.TlD.T2A.XlE.X2B, Z2.T1D.T2A.X1E.X2B, Z3.T1D.T2A.X1E.X2B, Z4.T1D.T2A.X1E.X2B, Z5.T1D.T2A.X1E.X2B, Z6.T1D.T2A.X1E.X2B, Z1.T1A.T2B.X1E.X2B, Z2.T1A.T2B.X1E.X2B, Z3.T1A.T2B.X1E.X2B, Z4.T1A.T2B.X1E.X2B, Z5.T1A.T2B.X1E.X2B, Z6.T1A.T2B.X1E.X2B, Z1.T1B.T2B.X1E.X2B, Z2.T1B.T2B.X1E.X2B, Z3.T1B.T2B.X1E.X2B, Z4.T1B.T2B.X1E.X2B, Z5.T1B.T2B.X1E.X2B, Z6.T1B.T2B.X1E.X2B, Z1.T1CT2B.X1E.X2B, Z2.T1C.T2B.X1E.X2B, Z3.T1C.T2B.X1E.X2B, Z4.T1C.T2B.X1E.X2B, Z5.T1C.T2B.X1E.X2B, Z6.T1C.T2B.X1E.X2B, Z1.T1D.T2B.X1E.X2B, Z2.T1D.T2B.X1E.X2B, Z3.T1D.T2B.X1E.X2B, Z4.T1D.T2B.X1E.X2B, Z5.T1D.T2B.X1E.X2B, Z6.T1D.T2B.X1E.X2B, Z1.T1A.T2C.X1E.X2B, Z2.T1A.T2C.X1E.X2B, Z3.T1A.T2C.X1E.X2B, Z4.T1A.T2C.X1E.X2B, Z5.T1A.T2C.X1E.X2B, Z6.T1A.T2C.X1E.X2B, Z1.T1B.T2C.X1E.X2B, Z2.T1B.T2C.X1E.X2B, Z3.T1B.T2C.X1E.X2B, Z4.T1B.T2C.X1E.X2B, Z5.T1B.T2C.X1E.X2B, Z6.T1B.T2C.X1E.X2B, Z1.T1C.T2C.X1E.X2B, Z2.T1CT2CX1E.X2B, Z3.T1C.T2C.X1E.X2B, Z4.T1C.T2C.X1E.X2B, Z5.T1C.T2C.X1E.X2B, Z6.T1C.T2C.X1E.X2B, Z1.T1D.T2C.X1E.X2B, Z2.T1D.T2C.X1E.X2B, Z3.T1D.T2C.X1E.X2B, Z4.T1D.T2C.X1E.X2B, Z5.T1D.T2C.X1E.X2B, Z6.T1D.T2C.X1E.X2B, Z1.T1A.T2D.X1E.X2B, Z2.T1A.T2D.X1E.X2B, Z3.T1A.T2D.X1E.X2B, Z4.T1A.T2D.X1E.X2B, Z5.T1A.T2D.X1E.X2B, Z6.T1A.T2D.X1E.X2B, Z1.T1B.T2D.X1E.X2B, Z2.T1B.T2D.X1E.X2B, Z3.T1B.T2D.X1E.X2B, Z4.T1B.T2D.X1E.X2B, Z5.T1B.T2D.X1E.X2B, Z6.T1B.T2D.X1E.X2B, Z1.T1CT2D.X1E.X2B, Z2.T1C.T2D.X1E.X2B, Z3.T1C.T2D.X1E.X2B, Z4.T1C.T2D.X1E.X2B, Z5.T1C.T2D.X1E.X2B, Z6.T1C.T2D.X1E.X2B, Z1.T1D.T2D.X1E.X2B, Z2.T1D.T2D.X1E.X2B, Z3.T1D.T2D.X1E.X2B, Z4.T1D.T2D.X1E.X2B, Z5.T1D.T2D.X1E.X2B, Z6.T1D.T2D.X1E.X2B, Z1.T1A.T2A.X1A.X2C, Z2.T1A.T2A.X1A.X2C, Z3.T1 A.T2A.X1A.X2Q Z4.T1A.T2A.X1A.X2C, Z5.T1A.T2A.X1A.X2C, Z6.T1A.T2A.X1A.X2Q Z1.T1B.T2A.X1A.X2C, Z2.T1B.T2A.X1A.X2C, Z3.T1B.T2A.X1A.X2C, Z4.T1B.T2A.X1A.X2C, Z5.T1B.T2A.X1A.X2Q Z6.T1B.T2A.X1A.X2C, Z1.T1C.T2A.X1A.X2C, Z2.T1C.T2A.X1A.X2Q Z3.T1C.T2A.X1A.X2Q Z4.T1C.T2A.X1A.X2C, Z5.T1C.T2A.X1A.X2Q Z6.T1CT2A.X1A.X2Q Z1.T1D.T2A.X1A.X2C, Z2.T1D.T2A.X1A.X2Q Z3.T1D.T2A.X1A.X2Q Z4.T1D.T2A.X1A.X2Q Z5.T1D.T2A.X1A.X2Q Z6.T1D.T2A.X1A.X2Q Z1.T1A.T2B.X1A.X2Q Z2.T1A.T2B.X1A.X2Q Z3.T1A.T2B.X1A.X2C, Z4.T1A.T2B.X1A.X2Q Z5.T1A.T2B.X1A.X2Q Z6.T1A.T2B.X1A.X2Q Z1.T1B.T2B.X1A.X2Q Z2.T1B.T2B.X1A.X2C, Z3.T1B.T2B.X1A.X2Q Z4.T1B.T2B.X1A.X2Q Z5.T1B.T2B.X1A.X2Q Z6.T1B.T2B.X1A.X2Q Z1.T1C.T2B.X1A.X2C, Z2.T1C.T2B.X1A.X2Q Z3.T1C.T2B.X1A.X2C, Z4.T1C.T2B.X1A.X2Q Z5.T1C.T2B.X1A.X2Q Z6.T1C.T2B.X1A.X2Q Z1.T1D.T2B.X1A.X2C, Z2.T1D.T2B.X1A.X2Q Z3.T1D.T2B.X1A.X2Q Z4.T1D.T2B.X1A.X2Q Z5.T1D.T2B.X1A.X2Q Z6.T1D.T2B.X1A.X2Q Z1.T1A.T2C.X1A.X2Q Z2.T1A.T2C.X1A.X2Q Z3.T1A.T2C.X1A.X2Q Z4.T1A.T2C.X1A.X2Q Z5.T1A.T2C.X1A.X2Q Z6.T1A.T2C.X1A.X2C, Z1.T1B.T2CX1A.X2C, Z2.T1B.T2C.X1A.X2C Z3.T1B.T2CX1A.X2Q Z4.T1B.T2C.X1A.X2C, Z5.T1B.T2C.X1A.X2C, Z6.T1B.T2CX1A.X2Q Z1.T1C.T2C.X1A.X2C, Z2.T1C.T2C.X1A.X2C, Z3.T1C.T2C.X1A.X2Q Z4.T1C.T2C.X1A.X2C Z5.T1C.T2C.X1A.X2Q Z6.T1C.T2CX1A.X2Q Z1.T1D.T2CX1A.X2Q Z2.T1D.T2C.X1A.X2Q Z3.T1D.T2CX1A.X2C Z4.T1D.T2CX1A.X2Q Z5.T1D.T2C.X1A.X2Q Z6.T1D.T2C.X1A.X2Q Z1.T1A.T2D.X1A.X2Q Z2.T1A.T2D.X1A.X2C, Z3.T1A.T2D.X1A.X2Q Z4.T1A.T2D.X1A.X2Q Z5.T1A.T2D.X1A.X2Q Z6.T1A.T2D.X1A.X2Q Z1.T1B.T2D.X1A.X2Q Z2.T1B.T2D.X1A.X2Q Z3.T1B.T2D.X1A.X2Q Z4.T1B.T2D.X1A.X2Q Z5.T1B.T2D.X1A.X2Q Z6.T1B.T2D.X1A.X2Q Z1.T1C.T2D.X1A.X2Q Z2.T1CT2D.X1A.X2Q Z3.T1CT2D.X1A.X2Q Z4.T1CT2D.X1A.X2Q Z5.T1CT2D.X1A.X2Q Z6.T1CT2D.X1A.X2Q Z1.T1D.T2D.X1A.X2Q Z2.T1D.T2D.X1A.X2Q Z3.T1D.T2D.X1A.X2Q Z4.T1D.T2D.X1A.X2Q Z5.T1D.T2D.X1A.X2Q Z6.T1D.T2D.X1A.X2Q Z1.T1A.T2A.X1B.X2Q Z2.T1A.T2A.X1B.X2Q Z3.T1A.T2A.X1B.X2Q Z4.T1A.T2A.X1B.X2C, Z5.T1A.T2A.X1B.X2Q Z6.T1A.T2A.X1B.X2Q Z1.T1B.T2A.X1B.X2Q Z2.T1B.T2A.X1B.X2Q Z3.T1B.T2A.X1B.X2Q Z4.T1B.T2A.X1B.X2Q Z5.T1B.T2A.X1B.X2Q Z6.T1B.T2A.X1B.X2Q Z1.T1CT2A.X1B.X2Q Z2.T1CT2A.X1B.X2Q Z3.T1CT2A.X1B.X2Q Z4.T1CT2A.X1B.X2Q Z5.T1CT2A.X1B.X2Q Z6.T1CT2A.X1B.X2Q Z1.T1D.T2A.X1B.X2Q Z2.T1D.T2A.X1B.X2Q Z3.T1D.T2A.X1B.X2Q Z4.T1D.T2A.X1B.X2Q Z5.T1D.T2A.X1B.X2Q Z6.T1D.T2A.X1B.X2Q Z1.T1A.T2B.X1B.X2Q Z2.T1A.T2B.X1B.X2Q Z3.T1A.T2B.X1B.X2Q Z4.T1A.T2B.X1B.X2Q Z5.T1A.T2B.X1B.X2Q Z6.T1A.T2B.X1B.X2Q Z1.T1B.T2B.X1B.X2Q Z2.T1B.T2B.X1B.X2Q Z3.T1B.T2B.X1B.X2Q Z4.T1B.T2B.X1B.X2Q Z5.T1B.T2B.X1B.X2Q Z6.T1B.T2B.X1B.X2Q Z1.T1C.T2B.X1B.X2C, Z2.T1CT2B.X1B.X2C, Z3.T1C.T2B.X1B.X2C, Z4.T1C.T2B.X1B.X2C Z5.T1C.T2B.X1B.X2C, Z6.T1C.T2B.X1B.X2Q Z1.T1D.T2B.X1B.X2C, Z2.T1D.T2B.X1B.X2C, Z3.T1D.T2B.X1B.X2C, Z4.T1D.T2B.X1B.X2Q Z5.T1D.T2B.X1B.X2C, Z6.T1D.T2B.X1B.X2C, Z1.T1A.T2C.X1B.X2C Z2.T1A.T2CX1B.X2Q Z3.T1A.T2C.X1B.X2Q Z4.T1A.T2C.X1B.X2C, Z5.T1A.T2C.X1B.X2C, Z6.T1A.T2CX1B.X2C, Z1.T1B.T2C.X1B.X2C Z2.T1B.T2C.X1B.X2Q Z3.T1B.T2C.X1B.X2Q Z4.T1B.T2C.X1B.X2Q Z5.T1B.T2C.X1B.X2C, Z6.T1B.T2C.X1B.X2C, Z1.T1C.T2C.X1B.X2C, Z2.T1C.T2C.X1B.X2Q Z3.T1CT2C.X1B.X2Q Z4.T1C.T2C.X1B.X2C, Z5.T1C.T2C.X1B.X2C, Z6.T1C.T2C.X1B.X2Q Z1.T1D.T2C.X1B.X2C, Z2.T1D.T2C.X1B.X2Q Z3.T1D.T2C.X1B.X2Q Z4.T1D.T2C.X1B.X2Q Z5.T1D.T2C.X1B.X2Q Z6.T1D.T2C.X1B.X2Q Z1.T1A.T2D.X1B.X2Q Z2.T1A.T2D.X1B.X2C, Z3.T1A.T2D.X1B.X2Q Z4.TiA.T2D.XlB.X2C, Z5.T1A.T2D.X1B.X2C, Z6.T1A.T2D.X1B.X2Q Z1.T1B.T2D.X1B.X2Q Z2.T1B.T2D.X1B.X2Q Z3.T1B.T2D.X1B.X2Q Z4.T1B.T2D.X1B.X2C, Z5.T1B.T2D.X1B.X2Q Z6.T1B.T2D.X1B.X2Q Z1.T1C.T2D.X1B.X2C, Z2.T1C.T2D.X1B.X2Q Z3.T1C.T2D.X1B.X2Q Z4.T1C.T2D.X1B.X2Q Z5.T1C.T2D.X1B.X2Q Z6.T1C.T2D.X1B.X2Q Z1.T1D.T2D.X1B.X2Q Z2.T1D.T2D.X1B.X2Q Z3.T1D.T2D.X1B.X2Q Z4.T1D.T2D.X1B.X2C, Z5.T1D.T2D.X1B.X2Q Z6.T1D.T2D.X1B.X2C, Z1.T1A.T2A.X1C.X2Q Z2.T1A.T2A.X1C.X2Q Z3.T1A.T2A.X1C.X2Q Z4.T1A.T2A.X1C.X2Q Z5.T1A.T2A.X1C.X2Q Z6.T1 A.T2A.X1C.X2Q Z1.T1B.T2A.X1C.X2C, Z2.T1B.T2A.X1C.X2C, Z3.T1B.T2A.X1C.X2C, Z4.T1B.T2A.X1C.X2Q Z5.T1B.T2A.X1C.X2Q Z6.T1B.T2A.X1C.X2Q Z1.T1C.T2A.X1C.X2Q Z2.T1C.T2A.X1C.X2Q Z3.T1C.T2A.X1C.X2Q Z4.T1CT2A.X1CX2Q Z5.T1CT2A.X1CX2Q Z6.T1C.T2A.X1C.X2C, Z1.T1D.T2A.X1CX2C Z2.T1D.T2A.X1CX2Q Z3.T1D.T2A.X1C.X2C,
Z4.T1D.T2A.X1CX2Q 25.T1D.T2A.X1C.X2Q Z6.T1D.T2A.X1C.X2Q Z1.T1A.T2B.X1CX2Q Z2.T1A.T2B.X1C.X2Q Z3.T1A.T2B.X1C.X2Q Z4.T1A.T2B.X1C.X2Q Z5.T1A.T2B.X1C.X2Q Z6.T1A.T2B.X1C.X2Q Z1.T1B.T2B.X1C.X2Q Z2.T1B.T2B.X1CX2Q Z3.T1B.T2B.X1CX2Q Z4.T1B.T2B.X1C.X2Q Z5.T1B.T2B.X1CX2Q Z6.T1B.T2B.X1C.X2Q Z1.T1CT2B.X1CX2Q Z2.T1C.T2B.X1C.X2Q Z3.T1C.T2B.X1C.X2Q Z4.T1C.T2B.X1C.X2Q Z5.T1C.T2B.X1C.X2Q Z6.T1C.T2B.X1C.X2Q Z1.T1D.T2B.X1C.X2Q Z2.T1D.T2B.X1CX2Q Z3.T1D.T2B.X1CX2Q Z4.T1D.T2B.X1CX2Q Z5.T1D.T2B.X1C.X2Q Z6.T1D.T2B.X1C.X2Q Z1.T1A.T2C.X1CX2Q Z2.T1A.T2C.X1C.X2Q Z3.T1A.T2C.X1C.X2Q Z4.T1A.T2C.X1C.X2Q Z5.T1A.T2CX1CX2Q Z6.T1A.T2CX1C.X2Q Z1.T1B.T2C.X1C.X2Q Z2.T1B.T2CX1CX2Q Z3.T1B.T2C.X1CX2Q Z4.T1B.T2CX1C.X2Q Z5.T1B.T2C.X1CX2Q Z6.T1B.T2C.X1C.X2Q Z1.T1C.T2C.X1C.X2Q Z2.T1C.T2C.X1C.X2Q Z3.T1CT2CX1CX2Q Z4.T1C.T2C.X1C.X2Q Z5.T1C.T2CX1C.X2Q Z6.T1CT2CX1CX2Q Z1.T1D.T2CX1CX2Q Z2.T1D.T2CX1C.X2Q Z3.T1D.T2CX1C.X2Q Z4.T1D.T2CX1CX2Q Z5.T1D.T2CX1C.X2Q Z6.T1D.T2CX1CX2Q Z1.T1A.T2D.X1C.X2Q Z2.T1A.T2D.X1C.X2C Z3.T1A.T2D.X1CX2Q Z4.T1A.T2D.X1CX2C, Z5.T1A.T2D.X1C.X2Q Z6.T1A.T2D.X1C.X2C, Z1.T1B.T2D.X1C.X2C Z2.T1B.T2D.X1C.X2Q Z3.T1B.T2D.X1C.X2Q Z4.T1B.T2D.X1CX2Q Z5.T1B.T2D.X1CX2Q Z6.T1B.T2D.X1CX2Q Z1.T1CT2D.X1CX2Q Z2.T1CT2D.X1C.X2Q Z3.T1C.T2D.X1CX2Q Z4.T1C.T2D.X1C.X2C, Z5.T1CT2D.X1C.X2Q Z6.T1CT2D.X1C.X2Q Z1.T1D.T2D.X1CX2Q Z2.T1D.T2D.X1C.X2C, Z3.T1D.T2D.X1C.X2C Z4.T1D.T2D.X1C.X2C Z5.T1D.T2D.X1C.X2C, Z6.T1D.T2D.X1C.X2Q Z1.T1A.T2A.X1D.X2C, Z2.T1A.T2A.X1D.X2Q Z3.T1A.T2A.X1D.X2Q Z4.T1A.T2A.X1D.X2C, Z5.T1A.T2A.X1D.X2C Z6.T1A.T2A.X1D.X2Q Z1.T1B.T2A.X1D.X2C Z2.T1B.T2A.X1D.X2C, Z3.T1B.T2A.X1D.X2C, Z4.T1B.T2A.X1D.X2C, Z5.T1B.T2A.X1D.X2C, Z6.T1B.T2A.X1D.X2C, Z1.T1C.T2A.X1D.X2C Z2.T1C.T2A.X1D.X2Q Z3.T1C.T2A.X1D.X2C Z4.T1C.T2A.X1D.X2C Z5.T1C.T2A.X1D.X2Q Z6.T1CT2A.X1D.X2C, Z1.T1D.T2A.X1D.X2C, Z2.T1D.T2A.X1D.X2Q Z3.T1D.T2A.X1D.X2C, Z4.T1D.T2A.X1D.X2C, Z5.T1D.T2A.X1D.X2C, Z6.T1D.T2A.X1D.X2Q Z1.T1A.T2B.X1D.X2C Z2.T1A.T2B.X1D.X2C, Z3.T1A.T2B.X1D.X2Q Z4.T1A.T2B.X1D.X2C, Z5.T1A.T2B.X1D.X2C, Z6.T1A.T2B.X1D.X2C, Z1.T1B.T2B.X1D.X2C, Z2.T1B.T2B.X1D.X2C, Z3.T1B.T2B.X1D.X2C, Z4.T1B.T2B.X1D.X2C, Z5.T1B.T2B.X1D.X2C, Z6.T1B.T2B.X1D.X2Q Z1.T1C.T2B.X1D.X2C, Z2.T1CT2B.X1D.X2C, Z3.T1C.T2B.X1D.X2C Z4.T1C.T2B.X1D.X2C, Z5.T1C.T2B.X1D.X2C, Z6.T1C.T2B.X1D.X2Q Z1.T1D.T2B.X1D.X2Q Z2.T1D.T2B.X1D.X2Q Z3.T1D.T2B.X1D.X2Q Z4.T1D.T2B.X1D.X2Q Z5.T1D.T2B.X1D.X2Q Z6.T1D.T2B.X1D.X2Q Z1.T1A.T2CX1D.X2Q Z2.T1A.T2C.X1D.X2Q Z3.T1A.T2CX1D.X2Q Z4.T1A.T2C.X1D.X2Q Z5.T1A.T2CX1D.X2C, Z6.T1A.T2C.X1D.X2Q Z1.T1B.T2C.X1D.X2Q Z2.T1B.T2C.X1D.X2Q Z3.T1B.T2C.X1D.X2C, Z4.T1B.T2CX1D.X2Q Z5.T1B.T2C.X1D.X2Q Z6.T1B.T2C.X1D.X2Q Z1.T1C.T2C.X1D.X2C, Z2.T1CT2C.X1D.X2Q Z3.T1C.T2C.X1D.X2C, Z4.T1C.T2CX1D.X2Q Z5.T1C.T2CX1D.X2Q Z6.T1CT2CX1D.X2Q Z1.T1D.T2CX1D.X2Q Z2.T1D.T2CX1D.X2Q Z3.T1D.T2C.X1D.X2Q Z4.T1D.T2C.X1D.X2C, Z5.T1D.T2C.X1D.X2Q Z6.T1D.T2C.X1D.X2C, Z1.T1A.T2D.X1D.X2C Z2.T1A.T2D.X1D.X2Q Z3.T1A.T2D.X1D.X2Q Z4.T1A.T2D.X1D.X2C, Z5.T1A.T2D.X1D.X2C, Z6.T1A.T2D.X1D.X2C, Z1.T1B.T2D.X1D.X2C, Z2.T1B.T2D.X1D.X2C, Z3.T1B.T2D.X1D.X2C,
Z4.T1B.T2D.X1D.X2C Z5.T1B.T2D.X1D.X2Q Z6.T1B.T2D.X1D.X2Q Z1.T1C.T2D.X1D.X2C Z2.T1C.T2D.X1D.X2C Z3.T1C.T2D.X1D.X2Q Z4.T1C.T2D.X1D.X2C Z5.T1C.T2D.X1D.X2Q Z6.T1C.T2D.X1D.X2Q Z1J1D.T2D.X1D.X2Q Z2.T1D.T2D.X1D.X2Q Z3.T1D.T2D.X1D.X2Q Z4.T1D.T2D.X1D.X2Q Z5.T1D.T2D.X1D.X2Q Z6.T1D.T2D.X1D.X2Q Z1.T1A.T2A.X1E.X2Q Z2.T1A.T2A.X1E.X2Q Z3.T1A.T2A.X1E.X2Q Z4.T1A.T2A.X1E.X2Q Z5.T1A.T2A.X1E.X2Q Z6.T1A.T2A.X1E.X2Q Z1.T1B.T2A.X1E.X2Q Z2.T1B.T2A.X1E.X2Q Z3.T1B.T2A.X1E.X2Q Z4.T1B.T2A.X1E.X2Q Z5.T1B.T2A.X1E.X2Q Z6.T1B.T2A.X1E.X2Q Z1.T1C.T2A.X1E.X2Q Z2.T1C.T2A.X1E.X2Q Z3.T1C.T2A.X1E.X2Q Z4.T1C.T2A.X1E.X2Q Z5.T1C.T2A.X1E.X2Q Z6.T1C.T2A.X1E.X2Q Z1.T1D.T2A.X1E.X2Q Z2.T1D.T2A.X1E.X2C, Z3.T1D.T2A.X1E.X2Q Z4.T1D.T2A.X1E.X2Q Z5.T1D.T2A.X1E.X2Q Z6.T1D.T2A.X1E.X2Q Z1.T1A.T2B.X1E.X2Q Z2.T1A.T2B.X1E.X2Q Z3.T1A.T2B.X1E.X2Q Z4.T1A.T2B.X1E.X2Q Z5.T1A.T2B.X1E.X2Q Z6.T1A.T2B.X1E.X2Q Z1.T1B.T2B.X1E.X2Q Z2.T1B.T2B.X1E.X2Q Z3.T1B.T2B.X1E.X2Q Z4.T1B.T2B.X1E.X2Q Z5.T1B.T2B.X1E.X2Q Z6.T1B.T2B.X1E.X2Q Z1.T1C.T2B.X1E.X2Q Z2.T1CT2B.X1E.X2Q Z3.T1C.T2B.X1E.X2Q Z4.T1C.T2B.X1E.X2Q Z5.T1C.T2B.X1E.X2Q Z6.T1CT2B.X1E.X2Q Z1.T1D.T2B.X1E.X2Q Z2.T1D.T2B.X1E.X2Q Z3.T1D.T2B.X1E.X2Q Z4.T1D.T2B.X1E.X2Q Z5.T1D.T2B.X1E.X2Q Z6.T1D.T2B.X1E.X2Q Z1.T1A.T2C.X1E.X2Q Z2.T1A.T2CX1E.X2Q Z3.T1A.T2CX1E.X2Q Z4.T1A.T2CX1E.X2Q Z5.T1A.T2C.X1E.X2C, Z6.T1A.T2CX1E.X2Q Z1.T1B.T2CX1E.X2Q Z2.T1B.T2C.X1E.X2Q Z3.T1B.T2C.X1E.X2Q Z4.T1B.T2C.X1E.X2Q Z5.T1B.T2C.X1E.X2Q Z6.T1B.T2CX1E.X2Q Z1.T1C.T2C.X1E.X2C, Z2.T1C.T2C.X1E.X2Q Z3.T1C.T2C.X1E.X2C Z4.T1C.T2CX1E.X2Q Z5.T1C.T2CX1E.X2Q Z6.T1CT2CX1E.X2Q Z1.T1D.T2C.X1E.X2C, Z2.T1D.T2C.X1E.X2C, Z3.T1D.T2CX1E.X2C, Z4.T1D.T2C.X1E.X2C, Z5.T1D.T2CX1E.X2Q Z6.T1D.T2C.X1E.X2C, Z1.T1A.T2D.X1E.X2C, Z2.T1A.T2D.X1E.X2C, Z3.T1A.T2D.X1E.X2C Z4.T1A.T2D.X1E.X2C, Z5.T1A.T2D.X1E.X2C, Z6.T1A.T2D.X1E.X2Q Z1.T1B.T2D.X1E.X2C, Z2.T1B.T2D.X1E.X2C, Z3.T1B.T2D.X1E.X2C, Z4.T1B.T2D.X1E.X2C, Z5.T1B.T2D.X1E.X2Q Z6.T1B.T2D.X1E.X2Q Z1.T1CT2D.X1E.X2C, Z2.T1CT2D.X1E.X2Q Z3.T1CT2D.X1E.X2C Z4.T1CT2D.X1E.X2C, Z5.T1C.T2D.X1E.X2C, Z6.T1C.T2D.X1E.X2C, Z1.T1D.T2D.X1E.X2C Z2.T1D.T2D.X1E.X2C, Z3.T1D.T2D.X1E.X2C, Z4.T1D.T2D.X1E.X2C, Z5.T1D.T2D.X1E.X2Q Z6.T1D.T2D.X1E.X2C, Z1.T1A.T2A.X1A.X2D, Z2.T1A.T2A.X1A.X2D, Z3.T1A.T2A.X1A.X2D, Z4.T1A.T2A.X1A.X2D, Z5.T1A.T2A.X1A.X2D, Z6.T1A.T2A.X1A.X2D, Z1.T1B.T2A.X1A.X2D, Z2.T1B.T2A.X1A.X2D, Z3.T1B.T2A.X1A.X2D, Z4.T1B.T2A.X1A.X2D, Z5.T1B.T2A.X1A.X2D, Z6.T1B.T2A.X1A.X2D, Z1.T1C.T2A.X1A.X2D, Z2.T1C.T2A.X1A.X2D, Z3.T1C.T2A.X1A.X2D, Z4.T1C.T2A.X1A.X2D, Z5.T1CT2A.X1A.X2D, Z6.T1CT2A.X1A.X2D, Z1.T1D.T2A.X1A.X2D, Z2.T1D.T2A.X1A.X2D, Z3.T1D.T2A.X1A.X2D, Z4.T1D.T2A.X1A.X2D, Z5.T1D.T2A.X1A.X2D, Z6.T1D.T2A.X1A.X2D, Z1.T1A.T2B.X1A.X2D, Z2.T1A.T2B.X1A.X2D, Z3.T1A.T2B.X1A.X2D, Z4.T1A.T2B.X1A.X2D, Z5.T1A.T2B.X1A.X2D, Z6.T1A.T2B.X1A.X2D, Z1.T1B.T2B.X1A.X2D, Z2.T1B.T2B.X1A.X2D, Z3.T1B.T2B.X1A.X2D, Z4.T1B.T2B.X1A.X2D, Z5.T1B.T2B.X1A.X2D, Z6.T1B.T2B.X1A.X2D, Z1.T1CT2B.X1A.X2D, Z2.T1C.T2B.X1A.X2D, Z3.T1C.T2B.X1A.X2D, Z4.T1C.T2B.X1A.X2D, Z5.T1C.T2B.X1A.X2D, Z6.T1C.T2B.X1A.X2D, Z1.T1D.T2B.X1A.X2D, Z2.T1D.T2B.X1A.X2D, Z3.T1D.T2B.X1A.X2D, Z4.T1D.T2B.X1A.X2D, Z5.T1D.T2B.X1A.X2D, Z6.T1D.T2B.X1A.X2D, Z1.T1A.T2C.X1A.X2D, Z2.T1A.T2CX1A.X2D, Z3.T1A.T2C.X1A.X2D, Z4.T1A.T2CX1A.X2D, Z5.T1A.T2C.X1A.X2D, Z6.T1A.T2C.X1A.X2D, Z1.T1B.T2CX1A.X2D, Z2.T1B.T2C.X1A.X2D, Z3.T1B.T2CX1A.X2D, Z4.T1B.T2C.X1A.X2D, Z5.T1B.T2C.X1A.X2D, Z6.T1B.T2C.X1A.X2D, Z1.T1C.T2C.X1A.X2D, Z2.T1C.T2C.X1A.X2D, Z3.T1C.T2C.X1A.X2D, Z4.T1C.T2C.X1A.X2D, Z5.T1C.T2C.X1A.X2D, Z6.T1C.T2C.X1A.X2D, Z1.T1D.T2C.X1A.X2D, Z2.T1D.T2C.X1A.X2D, Z3.T1D.T2C.X1A.X2D, Z4.T1D.T2C.X1A.X2D, Z5.T1D.T2C.X1A.X2D, Z6.T1D.T2C.X1A.X2D, Z1.T1A.T2D.X1A.X2D, Z2.T1A.T2D.X1A.X2D, Z3.T1A.T2D.X1A.X2D, Z4.T1A.T2D.X1A.X2D, Z5.T1A.T2D.X1A.X2D, Z6.T1A.T2D.X1A.X2D, Z1.T1B.T2D.X1A.X2D, Z2.T1B.T2D.X1A.X2D, Z3.T1B.T2D.X1A.X2D, Z4.T1B.T2D.X1A.X2D, Z5.T1B.T2D.X1A.X2D, Z6.T1B.T2D.X1A.X2U Z1.T1C.T2D.X1A.X2D, Z2.T1C.T2D.X1A.X2D, Z3.T1C.T2D.X1A.X2D, Z4.T1C.T2D.X1A.X2D7 Z5.T1C.T2D.X1A.X2D, Z6.T1C.T2D.X1A.X2D, Z1.T1D.T2D.X1A.X2D, Z2.T1D.T2D.X1A.X2D, Z3.T1D.T2D.X1A.X2D, Z4.T1D.T2D.X1A.X2D, Z5.T1D.T2D.X1A.X2D, Z6.T1D.T2D.X1A.X2D, Z1.T1A.T2A.X1B.X2D, Z2.T1A.T2A.X1B.X2D, Z3.T1A.T2A.X1B.X2D, Z4.T1A.T2A.X1B.X2D, Z5.T1A.T2A.X1B.X2D, Z6.T1A.T2A.X1B.X2D, Z1.T1B.T2A.X1B.X2D, Z2.T1B.T2A.X1B.X2D, Z3.T1B.T2A.X1B.X2D, Z4.T1B.T2A.X1B.X2D, Z5.T1B.T2A.X1B.X2D, Z6.T1B.T2A.X1B.X2D, Z1.T1C.T2A.X1B.X2D, Z2.T1C.T2A.X1B.X2D, Z3.T1C.T2A.X1B.X2D, Z4.T1C.T2A.X1B.X2D, Z5.T1C.T2A.X1B.X2D, Z6.T1C.T2A.X1B.X2D, Z1.T1D.T2A.X1B.X2D, Z2.T1D.T2A.X1B.X2D, Z3.T1D.T2A.X1B.X2D, Z4.T1D.T2A.X1B.X2D, Z5.T1D.T2A.X1B.X2D, Z6.T1D.T2A.X1B.X2D, Z1.T1A.T2B.X1B.X2D, Z2.T1A.T2B.X1B.X2D, Z3.T1A.T2B.X1B.X2D, Z4.T1A.T2B.X1B.X2D, Z5.T1A.T2B.X1B.X2D, Z6.T1A.T2B.X1B.X2D, Z1.T1B.T2B.X1B.X2D, Z2.T1B.T2B.X1B.X2D, Z3.T1B.T2B.X1B.X2D, Z4.T1B.T2B.X1B.X2D, Z5.T1B.T2B.X1B.X2D, Z6.T1B.T2B.X1B.X2D, ZI.TIC.T2B.X1B.X2D, Z2.T1CT2B.X1B.X2D, Z3.T1C.T2B.X1B.X2D, Z4.T1C.T2B.X1B.X2D, Z5.T1C.T2B.X1B.X2D, Z6.T1C.T2B.X1B.X2D, Z1.T1D.T2B.X1B.X2D, Z2.T1D.T2B.X1B.X2D, Z3.T1D.T2B.X1B.X2D, Z4.T1D.T2B.X1B.X2D, Z5.T1D.T2B.X1B.X2D, Z6.T1D.T2B.X1B.X2D, Z1.T1A.T2C.X1B.X2D, Z2.T1A.T2C.X1B.X2D, Z3.T1A.T2C.X1B.X2D, Z4.T1A.T2C.X1B.X2D, Z5.T1A.T2C.X1B.X2D, Z6.T1A.T2C.X1B.X2D, Z1.T1B.T2C.X1B.X2D, Z2.T1B.T2C.X1B.X2D, Z3.T1B.T2CX1B.X2D, Z4.T1B.T2C.X1B.X2D, Z5.T1B.T2C.X1B.X2D, Z6.T1B.T2C.X1B.X2D, Z1.T1C.T2C.X1B.X2D, Z2.T1C.T2C.X1B.X2D, Z3.T1C.T2C. XlB. X2D, Z4.T1 C.T2C.X1B.X2D, Z5.T1C.T2C.X1B.X2D, Z6.T1C.T2C.X1B.X2D, Z1.T1D.T2C.X1B.X2D, Z2.T1D.T2C.X1B.X2D, Z3.T1D.T2C.X1B.X2D, Z4.T1D.T2C.X1B.X2D, Z5.T1D.T2C.X1B.X2D, Z6.T1D.T2CX1B.X2D, Z1.T1A.T2D.X1B.X2D, Z2.T1A.T2D.X1B.X2D, Z3.T1A.T2D.X1B.X2D, Z4.T1A.T2D.X1B.X2D, Z5.T1A.T2D.X1B.X2D, Z6.T1A.T2D.X1B.X2D, Z1.T1B.T2D.X1B.X2D, Z2.T1B.T2D.X1B.X2D, Z3.T1B.T2D.X1B.X2D, Z4.T1B.T2D.X1B.X2D, Z5.T1B.T2D.X1B.X2D, Z6.T1B.T2D.X1B.X2D, Z1.T1C.T2D.X1B.X2D, Z2.T1C.T2D.X1B.X2D, Z3.T1C.T2D.X1B.X2D, Z4.T1C.T2D.X1B.X2D, Z5.T1C.T2D.X1B.X2D, Z6.T1C.T2D.X1B.X2D, Z1.T1D.T2D.X1B.X2D, Z2.T1D.T2D.X1B.X2D, Z3.T1D.T2D.X1B.X2D, Z4.T1D.T2D.X1B.X2D, Z5.T1D.T2D.X1B.X2D, Z6.T1D.T2D.X1B.X2D, Z1.T1A.T2A.X1CX2D, Z2.T1A.T2A.X1C.X2D, Z3.T1A.T2A.X1C.X2D, Z4.T1A.T2A.X1C.X2D, Z5.T1A.T2A.X1C.X2D, Z6.T1A.T2A.X1C.X2D, Z1.T1B.T2A.X1CX2D, Z2.T1B.T2A.X1C.X2D, Z3.T1B.T2A.X1C.X2D, Z4.T1B.T2A.X1CX2D, Z5.T1B.T2A.X1CX2D, Z6.T1B.T2A.X1C.X2D, Z1.T1C.T2A.X1C.X2D, Z2.T1C.T2A.X1C.X2D, Z3.T1C.T2A.X1C.X2D, Z4.T1C.T2A.X1C.X2D, Z5.T1C.T2A.X1C.X2D, Z6.T1C.T2A.X1C.X2D, Z1.T1D.T2A.X1CX2D, Z2.T1D.T2A.X1C.X2D, Z3.T1D.T2A.X1CX2D, Z4.T1D.T2A.X1C.X2D, Z5.T1D.T2A.X1C.X2D, Z6.T1D.T2A.X1C.X2D, Z1.T1A.T2B.X1C.X2D, Z2.T1A.T2B.X1C.X2D, Z3.T1A.T2B.X1C.X2D, Z4.T1A.T2B.X1C.X2D, Z5.T1A.T2B.X1C.X2D, Z6.T1A.T2B.X1C.X2D, Z1.T1B.T2B.X1C.X2D, Z2.T1B.T2B.X1C.X2D, Z3.T1B.T2B.X1C.X2D, Z4.T1B.T2B.X1CX2D, Z5.T1B.T2B.X1C.X2D, Z6.T1B.T2B.X1C.X2D, Z1.T1C.T2B.X1C.X2D, Z2.T1C.T2B.X1C.X2D, Z3.T1CT2B.X1C.X2D, Z4.T1C.T2B.X1C.X2D, Z5.T1C.T2B.X1C.X2D, Z6.T1C.T2B.X1C.X2D, Z1.T1D.T2B.X1C.X2D, Z2.T1D.T2B.X1C.X2D, Z3.T1D.T2B.X1C.X2D, Z4.T1D.T2B.X1C.X2D, Z5.T1D.T2B.X1C.X2D, Z6.T1D.T2B.X1C.X2D, Z1.T1A.T2C.X1C.X2D, Z2.T1A.T2C.X1C.X2D, Z3.T1A.T2C.X1C.X2D, Z4.T1A.T2C.X1C.X2D, Z5.T1A.T2C.X1C.X2D, Z6.T1A.T2CX1C.X2D, Z1.T1B.T2C.X1C.X2D, Z2.T1B.T2C.X1C.X2D, Z3.T1B.T2C.X1C.X2D, Z4.T1B.T2C.X1C.X2D, Z5.T1B.T2C.X1C.X2D, Z6.T1B.T2C.X1C.X2D, Z1.T1C.T2C.X1C.X2D, Z2.T1C.T2C.X1C.X2D, Z3.T1C.T2C.X1C.X2D, Z4.T1C.T2C.X1C.X2D, Z5.T1C.T2C.X1C.X2D, Z6.T1C.T2C.X1C.X2D, Z1.T1D.T2C.X1C.X2D, Z2.T1D.T2C.X1C.X2D, Z3.T1D.T2C.X1C.X2D, Z4.T1D.T2CX1CX2D, Z5.T1D.T2C.X1C.X2D, Z6.T1D.T2C.X1C.X2D, Z1.T1A.T2D.X1C.X2D, Z2.T1A.T2D.X1C.X2D, Z3.T1A.T2D.X1C.X2D, Z4.T1A.T2D.X1C.X2D, Z5.T1A.T2D.X1C.X2D, Z6.T1A.T2D.X1C.X2D, Z1.T1B.T2D.X1CX2D, Z2.T1B.T2D.X1C.X2D, Z3.T1B.T2D.X1C.X2D, Z4.T1B.T2D.X1C.X2D, Z5.T1B.T2D.X1C.X2D, Z6.T1B.T2D.X1C.X2D, Z1.T1CT2D.X1C.X2D, Z2.T1C.T2D.X1C.X2D, Z3.T1C.T2D.X1C.X2D, Z4.T1C.T2D.X1C.X2D, Z5.T1C.T2D.X1C.X2D, Z6.T1CT2D.X1C.X2D, Z1.T1D.T2D.X1C.X2D, Z2.T1D.T2D.X1C.X2D, Z3.T1D.T2D.X1C.X2D, Z4.T1D.T2D.X1C.X2D, Z5.T1D.T2D.X1C.X2D, Z6.T1D.T2D.X1C.X2D, Z1.T1A.T2A.X1D.X2D, Z2.T1A.T2A.X1D.X2D, Z3.T1A.T2A.X1D.X2D, Z4.T1A.T2A.X1D.X2D, Z5.T1A.T2A.X1D.X2D, Z6.T1A.T2A.X1D.X2D, Z1.T1B.T2A.X1D.X2D, Z2.T1B.T2A.X1D.X2D, Z3.T1B.T2A.X1D.X2D, Z4.T1B.T2A.X1D.X2D, Z5.T1B.T2A.X1D.X2D, Z6.T1B.T2A.X1D.X2D, Z1.T1C.T2A.X1D.X2D, Z2.T1C.T2A.X1D.X2D, Z3.T1C.T2A.X1D.X2D, Z4.T1C.T2A.X1D.X2D, Z5.T1C.T2A.X1D.X2D, Z6.T1C.T2A.X1D.X2D, Z1.T1D.T2A.X1D.X2D, Z2.T1D.T2A.X1D.X2D, Z3.T1D.T2A.X1D.X2D, Z4.T1D.T2A.X1D.X2D, Z5.T1D.T2A.X1D.X2D, Z6.T1D.T2A.X1D.X2D, Z1.T1A.T2B.X1D.X2D, Z2.T1A.T2B.X1D.X2D, Z3.T1A.T2B.X1D.X2D, Z4.T1A.T2B.X1D.X2D, Z5.T1A.T2B.X1D.X2D, Z6.T1A.T2B.X1D.X2D, Z1.T1B.T2B.X1D.X2D, Z2.T1B.T2B.X1D.X2D, Z3.T1B.T2B.X1D.X2D, Z4.T1B.T2B.X1D.X2D, Z5.T1B.T2B.X1D.X2D, Z6.T1B.T2B.X1D.X2D, Z1.T1C.T2B.X1D.X2D, Z2.T1C.T2B.X1D.X2D, Z3.T1C.T2B.X1D.X2D, Z4.T1C.T2B.X1D.X2D, Z5.T1C.T2B.X1D.X2D, Z6.T1C.T2B.X1D.X2D, Z1.T1D.T2B.X1D.X2D, Z2.T1D.T2B.X1D.X2D, Z3.T1D.T2B.X1D.X2D, Z4.T1D.T2B.X1D.X2D, Z5.T1D.T2B.X1D.X2D, Z6.T1D.T2B.X1D.X2D, Z1.T1A.T2C.X1D.X2D, Z2.T1A.T2C.X1D.X2D, Z3.T1A.T2C.X1D.X2D, Z4.T1A.T2C.X1D.X2D, Z5.T1A.T2C.X1D.X2D, Z6.T1A.T2C.X1D.X2D, Z1.T1B.T2C.X1D.X2D, Z2.T1B.T2C.X1D.X2D, Z3.T1B.T2C.X1D.X2D, Z4.T1B.T2C.X1D.X2D, Z5.T1B.T2C.X1D.X2D, Z6.T1B.T2C.X1D.X2D, Z1.T1CT2CX1D.X2D, Z2.T1C.T2C.X1D.X2D, Z3.T1C.T2C.X1D.X2D, Z4.T1C.T2C.X1D.X2D, Z5.T1C.T2C.X1D.X2D, Z6.T1C.T2C.X1D.X2D, Z1.T1D.T2CX1D.X2D, Z2.T1D.T2C.X1D.X2D, Z3.T1D.T2C.X1D.X2D, Z4.T1D.T2CX1D.X2D, Z5.T1D.T2CX1D.X2D, Z6.T1D.T2CX1D.X2D, Z1.T1A.T2D.X1D.X2D, Z2.T1A.T2D.X1D.X2D, Z3.T1A.T2D.X1D.X2D, Z4.T1A.T2D.X1D.X2D, Z5.T1A.T2D.X1D.X2D, Z6.T1A.T2D.X1D.X2D, Z1.T1B.T2D.X1D.X2D, Z2.T1B.T2D.X1D.X2D, Z3.T1B.T2D.X1D.X2D, Z4.T1B.T2D.X1D.X2D, Z5.T1B.T2D.X1D.X2D, Z6.T1B.T2D.X1D.X2D, Z1.T1C.T2D.X1D.X2D, Z2.T1C.T2D.X1D.X2D, Z3.T1C.T2D.X1D.X2D, Z4.T1C.T2D.X1D.X2D, Z5.T1C.T2D.X1D.X2D, Z6.T1CT2D.X1D.X2D, Z1.T1D.T2D.X1D.X2D, Z2.T1D.T2D.X1D.X2D, Z3.T1D.T2D.X1D.X2D, Z4.T1D.T2D.X1D.X2D, Z5.T1D.T2D.X1D.X2D, Z6.T1D.T2D.X1D.X2D, Z1.T1A.T2A.X1E.X2D, Z2.T1A.T2A.X1E.X2D, Z3.T1A.T2A.X1E.X2D, Z4.T1A.T2A.X1E.X2D, Z5.T1A.T2A.X1E.X2D, Z6.T1A.T2A.X1E.X2D, Z1.T1B.T2A.X1E.X2D, Z2.T1B.T2A.X1E.X2D, Z3.T1B.T2A.X1E.X2D, Z4.T1B.T2A.X1E.X2D, Z5.T1B.T2A.X1E.X2D, Z6.T1B.T2A.X1E.X2D, Z1.T1C.T2A.X1E.X2D, Z2.T1C.T2A.X1E.X2D, Z3.T1C.T2A.X1E.X2U Z4.T1C.T2A.X1E.X2D, Z5.T1C.T2A.X1E.X2D, Z6.T1C.T2A.X1E.X2D, Z1.T1D.T2A.X1E.X2D, Z2.T1D.T2A.X1E.X2D, Z3.T1D.T2A.X1E.X2D, Z4.T1D.T2A.X1E.X2D, Z5.T1D.T2A.X1E.X2D, Z6.T1D.T2A.X1E.X2D, Z1.T1A.T2B.X1E.X2D, Z2.T1A.T2B.X1E.X2D, Z3.T1A.T2B.X1E.X2D, Z4.T1A.T2B.X1E.X2D, Z5.T1A.T2B.X1E.X2D, Z6.T1A.T2B.X1E.X2D, Z1.T1B.T2B.X1E.X2D, Z2.T1B.T2B.X1E.X2D, Z3.T1B.T2B.X1E.X2D, Z4.T1B.T2B.X1E.X2D, Z5.T1B.T2B.X1E.X2D, Z6.T1B.T2B.X1E.X2D, Z1.T1C.T2B.X1E.X2D, Z2.T1C.T2B.X1E.X2D, Z3.T1C.T2B.X1E.X2D, Z4.T1C.T2B.X1E.X2D, Z5.T1C.T2B.X1E.X2D, Z6.T1C.T2B.X1E.X2D, Z1.T1D.T2B.X1E.X2D, Z2.T1D.T2B.X1E.X2D, Z3.T1D.T2B.X1E.X2D, Z4.T1D.T2B.X1E.X2D, Z5.T1D.T2B.X1E.X2D, Z6.T1D.T2B.X1E.X2D, 21.T1A.T2C.X1E.X2D, Z2.T1A.T2C.X1E.X2D, Z3.T1A.T2C.X1E.X2D, Z4.T1A.T2C.X1E.X2D, Z5.T1A.T2C.X1E.X2D, Z6.T1A.T2C.X1E.X2D, Z1.T1B.T2C.X1E.X2D, Z2.T1B.T2C.X1E.X2D, Z3.T1B.T2C.X1E.X2D, Z4.T1B.T2C.X1E.X2D, Z5.T1B.T2C.X1E.X2D, Z6.T1B.T2C.X1E.X2D, Z1.T1C.T2C.X1E.X2D, Z2.T1C.T2C.X1E.X2D, Z3.T1C.T2C.X1E.X2D, Z4.T1C.T2C.X1E.X2D, Z5.T1C.T2C.X1E.X2D, Z6.T1C.T2C.X1E.X2D, Z1.T1D.T2C.X1E.X2D, Z2.T1D.T2C.X1E.X2D, Z3.T1D.T2C.X1E.X2D, Z4.T1D.T2C.X1E.X2D, Z5.T1D.T2C.X1E.X2D, Z6.T1D.T2C.X1E.X2D, Z1.T1A.T2D.X1E.X2D, Z2.T1A.T2D.X1E.X2D, Z3.T1A.T2D.X1E.X2D, Z4.T1A.T2D.X1E.X2D, Z5.T1A.T2D.X1E.X2D, Z6.T1A.T2D.X1E.X2D, Z1.T1B.T2D.X1E.X2D, Z2.T1B.T2D.X1E.X2D, Z3.T1B.T2D.X1E.X2D, Z4.T1B.T2D.X1E.X2D, Z5.T1B.T2D.X1E.X2D, Z6.T1B.T2D.X1E.X2D, Z1.T1C.T2D.X1E.X2D, Z2.T1C.T2D.X1E.X2D, Z3.T1C.T2D.X1E.X2D, Z4.T1C.T2D.X1E.X2D, Z5.T1C.T2D.X1E.X2D, Z6.T1C.T2D.X1E.X2D, Z1.T1D.T2D.X1E.X2D, Z2.T1D.T2D.X1E.X2D, Z3.T1D.T2D.X1E.X2D, Z4.T1D.T2D.X1E.X2D, Z5.T1D.T2D.X1E.X2D, Z6.T1D.T2D.X1E.X2D, Z1.T1A.T2A.X1A.X2E, Z2.T1A.T2A.X1A.X2E, Z3-T1A.T2A.X1A.X2E, Z4.T1A.T2A.X1A.X2E, Z5.T1A.T2A.X1A.X2E, Z6.T1A.T2A.X1A.X2E, Z1.T1B.T2A.X1A.X2E, Z2.T1B.T2A.X1A.X2E, Z3.T1B.T2A.X1A.X2E, Z4.T1B.T2A.X1A.X2E, Z5.T1B.T2A.X1A.X2E, Z6.T1B.T2A.X1A.X2E, Z1.T1C.T2A.X1A.X2E, Z2.T1C.T2A.X1A.X2E, Z3.T1C.T2A.X1A.X2E, Z4.T1C.T2A.X1A.X2E, Z5.T1C.T2A.X1A.X2E, Z6.T1C.T2A.X1A.X2E, Z1.T1D.T2A.X1A.X2E, Z2.T1D.T2A.X1A.X2E, Z3.T1D.T2A.X1A.X2E, Z4.T1D.T2A.X1A.X2E, Z5.T1D.T2A.X1A.X2E, Z6.T1D.T2A.X1A.X2E, Z1.T1A.T2B.X1A.X2E, Z2.T1A.T2B.X1A.X2E, Z3.T1A.T2B.X1A.X2E, Z4.T1A.T2B.X1A.X2E, Z5.T1A.T2B.X1A.X2E, Z6.T1A.T2B.X1A.X2E, Z1.T1B.T2B.X1A.X2E, Z2.T1B.T2B.X1A.X2E, Z3.T1B.T2B.X1A.X2E, Z4.T1B.T2B.X1A.X2E, Z5.T1B.T2B.X1A.X2E, Z6.T1B.T2B.X1A.X2E, Z1.T1C.T2B.X1A.X2E, Z2.T1C.T2B.X1A.X2E, Z3.T1C.T2B.X1A.X2E, Z4.T1C.T2B.X1A.X2E, Z5.T1C.T2B.X1A.X2E, Z6.T1CT2B.X1A.X2E, Z1.T1D.T2B.X1A.X2B, Z2.T1D.T2B.X1A.X2E, Z3.T1D.T2B.X1A.X2E, Z4.T1D.T2B.X1A.X2E, Z5.T1D.T2B.X1A.X2E, Z6.T1D.T2B.X1A.X2E, Z1.T1A.T2C.X1A.X2E, Z2.T1A.T2CX1A.X2E, Z3.T1A.T2C.X1A.X2E, Z4.T1A.T2C.X1A.X2E, Z5.T1A.T2C.X1A.X2E, Z6.T1A.T2C.X1A.X2E, Z1.T1B.T2C.X1A.X2E, Z2.T1B.T2C.X1A.X2E, Z3.T1B.T2C.X1A.X2E, Z4.T1B.T2C.X1A.X2E, Z5.T1B.T2C.X1A.X2E, Z6.T1B.T2C.X1A.X2E, Z1.T1C.T2C.X1A.X2E, Z2.T1C.T2C.X1A.X2E, Z3.T1C.T2C.X1A.X2E, Z4.T1C.T2C.X1A.X2E, Z5.T1C.T2C.X1A.X2E, Z6.T1C.T2C.X1A.X2E, Z1.T1D.T2C.X1A.X2E, Z2.T1D.T2C.X1A.X2E, Z3.T1D.T2C.X1A.X2E, Z4.T1D.T2C.X1A.X2E, Z5.T1D.T2C.X1A.X2E, Z6.T1D.T2C.X1A.X2E, Z1.T1A.T2D.X1A.X2E, Z2.T1A.T2D.X1A.X2E, Z3.T1A.T2D.X1A.X2E, Z4.T1A.T2D.X1A.X2E, Z5.T1A.T2D.X1A.X2E, Z6.T1A.T2D.X1A.X2E, Z1.T1B.T2D.X1A.X2E, Z2.T1B.T2D.X1A.X2E, Z3.T1B.T2D.X1A.X2E, Z4.T1B.T2D.X1A.X2E, Z5.T1B.T2D.X1A.X2E, Z6.T1B.T2D.X1A.X2E, Z1.T1C.T2D.X1A.X2E, Z2.T1C.T2D.X1A.X2E, Z3.T1C.T2D.X1A.X2E, Z4.T1CT2D.X1A.X2E, Z5.T1C.T2D.X1A.X2E, Z6.T1C.T2D.X1A.X2E, Z1.T1D.T2D.X1A.X2E, Z2.T1D.T2D.X1A.X2E, Z3.T1D.T2D.X1A.X2E, Z4.T1D.T2D.X1A.X2E, Z5.T1D.T2D.X1A.X2E, Z6.T1D.T2D.X1A.X2E, Z1.T1A.T2A.X1B.X2E, Z2.T1A.T2A.X1B.X2E, Z3.T1A.T2A.X1B.X2E, Z4.T1A.T2A.X1B.X2E, Z5.T1A.T2A.X1B.X2E, Z6.T1A.T2A.X1B.X2E, Z1.T1B.T2A.X1B.X2E, Z2.T1B.T2A.X1B.X2E, Z3.T1B.T2A.X1B.X2E, Z4.T1B.T2A.X1B.X2E, Z5.T1B.T2A.X1B.X2E, Z6.T1B.T2A.X1B.X2E, Z1.T1C.T2A.X1B.X2E, Z2.T1C.T2A.X1B.X2E, Z3.T1C.T2A.X1B.X2E, Z4.T1C.T2A.X1B.X2E, Z5.T1C.T2A.X1B.X2E, Z6.T1C.T2A.X1B.X2E, Z1.T1D.T2A.X1B.X2E, Z2.T1D.T2A.X1B.X2E, Z3.T1D.T2A.X1B.X2E, Z4.T1D.T2A.X1B.X2B, Z5.T1D.T2A.X1B.X2E, Z6.T1D.T2A.X1B.X2E, ZLT1A.T2B.X1B.X2E, Z2.T1A.T2B.X1B.X2E, Z3.T1A.T2B.X1B.X2E, Z4.T1A.T2B.X1B.X2E, Z5.T1A.T2B.X1B.X2E, Z6.T1A.T2B.X1B.X2E, Z1.T1B.T2B.X1B.X2E, Z2.T1B.T2B.X1B.X2E, Z3.T1B.T2B.X1B.X2E, Z4.T1B.T2B.X1B.X2E, Z5.T1B.T2B.X1B.X2E, Z6.T1B.T2B.X1B.X2E, Z1.T1C.T2B.X1B.X2E, Z2.T1C.T2B.X1B.X2E, Z3.T1C.T2B.X1B.X2E, Z4.T1C.T2B.X1B.X2E, Z5.T1C.T2B.X1B.X2E, Z6.T1C.T2B.X1B.X2E, Z1.T1D.T2B.X1B.X2E, Z2.T1D.T2B.X1B.X2E, Z3.T1D.T2B.X1B.X2E, Z4.T1D.T2B.X1B.X2E, Z5.T1D.T2B.X1B.X2E, Z6.T1D.T2B.X1B.X2E, Z1.T1A.T2C.X1B.X2E, Z2.T1A.T2C.X1B.X2E, Z3.T1A.T2C.X1B.X2E, Z4.T1A.T2C.X1B.X2E, Z5.T1A.T2C.X1B.X2E, Z6.T1A.T2C.X1B.X2E, Z1.T1B.T2CX1B.X2E, Z2.T1B.T2C.X1B.X2E, Z3.T1B.T2C.X1B.X2E, Z4.T1B.T2C.X1B.X2E, Z5.T1B.T2C.X1B.X2E, Z6.T1B.T2C.X1B.X2E, Z1.T1C.T2C.X1B.X2E, Z2.T1C.T2C.X1B.X2E, Z3.T1C.T2C.X1B.X2E, Z4.T1C.T2C.X1B.X2E, Z5.T1C.T2C.X1B.X2E, Z6.T1C.T2C.X1B.X2E, ZI.TID.T2C.X1B.X2E, Z2.T1D.T2C.X1B.X2E, Z3.T1D.T2C.X1B.X2E, Z4.T1D.T2C.X1B.X2E, Z5.T1D.T2C.X1B.X2E, Z6.T1D.T2C.X1B.X2E, Z1.T1A.T2D.X1B.X2E, Z2.T1A.T2D.X1B.X2E, Z3.T1A.T2D.X1B.X2E, Z4.T1A.T2D.X1B.X2E, Z5.T1A.T2D.X1B.X2E, Z6.T1A.T2D.X1B.X2E, Z1.T1B.T2D.X1B.X2E, Z2.T1B.T2D.X1B.X2E, Z3.T1B.T2D.X1B.X2E, Z4.T1B.T2D.X1B.X2E, Z5.T1B.T2D.X1B.X2E, Z6.T1B.T2D.X1B.X2E, Z1.T1C.T2D.X1B.X2E, Z2.T1C.T2D.X1B.X2E, Z3.T1C.T2D.X1B.X2E, Z4.T1C.T2D.X1B.X2E, Z5.T1C.T2D.X1B.X2E, Z6.T1C.T2D.X1B.X2E, Z1.T1D.T2D.X1B.X2E, Z2.T1D.T2D.X1B.X2E, Z3.T1D.T2D.X1B.X2E, Z4.T1D.T2D.X1B.X2E, Z5.T1D.T2D.X1B.X2E, Z6.T1D.T2D.X1B.X2E, Z1.T1A.T2A.X1CX2E, Z2.T1A.T2A.X1C.X2E, Z3.T1A.T2A.X1C.X2E, Z4.T1A.T2A.X1C.X2E, Z5.T1A.T2A.X1C.X2E, Z6.T1A.T2A.X1C.X2E, Z1.T1B.T2A.X1C.X2E, Z2.T1B.T2A.X1C.X2E, Z3.T1B.T2A.X1C.X2E, Z4.T1B.T2A.X1C.X2E, Z5.T1B.T2A.X1C.X2E, Z6.T1B.T2A.X1C.X2E, Z1.T1C.T2A.X1CX2E, Z2.T1C.T2A.X1C.X2E, Z3.T1C.T2A.X1C.X2E, Z4.T1C.T2A.X1C.X2E, Z5.T1C.T2A.X1CX2E, Z6.T1C.T2A.X1C.X2E, Z1.T1D.T2A.X1C.X2E, Z2.T1D.T2A.X1C.X2E, Z3.T1D.T2A.X1C.X2E, Z4.T1D.T2A.X1C.X2E, Z5.T1D.T2A.X1C.X2E, Z6.T1D.T2A.X1C.X2E, Z1.T1A.T2B.X1C.X2E, Z2.T1A.T2B.X1C.X2E, Z3.T1A.T2B.X1C.X2E, Z4.T1A.T2B.X1C.X2E, Z5.T1A.T2B.X1C.X2E, Z6.T1A.T2B.X1C.X2E, Z1.T1B.T2B.X1C.X2E, Z2.T1B.T2B.X1C.X2E, Z3.T1B.T2B.X1CX2E, Z4.T1B.T2B.X1C.X2E, Z5.T1B.T2B.X1C.X2E, Z6.T1B.T2B.X1C.X2E, Z1.T1CT2B.X1C.X2E, Z2.T1C.T2B.X1C.X2E, Z3.T1C.T2B.X1C.X2E, Z4.T1C.T2B.X1C.X2E, Z5.T1C.T2B.X1C.X2E, Z6.T1C.T2B.X1C.X2E, Z1.T1D.T2B.X1C.X2E, Z2.T1D.T2B.X1C.X2E, Z3.T1D.T2B.X1C.X2E, Z4.T1D.T2B.X1C.X2E, Z5.T1D.T2B.X1C.X2E, Z6.T1D.T2B.X1C.X2E, Z1.T1A.T2C.X1C.X2E, Z2.T1A.T2C.X1C.X2E, Z3.T1A.T2C.X1C.X2E, Z4.T1A.T2CX1CX2E, Z5.T1A.T2C.X1C.X2E, Z6.T1A.T2C.X1C.X2E, Z1.T1B.T2C.X1C.X2E, Z2.T1B.T2C.X1C.X2E, Z3.T1B.T2C.X1C.X2E, Z4.T1B.T2C.X1C.X2E, Z5.T1B.T2C.X1C.X2E, Z6.T1B.T2C.X1C.X2E, Z1.T1C.T2C.X1C.X2E, Z2.T1C.T2C.X1C.X2E, Z3.T1C.T2C.X1C.X2E, Z4.T1CT2CX1C.X2E, Z5.T1C.T2C.X1C.X2E, Z6.T1C.T2C.X1C.X2E, Z1.T1D.T2C.X1C.X2E, Z2.T1D.T2C.X1C.X2E, Z3.T1D.T2C.X1C.X2E, Z4.T1D.T2C.X1C.X2E, Z5.T1D.T2C.X1C.X2E, Z6.T1D.T2CX1C.X2E, Z1.T1A.T2D.X1C.X2E, Z2.T1A.T2D.X1C.X2E, Z3.T1A.T2D.X1C.X2E, Z4.T1A.T2D.X1CX2E, Z5.T1A.T2D.X1C.X2E, Z6.T1A.T2D.X1C.X2E, Z1.T1B.T2D.X1C.X2E, Z2.T1B.T2D.X1C.X2E, Z3.T1B.T2D.X1CX2B, Z4.T1B.T2D.X1CX2E, Z5.T1B.T2D.X1C.X2E, Z6.T1B.T2D.X1C.X2E, Z1.T1C.T2D.X1C.X2E, Z2.T1C.T2D.X1C.X2E, Z3.T1C.T2D.X1C.X2E, Z4.T1C.T2D.X1C.X2E, Z5.T1C.T2D.X1C.X2E, Z6.T1C.T2D.X1C.X2E, Z1.T1D.T2D.X1C.X2E, Z2.T1D.T2D.X1C.X2E, Z3.T1D.T2D.X1C.X2E, Z4.T1D.T2D.X1C.X2E, Z5.T1D.T2D.X1C.X2E, Z6.T1D.T2D.X1C.X2E, Z1.T1A.T2A.X1D.X2E, Z2.T1A.T2A.X1D.X2E, Z3.T1A.T2A.X1D.X2E, Z4.T1A.T2A.X1D.X2E, Z5.T1A.T2A.X1D.X2E, Z6.T1A.T2A.X1D.X2E, Z1.T1B.T2A.X1D.X2E, Z2.T1B.T2A.X1D.X2E, Z3.T1B.T2A.X1D.X2E, Z4.T1B.T2A.X1D.X2E, Z5.T1B.T2A.X1D.X2E, Z6.T1B.T2A.X1D.X2E, Z1.T1C.T2A.X1D.X2E, Z2.T1C.T2A.X1D.X2E, Z3.T1C.T2A.X1D.X2E, Z4.T1C.T2A.X1D.X2E, Z5.T1C.T2A.X1D.X2E, Z6.T1C.T2A.X1D.X2E, Z1.T1D.T2A.X1D.X2E, Z2.T1D.T2A.X1D.X2E, Z3.T1D.T2A.X1D.X2E, Z4.T1D.T2A.X1D.X2E, Z5.T1D.T2A.X1D.X2E, Z6.T1D.T2A.X1D.X2E, Z1.T1A.T2B.X1D.X2E, Z2.T1A.T2B.X1D.X2E, Z3.T1A.T2B.X1D.X2E, Z4.T1A.T2B.X1D.X2E, Z5.T1A.T2B.X1D.X2E, Z6.T1A.T2B.X1D.X2E, Z1.T1B.T2B.X1D.X2E, Z2.T1B.T2B.X1D.X2E, Z3.T1B.T2B.X1D.X2E, Z4.T1B.T2B.X1D.X2E, Z5.T1B.T2B.X1D.X2E, Z6.T1B.T2B.X1D.X2E, Z1.T1C.T2B.X1D.X2E, Z2.T1C.T2B.X1D.X2E, Z3.T1C.T2B.X1D.X2E, Z4.T1C.T2B.X1D.X2E, Z5.T1C.T2B.X1D.X2E, Z6.T1C.T2B.X1D.X2E, Z1.T1D.T2B.X1D.X2E, Z2.T1D.T2B.X1D.X2E, Z3.T1D.T2B.X1D.X2E, Z4.T1D.T2B.X1D.X2E, Z5.T1D.T2B.X1D.X2E, Z6.T1D.T2B.X1D.X2E, Z1.T1A.T2C.X1D.X2E, Z2.T1A.T2C.X1D.X2E, Z3.T1A.T2C.X1D.X2E, Z4.T1A.T2C.X1D.X2E, Z5.T1A.T2C.X1D.X2E, Z6.T1A.T2C.X1D.X2E, Z1.T1B.T2CX1D.X2E, Z2.T1B.T2C.X1D.X2E, Z3.T1B.T2C.X1D.X2E, Z4.T1B.T2CX1D.X2E, Z5.T1B.T2C.X1D.X2E, Z6.T1B.T2CX1D.X2E, Z1.T1C.T2C.X1D.X2E, Z2.T1C.T2C.X1D.X2E, Z3.T1C.T2C.X1D.X2E, Z4.T1CT2C.X1D.X2E, Z5.T1CT2C.X1D.X2E, Z6.T1C.T2C.X1D.X2E, Z1.T1D.T2C.X1D.X2E, Z2.T1D.T2C.X1D.X2E, Z3.T1D.T2C.X1D.X2E, Z4.T1D.T2C.X1D.X2E, Z5.T1D.T2C.X1D.X2E, Z6.T1D.T2C.X1D.X2E, Z1.T1A.T2D.X1D.X2E, Z2.T1A.T2D.X1D.X2E, Z3.T1A.T2D.X1D.X2E, Z4.T1A.T2D.X1D.X2E, Z5.T1A.T2D.X1D.X2E, Z6.T1A.T2D.X1D.X2E, Z1.T1B.T2D.X1D.X2E, Z2.T1B.T2D.X1D.X2E, Z3.T1B.T2D.X1D.X2E, Z4.T1B.T2D.X1D.X2E, Z5.T1B.T2D.X1D.X2E, Z6.T1B.T2D.X1D.X2E, Z1.T1C.T2D.X1D.X2E, Z2.T1C.T2D.X1D.X2E, Z3.T1C.T2D.X1D.X2E, Z4.T1C.T2D.X1D.X2E, Z5.T1CT2D.X1D.X2E, Z6.T1C.T2D.X1D.X2E, Z1.T1D.T2D.X1D.X2E, Z2.T1D.T2D.X1D.X2E, Z3.T1D.T2D.X1D.X2E, Z4.T1D.T2D.X1D.X2E, Z5.T1D.T2D.X1D.X2E, Z6.T1D.T2D.X1D.X2E, Z1.T1A.T2A.X1E.X2E, Z2.T1A.T2A.X1E.X2E, Z3.T1A.T2A.X1E.X2E, Z4.T1A.T2A.X1E.X2E, Z5.T1A.T2A.X1E.X2E, Z6.T1A.T2A.X1E.X2E, Z1.T1B.T2A.X1E.X2E, Z2.T1B.T2A.X1E.X2E, Z3.T1B.T2A.X1E.X2E, Z4.T]B.T2A.X1E.X2E, Z5.T1B.T2A.X1E.X2E, Z6.T1B.T2A.X1E.X2E, Z1.T1C.T2A.X1E.X2E, Z2.T1C.T2A.X1E.X2E, Z3.T1C.T2A.X1E.X2E, Z4.T1C.T2A.X1E.X2E, Z5.T1C.T2A.X1E.X2E, Z6.T1C.T2A.X1E.X2E, Z1.T1D.T2A.X1E.X2E, Z2.T1D.T2A.X1E.X2E, Z3.T1D.T2A.X1E.X2E, Z4.T1D.T2A.X1E.X2E, Z5.T1D.T2A.X1E.X2E, Z6.T1D.T2A.X1E.X2E, Z1.T1 A.T2B.X1E.X2E, Z2.T1A.T2B.X1E.X2E, Z3.T1A.T2B.X1E.X2E, Z4.T1A.T2B.X1E.X2E, Z5.T1A.T2B.X1E.X2E, Z6.T1A.T2B.X1E.X2E, Z1.T1B.T2B.X1E.X2E, Z2.T1B.T2B.X1E.X2E, Z3.T1B.T2B.X1E.X2E, Z4.T1B.T2B.X1E.X2E, Z5.T1B.T2B.X1E.X2E, Z6.T1B.T2B.X1E.X2E, Z1.T1C.T2B.X1E.X2E, Z2.T1C.T2B.X1E.X2E, Z3.T1CT2B.X1E.X2E, Z4.T1CT2B.X1E.X2E, Z5.T1C.T2B.X1E.X2E, Z6.T1C.T2B.X1E.X2E, Z1.T1D.T2B.X1E.X2E, Z2.T1D.T2B.X1E.X2E, Z3.T1D.T2B.X1E.X2E, Z4.T1D.T2B.X1E.X2E, Z5.T1D.T2B.X1E.X2E, Z6.T1D.T2B.X1E.X2E, Z1.T1A.T2C.X1E.X2E, Z2.T1A.T2C.X1E.X2E, Z3.T1A.T2C.X1E.X2E, Z4.T1A.T2C.X1E.X2E, Z5.T1A.T2C.X1E.X2E, Z6.T1A.T2CX1E.X2E, Z1.T1B.T2GX1E.X2E, Z2.T1B.T2CX1E.X2E, Z3.T1B.T2C.X1E.X2E, Z4.T1B.T2C.X1E.X2E, Z5.T1B.T2CX1E.X2E, Z6.T1B.T2C.X1E.X2E, Z1.T1C.T2C.X1E.X2E, Z2.T1C.T2C.X1E.X2E, Z3.T1C.T2C.X1E.X2E, Z4.T1C.T2C.X1E.X2E, Z5.T1C.T2C.X1E.X2E, Z6.T1C.T2C.X1E.X2E, Z1.T1D.T2C.X1E.X2E, Z2.T1D.T2C.X1E.X2E, Z3.T1D.T2C.X1E.X2E, Z4.T1D.T2C.X1E.X2E, Z5.T1D.T2C.X1E.X2E, Z6.T1D.T2C.X1E.X2E, Z1.T1A.T2D.X1E.X2E, Z2.T1A.T2D.X1E.X2E, Z3.T1 A.T2D.X1E.X2E, Z4.T1A.T2D.X1E.X2E, Z5.T1A.T2D.X1E.X2E, Z6.T1A.T2D.X1E.X2E, Z1.T1B.T2D.X1E.X2E, Z2.T1B.T2D.X1E.X2E, Z3.T1B.T2D.X1E.X2E, Z4.T1B.T2D.X1E.X2E, Z5.T1B.T2D.X1E.X2E, Z6.T1B.T2D.X1E.X2E, Z1.T1C.T2D.X1E.X2E, Z2.T1C.T2D.X1E.X2E, Z3.T1C.T2D.X1E.X2E, Z4.T1C.T2D.X1E.X2E, Z5.T1CT2D.X1E.X2E, Z6.T1C.T2D.X1E.X2E, Z1.T1D.T2D.X1E.X2E, Z2.T1D.T2D.X1E.X2E, Z3.T1D.T2D.X1E.X2E, Z4.T1D.T2D.X1E.X2E, Z5.T1D.T2D.X1E.X2E, and Z6.T1D.T2D.X1E.X2E.
In still another embodiment, selected compounds of Formula I are named below in tabular format (Table 12) as compounds of general Formula III (below):
Figure imgf000131_0001
Formula III where 1, 2, 3, 4 and 5 are defined in Tables 7-11, below. Each compound is designated in tabular form by combining the "code" representing each structural moiety using the following syntax: 1.2.3.4.5. Thus, for example, la.2a.3a.4a.5a represents the following structure:
Figure imgf000132_0001
Table 7: "1" Structures
Figure imgf000132_0002
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Table 8: "T Structures
Figure imgf000135_0002
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Table 9: "3" Structures
Figure imgf000139_0002
Figure imgf000140_0001
Table 10: "4" Structures
Figure imgf000140_0002
Figure imgf000141_0001
Table 11: "5" Structures
Figure imgf000141_0002
Figure imgf000142_0001
Table 12: List of Compound Structures of Formula II la.2a.3a.4a.5av lb.2a.3a.4a.5a., lf.2a.3a.4a.5av lh.2a.3a.4a.5a., lj.2a.3a.4a.5a., lp.2a.3a.4a.5av la.2b.3a.4a.5av lb.2b.3a.4a.5a., lf.2b.3a.4a.5a., lh.2b.3a.4a.5a., lj.2b.3a.4a.5a., lp.2b.3a.4a.5a., la.2e.3a.4a.5a., lb.2e.3a.4a.5a., lf.2e.3a.4a.5a., lh.2e.3a.4a.5a., lj.2e.3a.4a.5a., lp.2e.3a.4a.5a., la.2f.3a.4a.5a., lb.2f.3a.4a.5a., lf.2f.3a.4a.5a., lh.2f.3a.4a.5a., lj.2f.3a.4a.5a., lp.2f.3a.4a.5a., la.2i.3a.4a.5a., lb.2i.3a.4a.5a., lf.2i.3a.4a.5a., lh.2i.3a.4a.5a., lj.2i.3a.4a.5a., lρ.2i.3a.4a.5av la.2m.3a.4a.5av lb.2m.3a.4a.5a., lf.2m.3a.4a.5a., lh.2m.3a.4a.5a., lj.2m.3a.4a.5a., lp.2m.3a.4a.5a., la.2o.3a.4a.5a., lb.2o.3a.4a.5a., lf.2o.3a.4a.5a., lh.2o.3a.4a.5a., lj.2o.3a.4a.5a., lp.2o.3a.4a.5a., la.2u.3a.4a.5a., lb.2u.3a.4a.5a., lf.2u.3a.4a.5a., lh.2u.3a.4a.5a., lj.2u.3a.4a.5a., lp.2u.3a.4a.5a., la.2y.3a.4a.5a., lb.2y.3a.4a.5a., lf.2y.3a.4a.5av lh.2y.3a.4a.5av lj.2y.3a.4a.5a., lp.2y.3a.4a.5av la.2a.3b.4a.5a., lb.2a.3b.4a.5a., lf.2a.3b.4a.5a., lh.2a.3b.4a.5a., lj.2a.3b.4a.5a., lp.2a.3b.4a.5a., la.2b.3b.4a.5a., lb.2b.3b.4a.5a., lf.2b.3b.4a.5a., lh.2b.3b.4a.5a., lj.2b.3b.4a.5a., lp.2b.3b.4a.5a., la.2e.3b.4a.5a., lb.2e.3b.4a.5a., l£.2e.3b.4a.5av lh.2e.3b.4a.5av lj.2e.3b.4a.5a., lp.2e.3b.4a.5av la.2f.3b.4a.5a., lb.2f.3b.4a.5a., lf.2f.3b.4a.5a., lh.2f.3b.4a.5a., lj.2f.3b.4a.5a., lp.2f.3b.4a.5a., la.2i.3b.4a.5a., lb.2i.3b.4a.5a., lf.2i.3b.4a.5a., lh.2i.3b.4a.5av lj.2i.3b.4a.5a., lp.2i.3b.4a.5a., la.2m.3b.4a.5a., lb.2m.3b.4a.5a., lf.2m.3b.4a.5a., lh.2m.3b.4a.5av lj.2m.3b.4a.5a., lp.2m.3b.4a.5a., la.2o.3b.4a.5a., lb.2o.3b.4a.5a., lf.2o.3b.4a.5a., lh.2o.3b.4a.5a., lj.2o.3b.4a.5a., lp.2o.3b.4a.5a., la.2u.3b.4a.5a., lb.2u.3b.4a.5a., lf.2u.3b.4a.5a., lh.2u.3b.4a.5a., lj.2u.3b.4a.5a., lp.2u.3b.4a.5a., la.2y.3b.4a.5a., lb.2y.3b.4a.5a., lf.2y.3b.4a.5av lh.2y.3b.4a.5a., lj.2y.3b.4a.5a., lp.2y.3b.4a.5a., la.2a.3e.4a.5a., lb.2a.3e.4a.5a., lf.2a.3e.4a.5a.Λ lh.2a.3e.4a.5a., lj.2a.3e.4a.5a., lp.2a.3e.4a.5a., la.2b.3e.4a.5a., lb.2b.3e.4a.5a., lf.2b.3e.4a.5a., lh.2b.3e.4a.5a., lj.2b.3e.4a.5a., lp.2b.3e.4a.5a., la.2e.3e.4a.5a., lb.2e.3e.4a.5a., lf.2e.3e.4a.5a., lh.2e.3e.4a.5a., lj.2e.3e.4a.5a., lp.2e.3e.4a.5av la.2f.3e.4a.5a., lb.2f.3e.4a.5av lf.2f.3e.4a.5a., lh.2f.3e.4a.5a., lj.2f.3e.4a.5a., lp.2f.3e.4a.5a., la.2i.3e.4a.5av lb.2i.3e.4a.5a., lf.2i.3e.4a.5a., lh.2i.3e.4a.5a., lj.2i.3e.4a.5a., lp.2i.3e.4a.5av la.2m.3e.4a.5a., lb.2m.3e.4a.5a., lf.2m.3e.4a.5a., lh.2m.3e.4a.5a., lj.2m.3e.4a.5a., lp.2m.3e.4a.5a., la.2o.3e.4a.5a., lb.2o.3e.4a.5av lf.2o.3e.4a.5a., lh.2o.3e.4a.5av lj.2o.3e.4a.5a., lp.2o.3e.4a.5a., la.2u.3e.4a.5a., lb.2u.3e.4a.5a., lf.2u.3e.4a.5a., lh.2u.3e.4a.5av lj.2u.3e.4a.5a., lp.2u.3e.4a.5a-, la.2y.3e.4a.5a., lb.2y.3e.4a.5a., lf.2y.3e.4a.5a., lh.2y.3e.4a.5a., lj.2y.3e.4a.5a., lp.2y.3e.4a.5a., la.2a.3g.4a.5a., lb.2a.3g.4a.5a., lf.2a.3g.4a.5a., lh.2a.3g.4a.5a., lj.2a.3g.4a.5a., lp.2a.3g.4a.5a., la.2b.3g.4a.5a., lb.2b.3g.4a.5a., lf.2b.3g.4a.5a., lh.2b.3g.4a.5a., lj.2b.3g.4a.5a., lp.2b.3g.4a.5a., la.2e.3g.4a.5a., lb.2e.3g.4a.5a., lf.2e.3g.4a.5a., lh.2e.3g.4a.5a., lj.2e.3g.4a.5a., lp.2e.3g.4a.5a., la.2f.3g.4a.5a., lb.2f.3g.4a.5a., lf.2f.3g.4a.5a., lh.2f.3g.4a.5a., lj.2f.3g.4a.5a., lp.2f.3g.4a.5a., la.2i.3g.4a.5a., lb.2i.3g.4a.5a., lf.2i.3g.4a.5a., lh.2i.3g.4a.5a., lj.2i.3g.4a.5a., lp.2i.3g.4a.5a., la.2m.3g.4a.5a., lb.2m.3g.4a.5a., lf.2m.3g.4a.5a., lh.2m.3g.4a.5a., lj.2m.3g.4a.5a., lp.2m.3g.4a.5a., la.2o.3g.4a.5a., lb.2o.3g.4a.5a., lf.2o.3g.4a.5a., lh.2o.3g.4a.5a., lj.2o.3g.4a.5a., lp.2o.3g.4a.5a., la.2u.3g.4a.5a., lb.2u.3g.4a.5a., lf.2u.3g.4a.5a., lh.2u.3g.4a.5av lj.2u.3g.4a.5a., lp.2u.3g.4a.5a., la.2y.3g.4a.5a., lb.2y.3g.4a.5a., lf.2y.3g.4a.5a., lh.2y.3g.4a.5a., lj.2y.3g.4a.5a., lp.2y.3g.4a.5a., la.2a.3a.4d.5a., lb.2a.3a.4d.5a., lf.2a.3a.4d.5a., lh.2a.3a.4d.5a., lj.2a.3a.4d.5a., lp.2a.3a.4d.5a., la.2b.3a.4d.5a., lb.2b.3a.4d.5a., lf.2b.3a.4d.5a., lh.2b.3a.4d.5a., lj.2b.3a.4d.5a., lp.2b.3a.4d.5a., la.2e.3a.4d.5a., lb.2e.3a.4d.5a., lf.2e.3a.4d.5a., lh.2e.3a.4d.5a., lj.2e.3a.4d.5a., lp.2e.3a.4d.5a., la.2f.3a.4d.5a., lb.2f.3a.4d.5a., lf.2f.3a.4d.5a., lh.2f.3a.4d.5a., lj.2f.3a.4d.5a., lp.2f.3a.4d.5a., la.2i.3a.4d.5a., lb.2i.3a.4d.5a., lf.2i.3a.4d.5a., lh.2i.3a.4d.5a., lj.2i.3a.4d.5a., lp.2i.3a.4d.5a., la.2m.3a.4d.5a., lb.2m.3a.4d.5a., lf.2m.3a.4d.5a., lh.2m.3a.4d.5a., lj.2m.3a.4d.5a., lp.2m.3a.4d.5a., la.2o.3a.4d.5a., lb.2o.3a.4d.5a., lf.2o.3a.4d.5a., lh.2o.3a.4d.5a., lj.2o.3a.4d.5a., lp.2o.3a.4d.5av la.2u.3a.4d.5a., lb.2u.3a.4d.5a., lf.2u.3a.4d.5a., lh.2u.3a.4d.5a., lj.2u.3a.4d.5a., lp.2u.3a.4d.5a., la.2y.3a.4d.5a., lb.2y.3a.4d.5a., lf.2y.3a.4d.5av lh.2y.3a.4d.5av lj.2y.3a.4d.5a., lp.2y.3a.4d.5a., la.2a.3b.4d.5a., lb.2a.3b.4d.5a., lf.2a.3b.4d.5a., lh.2a.3b.4d.5a., lj.2a.3b.4d.5a., lp.2a.3b.4d.5a., la.2b.3b.4d.5a., lb.2b.3b.4d.5a., lf.2b.3b.4d.5a., lh.2b.3b.4d.5a., lj.2b.3b.4d.5a., lp.2b.3b.4d.5a., la.2e.3b.4d.5a., lb.2e.3b.4d.5a., lf.2e.3b.4d.5a., lh.2e.3b.4d.5a., lj.2e.3b.4d.5a., lp.2e.3b.4d.5a., la.2f.3b.4d.5av lb.2f.3b.4d.5av lf.2f.3b.4d.5a., lh.2f.3b.4d.5a., lj.2f.3b.4d.5a., lp.2f.3b.4d.5a., la.2i.3b.4d.5a., lb.2i.3b.4d.5a., lf.2i.3b.4d.5a., lh.2i.3b.4d.5a., lj.2i.3b.4d.5a., lp.2i.3b.4d.5a., la.2m.3b.4d.5a., lb.2m.3b.4d.5a., lf.2m.3b.4d.5a., lh.2m.3b.4d.5a., lj.2m.3b.4d.5a., lp.2m.3b.4d.5a., la.2o.3b.4d.5a., lb.2o.3b.4d.5a., lf.2o.3b.4d.5a., lh.2o.3b.4d.5a., lj.2o.3b.4d.5a., lp.2o.3b.4d.5a., la.2u.3b.4d.5a., lb.2u.3b.4d.5a., lf.2u.3b.4d.5a., lh.2u.3b.4d.5a., lj.2u.3b.4d.5a., lp.2u.3b.4d.5a., la.2y.3b.4d.5a., lb.2y.3b.4d.5a., lf.2y.3b.4d.5a., lh.2y.3b.4d.5a., lj.2y.3b.4d.5a., lp.2y.3b.4d.5a., la.2a.3e.4d.5av lb.2a.3e.4d.5a., lf.2a.3e.4d.5a., lh.2a.3e.4d.5a., lj.2a.3e.4d.5a., lp.2a.3e.4d.5a., la.2b.3e.4d.5a., lb.2b.3e.4d.5a., lf.2b.3e.4d.5a., lh.2b.3e.4d.5a., lj.2b.3e.4d.5a., lp.2b.3e.4d.5a., la.2e.3e.4d.5a., lb.2e.3e.4d.5a., lf.2e.3e.4d.5a., lh.2e.3e.4d.5a., lj.2e.3e.4d.5a., lp.2e.3e.4d.5a., la.2f.3e.4d.5a., lb.2f.3e.4d.5a., lf.2f.3e.4d.5a., lh.2f.3e.4d.5a., lj.2f.3e.4d.5a., lp.2f.3e.4d.5a., la.2i.3e.4d.5a., lb.2i.3e.4d.5a., lf.2i.3e.4d.5a., lh.2i.3e.4d.5a., lj.2i.3e.4d.5a., lp.2i.3e.4d.5a., la.2m.3e.4d.5a., lb.2m.3e.4d.5a., lf.2m.3e.4d.5a., lh.2m.3e.4d.5a., lj.2m.3e.4d.5a., lp.2m.3e.4d.5a., la.2o.3e.4d.5a., lb.2o.3e.4d.5a., lf.2o.3e.4d.5a., lh.2o.3e.4d.5a., lj.2o.3e.4d.5a., lp.2o.3e.4d.5a., la.2u.3e.4d.5a., lb.2u.3e.4d.5a., lf.2u.3e.4d.5a., lh.2u.3e.4d.5av lj.2u.3e.4d.5a., lp.2u.3e.4d.5a., la.2y.3e.4d.5a., lb.2y.3e.4d.5a., lf.2y.3e.4d.5a., lh.2y.3e.4d.5a., lj.2y.3e.4d.5a., lρ.2y.3e.4d.5a., la.2a.3g.4d.5a., lb.2a.3g.4d.5a., lf.2a.3g.4d.5a., lh.2a.3g.4d.5a., lj.2a.3g.4d.5a., lp.2a.3g.4d.5a., la.2b.3g.4d.5a., lb.2b.3g.4d.5a., lf.2b.3g.4d.5a., lh.2b.3g.4d.5av lj.2b.3g.4d.5a., lp.2b.3g.4d.5a., la.2e.3g.4d.5a., lb.2e.3g.4d.5a., lf.2e.3g.4d.5a., lh.2e.3g.4d.5a., lj.2e.3g.4d.5a., lp.2e.3g.4d.5a., la.2f.3g.4d.5a., lb.2f.3g.4d.5a., lf.2f.3g.4d.5a., lh.2f.3g.4d.5a., lj.2f.3g.4d.5a., lp.2f.3g.4d.5a., la.2i.3g.4d.5a., lb.2i.3g.4d.5a., lf.2i.3g.4d.5a., lh.2i.3g.4d.5a., lj.2i.3g.4d.5a., lp.2i.3g.4d.5a., la.2m.3g.4d.5a., lb.2m.3g.4d.5a., lf.2m.3g.4d.5a., lh.2m.3g.4d.5a., lj.2m.3g.4d.5a., lp.2m.3g.4d.5av la.2o.3g.4d.5a., lb.2o.3g.4d.5a., lf.2o.3g.4d.5a., lh.2o.3g.4d.5a., lj.2o.3g.4d.5a., lρ.2o.3g.4d.5a., la.2u.3g.4d.5a., lb.2u.3g.4d.5a., lf.2u.3g.4d.5a., lh.2u.3g.4d.5a., lj.2u.3g.4d.5a., lp.2u.3g.4d.5a., la.2y.3g.4d.5a., lb.2y.3g.4d.5a., lf.2y.3g.4d.5a., lh.2y.3g.4d.5a., lj.2y.3g.4d.5a., lp.2y.3g.4d.5a., la.2a.3a.4f.5a., lb.2a.3a.4f.5a., lf.2a.3a.4f.5a., lh.2a.3a.4f.5a., lj.2a.3a.4f.5av lp.2a.3a.4f.5a., la.2b.3a.4f.5a., lb.2b.3a.4f.5a., lf.2b.3a.4f.5a., lh.2b.3a.4f.5a., lj.2b.3a.4f.5a., lp.2b.3a.4f.5a., la.2e.3a.4f.5a., lb.2e.3a.4f.5a., lf.2e.3a.4f.5a., lh.2e.3a.4f.5a., lj.2e.3a.4f.5a., lp.2e.3a.4f.5av la.2f.3a.4f.5a., lb.2f.3a.4f.5a., lf.2f.3a.4f.5a., lh.2f.3a.4f.5a., lj.2f.3a.4f.5a., lp.2f.3a.4f.5a., la.2i.3a.4f.5a., lb.2i.3a.4f.5a., lf.2i.3a.4f.5a., lh.2i.3a.4f.5a., lj.2i.3a.4f.5a., lp.2i.3a.4f.5av la.2m.3a.4f.5a., lb.2m.3a.4f.5a., lf.2m.3a.4f.5a., lh.2m.3a.4f.5a., lj.2m.3a.4f.5a., lp.2m.3a.4f.5a., la.2o.3a.4f.5a., lb.2o.3a.4f.5a., lf.2o.3a.4f.5a., lh.2o.3a.4f.5a., lj.2o.3a.4f.5a., lp.2o.3a.4f.5a., la.2u.3a.4f.5a., lb.2u.3a.4f.5a., lf.2u.3a.4f.5a., lh.2u.3a.4f.5av Ij .2u.3a.4f.5a., lp.2u.3a.4f.5a., la.2y.3a.4f.5a., lb.2y.3a.4f.5a., lf.2y.3a.4f.5a., lh.2y.3a.4f.5a., lj.2y.3a.4f.5a., lp.2y.3a.4f.5av la.2a.3b.4f.5a., lb.2a.3b.4f.5a., lf.2a.3b.4f.5a., lh.2a.3b.4f.5a., lj.2a.3b.4f.5a., lp.2a.3b.4f.5a., la.2b.3b.4f.5a., lb.2b.3b.4f.5a., lf.2b.3b.4f.5a., lh.2b.3b.4f.5a., lj.2b.3b.4f.5a., lp.2b.3b.4f.5a., la.2e.3b.4f.5a., lb.2e.3b.4f.5a., lf.2e.3b.4f.5a., lh.2e.3b.4f.5a., lj.2e.3b.4f.5a., lp.2e.3b.4f.5a., la.2f.3b.4f.5a., lb.2f.3b.4f.5a., lf.2f.3b.4f.5a., lh.2f.3b.4f.5a., lj.2f.3b.4f.5a., lp.2f.3b.4f.5a., la.2i.3b.4f.5av lb.2i.3b.4f.5a., lf.2i.3b.4f.5a., lh.2L3b.4f.5a., lj.2i.3b.4f.5a., lp.2i.3b.4f.5a., la.2m.3b.4f.5a., lb.2m.3b.4f.5a., lf.2m.3b.4f.5a., lh.2m.3b.4f.5a., lj.2m.3b.4f.5a., lp.2m.3b.4f.5a., la.2o.3b.4f.5a., lb.2o.3b.4f.5a., lf.2o.3b.4f.5a., lh.2o.3b.4f.5a., lj.2o.3b.4f.5a., lp.2o.3b.4f.5a., la.2u.3b.4f.5a., lb.2u.3b.4f.5a., lf.2u.3b.4f.5a., lh.2u.3b.4f.5a., lj.2u.3b.4f.5a., lρ.2u.3b.4f.5av la.2y.3b.4f.5a., lb.2y.3b.4f.5a., lf.2y.3b.4f.5a., lh.2y.3b.4f.5a., lj.2y.3b.4f.5a., lp.2y.3b.4f.5a., la.2a.3e.4f.5a., lb.2a.3e.4f.5a., lf.2a.3e.4f.5a., lh.2a.3e.4f.5a., lj.2a.3e.4f.5a., lp.2a.3e.4f.5a-, la.2b.3e.4f.5a., lb.2b.3e.4f.5a., lf.2b.3e.4f.5a., lh.2b.3e.4f.5a., lj.2b.3e.4f.5a., lp.2b.3e.4f.5a., la.2e.3e.4f.5a., lb.2e.3e.4f.5a., lf.2e.3e.4f.5a., lh.2e.3e.4f.5a., lj.2e.3e.4f.5a., lp.2e.3e.4f.5a., la.2f.3e.4f.5a., lb.2f.3e.4f.5a., lf.2f.3e.4f.5a., lh.2f.3e.4f.5a., lj.2f.3e.4f.5a., lp.2f.3e.4f.5a., la.2i.3e.4f.5a., lb.2i.3e.4f.5a., lf.2i.3e.4f.5a., lh.2i.3e.4f.5a., lj.2i.3e.4f.5a., lp.2i.3e.4f.5a., la.2m.3e.4f.5a., lb.2m.3e.4f.5a., lf.2m.3e.4f.5a., lh.2m.3e.4f.5a., lj.2m.3e.4f.5a., lp.2m.3e.4f.5a., la.2o.3e.4f.5a., lb.2o.3e.4f.5a., lf.2o.3e.4f.5a., lh.2o.3e.4f.5a., lj.2o.3e.4f.5a., lp.2o.3e.4f.5a., la.2u.3e.4f.5a., lb.2u.3e.4f.5av lf.2u.3e.4f.5a., lh.2u.3e.4f.5a., lj.2u.3e.4f.5a., lp.2u.3e.4f.5a., la.2y.3e.4f.5a., lb.2y.3e.4f.5a., lf.2y.3e.4f.5a., lh.2y.3e.4f.5a., lj.2y.3e.4f.5a., lp.2y.3e.4f.5a., la.2a.3g.4f.5a., lb.2a.3g.4f.5a., lf.2a.3g.4f.5a., lh.2a.3g.4f.5a., lj.2a.3g.4f.5a., lp.2a.3g.4f.5a., la.2b.3g.4f.5a., lb.2b.3g.4f.5a., lf.2b.3g.4f.5a., lh.2b.3g.4f.5a., lj.2b.3g.4f.5a., lp.2b.3g.4f.5a., la.2e.3g.4f.5a., lb.2e.3g.4f.5a., lf.2e.3g.4f.5a., lh.2e.3g.4f.5a., lj.2e.3g.4f.5a., lp.2e.3g.4f.5a., la.2f.3g.4f.5a., lb.2f.3g.4f.5a., lf.2f.3g.4f.5a., lh.2f.3g.4f.5a., lj.2f.3g.4f.5a., lp.2f.3g.4f.5a., la.2i.3g.4f.5a., lb.2i.3g.4f.5a., lf.2i.3g.4f.5a., lh.2i.3g.4f.5a., lj.2i.3g.4f.5a., lp.2i.3g.4f.5a., la.2m.3g.4f.5av lb.2m.3g.4f.5a., lf.2m.3g.4f.5a., lh.2m.3g.4f.5a., lj.2m.3g.4f.5a., lp.2m.3g.4f.5a., la.2o.3g.4f.5a., lb.2o.3g.4f.5a., lf.2o.3g.4f.5a., lh.2o.3g.4f.5a., lj.2o.3g.4f.5a., lp.2o.3g.4f.5a., la.2u.3g.4f.5a., lb.2u.3g.4f.5a., lf.2u.3g.4f.5a., lh.2u.3g.4f.5a., lj.2u.3g.4f.5a., lp.2u.3g.4f.5a., la.2y.3g.4f.5a., lb.2y.3g.4f.5a., lf.2y.3g.4f.5a., lh.2y.3g.4f.5av l].2y.3g.4f.5a., lp.2y.3g.4f.5a., la.2a.3a.4g.5a., lb.2a.3a.4g.5a., lf.2a.3a.4g.5a., lh.2a.3a.4g.5a., lj.2a.3a.4g.5a., lp.2a.3a.4g.5a., la.2b.3a.4g.5a., lb.2b.3a.4g.5a., lf.2b.3a.4g.5a., lh.2b.3a.4g.5a., lj.2b.3a.4g.5a., lp.2b.3a.4g.5a., la.2e.3a.4g.5a., lb.2e.3a.4g.5a., lf.2e.3a.4g.5a., lh.2e.3a.4g.5a., lj.2e.3a.4g.5a., lp.2e.3a.4g.5a., la.2f.3a.4g.5a., lb.2f.3a.4g.5a., lf.2f.3a.4g.5a., lh.2f.3a.4g.5a., lj.2f.3a.4g.5a., lp.2f.3a.4g.5a., la.2i.3a.4g.5a., lb.2i.3a.4g.5a., lf.2i.3a.4g.5a., lh.2i.3a.4g.5a., lj.2i.3a.4g.5a., lp.2i.3a.4g.5a., la.2m.3a.4g.5a., lb.2m.3a.4g.5a., lf.2m.3a.4g.5a., lh.2m.3a.4g.5a., lj.2m.3a.4g.5a.; lp.2m.3a.4g.5a., la.2o.3a.4g.5a., lb.2o.3a.4g.5a., lf.2o.3a.4g.5a., lh.2o.3a.4g.5a., lj.2o.3a.4g.5a., lp.2o.3a.4g.5a., la.2u.3a.4g.5av lb.2u.3a.4g.5av lf.2u.3a.4g.5a., lh.2u.3a.4g.5a., lj.2u.3a.4g.5a., lρ.2u.3a.4g.5a., la.2y.3a.4g.5a., lb.2y.3a.4g.5a., lf.2y.3a.4g.5a., lh.2y.3a.4g.5a., lj.2y.3a.4g.5a., lp.2y.3a.4g.5a., la.2a.3b.4g.5a., lb.2a.3b.4g.5a., lf.2a.3b.4g.5a., lh.2a.3b.4g.5a., lj.2a.3b.4g.5a., lp.2a.3b.4g.5a., la.2b.3b.4g.5a., lb.2b.3b.4g.5a., lf.2b.3b.4g.5a., lh.2b.3b.4g.5a., lj.2b.3b.4g.5a., lp.2b.3b.4g.5av la.2e.3b.4g.5a., lb.2e.3b.4g.5a., lf.2e.3b.4g.5a., lh.2e.3b.4g.5a., lj.2e.3b.4g.5a., lp.2e.3b.4g.5a., la.2£.3b.4g.5a., lb.2f.3b.4g.5a., lf.2£.3b.4g.5av lh.2f.3b.4g.5a., lj.2f.3b.4g.5a., lp.2f.3b.4g.5a., la.2i.3b.4g.5a., lb.2i.3b.4g.5a., lf.2i.3b.4g.5a., lh.2i.3b.4g.5a., lj.2i.3b.4g.5a., lp.2i.3b.4g.5a., la.2m.3b.4g.5a., lb.2m.3b.4g.5a., lf.2m.3b.4g.5a., lh.2m.3b.4g.5a., lj.2m.3b.4g.5a., lp.2m.3b.4g.5a., la.2o.3b.4g.5a., lb.2o.3b.4g.5a., lf.2o.3b.4g.5a., lh.2o.3b.4g.5a., lj.2o.3b.4g.5a., lp.2o.3b.4g.5a., la.2u.3b.4g.5a., lb.2u.3b.4g.5a., lf.2u.3b.4g.5a., lh.2u.3b.4g.5a., lj.2u.3b.4g.5a., lp.2u.3b.4g.5a., la.2y.3b.4g.5a., lb.2y.3b.4g.5a., lf.2y.3b.4g.5a., lh.2y.3b.4g.5a., lj.2y.3b.4g.5a., lρ.2y.3b.4g.5av la.2a.3e.4g.5a., lb.2a.3e.4g.5a., lf.2a.3e.4g.5a., lh.2a.3e.4g.5a., lj.2a.3e.4g.5a., lp.2a.3e.4g.5a., la.2b.3e.4g.5a., lb.2b.3e.4g.5a., lf.2b.3e.4g.5a., lh.2b.3e.4g.5a., lj.2b.3e.4g.5a., lp.2b.3e.4g.5a., la.2e.3e.4g.5a., lb.2e.3e.4g.5a., lf.2e.3e.4g.5a., lh.2e.3e.4g.5a., lj.2e.3e.4g.5a., lp.2e.3e.4g.5a., la.2f.3e.4g.5a., lb.2f.3e.4g.5a., lf.2f.3e.4g.5a., lh.2f.3e.4g.5a., lj.2f.3e.4g.5a., lp.2f.3e.4g.5a., la.2i.3e.4g.5a., lb.2i.3e.4g.5a., lf.2i.3e.4g.5a., lh.2i.3e.4g.5a., lj.2i.3e.4g.5a., lp.2i.3e.4g.5a., la.2m.3e.4g.5a., lb.2m.3e.4g.5a., lf.2m.3e.4g.5a., lh.2m.3e.4g.5a., lj.2m.3e.4g.5a., lp.2m.3e.4g.5a., la.2o.3e.4g.5a., lb.2o.3e.4g.5a., lf.2o.3e.4g.5a., lh.2o.3e.4g.5a., lj.2o.3e.4g.5a., lp.2o.3e.4g.5a., la.2u.3e.4g.5a., lb.2u.3e.4g.5a., lf.2u.3e.4g.5a., lh.2u.3e.4g.5a., lj.2u.3e.4g.5a., lp.2u.3e.4g.5a., la.2y.3e.4g.5a., lb.2y.3e.4g.5a., lf.2y.3e.4g.5a., lh.2y.3e.4g.5a., lj.2y.3e.4g.5a., lp.2y.3e.4g.5a., la.2a.3g.4g.5a., lb.2a.3g.4g.5a., lf.2a.3g.4g.5a., lh.2a.3g.4g.5a., lj.2a.3g.4g.5a., lp.2a.3g.4g.5a., la.2b.3g.4g.5a., lb.2b.3g.4g.5a., lf.2b.3g.4g.5a., lh.2b.3g.4g.5a., lj.2b.3g.4g.5a., lp.2b.3g.4g.5a., la.2e.3g.4g.5a., lb.2e.3g.4g.5a., lf.2e.3g.4g.5a., lh.2e.3g.4g.5a., lj.2e.3g.4g.5a., lp.2e.3g.4g.5a., la.2f.3g.4g.5a., lb.2f.3g.4g.5a., lf.2f.3g.4g.5a., lh.2f.3g.4g.5a., lj.2f.3g.4g.5a., lp.2f.3g.4g.5a., la.2i.3g.4g.5a., lb.2i.3g.4g.5a., lf.2i.3g.4g.5a., lh.2i.3g.4g.5a., lj.2i.3g.4g.5a., lp.2i.3g.4g.5a., la.2m.3g.4g.5a., lb.2m.3g.4g.5a., lf.2m.3g.4g.5a., lh.2m.3g.4g.5a., lj.2m.3g.4g.5a., lp.2m.3g.4g.5a., la.2o.3g.4g.5a., lb.2o.3g.4g.5a., lf.2o.3g.4g.5a., lh.2o.3g.4g.5a., lj.2o.3g.4g.5a., lp.2o.3g.4g.5a., la.2u.3g.4g.5a., lb.2u.3g.4g.5a., lf.2u.3g.4g.5a., lh.2u.3g.4g.5av lj.2u.3g.4g.5a., lp.2u.3g.4g.5a., la.2y.3g.4g.5a., lb.2y.3g.4g.5a., lf.2y.3g.4g.5a., lh.2y.3g.4g.5a., lj.2y.3g.4g.5a., lp.2y.3g.4g.5a., la.2a.3a.4h.5a., lb.2a.3a.4h.5a., lf.2a.3a.4h.5a., lh.2a.3a.4h.5a., lj.2a.3a.4h.5a., lp.2a.3a.4h.5a., la.2b.3a.4h.5a., lb.2b.3a.4h.5a., lf.2b.3a.4h.5a., lh.2b.3a.4h.5a., lj.2b.3a.4h.5a., lp.2b.3a.4h.5a., la.2e.3a.4h.5a., lb.2e.3a.4h.5a., lf.2e.3a.4h.5a., lh.2e.3a.4h.5av lj.2e.3a.4h.5a., lp.2e.3a.4h.5a., la.2f.3a.4h.5a., lb.2f.3a.4h.5a., lf.2f.3a.4h.5av lh.2f.3a.4h.5av lj.2f.3a.4h.5a., lp.2f.3a.4h.5a., la.2i.3a.4h.5a., lb.2i.3a.4h.5a., lf.2i.3a.4h.5av lh.2i.3a.4h.5a., lj.2i.3a.4h.5a., lp.2i.3a.4h.5a., la.2m.3a.4h.5a., lb.2m.3a.4h.5a., lf.2m.3a.4h.5a., lh.2m.3a.4h.5a., lj.2m.3a.4h.5a., lp.2m.3a.4h.5a., la.2o.3a.4h.5a., lb.2o.3a.4h.5a., lf.2o.3a.4h.5av lh.2o.3a.4h.5a., lj.2o.3a.4h.5a., lp.2o.3a.4h.5a., la.2u.3a.4h.5a., lb.2u.3a.4h.5a., lf.2u.3a.4h.5a., lh.2u.3a.4h.5a., lj.2u.3a.4h.5a., lp.2u.3a.4h.5a., la.2y.3a.4h.5a., lb.2y.3a.4h.5av lf.2y.3a.4h.5a., lh.2y.3a.4h.5a., lj.2y.3a.4h.5a., lp.2y.3a.4h.5a., la.2a.3b.4h.5a., lb.2a.3b.4h.5a., lf.2a.3b.4h.5a., lh.2a.3b.4h.5a., lj-2a.3b.4h.5a., lp.2a.3b.4h.5a., la.2b.3b.4h.5a., lb.2b.3b.4h.5a., lf.2b.3b.4h.5a., lh.2b.3b.4h.5a., lj.2b.3b.4h.5a., lp.2b.3b.4h.5a., la.2e.3b.4h.5a., lb.2e.3b.4h.5a., lf.2e.3b.4h.5a., lh.2e.3b.4h.5a., lj.2e.3b.4h.5a., lp.2e.3b.4h.5a., la.2f.3b.4h.5a., lb.2f.3b.4h.5a., lf.2f.3b.4h.5a., lh.2f.3b.4h.5a., lj.2f.3b.4h.5a., lp.2f.3b.4h.5a., la.2i.3b.4h.5a., lb.2i.3b.4h.5a., lf.2i.3b.4h.5a., lh.2i.3b.4h.5a., lj.2i.3b.4h.5a., lp.2i.3b.4h.5a., la.2m.3b.4h.5a., lb.2m.3b.4h.5a., lf.2m.3b.4h.5a., lh.2m.3b.4h.5a., lj.2m.3b.4h.5a., lp.2m.3b.4h.5a., la.2o.3b.4h.5a., lb.2o.3b.4h.5a., lf.2o.3b.4h.5a., lh.2o.3b.4h.5a., lj.2o.3b.4h.5a., lp.2o.3b.4h.5a., la.2u.3b.4h.5a., lb.2u.3b.4h.5a., lf.2u.3b.4h.5a., lh.2u.3b.4h.5a., lj.2u.3b.4h.5a., lp.2u.3b.4h.5a., la.2y.3b.4h.5a., lb.2y.3b.4h.5a., lf.2y.3b.4h.5a., lh.2y.3b.4h.5a., lj.2y.3b.4h.5a., lp.2y.3b.4h.5a., la.2a.3e.4h.5a., lb.2a.3e.4h.5a., lf.2a.3e.4h.5a., lh.2a.3e.4h.5a., lj.2a.3e.4h.5a., lp.2a.3e.4h.5a., la.2b.3e.4h.5a., lb.2b.3e.4h.5a., lf.2b.3e.4h.5a., lh.2b.3e.4h.5a., lj.2b.3e.4h.5a., lp.2b.3e.4h.5a., la.2e.3e.4h.5a., lb.2e.3e.4h.5a., lf.2e.3e.4h.5a., lh.2e.3e.4h.5a., lj.2e.3e.4h.5a., lp.2e.3e.4h.5a., la.2f.3e.4h.5a., lb.2f.3e.4h.5a., lf.2f.3e.4h.5a., lh.2f.3e.4h.5a., lj.2f.3e.4h.5a., lp.2f.3e.4h.5a., la.2i.3e.4h.5a., lb.2i.3e.4h.5a., lf.2i.3e.4h.5a., lh.2i.3e.4h.5a., lj.2i.3e.4h.5a., lp.2i.3e.4h.5a., la.2m.3e.4h.5a., lb.2m.3e.4h.5a., lf.2m.3e.4h.5a., lh.2m.3e.4h.5a., Tj.2m.3e.4h.5a., lρ.2m.3e.4h.5a., la.2o.3e.4h.5a., lb.2o.3e.4h.5a., lf.2o.3e.4h.5a., lh.2o.3e.4h.5a., lj.2o.3e.4h.5a., lp.2o.3e.4h.5a., la.2u.3e.4h.5a., lb.2u.3e.4h.5a., lf.2u.3e.4h.5a., lh.2u.3e.4h.5a., lj.2u.3e.4h.5a., lp.2u.3e.4h.5a., la.2y.3e.4h.5a., lb.2y.3e.4h.5a., lf.2y.3e.4h.5a., lh.2y.3e.4h.5a., lj.2y.3e.4h.5a., lp.2y.3e.4h.5a., la.2a.3g.4h.5a., lb.2a.3g.4h.5a., lf.2a.3g.4h.5a., lh.2a.3g.4h.5a., lj.2a.3g.4h.5a., lp.2a.3g.4h.5a., la.2b.3g.4h.5a., lb.2b.3g.4h.5a., lf.2b.3g.4h.5a., lh.2b.3g.4h.5a., lj.2b.3g.4h.5a., lp.2b.3g.4h.5a., la.2e.3g.4h.5a., lb.2e.3g.4h.5a., lf.2e.3g.4h.5a., lh.2e.3g.4h.5a., lj.2e.3g.4h.5a., lp.2e.3g.4h.5a., la.2f.3g.4h.5a., lb.2f.3g.4h.5a., lf.2f.3g.4h.5a., lh.2f.3g.4h.5a., lj.2f.3g.4h.5a., lp.2f.3g.4h.5a., la.2i.3g.4h.5a., lb.2i.3g.4h.5a., lf.2i.3g.4h.5a., lh.2i.3g.4h.5a., lj.2i.3g.4h.5a., lp.2i.3g.4h.5a., la.2m.3g.4h.5a., lb.2m.3g.4h.5a., lf.2m.3g.4h.5a., lh.2m.3g.4h.5a., lj.2m.3g.4h.5a., lp.2m.3g.4h.5a., la.2o.3g.4h.5a., lb.2o.3g.4h.5a., lf.2o.3g.4h.5a., lh.2o.3g.4h.5a., lj.2o.3g.4h.5a., lp.2o.3g.4h.5a., la.2u.3g.4h.5a., lb.2u.3g.4h.5a., lf.2u.3g.4h.5a., lh.2u.3g.4h.5a., lj.2u.3g.4h.5a., lp.2u.3g.4h.5a., la.2y.3g.4h.5a., lb.2y.3g.4h.5a., lf.2y.3g.4h.5a., lh.2y.3g.4h.5av lj.2y.3g.4h.5a., lp.2y.3g.4h.5av la.2a.3a.4i.5av lb.2a.3a.4i.5a., lf.2a.3a.4i.5a., lh.2a.3a.4i.5a., lj.2a.3a.4i.5a., lp.2a.3a.4i.5a., la.2b.3a.4i.5av lb.2b.3a.4i.5a., lf.2b.3a.4i.5a., lh.2b.3a.4i.5a.r lj.2b.3a.4i.5a., lp.2b.3a.4i.5a., la.2e.3a.4i.5a., lb.2e.3a.4i.5a., lf.2e.3a.4i.5a., lh.2e.3a.4i.5av lj.2e.3a.4i.5a., lp.2e.3a.4i.5a., la.2f.3a.4i.5a., lb.2f.3a.4i.5a., lf.2f.3a.4i.5av lh.2f.3a.4i.5a.; lj.2f.3a.4i.5a., lp.2f.3a.4i.5a., la.2i.3a.4i.5a., lb.2i.3a.4i.5a., lf.2i.3a.4i.5av lh.2i.3a.4i.5a., lj.2i.3a.4i.5a., lρ.2i.3a.4i.5a., la.2m.3a.4i.5a., lb.2m.3a.4i.5av lf.2m.3a.4i.5a., lh.2m.3a.4i.5a., lj.2m.3a.4i.5a., lp.2m.3a.4i.5a., la.2o.3a.4i.5av lb.2o.3a.4i.5a., lf.2o.3a.4i.5a., lh.2o.3a.4i.5a., lj.2o.3a.4i.5a., lp.2o.3a.4i.5av la.2u.3a.4i.5av lb.2u.3a.4i.5av lf.2u.3a.4i.5a., lh.2u.3a.4i.5a., lj.2u.3a.4i.5a., lp.2u.3a.4i.5a., la.2y.3a.4i.5a., lb.2y.3a.4i.5a., lf.2y.3a.4i.5a., lh.2y.3a.4i.5a., lj.2y.3a.4i.5a., lp.2y.3a.4i.5av la.2a.3b.4i.5a., lb.2a.3b.4i.5a., lf.2a.3b.4i.5av lh.2a.3b.4i.5a., lj.2a.3b.4i.5a., lp.2a.3b.4i.5a., la.2b.3b.4i.5a., lb.2b.3b.4i.5av lf.2b.3b.4i.5a., lh.2b.3b.4i.5av lj.2b.3b.4i.5a., lp.2b.3b.4i.5a., la.2e.3b.4i.5a., lb.2e.3b.4i.5a., lf.2e.3b.4i.5a., lh.2e.3b.4i.5a., lj.2e.3b.4i.5a., lp.2e.3b.4i.5a., la.2f.3b.4i.5a., lb.2f.3b.4i.5av lf.2f.3b.4i.5a., lh.2f.3b.4i.5a., lj.2f.3b.4i.5a., lp.2f.3b.4i.5a., la.2i.3b.4i.5av lb.2i.3b.4i.5a., lf.2i.3b.4i.5av lh.2i.3b.4i.5a., lj.2i.3b.4i.5a., lp.2i.3b.4i.5a., la.2m.3b.4i.5a., lb.2m.3b.4i.5a., l£.2m.3b.4i.5a., lh.2m.3b.4i.5a., lj.2m.3b.4i.5a., lp.2m.3b.4i.5a., la.2o.3b.4i.5a., lb.2o.3b.4i.5a., lf.2o.3b.4i.5a., lh.2o.3b.4i.5a., lj.2o.3b.4i.5a., lρ.2o.3b.4i.5a., la.2u.3b.4i.5a., lb.2u.3b.4i.5a., lf.2u.3b.4i.5a., lh.2u.3b.4i.5a., lj.2u.3b.4i.5a., lp.2u.3b.4i.5a., la.2y.3b.4i.5a., lb.2y.3b.4i.5a., lf.2y.3b.4i.5a., lh.2y.3b.4i.5a., lj.2y.3b.4i.5a., lp.2y.3b.4L5a., la.2a.3e.4i.5a., lb.2a.3e.4i.5a., lf.2a.3e.4i.5a., lh.2a.3e.4i.5a., lj.2a.3e.4i.5a., lp.2a.3e.4i.5a., la.2b.3e.4i.5a., lb.2b.3e.4i.5a., lf.2b.3e.4i.5a., lh.2b.3e.4i.5a., lj.2b.3e.4i.5a., lp.2b.3e.4i.5av la.2e.3e.4i.5a-, lb.2e.3e.4i.5a., lf.2e.3e.4i.5a., lh.2e.3e.4i.5av lj.2e.3e.4i.5a., lp.2e.3e.4i.5a., la.2f.3e.4i.5av lb.2f.3e.4i.5a., lf.2£.3e.4i.5a., lh.2f.3e.4i.5a., lj.2f.3e.4i.5a., lρ.2f.3e.4i.5av la.2i.3e.4i.5a., lb.2i.3e.4i.5a., lf.2i.3e.4i.5a., lh.2i.3e.4i.5a., lj.2i.3e.4i.5a., lp.2i.3e.4i.5a., la.2m.3e.4i.5a., lb.2m.3e.4i.5a., lf.2m.3e.4i.5a., lh.2m.3e.4i.5a., lj.2m.3e.4i.5a., lp.2m.3e.4i.5a., la.2o.3e.4i.5a., lb.2o.3e.4i.5a., lf.2o.3e.4i.5a., lh.2o.3e.4i.5a., lj.2o.3e.4i.5a., lp.2o.3e.4i.5a., la.2u.3e.4i.5a., lb.2u.3e.4i.5av lf.2u.3e.4i.5av lh.2u.3e.4i.5a., lj.2u.3e.4i.5a., lp.2u.3e.4i.5a., la.2y.3e.4i.5a., lb.2y.3e.4i.5av lf.2y.3e.4i.5a., lh.2y.3e.4i.5av lj.2y.3e.4i.5av lp.2y.3e.4i.5a., la.2a.3g.4i.5a., lb.2a.3g.4i.5a., lf.2a.3g.4i.5a., lh.2a.3g.4i.5av lj.2a.3g.4i.5a., lp.2a.3g.4i.5a., l a.2b.3g.4i.5a., lb.2b.3g.4i.5av lf.2b.3g.4i.5a., lh.2b.3g.4i.5a., lj.2b.3g.4i.5a., lp.2b.3g.4i.5a., la.2e.3g.4i.5a., lb.2e.3g.4i.5a., lf.2e.3g.4i.5a., lh.2e.3g.4i.5a., lj.2e.3g.4i.5a., lp.2e.3g.4i.5a., la.2f.3g.4i.5a., lb.2f.3g.4i.5a., lf.2f.3g.4i.5a., lh.2f.3g.4i.5a., lj.2f.3g.4i.5av lp.2f.3g.4i.5a., la.2i.3g.4i.5a., lb.2i.3g.4i.5a., lf.2i.3g.4i.5a., lh.2i.3g.4i.5a., lj.2i.3g.4i.5a., lp.2i.3g.4i.5a., la.2m.3g.4i.5a., lb.2m.3g.4i.5a., lf.2m.3g.4i.5a., lh.2m.3g.4i.5a., lj.2m.3g.4i.5a., lp.2m.3g.4i.5a., la.2o.3g.4i.5a., lb.2o.3g.4i.5a., lf.2o.3g.4i.5a., lh.2o.3g.4i.5a., lj.2o.3g.4i.5a., lp.2o.3g.4i.5a., la.2u.3g.4i.5a., lb.2u.3g.4i.5a., lf.2u.3g.4i.5a., lh.2u.3g.4i.5a., lj.2u.3g.4i.5a., lp.2u.3g.4i.5a., la.2y.3g.4i.5a., lb.2y.3g.4i.5a., lf.2y.3g.4i.5a., lh.2y.3g.4i.5a., lj.2y.3g.4i.5a., lp.2y.3g.4i.5a., la.2a.3a.4a.5d., lb.2a.3a.4a.5d., lf.2a.3a.4a.5d., lh.2a.3a.4a.5d., lj.2a.3a.4a.5d., lp.2a.3a.4a.5d., la.2b.3a.4a.5d., lb.2b.3a.4a.5d., lf.2b.3a.4a.5d., lh.2b.3a.4a.5dv lj.2b.3a.4a.5d., lp.2b.3a.4a.5d., la.2e.3a.4a.5d., lb.2e.3a.4a.5d., lf.2e.3a.4a.5d., lh.2e.3a.4a.5d., lj.2e.3a.4a.5d., lp.2e.3a.4a.5d., la.2f.3a.4a.5d., lb.2f.3a.4a.5d., lf.2f.3a.4a.5d., lh.2f.3a.4a.5d., lj.2f.3a.4a.5d., lp.2f.3a.4a.5d., la.2i.3a.4a.5d., lb.2i.3a.4a.5d., lf.2i.3a.4a.5d., lh.2i.3a.4a.5dv lj.2i.3a.4a.5d., lp.2i.3a.4a.5d., la.2m.3a.4a.5d., lb.2m.3a.4a.5d., l£.2m.3a.4a.5d., lh.2m.3a.4a.5d., lj.2m.3a.4a.5d., lp.2m.3a.4a.5d., la.2o.3a.4a.5d., lb.2o.3a.4a.5d., lf.2o.3a.4a.5d., lh.2o.3a.4a.5d., lj.2o.3a.4a.5dv lp.2o.3a.4a.5d., la.2u.3a.4a.5d., lb.2u.3a.4a.5d., lf.2u.3a.4a.5d., lh.2u.3a.4a.5d., lj.2u.3a.4a.5d., lp.2u.3a.4a.5d., la.2y.3a.4a.5dv lb.2y.3a.4a.5dv lf.2y.3a.4a.5dv lh.2y.3a.4a.5d., lj.2y.3a.4a.5d., lp.2y.3a.4a.5d., la.2a.3b.4a.5d., lb.2a.3b.4a.5d., lf.2a.3b.4a.5d., lh.2a.3b.4a.5d., lj.2a.3b.4a.5d., lp.2a.3b.4a.5d., la.2b.3b.4a.5d., lb.2b.3b.4a.5d., lf.2b.3b.4a.5d., lh.2b.3b.4a.5d., lj.2b.3b.4a.5d., lp.2b.3b.4a.5d., la.2e.3b.4a.5d., lb.2e.3b.4a.5d., lf.2e.3b.4a.5d., lh.2e.3b.4a.5d., lj.2e.3b.4a.5d., lp.2e.3b.4a.5d., la.2£.3b.4a.5d., lb.2f.3b.4a.5d., lf.2f.3b.4a.5d., lh.2f.3b.4a.5d., lj.2f.3b.4a.5d., lp.2f.3b.4a.5d., la.2i.3b.4a.5d., lb.2i.3b.4a.5dv lf.2i.3b.4a.5d., lh.2i.3b.4a.5d., lj.2i.3b.4a.5d., lρ.2i.3b.4a.5d., la.2m.3b.4a.5d., lb.2m.3b.4a.5d., lf.2m.3b.4a.5d., lh.2m.3b.4a.5d., lj.2m.3b.4a.5dv lp.2m.3b.4a.5d., la.2o.3b.4a.5d., lb.2o.3b.4a.5d., lf.2o.3b.4a.5d., lh.2o.3b.4a.5d., lj.2o.3b.4a.5d., lp.2o.3b.4a.5d., la.2u.3b.4a.5d., lb.2u.3b.4a.5d., lf.2u.3b.4a.5d., lh.2u.3b.4a.5d., lj.2u.3b.4a.5d., lp.2u.3b.4a.5d., la.2y.3b.4a.5d., lb.2y.3b.4a.5d., lf.2y.3b.4a.5d., lh.2y.3b.4a.5d., lj.2y.3b.4a.5d., lp.2y.3b.4a.5d., la.2a.3e.4a.5d., lb.2a.3e.4a.5d., lf.2a.3e.4a.5d., lh.2a.3e.4a.5d., lj.2a.3e.4a.5d., lp.2a.3e.4a.5d., la.2b.3e.4a.5d., lb.2b.3e.4a.5d., lf.2b.3e.4a.5d., lh.2b.3e.4a.5d., lj.2b.3e.4a.5d., lp.2b.3e.4a.5d., la.2e.3e.4a.5d., lb.2e.3e.4a.5d., lf.2e.3e.4a.5d., lh.2e.3e.4a.5d., lj.2e.3e.4a.5d., lp.2e.3e.4a.5d., la.2f.3e.4a.5d., lb.2f.3e.4a.5d., lf.2f.3e.4a.5d., lh.2f.3e.4a.5d., lj.2f.3e.4a.5d., lp.2f.3e.4a.5d., la.2i.3e.4a.5d., lb.2i.3e.4a.5d., lf.2i.3e.4a.5d., lh.2i.3e.4a.5d., lj.2i.3e.4a.5d., lp.2i.3e.4a.5d-, la.2m.3e.4a.5d., lb.2m.3e.4a.5d., lf.2m.3e.4a.5d., lh.2m.3e.4a.5d., lj.2m.3e.4a.5d., lp.2m.3e.4a.5d., la.2o.3e.4a.5d., lb.2o.3e.4a.5d., lf.2o.3e.4a.5dv lh.2o.3e.4a.5d., lj.2o.3e.4a.5d., lp.2o.3e.4a.5d., la.2u.3e.4a.5d., lb.2u.3e.4a.5d., lf.2u.3e.4a.5d., lh.2u.3e.4a.5d., lj.2u.3e.4a.5dv lp.2u.3e.4a.5d., la.2y.3e.4a.5d., lb.2y.3e.4a.5d., lf.2y.3e.4a.5d., lh.2y.3e.4a.5d., lj.2y.3e.4a.5d., lp.2y.3e.4a.5d., la.2a.3g.4a.5d., lb.2a.3g.4a.5d., lf.2a.3g.4a.5d., lh.2a.3g.4a.5d., lj.2a.3g.4a.5d., lp.2a.3g.4a.5d., la.2b.3g.4a.5d., lb.2b.3g.4a.5d., lf.2b.3g.4a.5d., lh.2b.3g.4a.5d., lj.2b.3g.4a.5d., lp.2b.3g.4a.5d., la.2e.3g.4a.5d., lb.2e.3g.4a.5d., lf.2e.3g.4a.5d., lh.2e.3g.4a.5d., lj.2e.3g.4a.5d., lp.2e.3g.4a.5d., la.2f.3g.4a.5d., lb.2f.3g.4a.5d., lf.2f.3g.4a.5d., lh.2f.3g.4a.5d., lj.2f.3g.4a.5d., lp.2f.3g.4a.5d., la.2i.3g.4a.5d., lb.2i.3g.4a.5d., lf.2i.3g.4a.5d., lh.2i.3g.4a.5d., lj.2i.3g.4a.5d., lp.2i.3g.4a.5d., la.2m.3g.4a.5d., lb.2m.3g.4a.5d., lf.2m.3g.4a.5d., lh.2m.3g.4a.5dv lj.2m.3g.4a.5d., lp.2m.3g.4a.5dv la.2o.3g.4a.5d., lb.2o.3g.4a.5d., lf.2o.3g.4a.5d., lh.2o.3g.4a.5d., lj.2o.3g.4a.5dv lp.2o.3g.4a.5dv la.2u.3g.4a.5d., lb.2u.3g.4a.5d., lf.2u.3g.4a.5d., lh.2u.3g.4a.5d., lj.2u.3g.4a.5d., lp.2u.3g.4a.5d., la.2y.3g.4a.5d., lb.2y.3g.4a.5d., lf.2y.3g.4a.5d., lh.2y.3g.4a.5d., lj.2y.3g.4a.5d., lp.2y.3g.4a.5d., la.2a.3a.4d.5d., lb.2a.3a.4d.5d., lf.2a.3a.4d.5d., lh.2a.3a.4d.5d., lj.2a.3a.4d.5d., lp.2a.3a.4d.5d., la.2b.3a.4d.5dv lb.2b.3a.4d.5d., lf.2b.3a.4d.5d., lh.2b.3a.4d.5d., lj.2b.3a.4d.5d., lp.2b.3a.4d.5d., la.2e.3a.4d.5d., lb.2e.3a.4d.5d., lf.2e.3a.4d.5d., lh.2e.3a.4d.5d., lj.2e.3a.4d.5d., lp.2e.3a.4d.5d., la.2f.3a.4d.5d., lb.2f.3a.4d.5d., lf.2f.3a.4d.5d., lh.2f.3a.4d.5d., lj.2f.3a.4d.5d., lp.2f.3a.4d.5d., la.2i.3a.4d.5d., lb.2i.3a.4d.5d., lf.2i.3a.4d.5d., lh.2i.3a.4d.5d., lj.2i.3a.4d.5d., lp.2i.3a.4d.5d., la.2m.3a.4d.5d., lb.2m.3a.4d.5d., lf.2m.3a.4d.5d., lh.2m.3a.4d.5d., lj.2m.3a.4d.5d., lp.2m.3a.4d.5d., la.2o.3a.4d.5d., lb.2o.3a.4d.5d., lf.2o.3a.4d.5d., lh.2o.3a.4d.5d., lj.2o.3a.4d.5d., lp.2o.3a.4d.5d., la.2u.3a.4d.5d., lb.2u.3a.4d.5d., lf.2u.3a.4d.5d., lh.2u.3a.4d.5d., lj.2u.3a.4d.5d., lp.2u.3a.4d.5d., la.2y.3a.4d.5d., lb.2y.3a.4d.5dv lf.2y.3a.4d.5d., lh.2y.3a.4d.5d., lj.2y.3a.4d.5d., lp.2y.3a.4d.5d., la.2a.3b.4d.5d., lb.2a.3b.4d.5d., lf.2a.3b.4d.5d., lh.2a.3b.4d.5d., lj.2a.3b.4d.5d., lp.2a.3b.4d.5d., la.2b.3b.4d.5d., lb.2b.3b.4d.5d., lf.2b.3b.4d.5d., lh.2b.3b.4d.5d., lj.2b.3b.4d.5d., lp.2b.3b.4d.5d., la.2e.3b.4d.5d., lb.2e.3b.4d.5d., lf.2e.3b.4d.5d., lh.2e.3b.4d.5d., lj.2e.3b.4d.5d., lp.2e.3b.4d.5d., la.2f.3b.4d.5d., lb.2f.3b.4d.5d., lf.2f.3b.4d.5d., lh.2f.3b.4d.5d., lj.2f.3b.4d.5d., lp.2f.3b.4d.5d., la.2i.3b.4d.5d., lb.2i.3b.4d.5d., lf.2i.3b.4d.5d., lh.2i.3b.4d.5d., lj.2i.3b.4d.5d., lp.2i.3b.4d.5d., la.2m.3b.4d.5d., lb.2m.3b.4d.5d., lf.2m.3b.4d.5d., lh.2m.3b.4d.5d., lj.2m.3b.4d.5d., lp.2m.3b.4d.5d., la.2o.3b.4d.5d., lb.2o.3b.4d.5d., lf.2o.3b.4d.5d., lh.2o.3b.4d.5d., lj.2o.3b.4d.5d., lp.2o.3b.4d.5d., la.2u.3b.4d.5d., lb.2u.3b.4d.5d., lf.2u.3b.4d.5d., lh.2u.3b.4d.5d., lj.2u.3b.4d.5d., lp.2u.3b.4d.5d., la.2y.3b.4d.5d., lb.2y.3b.4d.5d., lf.2y.3b.4d.5d., lh.2y.3b.4d.5d., lj.2y.3b.4d.5d., lp.2y.3b.4d.5d., la.2a.3e.4d.5d., lb.2a.3e.4d.5d., lf.2a.3e.4d.5d., lh.2a.3e.4d.5d., lj.2a.3e.4d.5d., lp.2a.3e.4d.5d., la.2b.3e.4d.5d., lb.2b.3e.4d.5d., lf.2b.3e.4d.5d., lh.2b.3e.4d.5d., lj.2b.3e.4d.5d., lp.2b.3e.4d.5d., la.2e.3e.4d.5d., lb.2e.3e.4d.5d., lf.2e.3e.4d.5d., lh.2e.3e.4d.5d., lj.2e.3e.4d.5d., lp.2e.3e.4d.5d., la.2£.3e.4d.5d., lb.2f.3e.4d.5d., lf.2f.3e.4d.5d., lh.2f.3e.4d.5d., lj.2f.3e.4d.5d., lp.2f.3e.4d.5d., la.2i.3e.4d.5d., lb.2i.3e.4d.5d., lf.2i.3e.4d.5d., lh.2i.3e.4d.5d., lj.2i.3e.4d.5d., lp.2i.3e.4d.5d., la.2m.3e.4d.5d., lb.2m.3e.4d.5d., lf.2m.3e.4d.5d., lh.2m.3e.4d.5d., lj.2m.3e.4d.5d., lp.2m.3e.4d.5d., la.2o.3e.4d.5d., lb.2o.3e.4d.5d., lf.2o.3e.4d.5d., lh.2o.3e.4d.5d., lj.2o.3e.4d.5d., lp.2o.3e.4d.5d., la.2u.3e.4d.5d., lb.2u.3e.4d.5d., lf.2u.3e.4d.5d., lh.2u.3e.4d.5d., lj.2u.3e.4d.5d., lp.2u.3e.4d.5d., la.2y.3e.4d.5d., lb.2y.3e.4d.5d., lf.2y.3e.4d.5d., lh.2y.3e.4d.5d., lj.2y.3e.4d.5d., lp.2y.3e.4d.5d., la.2a.3g.4d.5d., lb.2a.3g.4d.5d., lf.2a.3g.4d.5d., lh.2a.3g.4d.5d., lj.2a.3g.4d.5d., lp.2a.3g.4d.5d., la.2b.3g.4d.5d., lb.2b.3g.4d.5d., lf.2b.3g.4d.5d., lh.2b.3g.4d.5d., lj.2b.3g.4d.5d., lp.2b.3g.4d.5d., la.2e.3g.4d.5d., lb.2e.3g.4d.5d-, lf.2e.3g.4d.5d., lh.2e.3g.4d.5d., lj.2e.3g.4d.5d-, lp.2e.3g.4d.5d., la.2f.3g.4d.5d., lb.2f.3g.4d.5d., lf.2f.3g.4d.5d., lh.2f.3g.4d.5dv lj.2f.3g.4d.5d., lp.2f.3g.4d.5d., la.2i.3g.4d.5d., lb.2i.3g.4d.5d., lf.2i.3g.4d.5d., lh.2i.3g.4d.5d., lj.2i.3g.4d.5d., lp.2i.3g.4d.5d., la.2m.3g.4d.5d., lb.2m.3g.4d.5d., lf.2m.3g.4d.5dv lh.2m.3g.4d.5d., lj.2m.3g.4d.5d., lp.2m.3g.4d.5d., la.2o.3g.4d.5d., lb.2o.3g.4d.5d., lf.2o.3g.4d.5d., lh.2o.3g.4d.5d., lj.2o.3g.4d.5dv lp.2o.3g.4d.5d., la.2u.3g.4d.5d., lb.2u.3g.4d.5d., lf.2u.3g.4d.5d., lh.2u.3g.4d.5d., lj.2u.3g.4d.5d., lp.2u.3g.4d.5d., la.2y.3g.4d.5dv lb.2y.3g.4d.5d., lf.2y.3g.4d.5d., lh.2y.3g.4d.5d., lj.2y.3g.4d.5d., lp.2y.3g.4d.5d., la.2a.3a.4f.5d., lb.2a.3a.4f.5d., lf.2a.3a.4f.5d., lh.2a.3a.4f.5d., lj.2a.3a.4f.5d., lp.2a.3a.4f.5d., la.2b.3a.4f.5d., lb.2b.3a.4f.5d., lf.2b.3a.4f.5d., lh.2b.3a.4f.5d., lj.2b.3a.4f.5d., lp.2b.3a.4f.5d., la.2e.3a.4f.5d., lb.2e.3a.4f.5d., lf.2e.3a.4f.5d., lh.2e.3a.4f.5d., lj.2e.3a.4f.5d., lp.2e.3a.4f.5d., la.2f.3a.4f.5d., lb.2f.3a.4f.5d., lf.2f.3a.4f.5d., lh.2f.3a.4f.5d., lj.2f.3a.4f.5dv lp.2f.3a.4f.5d., la.2i.3a.4f.5d., lb.2i.3a.4f.5d., lf.2i.3a.4f.5d., lh.2i.3a.4f.5d., lj.2i.3a.4f.5d., lp.2i.3a.4f.5d., la.2m.3a.4f.5d., lb.2m.3a.4f.5d., lf.2m.3a.4f.5d., lh.2m.3a.4f.5d., lj.2m.3a.4f.5d., lp.2m.3a.4f.5d., la.2o.3a.4f.5d., lb.2o.3a.4f.5d., lf.2o.3a.4f.5d., lh.2o.3a.4f.5d., lj.2o.3a.4f.5d., lp.2o.3a.4f.5d., la.2u.3a.4f.5d., lb.2u.3a.4f.5d., lf.2u.3a.4f.5d., lh.2u.3a.4f.5d., lj.2u.3a.4f.5d., lp.2u.3a.4f.5dv la.2y.3a.4f.5d., lb.2y.3a.4f.5d., lf.2y.3a.4f.5d., lh.2y.3a.4f.5d., lj.2y.3a.4f.5d., lp.2y.3a.4f.5d., la.2a.3b.4f.5d., lb.2a.3b.4f.5d., lf.2a.3b.4f.5d., lh.2a.3b.4f.5d., lj.2a.3b.4f.5d., lp.2a.3b.4f.5d., la.2b.3b.4f.5d., lb.2b.3b.4f.5d., lf.2b.3b.4f.5d., lh.2b.3b.4f.5d., lj.2b.3b.4f.5d., lp.2b.3b.4f.5d., la.2e.3b.4f.5d., lb.2e.3b.4f.5d., lf.2e.3b.4f.5d., lh.2e.3b.4f.5d., lj.2e.3b.4f.5d., lp.2e.3b.4f.5d., la.2f.3b.4f.5d., lb.2f.3b.4f.5d., lf.2f.3b.4f.5d., lh.2f.3b.4f.5dv lj.2f.3b.4f.5d., lp.2f.3b.4f.5d., la.2i.3b.4f.5d., lb.2i.3b.4f.5d., lf.2i.3b.4f.5d., lh.2i.3b.4f.5d., lj.2i.3b.4f.5d., lp.2i.3b.4f.5d., la.2m.3b.4f.5d., lb.2m.3b.4f.5d., lf.2m.3b.4f.5d., lh.2m.3b.4f.5d., lj.2m.3b.4f.5d., lp.2m.3b.4f.5d., la.2o.3b.4f.5d., lb.2o.3b.4f.5d., lf.2o.3b.4f.5d., lh.2o.3b.4f.5d., lj.2o.3b.4f.5d., lp.2o.3b.4f.5d., la.2u.3b.4f.5d., lb.2u.3b.4f.5d., lf.2u.3b.4f.5dv lh.2u.3b.4f.5d., lj.2u.3b.4f.5d., lp.2u.3b.4f.5d., la.2y.3b.4f.5d., lb.2y.3b.4f.5d., lf.2y.3b.4f.5d., lh.2y.3b.4f.5d., lj.2y.3b.4f.5d., lp.2y.3b.4f.5d., la.2a.3e.4f.5d., lb.2a.3e.4f.5d., lf.2a.3e.4f.5d., lh.2a.3e.4f.5d., lj.2a.3e.4f.5d., lp.2a.3e.4f.5d., la.2b.3e.4f.5d., lb.2b.3e.4f.5d., lf.2b.3e.4f.5d., lh.2b.3e.4f.5d., lj.2b.3e.4f.5d., lp.2b.3e.4f.5d., la.2e.3e.4f.5d., lb.2e.3e.4f.5d., lf.2e.3e.4f.5d., lh.2e.3e.4f.5d., lj.2e.3e.4f.5d., lp.2e.3e.4f.5d., la.2f.3e.4f.5d., lb.2f.3e.4f.5d., lf.2f.3e.4f.5d., lh.2f.3e.4f.5d., lj.2f.3e.4f.5d., lp.2f.3e.4f.5d., la.2i.3e.4f.5d., lb.2i.3e.4f.5d., lf.2i.3e.4f.5d., lh.2i.3e.4f.5d., lj.2i.3e.4f.5d., lp.2i.3e.4f.5d., la.2m.3e.4f.5d., lb.2m.3e.4f.5d., lf.2m.3e.4f.5d., lh.2m.3e.4f.5d., lj.2m.3e.4f.5d., lp.2m.3e.4f.5d., la.2o.3e.4f.5d., lb.2o.3e.4f.5d., lf.2o.3e.4f.5d., lh.2o.3e.4f.5dv lj.2o.3e.4f.5d., lp.2o.3e.4f.5d., la.2u.3e.4f.5d., lb.2u.3e.4f.5d., lf.2u.3e.4f.5d., lh.2u.3e.4f.5d., lj.2u.3e.4f.5d., lp.2u.3e.4f.5d., la.2y.3e.4f.5d., lb.2y.3e.4f.5d., lf.2y.3e.4f.5d., lh.2y.3e.4f.5d., lj.2y.3e.4f.5d., lp.2y.3e.4f.5d., la.2a.3g.4f.5d., lb.2a.3g.4f.5dv lf.2a.3g.4f.5d., lh.2a.3g.4f.5d., lj.2a.3g.4f.5d., lp.2a.3g.4f.5cl., la.2b.3g.4f.5d., lb.2b.3g.4f.5d., lf.2b.3g.4f.5dv lh.2b.3g.4f.5d., lj.2b.3g.4f.5d., lp.2b.3g.4f.5d., la.2e.3g.4f.5d., lb.2e.3g.4f.5d., lf.2e.3g.4f.5d., lh.2e.3g.4f.5d., lj.2e.3g.4f.5d., lp.2e.3g.4f.5d., la.2f.3g.4f.5d., lb.2f.3g.4f.5d., lf.2f.3g.4f.5d., lh.2f.3g.4f.5d., lj.2f.3g.4f.5d., lp.2f.3g.4f.5d., la.2i.3g.4f.5d., lb.2i.3g.4f.5d., lf.2i.3g.4f.5d., lh.2L3g.4f.5d., lj.2i.3g.4f.5d., lp.2i.3g.4f.5d., la.2m.3g.4f.5d., lb.2m.3g.4f.5d., lf.2m.3g.4f.5d., lh.2m.3g.4f.5d., lj.2m.3g.4f.5dv lp.2m.3g.4f.5d., la.2o.3g.4f.5d., lb.2o.3g.4f.5d., lf.2o.3g.4f.5d., lh.2o.3g.4f.5d., lj.2o.3g.4f.5d., lp.2o.3g.4f.5d., la.2u.3g.4f.5d., lb.2u.3g.4f.5d., lf.2u.3g.4f.5d., lh.2u.3g.4f.5d., lj.2u.3g.4f.5d., lp.2u.3g.4f.5d., la.2y.3g.4f.5d., lb.2y.3g.4f.5d., lf.2y.3g.4f.5d., lh.2y.3g.4f.5d., lj.2y.3g.4f.5d., lp.2y.3g.4f.5d., la.2a.3a.4g.5d., lb.2a.3a.4g.5d., lf.2a.3a.4g.5d., lh.2a.3a.4g.5d., lj.2a.3a.4g.5d., lp.2a.3a.4g.5d., la.2b.3a.4g.5d., lb.2b.3a.4g.5d., lf.2b.3a.4g.5d., lh.2b.3a.4g.5d., lj.2b.3a.4g.5d., lp.2b.3a.4g.5d., la.2e.3a.4g.5d., lb.2e.3a.4g.5d., lf.2e.3a.4g.5d., lh.2e.3a.4g.5d., lj.2e.3a.4g.5d., lp.2e.3a.4g.5d., la.2f.3a.4g.5d., lb.2f.3a.4g.5d., lf.2f.3a.4g.5d., lh.2f.3a.4g.5d., lj.2f.3a.4g.5d., lp.2f.3a.4g.5d., la.2L3a.4g.5d., lb.2i.3a.4g.5d., lf.2i.3a.4g.5d., lh.2i.3a.4g.5d., lj.2i.3a.4g.5d., lρ.2i.3a.4g.5d., la.2m.3a.4g.5d., lb.2m.3a.4g.5d., lf.2m.3a.4g.5d., lh.2m.3a.4g.5d., lj.2m.3a.4g.5d., lp.2m.3a.4g.5d., la.2o.3a.4g.5d., lb.2o.3a.4g.5d., lf.2o.3a.4g.5d., lh.2o.3a.4g.5d., lj.2o.3a.4g.5d., lp.2o.3a.4g.5d., la.2u.3a.4g.5d., lb.2u.3a.4g.5d., lf.2u.3a.4g.5d., lh.2u.3a.4g.5d., lj.2u.3a.4g.5d., lp.2u.3a.4g.5d., la.2y.3a.4g.5d., lb.2y.3a.4g.5d., lf.2y.3a.4g.5d., lh.2y.3a.4g.5d., lj.2y.3a.4g.5d., lp.2y.3a.4g.5dv la.2a.3b.4g.5d., lb.2a.3b.4g.5d., lf.2a.3b.4g.5d., lh.2a.3b.4g.5d., lj.2a.3b.4g.5d., lp.2a.3b.4g.5d., la.2b.3b.4g.5d., lb.2b.3b.4g.5d., lf.2b.3b.4g.5d., lh.2b.3b.4g.5d., lj.2b.3b.4g.5d., lp.2b.3b.4g.5d., la.2e.3b.4g.5d., lb.2e.3b.4g.5d., lf.2e.3b.4g.5d., lh.2e.3b.4g.5d., lj.2e.3b.4g.5d., lp.2e.3b.4g.5d., la.2f.3b.4g.5d., lb.2f.3b.4g.5d., lf.2f.3b.4g.5d., lh.2f.3b.4g.5d., lj.2f.3b.4g.5d., lp.2f.3b.4g.5d., la.2i.3b.4g.5d., lb.2i.3b.4g.5d., lf.2i.3b.4g.5d., lh.2L3b.4g.5d., lj.2i.3b.4g.5d., lp.2i.3b.4g.5d., la.2m.3b.4g.5d., lb.2m.3b.4g.5d., lf.2m.3b.4g.5d., lh.2m.3b.4g.5d., lj.2m.3b.4g.5d., lp.2m.3b.4g.5d., la.2o.3b.4g.5d., lb.2o.3b.4g.5d., lf.2o.3b.4g.5d., lh.2o.3b.4g.5d., lj.2o.3b.4g.5d., lp.2o.3b.4g.5d., la.2u.3b.4g.5d., lb.2u.3b.4g.5d., lf.2u.3b.4g.5d., lh.2u.3b.4g.5d., lj.2u.3b.4g.5d., lp.2u.3b.4g.5d., la.2y.3b.4g.5d., lb.2y.3b.4g.5d., lf.2y.3b.4g.5d., lh.2y.3b.4g.5d., lj.2y.3b.4g.5d., lp.2y.3b.4g.5d., la.2a.3e.4g.5dv lb.2a.3e.4g.5d., lf.2a.3e.4g.5d., lh.2a.3e.4g.5d., lj.2a.3e.4g.5d., lp.2a.3e.4g.5d., la.2b.3e.4g.5d., lb.2b.3e.4g.5d., lf.2b.3e.4g.5d., lh.2b.3e.4g.5d., lj.2b.3e.4g.5d., lp.2b.3e.4g.5d., la.2e.3e.4g.5d., lb.2e.3e.4g.5d., lf.2e.3e.4g.5d., lh.2e.3e.4g.5d., lj.2e.3e.4g.5d., lp.2e.3e.4g.5d., la.2f.3e.4g.5d., lb.2f.3e.4g.5d., lf.2f.3e.4g.5d., lh.2f.3e.4g.5d., lj.2f.3e.4g.5d., lp.2f.3e.4g.5d., la.2i.3e.4g.5d., lb.2i.3e.4g.5d., lf.2i.3e.4g.5d., lh.2i.3e.4g.5d., lj.2i.3e.4g.5d., lp.2i.3e.4g.5d., la.2m.3e.4g.5d., lb.2m.3e.4g.5d., lf.2m.3e.4g.5d., lh.2m.3e.4g.5d., lj.2m.3e.4g.5d., lp.2m.3e.4g.5d., la.2o.3e.4g.5d., lb.2o.3e.4g.5d., lf.2o.3e.4g.5d., lh.2o.3e.4g.5d., lj.2o.3e.4g.5d., lp.2o.3e.4g.5d., la.2u.3e.4g.5d., lb.2u.3e.4g.5d., lf.2u.3e.4g.5d., lh.2u.3e.4g.5d., lj.2u.3e.4g.5d., lp.2u.3e.4g.5d., la.2y.3e.4g.5d., lb.2y.3e.4g.5dv lf.2y.3e.4g.5d., lh.2y.3e.4g.5d., lj.2y.3e.4g.5d., lp.2y.3e.4g.5d., la.2a.3g.4g.5d., lb.2a.3g.4g.5dv lf.2a.3g.4g.5d., lh.2a.3g.4g.5d., lj.2a.3g.4g.5d., lp.2a.3g.4g.5d., la.2b.3g.4g.5d., lb.2b.3g.4g.5d., lf.2b.3g.4g.5d., lh.2b.3g.4g.5d., lj.2b.3g.4g.5dv lp.2b.3g.4g.5d., la.2e.3g.4g.5d., lb.2e.3g.4g.5d., lf.2e.3g.4g.5d., lh.2e.3g.4g.5d., lj.2e.3g.4g.5d., lp.2e.3g.4g.5d., la.2f.3g.4g.5d., lb.2f.3g.4g.5d., lf.2f.3g.4g.5dv lh.2f.3g.4g.5d., lj.2f.3g.4g.5d., lp.2f.3g.4g.5d., la.2i.3g.4g.5d., lb.2i.3g.4g.5d., lf.2i.3g.4g.5d., lh.2i.3g.4g.5d., lj.2i.3g.4g.5d., lp.2i.3g.4g.5d., la.2m.3g.4g.5d., lb.2m.3g.4g.5d., lf.2m.3g.4g.5d., lh.2m.3g.4g.5d., lj.2m.3g.4g.5d., lp.2m.3g.4g.5d., la.2o.3g.4g.5d., lb.2o.3g.4g.5d., lf.2o.3g.4g.5d., lh.2o.3g.4g.5d., lj.2o.3g.4g.5d., lp.2o.3g.4g.5d., la.2u.3g.4g.5d., lb.2u.3g.4g.5d., lf.2u.3g.4g.5d., lh.2u.3g.4g.5d., lj.2u.3g.4g.5d., lp.2u.3g.4g.5d., la.2y.3g.4g.5d., lb.2y.3g.4g.5d., lf.2y.3g.4g.5d., lh.2y.3g.4g.5d., lj.2y.3g.4g.5d., lp.2y.3g.4g.5d., la.2a.3a.4h.5d., lb.2a.3a.4h.5d., lf.2a.3a.4h.5d., lh.2a.3a.4h.5d., lj.2a.3a.4h.5d., lp.2a.3a.4h.5d., la.2b.3a.4h.5d., lb.2b.3a.4h.5d., lf.2b.3a.4h.5d., lh.2b.3a.4h.5d., lj.2b.3a.4h.5d., lp.2b.3a.4h.5d., la.2e.3a.4h.5d., lb.2e.3a.4h.5d., l£.2e.3a.4h.5d., lh.2e.3a.4h.5d., lj.2e.3a.4h.5d., lp.2e.3a.4h.5d., la.2f.3a.4h.5d., lb.2f.3a.4h.5d., lf.2f.3a.4h.5d., lh.2f.3a.4h.5d., lj.2f.3a.4h.5d., lp.2f.3a.4h.5d., la.2i.3a.4h.5d., lb.2i.3a.4h.5d., lf.2i.3a.4h.5d., lh.2i.3a.4h.5d., lj.2i.3a.4h.5d., lp.2i.3a.4h.5d., la.2m.3a.4h.5d., lb.2m.3a.4h.5d., lf.2m.3a.4h.5d., lh.2m.3a.4h.5d., lj.2m.3a.4h.5d., lp.2m.3a.4h.5d., la.2o.3a.4h.5d., lb.2o.3a.4h.5d., lf.2o.3a.4h.5d., lh.2o.3a.4h.5d., lj.2o.3a.4h.5d., lp.2o.3a.4h.5d., la.2u.3a.4h.5d., lb.2u.3a.4h.5d., lf.2u.3a.4h.5d., lh.2u.3a.4h.5d., lj.2u.3a.4h.5d., lp.2u.3a.4h.5d., la.2y.3a.4h.5d., lb.2y.3a.4h.5d., lf.2y.3a.4h.5d., lh.2y.3a.4h.5d., lj.2y.3a.4h.5d., lρ.2y.3a.4h.5d., la.2a.3b.4h.5d., lb.2a.3b.4h.5d., lf.2a.3b.4h.5d., lh.2a.3b.4h.5d., lj.2a.3b.4h.5d., lp.2a.3b.4h.5d., la.2b.3b.4h.5d., lb.2b.3b.4h.5d., lf.2b.3b.4h.5d., lh.2b.3b.4h.5d., lj.2b.3b.4h.5d., lp.2b.3b.4h.5d., la.2e.3b.4h.5d., lb.2e.3b.4h.5d., lf.2e.3b.4h.5d., lh.2e.3b.4h.5d., lj.2e.3b.4h.5d., lp.2e.3b.4h.5d., la.2f.3b.4h.5d., lb.2f.3b.4h.5d., lf.2f.3b.4h.5d., lh.2f.3b.4h.5d., lj.2f.3b.4h.5d., lp.2f.3b.4h.5d., la.2i.3b.4h.5d., lb.2i.3b.4h.5d., lf.2i.3b.4h.5d., lh.2i.3b.4h.5d., lj.2i.3b.4h.5d., ]p.2i.3b.4h.5d., la.2m.3b.4h.5d., lb.2m.3b.4h.5d., lf.2m.3b.4h.5d., lh.2m.3b.4h.5d., lj.2m.3b.4h.5d., lp.2m.3b.4h.5d., la.2o.3b.4h.5d., lb.2o.3b.4h.5d., lf.2o.3b.4h.5dv lh.2o.3b.4h.5d., lj.2o.3b.4h.5d., lp.2o.3b.4h.5d., la.2u.3b.4h.5d., lb.2u.3b.4h.5d-, lf.2u.3b.4h.5d., lh.2u.3b.4h.5d., lj.2u.3b.4h.5d., lp.2u.3b.4h.5d., la.2y.3b.4h.5d., lb.2y.3b.4h.5d., lf.2y.3b.4h.5d., lh.2y.3b.4h.5d., lj.2y.3b.4h.5d., lp.2y.3b.4h.5d., la.2a.3e.4h.5d., lb.2a.3e.4h.5d., lf.2a.3e.4h.5d., lh.2a.3e.4h.5d., lj.2a.3e.4h.5d., lp.2a.3e.4h.5d., la.2b.3e.4h.5d., lb.2b.3e.4h.5d., lf.2b.3e.4h.5d., lh.2b.3e.4h.5d., lj.2b.3e.4h.5d., lp.2b.3e.4h.5d., la.2e.3e.4h.5d., lb.2e.3e.4h.5d., lf.2e.3e.4h.5d., lh.2e.3e.4h.5d., lj.2e.3e.4h.5d., lp.2e.3e.4h.5d., la.2f.3e.4h.5d., lb.2f.3e.4h.5d., lf.2f.3e.4h.5d., lh.2f.3e.4h.5d., lj.2f.3e.4h.5d., lp.2f.3e.4h.5d., la.2i.3e.4h.5d., lb.2i.3e.4h.5d., lf.2i.3e.4h.5d., lh.2i.3e.4h.5d., lj.2i.3e.4h.5d., lp.2i.3e.4h.5d., la.2m.3e.4h.5d., lb.2m.3e.4h.5d., lf.2m.3e.4h.5d., lh.2m.3e.4h.5d., lj.2m.3e.4h.5d., lp.2m.3e.4h.5d., la.2o.3e.4h.5d., lb.2o.3e.4h.5dv lf.2o.3e.4h.5d., lh.2o.3e.4h.5d., lj.2o.3e.4h.5d., lp.2o.3e.4h.5d., la.2u.3e.4h.5d., lb.2u.3e.4h.5d., lf.2u.3e.4h.5d., lh.2u.3e.4h.5d., lj.2u.3e.4h.5d., lp.2u.3e.4h.5d., la.2y.3e.4h.5d., lb.2y.3e.4h.5d., lf.2y.3e.4h.5d., lh.2y.3e.4h.5d., lj.2y.3e.4h.5d., lp.2y.3e.4h.5d., la.2a.3g.4h.5d., lb.2a.3g.4h.5d., lf.2a.3g.4h.5d., lh.2a.3g.4h.5d., lj.2a.3g.4h.5d., lp.2a.3g.4h.5d., la.2b.3g-4h.5d., lb.2b.3g.4h.5d., lf.2b.3g.4h.5d., lh.2b.3g.4h.5d., l).2b.3g.4h.5d., lp.2b.3g.4h.5dv la.2e.3g.4h.5d., lb.2e.3g.4h.5d., lf.2e.3g.4h.5d., lh.2e.3g.4h.5d., lj.2e.3g.4h.5d., lp.2e.3g.4h.5d., la.2f.3g.4h.5d., lb.2f.3g.4h.5d., lf.2f.3g.4h.5d., lh.2f.3g.4h.5d., lj.2f.3g.4h.5d., lp.2£.3g.4h.5d., la.2i.3g.4h.5d., lb.2i.3g.4h.5d., lf.2i.3g.4h.5d., lh.2i.3g.4h.5d., lj.2i.3g.4h.5d., lp.2i.3g.4h.5d., la.2m.3g.4h.5d., lb.2m.3g.4h.5dv lf.2m.3g.4h.5d., lh.2m.3g.4h.5d., lj.2m.3g.4h.5d., lp.2m.3g.4h.5d., la.2o.3g.4h.5d., lb.2o.3g.4h.5d., l£.2o.3g.4h.5d., lh.2o.3g.4h.5d., lj.2o.3g.4h.5d., lp.2o.3g.4h.5d., la.2u.3g.4h.5d., lb.2u.3g.4h.5d., lf.2u.3g.4h.5d., lh.2u.3g.4h.5d., lj.2u.3g.4h.5d., lp.2u.3g.4h.5d., la.2y.3g.4h.5d., lb.2y.3g.4h.5d., lf.2y.3g.4h.5d., lh.2y.3g.4h.5d., lj.2y.3g.4h.5d., lp.2y.3g.4h.5d., la.2a.3a.4i.5d., lb.2a.3a.4i.5d., lf.2a.3a.4i.5d., lh.2a.3a.4i.5d., lj.2a.3a.4i.5d., lp.2a.3a.4L5d., la.2b.3a.4i.5d., lb.2b.3a.4i.5d., lf.2b.3a.4i.5d., lh.2b.3a.4i.5d., lj.2b.3a.4i.5d., lp.2b.3a.4i.5d., la.2e.3a.4i.5dv lb.2e.3a.4i.5d., lf.2e.3a.4i.5d., lh.2e.3a.4i.5d., lj.2e.3a.4i.5d., lp.2e.3a.4i.5d., la.2f.3a.4i.5d., lb.2f.3a.4i.5dv lf.2f.3a.4i.5d., lh.2f.3a.4i.5d., lj.2f.3a.4i.5dv lp.2f.3a.4i.5d., la.2i.3a.4i.5d., lb.2i.3a.4i.5d., lf.2i.3a.4i.5d., lh.2i.3a.4i.5d., lj.2i.3a.4i.5d., lp.2i.3a.4i.5d., la.2m.3a.4i.5d., lb.2m.3a.4i.5d., lf.2m.3a.4i.5d., lh.2m.3a.4i.5dv lj.2m.3a.4i.5d., lp.2m.3a.4i.5d., la.2o.3a.4i.5d., lb.2o.3a.4i.5d., lf.2o.3a.4i.5d., lh.2o.3a.4i.5d., lj.2o.3a.4L5d., lp.2o.3a.4i.5dv la.2u.3a.4i.5d., lb.2u.3a.4i.5d., lf.2u.3a.4i.5d., lh.2u.3a.4i.5d., lj.2u.3a.4i.5d., lp.2u.3a.4i.5d., la.2y.3a.4i.5d., lb.2y.3a.4i.5d., lf.2y.3a.4i.5d., lh.2y.3a.4i.5d., lj.2y.3a.4i.5d., lp.2y.3a.4i.5d., la.2a.3b.4i.5d., lb.2a.3b.4i.5d., lf.2a.3b.4i.5d., lh.2a.3b.4i.5d., lj.2a.3b.4i.5d., lp.2a.3b.4i.5d., la.2b.3b.4i.5d., lb.2b.3b.4i.5d., lf.2b.3b.4i.5d., lh.2b.3b.4i.5d., lj.2b.3b.4i.5d., lp.2b.3b.4i.5d., la.2e.3b.4i.5d., lb.2e.3b.4i.5d., lf.2e.3b.4i.5d., lh.2e.3b.4i.5d., lj.2e.3b.4i.5d., lp.2e.3b.4i.5d., la.2f.3b.4i.5d., lb.2f.3b.4i.5d., lf.2f.3b.4i.5d., lh.2f.3b.4i.5d., lj.2f.3b.4i.5d., lp.2f.3b.4i.5d., la.2i.3b.4i.5d., lb.2i.3b.4i.5d., lf.2i.3b.4i.5d., lh.2i.3b.4i.5d., lj.2i.3b.4i.5d., lp.2i.3b.4i.5d., la.2m.3b.4i.5d., lb.2m.3b.4i.5d., lf.2m.3b.4i.5d., lh.2m.3b.4i.5d., lj.2m.3b.4i.5d., lp.2m.3b.4i.5dv la.2o.3b.4i.5dv lb.2o.3b.4i.5d., lf.2o.3b.4i.5dv lh.2o.3b.4i.5d., lj.2o.3b.4i.5d., lp.2o.3b.4i.5d., la.2u.3b.4i.5d., lb.2u.3b.4i.5d., lf.2u.3b.4i.5d., lh.2u.3b.4i.5d., lj.2u.3b.4i.5d., lp.2u.3b.4i.5d., la.2y.3b.4i.5d., lb.2y.3b.4i.5d., lf.2y.3b.4i.5d., lh.2y.3b.4i.5d., l).2y.3b.4i.5d., lp.2y.3b.4i.5d., la.2a.3e.4i.5d., lb.2a.3e.4i.5d., lf.2a.3e.4i.5d., lh.2a.3e.4i.5d., lj.2a.3e.4i.5d., lp.2a.3e.4i.5d., la.2b.3e.4i.5d., lb.2b.3e.4i.5d., lf.2b.3e.4L5d., lh.2b.3e.4i.5d., lj.2b.3e.4i.5d., lp.2b.3e.4i.5d., la.2e.3e.4i.5d., lb.2e.3e.4i.5d., lf.2e.3e.4i.5d., lh.2e.3e.4i.5dv lj.2e.3e.4i.5d., lp.2e.3e.4i.5d., la.2f.3e.4i.5d., lb.2f.3e.4i.5d., lf.2f.3e.4i.5d., lh.2f.3e.4i.5d., lj.2f.3e.4i.5d., lp.2f.3e.4i.5d., la.2i.3e.4i.5d., lb.2i.3e.4i.5d., lf.2i.3e.4i.5d., lh.2i.3e.4i.5d., lj.2i.3e.4i.5d., lp.2i.3e.4i.5d., la.2m.3e.4i.5d., lb.2m.3e.4i.5d., lf.2m.3e.4i.5d., lh.2m.3e.4i.5d., lj.2m.3e.4i.5d., lp.2m.3e.4i.5d., la.2o.3e.4i.5d., lb.2o.3e.4i.5d., lf.2o.3e.4i.5dv lh.2o.3e.4i.5d., lj.2o.3e.4i.5d., lp.2o.3e.4i.5d., la.2u.3e.4i.5dv lb.2u.3e.4i.5dv lf.2u.3e.4i.5d., lh.2u.3e.4i.5d., lj.2u.3e.4i.5d., lp.2u.3e.4i.5d., la.2y.3e,4i.5d., lb.2y.3e.4i.5d., lf.2y.3e.4i.5d., lh.2y.3e.4i.5d., lj.2y.3e.4i.5d., lp.2y.3e.4i.5d., la.2a.3g.4i.5d., lb.2a.3g.4i.5d., lf.2a.3g.4i.5d., lh.2a.3g.4i.5d., lj.2a.3g.4i.5d., lp.2a.3g.4i.5d., la.2b.3g.4i.5d., lb.2b.3g.4i.5d., lf.2b.3g.4i.5d., lh.2b.3g.4i.5d., lj.2b.3g.4i.5d., lp.2b.3g.4i.5d., la.2e.3g.4i.5d., lb.2e.3g.4i.5d., lf.2e.3g.4i.5d., lh.2e.3g.4i.5d., lj.2e.3g.4i.5d., lp.2e.3g.4i.5d., la.2f.3g.4i.5d., lb.2f.3g.4i.5d., lf.2f.3g.4i.5d., lh.2f.3g.4i.5d., lj.2f.3g.4i.5d., lp.2f.3g.4i.5d., la.2i.3g.4i.5d., lb.2i.3g.4i.5d., lf.2i.3g.4i.5d., lh.2i.3g.4i.5d., lj.2i.3g.4i.5d-, lρ.2i.3g.4i.5d., la.2m.3g.4i.5d., lb.2m.3g.4i.5d., lf.2m.3g.4i.5d., lh.2m.3g.4i.5d., lj.2m.3g.4i.5d., lp.2m.3g.4i.5d., la.2o.3g.4i.5d., lb.2o.3g.4i.5d., lf.2o.3g.4i.5d., lh.2o.3g.4i.5d., lj.2o.3g.4i.5d., lp.2o.3g.4i.5d., la.2u.3g.4i.5d., lb.2u.3g.4i.5d., lf.2u.3g.4i.5d., lh.2u.3g.4i.5d., lj.2u.3g.4i.5d., lp.2u.3g.4i.5d., la.2y.3g.4i.5d., lb.2y.3g.4i.5d., lf.2y.3g.4i.5d., lh.2y.3g.4i.5d., lj.2y.3g.4i.5d., lp.2y.3g.4i.5d., la.2a.3a.4a.5f., lb.2a.3a.4a.5f., lf.2a.3a.4a.5f., lh.2a.3a.4a.5f., lj.2a.3a.4a.5f., lρ.2a.3a.4a.5f., la.2b.3a.4a.5f., lb.2b.3a.4a.5f., lf.2b.3a.4a.5f., lh.2b.3a.4a.5f., lj.2b.3a.4a.5f., lp.2b.3a.4a.5f., la.2e.3a.4a.5fv lb.2e.3a.4a.5f., lf.2e.3a.4a.5f., lh.2e.3a.4a.5f., lj.2e.3a.4a.5f., lp.2e.3a.4a.5f., la.2f.3a.4a.5f., lb.2f.3a.4a.5f., lf.2f.3a.4a.5f., lh.2f.3a.4a.5f., lj.2f.3a.4a.5f., lp.2f.3a.4a.5f., la.2i.3a.4a.5f., lb.2i.3a.4a.5f., lf.2i.3a.4a.5f., lh.2i.3a.4a.5f., lj.2i.3a.4a.5f., lp.2i.3a.4a.5f., la.2m.3a.4a.5f., lb.2m.3a.4a.5f., lf.2m.3a.4a.5f., lh.2m.3a.4a.5f., lj.2m.3a.4a.5f., lp.2m.3a.4a.5f., la.2o.3a.4a.5f., lb.2o.3a.4a.5f., lf.2o.3a.4a.5f., lh.2o.3a.4a.5f., lj.2o.3a.4a.5f., lp.2o.3a.4a.5f., la.2u.3a.4a.5f., lb.2u.3a.4a.5f., lf.2u.3a.4a.5f., lh.2u.3a.4a.5f., lj.2u.3a.4a.5f., lp.2u.3a.4a.5f., la.2y.3a.4a.5f., lb.2y.3a.4a.5f., lf.2y.3a.4a.5f., lh.2y.3a.4a.5fv lj.2y.3a.4a.5f., lp.2y.3a.4a.5f., la.2a.3b.4a.5f., Ib.2a.3b.4a.51, lf.2a.3b.4a.5f., lh.2a.3b.4a.5f., lj.2a.3b.4a.5f., lp.2a.3b.4a.5f., la.2b.3b.4a.5f., lb.2b.3b.4a.5f., lf.2b.3b.4a.5f., lh.2b.3b.4a.5f., lj.2b.3b.4a.5f., lp.2b.3b.4a.5f., la.2e.3b.4a.5f., lb.2e.3b.4a.5f., lf.2e.3b.4a.5f., lh.2e.3b.4a.5f., lj.2e.3b.4a.5f., lp.2e.3b.4a.5f., la.2f.3b.4a.5f., lb.2f.3b.4a.5f., lf.2f.3b.4a.5f., lh.2f.3b.4a.5f., lj.2f.3b.4a.5f., lp.2f.3b.4a.5f., la.2i.3b.4a.5fv lb.2i.3b.4a.5f., lf.2i.3b.4a.5f., lh.2i.3b.4a.5f., lj.2i.3b.4a.5f., lp.2i.3b.4a.5f., la.2m.3b.4a.5f., lb.2m.3b.4a.5f., lf.2m.3b.4a.5f., lh.2m.3b.4a.5f., lj.2m.3b.4a.5f., lp.2m.3b.4a.5f., la.2o.3b.4a.5f., lb.2o.3b.4a.5f., lf.2o.3b.4a.5f., lh.2o.3b.4a.5f., lj.2o.3b.4a.5f., lp.2o.3b.4a.5f., la.2u.3b.4a.5f., lb.2u.3b.4a.5f., lf.2u.3b.4a.5f., lh.2u.3b.4a.5f., lj.2u.3b.4a.5f., lp.2u.3b.4a.5f., la.2y.3b.4a.5f., lb.2y.3b.4a.5f., lf.2y.3b.4a.5f., lh.2y.3b.4a.5f., lj.2y.3b.4a.5f., lp.2y.3b.4a.5f., la.2a.3e.4a.5f., lb.2a.3e.4a.5f., lf.2a.3e.4a.5f., lh.2a.3e.4a.5f., lj.2a.3e.4a.5f., lp.2a.3e.4a.5f., la.2b.3e.4a.5f., lb.2b.3e.4a.5f., lf.2b.3e.4a.5f., lh.2b.3e.4a.5f., lj.2b.3e.4a.5f., lp.2b.3e.4a.5f., la.2e.3e.4a.5f., lb.2e.3e.4a.5f., lf.2e.3e.4a.5f., lh.2e.3e.4a.5f., lj.2e.3e.4a.5f., lp.2e.3e.4a.5£, la.2f.3e.4a.5fv lb.2f.3e.4a.5f., lf.2f.3e.4a.5£, lh.2f.3e.4a.5f., lj.2f.3e.4a.5f., lp.2£3e.4a.5£, la.2i.3e.4a.5fv lb.2i.3e.4a.5f., lf.2i.3e.4a.5£, lh.2i.3e.4a.5£, lj.2i.3e.4a.5f., lp.2L3e.4a.5f., la.2m.3e.4a.5f., lb.2m.3e.4a.5f., lf.2m.3e.4a.5f., lh.2m.3e.4a.5f., lj.2m.3e.4a.5£, lp.2m.3e.4a.5f., la.2o.3e.4a.5f., lb.2o.3e.4a.5f., lf.2o.3e.4a.5f., lh.2o.3e.4a.5f., lj.2o.3e.4a.5£, lp.2o.3e.4a.5f., la.2u.3e.4a.5f., lb.2u.3e.4a.5f., lf.2u.3e.4a.5f., lh.2u.3e.4a.5f., lj.2u.3e.4a.5fv lp.2u.3e.4a.5f., la.2y.3e.4a.5fv lb.2y.3e.4a.5f., lf.2y.3e.4a.5f., lh.2y.3e.4a.5f., lj.2y.3e.4a.5f., lp.2y.3e.4a.5f., la.2a.3g.4a.5f., lb.2a.3g.4a.5f., lf.2a.3g.4a.5f., lh.2a.3g.4a.5f., lj.2a.3g.4a.5f., lp.2a.3g.4a.5f., la.2b.3g.4a.5f., lb.2b.3g.4a.5f., lf.2b.3g.4a.5f., lh.2b.3g.4a.5f., lj.2b.3g.4a.5f., lp.2b.3g.4a.5f., la.2e.3g.4a.5f., lb.2e.3g.4a.5£, lf.2e.3g.4a.5f., lh.2e.3g.4a.5fv lj.2e.3g.4a.5f., lp.2e.3g.4a.5f., la.2f.3g.4a.5f., lb.2f.3g.4a.5f., lf.2f.3g.4a.5f., lh.2f.3g.4a.5f., lj.2f.3g.4a.5f., lp.2f.3g.4a.5f., la.2i.3g.4a.5f., lb.2i.3g.4a.5f., If .2i.3g.4a.5f., lh.2i.3g.4a.5f ., lj.2i.3g.4a.5f., lp.2i.3g.4a.5£, la.2m.3g.4a.5f., lb.2m.3g.4a.5f., lf.2m.3g.4a.5f., lh.2m.3g.4a.5f., lj.2m.3g.4a.5f., lp.2m.3g.4a.5f., la.2o.3g.4a.5f., lb.2o.3g.4a.5f., lf.2o.3g.4a.5f., lh.2o.3g.4a.5f., lj.2o.3g.4a.5f., lp.2o.3g.4a.5f., la.2u.3g.4a.5f., lb.2u.3g.4a.5f., lf.2u.3g.4a.5f., lh.2u.3g.4a.5f., lj.2u.3g.4a.5f., lp.2u.3g.4a.5f., la.2y.3g.4a.5f., lb.2y.3g.4a.5f., lf.2y.3g.4a.5f., lh.2y.3g.4a.5f., lj.2y.3g.4a.5f., lp.2y.3g.4a.5f., la.2a.3a.4d.5f., lb.2a.3a.4d.5f., lf.2a.3a.4d.5f., lh.2a.3a.4d.5f., lj.2a.3a.4d.5f., lp.2a.3a.4d.5f., la.2b.3a.4d.5f., lb.2b.3a.4d.5f., lf.2b.3a.4d.5f., lh.2b.3a.4d.5f., lj.2b.3a.4d.5f., lp.2b.3a.4d.5f., la.2e.3a.4d.5f., lb.2e.3a.4d.5f., lf.2e.3a.4d.5f., lh.2e.3a.4d.5f., lj.2e.3a.4d.5f., lp.2e.3a.4d.5f., la.2f.3a.4d.5f., lb.2f.3a.4d.5f., lf.2f.3a.4d.5f., lh.2f.3a.4d.5f., lj.2f.3a.4d.5f., lp.2f.3a.4d.5fv la.2i.3a.4d.5f., lb.2i.3a.4d.5f., lf.2i.3a.4d.5f., lh.2i.3a.4d.5f., lj.2i.3a.4d.5f., lp.2i.3a.4d.5f., la.2m.3a.4d.5f., lb.2m.3a.4d.5f., lf.2m.3a.4d.5f., lh.2m.3a.4d.5f., lj.2m.3a.4d.5£, lp.2m.3a.4d.5f., la.2o.3a.4d.5f., lb.2o.3a.4d.5f., lf.2o.3a.4d.5f., lh.2o.3a.4d.5f., lj.2o.3a.4d.5£, lp.2o.3a.4d.5f., la.2u.3a.4d.5f., lb.2u.3a.4d.5f., lf.2u.3a.4d.5f., lh.2u.3a.4d.5£, lj.2u.3a.4d.5f., lp.2u.3a.4d.5£, la.2y.3a.4d.5f., lb.2y.3a.4d.5£, lf.2y.3a.4d.5£, lh.2y.3a.4d.5£, lj.2y.3a.4d.5£, lρ.2y.3a.4d.5f., la.2a.3b.4d.5£, lb.2a.3b.4d.5£, lf.2a.3b.4d.5£, lh.2a.3b.4d.5f., lj.2a.3b.4d.5f., lp.2a.3b.4d.5£, la.2b.3b.4d.5£, lb.2b.3b.4d.5£, lf.2b.3b.4d.5f., lh.2b.3b.4d.5f., lj.2b.3b.4d.5f., lp.2b.3b.4d.5fv la.2e.3b.4d.5£, lb.2e.3b.4d.5£, lf.2e.3b.4d.5£, lh.2e.3b.4d.5f., lj.2e.3b.4d.5f., lp.2e.3b.4d.5f., la.2f.3b.4d.5f., lb.2f.3b.4d.5f., l£2f.3b.4d.5f., lh.2f.3b.4d.5£, lj.2f.3b.4d.5f., lp.2f.3b.4d.5£, la.2i.3b.4d.5f., lb.2i.3b.4d.5f., lf.2i.3b.4d.5f., lh.2i.3b.4d.5£, lj.2i.3b.4d.5£, lp.2i.3b.4d.5f., la.2m.3b.4d.5f., lb.2m.3b.4d.5£, lf.2m.3b.4d.5f., lh.2m.3b.4d.5f., lj.2m.3b.4d.5£, lp.2m.3b.4d.5f., la.2o.3b.4d.5£, lb.2o.3b.4d.5f., lf.2o.3b.4d.5f., lh.2o.3b.4d.5£, lj.2o.3b.4d.5f., lp.2o.3b.4d.5£, la.2u.3b.4d.5£, lb.2u.3b.4d.5f., lf.2u.3b.4d.5£, lh.2u.3b.4d.5f., lj.2u.3b.4d.5f., lp.2u.3b.4d.5f., la.2y.3b.4d.5f., lb.2y.3b.4d.5£, lf.2y.3b.4d.5f., lh.2y.3b.4d.5£, lj.2y.3b.4d.5f., lp.2y.3b.4d.5£, la.2a.3e.4d.5fv lb.2a.3e.4d.5f., lf.2a.3e.4d.5£, lh.2a.3e.4d.5f., lj.2a.3e.4d.5f., lp.2a.3e.4d.5f., la.2b.3e.4d.5fv lb.2b.3e.4d.5f., lf.2b.3e.4d.5f., lh.2b.3e.4d.5f., lj.2b.3e.4d.5f., lp.2b.3e.4d.5f., la.2e.3e.4d.5f., lb.2e.3e.4d.5f., lf.2e.3e.4d.5f., lh.2e.3e.4d.5f., lj.2e.3e.4d.5f., lp.2e.3e.4d.5f., la.2f.3e.4d.5f., lb.2f.3e.4d.5f., lf.2f.3e.4d.5f., lh.2f.3e.4d.5fv lj.2f.3e.4d.5f., lp.2f.3e.4d.5f., la.2i.3e.4d.5f., lb.2i.3e.4d.5f., lf.2i.3e.4d.5fv lh.2i.3e.4d.5f., lj.2i.3e.4d.5f., lp.2i.3e.4d.5fv la.2m.3e.4d.5f., lb.2m.3e.4d.5f., lf.2m.3e.4d.5f., lh.2m.3e.4d.5f., lj.2m.3e.4d.5f., lp.2m.3e.4d.5f., la.2o.3e.4d.5f., lb.2o.3e.4d.5f., lf.2o.3e.4d.5f., lh.2o.3e.4d.5f., lj.2o.3e.4d.5f., lp.2o.3e.4d.5f., la.2u.3e.4d.5f., lb.2u.3e.4d.5f., lf.2u.3e.4d.5f., lh.2u.3e.4d.5f., lj.2u.3e.4d.5f., lp.2u.3e.4d.5f., la.2y.3e.4d.5f., lb.2y.3e.4d.5f., lf.2y.3e.4d.5f., lh.2y.3e.4d.5f., lj.2y.3e.4d.5f ., lp.2y.3e.4d.5f., la.2a.3g.4d.5f., lb.2a.3g.4d.5f., lf.2a.3g.4d.5f., lh.2a.3g.4d.5f., lj.2a.3g.4d.5f., lp.2a.3g.4d.5f., la.2b.3g.4d.5f., lb.2b.3g.4d.5f., lf.2b.3g.4d.5f., lh.2b.3g.4d.5f., lj.2b.3g.4d.5fv lp.2b.3g.4d.5f., la.2e.3g.4d.5f., lb.2e.3g.4d.5f., lf.2e.3g.4d.5f., lh.2e.3g.4d.5f., lj.2e.3g.4d.5f., lp.2e.3g.4d.5fv la.2f.3g.4d.5f., lb.2f.3g.4d.5f., lf.2f.3g.4d.5fv lh.2f.3g.4d.5fv lj.2f.3g.4d.5f., lp.2f.3g.4d.5f., la.2i.3g.4d.5f., lb.2i.3g.4d.5f., lf.2i.3g.4d.5f., lh.2i.3g.4d.5f., lj.2i.3g.4d.5f., lp.2i.3g.4d.5f., la.2m.3g.4d.5f., lb.2m.3g.4d.5f., lf.2m.3g.4d.5f., lh.2m.3g.4d.5f., lj.2m.3g.4d.5f., lp.2m.3g.4d.5f., la.2o.3g.4d.5f., lb.2o.3g.4d.5f., lf.2o.3g.4d.5f., lh.2o.3g.4d.5f., lj.2o.3g.4d.5f., lp.2o.3g.4d.5f., la.2u.3g.4d.5f., lb.2u.3g.4d.5f., lf.2u.3g.4d.5f., lh.2u.3g.4d.5f., lj.2u.3g.4d.5f., lp.2u.3g.4d.5f., la.2y.3g.4d.5f., lb.2y.3g.4d.5f., lf.2y.3g.4d.5f., lh.2y.3g.4d.5f., lj.2y.3g.4d.5f., lp.2y.3g.4d.5f., la.2a.3a.4f.5f., lb.2a.3a.4f.5f., lf.2a.3a.4f.5f., lh.2a.3a.4f.5f., lj.2a.3a.4f.5f., lp.2a.3a.4f.5f., la.2b.3a.4f.5f., lb.2b.3a.4f.5f., lf.2b.3a.4f.5f., lh.2b.3a.4f.5f., lj.2b.3a.4f.5f., lp.2b.3a.4f.5f., la.2e.3a.4f.5f., lb.2e.3a.4f.5f., lf.2e.3a.4f.5f., lh.2e.3a.4f.5f., lj.2e.3a.4f.5f., lp.2e.3a.4f.5f., la.2f.3a.4f.5f., lb.2f.3a.4f.5f., lf.2f.3a.4f.5f., lh.2f.3a.4f.5f., lj.2f.3a.4f.5f., lp.2f.3a.4f.5f., la.2i.3a.4f.5f., lb.2i.3a.4f.5f., lf.2i.3a.4f.5f., lh.2i.3a.4f.5f., lj.2i.3a.4f.5f., lp.2i.3a.4f.5f., l a.2m.3a.4f.5f., lb.2m.3a.4f.5f., lf.2m.3a.4f.5f., lh.2m.3a.4f.5f., lj.2m.3a.4f.5f., lp.2m.3a.4f.5f., la.2o.3a.4f.5f., lb.2o.3a.4f.5f., lf.2o.3a.4f.5f., lh.2o.3a.4f.5f., lj.2o.3a.4f.5f-, lp.2o.3a.4f.5f., la.2u.3a.4f.5f., lb.2u.3a.4f.5f., lf.2u.3a.4f.5f., lh.2u.3a.4f.5f., lj.2u.3a.4f.5f., lp.2u.3a.4f.5f., la.2y.3a.4f.5f., lb.2y.3a.4f.5f., lf.2y.3a.4f.5fv lh.2y.3a.4f.5f., lj.2y.3a.4f.5fv lp.2y.3a.4f.5f., la.2a.3b.4f.5fv lb.2a.3b.4f.5fv lf.2a.3b.4f.5f., lh.2a.3b.4f.5f., lj.2a.3b.4f.5f., lp.2a.3b.4f.5f., la.2b.3b.4f.5f., lb.2b.3b.4f.5f., lf.2b.3b.4f.5f., lh.2b.3b.4f.5fv lj.2b.3b.4f.5f., lp.2b.3b.4f.5fv la.2e.3b.4f.5f., lb.2e.3b.4f.5f., lf.2e.3b.4f.5f., lh.2e.3b.4f.5f., lj.2e.3b.4f.5f., lp.2e.3b.4f.5f., la.2f.3b.4f.5f., lb.2f.3b.4f.5f., lf.2f.3b.4f.5f., lh.2f.3b.4f.5f., lj.2f.3b.4f.5f., lp.2f.3b.4f.5f., la.2i.3b.4f.5f., lb.2i.3b.4f.5f., lf.2i.3b.4f.5f., lh.2i.3b.4f.5f., lj.2i.3b.4f.5f., lp.2i.3b.4f.5f., la.2m.3b.4f.5f., lb.2m.3b.4f.5f., lf.2m.3b.4f.5f., lh.2m.3b.4f.5f., lj.2m.3b.4f.5f., lρ.2m.3b.4f.5fv la.2o.3b.4f.5f., lb.2o.3b.4f.5f., lf.2o.3b.4f.5f., lh.2o.3b.4f.5f., lj.2o.3b.4f.5f., lp.2o.3b.4f.5f., la.2u.3b.4f.5f., lb.2u.3b.4f.5f., lf.2u.3b.4f.5f., lh.2u.3b.4f.5f., lj.2u.3b.4f.5f., lp.2u.3b.4f.5f., la.2y.3b.4f.5f., lb.2y.3b.4f.5f., lf.2y.3b.4f.5f., lh.2y.3b.4f.5f., lj.2y.3b.4f.5f., lp.2y.3b.4f.5f., la.2a.3e.4f.5f., lb.2a.3e.4f.5f., lf.2a.3e.4f.5f., lh.2a.3e.4f.5f., lj.2a.3e.4f.5f., lp.2a.3e.4f.5£, la.2b.3e.4f.5f., lb.2b.3e.4f.5f., lf.2b.3e.4f.5f., lh.2b.3e.4f.5f., lj.2b.3e.4f.5f., lp.2b.3e.4f.5f., la.2e.3e.4f.5f., lb.2e.3e.4f.5f., lf.2e.3e.4f.5f., lh.2e.3e.4f.5f., lj.2e.3e.4f.5f., lp.2e.3e.4f.5f., la.2f.3e.4f.5fv lb.2f.3e.4f.5f., lf.2f.3e.4f.5f., lh.2f.3e.4f.5f., lj.2f.3e.4f.5f., lp.2f.3e.4f.5fv la.2i.3e.4f.5f., lb.2L3e.4f.5f., lf.2i.3e.4f.5f., lh.2i.3e.4f.5f., lj.2i.3e.4f.5f., lp.2i.3e.4f.5f., la.2m.3e.4f.5f., lb.2m.3e.4f.5f., lf.2m.3e.4f.5f., lh.2m.3e.4f.5f., lj.2m.3e.4f.5f., lp.2m.3e.4f.5f., la.2o.3e.4f.5f., lb.2o.3e.4f.5f., lf.2o.3e.4f.5f., lh.2o.3e.4f.5f., lj.2o.3e.4f.5f., lp.2o.3e.4f.5f., la.2u.3e.4f.5f., lb.2u.3e.4f.5f., lf.2u.3e.4f.5f., lh.2u.3e.4f.5f., lj.2u.3e.4f.5f., lp.2u.3e.4f.5f., la.2y.3e.4f.5f., lb.2y.3e.4f.5f., lf.2y.3e.4f.5f., lh.2y.3e.4f.5f., lj.2y.3e.4f.5f., lp.2y.3e.4f.5f., la.2a.3g.4f.5f., lb.2a.3g.4f.5f., lf.2a.3g.4f.5f., lh.2a.3g.4f.5f., lj.2a.3g.4f.5f., lp.2a.3g.4f.5f., la.2b.3g.4f.5f., lb.2b.3g.4f.5f., lf.2b.3g.4f.5f., lh.2b.3g.4f.5f., lj.2b.3g.4f.5f., lp.2b.3g.4f.5f., la.2e.3g.4f.5f., lb.2e.3g.4f.5f., lf.2e.3g.4f.5f., lh.2e.3g.4f.5f., lj.2e.3g.4f.5f., lp.2e.3g.4f.5f., la.2f.3g.4f.5f., lb.2f.3g.4f.5f., lf.2f.3g.4f.5f., lh.2f.3g.4f.5f., lj.2f.3g.4f.5f., lp.2f.3g.4f.5f., la.2i.3g.4f.5f., lb.2i.3g.4f.5f ., lf.2i.3g.4f.5L, lh.2i.3g.4f.5f., lj.2i.3g.4f.5f., lp.2i.3g.4f.5f., la.2m.3g.4f.5f., lb.2m.3g.4f.5f., lf.2m.3g.4f.5f., lh.2m.3g.4f.5f., lj.2m.3g.4f.5f., lp.2m.3g.4f.5f., la.2o.3g.4f.5f., lb.2o.3g.4f.5f., lf.2o.3g.4f.5f., lh.2o.3g.4f.5f., lj.2o.3g.4f.5f., lp.2o.3g.4f.5f., la.2u.3g.4f.5f., lb.2u.3g.4f.5f., lf.2u.3g.4f.5f., lh.2u.3g.4f.5f., lj.2u.3g.4f.5fv lp.2u.3g.4f.5f., la.2y.3g.4f.5f., lb.2y.3g.4f.5f., lf.2y.3g.4f.5f., lh.2y.3g.4f.5f., lj.2y.3g.4f.5f., lp.2y.3g.4f.5f., la.2a.3a.4g.5f., lb.2a.3a.4g.5f., lf.2a.3a.4g.5f., lh.2a.3a.4g.5f., lj.2a.3a.4g.5f., lp.2a.3a.4g.5f., la.2b.3a.4g.5f., lb.2b.3a.4g.5f., lf.2b.3a.4g.5f., lh.2b.3a.4g.5f., lj.2b.3a.4g.5f., lp.2b.3a.4g.5f., la.2e.3a.4g.5f., lb.2e.3a.4g.5fv lf.2e.3a.4g.5f., lh.2e.3a.4g.5f., lj.2e.3a.4g.5f., lp.2e.3a.4g.5f., la.2f.3a.4g.5f., lb.2f.3a.4g.5f., lf.2f.3a.4g.5f., lh.2f.3a.4g.5f., lj.2f.3a.4g.5f., lp.2f.3a.4g.5f., la.2i.3a.4g.5f., lb.2i.3a.4g.5f., lf.2i.3a.4g.5f., lh.2i.3a.4g.5f., lj.2i.3a.4g.5f., lp.2i.3a.4g.5f., la.2m.3a.4g.5f., lb.2m.3a.4g.5f., lf.2m.3a.4g.5f., lh.2m.3a.4g.5f., lj.2m.3a.4g.5f., lp.2m.3a.4g.5f., la.2o.3a.4g.5f., lb.2o.3a.4g.5f., lf.2o.3a.4g.5f., lh.2o.3a.4g.5f., lj.2o.3a.4g.5f., lp.2o.3a.4g.5f., la.2u.3a.4g.5f., lb.2u.3a.4g.5f., lf.2u.3a.4g.5f., lh.2u.3a.4g.5f., lj.2u.3a.4g.5f., lp.2u.3a.4g.5f., la.2y.3a.4g.5f., lb.2y.3a.4g.5f., lf.2y.3a.4g.5f., lh.2y.3a.4g.5f., lj.2y.3a.4g.5f., lp.2y.3a.4g.5f., la.2a.3b.4g.5f., lb.2a.3b.4g.5f., lf.2a.3b.4g.5f., lh.2a.3b.4g.5f., lj.2a.3b.4g.5f., lp.2a.3b.4g.5f., la.2b.3b.4g.5f., lb.2b.3b.4g.5f., lf.2b.3b.4g.5f., lh.2b.3b.4g.5fv lj.2b.3b.4g.5f., lp.2b.3b.4g.5f., la.2e.3b.4g.5f., lb.2e.3b.4g.5f., lf.2e.3b.4g.5fv lh.2e.3b.4g.5f., lj.2e.3b.4g.5f., lp.2e.3b.4g.5f., la.2f.3b.4g.5f., lb.2f.3b.4g.5f., lf.2f.3b.4g.5f., lh.2f.3b.4g.5f., lj.2f.3b.4g.5f., lp.2f.3b.4g.5f., la.2i.3b.4g.5f., lb.2i.3b.4g.5f., lf.2i.3b.4g.5f., lh.2i.3b.4g.5f., lj.2i.3b.4g.5f., lp.2i.3b.4g.5f., la.2m.3b.4g.5f., lb.2m.3b.4g.5f., lf.2m.3b.4g.5f., lh.2m.3b.4g.5f., lj.2m.3b.4g.5f., lp.2m.3b.4g.5f., la.2o.3b.4g.5f., lb.2o.3b.4g.5f.; lf.2o.3b.4g.5f., lh.2o.3b.4g.5f., lj.2o.3b.4g.5f., lp.2o.3b.4g.5f., la.2u.3b.4g.5f., lb.2u.3b.4g.5f., lf.2u.3b.4g.5f., lh.2u.3b.4g.5f., lj.2u.3b.4g.5f., lp.2u.3b.4g.5f., la.2y.3b.4g.5f., lb.2y.3b.4g.5f., lf.2y.3b.4g.5f., lh.2y.3b.4g.5f., lj.2y.3b.4g.5f., lp.2y.3b.4g.5f., la.2a.3e.4g.5f., lb.2a.3e.4g.5f., lf.2a.3e.4g.5f., lh.2a.3e.4g.5f., lj.2a.3e.4g.5f., lp.2a.3e.4g.5f., la.2b.3e.4g.5f., lb.2b.3e.4g.5f., lf.2b.3e.4g.5f., lh.2b.3e.4g.5f., lj.2b.3e.4g.5f., lp.2b.3e.4g.5f., la.2e.3e.4g.5f., lb.2e.3e.4g.5f., lf.2e.3e.4g.5f., lh.2e.3e.4g.5f., lj.2e.3e.4g.5f., lp.2e.3e.4g.5f., la.2f.3e.4g.5f., lb.2f.3e.4g.5f., lf.2f.3e.4g.5f., lh.2f.3e.4g.5f., lj.2f.3e.4g.5f., lp.2f.3e.4g.5f., la.2i.3e.4g.5f., lb.2i.3e.4g.5f., lf.2i.3e.4g.5f., lh.2i.3e.4g.5f., lj.2i.3e.4g.5f., lp.2i.3e.4g.5f., la.2m.3e.4g.5f., lb.2m.3e.4g.5f., lf.2m.3e.4g.5f., lh.2m.3e.4g.5f., lj.2m.3e.4g.5f., lp.2m.3e.4g.5f., la.2o.3e.4g.5f., lb.2o.3e.4g.5f., lf.2o.3e.4g.5f., lh.2o.3e.4g.5f., lj.2o.3e.4g.5f., lp.2o.3e.4g.5f., la.2u.3e.4g.5f., lb.2u.3e.4g.5f., lf.2u.3e.4g.5f., lh.2u.3e.4g.5f., lj.2u.3e.4g.5f., lp.2u.3e.4g.5f., la.2y.3e.4g.5f., lb.2y.3e.4g.5f., lf.2y.3e.4g.5f., lh.2y.3e.4g.5f., lj.2y.3e.4g.5f., lp.2y.3e.4g.5f., la.2a.3g.4g.5f., lb.2a.3g.4g.5f., lf.2a.3g.4g.5f., lh.2a.3g.4g.5f., lj.2a.3g.4g.5f., lp.2a.3g.4g.5f., la.2b.3g.4g.5f., lb.2b.3g.4g.5f., lf.2b.3g.4g.5f., lh.2b.3g.4g.5f., lj.2b.3g.4g.5f., lp.2b.3g.4g.5f., la.2e.3g.4g.5f., lb.2e.3g.4g.5f., lf.2e.3g.4g.5f., lh.2e.3g.4g.5f., lj.2e.3g.4g.5f., lp.2e.3g.4g.5f., la.2f.3g.4g.5f., lb.2f.3g.4g.5f., lf.2f.3g.4g.5f., lh.2f.3g.4g.5f., lj.2f.3g.4g.5f., lp.2f.3g.4g.5f., la.2i.3g.4g.5f., lb.2i.3g.4g.5f., lf.2i.3g.4g.5f., lh.2i.3g.4g.5f., lj.2i.3g.4g.5f., lp.2i.3g.4g.5f., la.2m.3g.4g.5f., lb.2m.3g.4g.5f., lf.2m.3g.4g.5f., lh.2m.3g.4g.5f., lj.2m.3g.4g.5f., lp.2m.3g.4g.5f., la.2o.3g.4g.5f., lb.2o.3g.4g.5f., lf.2o.3g.4g.5f., lh.2o.3g.4g.5f., lj.2o.3g.4g.5f., lp.2o.3g.4g.5f., la.2u.3g.4g.5f., lb.2u.3g.4g.5f., lf.2u.3g.4g.5f., lh.2u.3g.4g.5fv lj.2u.3g.4g.5f., lp.2u.3g.4g.5f., la.2y.3g.4g.5f., lb.2y.3g.4g.5f., lf.2y.3g.4g.5f., lh.2y.3g.4g.5f., lj.2y.3g.4g.5f., lp.2y.3g.4g.5f., la.2a.3a.4h.5f., lb.2a.3a.4h.5f., lf.2a.3a.4h.5f., lh.2a.3a.4h.5f., lj.2a.3a.4h.5f., lp.2a.3a.4h.5f., la.2b.3a.4h.5f., lb.2b.3a.4h.5f., lf.2b.3a.4h.5f., lh.2b.3a.4h.5f., lj.2b.3a.4h.5f., lp.2b.3a.4h.5f., la.2e.3a.4h.5f., lb.2e.3a.4h.5f., lf.2e.3a.4h.5£, lh.2e.3a.4h.5f., lj.2e.3a.4h.5f., lp.2e.3a.4h.5f., la.2f.3a.4h.5f., lb.2f.3a.4h.5f., lf.2f.3a.4h.5f., lh.2f.3a.4h.5f., lj.2f.3a.4h.5f., lp.2f.3a.4h.5f., la.2i.3a.4h.5f., lb.2i.3a.4h.5f., lf.2i.3a.4h.5f., lh.2i.3a.4h.5f., lj.2i.3a.4h.5f., lp.2i.3a.4h.5f., la.2m.3a.4h.5f., lb.2m.3a.4h.5f., lf.2m.3a.4h.5f., lh.2m.3a.4h.5f., lj.2m.3a.4h.5f., lp.2m.3a.4h.5f., la.2o.3a.4h.5f., lb.2o.3a.4h.5f., lf.2o.3a.4h.5f., lh.2o.3a.4h.5f., lj.2o.3a.4h.5f., lp.2o.3a.4h.5f., la.2u.3a.4h.5f., lb.2u.3a.4h.5f., lf.2u.3a.4h.5f., lh.2u.3a.4h.5f., lj.2u.3a.4h.5f., lp.2u.3a.4h.5f., la.2y.3a.4h.5f., lb.2y.3a.4h.5f., lf.2y.3a.4h.5f., lh.2y.3a.4h.5f., lj.2y.3a.4h.5f., lp.2y.3a.4h.5f., la.2a.3b.4h.5f., lb.2a.3b.4h.5f., lf.2a.3b.4h.5f., lh.2a.3b.4h.5f., lj.2a.3b.4h.5f., lp.2a.3b.4h.5f., la.2b.3b.4h.5f., lb.2b.3b.4h.5f., lf.2b.3b.4h.5f., lh.2b.3b.4h.5f., lj.2b.3b.4h.5f., lp.2b.3b.4h.5f., la.2e.3b.4h.5f., lb.2e.3b.4h.5f., lf.2e.3b.4h.5f., lh.2e.3b.4h.5f., lj.2e.3b.4h.5f., lp.2e.3b.4h.5f., la.2f.3b.4h.5f., lb.2f.3b.4h.5f., lf.2f.3b.4h.5f., lh.2f.3b.4h.5f., lj.2f.3b.4h.5f., lp.2f.3b.4h.5f., la.2i.3b.4h.5f., lb.2i.3b.4h.5f., lf.2i.3b.4h.5f., lh.2i.3b.4h.5fv lj.2i.3b.4h.5f., lp.2i.3b.4h.5f., la.2m.3b.4h.5f., lb.2m.3b.4h.5f., lf.2m.3b.4h.5f., lh.2m.3b.4h.5f., lj.2m.3b.4h.5f., lp.2m.3b.4h.5fv la.2o.3b.4h.5f., lb.2o.3b.4h.5f., lf.2o.3b.4h.5f., lh.2o.3b.4h.5f., lj.2o.3b.4h.5f., lp.2o.3b.4h.5f., la.2u.3b.4h.5f., lb.2u.3b.4h.5f., lf.2u.3b.4h.5fv lh.2u.3b.4h.5f., lj.2u.3b.4h.5f., lp.2u.3b.4h.5f., la.2y.3b.4h.5f., lb.2y.3b.4h.5f., lf.2y.3b.4h.5f., lh.2y.3b.4h.5f., lj.2y.3b.4h.5f., lp.2y.3b.4h.5f., la.2a.3e.4h.5f., lb.2a.3e.4h.5f., lf.2a.3e.4h.5f., lh.2a.3e.4h.5f., lj.2a.3e.4h.5f., lp.2a.3e.4h.5f., la.2b.3e.4h.5f., lb.2b.3e.4h.5f., lf.2b.3e.4h.5f., lh.2b.3e.4h.5f., lj.2b.3e.4h.5f., lρ.2b.3e.4h.5f.7 la.2e.3e.4h.5£, lb.2e.3e.4h.5f., lf.2e.3e.4h.5f., lh.2e.3e.4h.5f., lj.2e.3e.4h.5f., lp.2e.3e.4h.5t, la.2f.3e.4h.5f., lb.2f.3e.4h.5f., lf.2f.3e.4h.5f., lh.2f.3e.4h.5f., lj.2f.3e.4h.5f., lp.2f.3e.4h.5f., la.2i.3e.4h.5f., lb.2i.3e.4h.5f., lf.2i.3e.4h.5f., lh.2i.3e.4h.5f., lj.2i.3e.4h.5f., lp.2i.3e.4h.5f., la.2m.3e.4h.5f., lb.2m.3e.4h.5f., lf.2m.3e.4h.5f., lh.2m.3e.4h.5f., lj.2m.3e.4h.5f., lp.2m.3e.4h.5f., la.2o.3e.4h.5f., lb.2o.3e.4h.5f., lf.2o.3e.4h.5f., lh.2o.3e.4h.5f., lj.2o.3e.4h.5f., lp.2o.3e.4h.5f., la.2u.3e.4h.5f., lb.2u.3e.4h.5f., lf.2u.3e.4h.5f., lh.2u.3e.4h.5f., lj.2u.3e.4h.5f., lp.2u.3e.4h.5f., la.2y.3e.4h.5f., lb.2y.3e.4h.5f., lf.2y.3e.4h.5fv lh.2y.3e.4h.5f., lj.2y.3e.4h.5f., lp.2y.3e.4h.5f., la.2a.3g.4h.5f., lb.2a.3g.4h.5f., lf.2a.3g.4h.5f., lh.2a.3g.4h.5f., lj.2a.3g.4h.5f., lp.2a.3g.4h.5f., la.2b.3g.4h.5f., lb.2b.3g.4h.5f., lf.2b.3g.4h.5f., lh.2b.3g.4h.5f., lj.2b.3g.4h.5f., lp.2b.3g.4h.5f., la.2e.3g.4h.5f., lb.2e.3g.4h.5f., lf.2e.3g.4h.5fv lh.2e.3g.4h.5f., lj.2e.3g.4h.5f., lp.2e.3g.4h.5f., la.2f.3g.4h.5f., lb.2f.3g.4h.5£, lf.2f.3g.4h.5f., lh.2f.3g.4h.5f., lj.2f.3g.4h.5f., lp.2f.3g.4h.5f., la.2i.3g.4h.5f., lb.2i.3g.4h.5f., lf.2i.3g.4h.5f., lh.2i.3g.4h.5f., lj.2i.3g.4h.5f., lp.2i.3g.4h.5f., la.2m.3g.4h.5f., lb.2m.3g.4h.5f., lf.2m.3g.4h.5f., lh.2m.3g.4h.5f., lj.2m.3g.4h.5f., lp.2m.3g.4h.5f., la.2o.3g.4h.5f., lb.2o.3g.4h.5f., lf.2o.3g.4h.5fv lh.2o.3g.4h.5f., lj.2o.3g.4h.5f., lp.2o.3g.4h.5f., la.2u.3g.4h.5fv lb.2u.3g.4h.5f., lf.2u.3g.4h.5fv lh.2u.3g.4h.5f., lj.2u.3g.4h.5f., lp.2u.3g.4h.5f., la.2y.3g.4h.5f., lb.2y.3g.4h.5f., lf.2y.3g.4h.5f., lh.2y.3g.4h.5f., lj.2y.3g.4h.5f., lp.2y.3g.4h.5f., la.2a.3a.4i.5f., lb.2a.3a.4i.5f., lf.2a.3a.4i.5f., lh.2a.3a.4i.5f., lj.2a.3a.4i.5f., lp.2a.3a.4i.5f., la.2b.3a.4i.5f., lb.2b.3a.4i.5f., lf.2b.3a.4i.5f., lh.2b.3a.4i.5f., lj.2b.3a.4i.5f., lp.2b.3a.4i.5f., la.2e.3a.4i.5f., lb.2e.3a.4i.5f., lf.2e.3a.4i.5f., lh.2e.3a.4i.5f., lj.2e.3a.4i.5f., lp.2e.3a.4i.5f., la.2f.3a.4i.5f., lb.2f.3a.4i.5f., lf.2f.3a.4i.5f., lh.2f.3a.4i.5f., lj.2f.3a.4i.5f., lp.2f.3a.4i.5f., la.2i.3a.4L5f., lb.2i.3a.4i.5f., lf.2i.3a.4i.5f., lh.2i.3a.4i.5f., lj.2i.3a.4i.5f., lp.2i.3a.4i.5f., la.2m.3a.4i.5f., lb.2m.3a.4i.5f., lf.2m.3a.4i.5f., lh.2m.3a.4L5f., lj.2m.3a.4i.5f., lp.2m.3a.4L5f., la.2o.3a.4i.5f., lb.2o.3a.4i.5f., lf.2o.3a.4i.5f., lh.2o.3a.4i.5f., lj.2o.3a.4i.5f., lp.2o.3a.4i.5f., la.2u.3a.4i.5f., lb.2u.3a.4i.5f., lf.2u.3a.4i.5f., lh.2u.3a.4i.5f., lj.2u.3a.4i.5f., lp.2u.3a.4i.5f., la.2y.3a.4i.5f., lb.2y.3a.4i.5f., lf.2y.3a.4i.5f., lh.2y.3a.4i.5f., lj.2y.3a.4i.5f., lp.2y.3a.4i.5f., la.2a.3b.4i.5f., lb.2a.3b.4i.5f., lf.2a.3b.4i.5f., lh.2a.3b.4i.5f., lj.2a.3b.4i.5f., lp.2a.3b.4i.5f., la.2b.3b.4i.5f., lb.2b.3b.4i.5f., lf.2b.3b.4i.5f., lh.2b.3b.4i.5f., lj.2b.3b.4i.5f., lp.2b.3b.4i.5f., la.2e.3b.4i.5f., lb.2e.3b.4i.5f., lf.2e.3b.4i.5fv lh.2e.3b.4i.5f., lj.2e.3b.4i.5f., lp.2e.3b.4i.5f., la.2f.3b.4i.5f., lb.2f.3b.4i.5f., lf.2f.3b.4i.5f., lh.2f.3b.4i.5fv lj.2f.3b.4i.5f., lp.2f.3b.4i.5f., la.2i.3b.4i.5f., lb.2i.3b.4i.5£., lf.2i.3b.4i.5f., lh.2i.3b.4i.5f., lj.2i.3b.4i.5f., lp.2i.3b.4i.5f., la.2m.3b.4i.5f., lb.2m.3b.4i.5f., lf.2m.3b.4i.5f., lh.2m.3b.4i.5f., lj.2m.3b.4i.5f., lp.2m.3b.4i.5f., la.2o.3b.4i.5f., lb.2o.3b.4i.5f., lf.2o.3b.4i.5f., lh.2o.3b.4i.5fv lj.2o.3b.4i.5fv lp.2o.3b.4i.5f., la.2u.3b.4i.5£, lb.2u.3b.4i.5f., lf.2u.3b.4i.5f., lh.2u.3b.4i.5f., lj.2u.3b.4i.5f., lp.2u.3b.4i.5f., la.2y.3b.4i.5f., lb.2y.3b.4i.5f., lf.2y.3b.4i.5f., lh.2y.3b.4i.5f., lj.2y.3b.4i.5f., lp.2y.3b.4i.5f., la.2a.3e.4i.5f., lb.2a.3e.4i.5f., lf.2a.3e.4i.5f., lh.2a.3e.4i.5f., lj.2a.3e.4i.5f., lp.2a.3e.4i.5f., la.2b.3e.4i.5f., lb.2b.3e.4i.5f., lf.2b.3e.4i.5£, lh.2b.3e.4i.5f., lj.2b.3e.4i.5f., lρ.2b.3e.4i.5f., la.2e.3e.4i.5f., lb.2e.3e.4i.5f., lf.2e.3e.4i.5f., lh.2e.3e.4i.5f., lj.2e.3e.4i.5f., lp.2e.3e.4i.5f., la.2f.3e.4i.5fv lb.2f.3e.4i.5f., lf.2f.3e.4i.5f., lh.2f.3e.4i.5f., lj.2f.3e.4i.5f., lp.2f.3e.4i.5f., la.2i.3e.4i.5f., lb.2i.3e.4i.5f., lf.2i.3e.4i.5f., lh.2i.3e.4i.5f., lj.2i.3e.4i.5f., lp.2i.3e.4i.5f., la.2m.3e.4i.5f., lb.2m.3e.4i.5f., lf.2m.3e.4i.5f., lh.2m.3e.4i.5f., lj.2m.3e.4i.5fv lp.2m.3e.4i.5f., la.2o.3e.4i.5f., lb.2o.3e.4i.5f., lf.2o.3e.4i.5f., lh.2o.3e.4i.5f., lj.2o.3e.4i.5f., lp.2o.3e.4i.5f., la.2u.3e.4i.5f., lb.2u.3e.4i.5f., lf.2u.3e.4i.5f., lh.2u.3e.4i.5f., lj.2u.3e.4i.5f., lp.2u.3e.4i.5f., la.2y.3e.4i.5f., lb.2y.3e.4i.5f., lf.2y.3e.4i.5f., lh.2y.3e.4i.5f., lj.2y.3e.4i.5f., lp.2y.3e.4i.5f., la.2a.3g.4i.5f., lb.2a.3g.4i.5f., lf.2a.3g.4i.5f., lh.2a.3g.4i.5f., lj.2a.3g.4i.5f., lp.2a.3g.4i.5f., la.2b.3g.4i.5f., lb.2b.3g.4i.5f., lf.2b.3g.4i.5f., lh.2b.3g.4i.5f., lj.2b.3g.4i.5f., lp.2b.3g.4i.5f., la.2e.3g.4i.5f., lb.2e.3g.4i.5f., lf.2e.3g.4i.5f., lh.2e.3g.4i.5f., lj.2e.3g.4i.5f., lp.2e.3g.4i.5f., la.2f.3g.4i.5f., lb.2f.3g.4i.5f., lf.2f.3g.4i.5f., lh.2f.3g.4i.5f., lj.2f.3g.4i.5f., lp.2f.3g.4i.5f., la.2i.3g.4i.5f., lb.2i.3g.4i.5f., lf.2i.3g.4i.5f., lh.2i.3g.4i.5f., lj.2i.3g.4i.5f., lp.2i.3g.4i.5f., la.2m.3g.4i.5f., lb.2m.3g.4i.5f., lf.2m.3g.4i.5f., lh.2m.3g.4i.5f., lj.2m.3g.4i.5f., lp.2m.3g.4i.5f., la.2o.3g.4i.5f., lb.2o.3g.4i.5f., lf.2o.3g.4i.5f., lh.2o.3g.4i.5f., lj.2o.3g.4i.5f., lp.2o.3g.4i.5f., la.2u.3g.4i.5f., lb.2u.3g.4i.5f., lf.2u.3g.4i.5f., lh.2u.3g.4i.5f., lj.2u.3g.4i.5f., lp.2u.3g.4i.5f., la.2y.3g.4i.5f., lb.2y.3g.4i.5f., lf.2y.3g.4i.5f., lh.2y.3g.4i.5f., lj.2y.3g.4i.5f., lp.2y.3g.4i.5f., la.2a.3a.4a.5g., lb.2a.3a.4a.5g., lf.2a.3a.4a.5g., lh.2a.3a.4a.5g., lj.2a.3a.4a.5g., lp.2a.3a.4a.5g., la.2b.3a.4a.5g., lb.2b.3a.4a.5g., lf.2b.3a.4a.5g., lh.2b.3a.4a.5g., lj.2b.3a.4a.5g., lp.2b.3a.4a.5g., la.2e.3a.4a.5g., lb.2e.3a.4a.5g., lf.2e.3a.4a.5g., lh.2e.3a.4a.5g., lj.2e.3a.4a.5g., lp.2e.3a.4a.5g., la.2f.3a.4a.5g., lb.2f.3a.4a.5g., lf.2f.3a.4a.5g., lh.2f.3a.4a.5g., lj.2f.3a.4a.5gv lp.2f.3a.4a.5g., la.2i.3a.4a.5g., lb.2i.3a.4a.5g., lf.2i.3a.4a.5g., lh.2i.3a.4a.5g., lj.2i.3a.4a.5g., lp.2i.3a.4a.5g., la.2m.3a.4a.5g., lb.2m.3a.4a.5g., lf.2m.3a.4a.5g., lh.2m.3a.4a.5gv lj.2m.3a.4a.5gv lp.2m.3a.4a.5g., la.2o.3a.4a.5g., lb.2o.3a.4a.5g., lf.2o.3a.4a.5g., lh.2o.3a.4a.5g., lj.2o.3a.4a.5g., lp.2o.3a.4a.5g., la.2u.3a.4a.5g., lb.2u.3a.4a.5g., lf.2u.3a.4a.5g., lh.2u.3a.4a.5g., lj.2u.3a.4a.5g., lp.2u.3a.4a.5g., la.2y.3a.4a.5g., lb.2y.3a.4a.5g., lf.2y.3a.4a.5g., lh.2y.3a.4a.5g., lj.2y.3a.4a.5g., lp.2y.3a.4a.5g., la.2a.3b.4a.5g., lb.2a.3b.4a.5gv lf.2a.3b.4a.5g., lh.2a.3b.4a.5g., lj.2a.3b.4a.5g., lp.2a.3b.4a.5gv la.2b.3b.4a.5g., lb.2b.3b.4a.5g., lf.2b.3b.4a.5g., lh.2b.3b.4a.5gv lj.2b.3b.4a.5g-, lp.2b.3b.4a.5g., la.2e.3b.4a.5g., lb.2e.3b.4a.5g., lf.2e.3b.4a.5g., lh.2e.3b.4a.5g., lj.2e.3b.4a.5g., lp.2e.3b.4a.5g., la.2f.3b.4a.5g., lb.2f.3b.4a.5g., lf.2f.3b.4a.5g., lh.2f.3b.4a.5g., lj.2f.3b.4a.5g., lp.2f.3b.4a.5g., la.2i.3b.4a.5g., lb.2L3b.4a.5g., lf.2i.3b.4a.5g., lh.2i.3b.4a.5g., lj.2i.3b.4a.5g., lp.2i.3b.4a.5g., la.2m.3b.4a.5g., lb.2m.3b.4a.5g., lf.2m.3b.4a.5g., lh.2m.3b.4a.5g., lj.2m.3b.4a.5g., lp.2m.3b.4a.5g., la.2o.3b.4a.5g., lb.2o.3b.4a.5g., If .2o.3b.4a.5g., lh.2o.3b.4a.5g., lj.2o.3b.4a.5g., lp.2o.3b.4a.5g., la.2u.3b.4a.5g., lb.2u.3b.4a.5g., lf.2u.3b.4a.5g., lh.2u.3b.4a.5g., lj.2u.3b.4a.5g., lp.2u.3b.4a.5g., la.2y.3b.4a.5g., lb.2y.3b.4a.5g., lf.2y.3b.4a.5g., lh.2y.3b.4a.5g., lj.2y.3b.4a.5g., lp.2y.3b.4a.5gv la.2a.3e.4a.5g., lb.2a.3e.4a.5g., lf.2a.3e.4a.5g., lh.2a.3e.4a.5g., lj.2a.3e.4a.5g., lp.2a.3e.4a.5g., la.2b.3e.4a.5g., lb.2b.3e.4a.5g., l£.2b.3e.4a.5g., lh.2b.3e.4a.5g., lj.2b.3e.4a.5g., lp.2b.3e.4a.5g., la.2e.3e.4a.5g., lb.2e.3e.4a.5g., lf.2e.3e.4a.5g., lh.2e.3e.4a.5g., lj.2e.3e.4a.5g., lp.2e.3e.4a.5g., la.2f.3e.4a.5g., lb.2f.3e.4a.5g., lf.2f.3e.4a.5gv lh.2f.3e.4a.5g., lj.2f.3e.4a.5gv lp.2f.3e.4a.5g., la.2i.3e.4a.5g., lb.2i.3e.4a.5g., lf.2i.3e.4a.5g., lh.2i.3e.4a.5g., lj.2i.3e.4a.5g., lp.2i.3e.4a.5g., la.2m.3e.4a.5g., lb.2m.3e.4a.5g., lf.2m.3e.4a.5g., lh.2m.3e.4a.5g., lj.2m.3e.4a.5g., lp.2m.3e.4a.5g., la.2o.3e.4a.5g., lb.2o.3e.4a.5g., lf.2o.3e.4a.5g., lh.2o.3e.4a.5g., lj.2o.3e.4a.5g., lp.2o.3e.4a.5g., la.2u.3e.4a.5g., lb.2u.3e.4a.5g., lf.2u.3e.4a.5g., lh.2u.3e.4a.5g., lj.2u.3e.4a.5g., lp.2u.3e.4a.5g., la.2y.3e.4a.5g., lb.2y.3e.4a.5g., lf.2y.3e.4a.5g., lh.2y.3e.4a.5g., lj.2y.3e.4a.5g., lp.2y.3e.4a.5g., la.2a.3g.4a.5g., lb.2a.3g.4a.5g., lf.2a.3g.4a.5g., lh.2a.3g.4a.5g., lj.2a.3g.4a.5g., lp.2a.3g.4a.5g., la.2b.3g.4a.5g., lb.2b.3g.4a.5g., lf.2b.3g.4a.5g., lh.2b.3g.4a.5g., lj.2b.3g.4a.5g., lp.2b.3g.4a.5gv la.2e.3g.4a.5g., lb.2e.3g.4a.5g., lf.2e.3g.4a.5g., lh.2e.3g.4a.5g., lj.2e.3g.4a.5g., lp.2e.3g.4a.5g., la.2f.3g.4a.5g., lb.2f.3g.4a.5g., lf.2f.3g.4a.5g., lh.2f.3g.4a.5g., lj.2f.3g.4a.5g., lp.2f.3g.4a.5gv la.2i.3g.4a.5g., lb.2i.3g.4a.5g., lf.2i.3g.4a.5g., lh.2i.3g.4a.5g., lj.2i.3g.4a.5g., lp.2i.3g.4a.5g., la.2m.3g.4a.5g., lb.2m.3g.4a.5g., lf.2m.3g.4a.5g., lh.2m.3g.4a.5g., lj.2m.3g.4a.5g., lp.2m.3g.4a.5g., la.2o.3g.4a.5g., lb.2o.3g.4a.5g., lf.2o.3g.4a.5g., lh.2o.3g.4a.5g., lj.2o.3g.4a.5g., lρ.2o.3g.4a.5g., la.2u.3g.4a.5g., lb.2u.3g.4a.5g., lf.2u.3g.4a.5g., lh.2u.3g.4a.5g., lj.2u.3g.4a.5g., lp.2u.3g.4a.5g., la.2y.3g.4a.5g., lb.2y.3g.4a.5g., lf.2y.3g.4a.5g., lh.2y.3g.4a.5g., lj.2y.3g.4a.5g., lp.2y.3g.4a.5g., la.2a.3a.4d.5g., lb.2a.3a.4d.5g., lf.2a.3a.4d.5g., lh.2a.3a.4d.5g., lj.2a.3a.4d.5g., lp.2a.3a.4d.5g., la.2b.3a.4d.5g., lb.2b.3a.4d.5g., lf.2b.3a.4d.5g., lh.2b.3a.4d.5g., lj.2b.3a.4d.5g., lp.2b.3a.4d.5g., la.2e.3a.4d.5g., lb.2e.3a.4d.5g., lf.2e.3a.4d.5g., lh.2e.3a.4d.5g., lj.2e.3a.4d.5g., lp.2e.3a.4d.5g., la.2f.3a.4d.5g., lb.2f.3a.4d.5g., lf.2f.3a.4d.5g., lh.2f.3a.4d.5g., lj.2f.3a.4d.5g., lp.2f.3a.4d.5g., la.2i.3a.4d.5g., lb.2i.3a.4d.5g., lf.2i.3a.4d.5g., lh.2i.3a.4d.5g., lj.2i.3a.4d.5g., lp.2i.3a.4d.5g., la.2m.3a.4d.5g., lb.2m.3a.4d.5g., lf.2m.3a.4d.5g., lh.2m.3a.4d.5g., lj.2m.3a.4d.5g., lp.2m.3a.4d.5g., la.2o.3a.4d.5g., lb.2o.3a.4d.5g., lf.2o.3a.4d.5g., lh.2o.3a.4d.5g., lj.2o.3a.4d.5g., lp.2o.3a.4d.5g., la.2u.3a.4d.5g., lb.2u.3a.4d.5g., lf.2u.3a.4d.5g., lh.2u.3a.4d.5g., lj.2u.3a.4d.5g., lp.2u.3a.4d.5g., la.2y.3a.4d.5g., lb.2y.3a.4d.5gv lf.2y.3a.4d.5g., lh.2y.3a.4d.5g., lj.2y.3a.4d.5g., lp.2y.3a.4d.5g., la.2a.3b.4d.5g., lb.2a.3b.4d.5g., lf.2a.3b.4d.5g., lh.2a.3b.4d.5g., lj.2a.3b.4d.5g., lp.2a.3b.4d.5g., la.2b.3b.4d.5g., lb.2b.3b.4d.5g., lf.2b.3b.4d.5g., lh.2b.3b.4d.5g., lj.2b.3b.4d.5g., lp.2b.3b.4d.5gv la.2e.3b.4d.5g., lb.2e.3b.4d.5g., lf.2e.3b.4d.5g., lh.2e.3b.4d.5g., lj.2e.3b.4d.5g., lp.2e.3b.4d.5g., la.2f.3b.4d.5g., lb.2f.3b.4d.5g., lf.2f.3b.4d.5g., lh.2f.3b.4d.5g., lj.2f.3b.4d.5g., lp.2f.3b.4d.5g., la.2i.3b.4d.5g., lb.2i.3b.4d.5g., lf.2i.3b.4d.5g., lh.2i.3b.4d.5g., lj.2i.3b.4d.5g., lp.2i.3b.4d.5g., la.2m.3b.4d.5g., lb.2m.3b.4d.5g., lf.2m.3b.4d.5gv lh.2m.3b.4d.5g., lj.2m.3b.4d.5g., lp.2m.3b.4d.5g., la.2o.3b.4d.5g., lb.2o.3b.4d.5g., lf.2o.3b.4d.5g., lh.2o.3b.4d.5g., lj.2o.3b.4d.5g., lp.2o.3b.4d.5g., la.2u.3b.4d.5g., lb.2u.3b.4d.5g., lf.2u.3b.4d.5g., lh.2u.3b.4d.5g., lj.2u.3b.4d.5g., lp.2u.3b.4d.5g., la.2y.3b.4d.5gv lb.2y.3b.4d.5g., lf.2y.3b.4d.5g., lh.2y.3b.4d.5g., lj.2y.3b.4d.5g., lp.2y.3b.4d.5g., la.2a.3e.4d.5g., lb.2a.3e.4d.5g., lf.2a.3e.4d.5g., lh.2a.3e.4d.5g., lj.2a.3e.4d.5g., lp.2a.3e.4d.5g., la.2b.3e.4d.5g., lb.2b.3e.4d.5g., lf.2b.3e.4d.5g., lh.2b.3e.4d.5g., lj.2b.3e.4d.5g., lp.2b.3e.4d.5g., la.2e.3e.4d.5gv lb.2e.3e.4d.5g., lf.2e.3e.4d.5g., lh.2e.3e.4d.5g., lj.2e.3e.4d.5g., lp.2e.3e.4d.5g., la.2f.3e.4d.5g., lb.2f.3e.4d.5g., lf.2f.3e.4d.5g., lh.2f.3e.4d.5g., lj.2f.3e.4d.5g., lρ.2f.3e.4d.5g., la.2i.3e.4d.5g., lb.2i.3e.4d.5g., lf.2i.3e.4d.5g., lh.2i.3e.4d.5g., lj.2i.3e.4d.5g., lp.2i.3e.4d.5g., la.2m.3e.4d.5g., lb.2m.3e.4d.5gv lf.2m.3e.4d.5g., lh.2m.3e.4d.5g., lj.2m.3e.4d.5g., lp.2m.3e.4d.5g., la.2o.3e.4d.5g., lb.2o.3e.4d.5g., lf.2o.3e.4d.5g., lh.2o.3e.4d.5g., lj.2o.3e.4d.5g., lp.2o.3e.4d.5g., la.2u.3e.4d.5g., lb.2u.3e.4d.5g., lf.2u.3e.4d.5gv lh.2u.3e.4d.5g., lj.2u.3e.4d.5g., lp.2u.3e.4d.5g., la.2y.3e.4d.5g., lb.2y.3e.4d.5g., lf.2y.3e.4d.5g., lh.2y.3e.4d.5g., lj.2y.3e.4d.5g., lp.2y.3e.4d.5g., la.2a.3g.4d.5g., lb.2a.3g.4d.5g., lf.2a.3g.4d.5g., lh.2a.3g.4d.5g., lj.2a.3g.4d.5g., lp.2a.3g.4d.5g., la.2b.3g.4d.5g., lb.2b.3g.4d.5gv lf.2b.3g.4d.5g., lh.2b.3g.4d.5g., lj.2b.3g.4d.5g., lp.2b.3g.4d.5g., la.2e.3g.4d.5g., lb.2e.3g.4d.5g., lf.2e.3g.4d.5g., lh.2e.3g.4d.5g., lj.2e.3g.4d.5g., lp.2e.3g.4d.5g., la.2f.3g.4d.5g., lb.2f.3g.4d.5g., lf.2f.3g.4d.5g., lh.2f.3g.4d.5g., lj.2f.3g.4d.5g., lp.2f.3g.4d.5g., la.2i.3g.4d.5g., lb.2i.3g.4d.5g., lf.2i.3g.4d.5g., lh.2i.3g.4d.5g., lj.2i.3g.4d.5g., lp.2i.3g.4d.5g., la.2m.3g.4d.5g., lb.2m.3g.4d.5g., lf.2m.3g.4d.5g., lh.2m.3g.4d.5g., lj.2m.3g.4d.5g., lp.2m.3g.4d.5g., la.2o.3g.4d.5g., lb.2o.3g.4d.5g., lf.2o.3g.4d.5g., lh.2o.3g.4d.5g., lj.2o.3g.4d.5g., lp.2o.3g.4d.5g., la.2u.3g.4d.5g., lb.2u.3g.4d.5g., lf.2u.3g.4d.5g., lh.2u.3g.4d.5g., lj.2u.3g.4d.5g., lp.2u.3g.4d.5g., la.2y.3g.4d.5g., lb.2y.3g.4d.5g., lf.2y.3g.4d.5g., lh.2y.3g.4d.5g., lj.2y.3g.4d.5g-, lp.2y.3g.4d.5g., la.2a.3a.4f.5g., lb.2a.3a.4f.5g., lf.2a.3a.4f.5g., lh.2a.3a.4f.5g., lj.2a.3a.4f.5g., lp.2a.3a.4f.5g., la.2b.3a.4f.5g., lb.2b.3a.4f.5g., lf.2b.3a.4f.5g., lh.2b.3a.4f.5g., lj.2b.3a.4f.5g., lp.2b.3a.4f.5g., la.2e.3a.4f.5g., lb.2e.3a.4f.5g., lf.2e.3a.4f.5g., lh.2e.3a.4f.5g., lj.2e.3a.4f.5g., lp.2e.3a.4f.5g., la.2f.3a.4f.5g., lb.2f.3a.4f.5g., lf.2f.3a.4f.5g., lh.2f.3a.4f.5g., lj.2f.3a.4f.5g., lp.2f.3a.4f.5g., la.2i.3a.4f.5g., lb.2i.3a.4f.5g., lf.2i.3a.4f.5g., lh.2i.3a.4f.5g., lj.2i.3a.4f.5g., lp.2i.3a.4f.5g., la.2m.3a.4f.5g., lb.2m.3a.4f.5g., lf.2m.3a.4f.5gv lh.2m.3a.4f.5g., lj.2m.3a.4f.5g., lp.2m.3a.4f.5g., la.2o.3a.4f.5g., lb.2o.3a.4f.5g., If .2o.3a.4£.5g., lh.2o.3a.4f.5g., lj.2o.3a.4f.5g., lp.2o.3a.4f.5g., la.2u.3a.4f.5gv lb.2u.3a.4f.5g., lf.2u.3a.4f.5gv lh.2u.3a.4f.5g., lj.2u.3a.4f.5g., lp.2u.3a.4f.5g., la.2y.3a.4f.5g., lb.2y.3a.4f.5g., lf.2y.3a.4f.5g., lh.2y.3a.4f.5g., lj.2y.3a.4f.5g., lp.2y.3a.4f.5g., la.2a.3b.4f.5g., lb.2a.3b.4f.5g., lf.2a.3b.4f.5g., lh.2a.3b.4f.5g., lj.2a.3b.4f.5g., lp.2a.3b.4f.5g., la.2b.3b.4f.5g., lb.2b.3b.4f.5g., lf.2b.3b.4f.5g., lh.2b.3b.4f.5g., lj.2b.3b.4f.5g., lp.2b.3b.4f.5g., la.2e.3b.4f.5g., lb.2e.3b.4f.5g., lf.2e.3b.4f.5g., lh.2e.3b.4f.5g., lj.2e.3b.4f.5g., lp.2e.3b.4f.5g., la.2f.3b.4f.5g., lb.2f.3b.4f.5g., lf.2f.3b.4f.5g., lh.2f.3b.4f.5g., lj.2f.3b.4f.5g., lp.2f.3b.4f.5g., la.2i.3b.4f.5g., lb.2i.3b.4f.5g., lf.2i.3b.4f.5g., lh.2i.3b.4f.5g., lj.2i.3b.4f.5g., lp.2i.3b.4f.5g., la.2m.3b.4f.5g., lb.2m.3b.4f.5g., lf.2m.3b.4f.5g., lh.2m.3b.4f.5g., lj.2m.3b.4f.5g., lp.2m.3b.4f.5g., la.2o.3b.4f.5gv lb.2o.3b.4f.5gv lf.2o.3b.4f.5g.y lh.2o.3b.4f.5g., lj.2o.3b.4f.5g., lp.2o.3b.4f.5g., la.2u.3b.4f.5g., lb.2u.3b.4f.5g., lf.2u.3b.4f.5g., lh.2u.3b.4f.5g., lj.2u.3b.4f.5g., lp.2u.3b.4f.5g., la.2y.3b.4f.5g., lb.2y.3b.4f.5g., lf.2y.3b.4f.5g., lh.2y.3b.4f.5g., lj.2y.3b.4f.5g., lp.2y.3b.4f.5g., la.2a.3e.4f.5g., lb.2a.3e.4f.5g., lf.2a.3e.4f.5g., lh.2a.3e.4f.5g., lj.2a.3e.4f.5g., lp.2a.3e.4f.5g., la.2b.3e.4f.5g., lb.2b.3e.4f.5g., lf.2b.3e.4f.5g., lh.2b.3e.4f.5g., lj.2b.3e.4f.5g., lp.2b.3e.4f.5g., la.2e.3e.4f.5g., lb.2e.3e.4f.5g., lf.2e.3e.4f.5g., lh.2e.3e.4f.5g., lj.2e.3e.4f.5g., lp.2e.3e.4f.5g., la.2f.3e.4f.5g., lb.2f.3e.4f.5g., lf.2f.3e.4f.5g., lh.2f.3e.4f.5g., lj.2f.3e.4f.5g., lp.2f.3e.4f.5g., la.2i.3e.4f.5g., lb.2i.3e.4f.5g., lf.2i.3e.4f.5g., lh.2i.3e.4f.5g., lj.2i.3e.4f.5g., lp.2i.3e.4f.5g-, la.2m.3e.4f.5g., lb.2m.3e.4f.5g., lf.2m.3e.4f.5g., lh.2m.3e.4f.5g., lj.2m.3e.4f.5g., lp.2m.3e.4f.5g., la.2o.3e.4f.5g., lb.2o.3e.4f.5g., lf.2o.3e.4f.5g., lh.2o.3e.4f.5g., lj.2o.3e.4f.5g., lp.2o.3e.4f.5g., la.2u.3e.4f.5g., lb.2u.3e.4f.5g., lf.2u.3e.4f.5g., lh.2u.3e.4f.5g., lj.2u.3e.4f.5g., lp.2u.3e.4f.5g., la.2y.3e.4f.5g., lb.2y.3e.4f.5g., lf.2y.3e.4f.5g., lh.2y.3e.4f.5g., lj.2y.3e.4f.5g., lp.2y.3e.4f.5g., la.2a.3g.4f.5g., lb.2a.3g.4f.5g., lf.2a.3g.4f.5g., lh.2a.3g.4f.5g., lj.2a.3g.4f.5g., lp.2a.3g.4f.5g., la.2b.3g.4f.5g., lb.2b.3g.4f.5gv lf.2b.3g.4f.5g., lh.2b.3g.4f.5g., lj.2b.3g.4f.5g., lp.2b.3g.4f.5g., la.2e.3g.4f.5g., lb.2e.3g.4f.5g., lf.2e.3g.4f.5g., lh.2e.3g.4f.5g., lj.2e.3g.4f.5g., lp.2e.3g.4f.5g., la.2f.3g.4f.5g., lb.2f.3g.4f.5g., lf.2f.3g.4f.5g., lh.2f.3g.4f.5g., lj.2f.3g.4f.5g., lp.2f.3g.4f.5g., la.2i.3g.4f.5g., lb.2i.3g.4f.5g., lf.2i.3g.4f.5g., lh.2i.3g.4f.5g., lj.2i.3g.4f.5g., lp.2i.3g.4f.5g., la.2m.3g.4f.5g., lb.2m.3g.4f.5g., lf.2m.3g.4f.5g., lh.2m.3g.4f.5g., lj.2m.3g.4f.5g., lp.2m.3g.4f.5g., la.2o.3g.4f.5g., lb.2o.3g.4f.5g., lf.2o.3g.4f.5g., lh.2o.3g.4f.5g., lj.2o.3g.4f.5g., lp.2o.3g.4f.5g., la.2u.3g.4f.5g., lb.2u.3g.4£.5g., lf.2u.3g.4f.5g., lh.2u.3g.4f.5g., lj.2u.3g.4f.5g., lp.2u.3g.4f.5g., la.2y.3g.4f.5g., lb.2y.3g.4f.5g., lf.2y.3g.4f.5g., lh.2y.3g.4f.5g., lj.2y.3g.4f.5g., lp.2y.3g.4f.5g., la.2a.3a.4g.5g., lb.2a.3a.4g.5gv lf.2a.3a.4g.5g., lh.2a.3a.4g.5g., lj.2a.3a.4g.5g., lp.2a.3a.4g.5g., la.2b.3a.4g.5g., lb.2b.3a.4g.5g., lf.2b.3a.4g.5g., lh.2b.3a.4g.5g., lj.2b.3a.4g.5g., lp.2b.3a.4g.5g., la.2e.3a.4g.5g., lb.2e.3a.4g.5g., lf.2e.3a.4g.5g., lh.2e.3a.4g.5g., lj.2e.3a.4g.5g., lp.2e.3a.4g.5g., la.2f.3a.4g.5g., lb.2f.3a.4g.5g., lf.2f.3a.4g.5g., lh.2f.3a.4g.5g., lj.2f.3a.4g.5g., lp.2f.3a.4g.5g., la.2i.3a.4g.5g., lb.2i.3a.4g.5gv lf.2i.3a.4g.5g., lh.2i.3a.4g.5g., lj.2i.3a.4g.5g., lp.2i.3a.4g.5g., la.2m.3a.4g.5g., lb.2m.3a.4g.5g., lf.2m.3a.4g.5g., lh.2m.3a.4g.5g., lj.2m.3a.4g.5gv lp.2m.3a.4g.5g., la.2o.3a.4g.5g., lb.2o.3a.4g.5g., lf.2o.3a.4g.5g., lh.2o.3a.4g.5g., lj.2o.3a.4g.5g., lp.2o.3a.4g.5g., la.2u.3a.4g.5gv lb.2u.3a.4g.5g., lf.2u.3a.4g.5g., lh.2u.3a.4g.5g., lj.2u.3a.4g.5gv lp.2u.3a.4g.5g., la.2y.3a.4g.5g., lb.2y.3a.4g.5g., lf.2y.3a.4g.5g., lh.2y.3a.4g.5g., lj.2y.3a.4g.5g., lp.2y.3a.4g.5g., la.2a.3b.4g.5g., lb.2a.3b.4g.5g., lf.2a.3b.4g.5g.Λ lh.2a.3b.4g.5g., lj.2a.3b.4g.5g., lp.2a.3b.4g.5g., la.2b.3b.4g.5g., lb.2b.3b.4g.5g., lf.2b.3b.4g.5gv lh.2b.3b.4g.5g., lj.2b.3b.4g.5g., lp.2b.3b.4g.5g., la.2e.3b.4g.5gv lb.2e.3b.4g.5g., lf.2e.3b.4g.5g., lh.2e.3b.4g.5g., lj.2e.3b.4g.5g., lp.2e.3b.4g.5g., la.2f.3b.4g.5g., lb.2f.3b.4g.5g., lf.2f.3b.4g.5g., lh.2f.3b.4g.5g., lj.2f.3b.4g.5g., lp.2f.3b.4g.5g., la.2i.3b.4g.5g., lb.2i.3b.4g.5g., lf.2i.3b.4g.5g., lh.2i.3b.4g.5g., lj.2i.3b.4g.5g., lp.2i.3b.4g.5g., la.2m.3b.4g.5g., lb.2m.3b.4g.5g., lf.2m.3b.4g.5gv lh.2m.3b.4g.5g., lj.2m.3b.4g.5g., lp.2m.3b.4g.5g., la.2o.3b.4g.5g., lb.2o.3b.4g.5g., lf.2o.3b.4g.5g., lh.2o.3b.4g.5g., lj.2o.3b.4g.5g., lp.2o.3b.4g.5g., la.2u.3b.4g.5g., lb.2u.3b.4g.5g., lf.2u.3b.4g.5g., lh.2u.3b.4g.5g., lj.2u.3b.4g.5g., lp,2u.3b.4g.5g., la.2y.3b.4g.5g., lb.2y.3b.4g.5g., lf.2y.3b.4g.5g., lh.2y.3b.4g.5g., lj.2y.3b.4g.5g., lp.2y.3b.4g.5g., la.2a.3e.4g.5g., lb.2a.3e.4g.5g., lf.2a.3e.4g.5g., lh.2a.3e.4g.5g., lj.2a.3e.4g.5g., lp.2a.3e.4g.5g., la.2b.3e.4g.5g., lb.2b.3e.4g.5g., lf.2b.3e.4g.5g., lh.2b.3e.4g.5g., lj.2b.3e.4g.5g., lp.2b.3e.4g.5g., la.2e.3e.4g.5g., lb.2e.3e.4g.5g., lf.2e.3e.4g.5g., lh.2e.3e.4g.5g., lj.2e.3e.4g.5g., lp.2e.3e.4g.5g., la.2f.3e.4g.5g., lb.2f.3e.4g.5g., lf.2f.3e.4g.5g., lh.2f.3e.4g.5g., lj.2f.3e.4g.5g., lp.2f.3e.4g.5g., la.2i.3e.4g.5g., lb.2i.3e.4g.5g., lf.2i.3e.4g.5g., lh.2i.3e.4g.5g., lj.2i.3e.4g.5g., lp.2i.3e.4g.5g., la.2m.3e.4g.5g., lb.2m.3e.4g.5g., lf.2m.3e.4g.5g., lh.2m.3e.4g.5g., lj.2m.3e.4g.5g., lp.2m.3e.4g.5g., la.2o.3e.4g.5g., lb.2o.3e.4g.5g., lf.2o.3e.4g.5g., lh.2o.3e.4g.5g., lj.2o.3e.4g.5g., lp.2o.3e.4g.5g., la.2u.3e.4g.5g., lb.2u.3e.4g.5g., lf.2u.3e.4g.5g., lh.2u.3e.4g.5g., lj.2u.3e.4g.5g., lp.2u.3e.4g.5g., la.2y.3e.4g.5g., lb.2y.3e.4g.5g., lf.2y.3e.4g.5g., lh.2y.3e.4g.5g., lj.2y.3e.4g.5g., lp.2y.3e.4g.5g., la.2a.3g.4g.5g., lb.2a.3g.4g.5g., lf.2a.3g.4g.5g., lh.2a.3g.4g.5g., lj.2a.3g.4g.5g., lp.2a.3g.4g.5g., la.2b.3g.4g.5g., lb.2b.3g.4g.5gv lf.2b.3g.4g.5g., lh.2b.3g.4g.5g., lj.2b.3g.4g.5g., lp.2b.3g.4g.5g., la.2e.3g.4g.5g., lb.2e.3g.4g.5g., lf.2e.3g.4g.5g., lh.2e.3g.4g.5g., lj.2e.3g.4g.5g., lp.2e.3g.4g.5g., la.2f.3g.4g.5g., lb.2f.3g.4g.5g., lf.2f.3g.4g.5g., lh.2f.3g.4g.5g., lj.2f.3g.4g.5g., lp.2f.3g.4g.5g., la.2i.3g.4g.5g., lb.2i.3g.4g.5g., lf.2i.3g.4g.5g., lh.2i.3g.4g.5g., lj.2i.3g.4g.5g., lp.2i.3g.4g.5g., la.2m.3g.4g.5g., lb.2m.3g.4g.5g., lf.2m.3g.4g.5g., lh.2m.3g.4g.5g., lj.2m.3g.4g.5g., lp.2m.3g.4g.5g., la.2o.3g.4g.5g., lb.2o.3g.4g.5g., lf.2o.3g.4g.5g., lh.2o.3g.4g.5g., lj.2o.3g.4g.5g., lp.2o.3g.4g.5g., la.2u.3g.4g.5g., lb.2u.3g.4g.5g., lf.2u.3g.4g.5g., lh.2u.3g.4g.5g., lj.2u.3g.4g.5g., lp.2u.3g.4g.5g., la.2y.3g.4g.5g., lb.2y.3g.4g.5g., If .2y.3g.4g.5g., lh.2y.3g.4g.5g., lj.2y.3g.4g.5g., lp.2y.3g.4g.5g., la.2a.3a.4h.5g., lb.2a.3a.4h.5gv lf.2a.3a.4h.5g., lh.2a.3a.4h.5g., lj.2a.3a.4h.5g., lp.2a.3a.4h.5g., la.2b.3a.4h.5g., lb.2b.3a.4h.5g., lf.2b.3a.4h.5g., lh.2b.3a.4h.5g., lj.2b.3a.4h.5g., lp.2b.3a.4h.5g., la.2e.3a.4h.5g., lb.2e.3a.4h.5g., lf.2e.3a.4h.5gv lh.2e.3a.4h.5g., lj.2e.3a.4h.5g., lp.2e.3a.4h.5g., la.2f.3a.4h.5g., lb.2f.3a.4h.5g., lf.2f.3a.4h.5g., lh.2f.3a.4h.5g., lj.2f.3a.4h.5g., lp.2f.3a.4h.5g., la.2i.3a.4h.5gv lb.2i.3a.4h.5g., lf.2i.3a.4h.5gv lh.2i.3a.4h.5g., lj.2i.3a.4h.5g., lp.2i.3a.4h.5g., la.2m.3a.4h.5g., lb.2m.3a.4h.5g., lf.2m.3a.4h.5g., lh.2m.3a.4h.5g., lj.2m.3a.4h.5g., lρ.2m.3a.4h.5g., la.2o.3a.4h.5g., lb.2o.3a.4h.5g., lf.2o.3a.4h.5g., lh.2o.3a.4h.5g., lj.2o.3a.4h.5g., lp.2o.3a.4h.5gv la.2u.3a.4h.5g., lb.2u.3a.4h.5g., lf.2u.3a.4h.5g., lh.2u.3a.4h.5g., lj.2u.3a.4h.5gv lp.2u.3a.4h.5g., la.2y.3a.4h.5g., lb.2y.3a.4h.5g., lf.2y.3a.4h.5g., lh.2y.3a.4h.5g., lj.2y.3a.4h.5g., lp.2y.3a.4h.5g., la.2a.3b.4h.5g., lb.2a.3b.4h.5g., lf.2a.3b.4h.5g., lh.2a.3b.4h.5g., lj.2a.3b.4h.5g., lp.2a.3b.4h.5g., la.2b.3b.4h.5g., lb.2b.3b.4h.5g., lf.2b.3b.4h.5g., lh.2b.3b.4h.5g., lj.2b.3b.4h.5g., lp.2b.3b.4h.5g., la.2e.3b.4h.5g., lb.2e.3b.4h.5g., lf.2e.3b.4h.5g., lh.2e.3b.4h.5g.y lj.2e.3b.4h.5g., lp.2e.3b.4h.5g., la.2f.3b.4h.5g., lb.2f.3b.4h.5g., lf.2f.3b.4h.5g., lh.2f.3b.4h.5g., lj.2f.3b.4h.5g., lp.2f.3b.4h.5g., la.2i.3b.4h.5g., lb.2i.3b.4h.5g., lf.2i.3b.4h.5g., lh.2i.3b.4h.5g., lj.2i.3b.4h.5g., lp.2i.3b.4h.5g., la.2m.3b.4h.5g., lb.2m.3b.4h.5g., lf.2m.3b.4h.5g., lh.2m.3b.4h.5g., lj.2m.3b.4h.5g., lp.2m.3b.4h.5g., la.2o.3b.4h.5g-, lb.2o.3b.4h.5gv lf.2o.3b.4h.5g., lh.2o.3b.4h.5g., lj.2o.3b.4h.5g., lp.2o.3b.4h.5g., la.2u.3b.4h.5g., lb.2u.3b.4h.5g., lf.2u.3b.4h.5g., lh.2u.3b.4h.5g., lj.2u.3b.4h.5g., lp.2u.3b.4h.5g., la.2y.3b.4h.5g., lb.2y.3b.4h.5g., lf.2y.3b.4h.5g., lh.2y.3b.4h.5g., lj.2y.3b.4h.5g., lp.2y.3b.4h.5g., la.2a.3e.4h.5g., lb.2a.3e.4h.5g., lf.2a.3e.4h.5g., lh.2a.3e.4h.5g., lj.2a.3e.4h.5g., lp.2a.3e.4h.5gv la.2b.3e.4h.5g., lb.2b.3e.4h.5g., lf.2b.3e.4h.5g., lh.2b.3e.4h.5g., lj.2b.3e.4h.5g., lp.2b.3e.4h.5g., la.2e.3e.4h.5g., lb.2e.3e.4h.5g., lf.2e.3e.4h.5g., lh.2e.3e.4h.5g., lj.2e.3e.4h.5g., lp.2e.3e.4h.5g., la.2f.3e.4h.5g., lb.2f.3e.4h.5g., lf.2f.3e.4h.5gv lh.2f.3e.4h.5g., lj.2f.3e.4h.5g., lp.2f.3e.4h.5g., la.2i.3e.4h.5g., lb.2i.3e.4h.5g., lf.2i.3e.4h.5g., lh.2i.3e.4h.5g., lj.2i.3e.4h.5g., lp.2i.3e.4h.5g., la.2m.3e.4h.5g., lb.2m.3e.4h.5g., lf.2m.3e.4h.5g., lh.2m.3e.4h.5g., lj.2m.3e.4h.5g., lp.2m.3e.4h.5g., la.2o.3e.4h.5g., lb.2o.3e.4h.5g., lf.2o.3e.4h.5g., lh.2o.3e.4h.5g., lj.2o.3e.4h.5g., lp.2o.3e.4h.5g., la.2u.3e.4h.5g., lb.2u.3e.4h.5g., lf.2u.3e.4h.5g., lh.2u.3e.4h.5g., lj.2u.3e.4h.5g., lp.2u.3e.4h.5g., la.2y.3e.4h.5g., lb.2y.3e.4h.5g., lf.2y.3e.4h.5g., lh.2y.3e.4h.5g., lj.2y.3e.4h.5g., lp.2y.3e.4h.5g., la.2a.3g.4h.5g., lb.2a.3g.4h.5g., lf.2a.3g.4h.5g., lh.2a.3g.4h.5gv lj.2a.3g.4h.5g., lp.2a.3g.4h.5g., la.2b.3g.4h.5g., lb.2b.3g.4h.5g., lf.2b.3g.4h.5g., lh.2b.3g.4h.5g., lj.2b.3g.4h.5g., lp.2b.3g.4h.5g., la.2e.3g.4h.5g., lb.2e.3g.4h.5g., lf.2e.3g.4h.5g., lh.2e.3g.4h.5g., lj.2e.3g.4h.5g., lp.2e.3g.4h.5g., la.2f.3g.4h.5gv lb.2f.3g.4h.5g., lf.2f.3g.4h.5g., lh.2f.3g.4h.5g., lj.2f.3g.4h.5g., lp.2f.3g.4h.5g., la.2i.3g.4h.5g., lb.2i.3g.4h.5g., lf.2i.3g.4h.5g., lh.2i.3g.4h.5g., lj.2i.3g.4h.5g., lp.2i.3g.4h.5g., la.2m.3g.4h.5gv lb.2m.3g.4h.5g., lf.2m.3g.4h.5g., lh.2m.3g.4h.5g., lj.2m.3g.4h.5g., lp.2m.3g.4h.5g., la.2o.3g.4h.5g., lb.2o.3g.4h.5g., lf.2o.3g.4h.5g., lh.2o.3g.4h.5g., lj.2o.3g.4h.5g., lp.2o.3g.4h.5g., la.2u.3g.4h.5g., lb.2u.3g.4h.5g., lf.2u.3g.4h.5g., lh.2u.3g.4h.5g., lj.2u.3g.4h.5g., lp.2u.3g.4h.5g., la.2y.3g.4h.5g., lb.2y.3g.4h.5g., lf.2y.3g.4h.5g., lh.2y.3g.4h.5g., lj.2y.3g.4h.5g., lp.2y.3g.4h.5g., la.2a.3a.4i.5g., lb.2a.3a.4i.5g., lf.2a.3a.4i.5gv lh.2a.3a.4i.5g., lj.2a.3a.4i.5g., lp.2a.3a.4i.5g., la.2b.3a.4i.5g., lb.2b.3a.4i.5g., lf.2b.3a.4L5g., lh.2b.3a.4i.5g., lj.2b.3a.4i.5g., lp.2b.3a.4i.5g., la.2e.3a.4i.5gv lb.2e.3a.4i.5g., lf.2e.3a.4i.5g., lh.2e.3a.4i.5g., lj.2e.3a.4i.5g., lp.2e.3a.4i.5g., la.2f.3a.4i.5g., lb.2f.3a.4i.5gv lf.2f.3a.4i.5g., lh.2f.3a.4i.5g., lj.2f.3a.4i.5g., lp.2f.3a.4i.5g., la.2i.3a.4i.5g., lb.2i.3a.4i.5g., lf.2i.3a.4i.5g., lh.2i.3a.4i.5g., lj.2i.3a.4i.5g., lp.2i.3a.4i.5g., la.2m.3a.4i.5g., lb.2m.3a.4i.5gv lf.2m.3a.4i.5g., lh.2m.3a.4i.5g-, lj.2m.3a.4i.5g., lp.2m.3a.4i.5g., la.2o.3a.4i.5g., lb.2o.3a.4i.5g., lf.2o.3a.4i.5g., lh.2o.3a.4i.5g., lj.2o.3a.4i.5g., lp.2o.3a.4i.5g., la.2u.3a.4i.5g., lb.2u.3a.4i.5g., lf.2u.3a.4i.5g., lh.2u.3a.4i.5g., lj.2u.3a.4i.5g., lp.2u.3a.4i.5g-, la.2y.3a.4i.5g., lb.2y.3a.4i.5g., lf.2y.3a.4i.5g-, lh.2y.3a.4i.5g., lj.2y.3a.4i.5gv lp.2y.3a.4i.5g., la.2a.3b.4i.5g., lb.2a.3b.4i.5gv lf.2a.3b.4i.5g., lh.2a.3b.4i.5g-, lj.2a.3b.4i.5g., lp.2a.3b.4i.5g., la.2b.3b.4i.5g-, lb.2b.3b.4i.5g., lf.2b.3b.4i.5g., lh.2b.3b.4i.5g., lj.2b.3b.4i.5g., lp.2b.3b.4i.5g., la.2e.3b.4i.5g., lb.2e.3b.4i.5g., lf.2e.3b.4i.5g., lh.2e.3b.4i.5g., lj.2e.3b.4i.5g., lp.2e.3b.4i.5g., la.2f.3b.4i.5g., lb.2f.3b.4i.5g., lf.2f.3b.4i.5g., lh.2f.3b.4i.5g-, lj.2f.3b.4i.5g., lp.2f.3b.4i.5g., la.2i.3b.4i.5g., lb.2i.3b.4i.5g., lf.2i.3b.4i.5g-, lh.2i.3b.4i.5g., lj.2i.3b.4i.5g., lp.2i.3b.4i.5g., la.2m.3b.4i.5g., lb.2m.3b.4i.5g., lf.2m.3b.4i.5g., lh.2m.3b.4i.5g-, lj.2m.3b.4i.5g., lp.2m.3b.4i.5g., la.2o.3b.4i.5g-, lb.2o.3b.4i.5g., lf.2o.3b.4i.5g., lh.2o.3b.4i.5g., lj.2o.3b.4i.5g-, lp.2o.3b.4i.5g., la.2u.3b.4i.5g., lb.2u.3b.4i.5g., lf.2u.3b.4i.5g., lh.2u.3b.4i.5g., lj.2u.3b.4i.5g., lp.2u.3b.4i.5g., la.2y.3b.4i.5g., lb.2y.3b.4i.5g., lf.2y.3b.4i.5g., lh.2y.3b.4i.5g., lj.2y.3b.4i.5g., lp.2y.3b.4i.5g., la.2a.3e.4i.5g., lb.2a.3e.4i.5g., lf.2a.3e.4i.5g., lh.2a.3e.4i.5g., lj.2a.3e.4i.5g., lp.2a.3e.4i.5g., la.2b.3e.4i.5g., lb.2b.3e.4i.5g., lf.2b.3e.4i.5gv lh.2b.3e.4i.5g., lj.2b.3e.4i.5g., lp.2b.3e.4i.5g., la.2e.3e.4L5g., lb.2e.3e.4i.5g., lf.2e.3e.4i.5g., lh.2e.3e.4i.5g., lj.2e.3e.4i.5g., lp.2e.3e.4i.5g., la.2f.3e.4i.5g., lb.2f.3e.4i.5g-, lf.2f.3e.4i.5g., lh.2f.3e.4i.5g., lj.2f.3e.4i.5g., lp.2f.3e.4i.5g., la.2i.3e.4i.5g., lb.2i.3e.4i.5g., lf.2i.3e.4i.5g., lh.2i.3e.4i.5g., lj.2i.3e.4i.5g., lp.2i.3e.4i.5g., la.2m.3e.4i.5g-, lb.2m.3e.4i.5g., lf.2m.3e.4i.5g., lh.2m.3e.4i.5g., lj.2m.3e.4i.5g., lp.2m.3e.4i.5g-, la.2o.3e.4i.5g., lb.2o.3e.4i.5g-, lf.2o.3e.4i.5g., lh.2o.3e.4i.5g., lj.2o.3e.4i.5g., lp.2o.3e.4i.5g., la.2u.3e.4i.5g., lb.2u.3e.4i.5g., lf.2u.3e.4i.5g., lh.2u.3e.4i.5g., lj.2u.3e.4i.5g., lp.2u.3e.4i.5g., la.2y.3e.4i.5g., lb.2y.3e.4i.5g., lf.2y.3e.4i.5g., lh.2y.3e.4i.5g., lj.2y.3e.4i.5g., lp.2y.3e.4i.5g., la.2a.3g.4i.5g., lb.2a.3g.4i.5g., lf.2a.3g.4i.5g., lh.2a.3g.4i.5g., lj.2a.3g.4i.5g., lp.2a.3g.4i.5g., la.2b.3g.4i.5g., lb.2b.3g.4i.5g., lf.2b.3g.4i.5g., lh.2b.3g.4i.5g., lj.2b.3g.4i.5g., lp.2b.3g.4i.5g., la.2e.3g.4i.5g., lb.2e.3g.4i.5g., lf.2e.3g.4i.5g., lh.2e.3g.4i.5g., lj.2e.3g.4i.5g., lp.2e.3g.4i.5g., la.2f.3g.4i.5g., lb.2f.3g.4i.5g., lf.2f.3g.4i.5g., lh.2f.3g.4i.5g., lj.2f.3g.4i.5g., lp.2f.3g.4i.5g., la.2i.3g.4i.5g., lb.2i.3g.4i.5g., lf.2i.3g.4i.5g., lh.2i.3g.4i.5g., lj.2i.3g.4i.5g., lp.2i.3g.4i.5g., la.2m.3g.4i.5g., lb.2m.3g.4i.5g-, lf.2m.3g.4i.5g., lh.2m.3g.4i.5g., lj.2m.3g.4i.5g., lp.2m.3g.4i.5g., la.2o.3g.4i.5g., lb.2o.3g.4i.5g., lf.2o.3g.4i.5g., lh.2o.3g.4i.5g., lj.2o.3g.4i.5g., lp.2o.3g.4i.5g., la.2u.3g.4i.5g., lb.2u.3g.4i.5g., lf.2u.3g.4i.5g., lh.2u.3g.4i.5g., lj.2u.3g.4i.5g., lp.2u.3g.4i.5g., la.2y.3g.4i.5g., lb.2y.3g.4i.5g., lf.2y.3g.4i.5gv lh.2y.3g.4i.5gv lj.2y.3g.4i.5gv lp.2y.3g.4i.5gv la.2a.3a.4a.5h., lb.2a.3a.4a.5h., lf.2a.3a.4a.5h., lh.2a.3a.4a.5h., lj.2a.3a.4a.5h., lp.2a.3a.4a.5h., la.2b.3a.4a.5h., lb.2b.3a.4a.5h., lf.2b.3a.4a.5hv lh.2b.3a.4a.5hv lj.2b.3a.4a.5h., lp.2b.3a.4a.5h., la.2e.3a.4a.5h., lb.2e.3a.4a.5h., lf.2e.3a.4a.5h., lh.2e.3a.4a.5h., lj.2e.3a.4a.5h., lp.2e.3a.4a.5h., la.2f.3a.4a.5h., lb.2f.3a.4a.5h., lf.2f.3a.4a.5h., lh.2£.3a.4a.5h., lj.2f.3a.4a.5h., lp.2f.3a.4a.5h., la.2i.3a.4a.5h., lb.2L3a.4a.5h., lf.2i.3a.4a.5h., lh.2i.3a.4a.5h., lj.2i.3a.4a.5hv lp.2i.3a.4a.5h., la.2m.3a.4a.5h., lb.2m.3a.4a.5h., lf.2m.3a.4a.5h., lh.2m.3a.4a.5h., lj.2m.3a.4a.5h., lp.2m.3a.4a.5h., la.2o.3a.4a.5h., lb.2o.3a.4a.5h., lf.2o.3a.4a.5h., lh.2o.3a.4a.5h., lj.2o.3a.4a.5h., lp.2o.3a.4a.5h., la.2u.3a.4a.5h., lb.2u.3a.4a.5hv lf.2u.3a.4a.5h., lh.2u.3a.4a.5h., lj.2u.3a.4a.5h., lp.2u.3a.4a.5h., la.2y.3a.4a.5h., lb.2y.3a.4a.5h., lf.2y.3a.4a.5h., lh.2y.3a.4a.5hv lj.2y.3a.4a.5h., lp.2y.3a.4a.5h., la.2a.3b.4a.5h., lb.2a.3b.4a.5h., lf.2a.3b.4a.5h., lh.2a.3b.4a.5h., lj.2a.3b.4a.5h., lp.2a.3b.4a.5h., la.2b.3b.4a.5h., lb.2b.3b.4a.5h., lf.2b.3b.4a.5h., lh.2b.3b.4a.5h., lj.2b.3b.4a.5h., lp.2b.3b.4a.5h., la.2e.3b.4a.5h., lb.2e.3b.4a.5h., lf.2e.3b.4a.5hv lh.2e.3b.4a.5h., lj.2e.3b.4a.5h., lp.2e.3b.4a.5h., la.2f.3b.4a.5h., lb.2f.3b.4a.5h., lf.2f.3b.4a.5h., lh.2f.3b.4a.5h., lj.2f.3b.4a.5h., lp.2f.3b.4a.5h., la.2i.3b.4a.5h., lb.2i.3b.4a.5h., lf.2i.3b.4a.5h., lh.2i.3b.4a.5h., lj.2i.3b.4a.5h., lp.2i.3b.4a.5h., la.2m.3b.4a.5h., lb.2m.3b.4a.5h., lf.2m.3b.4a.5h., lh.2m.3b.4a.5h., lj.2m.3b.4a.5h., lp.2m.3b.4a.5h., Ia.2o3b.4a.5h., lb.2o.3b.4a.5h., lf.2o.3b.4a.5h., lh.2o.3b.4a.5h., lj.2o.3b.4a.5h., lp.2o.3b.4a.5h., la.2u.3b.4a.5h., lb.2u.3b.4a.5h., lf.2u.3b.4a.5h., lh.2u.3b.4a.5h., lj.2u.3b.4a.5h., lp.2u.3b.4a.5h., la.2y.3b.4a.5h., lb.2y.3b.4a.5h., lf.2y.3b.4a.5h., lh.2y.3b.4a.5h., lj.2y.3b.4a.5h., lp.2y.3b.4a.5h., la.2a.3e.4a.5h., lb.2a.3e.4a.5h., lf.2a.3e.4a.5hv lh.2a.3e.4a.5h., lj.2a.3e.4a.5h., lp.2a.3e.4a.5h., la.2b.3e.4a.5h., lb.2b.3e.4a.5h., lf.2b.3e.4a.5h., lh.2b.3e.4a.5h., lj.2b.3e.4a.5h., lp.2b.3e.4a.5h., la.2e.3e.4a.5h., lb.2e.3e.4a.5h., lf.2e.3e.4a.5h., lh.2e.3e.4a.5h., lj.2e.3e.4a.5h., lp.2e.3e.4a.5h., la.2f.3e.4a.5h., lb.2f.3e.4a.5h., lf.2f.3e.4a.5h., lh.2f.3e.4a.5h., lj.2f.3e.4a.5h., lp.2f.3e.4a.5h., la.2i.3e.4a.5h., lb.2i.3e.4a.5h., lf.2i.3e.4a.5h., lh.2i.3e.4a.5h., lj.2i.3e.4a.5h., lp.2i.3e.4a.5h., la.2m.3e.4a.5h., lb.2m.3e.4a.5h., lf.2m.3e.4a.5h., lh.2m.3e.4a.5h., lj.2m.3e.4a.5h., lp.2m.3e.4a.5h., la.2o.3e.4a.5h., lb.2o.3e.4a.5h., lf.2o.3e.4a.5h., lh.2o.3e.4a.5h., lj.2o.3e.4a.5h., lρ.2o.3e.4a.5h., la.2u.3e.4a.5h., lb.2u.3e.4a.5hv lf.2u.3e.4a.5h., lh.2u.3e.4a.5h., lj.2u.3e.4a.5h., lp.2u.3e.4a.5h., la.2y.3e.4a.5h., lb.2y.3e.4a.5h., lf.2y.3e.4a.5h., lh.2y.3e.4a.5h., lj.2y.3e.4a.5h., lp.2y.3e.4a.5h., la.2a.3g.4a.5h., lb.2a.3g.4a.5h., lf.2a.3g.4a.5h., lh.2a.3g.4a.5h., lj.2a.3g.4a.5h., lp.2a.3g.4a.5h., la.2b.3g.4a.5h., lb.2b.3g.4a.5h., lf.2b.3g.4a.5h., lh.2b.3g.4a.5hv lj.2b.3g.4a.5h., lp.2b.3g.4a.5h., la.2e.3g.4a.5h., lb.2e.3g.4a.5h., lf.2e.3g.4a.5h., lh.2e.3g.4a.5h., lj.2e.3g.4a.5h., lp.2e.3g.4a.5h., la.2f.3g.4a.5h., lb.2f.3g.4a.5h., lf.2f.3g.4a.5h., lh.2f.3g.4a.5h., lj.2f.3g.4a.5h., lp.2f.3g.4a.5h., la.2i.3g.4a.5h., lb.2i.3g.4a.5h., lf.2i.3g.4a.5h., lh.2i.3g.4a.5h., lj.2i.3g.4a.5h., lp.2i.3g.4a.5h., la.2m.3g.4a.5h., lb.2m.3g.4a.5h., lf.2m.3g.4a.5h., lh.2m.3g.4a.5h., lj.2m.3g.4a.5h., lρ.2m.3g.4a.5hv la.2o.3g.4a.5h., lb.2o.3g.4a.5h., lf.2o.3g.4a.5h., lh.2o.3g.4a.5hv lj.2o.3g.4a.5hv lp.2o.3g.4a.5h., la.2u.3g.4a.5h., lb.2u.3g.4a.5h., lf.2u.3g.4a.5h., lh.2u.3g.4a.5h., lj.2u.3g.4a.5h., lp.2u.3g.4a.5h., la.2y.3g.4a.5hv lb.2y.3g.4a.5h., lf.2y.3g.4a.5h., lh.2y.3g.4a.5h., lj.2y.3g.4a.5h., lp.2y.3g.4a.5h., la.2a.3a.4d.5h., lb.2a.3a.4d.5h., If .2a.3a.4d.5h., lh.2a.3a.4d.5h., lj.2a.3a.4d.5h., lp.2a.3a.4d.5h., la.2b.3a.4d.5h., lb.2b.3a.4d.5h., lf.2b.3a.4d.5h., lh.2b.3a.4d.5h., lj.2b.3a.4d.5h., lp.2b.3a.4d.5h., la.2e.3a.4d.5h., lb.2e.3a.4d.5h., lf.2e.3a.4d.5hv lh.2e.3a.4d.5h., lj.2e.3a.4d.5h., lp.2e.3a.4d.5h., la.2f.3a.4d.5hv lb.2f.3a.4d.5h., lf.2f.3a.4d.5h., lh.2f.3a.4d.5h., lj.2f.3a.4d.5h., lp.2f.3a.4d.5h., la.2i.3a.4d.5h., lb.2i.3a.4d.5h., lf.2i.3a.4d.5h., lh.2i.3a.4d.5h., lj.2i.3a.4d.5h., lp.2i.3a.4d.5h., la.2m.3a.4d.5h., lb.2m.3a.4d.5h., lf.2m.3a.4d.5h., lh.2m.3a.4d.5h., lj.2m.3a.4d.5h., lp.2m.3a.4d.5h., la.2o.3a.4d.5h., lb.2o.3a.4d.5h., lf.2o.3a.4d.5h., lh.2o.3a.4d.5h., lj.2o.3a.4d.5h., lp.2o.3a.4d.5h., la.2u.3a.4d.5h., lb.2u.3a.4d.5h., lf.2u.3a.4d.5h., lh.2u.3a.4d.5h., lj.2u.3a.4d.5h., lp.2u.3a.4d.5h., la.2y.3a.4d.5h., lb.2y.3a.4d.5h., lf.2y.3a.4d.5h., lh.2y.3a.4d.5h., lj.2y.3a.4d.5h., lp.2y.3a.4d.5h., la.2a.3b.4d.5h., lb.2a.3b.4d.5h., lf.2a.3b.4d.5h., lh.2a.3b.4d.5h., lj.2a.3b.4d.5h., lp.2a.3b.4d.5h., la.2b.3b.4d.5h., lb.2b.3b.4d.5h., lf.2b.3b.4d.5hv lh.2b.3b.4d.5h., lj.2b.3b.4d.5h., lp.2b.3b.4d.5h., la.2e.3b.4d.5h., lb.2e.3b.4d.5h., lf.2e.3b.4d.5h., lh.2e.3b.4d.5h., lj.2e.3b.4d.5h., lρ.2e.3b.4d.5h., la.2f.3b.4d.5h., lb.2f.3b.4d.5h., lf.2f.3b.4d.5h., lh.2f.3b.4d.5h., lj.2f.3b.4d.5h., lp.2f.3b.4d.5h., la.2i.3b.4d.5h., lb.2i.3b.4d.5h., lf.2i.3b.4d.5h., lh.2i.3b.4d.5h., lj.2i.3b.4d.5h., lp.2i.3b.4d.5hv la.2m.3b.4d.5h., lb.2m.3b.4d.5h., lf.2m.3b.4d.5h., lh.2m.3b.4d.5h., lj.2m.3b.4d.5h., lp.2m.3b.4d.5h., la.2o.3b.4d.5h., lb.2o.3b.4d.5h., lf.2o.3b.4d.5h., lh.2o.3b.4d.5h., lj.2o.3b.4d.5h., lp.2o.3b.4d.5h., la.2u.3b.4d.5h., lb.2u.3b.4d.5h., lf.2u.3b.4d.5h., lh.2u.3b.4d.5h., lj.2u.3b.4d.5h., lp.2u.3b.4d.5h., la.2y.3b.4d.5h., lb.2y.3b.4d.5h., lf.2y.3b.4d.5h., lh.2y.3b.4d.5h., lj.2y.3b.4d.5h., lp.2y.3b.4d.5h., la.2a.3e.4d.5h., lb.2a.3e.4d.5h., lf.2a.3e.4d.5h., lh.2a.3e.4d.5h., lj.2a.3e.4d.5h., lp.2a.3e.4d.5h., la.2b.3e.4d.5h., lb.2b.3e.4d.5h., lf.2b.3e.4d.5h., lh.2b.3e.4d.5hv lj.2b.3e.4d.5h., lp.2b.3e.4d.5h., la.2e.3e.4d.5h., lb.2e.3e.4d.5hv lf.2e.3e.4d.5h., lh.2e.3e.4d.5h., lj.2e.3e.4d.5h., lp.2e.3e.4d.5h., la.2f.3e.4d.5hv lb.2f.3e.4d.5h., lf.2f.3e.4d.5h., lh.2f.3e.4d.5h., lj.2f.3e.4d.5h., lp.2f.3e.4d.5h., la.2i.3e.4d.5h., lb.2i.3e.4d.5h., lf.2i.3e.4d.5h., lh.2i.3e.4d.5h., lj.2i.3e.4d.5h., lp.2i.3e.4d.5h., la.2m.3e.4d.5h., lb.2m.3e.4d.5h., lf.2m.3e.4d.5h., lh.2m.3e.4d.5h., lj.2m.3e.4d.5h., lp.2m.3e.4d.5h., la.2o.3e.4d.5h., lb.2o.3e.4d.5h., lf.2o.3e.4d.5h., lh.2o.3e.4d.5h., lj.2o.3e.4d.5h., lp.2o.3e.4d.5h., la.2u.3e.4d.5h., lb.2u.3e.4d.5h., lf.2u.3e.4d.5h., lh.2u.3e.4d.5h., lj.2u.3e.4d.5h., lp.2u.3e.4d.5h., la.2y.3e.4d.5h., lb.2y.3e.4d.5h., lf.2y.3e.4d.5h., lh.2y.3e.4d.5h., lj.2y.3e.4d.5h., lp.2y.3e.4d.5h., la.2a.3g.4d.5h., lb.2a.3g.4d.5h., lf.2a.3g.4d.5h., lh.2a.3g.4d.5h., lj.2a.3g.4d.5h., lp.2a.3g.4d.5h., la.2b.3g.4d.5h., lb.2b.3g.4d.5h., lf.2b.3g.4d.5h., lh.2b.3g.4d.5h., lj.2b.3g.4d.5K, lp.2b.3g.4d.5h., la.2e.3g.4d.5h., lb.2e.3g.4d.5h., lf.2e.3g.4d.5h., lh.2e.3g.4d.5h., lj.2e.3g.4d.5h., lp.2e.3g.4d.5hv la.2f.3g.4d.5h., lb.2f.3g.4d.5h., lf.2f.3g.4d.5h., lh.2f.3g.4d.5h., lj.2f.3g.4d.5h., lp.2f.3g.4d.5h., la.2i.3g.4d.5h., lb.2i.3g.4d.5h., lf.2i.3g.4d.5h., lh.2i.3g.4d.5h., lj.2i.3g.4d.5h., lp.2i.3g.4d.5h., la.2m.3g.4d.5h., lb.2m.3g.4d.5h., lf.2m.3g.4d.5h., lh.2m.3g.4d.5h., lj.2m.3g.4d.5h., lp.2m.3g.4d.5h., la.2o.3g.4d.5h., lb.2o.3g.4d.5h., lf.2o.3g.4d.5h., lh.2o.3g.4d.5hv lj.2o.3g.4d.5h., lp.2o.3g.4d.5h., la.2u.3g.4d.5h., lb.2u.3g.4d.5h., lf.2u.3g.4d.5h., lh.2u.3g.4d.5h., lj.2u.3g.4d.5h., lp.2u.3g.4d.5h., la.2y.3g.4d.5hv lb.2y.3g.4d.5hv lf.2y.3g.4d.5hv lh.2y.3g.4d.5h., lj.2y.3g.4d.5h., lp.2y.3g.4d.5h., la.2a.3a.4f.5hv lb.2a.3a.4f.5h., lf.2a.3a.4f.5h., lh.2a.3a.4f.5h., lj.2a.3a.4f.5h., lp.2a.3a.4f.5h., la.2b.3a.4f.5h., lb.2b.3a.4f.5h., lf.2b.3a.4f.5h., lh.2b.3a.4f.5h., lj.2b.3a.4f.5h., lp.2b.3a.4f.5h., la.2e.3a.4f.5h., lb.2e.3a.4f.5h., lf.2e.3a.4f.5h., lh.2e.3a.4f.5h., lj.2e.3a.4f.5h., lp.2e.3a.4f.5h., la.2f.3a.4f.5h., lb.2f.3a.4f.5h., lf.2f.3a.4f.5h., lh.2f.3a.4f.5h., lj.2f.3a.4f.5h., lp.2f.3a.4f.5h., la.2i.3a.4f.5h., lb.2i.3a.4f.5h., lf.2i.3a.4f.5h., lh.2i.3a.4f.5h., lj.2i.3a.4f .5hv lp.2i.3a.4f.5h., la.2m.3a.4f.5h., lb.2m.3a.4f.5h., lf.2m.3a.4f.5h., lh.2m.3a.4f.5h., lj.2m.3a.4f.5h., lp.2m.3a.4f.5h., la.2o.3a.4f.5h., lb.2o.3a.4f.5h., lf.2o.3a.4f.5h., lh.2o.3a.4f.5h., lj.2o.3a.4f.5h., lp.2o.3a.4f.5h., la.2u.3a.4f.5h., lb.2u.3a.4f.5h., lf.2u.3a.4f.5h., lh.2u.3a.4f.5h., lj.2u.3a.4f.5h., lp.2u.3a.4f.5h., la.2y.3a.4f.5h., lb.2y.3a.4f.5h., lf.2y.3a.4f.5h., lh.2y.3a.4f.5h., lj.2y.3a.4f.5h., lp.2y.3a.4f.5h., la.2a.3b.4f.5hv lb.2a.3b.4f.5h., lf.2a.3b.4f.5h., lh.2a.3b.4f.5hv lj.2a.3b.4f.5h., lp.2a.3b.4f.5h., la.2b.3b.4f.5h., lb.2b.3b.4f.5h., lf.2b.3b.4f.5h., lh.2b.3b.4f.5h., lj.2b.3b.4f.5h., lp.2b.3b.4f.5h., la.2e.3b.4f.5h., lb.2e.3b.4f.5h., lf.2e.3b.4f.5hv lh.2e.3b.4f.5h., lj.2e.3b.4f.5h., lp.2e.3b.4f.5h., la.2f.3b.4f.5h., lb.2f.3b.4f.5h., lf.2f.3b.4f.5h., lh.2f.3b.4f.5h., lj.2f.3b.4f.5h., lp.2f.3b.4f.5h., la.2i.3b.4f.5h., lb.2i.3b.4f.5h., lf.2i.3b.4f.5h., lh.2i.3b.4f.5h., lj.2i.3b.4f.5h., lp.2i.3b.4f.5h., la.2m.3b.4f.5h., lb.2m.3b.4f.5h., lf.2m.3b.4f.5hv lh.2m.3b.4f.5h., lj.2m.3b.4f.5h., lp.2m.3b.4f.5h., la.2o.3b.4f.5h., lb.2o.3b.4f.5h., lf.2o.3b.4f.5h., lh.2o.3b.4f.5h., lj.2o.3b.4f.5h., lp.2o.3b.4f.5h., la.2u.3b.4f.5h., lb.2u.3b.4f.5h., lf.2u.3b.4f.5h., lh.2u.3b.4f.5h., lj.2u.3b.4f.5h., lp.2u.3b.4f.5h., la.2y.3b.4f.5h., lb.2y.3b.4f.5h., lf.2y.3b.4f.5h., lh.2y.3b.4f.5h., lj.2y.3b.4f.5h., lp.2y.3b.4f.5h., la.2a.3e.4f.5h., lb.2a.3e.4f.5h., lf.2a.3e.4f.5h., lh.2a.3e.4f.5h., lj.2a.3e.4f.5h., lp.2a.3e.4f.5h., la.2b.3e.4f.5h., lb.2b.3e.4f.5h., lf.2b.3e.4f.5h., lh.2b.3e.4f.5h., lj.2b.3e.4f.5h., lp.2b.3e.4f.5h., la.2e.3e.4f.5h., lb.2e.3e.4f.5h., lf.2e.3e.4f.5h., lh.2e.3e.4f.5h., lj.2e.3e.4f.5h., lp.2e.3e.4f.5h., la.2f.3e.4f.5h., lb.2f.3e.4f.5h., lf.2f.3e.4f.5h., lh.2f.3e.4f.5h., lj.2f.3e.4f.5h., lp.2f.3e.4f.5h., la.2I.3e.4f.5h., lb.2i.3e.4f.5h., lf.2i.3e.4f.5h., lh.2i.3e.4f.5h., lj.2i.3e.4f.5h., lp.2i.3e.4f.5h., la.2m.3e.4f.5h., lb.2m.3e.4f.5h., lf.2m.3e.4f.5h., lh.2m.3e.4f.5h., lj.2m.3e.4f.5h., lp.2m.3e.4f.5h., la.2o.3e.4f.5h., lb.2o.3e.4f.5h., lf.2o.3e.4f ,5h., lh.2o.3e.4f.5h., lj.2o.3e.4f.5h., lp.2o.3e.4f.5h., la.2u.3e.4f.5hv lb.2u.3e.4f.5h., lf.2u.3e.4f.5h., lh.2u.3e.4f.5h., lj.2u.3e.4f.5h., lp.2u.3e.4f.5h., la.2y.3e.4f.5h., lb.2y.3e.4f.5h., lf.2y.3e.4f.5h., lh.2y.3e.4f.5h., lj.2y.3e.4f.5h., lp.2y.3e.4f.5h., la.2a.3g.4f.5h., lb.2a.3g.4f.5h., lf.2a.3g.4f.5h., lh.2a.3g.4f.5h., lj.2a.3g.4f.5h., lp.2a.3g.4f.5h., la.2b.3g.4f.5hv lb.2b.3g.4f.5h., lf.2b.3g.4f.5h., lh.2b.3g.4f.5h., lj.2b.3g.4f.5h., lp.2b.3g.4f.5h., la.2e.3g.4f.5hv lb.2e.3g.4f.5hv lf.2e.3g.4f.5h., lh.2e.3g.4f.5h., lj.2e.3g.4f.5h., lp.2e.3g.4f.5hv la.2f.3g.4f.5hv lb.2f.3g.4f.5h., lf.2f.3g.4f.5h., lh.2f.3g.4f.5h., lj.2f.3g.4f.5h., lp.2f.3g.4f.5h., la.2i.3g.4f.5h., lb.2i.3g.4f.5hv lf.2i.3g.4f.5hv lh.2i.3g.4f.5hv lj.2i.3g.4f.5h., lp.2i.3g.4f.5h., la.2m.3g.4f.5h., lb.2m.3g.4f.5h., lf.2m.3g.4f.5h., lh.2m.3g.4f.5h., lj.2m.3g.4f.5hv lp.2m.3g.4f.5hv la.2o.3g.4f.5h., lb.2o.3g.4f.5h., lf.2o.3g.4f.5h., lh.2o.3g.4f.5h., lj.2o.3g.4f.5h., lp.2o.3g.4f.5h., la.2u.3g.4f.5h., lb.2u.3g.4f.5hv lf.2u.3g.4f.5h., lh.2u.3g.4f.5h., lj.2u.3g.4f.5h., lp.2u.3g.4f.5h., la.2y.3g.4f.5h., lb.2y.3g.4f.5h., lf.2y.3g.4f.5hv lh.2y.3g.4f.5h., lj.2y.3g.4f.5h., lp.2y.3g.4f.5h., la.2a.3a.4g.5h., lb.2a.3a.4g.5h., lf.2a.3a.4g.5h., lh.2a.3a.4g.5h., lj.2a.3a.4g.5h., lp.2a.3a.4g.5h., la.2b.3a.4g.5h., lb.2b.3a.4g.5h., lf.2b.3a.4g.5h., lh.2b.3a.4g.5h., lj.2b.3a.4g.5h., lp.2b.3a.4g.5h., la.2e.3a.4g.5h., lb.2e.3a.4g.5h., lf.2e.3a.4g.5h., lh.2e.3a.4g.5hv lj.2e.3a.4g.5h., lp.2e.3a.4g.5h., la.2f.3a.4g.5h., lb.2f.3a.4g.5h., lf.2f.3a.4g.5h., lh.2f.3a.4g.5h., lj.2f.3a.4g.5h., lp.2f.3a.4g.5h., la.2i.3a.4g.5h., lb.2i.3a.4g.5h., lf.2i.3a.4g.5h., lh.2i.3a.4g.5h., lj.2i.3a.4g.5h., lp.2i.3a.4g.5h., la.2m.3a.4g.5h., lb.2m.3a.4g.5h., lf.2m.3a.4g.5h., lh.2m.3a.4g.5h., lj.2m.3a.4g.5hv lp.2m.3a.4g.5h., la.2o.3a.4g.5h., lb.2o.3a.4g.5h., lf.2o.3a.4g.5h., lh.2o.3a.4g.5h., lj.2o.3a.4g.5h., lp.2o.3a.4g.5h., la.2u.3a.4g.5h., lb.2u.3a.4g.5h., lf.2u.3a.4g.5h., lh.2u.3a.4g.5h., lj.2u.3a.4g.5h., lp.2u.3a.4g.5h., la.2y.3a.4g.5h., lb.2y.3a.4g.5h., lf.2y.3a.4g.5h., lh.2y.3a.4g.5h., lj.2y.3a.4g.5h., lp.2y,3a.4g.5h., la.2a.3b.4g.5h., lb.2a.3b.4g.5h., lf.2a.3b.4g.5h., lh.2a.3b.4g.5h., lj.2a.3b.4g.5h., lp.2a.3b.4g.5h., la.2b.3b.4g.5h., lb.2b.3b.4g.5h., lf.2b.3b.4g.5h., lh.2b.3b.4g.5h., lj.2b.3b.4g.5h., lp.2b.3b.4g.5h., la.2e.3b.4g.5h., lb.2e.3b.4g.5h., lf.2e.3b.4g.5h., lh.2e.3b.4g.5h., lj.2e.3b.4g.5h., lp.2e.3b.4g.5h., la.2f.3b.4g.5h., lb.2f.3b.4g.5hv lf.2f.3b.4g.5h., lh.2f.3b.4g.5h., lj.2f.3b.4g.5h., lp.2f.3b.4g.5h., la.2i.3b.4g.5h., lb.2i.3b.4g.5h., lf.2i.3b.4g.5h., lh.2i.3b.4g.5h., lj.2i.3b.4g.5h., lp.2i.3b.4g.5h., la.2m.3b.4g.5h., lb.2m.3b.4g.5h., lf.2m.3b.4g.5h., lh.2m.3b.4g.5h., lj.2m.3b.4g.5h., lp.2m.3b.4g.5h., la.2o.3b.4g.5h., lb.2o.3b.4g.5h., lf.2o.3b.4g.5h., lh.2o.3b.4g.5h., lj.2o.3b.4g.5h., lp.2o.3b.4g.5h., la.2u.3b.4g.5h., lb.2u.3b.4g.5h., lf.2u.3b.4g.5h., lh.2u.3b.4g.5h., lj.2u.3b.4g.5h., lp.2u.3b.4g.5h., la.2y.3b.4g.5h., lb.2y.3b.4g.5h., lf.2y.3b.4g.5h., lh.2y.3b.4g.5h., lj.2y.3b.4g.5h., lp.2y.3b.4g.5h., la.2a.3e.4g.5h., lb.2a.3e.4g.5h., lf.2a.3e.4g.5h., lh.2a.3e.4g.5h., lj.2a.3e.4g.5h., lp.2a.3e.4g.5h., la.2b.3e.4g.5h., lb.2b.3e.4g.5h., lf.2b.3e.4g.5h., lh.2b.3e.4g.5h., lj.2b.3e.4g.5h., lp.2b.3e.4g.5h., la.2e.3e.4g.5h., lb.2e.3e.4g.5h., lf.2e.3e.4g.5h., lh.2e.3e.4g.5h., lj.2e.3e.4g.5h., lp.2e.3e.4g.5h., la.2f.3e.4g.5h., lb.2f.3e.4g.5h., lf.2f.3e.4g.5h., lh.2f.3e.4g.5h., lj.2f.3e.4g.5h., lp.2f.3e.4g.5h., la.2i.3e.4g.5hv lb.2i.3e.4g.5h., lf.2i.3e.4g.5h., lh.2i.3e.4g.5h., lj.2i.3e.4g.5h., lp.2i.3e.4g.5h., la.2m.3e.4g.5h., lb.2m.3e.4g.5h., lf.2m.3e.4g.5h., lh.2m.3e.4g.5h., lj.2m.3e.4g.5h., lp.2m.3e.4g.5h., la.2o.3e.4g.5h., lb.2o.3e.4g.5h., lf.2o.3e.4g.5h., lh.2o.3e.4g.5h., lj.2o.3e.4g.5h., lp.2o.3e.4g.5h., la.2u.3e.4g.5h., lb.2u.3e.4g.5h., lf.2u.3e.4g.5h., lh.2u.3e.4g.5h., lj.2u.3e.4g.5h., lp.2u.3e.4g.5h., la.2y.3e.4g.5h., lb.2y.3e.4g.5h., lf.2y.3e.4g.5h., lh.2y.3e.4g.5h., lj.2y.3e.4g.5h., lp.2y.3e.4g.5h., la.2a.3g.4g.5h., lb.2a.3g.4g.5hv lf.2a.3g.4g.5h., lh.2a.3g.4g.5h., lj.2a.3g.4g.5h., lp.2a.3g.4g.5h., la.2b.3g.4g.5h., lb.2b.3g.4g.5h., lf.2b.3g.4g.5hv lh.2b.3g.4g.5h., lj.2b.3g.4g.5h., lp.2b.3g.4g.5h., la.2e.3g.4g.5h., lb.2e.3g.4g.5h., lf.2e.3g.4g.5hv lh.2e.3g.4g.5h., lj.2e.3g.4g.5h., lp.2e.3g.4g.5h., la.2f.3g.4g.5h., lb.2f.3g.4g.5h., lf.2f.3g.4g.5h., lh.2f.3g.4g.5h., lj.2f.3g.4g.5h., lp.2£.3g.4g.5h., la.2i.3g.4g.5h., lb.2i.3g.4g.5h., lf.2i.3g.4g.5h., lh.2i.3g.4g.5h., lj.2i.3g.4g.5h., lp.2i.3g.4g.5h., la.2m.3g.4g.5h., lb.2m.3g.4g.5h., lf.2m.3g.4g.5h., lh.2m.3g.4g.5h., lj.2m.3g.4g.5h., lp.2m.3g.4g.5h., la.2o.3g.4g.5h., lb.2o.3g.4g.5h., lf.2o.3g.4g.5h., lh.2o.3g.4g.5h., lj.2o.3g.4g.5h., lp.2o.3g.4g.5h., la.2u.3g.4g.5h., lb.2υ.3g.4g.5h., lf.2u.3g.4g.5h., lh.2u.3g.4g.5h., lj.2u.3g.4g.5h., lp.2u.3g.4g.5h., la.2y.3g.4g.5h., lb.2y.3g.4g.5h., lf.2y.3g.4g.5h., lh.2y.3g.4g.5h., lj.2y.3g.4g.5h., lp.2y.3g.4g.5h., la.2a.3a.4h.5h., lb.2a.3a.4h.5h., lf.2a.3a.4h.5h., lh.2a.3a.4h.5h., lj.2a.3a.4h.5h., lp.2a.3a.4h.5h., la.2b.3a.4h.5h., lb.2b.3a.4h.5h., lf.2b.3a.4h.5h., lh.2b.3a.4h.5h., lj.2b.3a.4h.5h., lp.2b.3a.4h.5h., la.2e.3a.4h.5h., lb.2e.3a.4h.5h., lf.2e.3a.4h.5h., lh.2e.3a.4h.5h., lj.2e.3a.4h.5h., lp.2e.3a.4h.5h., la.2f.3a.4h.5h., lb.2f.3a.4h.5hv lf.2f.3a.4h.5h., lh.2f.3a.4h.5h., lj.2f.3a.4h.5h., lp.2f.3a.4h.5h., la.2i.3a.4h.5h., lb.2i.3a.4h.5h., lf.2i.3a.4h.5h., lh.2i.3a.4h.5h., lj.2i.3a.4h.5h., lp.2i.3a.4h.5h., la.2m.3a.4h.5h., lb.2m.3a.4h.5h., lf.2m.3a.4h.5h., lh.2m.3a.4h.5h., lj.2m.3a.4h.5h., lp.2m.3a.4h.5h., la.2o.3a.4h.5h., lb.2o.3a.4h.5h., lf.2o.3a.4h.5h., lh.2o.3a.4h.5h., lj.2o.3a.4h.5h., lp.2o.3a.4h.5h., la.2u.3a.4h.5h., lb.2u.3a.4h.5h., lf.2u.3a.4h.5h., lh.2u.3a.4h.5h., lj.2u.3a.4h.5h., lp.2u.3a.4h.5h., la.2y.3a.4h.5h., lb.2y.3a.4h.5h., lf.2y.3a.4h.5h., lh.2y.3a.4h.5h., lj.2y.3a.4h.5h., lρ.2y.3a.4h.5h., la.2a.3b.4h.5h., lb.2a.3b.4h.5h., lf.2a.3b.4h.5h., lh.2a.3b.4h.5h., lj.2a.3b.4h.5h., lρ.2a.3b.4h.5h., la.2b.3b.4h.5h., lb.2b.3b.4h.5h., lf.2b.3b.4h.5h., lh.2b.3b.4h.5h., lj.2b.3b.4h.5h., lp.2b.3b.4h.5h., la.2e.3b.4h.5h., lb.2e.3b.4h.5hv lf.2e.3b.4h.5h., lh.2e.3b.4h.5h., lj.2e.3b.4h.5h., lp.2e.3b.4h.5h., la.2f.3b.4h.5h., lb.2f.3b.4h.5h., lf.2f.3b.4h.5h., lh.2f.3b.4h.5h., lj.2f.3b.4h.5h., lp.2f.3b.4h.5h., la.2i.3b.4h.5h., lb.2i.3b.4h.5h., lf.2i.3b.4h.5h., lh.2i.3b.4h.5h., lj.2i.3b.4h.5h., lp.2i.3b.4h.5h., la.2m.3b.4h.5h., lb.2m.3b.4h.5h., lf.2m.3b.4h.5h., lh.2m.3b.4h.5h., lj.2m.3b.4h.5h., lp.2m.3b.4h.5h., la.2o.3b.4h.5h., lb.2o.3b.4h.5h., lf.2o.3b.4h.5h., lh.2o.3b.4h.5h., lj.2o.3b.4h.5h., lp.2o.3b.4h.5h., la.2u.3b.4h.5h., lb.2u.3b.4h.5h., lf.2u.3b.4h.5h., lh.2u.3b.4h.5h., lj.2u.3b.4h.5h., lp.2u.3b.4h.5h., la.2y.3b.4h.5h., lb.2y.3b.4h.5h., lf.2y.3b.4h.5h., lh.2y.3b.4h.5h., lj.2y.3b.4h.5h., lp.2y.3b.4h.5h., la.2a.3e.4h.5h., lb.2a.3e.4h.5h., lf.2a.3e.4h.5h., lh.2a.3e.4h.5h., lj.2a.3e.4h.5hv lp.2a.3e.4h.5h., la.2b.3e.4h.5h., lb.2b.3e.4h.5h., lf.2b.3e.4h.5h., lh.2b.3e.4h.5h., lj.2b.3e.4h.5h., lp.2b.3e.4h.5h., la.2e.3e.4h.5h., lb.2e.3e.4h.5h., lf.2e.3e.4h.5h., lh.2e.3e.4h.5h., lj.2e.3e.4h.5h., lp.2e.3e.4h.5h., la.2f.3e.4h.5h., lb.2f.3e.4h.5h., lf.2f.3e.4h.5h., lh.2f.3e.4h.5h., lj.2f.3e.4h.5h., lp.2f.3e.4h.5h., la.2i.3e.4h.5h., lb.2L3e.4h.5h., lf.2i.3e.4h.5h., lh.2i.3e.4h.5h., lj.2i.3e.4h.5h., lp.2i.3e.4h.5h., la.2m.3e.4h.5h., lb.2m.3e.4h.5h., lf.2m.3e.4h.5h., lh.2m.3e.4h.5h., lj.2m.3e.4h.5h., lρ.2m.3e.4h.5h., la.2o.3e.4h.5h., lb.2o.3e.4h.5h., lf.2o.3e.4h.5h., lh.2o.3e.4h.5h., lj.2o.3e.4h.5h., lp.2o.3e.4h.5h., la.2u.3e.4h.5h., lb.2u.3e.4h.5h., lf.2u.3e.4h.5h., lh.2u.3e.4h.5h., lj.2u.3e.4h.5h., lp.2u.3e.4h.5h., la.2y.3e.4h.5h., lb.2y.3e.4h.5h., lf.2y.3e.4h.5h., lh.2y.3e.4h.5h., lj.2y.3e.4h.5h., lp.2y.3e.4h.5h., la.2a.3g.4h.5h., lb.2a.3g.4h.5h., lf.2a.3g.4h.5h., lh.2a.3g.4h.5h., lj.2a.3g.4h.5h., lp.2a.3g.4h.5h., la.2b.3g.4h.5h., lb.2b.3g.4h.5h., lf.2b.3g.4h.5h., lh.2b.3g.4h.5h., lj.2b.3g.4h.5h., lp.2b.3g.4h.5h., la.2e.3g.4h.5h., lb.2e.3g.4h.5h., lf.2e.3g.4h.5h., lh.2e.3g.4h.5h., lj.2e.3g.4h.5h., lp.2e.3g.4h.5h., la.2f.3g.4h.5h., lb.2f.3g.4h.5hv lf.2f.3g.4h.5h., lh.2f.3g.4h.5h., lj.2f.3g.4h.5h., lp.2£.3g.4h.5h., la.2i.3g.4h.5h., lb.2i.3g.4h.5h., lf.2i.3g.4h.5h., lh.2i.3g.4h.5h., lj.2i.3g.4h.5h., lp.2i.3g.4h.5h., la.2m.3g.4h.5h., lb.2m.3g.4h.5h., lf.2m.3g.4h.5h., lh.2m.3g.4h.5h., lj.2m.3g.4h.5h., lp.2m.3g.4h.5h., la.2o.3g.4h.5h., lb.2o.3g.4h.5h., lf.2o.3g.4h.5h., lh.2o.3g.4h.5h., lj.2o.3g.4h.5h., lp.2o.3g.4h.5h., la.2u.3g.4h.5h., lb.2u.3g.4h.5h., lf.2u.3g.4h.5h., lh.2u.3g.4h.5h., lj.2u.3g.4h.5h., lp.2u.3g.4h.5h., la.2y.3g.4h.5h., lb.2y.3g.4h.5h., lf.2y.3g.4h.5h., lh.2y.3g.4h.5h., lj.2y.3g.4h.5h., lp.2y.3g.4h.5h., la.2a.3a.4i.5h., lb.2a.3a.4i.5h., lf.2a.3a.4i.5h., lh.2a.3a.4i.5h., lj.2a.3a.4i.5h., lp.2a.3a.4i.5h., la.2b.3a.4i.5h., lb.2b.3a.4i.5h., lf.2b.3a.4i.5h., lh.2b.3a.4i.5h., lj.2b.3a.4i.5h., lp.2b.3a.4i.5h., la.2e.3a.4i.5h., lb.2e.3a.4i.5h., lf.2e.3a.4i.5h., lh.2e.3a.4i.5h., lj.2e.3a.4i.5h., lp.2e.3a.4i.5h., la.2f.3a.4i.5h., lb.2f.3a.4i.5h., lf.2f.3a.4i.5h., lh.2f.3a.4i.5h., lj.2f.3a.4i.5h., lp.2f.3a.4i.5h., la.2i.3a.4i.5h., lb.2i.3a.4i.5h., lf.2i.3a.4i.5h., lh.2i.3a.4i.5h., lj.2i.3a.4i.5h., lp.2i.3a.4i.5h., la.2m.3a.4i.5h., lb.2m.3a.4i.5h., lf.2m.3a.4i.5h., lh.2m.3a.4i.5h., lj.2m.3a.4i.5h., lp.2m.3a.4i.5h., la.2o.3a.4i.5h., lb.2o.3a.4i.5hv lf.2o.3a.4i.5h., lh.2o.3a.4i.5h., lj.2o.3a.4i.5h., lp.2o.3a.4i.5h., la.2u.3a.4i.5h., lb.2u.3a.4i.5h., lf.2u.3a.4i.5h., lh.2u.3a.4i.5h., lj.2u.3a.4i.5h., lp.2u.3a.4i.5h., la.2y.3a.4i.5h., lb.2y.3a.4i.5h., lf.2y.3a.4i.5h., lh.2y.3a.4i.5h., lj.2y.3a.4i.5h., lp.2y.3a.4i.5h., la.2a.3b.4i.5h., lb.2a.3b.4i.5h., lf.2a.3b.4i.5h., lh.2a.3b.4i.5h., lj.2a.3b.4i.5h., lp.2a.3b.4i.5h., la.2b.3b.4i.5h., lb.2b.3b.4i.5h., lf.2b.3b.4i.5h., lh.2b.3b.4i.5h., lj.2b.3b.4i.5h., lp.2b.3b.4i.5h., la.2e.3b.4i.5h., lb.2e.3b.4i.5h., lf.2e.3b.4i.5h., lh.2e.3b.4i.5h., lj.2e.3b.4i.5h., lp.2e.3b.4i.5h., la.2f.3b.4i.5h., lb.2f.3b.4i.5h., lf.2f.3b.4i.5h., lh.2f.3b.4i.5h., lj.2f.3b.4i.5h., lp.2f.3b.4i.5h., la.2i.3b.4i.5h., lb.2i.3b.4i.5h., lf.2i.3b.4i.5h., lh.2i.3b.4i.5h., lj.2i.3b.4i.5h., lp.2i.3b.4i.5h., la.2m.3b.4i.5h., lb.2m.3b.4i.5h., lf.2m.3b.4i.5h., lh.2m.3b.4i.5h., lj.2m.3b.4i.5h., lp.2m.3b.4i.5h., la.2o.3b.4i.5h., lb.2o.3b.4i.5h., lf.2o.3b.4i.5h., lh.2o.3b.4i.5h., lj.2o.3b.4i.5h., lp.2o.3b.4i.5h., la.2u.3b.4i.5h., lb.2u.3b.4i.5h., lf.2u.3b.4i.5h., lh.2u.3b.4i.5h., lj.2u.3b.4i.5h., lp.2u.3b.4i.5hv la.2y.3b.4i.5h., lb.2y.3b.4i.5h., lf.2y.3b.4i.5h., lh.2y.3b.4i.5h., lj.2y.3b.4i.5h., lp.2y.3b.4i.5h., la.2a.3e.4i.5h., lb.2a.3e.4i.5hv lf.2a.3e.4i.5h., lh.2a.3e.4i.5h., lj.2a.3e.4i.5h., lp.2a.3e.4i.5h., la.2b.3e.4i.5h., lb.2b.3e.4i.5h., lf.2b.3e.4i.5hv lh.2b.3e.4i.5h., lj.2b.3e.4i.5h., lp.2b.3e.4i.5h., la.2e.3e.4i.5h., lb.2e.3e.4i.5h., lf.2e.3e.4i.5h., lh.2e.3e.4i.5h., lj.2e.3e.4i.5h., lp.2e.3e.4i.5h., la.2f.3e.4i.5h., lb.2f.3e.4i.5h., lf.2f.3e.4i.5h., lh.2f.3e.4i.5h., lj.2f.3e.4i.5h., lp.2f.3e.4i.5h., la.2i.3e.4i.5h., lb.2i.3e.4i.5h., lf.2i.3e.4i.5h., lh.2i.3e.4i.5h., lj.2i.3e.4i.5h., lp.2i.3e.4i.5hv la.2m.3e.4i.5h., lb.2m.3e.4i.5h., lf.2m.3e.4i.5h., lh.2m.3e.4i.5h., lj.2m.3e.4i.5h., lp.2m.3e.4i.5hv la.2o.3e.4i.5h., lb.2o.3e.4i.5h., lf.2o.3e.4i.5h., lh.2o.3e.4i.5h., lj.2o.3e.4i.5h., lp.2o.3e.4i.5hv la.2u.3e.4i.5hv lb.2u.3e.4i.5hv lf.2u.3e.4i.5h., lh.2u.3e.4i.5h., lj.2u.3e.4i.5h., lp.2u.3e.4i.5h., la.2y.3e.4i.5h., lb.2y.3e.4i.5h., lf.2y.3e.4i.5h., lh.2y.3e.4i.5h., lj.2y.3e.4i.5h., lp.2y.3e.4i.5h., la.2a.3g.4i.5h., lb.2a.3g.4i.5h., lf.2a.3g.4i.5h., lh.2a.3g.4i.5h., lj.2a.3g.4i.5h., lp.2a.3g.4i.5h., la.2b.3g.4i.5h., lb.2b.3g.4i.5h., lf.2b.3g.4i.5h., lh.2b.3g.4i.5h., lj.2b.3g.4i.5h., lp.2b.3g.4i.5h., la.2e.3g.4i.5h., lb.2e.3g.4i.5h., lf.2e.3g.4i.5h., lh.2e.3g.4i.5h., lj.2e.3g.4i.5h., lp.2e.3g.4i.5h., la.2f.3g.4i.5h., lb.2f.3g.4i.5h., lf.2f.3g.4i.5h., lh.2f.3g.4i.5h., lj.2f.3g.4i.5h., lp.2f.3g.4i.5h., la.2i.3g.4i.5h., lb.2i.3g.4i.5hv lf.2i.3g.4i.5h., lh.2i.3g.4i.5h., lj.2i.3g.4i.5h., lp.2i.3g.4i.5h., la.2m.3g.4i.5h., lb.2m.3g.4i.5hv lf.2m.3g.4i.5h., lh.2m.3g.4i.5h., lj.2m.3g.4i.5h., lρ.2m.3g.4i.5h., la.2o.3g.4i.5h., lb.2o.3g.4i.5h., lf.2o.3g.4i.5h., lh.2o.3g.4i.5h., lj.2o.3g.4i.5h., lp.2o.3g.4L5h., la.2u.3g.4i.5h., lb.2u.3g.4i.5h., lf.2u.3g.4i.5h., lh.2u.3g.4i.5h., lj.2u.3g.4i.5h., lp.2u.3g.4i.5h., la.2y.3g.4i.5h., lb.2y.3g.4i.5h., lf.2y.3g.4i.5h., lh.2y.3g.4i.5h., lj.2y.3g.4i.5h., lp.2y.3g.4i.5h., la.2a.3a.4a.5i., lb.2a.3a.4a.5i., lf.2a.3a.4a.5i., lh.2a.3a.4a.5i., lj.2a.3a.4a.5i., lp.2a.3a.4a.5i, la.2b.3a.4a.5i., lb.2b.3a.4a.5i., lf.2b.3a.4a.5i., lh.2b.3a.4a.5i., lj.2b.3a.4a.5i, lp.2b.3a.4a.5i., la.2e.3a.4a.5i., lb.2e.3a.4a.5i., lf.2e.3a.4a.5i., lh.2e.3a.4a.5i., lj.2e.3a.4a.5L, lp.2e.3a.4a.5i., la.2f.3a.4a.5L, lb.2f.3a.4a.5i., lf.2f.3a.4a.5i., lh.2f.3a.4a.5i., lj.2f.3a.4a.5i., lp.2f.3a.4a.5i., la.2i.3a.4a.5i., lb.2i.3a.4a.5i., lf.2i.3a.4a.5i., lh.2i.3a.4a.5i., lj.2i.3a.4a.5L, lp.2i.3a.4a.5L, la.2m.3a.4a.5i., lb.2m.3a.4a.5L, lf.2m.3a.4a.5i., lh.2m.3a.4a.5L, lj.2m.3a.4a.5L, lp.2m.3a.4a.5i., la.2o.3a.4a.5L, lb.2o.3a.4a.5i., lf.2o.3a.4a.5i., lh.2o.3a.4a.5L, lj.2o.3a.4a.5i., lp.2o.3a.4a.5L, la.2u.3a.4a.5i., lb.2u.3a.4a.5i., lf.2u.3a.4a.5i., lh.2u.3a.4a.5i., lj.2u.3a.4a.5L, lρ.2u.3a.4a.5i., la.2y.3a.4a.5i., lb.2y.3a.4a.5i., lf.2y.3a.4a.5i., lh.2y.3a.4a.5i., lj.2y.3a.4a.5i., lp.2y.3a.4a.5L, la.2a.3b.4a.5i., lb.2a.3b.4a.5L, lf.2a.3b.4a.5i., lh.2a.3b.4a.5L, lj.2a.3b.4a.5i., lp.2a.3b.4a.5i., la.2b.3b.4a.5L, lb.2b.3b.4a.5i., lf.2b.3b.4a.5i., lh.2b.3b.4a.5i., lj.2b.3b.4a.5i., lp.2b.3b.4a.5i., la.2e.3b.4a.5i., lb.2e.3b.4a.5i., lf.2e.3b.4a.5i., lh.2e.3b.4a.5i., lj.2e.3b.4a.5i., lp.2e.3b.4a.5L, la.2f.3b.4a.5i., lb.2f.3b.4a.5i., lf.2f.3b.4a.5i., lh.2f.3b.4a.5L, lj.2f.3b.4a.5i., lp.2f.3b.4a.5i., la.2i.3b.4a.5i., lb.2i.3b.4a.5L, lf.2i.3b.4a.5L, lh.2i.3b.4a.5i., lj.2L3b.4a.5i., lp.2L3b.4a.5i., la.2m.3b.4a.5L, lb.2m.3b.4a.5i., lf.2m.3b.4a.5L, lh.2m.3b.4a.5i., lj.2m.3b.4a.5L, lp.2m.3b.4a.5L, la.2o.3b.4a.5i., lb.2o.3b.4a.5L, lf.2o.3b.4a.5i., lh.2o.3b.4a.5L, lj.2o.3b.4a.5i., lp.2o.3b.4a.5i., la.2u.3b.4a.5L, lb.2u.3b.4a.5i., lf.2u.3b.4a.5i., lh.2u.3b.4a.5L, lj.2u.3b.4a.5i., lp.2u.3b.4a.5L, la.2y.3b.4a.5L, lb.2y.3b.4a.5L, lf.2y.3b.4a.5L, lh.2y.3b.4a.5L, lj.2y.3b.4a.5i., lp.2y.3b.4a.5i., la.2a.3e.4a.5i., lb.2a.3e.4a.5i., lf.2a.3e.4a.5L, lh.2a.3e.4a.5i., lj.2a.3e.4a.5i., lp.2a.3e.4a.5i., la.2b.3e.4a.5L, lb.2b.3e.4a.5i., lf.2b.3e.4a.5i., lh.2b.3e.4a.5i., lj.2b.3e.4a.5i., lp.2b.3e.4a.5i., la.2e.3e.4a.5L, lb.2e.3e.4a.5L, lf.2e.3e.4a.5i., lh.2e.3e.4a.5i., lj.2e.3e.4a.5L, lp.2e.3e.4a.5i., la,2f.3e.4a.5L, lb.2f.3e.4a.5i., lf.2f.3e.4a.5i., lh.2f.3e.4a.5i., lj.2f.3e.4a.5L, lp.2f.3e.4a.5iv la.2i.3e.4a.5i., lb.2i.3e.4a.5i., lf.2i.3e.4a.5i., lh.2i.3e.4a.5iv lj.2i.3e.4a.5iv lp.2i.3e.4a.5i., la.2m.3e.4a.5i., lb.2m.3e.4a.5iv lf.2m.3e.4a.5iv lh.2m.3e.4a.5iv lj.2m.3e.4a.5i., lp.2m.3e.4a.5i., la.2o.3e.4a.5i., lb.2o.3e.4a.5i., lf.2o.3e.4a.5i., lh.2o.3e.4a.5i., lj.2o.3e.4a.5i., lp.2o.3e.4a.5L, la.2u.3e.4a.5i, lb.2u.3e.4a.5iv If .2u.3e.4a.5i., lh.2u.3e.4a.5i., lj.2u.3e.4a.5i., lp.2u.3e.4a.5i., la.2y.3e.4a.5L, lb.2y.3e.4a.5i., lf.2y.3e.4a.5i., lh.2y.3e.4a.5i., lj.2y.3e.4a.5i., lp.2y.3e.4a.5L, la.2a.3g.4a.5i., lb.2a.3g.4a.5i., lf.2a.3g.4a.5i., lh.2a.3g.4a.5iv lj.2a.3g.4a.5i., lp.2a.3g.4a.5i., la.2b.3g.4a.5i., lb.2b.3g.4a.5iv lf.2b.3g.4a.5i., lh.2b.3g.4a.5i., lj.2b.3g.4a.5L, lp.2b.3g.4a.5L, la.2e.3g.4a.5i., lb.2e.3g.4a.5L, lf.2e.3g.4a.5L, lh.2e.3g.4a.5i., lj.2e.3g.4a.5L, lp.2e.3g.4a.5L, la.2f.3g.4a.5i., lb.2f.3g.4a.5L, lf.2f.3g.4a.5i., lh.2f.3g.4a.5L, lj.2f.3g.4a.5i., lρ.2f.3g.4a.5i., la.2L3g.4a.5L, lb.2i.3g.4a.5L, lf.2L3g.4a.5L, lh.2i.3g.4a.5i., lj.2i.3g.4a.5i., lp.2i.3g.4a.5i., la.2m.3g.4a.5i., lb.2m.3g.4a.5L, lf.2m.3g.4a.5i., lh.2m.3g.4a.5i., lL2m.3g,4a.5L, lp.2m.3g.4a.5iv la.2o.3g.4a.5i., lb.2o.3g.4a.5i., lf.2o.3g.4a.5i., lh.2o.3g.4a.5L, lj.2o.3g.4a.5i., lp.2o.3g.4a.5i., la.2u.3g.4a.5i., lb.2u.3g.4a.5L, lf.2u.3g.4a.5L, lh.2u.3g.4a.5i., lj.2u.3g.4a.5L, lp.2u.3g.4a.5i., la.2y.3g.4a.5L, lb.2y.3g.4a.5L, lf.2y.3g.4a.5L, lh.2y.3g.4a.5L, lj.2y.3g.4a.5L, lp.2y.3g.4a.5L, la.2a.3a.4d.5L, lb.2a.3a.4d.5i., lf.2a.3a.4d.5i., lh.2a.3a.4d.5i., lj.2a.3a.4d.5L, lp.2a.3a.4d.5L, la.2b.3a.4d.5L, lb.2b.3a.4d.5i., lf.2b.3a.4d.5L, lh.2b.3a.4d.5i., lj.2b.3a.4d.5i., lp.2b.3a.4d.5L, la.2e.3a.4d.5i., lb.2e.3a.4d.5i., lf.2e.3a.4d.5L, lh.2e.3a.4d.5L, lj.2e.3a.4d.5L, lp.2e.3a.4d.5i., la.2f.3a.4d.5i., lb.2f.3a.4d.5i., lf.2f.3a.4d.5L, lh.2f.3a.4d.5L, lj.2f.3a.4d.5i., lp.2f.3a.4d.5L, la.2L3a.4d.5L, lb.2L3a.4d.5L, lf.2L3a.4d.5L, lh.2i.3a.4d.5i., lj.2L3a.4d.5i., lp.2L3a.4d.5L, la.2m.3a.4d.5L, lb.2m.3a.4d.5L, lf.2m.3a.4d.5L, lh.2m.3a.4d.5L, lj.2m.3a.4d.5i., lp.2m.3a.4d.5i., la.2o.3a.4d.5L, lb.2o.3a.4d.5i., lf.2o.3a.4d.5L, lh.2o.3a.4d.5i., lj.2o.3a.4d.5L, lp.2o.3a.4d.5L, la.2u.3a.4d.5i., lb.2u.3a.4d.5L, lf.2u.3a.4d.5i., lh.2u.3a.4d.5L, lj.2u.3a.4d.5i., lp.2u.3a.4d.5L, la.2y.3a.4d.5L, lb.2y.3a.4d.5L, lf.2y.3a.4d.5L, lh.2y.3a.4d.5L, lj.2y.3a.4d.5L, lp.2y.3a.4d.5i., la.2a.3b.4d.5L, lb.2a.3b.4d.5L, lf.2a.3b.4d.5i., lh.2a.3b.4d.5i., lj.2a.3b.4d.5i., lp.2a.3b.4d.5i., la.2b.3b.4d.5L, lb.2b.3b.4d.5i., lf.2b.3b.4d.5L, lh.2b.3b.4d.5i., lj.2b.3b.4d.5i., lp.2b.3b.4d.5L, la.2e.3b.4d.5i., lb.2e.3b.4d.5L, lf.2e.3b.4d.5L, lh.2e.3b.4d.5i., lj.2e.3b.4d.5L, lp.2e.3b.4d.5i., la.2f.3b.4d.5L, lb.2f.3b.4d.5i., lf.2f.3b.4d.5L, lh.2f.3b.4d.5L, lj.2f.3b.4d.5L, lp.2f.3b.4d.5i., la.2i.3b.4d.5i., lb.2L3b.4d.5L, lf.2L3b.4d.5L, lh.2i.3b.4d.5L, lj.2i.3b.4d.5i., lp.2i.3b.4d.5i., la.2m.3b.4d.5i., lb.2m.3b.4d.5L, lf.2m.3b.4d.5L, lh.2m.3b.4d.5L, lj.2m.3b.4d.5L, lp.2m.3b.4d.5i., la.2o.3b.4d.5L, lb.2o.3b.4d.5L, lf.2o.3b.4d.5L, lh.2o.3b.4d.5i., l].2o.3b.4d.5i., lρ.2o.3b.4d.5i., la.2u.3b.4d.5L, lb.2u.3b.4d.5i., lf.2u.3b.4d.5L, lh.2u.3b.4d.5L, lj.2u.3b.4d.5L, lp.2u.3b.4d.5L, la.2y.3b.4d.5L, lb.2y.3b.4d.5L, lf.2y.3b.4d.5L, lh.2y.3b.4d.5L, lj.2y.3b.4d.5L, lp.2y.3b.4d.5L, la.2a.3e.4d.5L, lb.2a.3e.4d.5i., lf.2a.3e.4d.5L, lh.2a.3e.4d.5L, lj.2a.3e.4d.5L, lp.2a.3e.4d.5i., la.2b.3e.4d.5i., lb.2b.3e.4d.5L, lf.2b.3e.4d.5i., lh.2b.3e.4d.5i., lj.2b.3e.4d.5i., lp.2b.3e.4d.5iv la.2e.3e.4d.5i., lb.2e.3e.4d.5i., lf.2e.3e.4d.5i., lh.2e.3e.4d.5i., lj.2e.3e.4d.5i., lp.2e.3e.4d.5i., la.2f.3e.4d.5i., lb.2f.3e.4d.5L, lf.2f.3e.4d.5i., lh.2f.3e.4d.5i., lj.2f.3e.4d.5i., lp.2f.3e.4d.5i, la.2i.3e.4d.5i., lb.2i.3e.4d.5i., lf.2i.3e.4d.5i., lh.2i.3e.4d.5i., lj.2i.3e.4d.5i., lp.2i.3e.4d.5iv la.2m.3e.4d.5i., lb.2m.3e.4d.5i., lf.2m.3e.4d.5L, lh.2m.3e.4d.5i., lj.2m.3e.4d.5i., lp.2m.3e.4d.5i., la.2o.3e.4d.5i., lb.2o.3e.4d.5i, lf.2o.3e.4d.5i., lh.2o.3e.4d.5iv lj.2o.3e.4d.5i., lp.2o.3e.4d.5i., la.2u.3e.4d.5L, lb.2u.3e.4d.5i., lf.2u.3e.4d.5i, lh.2u.3e.4d.5i., lj.2u.3e.4d.5i., lp.2u.3e.4d.5L, la.2y.3e.4d.5i., lb.2y.3e.4d.5i., lf.2y.3e.4d.5i., lh.2y.3e.4d.5i., l].2y.3e.4d.5i., lp.2y.3e.4d.5i., la.2a.3g.4d.5i., lb.2a.3g.4d.5i., lf.2a.3g.4d.5i., lh.2a.3g.4d.5i., lj.2a.3g.4d.5i., lp.2a.3g.4d.5L, la.2b.3g.4d.5i., lb.2b.3g.4d.5i., lf.2b.3g.4d.5i., lh.2b.3g.4d.5i., lj.2b.3g.4d.5i., lp.2b.3g.4d.5i., la.2e.3g.4d.5i., lb.2e.3g.4d.5L, lf.2e.3g.4d.5i., lh.2e.3g.4d.5i., lj.2e.3g.4d.5i., lp.2e.3g.4d.5i., la.2f.3g.4d.5i., lb.2f.3g.4d.5i., lf.2f.3g.4d.5i., lh.2f.3g.4d.5L, lj.2f.3g.4d.5i., lp.2f.3g.4d.5i., la.2i.3g.4d.5i., lb.2i.3g.4d.5i., lf.2i.3g.4d.5i., lh.2i.3g.4d.5i., Ij.2i3g.4d.5i., lp.2i.3g.4d.5L, la.2m.3g.4d.5i., lb.2m.3g.4d.5i., lf.2m.3g.4d.5i., lh.2m.3g.4d.5L, lj.2m.3g.4d.5i., lp.2m.3g.4d.5i., la.2o.3g.4d.5i., lb.2o.3g.4d.5i., lf.2o.3g.4d.5i., lh.2o.3g.4d.5i., lj.2o.3g.4d.5i., lp.2o.3g.4d.5i., la.2u.3g.4d.5i., lb.2u.3g.4d.5L, lf.2u.3g.4d.5i., lh.2u.3g.4d.5i., lj.2u.3g.4d.5i., lp.2u.3g.4d.5i., la.2y.3g.4d.5i., lb.2y.3g.4d.5i., lf.2y.3g.4d.5i., lh.2y.3g.4d.5i., lj.2y.3g.4d.5i., lp.2y.3g.4d.5i., la.2a.3a.4f.5i., lb.2a.3a.4f.5i., lf.2a.3a.4f.5i., lh.2a.3a.4f.5i., lj.2a.3a.4f.5i., lp.2a.3a.4f.5i., la.2b.3a.4f.5iv lb.2b.3a.4f.5i., lf.2b.3a.4f.5i., lh.2b.3a.4f.5i., lj.2b.3a.4f.5i., lp.2b.3a.4f.5iv la.2e.3a.4f.5i., lb.2e.3a.4f.5i., lf.2e.3a.4f.5L, lh.2e.3a.4f.5i., lj.2e.3a.4f.5i., lp.2e.3a.4f.5i., la.2f.3a.4f.5i., lb.2f.3a.4f.5i., lf.2f.3a.4f.5i., lh.2f.3a.4f.5L, lj.2f.3a.4f.5i., lp.2f.3a.4f.5i., la.2i.3a.4f.5i., lb.2i.3a.4f.5i., lf.2i.3a.4f.5i., lh.2i.3a.4f.5i., lj.2i.3a.4f.5i., lp.2i.3a.4f.5i., la.2m.3a.4f.5i., lb.2m.3a.4f.5i., lf.2m.3a.4f.5i., lh.2m.3a.4f.5i., lj.2m.3a.4f.5i., lp.2m.3a.4f.5i., la.2o.3a.4f.5i., lb.2o.3a.4f.5i., lf.2o.3a.4f.5i., lh.2o.3a.4f.5L, lj.2o.3a.4f.5i., lp.2o.3a.4f.5iv la.2u.3a.4f.5i., lb.2u.3a.4f.5i., lf.2u.3a.4f.5L, lh.2u.3a.4f.5i., lj.2u.3a.4f.5i., lp.2u.3a.4f.5i., la.2y.3a.4f.5i., lb.2y.3a.4f.5i., lf.2y.3a.4f.5i., lh.2y.3a.4f.5i., lj.2y.3a.4f.5i., lp.2y.3a.4f.5L, la.2a.3b.4f.5L, lb.2a.3b.4f.5i., lf.2a.3b.4f.5i., lh.2a.3b.4f.5i., lj.2a.3b.4f.5L, lp.2a.3b.4f.5i., la.2b.3b.4f.5i., lb.2b.3b.4f.5i., lf.2b.3b.4f.5i., lh.2b.3b.4f.5i., lj.2b.3b.4f.5i., lp.2b.3b.4f.5i., la.2e.3b.4f.5i., lb.2e.3b.4f.5i., lf.2e.3b.4f.5L, lh.2e.3b.4f.5i., lj.2e.3b.4f.5i., lp.2e.3b.4f.5i., la.2f.3b.4f.5i., lb.2f.3b.4f.5i., lf.2f.3b.4f.5L, lh.2f.3b.4f.5i., lj.2f.3b.4f.5i., lp.2f.3b.4f.5i., la.2i.3b.4f.5i., lb.2i.3b.4f.5i., lf.2i.3b.4f.5i., lh.2i.3b.4f.5i., lj.2i.3b.4f.5i., lp.2i.3b.4f.5i., la.2m.3b.4f.5i., lb.2m.3b.4f.5i., lf.2m.3b.4f.5i., lh.2m.3b.4f.5i., lj.2m.3b.4f.5i., lp.2m.3b.4f.5i., la.2o.3b.4f.5i-, lb.2o.3b.4f.5i., lf.2o.3b.4f.5i., lh.2o.3b.4f.5i., lj.2o.3b.4f.5i., lp.2o.3b.4f.5i., la.2u.3b.4f.5i., lb.2u.3b.4f.5L, lf.2u.3b.4f.5i., lh.2u.3b.4f.5L, lj.2u.3b.4f.5i., lp.2u.3b.4f.5i., la.2y.3b.4f.5i., lb.2y.3b.4f.5i., lf.2y.3b.4f.5L, lh.2y.3b.4f.5i., lj.2y.3b.4f.5iv lp.2y.3b.4f.5L, la.2a.3e.4f.5L, lb.2a.3e.4f.5L, lf.2a.3e.4f.5i., lh.2a.3e.4f.5L, lj.2a.3e.4f.5i., lp.2a.3e.4f.5i., la.2b.3e.4f.5L, lb.2b.3e.4f.5i., lf.2b.3e.4f.5i., lh.2b.3e.4f.5i., lj.2b.3e.4f.5i., lp.2b.3e.4f.5i., la.2e.3e.4f.5L, lb.2e.3e.4f.5iv lf.2e.3e.4f.5L, lh.2e.3e.4f.5iv lj.2e.3e.4f.5i., lp.2e.3e.4f.5i., la.2f.3e.4f.5i., lb.2f.3e.4f.5i., lf.2f.3e.4f.5i., lh.2f.3e.4f.5L, lj.2f.3e.4f.5L, lp.2f.3e.4f.5i., la.2i.3e.4f.5i., lb.2L3e.4f.5L, lf.2i.3e.4f.5i., lh.2i.3e.4f.5iv lj.2i.3e.4f.5i., lp.2i.3e.4f.5i., la.2m.3e.4f.5i., lb.2m.3e.4f.5i., lf.2m.3e.4f.5i., lh.2m.3e.4f.5i., lj.2m.3e.4f.5i., lp.2m.3e.4f.5i., la.2o.3e.4f.5i., lb.2o.3e.4f.5i., lf.2o.3e.4f.5i., lh.2o.3e.4f.5L, lj.2o.3e.4f.5i., lp.2o.3e.4f.5i., la.2u.3e.4f.5L, lb.2u.3e.4f.5iv lf.2u.3e.4f.5i., lh.2u.3e.4f.5i., lj.2u.3e.4f.5L, lp.2u.3e.4f.5i., la.2y.3e.4f.5i., lb.2y.3e.4f.5i., lf.2y.3e.4f.5i., lh.2y.3e.4f.5i., lj.2y.3e.4f.5L, lp.2y.3e.4f.5L, la.2a.3g.4f.5i., lb.2a.3g.4f.5i., lf.2a.3g.4f.5i., lh.2a.3g.4f.5i., lj.2a.3g.4f.5iv lp.2a.3g.4f.5L, la.2b.3g.4f.5L, lb.2b.3g.4f.5i., lf.2b.3g.4f.5L, lh.2b.3g.4f.5i., lj.2b.3g.4f.5L, lp.2b.3g.4f.5L, la.2e.3g.4f.5L, lb.2e.3g.4f.5L, lf.2e.3g.4f.5L, lh.2e.3g.4f.5i., lj.2e.3g.4f.5i., lρ.2e.3g.4f.5L, la.2f.3g.4f.5L, lb.2f.3g.4f.5L, lf.2f.3g.4f.5i., lh.2f.3g.4f.5i., lj.2f.3g.4f.5i., lp.2f.3g.4f.5L, la.2i.3g.4f.5i., lb.2i.3g.4f.5i., lf.2i.3g.4f.5i., lh.2L3g.4f.5L, lj.2i.3g.4f.5i., lp.2i.3g.4f.5iv la.2m,3g.4f.5L, lb.2m.3g.4f.5L, lf.2m.3g.4f.5i., lh.2m.3g.4f.5i., lj.2m.3g.4f.5L, lp.2m.3g.4f.5i., la.2o.3g.4f.5i., lb.2o.3g.4f.5i., lf.2o.3g.4f.5i., lh.2o.3g.4f.5L, lj.2o.3g.4f.5i., lp.2o.3g.4f.5i., la.2u.3g.4f.5L, lb.2u.3g.4f.5i., lf.2u.3g.4f.5L, lh.2u.3g.4f.5i., lj.2u.3g.4f.5i., lp.2u.3g.4f.5L, la.2y.3g.4f.5i., lb.2y.3g.4f.5L, lf.2y.3g.4f.5i., lh.2y.3g.4f.5i., lj.2y,3g.4f.5i., lp.2y.3g.4f.5i., la.2a.3a.4g.5L, lb.2a.3a.4g.5i., lf.2a.3a.4g.5L, lh.2a.3a.4g.5L, lj.2a.3a.4g.5L, lp.2a.3a.4g.5L, la.2b.3a.4g.5i., lb.2b.3a.4g.5L, lf.2b.3a.4g.5L, lh.2b.3a.4g.5iv lj.2b.3a.4g.5L, lp.2b.3a.4g.5L, la.2e.3a.4g.5L, lb.2e.3a.4g.5L, lf.2e.3a.4g.5L, lh.2e.3a.4g.5i., lj.2e.3a.4g.5i., lp.2e.3a.4g.5L, la.2f.3a.4g.5L, lb.2f.3a.4g.5i., lf.2f.3a.4g.5L, lh.2f.3a.4g.5i., lj.2f.3a.4g.5L, lp.2f.3a.4g.5L, la.2i.3a.4g.5i., lb.2i.3a.4g.5i., lf.2i.3a.4g.5i., lh.2i.3a.4g.5i., lj.2L3a.4g.5L, lp.2L3a.4g.5L, la.2m.3a.4g.5i., lb.2m.3a.4g.5L, lf.2m.3a.4g.5i., lh.2m.3a.4g.5L, lj.2m.3a.4g.5L, lp.2m.3a.4g.5L, la.2o.3a.4g.5i., lb.2o.3a.4g.5i., lf.2o.3a.4g.5L, lh.2o.3a.4g.5i., lj.2o.3a.4g.5L, lp.2o.3a.4g.5L, la.2u.3a.4g.5L, lb.2u.3a.4g.5L, lf.2u.3a.4g.5L, lh.2u.3a.4g.5L, lj.2u.3a.4g.5L, lp.2u.3a.4g.5i., la.2y.3a.4g.5L, lb.2y.3a.4g.5i., lf.2y.3a.4g.5L, lh.2y.3a.4g.5L, lj.2y.3a.4g.5L, lp.2y.3a.4g.5L, la.2a.3b.4g.5i., lb.2a.3b.4g.5L, lf.2a.3b.4g.5L, lh.2a.3b.4g.5L, lj.2a.3b.4g.5i., lp.2a.3b.4g.5L, la.2b.3b.4g.5i., lb.2b.3b.4g.5L, lf.2b.3b.4g.5L, lh.2b.3b.4g.5i., lj.2b.3b.4g.5L, lp.2b.3b.4g.5L, la.2e.3b.4g.5i., lb.2e.3b.4g.5i., lf.2e.3b.4g.5i., lh.2e.3b.4g.5i., lj.2e.3b.4g.5L, lp.2e.3b.4g.5L, la.2f.3b.4g.5i., lb.2f.3b.4g.5L, lf.2f.3b.4g.5L, lh.2f.3b.4g.5i., lj.2f.3b.4g.5L, lp.2f.3b.4g.5i., la.2L3b.4g.5L, lb.2i.3b.4g.5i., lf.2L3b.4g.5L, lh.2i.3b.4g.5i., lj.2i.3b.4g.5i., lp.2i.3b.4g.5i., la.2m.3b.4g.5L, lb.2m.3b.4g.5L, lf.2m.3b.4g.5i., lh.2m.3b.4g.5i., lj.2m.3b.4g.5L, lp.2m.3b.4g.5L, la.2o.3b.4g.5i., lb.2o.3b.4g.5i., lf.2o.3b.4g.5L, lh.2o.3b.4g.5L, lj.2o.3b.4g.5i., lp.2o.3b.4g.5L, la.2u.3b.4g.5iv lb.2u.3b.4g.5i., lf.2u.3b.4g.5i., lh.2u.3b.4g.5i., lj.2u.3b.4g.5i., lp.2u.3b.4g.5i., la.2y.3b.4g.5L, lb.2y.3b.4g.5i., lf.2y.3b.4g.5i, lh.2y.3b.4g.5L, lj.2y.3b.4g.5iv lp.2y.3b.4g.5i., la.2a.3e.4g.5i., lb.2a.3e.4g.5i., lf.2a.3e.4g.5iv lh.2a.3e.4g.5L, lj.2a.3e.4g.5i., lp.2a.3e.4g.5i., la.2b.3e.4g.5i., lb.2b.3e.4g.5i., lf.2b.3e.4g.5i., lh.2b.3e.4g.5i., lj.2b.3e.4g.5i., lp.2b.3e.4g.5i., la.2e.3e.4g.5i., lb.2e.3e.4g.5L, lf.2e.3e.4g.5i., lh.2e.3e.4g.5i., lj.2e.3e.4g.5i., lp.2e.3e.4g.5i., la.2f.3e.4g.5i., lb.2f.3e.4g.5L, lf.2f.3e.4g.5i., lh.2f.3e.4g.5i., lj.2f.3e.4g.5i., lp.2f.3e.4g.5i., la.2i.3e.4g.5i., lb.2i.3e.4g.5i., lf.2i.3e.4g.5i., lh.2i.3e.4g.5i., lj.2i.3e.4g.5i., lp.2i.3e.4g.5i., la.2m.3e.4g.5i., lb.2m.3e.4g.5i., lf.2m.3e.4g.5i., lh.2m.3e.4g.5i., lj.2m.3e.4g.5i., lp.2m.3e.4g.5i., la.2o.3e.4g.5i., lb.2o.3e.4g.5i., lf.2o.3e.4g.5i., lh.2o.3e.4g.5i., lj.2o.3e.4g.5i., lp.2o.3e.4g.5L, la.2u.3e.4g.5i., lb.2u.3e.4g.5L, lf.2u.3e.4g.5i., lh.2u.3e.4g.5i., lj.2u.3e.4g.5L, lp.2u.3e.4g.5i., la.2y.3e.4g.5i., lb.2y.3e.4g.5i., lf.2y.3e.4g.5i., lh.2y.3e.4g.5i., lj.2y.3e.4g.5i., lp.2y.3e.4g.5i., la.2a.3g.4g.5i, lb.2a.3g.4g.5i., lf.2a.3g.4g.5i., lh.2a.3g.4g.5i., lj.2a.3g.4g.5i., lp.2a.3g.4g.5i., la.2b.3g.4g.5i., lb.2b.3g.4g.5iv lf.2b.3g.4g.5i., lh.2b.3g.4g.5i., lj.2b.3g.4g.5i., lp.2b.3g.4g.5i., la.2e.3g.4g.5i., lb.2e.3g.4g.5i., lf.2e.3g.4g.5i., lh.2e.3g.4g.5i., lj.2e.3g.4g.5i., lp.2e.3g.4g.5L, la.2f.3g.4g.5i., lb.2£.3g.4g.5i., lf.2f.3g.4g.5i., lh.2f.3g.4g.5i., lj.2f.3g.4g.5i., lp.2f.3g.4g.5i., la.2i.3g.4g.5i., lb.2i.3g.4g.5i., lf.2i.3g.4g.5i., lh.2i.3g.4g.5L, lj.2i.3g.4g.5i., lp.2i.3g.4g.5i., la.2m.3g.4g.5i., lb.2m.3g.4g.5i., lf.2m.3g.4g.5i., lh.2m.3g.4g.5iv lj.2m.3g.4g.5i., lρ.2m.3g.4g.5i., la.2o.3g.4g.5L, lb.2o.3g.4g.5i., lf.2o.3g.4g.5i., lh.2o.3g.4g.5i., lj.2o.3g.4g.5i., lp.2o.3g.4g.5i., la.2u.3g.4g.5i., lb.2u.3g.4g.5i., lf.2u.3g.4g.5i., lh.2u.3g.4g.5L, lj.2u.3g.4g.5i., lp.2u.3g.4g.5i., la.2y.3g.4g.5L, lb.2y.3g.4g.5i., lf.2y.3g.4g.5i., lh.2y.3g.4g.5i., lj.2y.3g.4g.5i., lp.2y.3g.4g.5i., la.2a.3a.4h.5i., lb.2a.3a.4h.5i., lf.2a.3a.4h.5i., lh.2a.3a.4h.5i., lj.2a.3a.4h.5i., lp.2a.3a.4h.5i., la.2b.3a.4h.5i., lb.2b.3a.4h.5i., lf.2b.3a.4h.5i., lh.2b.3a.4h.5i., lj.2b.3a.4h.5i., lp.2b.3a.4h.5i., la.2e.3a.4h.5i., lb.2e.3a.4h.5i., lf.2e.3a.4h.5i., lh.2e.3a.4h.5i., lj.2e.3a.4h.5i., lp.2e.3a.4h.5i., la.2f.3a.4h.5i., lb.2f.3a.4h.5i., lf.2f.3a.4h.5i., lh.2f.3a.4h.5i., lj.2f.3a.4h.5i., lp.2f.3a.4h.5i., la.2i.3a.4h.5i., lb.2i.3a.4h.5i., lf.2i.3a.4h.5i., lh.2i.3a.4h.5i., lj.2i.3a.4h.5i., lp.2i.3a.4h.5i., la.2m.3a.4h.5iv lb.2m.3a.4h.5i., lf.2m.3a.4h.5i., lh.2m.3a.4h.5L, lj.2m.3a.4h.5i., lp.2m.3a.4h.5i., la.2o.3a.4h.5L, lb.2o.3a.4h.5i., lf.2o.3a.4h.5i., lh.2o.3a.4h.5i., lj.2o.3a.4h.5i., lp.2o.3a.4h.5i., la.2u.3a.4h.5i., lb.2u.3a.4h.5i., lf.2u.3a.4h.5i., lh.2u.3a.4h.5i., lj.2u.3a.4h.5i., lp.2u.3a.4h.5i., la.2y.3a.4h.5iv lb.2y.3a.4h.5i., lf.2y.3a.4h.5i., lh.2y.3a.4h.5i., lj.2y.3a.4h.5i., lp.2y.3a.4h.5i., la.2a.3b.4h.5i., lb.2a.3b.4h.5i., lf.2a.3b.4h.5i., lh.2a.3b.4h.5i., lj.2a.3b.4h.5i., lp.2a.3b.4h.5i., la.2b.3b.4h.5i., lb.2b.3b.4h.5i., lf.2b.3b.4h.5i., lh.2b.3b.4h.5L, lj.2b.3b.4h.5i., lp.2b.3b.4h.5i., la.2e.3b.4h.5i., lb.2e.3b.4h.5i., lf.2e.3b.4h.5i., lh.2e.3b.4h.5i., lj.2e.3b.4h.5i., lp.2e.3b.4h.5i., la.2f.3b.4h.5i., lb.2f.3b.4h.5i., lf.2f.3b.4h.5i., lh.2f.3b.4h.5i., lj.2f.3b.4h.5i., lp.2f.3b.4h.5i., la.2i.3b.4h.5i., lb.2i.3b.4h.5i., lf.2i.3b.4h.5i., lh.2i.3b.4h.5i., lj.2i.3b.4h.5i., lp.2i.3b.4h.5L, la.2m.3b.4h.5i., lb.2m.3b.4h.5i., lf.2m.3b.4h.5i., lh.2m.3b.4h.5i., lj.2m.3b.4h.5i., lp.2m.3b.4h.5i., la.2o.3b.4h.5i., lb.2o.3b.4h.5i., lf.2o.3b.4h.5iv lh.2o.3b.4h.5L, lj.2o.3b.4h.5i., lp.2o.3b.4h.5i., la.2u.3b.4h.5iv lb.2u.3b.4h.5i., lf.2u.3b.4h.5iv lh.2u.3b.4h.5i., lj.2u.3b.4h.5i., lp.2u.3b.4h.5L, la.2y.3b.4h.5i., lb.2y.3b.4h.5L, lf.2y.3b.4h.5i., lh.2y.3b.4h.5i., lj.2y.3b.4h.5i., lp.2y.3b.4h.5i., la.2a.3e.4h.5L, lb.2a.3e.4h.5i., lf.2a.3e.4h.5i., lh.2a.3e.4h.5i., lj.2a.3e.4h.5i., lp.2a.3e.4h.5L, la.2b.3e.4h.5i., lb.2b.3e.4h.5i., lf.2b.3e.4h.5i., lh.2b.3e.4h.5i., lj.2b.3e.4h.5i., lp.2b.3e.4h.5i., la.2e.3e.4h.5i., lb.2e.3e.4h.5i., lf.2e.3e.4h.5i., lh.2e.3e.4h.5i., lj.2e.3e.4h.5i., lp.2e.3e.4h.5i., la.2f.3e.4h.5i., lb.2f.3e.4h.5i., lf.2f.3e.4h.5i., lh.2f.3e.4h.5i., lj.2f.3e.4h.5i., lp.2f.3e.4h.5i., la.2i.3e.4h.5i., lb.2i.3e.4h.5i., lf.2i.3e.4h.5i, lh.2i.3e.4h.5i., lj.2i.3e.4h.5i., lp.2i.3e.4h.5i., la.2m.3e.4h.5L, lb.2m.3e.4h.5i., lf.2m.3e.4h.5i., lh.2m.3e.4h.5i., lj.2m.3e.4h.5i., lp.2m.3e.4h.5i., la.2o.3e.4h.5i., lb.2o.3e.4h.5L, lf.2o.3e.4h.5i., lh.2o.3e.4h.5i., lj.2o.3e.4h.5i., lp.2o.3e.4h.5i., la.2u.3e.4h.5L, lb.2u.3e.4h.5iv lf.2u.3e.4h.5i., lh.2u.3e.4h.5i., lj.2u.3e.4h.5i., lp.2u.3e.4h.5i., la.2y.3e.4h.5i., lb.2y.3e.4h.5i., lf.2y.3e.4h.5i., lh.2y.3e.4h.5i., lj.2y.3e.4h.5i., lp.2y.3e.4h.5i., la.2a.3g.4h.5i., lb.2a.3g.4h.5i., lf.2a.3g.4h.5i., lh.2a.3g.4h.5i., lj.2a.3g.4h.5i., lp.2a.3g.4h.5i., la.2b.3g.4h.5i., lb.2b.3g.4h.5L, lf.2b.3g.4h.5i., lh.2b.3g.4h.5i., lj.2b.3g.4h.5i., lp.2b.3g.4h.5i., l a.2e.3g.4h.5i., lb.2e.3g.4h.5i., lf.2e.3g.4h.5L, lh.2e.3g.4h.5i., lj.2e.3g.4h.5i., lp.2e.3g.4h.5i., la.2f.3g.4h.5i., lb.2f.3g.4h.5i., lf.2f.3g.4h.5i., lh.2f.3g.4h.5i., lj.2f.3g.4h.5i., lp.2f.3g.4h.5i., la.2i.3g.4h.5i., lb.2i.3g.4h.5iv lf.2i.3g.4h.5i., lh.2i.3g.4h.5i., lj.2i.3g.4h.5i., lp.2i.3g.4h.5i., la.2m.3g.4h.5i., lb.2m.3g.4h.5i., lf.2m.3g.4h.5i., lh.2m.3g.4h.5i., lj.2m.3g.4h.5iv lp.2m.3g.4h.5i., la.2o.3g.4h.5i., lb.2o.3g.4h.5i., lf.2o.3g.4h.5i., lh.2o.3g.4h.5i., lj.2o.3g.4h.5i., lp.2o.3g.4h.5i., la.2u.3g.4h.5i., lb.2u.3g.4h.5i., lf.2u.3g.4h.5i., lh.2u.3g.4h.5i., lj.2u.3g.4h.5L, lp.2u.3g.4h.5i., la.2y.3g.4h.5i., lb.2y.3g.4h.5iv lf.2y.3g.4h.5i., lh.2y.3g.4h.5iv lj.2y.3g.4h.5i., lp.2y.3g.4h.5i., la.2a.3a.4i.5i., lb.2a.3a.4i.5i., lf.2a.3a.4i.5i., lh.2a.3a.4i.5i., lj.2a.3a.4i.5i., lp.2a.3a.4i.5i., la.2b.3a.4i.5i., lb.2b.3a.4i.5i., lf.2b.3a.4i.5i., lh.2b.3a.4i.5i., lj.2b.3a.4i.5i., lp.2b.3a.4i.5i., la.2e.3a.4i.5i., lb.2e.3a.4i.5i., lf.2e.3a.4i.5i., lh.2e.3a.4i.5i., lj.2e.3a.4i.5i., lp.2e.3a.4i.5i., la.2f.3a.4i.5i., lb.2f.3a.4i.5i., lf.2f.3a.4i.5i., lh.2f.3a.4i.5i., lj.2f.3a.4i.5i., lp.2f.3a.4i.5i., la.2i.3a.4i.5i., lb.2i.3a.4i.5i., lf.2i.3a.4i.5i., lh.2i.3a.4i.5i., lj.2i.3a.4i.5L, lp.2i.3a.4i.5i., la.2m.3a.4i.5i., lb.2m.3a.4i.5i., lf.2m.3a.4i.5i., lh.2m.3a.4i.5i., lj.2m.3a.4i.5i., lp.2m.3a.4i.5L, la.2o.3a.4i.5i., lb.2o.3a.4i.5i., lf.2o.3a.4i.5i., lh.2o.3a.4i.5i., lj.2o.3a.4i.5i., lp.2o.3a.4i.5i., la.2u.3a.4i.5i., lb.2u.3a.4i.5i., lf.2u.3a.4i.5i., lh.2u.3a.4i.5iv lj.2u.3a.4i.5i.7 lp.2u.3a.4i.5i., la.2y.3a.4i.5i., lb.2y.3a.4i.5i., lf.2y.3a.4i.5iv lh.2y.3a.4i.5i., lj.2y.3a.4i.5L, lp.2y.3a.4i.5i., la.2a.3b.4i.5i., lb.2a.3b.4i.5i., lf.2a.3b.4i.5i., lh.2a.3b.4i.5i., lj.2a.3b.4i.5i., lp.2a.3b.4i.5i., la.2b.3b.4i.5i., lb.2b.3b.4i.5i., lf.2b.3b.4L5L, lh.2b.3b.4i.5L, lj.2b.3b.4i.5i., lp.2b.3b.4i.5i., la.2e.3b.4i.5i., lb.2e.3b.4i.5i., lf.2e.3b.4i.5i., lh.2e.3b.4i.5i., lj.2e.3b.4L5L, lp.2e.3b.4L5i., la.2f.3b.4i.5i., lb.2f.3b.4i.5L, lf.2f.3b.4i.5i., lh.2f.3b.4i.5i., lj.2f.3b.4i.5i., lp.2f.3b.4i.5L, la.2i.3b.4i.5i., lb.2i.3b.4i.5i., lf.2i.3b.4i.5i., lh.2i.3b.4i.5i., lj.2i.3b.4i.5i., lp.2i.3b.4i.5i., la.2m.3b.4i.5i., lb.2m.3b.4i.5i., lf.2m.3b.4i.5i., lh.2m.3b.4i.5i., lj.2m.3b.4i.5iv lp.2m.3b.4i.5i., la.2o.3b.4i.5i., lb.2o.3b.4i.5i., lf.2o.3b.4i.5i., lh.2o.3b.4i.5i., lj.2o.3b.4i.5i., lp.2o.3b.4i.5i., la.2u.3b.4i.5i., lb.2u.3b.4i.5i., lf.2u.3b.4i.5i., lh.2u.3b.4i.5i., lj.2u.3b.4i.5i., lp.2u.3b.4i.5i., la.2y.3b.4i.5i., lb.2y.3b.4i.5iv lf.2y.3b.4i.5i., lh.2y.3b.4i.5L, lj.2y.3b.4i.5i., lp.2y.3b.4L5i., la.2a.3e.4i.5iv lb.2a.3e.4i.5i., lf.2a.3e.4i.5i., lh.2a.3e.4i.5i., lj.2a.3e.4i.5L, lp.2a.3e.4i.5i., la.2b.3e.4i.5i., lb.2b.3e.4i.5i., lf.2b.3e.4i.5i., lh.2b.3e.4i.5i., lj.2b.3e.4i.5i., lp.2b.3e.4i.5i., la.2e.3e.4i.5i., lb.2e.3e.4i.5i., lf.2e.3e.4i.5i., lh.2e.3e.4i.5i., lj.2e.3e.4i.5i., lp.2e.3e.4i.5i., la.2f.3e.4i.5i., lb.2f.3e.4i.5i, lf.2f.3e.4i.5iv lh.2f.3e.4i.5i., lj.2f.3e.4i.5i., lp.2f.3e.4i.5i., la.2i.3e.4i.5i., lb.2i.3e.4i.5i., lf.2i.3e.4i.5i., lh.2i.3e.4i.5i., lj.2L3e.4i.5i., lp.2i.3e.4i.5i., la.2m.3e.4i.5i, lb.2m.3e.4i.5i., lf.2m.3e.4i.5i., lh.2m.3e.4i.5iv lj.2m.3e.4i.5L, lp.2m.3e.4i.5i., la.2o.3e.4i.5i., lb.2o.3e.4i.5i., lf.2o.3e.4i.5i., lh.2o.3e.4i.5i., lj.2o.3e.4i.5i., lp.2o.3e.4i.5i., la.2u.3e.4i.5i., lb.2u.3e.4i.5L, lf.2u.3e.4i.5i., lh.2u.3e.4i.5i., lj.2u.3e.4i.5i., lp.2u.3e.4i.5i., la.2y.3e.4i.5L, lb.2y.3e.4i.5i., lf.2y.3e.4i.5i., lh.2y.3e.4i.5L, lj.2y.3e.4i.5i., lp.2y.3e.4i.5iv la.2a.3g.4i.5i., lb.2a.3g.4i.5iv lf.2a.3g.4i.5i., lh.2a.3g.4i.5i., lj.2a.3g.4i.5i., lp.2a.3g.4i.5i., la.2b.3g.4i.5i., lb.2b.3g.4i.5i., lf.2b.3g.4i.5i., lh.2b.3g.4i.5i., lj.2b.3g.4i.5L, lp.2b.3g.4i.5i., la.2e.3g.4i.5i., lb.2e.3g.4i.5i., lf.2e.3g.4i.5i., lh.2e.3g.4i.5i., lj.2e.3g.4i.5i., lρ.2e.3g.4i.5i., la.2f.3g.4i.5i., lb.2f.3g.4i.5i., lf.2f.3g.4i.5i., lh.2f.3g.4i.5i., lj.2f.3g.4i.5i., lp.2f.3g.4i.5i., la.2i.3g.4i.5i., lb.2i.3g.4i.5i., lf.2i.3g.4i.5i., lh.2i.3g.4i.5i., lj.2i.3g.4i.5i., lρ.2i.3g.4i.5i., la.2m.3g.4i.5L, lb.2m.3g.4i.5i., lf.2m.3g.4i.5i., lh.2m.3g.4L5i., lj.2m.3g.4i.5i., lp.2m.3g.4L5L, la.2o.3g.4i.5i., lb.2o.3g.4i.5iv lf.2o.3g.4i.5i., lh.2o.3g.4i.5i., lj.2o.3g.4i.5i., lp.2o.3g.4i.5i., la.2u.3g.4i.5i., lb.2u.3g.4i.5L, lf.2u.3g.4i.5iv lh.2u.3g.4i.5i., lj.2u.3g.4i.5i., lp.2u.3g.4i.5i., la.2y.3g.4i.5i., lb.2y.3g.4i.5i., lf.2y.3g.4i.5i., lh.2y.3g.4i.5i., lj.2y.3g.4i.5i., and lp.2y.3g.4i.5L.
In still yet another embodiment, the compound of the present invention has an inhibition activity against P450 at a level equal to or better than the inhibition activity of a compound as represented by an ICso of less than about 2000 nM, less than about 1500 nM, less than about 1000 nM, less than about 900 nM, less than about 800 nM, less than about 700 nM, less than about 650 nM, less than about 600 nM, less than about 550 nM, less than about 500 nM, less than about 400 nM, less than about 350 nM, less than about 300 nM, less than about 250 nM, less than about 200 nM, less than about 100 nM, or less than about 50 nM. In still yet another embodiment, the compound of the present invention has an inhibition activity against an isozyme of P450, e.g., 3A in a range represented by ICso from about 2000 nM to about 100 nM, from about 1000 nJVI to about 100 nM, from about 900 nM to about 200 nM, from about 800 nM to about 300 nM, from about 700 nM to about 200 nM, from about 600 nM to about 200 nM, from about 500 nM to about 200 nM, from about 700 nM to about 300 nM, from about 600 nM to about 300 nM, from about 700 nM to about 400 nM, from about 600 nM to about 400 nM, from about 400 nM to about 100 nM, from about 300 nM to about 100 nM, or from about 600 nM to about 150 nM.
In still yet another embodiment, the compound of the present invention has an inhibition activity against P450 at a level equal to or better than the inhibition activity of a compound as represented by an ICso of less than about 2000 nM, less than about 1500 nM, less than about 1000 nM, less than about 900 nM, less than about 800 nM, less than about 700 nM, less than about 650 nM, less than about 600 nM, less than about 550 nM, less than about 500 nM, less than about 400 nM, less than about 350 nM, less than about 300 nM, less than about 250 nM, less than about 200 nM, less than about 100 nM, or less than about 50 nM, provided that such compound also does not substantially exhibit biological activities other than its inhibition activity against P450. For example, the compound of the present invention can have a reduced or not significant activity of protease inhibition, including without any limitation a level of protease inhibition as represented by HIV ECso of greater than about 1000 nM, greater than about 900 nM, greater than about 800 nM, greater than about 700 nM, greater than about 600 nM, greater than about 500 nM, greater than about 400 nM, greater than about 300 nM, greater than about 200 nM, greater than about 100 nM, greater than about 50 nM, greater than about 40 nM, greater than about 30 nM, greater than about 20 nM, greater than about 10 nM, greater than about 5 nM, or greater than about 1 nM.
In yet another embodiment the compound of the present invention has an inhibition activity specifically against one or more isozymes of P450 including without limitation 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2El, and 3A4, 5, 7, etc.
In yet another embodiment, the compound of the present invention has an inhibition activity specifically against an isozyme of P450 that is involved in metabolizing anti-viral drugs, e.g., indinavir, nelfinavir, ritonavir, saquinavir etc.
In still yet another embodiment, the compound of the present invention has an inhibition activity specifically against one or more isozymes of P450, but not the other(s). For example, the compound of the present invention can have an inhibition activity specifically against P450 3 A, but a reduced, insubstantial, or minimum inhibition activity against another isozyme of P450, e.g., P450 2C9.
Pharmaceutical Formulations
The compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, binders and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986), herein incorporated by reference in its entirety. Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxy alky lmethylceilulose, stearic acid and the like. The pH of the formulations ranges from about 3 to about 11, but is ordinarily about 7 to 10. While it is possible for the active ingredients to be administered alone it may be preferable to present them as pharmaceutical formulations. The formulations of the invention, both for veterinary and for human use, comprise at least one active ingredient, e.g. a compound of the present invention, together with one or more acceptable carriers and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.
The formulations include those suitable for the foregoing administration routes. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.), herein incorporated by reference in its entirety. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in- water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste.
A tablet is made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient.
For administration to the eye or other external tissues e.g., mouth and skin, the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in- water cream base.
If desired, the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogs.
The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
Emulgents and emulsion stabilizers suitable for use in the formulation of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. The cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used.
Pharmaceutical formulations according to the present invention comprise one or more compounds of the invention together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents. Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable exάpient which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl mono stearate or glyceryl distearate alone or with a wax may be employed.
Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth herein, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional exdpients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as poly oxy ethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
The pharmaceutical compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.
The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a time-release formulation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight: weight). The pharmaceutical composition can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion may contain from about 3 to 500 μg of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
Formulations suitable for administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.
Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 μm (including particle sizes in a range between. 0.1 and 500 μm in increments such as 0.5 μm, 1 μm, 30 μm, 35 μm, etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs. Suitable formulations include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of infections as described herein.
Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
The formulations are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
It should be understood that in addition to the ingredients provided by the present invention the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
The invention further provides veterinary compositions comprising at least one active ingredient, e.g., a compound of the present invention together with a veterinary carrier.
Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route. Compounds of the invention can also be formulated to provide controlled release of the active ingredient to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the active ingredient. Accordingly, the invention also provided compositions comprising one or more compounds of the invention formulated for sustained or controlled release.
The effective dose of an active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses) or against an active disease or condition, the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies. The effective dose can be expected to be from about 0.0001 to about 100 mg/kg body weight per day. Typically, from about 0.01 to about 10 mg/kg body weight per day. More typically, from about 0.01 to about 5 mg/kg body weight per day. More typically, from about 0.05 to about 0.5 mg/kg body weight per day. For example, the daily candidate dose for an adult human of approximately 70 kg body weight will range from 1 mg to 1000 mg, or between 5 mg and 500 mg, and may take the form of single or multiple doses.
In yet another embodiment, the present application discloses pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and a pharmaceutically acceptable carrier or exipient.
In yet another embodiment, the present application discloses pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional therapeutic agent, and a pharmaceutically acceptable carrier or exipient. According to the present invention, the therapeutic agent used in combination with the compound of the present invention can be any agent having a therapeutic effect when used in combination with the compound of the present invention. For example, the therapeutic agent used in combination with the compound of the present invention can be any agent that is accessible to oxidative metabolism by cytochrome P450 enzymes, especially cytochrome P450 monooxygenase, e.g., 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2El, 3A4,5,7, etc.
In another example, the therapeutic agent used in combination with the compound of the present invention can be any anti- viral agent e.g., anti-HIV, anti- HCV, etc., anti -bacterial agent, anti-fungal agent, immuno-modulator, e.g., immunosuppressant, anti-neoplastic agent, chemotherapeutic agent, agents useful for treating cardiovascular conditions, neurological conditions, etc.
In yet another example, the therapeutic agent used in combination with the compound of the present invention can be any proton pump inhibitor, anti- epileptics, NSAID, oral hypoglycemic agent, angiotensin II, sulfonylureas, beta blocker, antidepressant, antipsychotics, or anesthetics, or a combination thereof.
In yet another example, the therapeutic agent used in combination with the compound of the present invention can be any 1) macrolide antibiotics, e.g., clarithromycin, erythromycin, telithromydn, 2) anti-arrhythmics, e.g., quinidine=>3-OH, 3) benzodiazepines, e.g., alprazolam, diazepam=>3OH, midazolam, triazolam, 4) immune modulators, e.g., cyclosporine, tacrolimus (FK506), 5) HIV antivirals, e.g., indinavir, nelfinavir, ritonavir, saquinavir, 6) prokinetic, e.g., cisapride, 7) antihistamines, e.g., astemizole, chlorpheniramine, terfenidine, 8) calcium channel blockers, e.g., amlodipine, diltiazem, felodipine, lercanidipine, nifedipine, nisoldipine, nitrendipine, verapamil, 9) HMG CoA reductase inhibitors, e.g., atorvastatin, cerivastatin, lovastatin, simvastatin, or 10) steroid 6beta-OH, e.g., estradiol, hydrocortisone, progesterone, testosterone. In still yet another example, the therapeutic agent used in combination with the compound of the present invention can be any alf entanyl, aprepitant, aripiprazole, buspirone, cafergot, caffeine, TMU, cilostazol, cocaine, codeine- N- demethylation, dapsone, dextromethorphan, docetaxel, domperidone, eplerenone, fentanyl, finasteride, gleevec, haloperidol, irinotecan, LAAM, lidocaine, methadone, nateglinide, ondansetron, pimozide, propranolol, quetiapine, quinine, salmeterol, sildenafil, sirolimus, tamoxifen, taxol, terfenadine, trazodone, vincristine, zaleplon, or Zolpidem or a combination thereof.
In one embodiment, the present application discloses pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional therapeutic agent selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, non-nucleoside inhibitors of HCV, CCR5 inhibitors, and combinations thereof, and a pharmaceutically acceptable carrier or exipient.
In another embodiment, the present application provides pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional therapeutic agent selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AGl 776), L-756423, RO0334649, KNI-272, DPC- 681, DPC-684, GW640385X, DG17, PPL-100, DG35, AG 1859, capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, TMC-120, TMC-278 (rilpivϊrene), BILR 355 BS, VRX 840773, UK-453061, RDEA806, zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, Radvir (±-FTC), D-d4FC, phosphazide, fozivudine tidoxil, apricitibine AVX754, amdoxovir, KP-1461, and fosalvudine tidoxil (formerly HDP 99.0003), tenofovir disoproxil fumarate, adefovir dipivoxil, GS-9131, curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric add, 3,5- dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, L-870810, MK-0518 (raltegravir), elvitegravir, BMS-538158, GSK364735C, BMS-707035, MK- 2048, BA 011, enfuvirtide, sifuvirtide, FB006M, TRI-1144, AMD-070, SPOlA, BMS- 488043, BlockAide/ CR, immunitin, benzimidazole derivatives, benzo-1,2,4- thiadiazine derivatives, phenylalanine derivatives, aplaviroc, vicriviroc, and maraviroc, cyclosporine, FK-506, rapamycin, taxol, taxotere, clarithromycin, A- 77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629 (N,N-dimethylglycyl-N-(2-hydroχy-3-(((4-methoxyρhenyl)sulρhonyl)(2- methylpropyl)amino)-l -(phenylmethyl)propyl)-3-methyl-L-valinamide), KNI- 272, CGP 53437, CGP 57813 and U-103017 and a pharmaceutically acceptable carrier or exipient.
In still another embodiment, the present invention provides pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with two or three additional therapeutic agents. For example, a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, is combined with two or three additional therapeutic agents selected from the classes of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and HIV integrase inhibitors. The two or three additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, or they can be selected from different classes of therapeutic agents. The compounds of the present invention in such ternary or quaternary combinations can include any of the compounds of Formula I disclosed herein, for example a compounds of Formula IIA-D or Formula IV. In a particular embodiment, the pharmaceutical compositions of the present invention comprises a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, combined with two or three additional therapeutic agents selected from the classes of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and HIV integrase inhibitors. In a still more particular embodiment, the pharmaceutical composition of the present invention comprises Example P, S, or X, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with two or three additional therapeutic agents selected from the classes of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and HIV integrase inhibitors. For example, such combinations can comprise Example P, S, or X, or a pharmaceutically acceptable salt, solvate, and/or ester thereof in combination with two or three additional therapeutic agents selected from the group consisting of tenofovir disoproxil fumarate, GS-9131, emtridtabine, elvitegravir, efavrenz, atazanavir, darunavir, raltegravir, and rilpivirine (or pharmaceutically acceptable salts, solvates, and/or esters thereof). Specific embodiments of ternary combinations comprise, for example, Example P/tenofovir disoproxil fumarate/GS-9131, Example P/tenofovir disoproxil fumarate/emtricitabine, Example P/tenofovir disoproxil fumar ate/el vitegravir, Example P/tenofovir disoproxil fumarate/efavrenz, Example P/tenofovir disoproxil fumarate/atazanavir, Example P/tenofovir disoproxil fumarate/darunavir, Example P/tenofovir disoproxil fumarate/raltegravir, Example P/tenofovir disoproxil fumarate/rilpivirine, Example P/GS-9131/emtricitabine, Example P/GS-9131/eIvitegravir, Example P/GS-9131/efavrenz, Example P/GS~9131/atazanavir, Example P/GS- 9131/darunavir, Example P/GS-9131/raltegravir, Example P/GS-9131/rilρivirine, Example P/emtricitabine/elvitegravir, Example P/erntricitabine/efavrenz, Example P/emtricitabine/atazanavir, Example P/emtricitabine/darunavir, Example P/emtricitabine/raltegravir, Example P/emtricitabine/rilpivirine, Example P/elvitegravir/efavrenz, Example P/elvitegravir/atazanavir, Example P/elvitegravir/darunavir, Example P/elvitegravir/raltegravϊr, Example P/elvitegravir/rilpivirine, Example P/efavrenz/atazanavir, Example P/efavrenz/damnavir, Example P/efavrenz/raltegravir, Example P/efavrenz/rilpivirine, Example P/atazanavir/darunavir, Example P/atazanavir/raltegravir, Example P/atazanavir/rilpivirine, Example P/darunavir/raltegravir, Example P/darunavir/rilpivirine, Example P/raltegravir/rilpivirine, Example S/tenofovir disoproxil fumarate/GS-9131, Example S/tenofovir disoproxil fumarate/emtricitabine, Example S/tenofovir disoproxil fumarate/elvitegravir, Example S/tenofovir disoproxil fumarate/efavrenz, Example S/tenofovir disoproxil fumarate/atazanavir, Example S/tenofovir disoproxil fumarate/darunavir, Example S/tenofovir disoproxil fumarate/raltegravir, Example S/tenofovir disoproxil fumarate/rilpivirine, Example S/GS-9131/emtricitabine, Example S/GS-9131/elvitegravir, Example S/GS-9131/efavrenz, Example S/GS-9131/atazanavir, Example S/GS- 9131/darunavir, Example S/GS-9131/raltegravir, Example S/GS-9131/riIpivirine, Example S/emtricitabine/elvitegravir, Example S/emtricitabine/efavrenz, Example S/emtricitabine/atazanavir, Example S/emtricitabine/darunavir, Example S/emtricitabine/raltegravir, Example S/emtπcitabine/rilpivirine, Example S/elvite gr a vir/ef avrenz, Example S/elvitegravir/atazanavir, Example S/elvitegravir/darunavir, Example S/elvitegravir/raltegravir, Example S/elvitegravir/rirpivirine, Example S/efavrenz/atazanavir, Example S/efavrenz/darunavir, Example S/efavrenz/raltegravir, Example S/efavrenz/rilpivirine, Example S/atazanavir/darunavir, Example S/atazanavir/raltegravir, Example S/atazanavir/rilpivirine, Example S/darunavir/raltegravir, Example S/darunavir/rilpivirine, Example S/raltegravir/rilpivirine, Example X/tenofovir disoproxil fumarate/GS-9131, Example X/tenofovir disoproxil fumarate/emtricitabine, Example X/tenofovir disoproxil fumarate/elvitegravir, Example X/tenofovir disoproxil fumarate/ef avrenz, Example X/tenofovir disoproxil fumarate/atazanavir, Example X/tenofovir disoproxil fumarate/daranavir, Example X/tenofovir disoproxil fumarate/raltegravir, Example X/tenofovir disoproxil fumarate/rilpivirine/ Example X/GS-9131/emtricitabine, Example X/GS-9131/elvitegravir, Example X/GS-9131/efavrenz, Example X/GS~9131/atazanavir, Example X/GS- 9131/darunavir, Example X/GS-9131/raltegravir, Example X/GS-9131/rilpivirine, Example X/emtricitabine/elvitegravir, Example X/emtricitabine/ef avrenz, Example X/emtricitabine/atazanavir, Example X/emtricitabine/darunavir, Example X/emtricitabine/raltegravir, Example X/emtricitabine/rilpivirine, Example X/elvitegravir/efavrenz, Example X/elvitegravir/atazanavir, Example X/elvitegravir/darunavir, Example X/elvitegravir/raltegravir, Example X/elvitegravir/rilpivirine, Example X/efavrenz/atazanavir, Example X/efavrenz/darunavir, Example X/efavrenz/raltegravir, Example X/efavrenz/rilpivirine, Example X/atazanavir/darunavir, Example X/atazanavir/raltegravir, Example X/atazanavir/rilpivirine, Example X/darunavir/raltegravir, Example X/darunavir/rilpivirine, and Example X/raltegravir/rilpivirine (including pharmaceutically acceptable salts, solvates, and/or esters of any of the above).
Specific embodiments of quaternary combinations comprise, for example, Example P/tenofovir disoproxil fumarate/GS-9131/emtricitabine, Example P/tenofovir disoproxil fumarate/GS-9131/elvitegravir, Example P/tenofovir disoproxil fumarate/GS-9131/efavrenz, Example P/tenofovir disoproxil fumarate/GS-9131/atazanavir, Example P/tenofovir disoproxil fumarate/GS- 9131/darunavir, Example P/tenofovir disoproxil fumarate/GS-9131/raltegravir, Example P/tenofovir disoproxil fumarate/GS-9131/rilpiviiϊne, Example P/tenofovir disoproxil fumarate/emtriritabine/elvitegravir, Example P/tenofovir disoproxil fumarate/emtricitabme/efavrenz, Example P/tenofovir disoproxil fumarate/emtricitabine/atazanavir, Example P/tenofovir disoproxil fumarate/emtricitabine/damnavir, Example P/tenofovir disoproxil fumarate/emtricitabine/raltegravir, Example P/tenofovir disoproxil fumarate/emtricitabine/rilpivirine, Example P/tenofovir disoproxil fumarate/elvitegravir/efavrenz, Example P/tenofovir disoproxil fumarate/elvitegravir/atazanavir, Example P/tenofovir disoproxil fumarate/elvitegravir/damnavir, Example P/tenofovir disoproxil fumarate/elvitegravir/raltegravir, Example P/tenofovir disoproxil fumarate/elvitegravir/rilpivirine, Example P/tenofovir disoproxil fumarate/efavrenz/atazanavir, Example P/tenofovir disoproxil fumarate/efavrenz/darunavir, Example P/tenofovir disoproxil fumarate/efavrenz/raltegravir, Example P/tenofovir disoproxil fumarate/efavrenz/rilpivirine, Example P/tenofovir disoproxil fumarate/atazanavir/darunavir, Example P/tenofovir disoproxil fumarate/atazanavir/raltegravir, Example P/tenofovir disoproxil fumarate/atazanavir/rilpivirine, Example P/tenofovir disoproxil fumarate/darunavir/raltegravir, Example P/tenofovir disoproxil fumarate/darunavir/rilpivirine, Example P/tenofovir disoproxil fumarate/raltegravir/rilpivirine, Example P/GS-9131/emtricitabine/elvitegravir, Example P/GS-9131/emtricitabme/efavrenz, Example P/GS- 9131/emtricitabine/atazanavir, Example P/GS-9131/emtridtabine/darunavir, Example P/GS-9131/emtricitabine/raltegravir, Example P/GS- 9131/emtricitabine/rilpivirme, Example P/GS-9131/elvitegravir/efavrenz, Example P/GS-9131/eIvitegravir/atazanavir, Example P/GS-9131/elvitegravir/darunavir, Example P/GS-9131/elvitegravir/raltegravir, Example P/GS- 9131/elvitegravir/rilpivirine, Example P/GS-9131/efavrenz/atazanavir, Example P/GS-9131/efavrenz/damnavir, Example P/GS-9131/efavrenz/raltegravir, Example P/GS-9131/efavrenz/rilpivirine, Example P/GS-9131/atazanavir/darunavir, Example P/GS-9131/atazanavir/raltegravir, Example P/GS- 9131/atazanavir/rilpivirine, Example P/GS-9131/darunavir/raltegravir, Example P/GS-9131/darunavir/rilpivirine, Example P/GS-9131/raltegravir/rilpivirine, Example P/emtricitabine/elvitegravir/efavrenz, Example P/emtricitabine/elvitegravir/atazanavir, Example P/emtricitabine/elvitegravir/darunavir, Example P/emtricitab ine/elvitegr a vir/raltegr avir, Ex ample P/emtricitabine/elvitegravir/rilpivirine, Example P/emtricitabine/efavrenz/atazanavir, Example P/emtr icitabine/ef a vrenz/d aruna vir, Ex ample P/emtricitabine/efavrenz/raltegravir, Example P/emtricitab ine/ef a vrenz/rilpivirine, Example P/emtricitabine/atazanavir/darunavir, Example P/emtricitabine/atazana vir/r alte gr a vir, Example P/emtricitabrne/atazanavir/rilpivirine, Example P/emtricitabine/darunavir/raltegravir, Example P/emtricitabine/darunavir/rilpivirine, Example P/emtricitabine/r altegra vir/rilpi virine, Examp Ie
P/elvitegravir/efavrenz/atazanavir, Example P/elvitegravir/efavrenz/darunavir, Example P/elvitegravir/efavrenz/raltegravir, Example
P/elvitegravir/efavrenz/rilpivirine, Example P/elvitegravir/atazanavir/darunavir, Example P/e lvitegr a vir/atazana vir/r altegra vir, Example P/elvitegravir/atazanavir/rilpivirine, Example
P/elvitegravir/darunavir/raltegravir, Example P/elvitegravir/darunavir/rilpivirine, Example P/elvitegravir/raltegravir/rilpivirine, Example
P/efavrenz/atazanavir/darunavir, Example P/efavrenz/atazana.vir/raltegravir, Example P/efavrenz/atazanavir/rilpiviπne, Example
P/efavrenz/darunavir/raltegravir, Example P/efavrenz/darunavir/rilpivirine, Example P/efavrenz/raltegravir/rilpivirine, Example
P/atazanavir/darunavir/raltegravir, Example P/atazanavir/darunavir/rilpivirine, Example P/darunavir/raltegravir/rilpivirine, Example S/tenofovir disoproxil fumarate/GS-9131/emtricitabine, Example S/tenofovir disoproxil jfumarate/GS- 9131/elvitegravir, Example S/tenofovir disoproxil fιimarate/GS-9131/efavrenz, Example S/tenofovir disoproxil fumarate/GS-9131/atazanavir, Example S/tenofovir disoproxil iumarate/GS-9131/darunavir, Example S/tenofovir disoproxil fumarate/GS-9131/raltegravir, Example S/tenofovir disoproxil fumarate/GS-9131/rilpivirine, Example S/tenofovir disoproxil fumarate/emtricitabine/elvitegravir, Example S/tenofovir disoproxil fumarate/emtricitabine/efavrenz, Example S/teno£ovir disoproxil fumarate/emtricitabine/atazanavir, Example S/tenofovir disoproxil fumarate/emtricitabine/darunavir, Example S/tenofovir disoproxil fumarate/emtricitabine/raltegravir, Example S/tenofovir disoproxil fumarate/emtricitabine/rilpivirine, Example S/tenofovir disoproxil fumarate/elvitegravir/efavrenz, Example S/tenofovir disoproxil fumarate/elvitegravir/atazanavir, Example S/tenofovir disoproxil fumarate/elvitegravir/darunavπv Example S/tenofovir disoproxil fumarate/elvitegravir/raltegravir, Example S/tenofovir disoproxil fumarate/elvitegravir/rilpivirine, Example S/tenofovir disoproxil fumarate/efavrenz/atazanavir, Example S/tenofovir disoproxil fumarate/efavrenz/darunavir, Example S/tenofovir disoproxil fumarate/efavrenz/raltegravir, Example S/tenofovir disoproxil fumarate/efavrenz/rilpivirine, Example S/tenofovir disoproxil fumarate/atazanavir/darunavir, Example S/tenofovir disoproxil fumarate/atazanavir/raltegravir, Example S/tenofovir disoproxil fumarate/atazanavir/rilpivirine, Example S/tenofovir disoproxil fumarate/darunavir/raltegravir, Example S/tenofovir disoproxil fumarate/darunavir/rilpivirine, Example S/tenofovir disoproxil fumarate/raltegravir/rilpivirine, Example S/GS-9131/emtricitabine/elvitegravir, Example S/GS-9131/emtricitabine/efavrenz, Example S/GS- 9131/emtricitabine/atazanavir, Example S/GS-9131/emtricitabine/darunavir, Example S/GS-9131/emtricitabine/raltegravir, Example S/GS- 9131/emtricitabine/rilpivirine, Example S/GS-9131/elvitegravir/efavrenz, Example S/GS-9131/elvitegravir/atazanavir, Example S/GS-9131/elvitegravir/darunavir, Example S/GS-9131/elvitegravir/raltegravir, Example S/GS- 9131/elvitegravir/rilpivirine, Example S/GS-9131/efavrenz/atazanavir, Example S/GS-9131/efavrenz/darunavir, Example S/GS-9131/efavrenz/raltegravir, Example S/GS-9131/efavrenz/rilpivirin.e, Example S/GS-9131/atazanavir/darunavir, Example S/GS-9131/atazanavir/raltegravir, Example S/GS- 9131/atazanavir/rilpivirine, Example S/GS-9131/darunavir/raltegravir, Example S/GS-9131/daninavir/rilpivirine, Example S/GS-9131/raltegravir/rilpivirine, Example S/emtricitabine/elvitegravir/efavrenz, Example S/emtricitab ine/el vitegr a vir/atazanavir, Example S/emtricitabine/elvitegravir/darunaviiv Example S/emtricitabine/elvitegravir/raltegravir, Example S/emtricitabine/elvitegravir/rilpivirine, Example S/emtricitabine/efavrenz/atazanavrr, Example S/emtricitabine/efavrenz/darunavir, Example S/emtricitabine/efavrenz/raltegravir, Example S/emtricitabine/efavrenz/rilpivirine, Example S/emtricitabine/ataza na vir/daruna vir, Examp Ie S/emtricitablne/atazanavir/raltegravir, Example S/emtricitabine/atazana vir/rilpi virine, Examp Ie S/emtricitabine/darunavir/raltegravir, Example S/emtricitabine/darunavir/rilpivirine, Example S/emtricitabine/raltegravir/rilpivirine, Example
S/el vitegr a vir/efavrenz/atazana vir, Example S/elvitegravir/efavrenz/darunavir, Example S/elvitegravir/efavrenz/raltegravir, Example
S/elvitegravir/efavrenz/rilpivirine, Example S/elvitegravir/atazanavir/darunavir, Example S/elvitegravir/atazanavir/raltegravir, Example S/el vitegr avir/atazanavir/r ilpi virine, Examp Ie
S/elvitegravir/darunavir/raltegravir, Example S/elvitegravir/darunavir/rilpivirine, Example S/elvitegravir/raltegravir/rilpivirine, Example S/efavrenz/atazanavir/darunavir, Example S/efavrenz/atazanavir/raltegravir, Example S/efavrenz/atazanavir/rilpivirine, Example
S/efavrenz/darunavir/raltegravir, Example S/efavrenz/darunavir/rilpivirine, Example S/efavrenz/raltegravir/rilpivirine, Example
S/atazana vir/d aruna vir/r altegra vir, Example S/atazana vir/d arunavir/rilpi vir ine, Example S/darunavir/raltegravir/rilpivirine, Example X/tenofovir disoproxil fumarate/GS-9131/emtricitabine, Example X/tenofovir disoproxil fumarate/GS- 9131/elvitegravir, Example X/tenofovir disoproxil fumarate/GS-9131/efavrenz, Example X/tenofovir disoproxil fumarate/GS-9131/atazanavir, Example X/tenofovir disoproxil fumarate/GS-9131/darunavir, Example X/tenofovir disoproxil fumarate/GS-9131/raltegravir, Example X/tenofovir disoproxil fumarate/GS-9131/rilpivirine, Example X/tenofovir disoproxil fumarate/emtricitabine/elvitegravir, Example X/tenofovir disoproxil fumarate/emtridtabine/efavrenz/ Example X/tenofovir disoproxil fumarate/emtricitabine/atazanavir, Example X/tenofovir disoproxil fumarate/emtiϊcitabine/darunavir, Example X/tenofovir disoproxil fumarate/emtricitabine/raltegravir, Example X/tenofovir disoproxil fumarate/emtrititabine/rilpivirine, Example X/tenofovir disoproxil fumar ate/el vitegra vir /ef a vrenz, Example X/tenofovir disoproxil fumarate/elvitegravir/atazanavir, Example X/tenofovir disoproxil fumarate/elvitegravir/darunavir, Example X/tenofovir disoproxil fumarate/elvitegravir/raltegravir, Example X/tenofovir disoproxil fumarate/elvitegravir/rilpivirine, Example X/tenofovir disoproxil fumarate/efavrenz/atazanavir, Example X/tenofovir disoproxil fumarate/efavrenz/damnavir, Example X/tenofovir disoproxil fumarate/efavrenz/raltegravir, Example X/tenofovir disoproxil fumarate/efavrenz/rilpivirine/ Example X/tenofovir disoproxil fumarate/atazanavir/damnavir, Example X/tenofovir disoproxil fumarate/atazanavir/raltegravir, Example X/tenofovir disoproxil fumar ate/a tazanavir/rilpivirine, Example X/tenofovir disoproxil fumarate/darunavir/raltegravir, Example X/tenofovir disoproxil fumarate/darunavir/rilpivirine, Example X/tenofovir disoproxil f umar ate/r altegr a vir/rilpi vir ine, Example X/GS-9131 /emtricitabine/elvitegr a vir, Example X/GS-9131/emtricitabine/efavrenz, Example X/GS- 9131/emtridtabine/atazanavir, Example X/GS-9131/emtricitabine/darunavir, Example X/GS-9131/emtricitabine/raltegravir, Example X/GS- 9131/emtrititabine/rilpivirine, Example X/GS-9131/elvitegravir/efavrenz, Example X/GS-9131/elvitegravir/atazanavir, Example X/GS-9131/elvitegravir/darunavir, Example X/GS-9131/elvitegravir/raltegravir, Example X/GS- 9131/elvitegravir/rilpiviriney Example X/GS-9131/efavrenz/atazanavir, Example X/GS-9131/efavrenz/darunavir, Example X/GS-9131/efavrenz/raltegravir, Example X/GS-9131/efavrenz/rilpivirine, Example X/GS-9131/atazanavir/darunavir, Example X/GS-9131/atazanavir/raltegravir/ Example X/GS- 9131/atazanavir/rilpivirine, Example X/GS-9131/darunavir/raltegravir, Example X/GS-9131/darunavir/rilpivirine, Example X/GS-9131/raltegravir/rilpivirine, Example X/emtricitabine/elvitegravir/efavrenz, Example X/emtricitabine/elvitegravir/atazanavir, Example X/emtricitabine/elvitegravir/darunavir, Example X/emtricitabine/elvitegravir/raltegravir, Example X/emtr icitab ine/elvitegra vir/rilpivir ine, Ex ample X/emtricitabme/efavrenz/atazanavir, Example X/emtricitabine/efavrenz/darunavir, Example X/emtricitabine/efavrenz/raltegravir, Example X/emtricitabine/efavrenz/rilpivirine, Example X/emtricitabine/atazaπavir/darunavir, Example X/emtricitabine/atazanavir/raltegravir, Example X/emtricitabine/atazanavir/rilpivirine, Example X/emtricitabine/darunavir/raltegravir, Example X/emtrititabine/darunavir/rirpivirine, Example X/emtricitabine/raltegravir/rilpivirine, Example
X/el vite gr avir/ef a vrenz/atazaπa vir, Examp Ie X/el vite gra vir/ef avr enz/d arunavir, Example X/el vitegr a vir/ef a vrenz/ralte gravis Example
X/elvitegravir/efavrenz/rilpivirine, Example X/elvitegravir/atazanavir/darunavir, Example X/elvitegravir/atazanavir/raltegravir, Example X/elvitegravir/atazanavir/rilpivirine, Example X/el vitegr avir/d arunavir /raltegr a vir, Example X/elvitegravir/darunavir/rilpivirine, Example
X/elvitegravir/raltegravir/rilpivirine, Example X/efavrenz/atazanavir/darunavir, Example X/efavrenz/atazanavir/raltegravir, Example
X/efavrenz/atazanavir/rilpivirine, Example X/ef a vrenz/d arunavir /raltegravir, Example X/ef avrenz/darunavir/rilpivirine, Example
X/efavrenz/raltegravir/rilpivirine, Example X/atazanaviτ/darunavir/raltegravir, Example X/atazanavir/darunavir/rilpivirine, and Example X/darunavir/raltegravir/rilpivirine (including pharmaceutically acceptable salts, solvates, and/or esters of any of the above).
In yet another embodiment, the present application provides a combination pharmaceutical agent comprising: a) a first pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, or ester thereof; and b) a second pharmaceutical composition comprising at least one additional therapeutic agent selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gpl20 inhibitors, CCR5 inhibitors, interferons, ribavirin analogs, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, and combinations thereof.
Routes of Administration
One or more compounds of the invention {herein referred to as the active ingredients) are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient. An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.
Combination Therapy
In one embodiment, the compounds of the present invention can be used alone, e.g., for inhibiting cytochrome P450 monooxygenase. In another embodiment, the compounds of the present invention are used in combination with other active therapeutic ingredients or agents. Preferably, the other active therapeutic ingredients or agents are metabolized or accessible to the oxidative metabolism by cytochrome P450 enzymes, e.g., monooxygenase enzymes such as 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2El, 3A4,5,7, etc. Combinations of the compounds of the present invention are typically selected based on the condition to be treated, cross-reactivities of ingredients and pharmaco-properties of the combination. For example, when treating an infection (e.g., HIV or HCV), the compositions of the invention are combined with anti- infective agents (such as those described herein).
In one embodiment, non-limiting examples of suitable combinations include combinations of one or more compounds of the present invention with one or more anti-viral agents, e.g., anti-HIV, anti-HCV, etc., anti-bacterial agents, anti-fungal agents, immuno-modulators, e.g., immunosuppressant, anti-neoplastic agents, chemo therapeutic agents, agents useful for treating cardiovascular conditions, neurological conditions, etc.
In another embodiment, non-limiting examples of suitable combinations include combinations of one or more compounds of the present invention with one or more proton pump inhibitors, anti-epileptics, NSAIDs, oral hypoglycemic agents, angiotensin II, sulfonylureas, beta blockers, antidepressants, antipsychotics, or anesthetics, or a combination thereof.
In yet another embodiment, non-limiting examples of suitable combinations include combinations of one or more compounds of the present invention with one or more 1) macrolide antibiotics, e.g., clarithromycin, erythromycin, telithromycin, 2) anti-arrhythmics, e.g., quinidine=>3-OH, 3) benzodiazepines, e.g., alprazolam, diazepam=>3OH, midazolam, triazolam, 4) immune modulators, e.g., cyclosporins, tacrolimus (FK506), 5) HIV antivirals, e.g., indinavir, nelfinavir, ritonavir, saquinavir, 6) prokinetic, e.g., cisapride, 7) antihistamines, e.g., astemizole, chlorpheniramine, terfenidine, 8) calcium channel blockers, e.g., amlodipine, diltiazem, felodipine, lercanidipine, nifedipine, nisoldipine, nitrendipine, verapamil, 9) HMG CoA reductase inhibitors, e.g., atorvastatin, cerivastatin, lovastatin, simvastatin, or 10) steroid 6beta-OH, e.g., estradiol, hydrocortisone, progesterone, testosterone.
In still yet another embodiment, non-limiting examples of suitable combinations include combinations of one or more compounds of the present invention with one or more compounds selected from the group consisting of alfentanyl, aprepitant, aripiprazole, buspirone, cafergot, caffeine=>TMU, cilostazol, cocaine, codeine- N-demethylation, dapsone, dextromethorphan, docetaxel, domperidone, eplerenone, fentanyl, finasteride, gleevec, haloperidol, irinotecan, LAAM, lidocaine, methadone, nateglinide, odanestron, pimozide, propranolol, quetiapine, quinine, salmeterol, sildenafil, sirolimus, tamoxifen, taxol, terfenadine, trazodone, vincristine, zaleplon, and Zolpidem or a combination thereof.
In still yet another embodiment, non-limiting examples of suitable combinations include combinations of one or more compounds of the present invention with one or more HIV protease inhibiting compounds, HIV non- nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gpl20 inhibitors, CCR5 inhibitor and other drugs for treating HIV, interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, nucleoside or nucleotide inhibitors of HCV, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.
More specifically, one or more compounds of the present invention may be combined with one or more compounds selected from the group consisting of 1) amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, damnavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, GS-8374, PPL-100, DG35, and AG 1859, 2) a HIV non- rmcleoside inhibitor of reverse transcriptase, e.g., capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC- 083, DPC-961, DPC-963, MIV-150, and TMC-120, TMC-278 (rilpivirene), efavirenz, BILR 355 BS, VRX 840773, UK-453061, and RDEA806, 3) a HIV nucleoside inhibitor of reverse transcriptase, e.g., zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±-FTC), D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, apricitibine (AVX754), GS-7340, KP-1461, and fosalvudine tidoxil (formerly HDP 99.0003), 4) a HIV nucleotide inhibitor of reverse transcriptase, e.g., tenofovir disoproxil fumarate and adefovir dipivoxil, 5) a HIV integrase inhibitor, e.g., curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5- dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, and L- 870810, MK-0518 (raltegravir), elvitegravir, BMS-538158, GSK364735C, BMS- 707035, MK-2048, and BA 011, 6) a gp41 inhibitor, e.g., enfuvirtide, sifuvirtide, FB006M, and TRI-1144, 7) a CXCR4 inhibitor, e.g., AMD-070, 8) an entry inhibitor, e.g., SPOlA, 9) a gρl20 inhibitor, e.g., BMS-488043 or BlockAide/ CR, 10) a G6PD and NADH-oxidase inhibitor, e.g., immunitin, 11) a CCR5 inhibitor, e.g., aplaviroc, vicriviroc, maraviroc, PRO-140, INCB15050, PF-232798 (Pfizer), and CCR5mAbOO4, 12) other drugs for treating HIV, e.g., BAS-100, SPI-452, REP 9, SP- 01 A, TNX-355, DES6, ODN-93, ODN-112, VGV-I, PA-457 (bevirimat), Ampligen, HRG214, Cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO- 025, BAY 50-4798, MDXOlO (ipilimumab), PBS 119, ALG 889, and PA-1050040 (PA-040), 13) an interferon, e.g., pegylated rIFN-alpha 2b, pegylated rlFN-alpha 2a, rIFM-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), feron, reaferon, intermax alpha, r-IFN-beta, infergen + actimmune, IFN-omega with DUROS, albuferon, locteron, Albuferoπ, Rebif, Oral interferon alpha, IFNalpha-2b XL, AVI- 005, PEG-Infergen, and Pegylated IFN-beta, 14) a ribavirin analog, e.g., rebetol, copegus, viramidine (taribavirin), 15) a NS5b polymerase inhibitor, e.g., NM-283, valopidtabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048), VCH-759, PF-868554, and GSK625433, 16) A NS3 protease inhibitor, e.g., SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339, and ITMN-191, 17) an alpha-glucosidase 1 inhibitor, e.g., MX-3253 (celgosivir), UT-231B, 18) hepatoprotectants, e.g., IDN-6556, ME 3738, LB-84451, and MitoQ, 19) a non-nucleoside inhibitor of HCV, e.g., benztmidazole derivatives, benzo- 1,2,4-thiadiazine derivatives, phenylalanine derivatives, A-831, GS-9190, and A- 689; and 20) other drugs for treating HCV, e.g., zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN- 7000, dvacir, GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, tarvacin, EHC- 18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, Bavituximab, Oglufanide, and VX-497 (merimepodib).
It is also contemplated that the compounds of the present invention can be used with any other active therapeutic agent or ingredient which is appreciably metabolized by cytochrome P450 monooxygenase enzymes, e.g. cytochrome P450 monooxygenase 3A, thereby reducing the amount or rate at which the other active therapeutic agent or ingredient is metabolized, whereby the pharmacokinetics of the other active therapeutic agent or ingredient is improved. Such improvements can include elevating the blood plasma levels of the other therapeutic agent or ingredient or maintaining a more therapeutically effective blood plasma level of the other therapeutic active agent or ingredient — compared to blood plasma levels of the other therapeutic agent or ingredient administered without the compound of the present invention.
It is also possible to combine any compound of the invention with one or more other active therapeutic agents in a unitary dosage form for simultaneous or sequential administration to a patient. The combination therapy may be administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations.
Co-administration of a compound of the invention with one or more other active therapeutic agents generally refers to simultaneous or sequential administration of a compound of the invention and one or more other active therapeutic agents, such that therapeutically effective amounts of the compound of the invention and one or more other active therapeutic agents are both present in the body of the patient.
Co-administration includes administration of unit dosages of the compounds of the invention before or after administration of unit dosages of one or more other active therapeutic agents, for example, administration of the compounds of the invention within seconds, minutes, or hours of the administration of one or more other active therapeutic agents. For example, a unit dose of a compound of the invention can be administered first, followed within seconds or minutes by administration of a unit dose of one or more other active therapeutic agents. Alternatively, a unit dose of one or more other therapeutic agents can be administered first, followed by administration of a unit dose of a compound of the invention within seconds or minutes. In some cases, it may be desirable to administer a unit dose of a compound of the invention first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more other active therapeutic agents. In other cases, it may be desirable to administer a unit dose of one or more other active therapeutic agents first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the invention.
The combination therapy may provide "synergy" and "synergistic effect", i.e. the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately. A synergistic effect may be attained when the active ingredients are: (1) co- formulated and administered or delivered simultaneously in a combined formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen. When delivered in alternation therapy, a synergistic effect may be attained when the compounds are administered or delivered sequentially, e.g., in separate tablets, pills or capsules, or by different injections in separate syringes. In general, during alternation therapy, an effective dosage of each active ingredient is administered sequentially, i.e. serially, whereas in combination therapy, effective dosages of two or more active ingredients are administered together.
In yet another embodiment, the present application provides a method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
In yet another embodiment, the present application provides a method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a combination comprising said drug and a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof. In yet another embodiment, the present application provides a method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase 3A, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
In yet another embodiment, the present application provides a method for increasing blood plasma levels of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
In yet another embodiment, the present application provides a method for increasing blood plasma levels of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a combination comprising said drug and a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
In yet another embodiment, the present application provides a method for increasing blood plasma levels of a drug which is metabolized by cytochrome P450 monooxygenase 3A, comprising administering to a patient treated "with said drug, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
In yet another embodiment, the present application provides a method for increasing blood plasma levels of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and wherein the amount of the compound of the present invention administered is effective to inhibit cytochrome P450 monooxygenase.
In yet another embodiment, the present application provides a method for inhibiting cytochrome P450 monooxygenase in a patient comprising administering to a patient in need thereof an amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, effective to inhibit cytochrome P450 monooxygenase.
In yet another embodiment, the present application provides a method for inhibiting cytochrome P450 monooxygenase 3A in a patient comprising administering to a patient in need thereof an amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, effective to inhibit cytochrome P450 monooxygenase 3A.
In yet another embodiment, the present application provides a method for inhibiting cytochrome P450 monooxygenase comprising contacting cytochrome P450 monooxygenase with an amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, effective to inhibit cytochrome P450 monooxygenase.
In yet another embodiment, the present application provides a method for inhibiting cytochrome P450 monooxygenase 3A comprising contacting cytochrome P450 monooxygenase 3 A with an amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, effective to inhibit cytochrome P450 monooxygenase 3 A.
In yet another embodiment, the present application provides a method for treating an HIV infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.
In yet another embodiment, the present application provides a method for treating an HIV infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, and GW640385X, DG17, PPL-100, DG35, AG 1859, capravirine, emivirine, delaviridine, efavirenz, nevirapine, {+) calanolide A, etravirine, GW5634, DPC-083, DPO961, DPC-963, MIV-150, TMC-120, TMC-278 (rilpivirene), efavirenz, BILR 355 BS, VRX 840773, , UK-453061, RDEA806, zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±-FTC), D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, apricitibine (AVX754), amdoxovir, KP-1461, fosalvudine tidoxil (formerly HDP 99.0003), tenofovir disoproxil fumarate, adefovir dipivoxil, curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquink acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurin tricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, L-870810, MK-0518 (raltegravir), elvitegravir, BMS-538158, GSK364735C, BMS-707035, MK-2048, and BA 011, enfuvirtide, sifuvirtide, FB006M, and TRI-1144, AMD-070, an entry inhibitor, SPOlA, BMS-488043, BlockAide/ CR, a G6PD and NADH-oxidase inhibitor, immunitin, aplaviroc, vicriviroc, maraviroc, maraviroc, PRO-140, INCB15050, PF- 232798 (Pfizer), CCR5mAb004, BAS-100, SPI-452, REP 9, SP-OlA, TNX-355, DES6, ODN-93, ODN-112, VGV-I, PA-457 (bevirimat), Ampligen, HRG214, Cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDXOlO (ipilimumab), PBS 119, ALG 889, and PA-1050040 (PA-040).
In yet another embodiment, the present application provides a method for treating an HCV infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), feron, reaferon, intermax alpha, r-IFN-beta, infergen + actimmune, IFN-omega with DUROS, locteron, albuferon, rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and pegylated IFN-beta, rebetol, copegus, viramidine (taribavirin), NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048), VCH-759, PF-868554, GSK625433, SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339, ITMN-191, MX-3253 (celgosivir), UT-231B, IDN-6556, ME 3738, LB-84451, MitoQ, benzimidazole derivatives, benzo-l,2,4-thiadiazine derivatives, phenylalanine derivatives, A-831, A-689, zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, Bavituximab, Oglufanide, and VX-497 (merimepodib). In still yet another embodiment, the present application provides for the use of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for inhibiting cytochrome P450 monooxygenase in a patient.
In still yet another embodiment, the present application provides for the use of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for treating an HIV infection.
In still yet another embodiment, the present application provides for the use of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for increasing blood plasma levels of the drug which is metabolized by cytochrome P450 monooxygenase.
In still yet another embodiment, the present application provides for the use of a compound of the present invention or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
Examples
Preparation of Example A
Scheme 1
Figure imgf000218_0001
Example A
Compound 2
To a solution of Compound 1 (ritonavir) (1.8 g, 2.5 mmol) in 1,2- dichloroethane (15 mL) was added l,r-thiocarbonyldiimidazole (890 mg, 5.0 mmol). The mixture was heated at 750C for 6 hours and cooled to 25°C. Evaporation under reduced pressure gave a white solid. Purification by flash column chromatography (stationary phase: silica gel; eluent: EtOAc) gave Compound 2 (1.6 g). m/z: 831.1 (M+H)+. Example A
To the refluxing solution of tributyltin hydride (0.78 mL, 2.9 mmol) in toluene (130 mL) was added a solution of Compound 2 (1.6 g, 1.9 mmol) and 2,2'- azobisisobutyronitrile (31 mg, 0.19 mmol) in toluene (30 mL) over 30 minutes. The mixture was heated at 115°C for 6 hours and cooled to 250C. Toluene was removed under reduced pressure. Purification by flash column chromatography (stationary phase: silica gel; eluent: hexane/EtOAc = 1/10) gave Example A (560 mg). m/z: 705.2 (M+H)+. 1H-NMR (CDCb) δ 8.79 (1 H, s), 7.82 (1 H, s), 7.26-7.05 (10 H, m), 6.98 (1 H, s), 6.28 (1 H, m), 6.03 (1 H, m), 5.27 (1 H7 m), 5.23 (2 H, s), 4.45-4.22 (2 H, m), 4.17 (1 H, m), 3.98 (1 H, m), 3.75 (1 H, m), 3.25 (1 H, m), 2.91 (3 H, s), 2.67 (4 H, m), 2.36 (1 H, m), 1.6-1.2 (10 H, m), 0.85 (6 H, m).
Preparation of Example B Scheme 2
Figure imgf000219_0001
Example B
Example B
To a solution of Compound 1 (ritonavir) (98 mg, 0.136 mmol) in dichloromethane (4 mL) was added Dess-Martin periodinane (61 mg, 0.143 mmol). The mixture was stirred at room temperature for 6 hours. The mixture was then partitioned between dichloromethane and brine, the dichloromethane layer was separated, dried and evaporated to dryness. Purification with CombiFlash® (stationary phase: silica gel; eluent: 40-80% EtOAc/Hexane gradient) gave Example B as a white solid. Example B was further purified by trituration with MeOH/hexane to give 83 mg of a white solid, m/z: 719 (M+H)+. Preparation of Example C Scheme 3
Figure imgf000220_0001
3 4
I. cyclopropylamine, MeCN, rt
Compound 3
Compound 3 was prepared according to the procedures of T. Med. Chem. 1998, 41, 602, herein incorporated by reference in its entirety for all purposes. Compound 4
A flask was charged with cyclopropylamine (8.2 mL, 117.8 mmol) at room temperature. A solution of Compound 3 (1 g, 4.71 mmol) in MeCN (8.5 mL) was added dropwise over 5 min. to produce a clear yellow solution that was allowed to stand at room temperature overnight. Volatiles were removed in vacuo, and the resulting residue was purified via silica gel chromatography (gradient elution, 0 to 50% EtOAc/hexane) to afford 0.65 g (70%) of 4 as a yellow liquid (LC/MS mlz 197 (M+H)+; 218 (M+Na)+). Scheme 4
Figure imgf000220_0002
Ii. rt, DCM; ill. 1 M LiOH, THF/H2O
Compound 5
Compound 5 was purchased from Aldrich or alternatively prepared according to the procedures of T. Org. Chem. 1994, 59, 1937, herein incorporated by reference in its entirety for all purposes. Compound 6 To a solution of Compound 4 in DCM (3 mL) at room temperature was added 5 (0.1 mL, 0.695 mmol). The resulting clear solution was allowed to stand at room temperature for 2 h. The solvent was removed in vacuo, and the residue was chromatographed directly using silica gel chromatography (gradient elution, 0 to 50% EtOAc/hexane) to produce 0.218 g (89%) of 6 (LC/MS mlz 354 (M+H)+; 729 (2M + Na)+) as a colorless glass. Compound 7
Compound 6 was taken up in THF (5 mL) at room temperature, and LiOH (1 M in H2O) was added. The resulting reaction mixture was then stirred vigorously for 1.5 h. The reaction mixture was acidified with 1 M HCl to a pH of 3 (monitored using pH test strips). The acidified reaction mixture was then extracted several times with EtOAc. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to produce 0.20 g (quantitative yield) of 7 (LC/MS mlz 340 (M+H)+) as a colorless film. This material was used without further purification. Scheme 5
Figure imgf000221_0001
7 8 Example C
IV. EDC, HOBt, DIPEA, THF
Example C
Compounds 7 (0.034 g, 0.100 mmol) and 8, (0.034 g, 0.083 mmol) were diluted in THF (2 mL) at room temperature. To the resulting solution were added N,N-diisopropylethylamine (0.022 mL, 0.125 mmol), EDC (0.018 mL, 0.099 mmol) and HOBt (0.013 g, 0.099 mmol). The solution was then allowed to stand overnight at room temperature. The solvent was removed in vacuo and the residue was taken up in MeCN (0.5 mL) and passed through an Acrodisc LC13 PVDF filter (0.45 μM) prior to purification by preparatory HPLC to afford 0.043 g (71%) of Example C as a fluffy white solid. (1H-NMR (300 MHz, CDCb) δ 8.79 (s, IH); 7.82 (s, IH); 7.27-7.02 (m, 10 H); 6.81 (s, IH); 5.97 (br d, / = 8.7 Hz, IH); 5.76 (br cl, /= 7.2 Hz, IH); 5.21 (dt, J = 7.5, 12.6 Hz, 2H); 5.02, br d, J - 8.4 Hz, IH); 4.58 (s, 2H); 4.16 (m, IH); 3.99 (br t, / = 6.6 Hz, IH); 3.79 (m, IH); 3.27 (pent, / = 6.6 Hz, IH); 2.85-2.50 (m, 3H); 2.23 (m, IH); 1.82 (br s, 2H); 1.60-1.22 (m, 4H); 1.36 (d, 7 = 6.6 Hz, 6H); 0.91 (d, 7 = 6.6 Hz, 3H); 0.90-0.7 (m, 4H); 0.80 (d, J = 6.6 Hz, 3H); LC/MS mlz 731 (M+)).
Preparation of Examples D-I Scheme 6
Figure imgf000222_0001
a: R = H b: R = CH3
I. Et3N/DMAP/THF/65 0C; Jl. CH2CI2/25 0C; III. c: R= CH2CH3 a. NaOH/dioxane/H2O; d: R = CH2OBn b. HCI e: R = CH(O-t-Bu)CH3 f : R = CH(OH)CH3
Compound 9
Compound 9 was prepared according to the procedures of T. Med. Chem.
1998, 41, 602. Compound 10
The structures of Compound 10 were prepared according to the procedures of T. Med. Chem. 1998, 41, 602. Compound 11
The structures of Compound 11 were purchased from Aldrich or prepared according to the procedures of J. Org. Chem. 1994, 59, 1937. Compound 12
Method 1: To a solution of Compound 9 (0.8 mmol) in THF (2 mL) was added a carbamate of Compound 10 (0.6 mmol), followed by DMAP (16 mg) and triethylamine (0.25 mL). The resulting mixture was heated at 7O0C for two hours and diluted with EtOAc. The organic phase was separated, and washed sequentially with saturated aqueous Na2CO3, water, and brine, then concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 1/1 - 1/3 hexanes/EtOAc gradient) gave compounds of Structure 12.
Method 2: To a solution of Compound 9 (2.4 mmol) in CH2CI2 (2 mL) was added an isocyanate of Compound 11 (2 mmol). The resulting mixture was stirred for 4 hours and concentrated. Purification of the residue by flash column chromatography (silica gel, hexane/EtOAc 1/1 - 1/3) gave structures of Compound 12. Compound 13
To a solution of structures of Compound 12 (1.8 mmol) in dioxane (8 mL) and water (8 mL) was added sodium hydroxide (3.6 mmol). The resulting reaction mixture was stirred for 1 hour and acidified with HCl in dioxane (3.6 mmol). The reaction mixture was extracted with EtOAc and the organic phase was dried with anhydrous MgSO4. Concentration of the dried organic phase gave structures of Compound 13. Scheme 7
Figure imgf000224_0001
U 15 16
I. Et3NZDCM
Compound 16
To a solution of Compound 15 (obtained commercially from Molekula) (17 mmol) in DCM (40 niL) was added Compound 14 (19 mmol), followed by tiϊethylamine (26 mmol). The resulting reaction mixture was stirred for 12 hour and concentrated under reduced pressure. The reaction mixture was diluted with EtOAc and washed sequentially with saturated aqueous Na2CO3, water, and brine. The solvent was removed under reduced pressure. Purification of the residue by flash column chromatography (silica gel, eluent: hexanes/EtOAc = 1/1) gave Compound 16 (4.7 g).
Scheme 8
Figure imgf000225_0001
Examples:
D: R = H
E: R = CH3
F: R = CH2CH3
G: R = CH2OBn
H: R = CH(O-t-Bu)CH3
I: R = CH(OH)CH3
ϊ. a. n-BuLI/-78 C; b.i-Bu2AI(OMe); II. a. Ac2O/pyridine; b. Na-Hg/MeOH/THF; III. Na/NH3/-33 C; IV. a. H2/10%Pd/C; b. TFA/DCM; V. 16/Et3N; Vl. acid of structure 13/EDC/HOBt
Compound 17
Compound 17 was prepared according to the procedures of Tetrahedron 1997, 53, 4769, herein incorporated by reference in its entirety for all purposes. Compound 18
Compound 18 was prepared according to the procedures of T- Org. Chem. 1987, 52, 3759, herein incorporated by reference in its entirety for all purposes. Compound 19
A suspension of Compound 18 (7.4 mmol) in THF (200 mL) was heated under reflux until a clear solution was obtained. The solution was cooled to -780C and n-butyllithium (14.8 mmol) was added dropwise to provide a solution of the dianion of sulfone 18.
To a DIBAL-H solution (7.8 mmol) at O0C was added a solution of MeOH (7.8 mmol) in THF (5 mL). The mixture was stirred for 5 minutes and cooled to - 78°C. A solution of Compound 17 (6.6 mmol) in THF (5 mL) was added to the above DIBAL-H/MeOH solution, and the resulting reaction mixture was stirred for another 5 minutes. The resulting solution of aldehyde complexes was transferred to solution of the dianion of sulfone 18. The resulting mixture was stirred at -78°C for 30 minutes, quenched with an aqueous solution of NH4CI, and warmed to 250C. The mixture was then extracted with EtOAc, and concentrated to give Compound 19 as a mixture of diastereomers. (m/z 737.3 (M+Na)\ Example 20
To a solution of Compound 19 in DCM (20 mL) was added AC2O (1.5 mL), followed by pyridine (3 mL). The resulting mixture was stirred for 12 hours and concentrated. The concentrate was dissolved in MeOH (30 mL) and cooled to O0C. NaH2PO4 (4.9 g) was added to the solution, followed by freshly prepared Na-Hg (6%, 6 g). The resulting mixture was warmed to 25°C and stirred for 12 hours. Water (50 mL) was then added, and the mixture was filtered and concentrated. The concentrate was diluted with EtOAc and washed with brine. The organic phase was concentrated. Purification by flash column chromatography (silica gel, eluent: hexanes/EtOAc = 10/1) gave Compound 20 (1.4 g). Compound 21
To liquid ammonia (25 mL) at -33°C was added a solution of Compound 20 (1.4 g) in THF (2.5 mL). Sodium was slowly added until the blue color of the solution persisted. The resulting mixture was stirred for 1 hour. Solid NHUCl {6 g) was then added slowly, the mixture was warmed to 250C, and the ammonia was evaporated. The mixture was diluted with EtOAc, and washed sequentially with water and brine. The solvent was removed under reduced pressure. Purification of the resulting residue by flash column chromatography (silica gel, eluent: hexanes/EtOAc = 5/1) gave Compound 21 (1.15 g). Compound 22
A mixture of Compound 21 (1.15 g) and 10%Pd/C (160 mg) in MeOH (20 mL) was hydrogenated for 12 hours. CELITE was added and the resulting mixture was stirred for 5 minutes. The mixture was then filtered and concentrated to give an intermediate (1 g). The intermediate (700 mg) was dissolved in DCM (20 mL) and TFA (4 mL), and the resulting mixture was stirred for 4 hours, then concentrated under reduced pressure. The concentrated mixture was diluted with EtOAc, and washed sequentially with saturated aqueous Na2CO3, water, and brine. Concentration of the washed EtOAc mixture gave Compound 22 (420 mg). Compound 8
To a solution of Compound 22 (1.57 mmol) in CH3CN (16 mL) was added Compound 16 (1.57 mmol), followed by diisopropylethylamine (3.14 mmol). The resulting mixture was stirred for 12 hours. The mixture was then diluted with EtOAc, and washed sequentially with saturated aqueous Na2CO3, water and brine. Purification by reverse-phase HPLC (Phenomenex Synergi® Comb-HTS column, eluent: 25% - 100% CH3CN in water) gave Compound 8 (460 mg). Example D
To the solution of Compound 13a (R= H; 0.08 mmol) and Compound 8 (0.06 mmol) in THF (1 mL) were added HOBt (15 mg), EDC (26 mg), and disopropylethylamine (0.25 mL). The mixture was stirred for 12 hours and concentrated. Purification by reverse phase HPLC (Phenomenex Synergi® Comb- HTS column, eluent: 25% - 100% CHaCN in water) gave Example D (27 mg). m/z 663.1 (M-fH)+. 1H-NMR (CDCl3) δ 8.79 (1 H, s), 7.83 (1 H, s), 7.25-7.04 (10 H, m), 6.98 (1 H, s), 6.25 (1 H7 m)7 5-25 (3 H, m), 4.40 (2 H7 s), 4.12 (1 H7 m), 3.8 (3 H, m), 3.22 (1 H, m), 2.95 (3 H, s), 2.70 (4 H, m), 1.60 (4 H, m), 1.26 (6 H7 d, J = 7 Hz). Example E
Example E was prepared following the procedure for Example D (30 mg), except that Compound 13b was used instead of Compound 13a. m/z 677.1 (M+H)+. Example F
Compound F was prepared following the procedure for Example D (40 mg), except that Compound 13c was used instead of Compound 13a. m/z 691.2 (M+H)+. 1H-NMR (CDCl3) δ 8.80 (1 H7 s), 7.83 (1 H7. s), 7.25-7.06 (10 H, m), 6.98 (1 H7 s), 6.35 (1 H, m)7 6.23 (1 H, m), 5.24 (2 H, s), 5.12 (1 H7 m)7 4.34 (2 H7 s), 4.10 (2 H, m), 3.78 (1 H, m), 3.23 (1 H, m), 2.90 (3 H, s), 2.68 (4 H7 m), 1.90 (2 H, m), 1.7-1.4 (4 H7 m), 1.36 (6 H, d, J = 7.0 Hz), 0.90 (3 H7 1, J = 7.3 Hz) Example G
Example G was prepared following the procedure for Example D (84 mg), except that Compound 13d was used instead of Compound 13a. m/z 783.2 (M+H)\ Example H
Example H was prepared following the procedure for Example D (90 mg)7 except that Compound 13e was used instead of Compound 13a. m/z 763.2 (M+H)+. Example I
Example H (24 mg) was dissolved in TFA (2 mL) and the mixture was stirred for 12 hours, then concentrated. Purification by reverse phase HPLC (Phenomenex Synergi® Comb-HTS column, eluent: 25% - 100% CH3CN in water) gave Example I (14 mg). m/z 707.2 (M+H)+. 1H-NMR (CDCb) δ 8,82 (1 H, s), 7.85 (1 H, s), 7.26-7.04 (10 H, m), 7.0 (1 H, s), 5.25 (2 H, s), 4.86 (1 H, m), 4.56 (1 H, m), 4.37 (2 H, m), 4.13 (1 H, m), 4.06 (1 H, m), 3.86 (1 H, m), 3.32 (1 H, m), 2.99 (3 H, s), 2.8-2.6 (4 H, m), 1.6-1.4 (4 H, m), 1.37 (6 H, m), 1.15 (3 H, m). Preparation of Example T Scheme 9
Figure imgf000229_0001
Example I
Compound 23 was prepared following the procedure for Compound 13, with the exception that methyl 3-isocyanatopropionate was used instead of Compound 11.
Example J was prepared following the procedure for Example D (37 mg), except that Compound 23 was used instead of Compound 13a. m/z 677.2 (M+H)+.
Preparation of Example K Scheme 10
Figure imgf000230_0001
Figure imgf000230_0002
1. NaN3/DMF; II. PPh3/H2O; 111. a. CI3COCOOCCI3; b. HCI-NH2CHiPrCO2Et; IV. a. NaOH; b. HCI; V. EDC/HOBt/compound 8
Example K Compound 3a
Compound 5a was prepared following the literature procedure of Synthesis 823, 1976, herein incorporated by reference in its entirety for all purposes. Compound 3b
To the solution of Compound 3a (700 mg, 3.9 mmol) in THF (10 mL) was added water (69 μL, 3.9 mmol), followed by triphenylphosphine (1.06 g, 4.0 mmol). The mixture was stirred for 12 hours. Solvents were removed and the mixture was dried to give Compound 3b, which was used for next step without further purification. Compound 3c
To a solution of triphosgene (110 mg, 0.37 mmol) in CH2CI2 (2 mL) at 00C was added a solution of Compound 3b (1 mmol) and iPrNEt2 (0.38 mL, 2.2 mmol) in CH2CI2 (3.5 mL) over 30 minutes period. The mixture was stirred for 30 minutes, and a solution of amino N-methyl leucine methyl ester HCl salt (182 mg, 1 mmol) and iPrNEti (0.34 mL, 2.2 mmol) in CH2CI2 (2 mL) was added. The mixture was stirred for 12 hours, and diluted with EtOAc. The solution was washed with sat. Na2CO3 (2x), water (2x), and brine, and dried over Na2SO4. Concentration and purification with silica gel flash column gave Compound 5c (300 mg). Compound 3d
Compound 3d was prepared following the procedure for Compound 13, with the exception that Compound 3c was used instead of Compound 12. Example K
Example K was prepared following the procedure for Example D (7 mg), except that Compound 3d was used instead of Compound 13a. m/z 705.2 (M+H)+. 1H-NMR (CDCb) δ 8.8 (1 H, m), 7.86 (1 H, s), 7.26-6.8 (11 H, m), 6.10 (1 H, m), 5.5- 5.10 (4 H, m), 4.46 (2 H, m), 4.2-3.75 (3 H, m), 3.25 (1 H, m), 2.82/2.4 (3 H), 2.8-2.5 (4 H, m), 2.17 (1 H, m), 1.7-1.2 (10 H, m), 0.8 (6 H, m).
Preparation of Example L Scheme 11
Figure imgf000232_0001
Example L
I. Et3N
Example L
To a solution of Compound 22 (1.57 mmol) in CH3CN (16 mL) was added Compound 16 (3.14 mmol), followed by triethylamine (4.71 mmol). The resulting mixture was stirred for 12 hours. The reaction mixture was diluted with EtOAc and washed sequentially with saturated aqueous Na2CO3, water, and brine. The solvent was removed under reduced pressure. Purification of the residue by flash column chromatography (silica gel, eluent: hexanes/EtOAc = 1/1) gave Example L (460 mg). m/z 551.2 (M+H)+. 1H-NMR (CDCIs) 6 8.81 (2 H, s), 7.85 (2 H, s), 7.26-7.0 (10 H, m), 5.24 (4 H, s), 4.50 (2 H, m), 3.87 (2 H, m), 2.73 (4 H, m), 1.4-1.2 (4 H, m).
Alternate Preparation of Compound 22 Scheme 12
Figure imgf000233_0001
/ Ph ,Ph
1)1
CbzHN.^^. ^ . H2N
NHCbz " V v NH2
Ph^ PrT
27 22
I. TCDl/THF/65 0C; H. P(OEt}3/160 °C; III. 10%Pd/C/i-PrOH/EtOAc
Compound 25
Compound 25 was prepared following the literature procedure described in T, Org. Chem. 1996, 61, 444 (herein incorporated by reference in its entirety), except that the L-isomer was prepared instead of the D-isomer. Compound 26
A mixture of Compound 25 (7.4 g) and l,l'-thiocarbonyldiimidaxole (4.5 g) in THF (260 mL) was heated at 650C for 54 hours. Solvent was removed from the mixture under reduced pressure. Purification by flash column chromatography (silica gel, hexanes/EtOAc = 1/1) gave Compound 26 (7.33 g). Compound 27
The mixture of Compound 26 (7.3 g) and triethylphosphite (100 mL) was heated at 160βC for 4 hours. Excess reagents were removed under reduced pressure. Purification by flash column chromatography (silica gel, hexanes/EtOAc = 3/1) gave Compound 27 (5 g). Compound 22
A mixture of Compound 27 (250 mg) in i-PrOH/EtOAc (5mL/5mL) was hydrogenated for 14 hours in the presence of 10%Pd/C (75 mg). CELITE was added to the mixture, and the mixture was stirred for 5 minutes. Filtration and evaporation of solvents gave Compound 22 (116 mg).
The skilled practitioner will recognize that the procedure outlined in Scheme 12 can be used to prepare a variety of 1,4-substituted 1,4-diamines analogous to Compound 22. For example, an amine-protected 2,3-dihydroχy-l,4- diamine analogous to Compound 25 can be prepared:
Figure imgf000234_0001
Analogs of Compound 25 wherein L3, A, Ar, and P are as defined herein, and protecting group "P" is any amine protecting group described in described in Protective Groups in Organic Synthesis, Theodora W. Greene and Peter G. M. Wuts (John Wiley & Sons, Inc., New York, 1999, ISBN 0-471-16019-9), which is herein incorporated by reference in its entirety for all purposes. The analogs of Compound 25 can then be transformed, according to the methods outlined in Scheme 12, to form analogs of
Compound 26:
Figure imgf000234_0002
Analogs of Compound 26; analogs of Compound 27:
Figure imgf000235_0001
Analogs of Compound 27; and analogs of Compound 22: r)p
Figure imgf000235_0002
Analogs of Compound 22.
Preparation of Examples M and N Scheme 13
Figure imgf000235_0003
I. a. LiOH, THF/H2O, 25 0C; b. HCi Compound 29
Compound 28 was prepared using a procedure similar to that used to prepare Compound 6 (described in Scheme 4) except that Compound 9 was used instead of Compound 4.
To a solution of Compound 28 (0.757 g, 2.31 mmol) in THF (9 mL) at room temperature was added freshly prepared IM LiOH (4.6 mL, 4.6 mmol). After 1.5 h, I M HCl (7 mL, 7 mmol) was added and the reaction mixture extracted thoroughly with EtOAc (5 X 15mL). The combined organic layers were dried over anhydrous Na2SO4 and the volatiles removed in vacuo to afford 0.677 g (93%) of Compound 29 as a colorless glassy solid (LC/MS miz 314.0 (M+H)+) that was used in the following procedures without further purification. Scheme 14
Figure imgf000236_0001
,Ph ,Ph
VlI H2N.
\^ 8θcHN^^NHBoc ^NH2- 2TFA ^ 37 38
I. a. PhCHO, MeOH; b. NaBH4; c. BoC2O, THF/H2O. II. Pyr«SO3, Et3N, DMSO 0 °C. Ill, n-BuLi, MeOAI(Z-Bu)2, THF, -78 0C. IV. a. Ac2O, pyr, CH2Cl2, b. 6% Na/Hg, Na2HPO4, MeOH. V. H2, 10% Pd/Cs MeOH. Vi. Na/NH3, THF, -35 0C. VII. 20% TFA/DCM.
Compound 30
Compound 30 was purchased from Aldrich Chemical Co., and used without further purification. Compound 31
To a solution of Compound 30 (8.25 g, 80 mmol) in MeOH (50 mL), was added benzaldehyde (8.1 mL, 80 mmol) and the resulting solution was allowed to stir at room temperature. After 2 h, the reaction mixture was cooled to 00C and NaBH4 (3.33 g, 88 mmol) was added in portions. After allowing the reaction mixture to warm to room temperature over 2 h, glacial acetic acid (2 mL) was added. The resulting viscous solution was concentrated in vacuo. EtOAc and H2O (50 mL each) were added and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with saturated NaHCOs, brine, and concentrated in vacuo. The resulting material was taken up in THF (25 ml) and H2O (25 mL) at room temperature and BOC2O (15.1 g, 69.2 mmol) was added to produce an opaque suspension that was stirred vigorously for 2 h at room temperature. THF was removed in vacuo, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous MgSO4 and concentrated in vacuo. Chromatography on Siθ2 (3/1 Hex/EtOAC) afforded 18.5 g (79%) of Compound 31 as a colorless oil (LC/MS mfz 293.9 (M+H)+. Compound 32
Compound 31 (5.95 g, 20.3 mmol) and EtsN (9.9 mL, 71 mmol) were diluted in DMSO (65 mL) and allowed to age at room temperature for 30 min before cooling to 00C. Pyridine »SO3 was added in one portion and the reaction mixture was maintained at 5°C to prevent freezing. After 45 min, the reaction mixture was poured into icewater and extracted with EtOAc. The combined organic layers were washed with saturated NaHCO3, H2O, and dried over anhydrous MgSO4 prior to concentration in vacuo (bath temperature 25 0C) to produce 4.39 g (74%) of Compound 32 as a clear, yellow colored oil that was used without further purification. 1H-NMR (CDCk, 300 MHz) δ (major rotamer) 9.36 (br s, IH); 5.01 (ά, ] = 15 Hz, IH); 4.12 (d, / = 15 Hz, IH); 3.45 (m, IH); 2.04-1.88 (m, IH); 1.80-1.58 (m, IH); 1.54-1.20 (n% 2H); 1.47 (s, 9H); 0.91 (t, ] = 72 Hz, 3H). (minor rotamer) 9.46 (br s, IH); 4.71 (d, / = 15 Hz, IH); 4.20 (d, / - 15 Hz, IH); 3.78 (m, IH); 2.04-1.88 (m, IH); 1.80-1.58 (m, IH); 1.54-1.20 (m, 2H); 1.47 (s, 9H); 0.91 (t, / = 7.2 Hz7 3H) Compound 34
A suspension of Compound 33 (6.23 g, 16.6 mmol) in THF (500 mL) was heated under reflux until a homogeneous solution was obtained. The solution was cooled to -78°C and 1.6M n-BuLi (19.7 mL, 31.5 mmol) was introduced to produce a clear yellow solution. Meanwhile, DIBAL-OMe was prepared by dilution of DIBAL-H (IM in hexanes, 18.1 mL, 18.1 mmol) in THF (8 mL) and cooling to 00C prior to addition of MeOH (0.73 mL, 18.1 mmol). This solution was allowed to age while Compound 32 (4.39 g, 15.1 mmol) was diluted in THF (15 mL) and cooled to -78°C The DIBAL-OMe solution was cannulated to the solution of Compound 32 and allowed to age for 5 min prior to caπnulation to the sulfur dianion solution. The resulting clear yellow solution was allowed to age at -780C for Ih. The reaction was quenched by addition of saturated NHtCl (100 mL) at -78°C and allowed to warm to room temperature. Water was added until all precipitated solids were dissolved and the layers separated. The THF layer was concentrated in vacuo while the aqueous layer was extracted with EtOAc. The recombined organic layers were washed with brine, and the resulting emulsion was treated with solid NaOH until homogeneous bilayers resulted. The aqueous layer was extracted with EtOAc and the combined organics dried over anhydrous Na∑SOi. Concentration in vacuo produced 9.57 g (95%) of Compound 34 as an amorphous white solid (LC/MS mfz: 689.3 (M+Na)+) that was used in the following procedures without further purification. Compound 35
Crude Compound 34 was suspended in CH2CI2 (65 mL) followed by addition of pyridine (6.7 mL, 83 mmol) and acetic anhydride (3.5 mL, 36.5 mmol). The resulting solution was allowed to age at room temperature overnight. MeOH (6 mL) was added and after 10 min, the reaction was poured into brine. Addition of water produced a bilayer that was separated and the aqueous phase was repeatedly extracted with CH2CI2. The combined organic layers were dried over anhydrous MgSO4 and concentrated in vacuo to produce 8.95 g (88%) of a white solid that was immediately taken up in MeOH (100 mL). Na2HPO4 (11.4 g, 80.3 mmol) was added and the resulting slurry was cooled to O0C prior to addition of Na-Hg (6%, 14.5 g, 37.8 mmol) in portions. After aging at room temperature overnight H2O (30 mL) was added and the reaction was filtered through a celite pad. MeOH was removed in vacuo and the aqueous residue was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous MgSO4 and concentrated in vacuo to a yellow oil that was purified by chromatography on S1O2 (0-15% EtOAc/hexanes) to afford 2.14 g (34%) of Compound 35 as a colorless oil (LC/MS m/z: 531.2 (M+Na)+). Compound 36
Compound 35 (1.73 g, 3.4 mmol) was diluted in MeOH (7.5 mL) and 10% Pd/C (0.36 g, 0.34 mmol) was added. The atmosphere was replaced with a H2 balloon and the reaction mixture allowed to age at room temperature. After 2 h, the reaction mixture was filtered through a pad of celite, the filtrate was washed several times with MeOH, and the combined organic layers were concentrated in vacuo to afford 1.45 g (83%) of Compound 36 as a colorless oil (LC/MS m/z: 533.2 (M+Na)+) that was used in the following procedures without further purification. Compound 37
Compound 36 (0.528 g, 1.03 mmol) was diluted in THF (3 mL) and added to liquefied ammonia (approx. 20 mL) at -350C. Small pieces of Na were added until a blue color persisted. After 1.5 h, solid NHO was added in portions until the remaining Na was destroyed and the ammonia was allowed to escape at ambient temperature. Water and EtOAc (20 mL each) were added, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo to afford 0.395 g (91%) of Compound 37 as an amorphous white solid that was used without further purification in the following procedures (LC/MS m/z: 421.1 (M+H)+; 443.2 (M+Na)+ ). Compound 38 Compound 37 (0.362 g, 0.861 mmol) was diluted in CH2CI2 (3.2 mL). Trifluoroacetic acid (0.8 mL) was added and the clear solution was allowed to age overnight. Following concentration in vacuo, the residue was azeotroped with toluene several times to remove residual TFA. 0.382 g (99%) of the bis- trifluoroacetate salt of Compound 38 was collected as a colorless oil that was used without further purification (LC/MS ra/z: 221.1(M+H)+). Scheme 15
Figure imgf000240_0001
\ carbonate 16, DlPEA, MeCN, Ii aαd 29, EDC, HOBt, DiPEA1 THF
Compounds 39 and 40
Compound 38 (0.382 g, 0.852 mmol) was diluted in MeCN (10 mL) and N,N-diisopropylethylamine (0.60 mL, 3.41 mmol) was added, followed by a solution of Compound 16 in MeCN (1.5 mL). The clear, yellow solution was allowed to age at room temperature for 4h and the volatiles were removed in vacuo. The residue was taken up in a 3/1 CHCb/IPA (v/v, 13 mL) and treated with saturated Na∑COϊ (3 mL). The resulting suspension was diluted with HiO (3 mL), and the aqueous phase thoroughly extracted with 3/1 CHCls/IPA. The combined organic layers were dried over a 3/2 (w/w) mixture of anhydrous Na2Sθ4/anhydrous Na2COa and concentrated in vacuo. Chromatography on S1O2 (0-20% MeOH/CH2Cl2) afforded 0.043 g (14%) of Compound 39 as a colorless film (LC/MS mlz: 362.1 (M+H)+) and 0.105 g (34%) of Compound 40 as a colorless film (LC/MS mlz: 362.1 (M+H)+). Example M
A flask was charged with Compound 39 (0.048 g, 0.133 mmol) and Compound 29 was added as a 0.2 M solution in THF (0.8 mL, 0.160 mmol). THF (1 mL) was added, followed by DIPEA (0.026 mL, 0.145 mmol), HOBt (0.022 g, 0.160 mmol) and finally EDC (0.028 mL, 0.160 mmol). The clear, colorless solution was allowed to age overnight. Volatiles were removed in vacuo and the residue chromato graphed on Siθ2 (0-20% MeOH/CH2CLz). Fractions containing the desired compound were concentrated in vacuo and submitted to preparatory LC/MS purification to afford 0.018 g (20%) of Example M as a colorless film LC/MS mlz; 657.2 (M+H)+; 1H-NMR (CDCb, 300 MHz) δ 8.95 (s, IH); 7.88 (br s, IH); 7.27-7.04 (m, 5H); 7.04 (s, IH); 6.60-6.20 (m, 2H); 5.22 (m, 2H); 5.12 (d, / = 9.3 Hz, IH); 4.50 (m, 2H); 4.01 (br s, IH); 3.83 (m, 2H); 3.38 (m, IH); 3.10-2.94 (m, 3H); 2.74 (m, 2H); 2.23 (m, IH); 1.64-1.15 (m, 8H); 1.40 (d, / - 6.9Hz, 6H); 0.96 (m, 6H); 0.83 (t, 7 = 6.9 Hz, 3H). Example N
Example N was prepared using procedures similar to those used to prepare Example M, using the following reagents: Compound 40 (0.055 g, 0.152 mmol); Compound 29 (0.92 mL of 0.2 M THF solution, 0.183 mmol); THF (1 mL); DIPEA (0.040 mL, 0.228 mmol); HOBt (0.025 g, 0.182 mmol); EDC (0.032 mL, 0.182 mmol). 0.087 g (87%) of Example N was isolated as a colorless film (LC/MS mlz: 657.2 (M+H)+; 1H-NMR CDCI3, 300 MHz) δ 8.84 (s, IH); 7.86 (s, IH); 7.27-7.04 (m, 5H); 7.04 (s, IH); 6.28 (br s, IH); 6.12 (br s, IH); 5.25 (m, 2H); 5.11 (d, J = 9.0 Hz, IH); 4.62-4.32 (m, 2H); 4.19 (m, IH); 4.01 (br s, IH); 3.53 (m, IH); 3.10-2.90 (m, 3H); 2.72 (d, 7 - 6.0 Hz, 2H); 2.29 (m, IH); 1.65-1.18 (m, 8H); 1.39 (d, J = 6.9 Hz, 6H); 1.00-0.78 (m, 9H). Preparation of Examples O and P
Scheme 16
Figure imgf000242_0001
Figure imgf000242_0002
I. TCDI/THF/65 0C; II. P(OEt)3/160 °C; ill. H2, 10% PdIC.
Compound 41
Compound 41 was prepared following the procedure described in /. Org. Chem. 1996, 61, 444-450.
Compound 42
A mixture of Compound 41 (1.73 g, 3 mmol) and 1,1'- thiocarbonyldiimidazole (1.14 g, 6.1 mmol) in THF (60 mL) was heated at 650C for 72 hours. Solvent was removed under reduced pressure. The mixture was diluted with EtOAc, and washed successively with IN HCl, water, and brine, and dried over MgSO4. Purification by flash column chromatography (silica gel, hexanes/EtOAc = 1/1) gave Compound 42 (980 mg). m/z: 611.1 (M+H)+.
Compound 43
A mixture of Compound 42 (980 mg) and triethyl phosphite (10 mL) was heated at 1600C for 14 hours. The excess reagents were removed under reduced pressure. Recrystallization from a mixture of hexanes (11 mL) and EtOAc (3.6 mL) gave Compound 57 (580 mg). m/z: 557.3 (M+Na)+.
Compound 44
A mixture of Compound 43 (580 mg) in i-PrOH/EtOAc (12 mL/12 mL) was hydrogenated under high pressure (100 psi) for 24 hours in the presence of 10%Pd/C (200 mg). Celite was added and the mixture was stirred for 5 minutes. Filtration and evaporation gave Compound 44 (285 mg). m/z: 269.1 (M+H)\
The skilled practitioner will recognize that the procedure outlined in Scheme 16 can be used to prepare a variety of 1,4-substituted 1,4-diamines analogous to Compound 44. For example/ an amine-protected 2,3-dihydroxy-l,4- diamine analogous to Compound 41 can be prepared:
Figure imgf000243_0001
Analogs of Compound 41 wherein L3, A, Ar, and P are as defined herein, and protecting group "P" is any amine protecting group described in described in Protective Groups in Organic Synthesis, Theodora W. Greene and Peter G. M. Wuts (John Wiley & Sons, Inc., New York, 1999, ISBN 0-471-16019-9). The analogs of Compound 41 can then be transformed, according to the methods outlined in Scheme 16, to form analogs of Compound 42:
Figure imgf000244_0001
Analogs of Compound 42; analogs of Compound 43:
Figure imgf000244_0002
Analogs of Compound 43; and analogs of Compound 44:
Figure imgf000244_0003
Analogs of Compound 44.
It will also be recognized that stereochemical configurations other than those shown (i.e., enantiomers or diasteriomers) can be prepared by the selection of analogs of Compound 41 having the appropriate stereochemical configuration at the chiral centers. Scheme 17
Figure imgf000245_0001
Compound 46
To the solution of Compound 45 (950 mg, 3.5 mmol) in CHsCN (36 mL) at 00C was added Compound 16 (892 mg, 3,2 mmol), followed by diisopropylethylamine (1.2 mL, 7 mmol). The mixture was stirred for 12 hours at 25°C. The mixture was diluted with EtOAc, and washed successively with saturated Na2CO3, water, and brine. Purification by flash column chromatography (silica gel, 100% EtOAc to ClHbCh/MeOH = 4/1 ) gave Compound 46 (770 mg). m/z: 410.1 (M+H)+.
The skilled practitioner will recognize that the procedure outlined in Scheme 17 can be used to prepare a variety of compounds analogous to Compound 46. For example, 1,4-diamines analogous to Compound 44 can be prepared as discussed above:
Figure imgf000245_0002
Analogs of Compound 44.
The analogs of Compound 44 can then be reacted with analogs of Compound 16:
Figure imgf000246_0001
Analogs of Compound 16,
(wherein Z2, X7 and R9 are as defined herein) to form analogs of Compound
46:
Figure imgf000246_0002
It will also be recognized that stereochemical configurations other than those shown (i.ev enantiomers or diasteriomers) can be prepared by the selection of analogs of Compound 44 having the appropriate stereochemical configuration at the chiral centers.
Scheme 18
Figure imgf000247_0001
Figure imgf000247_0002
I. CH2CI2/25 0C; II. a. NaOH/dioxane/H2O; b, HCf; III. amine 46/EDC/HOBt; IV. a. TFA; b. NaOH
Compound 47
Compound 47 is commercially available from TCI.
Compound 48
To a solution of Compound 9 (500 mg, 3 mmol) in CH2CI2 (3 mL) was added Compound 47 (500 mg, 2.5 mmol). The mixture was stirred for 14 hours. Purification by flash column chromatography (hexane-s/EtOAc = 1/1.5) gave Compound 48 (242 mg). m/z: 372.1 <M+H)+. Compound 49
To a solution of Compound 48 (240 mg, 0.65 mmol) in dioxane (4 mL) and water (4 mL) was added sodium hydroxide (40 mg, 1 mmol). The mixture was stirred for 1 hour and acidified with 4 N HCl in dioxane (0.25 mL, 1 mmol). The mixture was extracted with EtOAc and organic phase was dried with MgSO4. Concentration gave Compound 49 (200 mg). m/z: 356.2 (M-H)+.
Example O
To a solution of corresponding acid 49 (30 mg, 0.08 mmol) and Compound 46 (22 mg, 0.05 mmol) in THF (1 mL) were added HOBt (15 mg, 0.11 mmol), EDC (20 μL, 0.11 mmol), and disopropylethylamine (0.2 mL). The mixture was stirred for 12 hours and concentrated. Purification by flash column chromatography (hexanes/EtOAc = 1/5 to 0/100) gave Example O (17 mg). m/z: 749.3 (M+H)+.
Example P
To Example O (17 mg) was added TFA (2 mL). The mixture was stirred for 3 hours and concentrated. The mixture was diluted with THF (2 mL) and 1.0 N NaOH solution was added until pH 11. The mixture was stirred for 10 minutes, and extracted with EtOAc. The organic phase was washed with water and brine. Purification by flash column chromatography (EtOAc) gave Example P (12 mg). 1H-NMR (CDCb) δ 8.76 (1 H, s), 7.79 (1 H, s), 7.25-6.9 (11 H, m), 6.51 (1 H, broad), 5.42 (1 H, m), 5.18 (2 H, m), 4.42 (2 H, m), 4.22 (1 H, m), 4.10 (1 H, m), 3.95 (1 H, m), 3.79 (1 H, m), 3.58 (1 H, m), 3.23 (1 H, m), 2.93 (3 H, s), 2.9-2.5 (4 H, m), 1.6-1.2 ( 10 H, m); m/z: 693.2 (M+H)+ . Preparation of Examples O, R, and S
Scheme 19
Figure imgf000249_0001
I. CDI, DIPEA, CH2CI2; Ii. UOH, THF/H2O; Hi. Cmpd. 8, DIPEA, EDC, HOBt, THF; IV.a. HCI/dioxane; b. Na2CO3; V. (BrCH2CH2J2O, NaHCO3, DMF Compound 50
Compound 50 is commercially available from Chem Impex International, and used without further purification.
Compound 51
Compound 50 (7.0 g, 26.0 mmol) was dissolved in CH2CI2 (330 mL) and 1,1- carbonyldiimidazole (4.22 g, 26.0 mmol) was added, followed by i-PnNEt (19 mL, 104 mmoi). The solution was stirred at 25°C for 12 hours. Compound 9 (4.44 g, 26.0 mmol) was dissolved in 20 mL of CH2CI2 and added to the reaction mixture. The solution was stirred at 25°C for 7 hours. The solvent was removed in vacuo and the residue was diluted with ethyl acetate and washed with water and brine. The organic layers were dried (Na∑SO.*), filtered, and evaporated. Purification by Combiflash® (stationary phase: silica gel; eluent: 66-100% EtOAc/Hexane gradient) gave Compound 51 (7.34 g). m/z: 429.0 (M+H)+.
Compound 52
Compound 51 (7.34 g, 17.13 mmol) was dissolved in THF (90 mL) and IM aqueous LiOH (35 mL) was added. The mixture was stirred at 25°C for 0.5 hour. The reaction was quenched with IM HCl (51 mL) and the mixture was adjusted to pH 2. The mixture was extracted with ethyl acetate. The organic layers were dried over Na-SO^ filtered, and evaporated to provide Compound 52 (7.00 g). The recovered Compound 52 was used in the next step without further purification, m/z: 415.0 (M+H)+.
The skilled practitioner will recognize that the procedure outlined in Scheme 19 can be used to prepare a variety of compounds analogous to Compounds 51 and 52. For example, amines analogous to Compound 9 can be reacted with the appropriate amino ester analogous to Compound 50:
Figure imgf000251_0001
Cmpd 9 Analog Cmpd 50 Analog/ to form compounds analogous to Compound 51, which are further reacted to form compounds analogous to Compound 52:
Figure imgf000251_0002
Cmpd 51 Analogs Cmpd 52 Ana|Ogs. wherein R1, R2, R7, R8 and Y are as defined herein.
It will also be recognized that stereochemical configurations other than those shown (i.e., enantiomers or diasteriomers) can be prepared by the selection of analogs of Compound 50 having the appropriate stereochemical configuration at the chiral center.
Example O
Compound 52 (2.57 g, 6.21 mmol) was dissolved in THF (67 mL). Compound 8 (2.10 g, 5.13 mmol) was added, followed by HOBt (1.04 g, 7.70 mmol), 1-Pr2NEt (3.67 mL, 20.52 mmol), and EDC (1.82 mL, 10.26 mmol). The mixture was stirred at 25°C for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and washed sequentially with saturated aqueous NasCOϊ, water, and brine. The organic phase was dried over Na2SO4, filtered, and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 5% iPrOH/CH^Ck) gave Example Q (3.02 g). m/z: 806.2 (M+H)+. Example R
Example Q (3.02 g, 3.74 mmol) was suspended in 4.0 N HCl/dioxane solution (30 mL) and stirred at 250C for 3 hours. Solvent was removed under reduced pressure and Et2θ was poured into the reaction mixture. The resulting suspension was stirred vigorously for 1.5 hours. The solid was allowed to settle and the ether layer was decanted. Washing of the precipitate with Et2θ was repeated two more times. The product was dried in vacuo to afford a white solid (3.18 g, quantitative yield). Saturated aqueous Na2CO3 solution was added to above solid (3.18 g) with stirring until solid disappeared. The aqueous solution was extracted with ethyl acetate. The organic phases were dried over Na2SO4, filtered, and evaporated to afford Example R as a yellow foam (2.44g, 81%). The recovered Example R was used without further purification in the next step, m/z: 706.1 (M+H)+.
Example S
Method I:
Example R (1.0Og, 1.42 mmol) was dissolved in DMF (20 mL) and bromoethyl ether (196 μL, 1.56 mmol) was added dropwise, followed by NaHCOs (0.239 g, 2.84 mmol). The reaction mixture was stirred at 250C for 2 hours. The solution was heated to 65°C and stirred for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with EtOAc and washed sequentially with water and brine. The organic phase was dried over Na2$O4 filtered, and evaporated. Purification by reverse-phase HPLC (Phenomenex Synergi® Comb-HTS column, eluent: 5-95% CHaCN/water) gave Compound 70 (580 m.g, 53%). 1H NMR (CDCl3) & 8.98 (s, IH); 7.90 (s, IH); 7.75 (m, IH); 7.40-7.00 (m, HH), 6.55 (br s, IH); 5.58 (m, IH); 5.28, 5.19 (dAB, J=I 4 Hz, 2H); 4.70-4.37 (m, 3H); 3.99 (m, 5H); 3.76 (br s, IH); 3.65-3.30 (m, 3H); 2.97 (m, 5H); 2.90-2.60 (m, 6H); 2.28 (br s, IH); 1.91 (br s, IH); 1.60-1.30 (m, 10H). m/z: 776.2 (M+H)-
Method II:
Scheme 20
Figure imgf000253_0001
53 54
L NaIO4, H2O
Compound 54
Compound 54 was prepared following the procedure described in J. Med. Chem, 1993, 36, 1384 (herein incorporated by reference in its entirety for all purposes).
To solution of Compound 53 (0.550 g, 5.28 mmol) (Sigma- Aldrich) in H2O (8.8 mL) at O0C was added NaIQt (1.016 g, 4.75 mmol). The mixture was allowed to slowly warm to 250C and stirred for 12 hours. Solid NaHCθ3 was added to the reaction mixture until pH 7. CHCb (16 mL) was added and the mixture was allowed to stir for 5 minutes. The mixture was filtered and the solid was washed with CHCk (6 mL). The combined H2O/CHCI3 solution was used directly in the next step without further purification.
Scheme 21
Figure imgf000254_0001
I. NaBH3CN/CH3CN/H2O
Example S
To a solution of Example R (70 mg, 0.1 mmol) in CH3CN (5 mL) was added sodium cyanoborohydride (50 mg) in water (5 mL). To the above mixture was added a solution of dialdehyde Compound 54 (0.6 mmol) in CHQ3/H2O) (4 mL/ 1 mL). The mixture was stirred for 12 hours, and basified with saturated Na2CO3 solution. The mixture was extracted with EtOAc, and organic phase was washed with water and brine, and dried over Na2SO4. Purification by reverse-phase HPLC (Phenomenex Synergi® Comb-HTS column) gave Example S (57 mg).
Method III
Scheme 22
Figure imgf000255_0001
I. TFA, CH2CI2; fl. Cmpd 54, NaBH3CN, H2OZCH3CN; ill. LiOH, THF/H2O; IV. amine Cmpd 8, DIPEA, EDC, HOBt, THF
Compound 55
Compound 51 (0.28 g, 0.66 mmol) was dissolved in CH2CI2 (4 mL) and TFA (1 mL) was added dropwise. The reaction was allowed to stir at 250C for 1 hour. The solvent was removed under reduced pressure to afford Compound 55 (0.39 g). m/z: 329.0 (M+H)+. Compound 56
To a solution of Compound 55 (0.39 g, 0.89 mmol) in CH3CN (45 mL) was added NaBHsCN (0.45 g, 7.12 mmol) and H2O (45 mL). A solution of Compound 54 (0.55 g, 5.34 mmol) in CHCI3/H2O (40 mL) was added. The mixture was stirred at 25°C for 12 hours. The reaction mixture was made basic with saturated aqueous Na2CO3 and extracted sequentially with ethyl acetate and dichloromethane. The combined organic layers were washed sequentially with H2O and brine, dried over Na2SO4, filtered, and evaporated. Purification by Combiflash® (stationary phase: silica gel; eluent: 0-10% MeOH/CJHbCb gradient) gave Compound 56 (0.17 g). m/z: 399.1 (M+H)+. Compound 57
Compound 56 (377 mg, 0.95 mmol) was dissolved in THF (4 mL) and IM aqueous LiOH (1.90 mL) was added. The mixture was stirred at 25°C for 1 hour. The reaction was neutralized with IM HCl. THF was removed under reduced pressure and the aqueous solution was lyophilized to afford Compound 57 (365 mg). The material was used directly in the next step without further purification, m/z: 385.1 (M+H)+. Example 5
Example S (185 mg, 57%) was prepared following the same procedure as for Example Q, except that Compound 57 (160 mg, 0.42 mmol) was used instead of Compound 52. mass m/z: 776.2 (M+H)+.
The skilled practitioner will recognize that the procedure outlined in Scheme 22 can be used to prepare a variety of compounds analogous to Compounds 55-57:
Figure imgf000257_0001
Cmpd 51 Analogs Cmpd 55 Analogs
Figure imgf000257_0002
Cmpd 56 Analogs Cmpd 57 Analogs f. TFA, CH2CI2; I!. Ex. R, NaBH3CN, H2O/CH3CN; III. LiOH, THFZH2O wherein W, Rs and Y are as defined herein.
It will also be recognized that stereochemical configurations other than those shown (i.e., enantiomers or diasteriomers) can be prepared by the selection of analogs of Compound 51 having the appropriate stereochemical configuration at the chiral center.
Method IV Scheme 23
Figure imgf000258_0001
I. a. NaOH/H2O; b. BnBr; II. SO3/pyridine; IN. morpholine/NaBH(OAc)3; IV. a. NaOH; b. HCI
Compound 59
To a solution of Compound 122 (33 g, 112 mmol) (see Scheme 69) in ethanol (366 mL) at O0C was added a solution of sodium hydroxide (4.7 g, 117 mmol) in water (62 mL). The mixture was stirred for one hour at 250C, and solvents were removed under reduced pressure. The mixture was coevaporated with ethanol (3x400 mL), and dried at 600C for two hours under high vacuum to give a white solid. To the solution of above solid in DMF (180 mL) was added benzyl bromide (16.2 mL, 136 mmol). The mixture was stirred for 16 hours under darkness, and was quenched with water (300 mL). The mixture was extracted with EtOAc (4x300 mL). The combined organic phase was washed with water (5x) and brine, and dried over Na∑SO-*. Concentration gave Compound 59 (48 g), which was used in the next step without further purification. Compound 60
A mixture of Compound 59 (33 g, 74 mmol) in DMSO (225 mL) and EtaN (36 mL) was stirred for 30 minutes. The mixture was cooled to 0-100C, SO3- pyridine (45 g) was added, and the stirring was continued for 60 minutes. Ice (300 g) was added, and the mixture was stirred for 30 minutes. EtOAc (300 mL) was added and sat. Na2CO3 was added until pH was 9-10. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (2x300ml). The combined organic phases were washed with sat Na2CO3 (2x), water (3x), and brine. The mixture was dried over Na∑Sθ4 and concentrated to give Compound 60 (32 g), which was used directly in next step without further purification. Compound 61
To a solution of Compound 60 (32 g) in CHθCN (325 mL) was added morpholine (12.9 mL, 148 mmol), with a water bath around the reaction vessel, followed by HOAc (8.9 mL, 148 mmol), and NaBH(OAc)3 (47 g, 222 mmol). The mixture was stirred for 12 hours. CHbCN was removed under reduced pressure, and the mixture was diluted with EtOAc (300 mL). Sat. Na2CO3 was added until the pH was 9-10. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (2x300 mL). The combined organic phases were washed with sat Na2CO3 (2x), water (Ix), and brine (Ix). The mixture was dried over Na2SO4. The resulting residue was concentrated and purified by silica gel column chromatography (EtOAc to DCM/iPrOH =10/1) to give Compound 61 (30 g). Compound 57
To a solution of Compound 61 (26.5 g, 56 mmol) in ethanol (160 mL) at 00C was added a solution of sodium hydroxide (2.5 g, 62 mmol) in water (30 mL). The mixture was stirred for one hour at 25°C, and solvents were removed under reduced pressure. The mixture was diluted with water (200 mL), and was washed with CH2CI2 (6x100 mL). The water phase was acidified with 12 N HCl (5.2 mL), and was dried under reduced pressure to give Compound 57 (22 g). Example S Compound 57 was converted to Example S using the procedure described in Method III, above.
Preparation of Compounds T and U Scheme 24
Figure imgf000260_0001
Va. CH3COCI, DIPEA, CH2CI2; Vb. Compounds: CH3COOH, DIPEA, EDC, HOBt, THF; Vl. Ex. T: X=NHAc MsCI1 DIPEA, CH2CI2; Ex. U: X=NHMs
Example T Method I
The hydrochloride salt of Example R (100 mg, 0.13 mmol) was suspended in CH2CI2 (2 mL) and dissolved by addition of iPnNEt (69 uL). Acetyl chloride (11 μL) was added dropwise and the mixture was allowed to stir at 25°C for 4 hours. The solvent was removed in vacuo. Purification of the residue by flash column chromatography (stationary phase: silica gel; eluent: 8% iPrOH/CH-Ch) gave Example T (39 mg, 40%). m/z: 748.2 (M+H)+. 1H NMR (CDCb) δ 8.85 (s, IH); 7.87 (s, IH); 7.73 (s, IH); 7.40-7.00 (m, 13H); 6.45 (br s, IH); 5.70 (m, IH); 5.32, 5.22 ((JAB, /=13 Hz, 2H); 4.51 (s, 2H); 4.20-3.90 (m, 4H); 3.78 (m, IH); 3.38 (m, 2H); 3.20-2.50 (m, 8H); 1.95 (s, 4H); 1.82 (m, 2H); 1.41 (m, 6H). Method II
Saturated aqueous NazCOs solution was added to the hydrochloride salt of Example R (3.18 g, 3.46 mmol) while stirring until the solid disappeared. The aqueous solution was extracted with ethyl acetate. The organic phases were dried over Na2SO4, filtered, and evaporated to afford Example R as a yellow foam (2.44g, 81%). This material was used without further purification in the next step, m/z: 706.1 (M+H)\
Example R (300 mg, 0.43 mmol) was dissolved in THF (5.5 mL). Acetic acid (37 μL, 0.64 mmol) was added, followed by HOBt (85 mg, 0.64 mmol), iPr.NEt (304 μL, 1.70 mmol), and EDC (151 μL, 0.85 mmol). The reaction mixture was allowed to stir at 250C for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with EtOAc and washed sequentially with saturated aqueous Na2CO3, water, and brine. The organic phase was dried over Na2SO4, filtered, and evaporated. Purification by Combiflash® (stationary phase: silica gel; eluent: 10% MeOH/CIfcCk) gave Example T (249 mg, 77%). m/z: 748.2 (M+H)+. Example U
Example R (100 mg, 0.13 mmol) was suspended in OHbCh (2 mL) and dissolved by addition of iPnNEt (69 μL). Methane sulfonyl chloride (12 μL) was added dropwise and the mixture was allowed to stir at 25°C for 4 hours. The solvent was removed in vacuo. Purification of the residue by flash column chromatography (stationary phase: silica gel; eluent: 8% iPrOH/CHϊCb) gave Example U (55 mg, 54%). m/z: 784.2 (M+H)+. 1H NMR (CDCl3) & 8.90 (s, IH); 7.88 (s, IH); 7.40-7.00 (m, 12H); 6.54 (br s, IH); 6.19 (br s, IH); 5.25 (s, 2H); 4.53 (s, 2H); 4.38 (m, IH); 4.12 (m, IH); 3.79 (m, IH); 3.79 (m, IH); 3.48 (m, IH); 2.99 (s, 3H); 2.90 (m, 3H); 2.73 (m, 6H); 2.00 (m, IH); 1.79 (m, IH); 1.60-1.18 (m, 10H). Preparation of .Examples V, W, X and Y Scheme 25
Figure imgf000262_0001
I. Cmpd. 46, DIPEA, EDC, HOBt, THF; Compounds: H. HCE/dioxane; IHa. CH3COCI, DIPEA, Ex. X: X=NHAc CH2CI2; IHb. CH3COOH, DIPEA, EDC, Ex. Y: X=NHMs HOBt, THF; IV. IWsCi, DIPEA, CH2CI2
Example V
Example V (692 mg) was prepared following the same procedure used for preparing Example Q, except that Compound 46 was used instead of Compound 8. m/z: 806.2 (M+H)+. Example W
Example W (770 mg, quantitative yield) was prepared following the same procedure for Example R except that Example V was used instead of Example Q. m/z: 706.2 (M+H)+. Η NMR (CDsOD) & 9.86 (s, IH); 8.23 (s, IH); 7.66 (s, IH); 7.40- 7.00 (m, 10H); 5.29, 5.17 (du, /=13 Hz, 2H); 4.80-4.60 (m, 2H); 4.18 (s, 2H); 4.26 (m, 2H); 3.67 (br s, IH); 3.55 (m, 2H); 3.03 (m, 3H); 2.90-2.60 (m, 8H); 2.53 (s, 2H); 2.00- 1.80 (m, 2H); 1.85-1.30 (m, 10H). Example X Method I
Example X (107 mg, 55%) was prepared following the Method I procedure for Example T except that Example W was used instead of Example R. m/z: 748.2 (M+H)+. Η NMR (CDCb) δ 8.80 (s, IH); 7.85 (s, IH); 7.40 (m, IH); 7.38-7.00 (m, 10H), 6.94 (s, IH); 6.30 (m, 2H); 5.75 (m, IH); 5.30, 5.23 (CIAB, J=13 HZ, 2H); 4.54, 4.46 (dAB, /=8 Hz, 2H); 4.20-3.90 (m, 2H); 3.74 (br s, IH); 3.46 (br s, IH); 3.28 (m, IH); 2.98 (s, 3H); 2.83 (m, 3H); 2.72 (m, IH); 2.62 (m, IH); 2.05-1.20 (m, 15H). Method II
Example X (205 mg, 65%) was prepared following the Method II procedure for Example T except that Example W was used instead of Example R. m/z: 748.2 (M+H)+. Example Y
Example Y (106 mg, 50%) was prepared following the same procedure for Example U, except that Example W was used instead of Example R. m/z: 784.2 (M+H)+. 1H NMR (CDCl3) & 8.81 (s, IH); 7.85 (s, IH); 7.40-7.05 (m, 10H), 6.98 (s, IH); 6.22 (br s, IH); 5.78 (s, IH); 5.25 (m, 4H); 4.29 (m, 2H); 4.33 (br s, IH); 4.12 (br s, IH); 3.77 (br s, IH); 3.10 (br s, IH); 2.98 (s, 3H); 2.90 (s, 3H); 2.73 (m, 6H); 2.00- 1.20 (m, 12H). Preparation of Examples Z-AD
Scheme 26
BocHh
Figure imgf000264_0001
Figure imgf000264_0002
I. DIPEA, CH3CN; II. HCI/dioxane, EtOAc; III. acid 29, DIPEA, EDC, HOBt, THF
Compound 62
Tert-butyl 2-aminoethylcarbamate (62) is commercially available from AIcIrICh7 and was used without further purification. Compound 63
To a solution of Compound 62 (2.0 mmol) in CH3CN (15 mL) was added Compound 16 (1.82 mmol), followed by the addition of JV, N- diisopropylethylamine (0.61 mL). The mixture "was stirred at 25°C for 12 hours. The solvent was removed in vacuo, and the residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na2CO3, water, and brine. The organic layers were dried with Na2SO4, filtered, and evaporated. Purification by Combiflash® (stationary phase: silica gel; eluent: 25-100% EtOAc/hexane gradient) gave Compound 63. m/z: 301.9 (M+H)+. Compound 64
To a solution of Compound 63 (1.05 mmol) in EtOAc (3 mL) was added 4N HCl/dioxane solution (1.1 mL). The mixture was allowed to stir at 25°C for 12 hours. The solvent was removed under reduced pressure, and Compound 64 was obtained as a white powder. This material was used in the next step without further purification, m/z: 216.0 (M+H)+. Example Z
Compound 64 (70 mg, 0.29 mmol) was dissolved in THF (2.2 mL). Compound 29 (91 mg, 0.29 mmol) was added to the reaction flask as a 1.0M solution in THF, followed by HOBt (59 mg, 0.44 mmol), N,N- diisopropylethylamine (207 μL, 1.16 mmol), and EDC (103 μL, 0.58 mmol). The reaction was allowed to stir for 12 hours at 25°C and concentrated under reduced pressure. The residue was diluted with EtOAc and washed sequentially with saturated aqueous Na∑COs, water, and brine. The organic layers were dried with Na2SO4, filtered, and evaporated. Purification by Combiflash® (stationary phase: silica gel; eluent: 0-10% MeOH/CH∑Cb gradient) gave Example Z (54 mg, 38%). m/z: 497.1 (M+H)+. 1H NMR (CDCl3) δ 8.78 (s, IH); 7.83 (s, IH); 6.99 (s, IH); 6.80 (br s, IH); 6.22 (br s, IH); 5.87 (br s, IH); 5.25 (s, 2H); 4.43 (s, 2H); 3.97 (m, IH); 3.34 (m, 4H); 2,95 (s, 3H); 2.22 (m, 2H); 1.38 (d, ]=7 Hz, 6H); 0.97 (d, /=7 Hz, 6H). Example AA
Example AA was prepared following the procedures for steps I-III (Scheme 20) for Example Z7 with the exception that tert-butyl 3- aminopropylcarbamate was used instead of tert-butyl 2-aminoethykarbamate (Compound 62). After Combiflash® purification, 38 mg (34%) of Example AA was obtained, m/z: 511.1 (M+H)\ 1H NMR (CDCl3) 6 8.78 (s, IH); 7.84 (s, IH); 6.96 (s, 2H); 6.17 (br s, IH); 5.80 (m, IH); 5.26 (m, 2H); 4.44 (s, 2H); 4.09 (m, IH); 3.40-3.10 (in, 5H); 2.97 (s, 3H); 2.20 (m, IH); 1.60 (m, 2H); 1.36 (d, J=7 Hz, 6H); 0.96 (d, /=7 Hz, 6H). Example AB
Example AB was prepared following the procedures for steps HII (Scheme 20) for Example Z, with the exception that tert-butyl 1-piperazinecarboxylate was used instead of tert-butyl 2-aminoethylcarbamate (Compound 62). After Combiflash® purification, 64 mg (45%) of Example AB was obtained, m/z: 523.1 (M+H)+. 1H NMR (CDCb) δ 8.82 (s, IH); 7.89 (s, IH); 6.96 (s, IH); 5.93 (br s, IH); 5.35 (s, 2H); 4.62 (m, IH); 4.50 (m, 2H); 3.80-3.40 (m, 8H); 3.34 (m, IH); 3.00 (s, 3H); 1.97 (m, IH); 1.40 (d, J=7 Hz, 6H); 0.96, 0.93 (d, /=7 Hz, 6H). Example AC
Example AC was prepared following the procedures for steps I-III (Scheme 20) for Example Z, with the exception that tert-butyl 4-amino-l- piperidinecarboxylate was used instead of tert-butyl 2-aminoethylcarbamate (Compound 62). After Combiflash® purification, 60 mg (44%) of Example AC was obtained, m/z: 537.1 (M+H)+. 1H NMR (CDCb) δ 8.82 (s, IH); 7.87 (s, IH); 6.97 (s, IH); 5.82 (br s, IH); 5.30 (m, 3H); 4.80-4.40 (m, 5H); 4.03 (m, IH); 3.72 (br s, IH); 3.34 (m, IH); 3.18 (m, IH); 3.01 (s, 3H); 2.79 (m, IH); 2.20-1.90 (m, 4H); 1.40 (d, /=7 Hz, 6H); 0.97, 0.90 (d, /-7 Hz, 6H). Example AD
Example AD was prepared following the procedures I-III for Example Z, with the exception that tert-butyl 4-piperidinylcarbamate was used instead of tert- butyl 2-aminoethylcarbamate (Compound 62). After Combiflash® purification, 49 mg (36%) of Example AD was obtained, m/z: 537.1 (M+H)\ 1H NMR (CDCb) δ 8.82 (s, IH); 7.87 (s, IH); 7.01 (s, IH); 6.33 (br s, IH); 6.11 (br s, IH); 5.32 (s, 2H); 4.47 (s, 2H); 4.20-3.80 (m, 4H); 3.35 (m, IH); 3.10-2.80 (m, 6H); 2.21 (m, 2H); 1.90 (m, 2H); 1.40 (d, /=7 Hz, 6H); 0.97 (d, /=7 Hz, 6H). Preparation of Examples AE-AG
Scheme 27
Figure imgf000267_0001
I. CDI, DIPEA, CH2CI2; M. NaOH1 THF/H2O; III. Cmpd. 8, DIPEA, EDC, HOBt, THF; IV. neat TFA; V. (Boc)2Ot NH4HCO3, pyridine, dioxane, DMF
Compound 65
Compound 65 is commercially available from Chem Impex International, and was used without further purification. Compound 66
Compound 65 (956 mg, 4.0 mmol) was dissolved in CH2CI2 (45 mL) and 1,1-carbonyldiimidiazole {648 mg, 4.0 mmol) was added, followed by i-Pr2NEt (2.8 mL, 16 mmol). The solution was stirred at 25°C for 12 hours. Compound 9 (679 mg, 4.0 mmol) was dissolved in CH2CI2 (5 mL) and added to the reaction. The mixture was allowed to stir for 5 hours. Then, the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and filtered through celite. The ethyl acetate was then removed in vacuo. Purification by flash column chromatography (stationary phase: silica gel; eluent: EtOAc) gave Compound 66 (841 mg). m/z: 400.0 (M+H)+. Compound 67
Compound 66 (841 mg, 2.11 mmol) was dissolved in THF (9 mL) and 2N aqueous NaOH was added. The solution was stirred at 25°C for 2 hours. The reaction was adjusted to pH 2 with IN HCl. The mixture was extracted with ethyl acetate, dried over NasSO^ filtered, and evaporated. Compound 67 (772 mg) was used directly in the next step without further purification, m/z: 386.0 (M+H)+. Example AE
Compound 67 (569 mg, 1.48 mmol) was dissolved in THF (17 mL). Compound 8 (970 mg, 2.37 mmol) was added, followed by HOBt (300 mg, 2.22 mmol), i-PrcNEt (1.06 mL, 5.92 mmol), and EDC (0.52 mL, 2.96 mmol). The mixture was stirred at 25°C for 36 hours. The solvent was removed under reduced pressure. The resulting residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na?CO3, water, and brine. The organic phase was dried over Na2SO4, filtered, and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 8% iPrOH/CH≥CL) gave Example AE (3.02 g). m/z: 777.2 (M+H)+. Example AF Example AE (100 mg, 0.13 mmol) was dissolved in neat TFA (3 mL). The mixture was stirred at 25°C for 2 hours. The solvent was removed under reduced pressure. Purification by reverse-phase HPLC (Phenomenex Synergi® Comb-HTS column, eluent: 5-95% CH3CN/H2O gradient) gave Example AF (20 mg, 21%). m/z: 721.2 (M+H)+. 1H NMR (CDCU) δ 8.92 (s, IH); 7.91 (s, IH); 7.40-7.00 (m, HH); 6.41 (br s, IH); 6.12 (br S, IH); 5.40-5.00 (m, 3H); 4.70-4.50 (m, 3H); 4.05 (br s, IH); 3.81 (br s, IH); 3.51 (br s, IH); 2.97 (s, 3H); 2.90-2.60 (m, 6H); 1.41 (d, /=7 Hz, 10H). Example AG
Example AF (70 mgy 0.10 mmol) was dissolved in dioxane (0.5 mL). DMF (83 μh), pyridine (25 μL, 0.29 mmol), di-ferf-butyldicarbonate (27 mg, 0.13 mmol), and ammonium bicarbonate (15 mg, 0.19 mmol) were added. The mixture was stirred at 250C for 48 hours, then diluted with ethyl acetate and washed sequentially with water and brine. The organic phase was dried over Na-SO^ filtered, and evaporated. Purification by reverse-phase HPLC (Phenomenex Synergi® Comb-HTS column, eluent: 5-95% CH3CN/H2O gradient) gave Example AG (35 mg, 50%). 1H NMR (CDCl3) δ 8.80 (s, IH); 7.84 (s, IH); 7.40-7.00 (m, 10H); 7.08 (s, IH); 6.83 (m, IH); 6.65 (m, IH); 5.40-5.10 (m, 4H); 4.60-4.40 (m, 3H); 4.06 (m, IH); 3.79 (m, IH); 3.36 (m, IH); 2.97 (s, 3H); 2.90-2.60 (m, 6H); 2.45 (m, IH); 1.70-1.20 (m, 10H).
Preparation of Compounds 68 and 69 Scheme 28
Figure imgf000269_0001
15 68: R=methyl
69: R=cyclopropy!
I. a. MsCI, TEA, CH3CN; b. MeNH2/H2O; c. cyclopropyl amine
Compound 15 Compound 15 is commercially available from Molekula, and was used without further purification. Compound 68
Compound 15 (6.81 g, 59.1 mmol) was dissolved in CHsCN (340 mL) and methanesulfonyl chloride (7.03 mL, 65.1 mmol) was added, followed by triethylamine (9.03 mL, 65.1 mmol). After the mixture was stirred for 20 min, 40% wt. methylamine/ water (516 mL) was added to the reaction mixture. The solution was stirred for 12 hours at 25°C. Solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous NaiCθ3 and CHzCk. The organic phase was separated, dried over Na^SCU, filtered, and evaporated. Purification by flash chromatography (stationary phase: silica gel; eluent: 0-10% MeOH/CHαCb gradient) gave Compound 68 (5.07 g). m/z: 128.9 (M+H)÷. Compound 69
Compound 15 (10.0 g, 80 mmol) was dissolved in CH3CN (500 mL) and methanesulfonyl chloride (7.0 mL, 88 mmol) was added, followed by triethylamine (12.3 mL, 88 mmol). After the mixture was stirred for 2h, cyclop ropylamine (140 mL, 2000 mmol) in CH3CN (500 mL) was added to the reaction mixture. The solution was stirred for 36 hours at 25°C. Solvent was removed under reduced pressure and the slurry was partitioned between saturated aqueous Na2CO3 and 3:1 CIHbCkii-PrOH. The organic phase was separated, dried over Na2SO4, filtered, and evaporated. Compound 69 (12.81 g) was used in the next step without further purification, m/z: 155.0 (M+H)+. Preparation of Examples AH and Al Scheme 29 o γotBu
Figure imgf000271_0001
Figure imgf000271_0002
I. DIPEA, CH2CI2; II. LiOH, THF/H2O;
III. Cmpd. 8, HOBt, EDC, DIPEA, THF;
IV. a. neat TFA; b. NaOH, THF1 H2O
Compound 70
Compound 68 (1.00 g, 7.80 mmol) was dissolved in THF (25 mL) and Compound 1Oe (2.51 g, 7.09 mmol) was added, followed by N,N- dimethaminopyridine (200 mg, 1.63 mmol), and triethylamine (4.34 mL, 31.2 mmol). The mixture was allowed to stir at 60 0C for 6 hours. Solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na∑CCb, H2O, and brine. The organic layer was dried over Na2SO4, filtered, and evaporated. The resulting residue was purified by Combiflash® (stationary phase: silica gel; eluent: 20-100% EtOAc/Hexane gradient) to give Compound 70 (2.14 g). m/z: 343.9 (M+H)+. Compound 71 Compound 70 (2.14 g, 6.23 mmol) was dissolved in THF (25 mL) and IM aqueous LiOH (12.5 mL) was added. The mixture was stirred at 25°C for 2 hours. The reaction was quenched with IM HCl (15 mL) and the mixture was adjusted to pH 2. The mixture was extracted with ethyl acetate. The organic layers were dried over Na2SO*, filtered, and evaporated to provide Compound 71 (1.96 g). This material was used in the next step without further purification, m/z: 330.0 (M+H)\ Example AH
Compound 71 (43 mg, 0.13 mmol) was dissolved in THF (1.5 mL). Compound 8 (50 mg, 0.12 mmol) was added, followed by HOBt (24 mg, 0.18 mmol), iPriNEt (86 μL, 0.48 mmol), and EDC (42 μL, 0.24 mmol). The mixture was stirred at 25°C for 12 hours. The solvent was removed under reduced pressure, and the resulting residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na2CO3, water, and brine. The organic phase was dried over Na2SO4, filtered, and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 1-10% MeOH/CH'Ck gradient) gave Example AH (66 mg). m/z: 721.2 (M+H)+. Compound AI
Example AH (66 mg, 0.09 mmol) was dissolved in TFA and allowed to stir at 25 0C for 3 hours. The solvent was removed under reduced pressure and the residue was diluted with THF (3 mL) and 2N aqueous NaOH was added until pH 12. The mixture was allowed to stir for 20 min and extracted with EtOAc. The organic layer was washed sequentially with water and brine, dried over Na2SO4, filtered, and evaporated. Purification by flash chromatography (stationary phase: silica gel; eluent: 0-20% i-PrOH/CftCb gradient) gave Example AI (71 mg, 97%). m/z: 665.2 (M+H)+. 1H NMR (CDCb) δ 8.84 (s, IH); 8.80 (s, IH); 7.85 (s, IH); 7.79 (s, IH); 7.40-7.00 (m, 10H); 6.69 (m, IH); 5.34 (m, IH); 5.24 (s, 2H); 4.86 (m, 2H); 4.73, 4.59 (CUB, 7=16 Hz, 2H); 4.30 (s, IH); 4.15 (m, 2H); 3.86 (br s, IH); 2.88 (s, 3H); 2.85-
2.60 (m, 4H); 2.01 (s, IH); 1.58 (s, 2H); 1.44 (s, 2H); 1.09 (d, I= 6 Hz, 3H). Preparation of Examples Al and AK
Scheme 30
68 47
Figure imgf000273_0002
I. DlPEA, CH2Ci2; M. LiOH, THF/H2O;
III. Cmpd. 8, HOBt, EDC1 DIPEA, THF;
IV. a. neat TFA; b. NaOH, THF1 H2O
Compound 47
Compound 47 is commercially available from TCI America, and was used without further purification. Compound 72
Compound 72 was prepared following procedure for Compound 48 (Method II), except that Compound 68 was used instead of Compound 9. Compound 73 Compound 73 was prepared following procedure for Compound 49, except that Compound 72 was used instead of Compound 48. Example AT
Example AJ (70 mg) was prepared following the same procedure used to prepare Example AH, with the exception that Compound 73 (41 mg, 0.13 mmol) was used instead of Compound 71. m/z: 707.2 (M+H)+. Example AK
Example AK (43 mg, 67%) was prepared following the same procedure used to prepare Example AI, with the exception that Example AJ (70 mg, 0.10 mmol) was used instead of Example AH. m/z: 651.2 (M+H)+. 1H NMR (CDCb) δ 8.83 (s, 2H); 7.84 (s, IH); 7.79 (s, IH); 7.40-7.00 (m, 10H); 6.65 (br s, IH); 5.47 (br s, IH); 5.24 (s, 2H); 4.90 (m, IH); 4.82-4.50 (m, 2H); 4.30-4.00 (m, 3H); 3.84 (br s, IH); 3.49 (m, IH); 2.87 (s, 3H); 2.75 (br s, 5H); 1.60-1.20 (m, 4H).
Preparation of Examples AL and AM
Scheme 31
Figure imgf000275_0001
AM
I. DIPEA1 CH2CI2; II. LiOH, THF/H2O;
III. Cmpd. 8, HOBt, EDC, DIPEA, THF;
IV. a. neat TFA; b. NaOH, THF, H2O
Compound 74
Compound 69 (1.56 g, 10.1 mmol) was dissolved in CH2CI2 (10 mL). Compound 47 (1.7 g, 8.5 mmol) in CH2CI2 (20 mL) was added, followed by IPr2NEt (3.02 mL, 16.9 mmol). The reaction was stirred at 25 0C for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and washed sequentially with water and brine, dried over Na2SO4, filtered, and evaporated. Purification by Combiflash® (stationary phase: silica gel; eluent: 50-100% EtOAc/hexane gradient) gave Compound 74 (2.92 g). m/z: 356.0 (M+H)+. Compound 75
Compound 74 {0.97 mmol) was taken up in THF (3 mL) and treated with freshly prepared IM LiOH (2 mmol) and stirred vigorously for 1 h. The reaction was quenched with IM HCl (2.5 mmol) and extracted with EtOAc (3 X 15 mL). The combined organics were washed with brine (25 mL), dried over anhydrous Na2SO4and concentrated in vacuo to produce 0.331 g (quant) of Compound 75 as a colorless film ( m/z 342.0 (M+H)-). Example AL
Example AL (2.20 g) was prepared following the same procedure used to prepare Example AH, with the exception that Compound 75 (2.00 g, 4.88 mmol) was used instead of Compound 71. m/z: 733.2 (M+H)+. Example AM
Example AM (1.88 g, 92%) was prepared following the same procedure used to prepare Example AI, with the exception that Example AL (2.20 g, 3.01 mmol) was used instead of Example AH. m/z: 677.2 (M+H)+. 1H NMR (CDCl3) 6 8.79 (s, IH); 8.72 (s, IH); 7.82 (s, IH); 7.77 (s, IH); 7.40-7.00 (m, 10H); 6.59 (m, IH); 6.31 (m, IH); 5.23 (s, 2H); 5.00 (m, IH); 4.72, 4.60 (άw, /=15 Hz, 2H); 4.18 (s, 2H); 4.03 (m, IH); 3.84 (br s, IH); 3.48 (m, IH); 2.85-2.60 (m, 4H); 2.37 (br s, 2H); 1.58 (s, 2H); 1.41 (s, 2H); 0.93 (m, 2H); 0.76 (m, 2H). Scheme 32
Figure imgf000276_0001
I. compound 16, DIPEA, MeCN Compound 76
Compound 76 (rø/z 117.0 (M+H)+ of diamine) was prepared using a procedure similar to that used to prepare Compound 22 (described in Scheme 12) except that CBZ-L- alininol was used instead of CBZ-L-phenylalininol and Step III was performed with 1 M HCl added. Compound 77
Compound 77 (m/z 145.0 (M+H)+ of diamine) was prepared using a procedure similar to that used to prepare Compound 76 except that (S)-(+)-2-CBZ- amino-1-butanol was used instead of CBZ-L-alininoL Compound 78
Compound 76 (7.93 mmol) is added to a solution of NaOH (16.7 mmol) in H2O (5 mL) that is cooled to 0 0C and diluted with MeCN (40 mL). DIPEA is added (2.1 mL, 11.9 mmol). Compound 16 (7.9 mmol) is taken up in MeCN (40 mL) and added to the reaction solution dropwise via an addition funnel over 1 h. The resulting solution is allowed to warm to room temperature overnight. The solvent is removed in vacuo and the residue taken up in 3/1 CHCb/IPA (50 mL). The resulting solution is washed with sat. Na-COs (50 mL) and water is added until the aqueous layer is homogeneous. The aqueous layer is extracted with 3/1 CHCb/IPA (3 X 25 mL). The combined organics are washed with saturated Na2CO3 (50 mL), water (50 mL) and brine (50 mL) and are dried over anhydrous Na2SO4. The solvent is removed in vacuo and the residue purified by column chromatography on SiOi (100% EtOAc, then 0 to 20% MeOH/DCM) to produce 0.63 g (31%) of 78 as an off-white solid, (m/z 258.0 (M+H)+). Compound 79
Compound 79 (rø/z 286.1 (M+H)+) was prepared following the procedure for Compound 78 except that Compound 77 was used instead of Compound 76. Scheme 33
Figure imgf000278_0001
49
Figure imgf000278_0002
AN
Figure imgf000278_0003
AO
I. Cmpd. 79, HOBt, EDC, DIPEA, THF;
II. a. neat TFA; b. NaOH, THF, H2O
Example AN
Example AN (68 mg) was prepared following the same procedure used to prepare Example AH, with the exceptions that Compound 49 (68 mg, 0.19 mmol) was used instead of Compound 71, and Compound 79 (50 mg, 0.18 mmol) was used instead of Compound 8. m/z: 625.2 (M+H)-\ Example AO
Example AO (66 mg, 76%) was prepared following the same procedure used to prepare Example AI, with the exception that Example AN (43 mg, 0.13 mmol) was used instead of Example AH. m/z: 569.2 (M+H)+. 1H NMR (CDCb) δ 8.85 (s, IH); 7.89 (s, IH); 7.08 (s, IH); 6.81 (m, IH); 5.29 (s, 2H); 4.87 (m, IH); 4.63, 4.48 (&u», 7=16 Hz, 2H); 4.31 (m, IH); 4.11 (m, IH); 3.76 (m, 2H); 3.44 (m, 2H); 3.02 (m, 4H); 1.60-1.20 (m, 14H); 1.00-0.70 (m, 6H). Preparation of Examples AP and AO Scheme 34
Figure imgf000279_0001
12e 13e
Figure imgf000279_0002
AP
Figure imgf000279_0003
AQ
I. LiOH, THF/H20; (I. Cmpd. 79, HOBt, EDC, DIPEA, THF; 111. a. neat TFA; b. NaOH, THF1 H2O
Compound 13e
Compound 13e (1.39 g) was prepared following the same procedure used to prepare Compound 71, with the exception that Compound 12e (1.53 g, 3.97 mmol) was used instead of Compound 70 m/z: 372.0 (M+H)+. Example, AP
Example AP (87 mg) was prepared following the same procedure used to prepare Example AH, with the exception that Compound 13e (71 mg, 0.19 mmol) was used instead of Compound 71, and Compound 79 (50 mg, 0.18 mmol) was used instead of Compound 8. m/z: 639.2 (M+H)+. Compound AQ
Example AQ (61 mg, 76%) was prepared following the same procedure used to prepare Example AI, with the exception that Example AP (87 mg, 0.14 mmol) was used instead of Example AH. m/z: 583.2 (M+H)+. 1H NMR (CDCl3) δ 8.81 (s, IH); 7.87 (s, IH); 7.01 (s, IH); 6.87 (m, IH); 6.52 (s, IH); 5.28 (m, 2H); 4.47 (m, IH); 4.59, 4.43 (CUB, /=16 HZ, 2H); 4.45 (m, IH); 4.17 (br s, IH); 3.75 (br s, IH); 3.52 (br s, IH); 3.35 (br s, IH); 3.01 (m, 3H); 2.07 (br s, IH); 1.60-1.10 (m, 17H); 1.00- 0.70 (m, 6H). Preparation of Example AR
Scheme 35
Figure imgf000280_0001
80
Figure imgf000280_0002
I. CDI, DiPEA1 CH2CI2; II. LiOH, THF/H2O; III. Cmpd. 46, DfPEA, EDC, HOBt, THF
Compound 80
Compound 80 is commercially available from Chem Impex International, and was used without further purification. Compound 81
Compound 80 (2.0 g, 11.0 mmol) was dissolved in CH2CI2 (170 mL) and 1,1- carbonyldiimidazole (1.78 g, 11.0 mmol) was added, followed by iPrcNEt (7.83 mL, 43.8 mmol). The solution was allowed to stir at 25°C for 12 hours. Compound 9 (1.86 g, 11.0 mmol) was dissolved in 20 mL of CH2Chand added to the reaction mixture. The solution was stirred at 250C for 12 hours. The solvent was removed in vacuo and the residue was diluted with ethyl acetate and washed water and brine. The organic layers were dried over NasSCX filtered, and evaporated. Purification by Combiflash® (stationary phase: silica gel; eluent: 66-100% EtOAc/Hexane gradient) gave Compound 81 (0.252 mg). m/z: 343.0 (MH-H)+. Compound 82
Compound 82 (0.252 g, 0.74 mmol) was dissolved in THF (4 mL) and IM aqueous LiOH (1.48 mL) was added. The mixture was stirred at 25°C for 3 hours. The reaction was quenched with IM HCl (2 mL) and the mixture was adjusted to pH 2. The mixture was extracted with ethyl acetate. The organic layers were dried over Na2SO4, filtered, and evaporated to afford Compound 82 (0.18 g). This material was used in the next step without further purification, m/z: 329.1 (M+H)+. Example AR
Compound 82 (182 mg, 0.55 mmol) was dissolved in THF (7.15 mL). Compound 46 (225 mg, 0.55 mmol) was added, followed by HOBt (112 mg, 0.83 mmol), IPr2NEt (393 μL, 2.20 mmol), and EDC (194 μL, 1.10 mmol). The mixture was stirred at 25°C for 12 hours. The solvent was removed under reduced pressure. The residue was diluted ethyl acetate and washed sequentially with saturated aqueous Na2CO3, water, and brine. The organic phase was dried over Na2SO4, filtered, and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 5-10% MeOH/CH2Ch gradient) gave Example AR (208 mg, 53%). m/z: 720.2 (M+H)÷. Η NMR (CDCIs) δ 8.80 (s, IH); 7.84 (s, IH); 7.40-7.00 (m, 10H); 6.97 (s, IH); 6.83 (m, IH); 6.65 (br s, IH); 5.99 (m, IH); 5.40-5.10 (m, 4H); 4.52 (m, 3H); 4.06 (m, IH); 3.79 (m, IH); 3.34 (m, IH); 2.97 (s, 3H); 2.90- 2.60 (m, 5H); 2.50-2.40 (br s, IH); 1.80-1.20 (m, 10H). Preparation of Example AS Scheme 36
Figure imgf000282_0001
85a
Figure imgf000282_0002
83 84
Figure imgf000282_0003
AS
I. DIPEA, CH2CI2; H. LJOH, THF/H2O; III. Cmpd. 8, HOBt, EDC, DIPEA, THF
Compound 85a
Compound 85a was prepared following the same procedure as Compound 4, except that 4-chloromethylthiazole (purchased from TCI America) was used instead of Compound 3, and methylamine was used instead of isopropylamine. Compound 83
To compound 85a (0.40 g, 3.12 mmol) in CH2CI2 (9 mL) was added NrN- diisopropylethylamine (1.04 mL, 5.85 mmol), followed by Compound 5 (280 uL, 1.95 mmol). The reaction mixture was stirred for 3.5 hours at 25 0C. Solvent was removed under reduced pressure. Purification by Combiflash© (stationary phase: silica gel; eluent: 90-100% EtOAc/Hexane gradient) gave Compound 83 (0.51 g). m/z: 286.0 (M+H)+. Compound 84 Compound 83 (0.51 g, 1.77 mmol) was dissolved in THF (10 mL) and IM aqueous LiOH (3.54 mL) was added. The mixture was stirred at 25°C for 2 hours. The reaction was quenched with IM HCl (4.8 mL) and the mixture was adjusted to pH 2. The mixture was extracted with ethyl acetate. The organic layers were dried over Na2SO4, filtered, and evaporated to afford Compound 84 (0.430 g). This material was used in the next step without further purification, m/z: 272.0 (M+H)+. Example AS
Compound 84 (150 mg, 0.55 mmol) was dissolved in THF (7.15 mL). Compound 8 (225 mg, 0.55 mmol) was added, followed by HOBt (112 mg, 0.83 mmol), iPriNEt (393 μL, 2.20 mmol), and EDC (198 μL, 1.11 mmol). The mixture was stirred at 250C for 12 hours. The solvent was removed under reduced pressure. The residue was diluted ethyl acetate and washed sequentially with saturated aqueous Na2CO3, water, and brine. The organic phase was dried over Na2SO4, filtered, and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 7% i-PrOH/CH2Ch) gave Example AS (219 mg, 60%). m/z: 663.1 (M+H)+. Η NMR (CDCl3) δ 8.87 (s, IH); 8.76 (s, IH); 7.84 (s, IH); 7.40-7.00 (m, 10H); 6.22 (br s, IH); 5.73 (br s, IH); 5.22 (m, 2H); 4.50 (m, 2H); 4.16 (br s, IH); 4.05 (br s, IH); 3.75 (m, IH); 2.93 (s, 3H); 2.90-2.60 (m, 5H); 2.90 (m, IH); 2.31 (m, IH); 1.60-1.30 (m, 4H); 1.00-0.80 (m, 6H). Preparation of Example AT Scheme 37
Figure imgf000284_0001
68
Figure imgf000284_0002
I. DIPEA, CH2CI2; 11. LiOH1 THFZH2O; III. Cmpd 8, HOBt, EDC, DIPEA, THF
Compound 87
Compound 87 (386 mg) was prepared from Compound 86 following the same procedure used to prepare Compound 7 from Compound 6, except that Compound 68 was used was used instead of Compound 4. m/z 286.0 (M+H)+
Preparation of Example AU Scheme 38
Figure imgf000285_0001
85b 5
Figure imgf000285_0002
AU
I. DlPEA, CH2CI2; II. LiOH1 THF/H20; III. Cmpd. 8, HOBt, EDC, DIPEA, THF
Compound 85b
Compound 85b was prepared following the same procedure as Compound 4, except that 4-chloromethylthiazole (obtained from TCI America) was used instead of Compound 3. Compound 88
Compound 88 (341 mg) was prepared following the same procedure used to prepare Compound 83, with the exception that Compound 85b (300 mg, 1.95 mmol) was used instead of Compound 85a. m/z: 312.0
Figure imgf000285_0003
Compound 89
Compound 89 (341 mg) was prepared following the same procedure for 84, with the exception that Compound 88 (293 mg, 0.99 mmol) was used instead of Compound 83. m/z: 298.0 (M+H)+. Example AU Example AU (226 mg, 64%) was prepared following the same procedure used to prepare Example AS7 with the exception that Compound 89 (150 mg, 0.51 mmol) was used instead of Compound 84. m/z: 689.1 (M+H)+. 1H NMR (CDCb) δ 8.87 (s, IH); 8.74 (s, IH); 7.83 (s, IH); 7.40-7.00 (m, 10H); 6.21 (m, IH); 5.73 (m, IH); 5.29 (m, IH); 5.17 (m, 2H); 4.88 (d, /=16 Hz, IH); 4.47 (d, /=16 Hz, IH); 4.18 (m, IH); 3.75 (br s, IH); 2.90-2.60 (m, 6H); 2.51 (br s, IH); 2.31 (m, IH); 1.60-1.30 (m, 4H); 1.00-0.80 (m, 10H). Preparation of Example AV Scheme 39
Figure imgf000286_0001
I. DIPEA, CH2Ci2; II. LiOH, THF/H2O; III. Cmpd. 8, HOBt, EDC, DIPEA1 THF
Compound 90
Compound 90 (190 mg) was prepared following the procedure used to prepare Compound 4, except that 4-(chloromethyl)-2-methylthiazole was used instead of Compound 3. m/z 141.1 (M-H) Compound 91
Compound 91 (400 mg) was prepared following the same procedure used to prepare Compound 6 except that Compound 90 was used instead of Compound
4. m/z 300.0 (M+H)+
Compound 92
Compound 92 (188 mg) was prepared following the same procedure as Compound 7 except that Compound 91 was used instead of Compound 6. m/z 284.0 (M-H)- Example AV
Example AV (107 mg) was prepared following the procedure used to prepare Example C, except Compound 92 was used instead of Compound 7. 1H NMR (CDCl3) δ 8.76 (s, IH), 7.78 (s, IH), 7.27-7.07 (m, 10H), 6.93 (s, IH), 6.25 (m, 2H), 5.39 (m, IH), 5.19 (m, 2H),4.37-4.32(m, 2H),4.06 (m, IH), 3.81 (br s, IH), 2.83 (m, 4H), 2.65 (br s, 7H), 2.28-2.22 (m, IH), 1.51-1.37 (m, 4H), 0.82 (m, 6 H): m/z 677.2 (M+H)+
Preparation of Example AW Scheme 40
Figure imgf000288_0001
AW i,S0CI2/Me0H; Ii-DlPEA1CH2Ci2; III.LiOH,THF/H2O; IV, Cmpd 8, HOBt, EDC, IPEA1THF
Compound 93
Compound 93 is commercially available from TCI/ and was used without further purification. Compound 94
To a solution of Compound 93 (500 mg, 3.76 mmol) in methanol (20 mL) was added thionyl chloride (0.5 mL, 6.6 mmol) dropwise. The mixture was stirred at 60 QC for 20 minutes, and concentrated in vacuo to gave Compound 94. Compound 95
To a stirred solution of Compound 94 (3.7 mmol) and diisopropylethylamine (1.4 mL, 8.3 mmol) in dichloromethane (50 mL) was added CDI (609 mg, 3.7 mmol). The mixture was stirred for 12 hours. Compound 9 was added, and the mixture was stirred for 12 additional hours. Concentration and purification by flash column chromatography (0-100%: EtOAc/hexane) gave Compound 95 (100 mg). m/z 344.3 (M+H)+ Compound 96
Compound 96 (39 mg) was prepared following the same procedure used to prepare Compound 7 except that Compound 95 was used instead of Compound 6. m/z 328.3 (M-H)- Example AW
Example AW (107 mg) was prepared following the procedure for Example C, except that Compound 96 was used instead of Compound 7. 1H NMR (CDCb) δ 8.79 (s, IH), 7.82 (s, IH), 7.27-7.09 (m, 10H), 6.95 (s, IH), 6.23 (m, IH), 6.14 (s, IH), 5.22 (s, 3H), 4.45 (m, 2 H), 4.35-4.0 (m, 3 H), 3.8 (m, 1 H), 3.6 (m, 1 H), 3.25 (s, 3H), 3.21 (m, 2H), 2.95 (s, 3 H), 2.8-2.6 (m, 4 H), 2.0-1.4 (m, 4 H), 1.25 (m, 4 H), 1.05 (m,4H): m/z 721.3 (M+H)+ Preparation of Examples AX and AY Scheme 41
Figure imgf000289_0001
!.DMSO, Et3N, SO3 pyridine:
II. NaBH(OAc)3, AcOH, Methylamine/MeOH
Example AX To a solution of Example I (650 mg, 1.00 mmol) in DMSO (3.5 iriL) was added triethylamine (0.5 mL). The mixture was stirred for 30 minutes. Pyridine SO3 was added to the mixture at 5SC then stirred for 60 minutes. The mixture was poured on to ice-water, then stirred for 30 minutes. The mixture was diluted with EtOAc and washed with water, sat. NaHCO3, and brine. Concentration gave Example AX. m/z 705.2 (M+H)+ Example AY
To a stirred solution of Example AX (70 mg, 0.099 mmol) and methylamine (1.5 mL, 2M) in MeOH (1.5 mL) was added AcOH (119 mg, 1.99 mmol). The mixture was stirred for 2 hours. NaBH(O Ac)3 (94 mg) was added, and the mixture was stirred for 2 hours. Concentration and purification by prep. HPLC gave Example AY (30 mg). 1H NMR (CDCIa) δ 8.79 (s, IH), 7.82 (s, IH), 7.27-7.09 (m, 10H), 6.95 (s, IH), 6.23 (m, IH), 6.14 (s, IH), 5.22 (s, 2 H), 4.45 (m, 1 H), 4.35-4.0 (m, 4 H), 3.8 (m, 1 H), 3.6 (m, 1 H), 3.21 (m, 1 H), 2.95 (s, 3 H), 2.93 (s, 3H), 2.8-2.6 (m, 4 H), 2.0-1.4 (m, 4 H), 1.25 (m, 4 H), 1.05 (m, 4H): m/z 720.3 (M+H)+ Preparation of Example AZ Scheme 42
Figure imgf000290_0001
I. HOBt, EDC1 DIPEA, THF
Example AZ Compound AZ (61 mg) was prepared following the procedure for Example C/ except that Compound 87 was used instead of Compound 7 and Compound 79 was used instead of Compound 8. 1H NMR (CDCb) δ 8.77 (s, IH), 8.72 (s, IH), 7.78 (s, IH), 7.71 (s, IH), 6.23 (d, IH), 5.28-5.24 (m, 2H), 4.85 (d, IH), 4.71-4.57 (m, 2H), 4.08-4.03 (m, IH), 3.78 (br s, IH), 3.51 (br s, IH), 2.87 {s, 3H)7 2.33 (br s, IH), 2.13-2.06 (m, IH), 1.49-1.33 (m, 8H), 0.93-0.80 (m, 12 H): m/z 539.2 (M+H)+ Preparation of Examples BA and BB Scheme 43
Figure imgf000291_0001
i. a. CDI/iPr2NEt; b. Compound 9; ll.a. NaOH/THF/H20; b. HCI; ill. Cmpd 8/EDC/HOBt, IPEA, THF: IV. Et3SiH, TFA
Compound 97
Compound 97 is commercially available from TCI, and was used as received. Compound 98
To a stirred solution of Compound 97 (1 g, 2.2 mmol) and diisopropylethylamine ( 1.6 mL, 8.9 mmol) in dichloromethane (26 mL) was added CDI (362 mg, 2.2 mmol). The mixture was stirred for 12 hours. Compound 9 was added, and the mixture was stirred for 12 additional hours. Concentration and purification by flash column chromatography (0-8%: MeOH/DCM) gave Compound 98 (1.2 g). m/z 608.1 (M+H)+ Compound 99
Compound 99 (1.2 g) was prepared following the same procedure used to prepare Compound 67, with the exception that Compound 98 was used instead of Compound 66. m/z 592.2 (M-H)- Example BA
Example BA (111 mg) was prepared following the procedure used to prepare Example C, except that Compound 99 was used instead of Compound 7. m/z 986.1 (M+H)+ Example BB
To a stirred solution of Example BA (111 mg, 0.113 mmol) and TFA (1.4 mL) was added Et3SiH (0.1 mL). The mixture was stirred for 60 minutes, then concentrated and partitioned with EtOAc and sat. NaHCOs, followed by extraction with EtOAc (2X) and drying over Na2SU4. Concentration and purification by flash column chromatography (0-15%: MeOH/DCM) gave Example BB (50 mg).
1H-NMR (CDCb) δ 8.75 (s, 1 H), 7.79 (s, 1 H), 7.42 (s, 1 H), 7.22-7.12 (m, 9H), 6.99- 6.96 (m, 2H), 6-86 (s, IH), 6.71 (m, 2H), 5.51 (br s, 1 H), 5.17 (m, 2H), 4.57-4.52 (m, 1 H), 4.39-4.35 (m, 2 H), 4.07 (m, 1 H), 3.74 (br s 1 H), 3.28-3.19 (m, IH,), 3.09-2.76 (m, 6 H), 3.65-2.58 (m, 3 H), 1.49 (m, 2 H), 1.36-1.20 (m, 8 H); m/z 743.2 (M+H)+ Preparation of Example BC Scheme 44
Figure imgf000293_0001
BC I. HOBt, EDC, DIPEA, THF, Cmpd 29
Example BC
Example BC (95 mg) was prepared following the procedure used to prepare Example C, except that Compound 29 was used instead of Compound 7, and Compound 78 was used instead of Compound 8. 1H NMR (CDCIs) & 8.75 (s, IH)7 7.80 (s, IH), 6.93 (s, IH), 6.28 (d, IH), 6.18 (m, IH), 5.26-5.21 (m, 3H), 4.47-4.30 (m, 2H), 4.11-4.00 (m, IH), 3.91 (br s, IH), 3.59 (br s, IH), 3.28 (m, IH), 2.97-2.90 (m, 3H), 2.26-2.19 (m, IH), 1.39-1.24 (m, 10H), 1.09-1.01 (m, 6 H), 0.94-0.86 (m, 6 H): m/z 553.1 (M+H)+
Preparation of Examples BD and BE
Scheme 45
Figure imgf000294_0001
12e 13e
Figure imgf000294_0002
BD
Figure imgf000294_0003
BE
i. LiOH, THF/H20; II. Cmpd. 78, HOBt, EDC, DIPEA, THF; ill. a. neat TFA; b. NaOH, THF, H2O
Example BD
Example BD (148 mg) was prepared following the procedure used to prepare Example C, except that Compound 13e was used instead of Compound 7, and Compound 78 was used instead of amine 8. m/z 611.1 (M+H)+ Example BE
Example BD (148 mg, 0.242 mmol) was dissolved in TFA (3 mL) and allowed to stir at 25 0C for 3 hours. The solvent was removed under reduced pressure and the residue was diluted with THF (3 mL) and 2N aqueous NaOH was added until pH 10. The mixture was allowed to stir for 20 min and extracted with EtOAc. The organic layer was washed sequentially with water and brine, dried over Na2SO4, filtered, and evaporated. Purification by flash chromatography (0-10% MeOH/CHzCk) gave Example BE (109 mg). 1H NMR (CDCl3) δ 8.75 (s, IH), 7.80 (s, IH), 6.97-6.94 (d, 1 H), 6.90 (s, IH), 6.32 (br s, 1 H), 5.26-5.22 (m, 2H), 5.12 (d, IH), 4.51-4.39 (m, 3H), 4.25-4.22 (m, 2 H)7 3.87 (br s, IH), 3.62 (br s, 1 H), 3.27- 3.18 (m, 1 H), 2.94 (s, 3 H), 1.41-1.31 (m, 10 H), 1.13-1.00 (m, 9 H). m/z: 555.1 (M+H)\
Preparation of Example BF Scheme 46
Figure imgf000295_0001
I. LiOH, THF/H2O; Ii. Cmpd. 8, HOBt, EDC, DIPEA, THF
Compound 100
Compound 100 was prepared using the same method used to prepare Compound 122, except that Compound 9 was replaced with Compound 68 (see Scheme 70). Compound 101
Compound 100 (108 mg, 0.423 mmol) was dissolved in THF (2 mL), then 847 μl of 1 M LiOH/HϊO was added. After stirring overnight, 843 μl of 1 N HCl was added. Concentration gave Compound 101. Example BF
Example BF (24 mg) was prepared following the procedure used to prepare Example C, except that Compound 101 was used instead of Compound 7. 1H NMR (CDCk) δ 8.77 (s, IH), 8.73 (s, IH), 7.80 (s, IH), 7.74 (s, IH), 7.27-7.10 (m, 10H), 6.55-6.52 (d, IH), 5.84 (d, 1 H), 5.21-5.19 (m, 3 H), 4.77-4.53 (m, 2H), 4.39 (br s, 1 H)7 4.11-3.99 (m, 2 H), 3.81 (br s, IH), 3.58 (m, 2 H), 2.86 (s, 3 H), 2.81-1.72 (m, 5H), 2.04 (m, 1 H), 1.85 (m, 1 H), 1.66-1.37 (m, 6 H): m/z 665.2 (M+H)+ Preparation of Example BG
Scheme 47
Figure imgf000296_0001
I. Ethyltrifiuoroacetate, MeI, Cs2CO3, THF
Example BG
Example R (102 mg, 0.137 mmol) was dissolved in THF (2 mL), then 2 mL of ethyltrifluoroactate was added. Then 1.3 eq of MeI and excess CS2CO3 were added. After stirring for 1 day, the mixture was partitioned with EtOAc and sat. Na2CO37 extracted with EtOAc (2X), and dried over Na2SO4. Purification by flash chromatography (0-20% MeOH/CHiCh) gave Example BG (6.5 mg). 1H NMR (CD3OD) δ 9.94 (s, IH), 8.27 (s, IH), 7.73 (s, IH), 7.30-7.10 (m, 10H), 5.29, 5.17 (d 2H), 4.72 (s, 3H), 4.29 (m, IH), 4.15 (br s, IH), 3.83 (br s, IH), 3.61 (m, 2H), 3.07 (s, 3H), 2.93 (m, 2H), 2.82-2.70 (m, 4H), 2.68-2.58 (m, 2H), 2.42 (s, 3H), 2.05 (m, 2H), 1.70-1.40 (m, 10H). m/z: 720.2 (M+H)+. Preparation of Example BH Scheme 48
Figure imgf000297_0001
I. amine 59, HOBt, EDC, DIPEA, THF
Example BH
Example BH (78 mg) was prepared following the procedure used to prepare Example C1 except that Compound 87 was used instead of Compound 7, and Compound 46 was used instead of Compound 8. 1H NMR (CDCb) δ 8.73 (s, IH), 8.68 (s, IH), 7.76 (s, IH)7 7.68 (s, IH), 7.18-7.09 (m, 10H)1 6.26 (m, IH), 5.76 (m, IH), 5.22-5.18 (m, 4H), 4.71-4.65 (d, IH), 4.46-4.40 (d, IH), 4.11-4.04 (m, 2H), 3.81 (br s, IH), 3.14 (br s, IH), 2.83 (s, 3H), 2.76-2.52 (m, 4H), 1.88 (m, IH), 1.51-1.37 (m, 2H), 0.73-0.69 (m, 6 H) m/z 663.2 (M+H)*
Preparation of Examples BI and BT Scheme 49
Figure imgf000298_0001
i. Cmpd. 46/EDC/HOBtT IPEA, THF: II. Et3SiH, TFA
Example BI
Example BI (1.78 g) was prepared following the procedure used to prepare Example C, except that Compound 99 was used instead of Compound 7, and Compound 46 was used instead of Compound 8. m/z 986.1 (M+H)τ Example BT
Example BJ (728 mg) was prepared following the procedure used to prepare Example BB, except that Example BI was used instead of Example BA. 1H-NMR (CDC13) δ 8.75 (s, 1 H), 7.79 (s, 1 H), 7.42 (s, 1 H), 7.22-7.12 (m, 9H), 6.99- 6.96 (m, 2H), 6.86 (s, IH), 6.71 (m, 2H), 5.51 (br s, 1 H), 5.17 (m, 2H), 4.57-4.52 (m, 1 H), 4.39-4.35 (m, 2 H), 4.07 (m, 1 H), 3.74 (br s 1 H), 3.28-3.19 (m, IH,), 3.09-2.76 (m, 6 H), 3.65-2.58 (m, 3 H), 1.49 (m, 2 H), 1.36-1.20 (m, 8 H); m/z 743.2 (M+H)÷ Preparation of Compounds 104-115 Scheme 50
Figure imgf000299_0001
102 103 104
I. a. CDi, DIPEA, MeCN; b. Cmpd. 9, MeCN. II. 1M LiOH, THF.
Compound 102
Compound 102 is commercially available from Aldrich Chemical Co., and was used without further purification. Compound 103
Compound 102 (5.5 mmol) was suspended in MeCN (55 mL) and DIPEA (8.25 mmol) was added. Carbonyl diimidazole (5.5 mmol) was diluted in MeCN (20 mL) and the solution added slowly to the reaction mixture over 45 min. The resulting mixture was allowed to age overnight. Compound 9 (5.5 mmol) was diluted in MeCN (10 mL) and treated with DIPEA (8.25 mmol) before being added to the reaction mixture, which was then allowed to age overnight. The volatiles were removed in vacuo and the residue taken up in EtOAc (50 mL) and washed with IM HCl (50 mL). The layers were separated and the aqueous layer extracted with EtOAc (3 X 50 mL). The combined organic layers were washed with sat. Na2CO3 until the pH of the washes was ~ pH 8. A brine wash (30 mL) was followed by drying over anhydrous MgSO4. Following concentration in vacuo, the residue was purified on S1O2 (0-65% EtOAc/hex) to provide 0.340 g (20%) of Compound 103 as an amorphous white solid (m/z 314.0 (M+H)+). Compound 104
Compound 103 (1.1 mmol) was diluted in THF (5 mL) and treated with freshly prepared IM LiOH (2.2 mmol). The biphasic reaction was stirred vigorously for 2 h before being quenched with IM HCl (3 mmol). The reaction was extracted with EtOAc (5 X 15 mL) and the combined organics were washed with brine (30 mL), dried over anhydrous Na2SO4 and concentrated to provide 0.282 g (86%) of Compound 104 as an amorphous white powder that was used with further purification 1H-NMR (CDCb, 300 MHz): 7.06 (s, IH); 4.37 (s, IH); 3.28 (p, / = 6.9 Hz, IH); 3.00 (s, 3H); 1.62 (s, 6H); 1.39 (d, / - 6.9 Hz, 6H). Scheme 51
Figure imgf000300_0001
105 106
Figure imgf000300_0002
107 108
I. HCI, WIeOH; II. a. CDI, DIPEA, MeCN; b. Cmpd. 9, MeCN. III. 1M LiOH1 THF.
Compound 105
Compound 105 is commercially available from Aldrich Chemical Co., and was used without further purification. Compound 106
Racemic Compound 105 (12.2 mmol) was diluted in MeOH (100 mL). HCl/dioxane solution (4M, 25 mmol) was added and the solution was refluxed overnight. Volatiles were removed in vacuo to produce 2.60 g (97%) of Compound 106 as a racemic mixture. The foamy white solid was used without further purification (m/z 147.0 (M+H)+). Compound 107
Compound 106 (5 mmol) was diluted in MeCN (65 mL) and treated with DIPEA (25 mmol). The resulting solution was added slowly via addition funnel to a solution of CDI (5 mmol) in MeCN (30 mL) and allowed to age overnight. Compound 9 (5 mmol) and DIPEA (3 mmol) were added to the reaction solution which was allowed to age overnight. The volatiles were removed in vacuo and the residue was taken up in EtOAc and sat. Na2CO3 (30 mL each). The aqueous layer was extracted with EtOAc (3 X 25 mL) and the combined organics were washed with brine (50 mL) and dried over anhydrous MgSO4. Following concentration in vacuo, purification by column chromatography on S1O2 (0-10% MeOH/DCM) provided 0.36 g (21%) of racemic Compound 107 as a yellow oil (rø/z 343.1 (M+H)+). Compound 108
Compound 107 (1.05 mmol) was taken up in THF (5 mL) and treated with freshly prepared IM LiOH solution (2.1 mmol). The solution was stirred vigorously for 2 h and quenched with IM HCl (2.1 mmol). The volatiles were removed in vacuo, and the resulting oil was azeotroped with toluene until a quantitative yield of racemic Compound 108 was produced as an amorphous white solid that was used without further purification ( mlz 329.1 (M+H)+). Scheme 52
Figure imgf000301_0001
I. P-O2NC6H4O(CO)CI, NMiVI1 DCM, 0 0C to rt; II. Cmpd. 9, Et3N, DMAP, THF, 70 0C; IH. 1M LiOH, THF
Compound 109 Compound 109 is commercially available from Bachem, and was used as received. Compound 110
Compound 109 (4.1 mmol) was diluted in DCM (5 mL) and treated with N- methylmorpholine (8.2 mmol). This solution was added slowly to a DCM (5 mL) solution of 4-nitrophenyl chloroformate (4.1 mmol) at 0 0C. The reaction was then allowed to warm to room temperature overnight. The volatiles were removed in vacuo and the residue was taken up in EtOAc and sat. NaaCO3. The aqueous layer was extracted with EtOAc (3 X 10 mL) and the combined organics were washed with brine (30 mL) prior to being dried over anhydrous Na2SO4. Following concentration in vacuo, the residue was purified by column chromatography on SiOi (0-25% EtOAc/Hex) to produce 0.75 g (51%) of Compound 110 as an amorphous white solid (rø/z 354.8 (M+H)+). Compound 111
Compound 110 (1.1 mmol) was diluted in THF (3.5 mL). Compound 9 (1.4 mmol) was diluted in THF (3 mL), treated with Et3N (2.8 mmol) and transferred to the reaction solution. DMAP (0.11 mmol) was added and the reaction was heated to 70 0C for 2 h. After cooling to room temperature, EtOAc (10 mL) and sat. Na2CO3 were added. The aqueous phase was extracted with EtOAc (3 X 10 mL) and the combined organics were washed with saturated Na2CO3, H2O, and brine (15 mL each). After drying over anhydrous MgSO4, volatiles were removed in vacuo and the residue was purified by column chromatography on Siθ2 (0-50% EA/hex) to produce 0.346 g (82%) of Compound 111 (m/z 386.0 (M+H)+). Compound 112
Compound 111 (0.88 mmol) was taken up in THF (4 mL) and treated with freshly prepared IM LiOH (1.8 mmol). The reaction mixture was stirred vigorously for 1.5 h and quenched with IM HCl (2.5 mmol). The reaction mixture was extracted with EtOAc (3 X 10 mL), and the combined organics were washed with brine (30 mL) and dried over anhydrous Na2SO<s. Concentration in vacuo produced 0.300 g (92%) of Compound 112 as a colorless film that was used without further purification (m/z 372.0 (M+H)+).
Scheme 53
Figure imgf000303_0001
I. TMSCHN2, THF/MeOH; II. piperϊdϊne, DMF
Compound 113
Compound 113 is commercially available from Chern-Impex, and was used without further purification. Compound,!!!
Compound 113 (3.2 mmol) was diluted in THF (15 mL). TMSCHNi (3.2 mmol) was added slowly, followed by MeOH (5 mL). The solution rapidly became colorless, and heavy evolution of gas was observed. After aging overnight, the volatiles were removed in vacuo and the residue purified by column chromatography on SiOi (0-50% EtOAc/hex) to produce 0.805 g (52%) of Compound 114 (m/z 505.2 (M^Na)+). Compound .115
Compound 114 (1.7 mmol) was diluted in DMF (4 mL) and piperidine (1 mL) was added. After 30 min, the volatiles were removed in vacuo and the residue was purified by column chromatography on Siθ2 (0-5% MeOH/DCM) to provide 0.414 (94%) of Compound 115 as an amorphous white solid (m/z 261.0 (M+H)+). Preparation of Example BK Scheme 54
Figure imgf000304_0001
I. Cmpd. 29/EDC/HOBt/DIPEA/THF.
Compound BK
Compound 79 (0.70 mmol) and Compound 29 (0.91 mmol) were combined in THF (7 mL). HOBt (0.91 mmol), DIPEA (1.05 mmol) and EDC (0.91 mmol) were added consecutively at room temperature and the reaction was allowed to age overnight. The volatiles were removed in vacuo and the residue taken up in 3/1 CHCls/IPA and sat. Na2CO3 (15 mL each). The aqueous layer was extracted with 3/1 CHCb/IPA (3 X 10 mL) and the combined organics were washed with sat. Na2CO3, water, and brine (15 mL each). Following drying over anhydrous MgSθ4, the volatiles were removed in vacuo and the residue was purified by column chromatography on SiOi (0-10% MeOH/DCM) to produce 8.5 mg (2%) of Compound BK mlτ 581.2 (M+H)+; 1H-NMR (CDCb, 300 MHz): 8.91 (s, IH); 7.89 (s, IH); 7.15 (s, IH); 6.52-6.0 (br m, 2H); 5.26 (s, 2H); 5.18 (br d, / = 8.1 Hz, IH); 4.55 (s, 2H); 4.06 (br s, IH); 3.79 (br s, IH); 3.48 (m, 2H); 3.09 (s, 3H, minor rotamer); 3.01 (s, 3H, major rotamer); 2.34 (m, IH); 1.60-1.30 (m, 8H); 1.42 (d, / = 6.9 Hz, 6H); 0.98 (t, / = 7.2 Hz, 6H); 0.86 (m, 6H). Preparation of Example BL Scheme 55
Figure imgf000305_0001
I. Cmpd. 8/EDC/HOBt/DIPEA/THF.
Example BL
Example BL was prepared in a similar fashion to Example BK using Compound 104 (0.26 mmol) and Compound 8 (0.29 mmol) to produce 0.087 g (64%) of Example BL as an amorphous white solid rø/z 691.3 (M+H)+; 1H-NMR (CDCh, 300 MHz): 8.82 (s, IH); 7.82 (s, IH); 7.30-7.10 (m, HH); 7.06 (s, IH); 6.54 (d, / = 9.6 Hz, IH); 5.89 (d, / = 8.4 Hz, IH); 5.22 (s, IH); 5.07 (m, IH); 4.45 (AB d, / = 16.5 Hz, IH); 4.37 (AB d, / = 15.6 Hz, IH); 4.07 (m, 1 H); 3.68 (m, IH); 3.40 (m, IH); 3.06 (s, 3H, minor rotamer); 2.89 (s, 3H, major rotamer); 2.90-2.54 (m, 4H); 1.60- 1.25 (m, 16H).
Preparation of Example BMa and BMb Scheme 56
Figure imgf000306_0001
Figure imgf000306_0002
BMa and BMb I Cmpd. 8/EDC/HOBt/DIPEA/THF.
Examples BMa and BMb
Examples BMa and BMb were prepared in a similar fashion to Compound BK using racemic Compound 108 (0.36 mmol) and Compound 8 (0.28 mmol). The enantiomeric products were separated by preparatory HPLC (Chiralcel OD-H (250 X 4.6 mm, 70:30 Heptane/IP A, 30 min) to produce 0.008 g (4%) of enantiomer BMa (HPLC RT= 11.71 min) mlz 720.3 (M+H)+; 1H-NMR (CDCl3, 300 MHz): 8.73 (s, IH); 7.78 (s, IH); 7.41 (br s, IH); 7.30-7.00 (m, HH); 6.94 (s, IH); 5.40 (br s, IH); 5.18 (br s, 2H); 4.56 (AB d, / = 15 Hz, IH); 4.48 (AB d, / = 16 Hz7 IH); 4.39 (br s, IH); 4.05 (br s, IH); 3.73 (br s, IH); 3.25 (s, 3H, minor rotamer); 3.23 (m, IH); 2.98 (s, 3H, major rotamer); 2.82-2.30 (m, 10H); 1.60-1.20 (m, 6H); 1.32 (d, / = 7 Hz, 6H) and 0.010 g (5%) of enantiomer BMb (HPLC RT= 15.41 min). {mlz 720.3 (M+H)+; 1H- NMR (CDCk, 300 MHz): 8.78 (s, IH); 7.83 (s, IH); 7.38 (br d, / = 8 Hz, IH); 7.30- 7.7.05 (m, HH); 7.02 (s, IH); 5.52 (d, / = 9 Hz, IH); 5.25 (AB d J = 13 Hz, IH); 5.21 (AB d, / = 13 Hz, IH); 4.85-4.62 (m, 2H); 4.44 (d, / = 16 Hz, IH); 3.99 (br s, IH); 3.78 (br s, IH); 3.37 (br s, 3H, minor rotamer); 3.26 (m, IH); 3.07 (s, 3H, major rotamer); 2.77 (s, 6H); 2.86-2.60 (m, 4H); 1.6-1.3 (m, 6H); 1.35 (d , / = 7 Hz, 6H). Preparation of Examples BN and BO Scheme 57
Figure imgf000307_0001
Figure imgf000307_0002
I. Cmpd. 8/EDC/HOBt/DIPEA/THF; iϊ. TFA, 1M NaOH.
Example BN
Example BN was prepared in a similar fashion to Example BK using Compound 112 (0.78 rnmol) and Compound 8 {0.60 mmol) to produce 0.227 g (50%) of Compound BN as colorless film, (rø/z 763.3 (M+H)+). Example BO
Example BO was prepared in a similar fashion to Example AM using Example BN (0.29 mmol) to produce 0.149 g (72%) of Example BO as an amorphous white solid, (rø/z 707.3 (M+H)+; 1H-NMR (CDCb, 300 MHz): 8.82 (s, IH); 7.84 (s, IH); 7.26-7.03 (m, HH); 6.99 <s, IH); 6.69 (d, / = 9.6, IH); 6.42 (br s, IH); 5.47 (br d, / = 8.7 Hz7 IH); 5.27 (AB d, / = 13 Hz, IH); 5.22 (AB d, / = 13 Hz, IH); 4.55 (AB d, / = 16 Hz, IH); 4.43 (AB d, / - 16 Hz, IH); 4.18 (m, IH); 4.00 (m, 2H); 3.72 (br s, IH); 2.25 (m, IH); 2.99 (s, 3H); 2.84-2.60 (m, 3H); 2.54-2.42 (m, IH); 1.64-1.12 (m, 4H); 1.37 <d, / = 7 Hz, 6H); 1.11 (d, / = 6 Hz, 3H). Preparation of Examples BF-BR
Scheme 58
Figure imgf000308_0001
I. Cmpd. 78/EDC/HOBt/DlPEA/THF; II. 4M HCI/dioxane; 111. HCHO, NaHB(OAc)3, MeOH
Example BP
Example BP was prepared in a similar fashion to Example BK using Compound 52 (0.22 mmol) and Compound 78 (0.20 mmol) to produce 0.091 g (71%) of Example BP as colorless film (m/z 654.2 (M+H)τ). Example. BQ
Example BP (0.14 mmol) was treated with 4M HCI in dioxane (2 mL) to produce a white precipitate within 5 min. The solvents were removed, and the solid was taken up in MeOH. Concentration in vacuo afforded 0.083 g (99%) of the HCl salt of Example BQ as a colorless film (m/z 554.1 (M+H)+; 1H-NMR (CD3OD, 300 MHz): 10.03 (s, IH); 8.41 (s, IH); 7.81 (s, IH); 5.48 (s, 2H, minor rotamer); 5.35 (s, 2H, major rotamer); 4.74 (s, 2H); 4.34 (br s, IH); 3.90 (br s, IH); 3.78-3.54 (m, 2H); 3.20-2.98 (m, 5H); 2.20 (br s, IH); 2.07 (br s, IH); 1.60-1.4 (in, 10H); 1.12 (m,
6H).
Example BR
Example BQ (0.11 mmol) was taken up in MeOH (1.5 mL). Formaldehyde (37% in H2O, 13.4 mmol) was added and aged 10 min. NaHB(OAc)3 (0.324 mmol) was added, and the reaction mixture was allowed to age at room temperature overnight. More formaldehyde (13.4 mmol) and NaHB(OAφ (0.324 mmol) were added and allowed to age an additional 6 h at room temperature. The solvents were removed in vacuo and the product was isolated by preparatory HPLC to produce 0.058 g (77%) of the TFA salt of Example BR as an amorphous solid, mlz 582.3 (M+H)÷; 1H-NMR (CDsOD, 300 MHz): 9.07 (s, IH); 7.91 (s, IH); 7.25 (s, IH); 5.47 (s, 2H, minor rotamer); 5.28 (s, 2H, major rotamer); 4.59 (AB d, / = 16 Hz, IH); 4.53 (AB d, / = 16 Hz, IH); 4.31 (dd, / = 9.2, 5 Hz, IH); 3.88 (m, IH); 3.59 (m, IH); 3.32 (m, IH); 3.20 (m, 2H); 2.98 (s, 3H); 2.89 (br s, 6H); 2.23 (m, IH); 2.00 (m, IH); 1.44 (m, 4H); 1.37 (d, / = 7 Hz, 6H); 1.10 (m, 6H).
Preparation of Examples BS and BT Scheme 59
Figure imgf000310_0001
Figure imgf000310_0002
I. Cmpd. 8/EDC/HOBt/DIPEA/THF; II. TFA, 1M NaOH.
Compound 116
Compound 116 was prepared in a similar fashion to Compound 75 using Compound 4 (0.76 mmol) and Compound 47 (0,64 mmol) to produce 0.218 g (90%) of Compound 116 as a foamy white solid (m/z 384.1 (M+H)+). Example BS
Example BS was prepared in a similar fashion to Example BK using Compound 116 (0.28 mmol) and Compound 8 (0.25 mmol) to produce 0.139 g (72%) of Example BS as a colorless film (m/z 775.3 (M+H)+). Example BT
Example BT was prepared in a similar fashion to Example AM using Example BS (0.18 mmol) to produce 0.080 g (62%) of Example BT as an amorphous white solid, m/z 719.3 (M+H)+; 1H-NMR (CDCl3, 300 MHz): 8.79 (s, IH); 7.82 (s, IH); 7.27-7.0 (m, 10H); 6.98-6.82 (m, IH); 6.85 (s, IH); 6.44 (br s, IH); 5.30 (s, 2H, minor rotamer); 5.22 (s, 2H, major rotamer); 5.04 (br s, IH); 4.62 (AB d, / = 15 Hz, IH); 4.54 (AB d, / = 15 Hz, IH); 4.27 (br s, IH); 4.11 (br s, IH); 3.97 (br d,
/ = 10 Hz, IH); 3.82, br s, IH); 3.57 (br s, IH); 3.40-3.10 (m, 2H); 2.80-2.60 (m, 4H);
2.55 (m, IH); 1.54 (m, 2H); 1.46-1.30 (m, 2H); 1.35 (d, / = 7 Hz, 6H); 0.94-0.72 (m,
4H).
Preparation of Examples BU and BV
Scheme 60
Figure imgf000311_0001
I. Cmpd. 8/EDC/HOBt/DlPEA/THF; II. TFA, 1M NaOH.
Compound 117
Compound 117 was prepared in a similar fashion to Compound 13d except that Compound 4 (1.5 mmol) and the L-enantiomer of Compound 1Od (1.15 mmol) were used to ultimately produce 0.328 g (88%) of Compound 190 as a foamy white solid (m/z 398.1 (M+H)+). Example BU
Example BU was prepared in a similar fashion to Example AL using Compound 117 (0.33 mmol) and Compound 8 (0.30 mmol) to produce 0.196 g (84%) of Example BU as an amorphous white solid (m/z 789.3 (M+H)+). Example BV
Example BV was prepared in a similar fashion to Example AM using Example BU (0.29 mmol) to produce 0.140 g (77%) of Example BV as an amorphous white solid, mlz 733.3 (M+H)+; 1H-NMR (CDCl3, 300 MHz): 8.80 (s, IH); 7.84 (s, IH); 7.27-7.10 (m, 10H); 6.70-6.10 <m, IH); 6.86 (s, IH); 6.20 (br d, J = 7 Hz, IH); 5.24 (s, 2H); 4.81 (br d, / = 7 Hz, IH); 4.82 (s, 2H); 4.34 (br d J = 7 Hz, IH); 4.16 (br s, IH); 4.07 (br d, / = 6 Hz, IH); 3.86 (br s, IH); 3.38 (br s, IH); 2.69 (m, 6H); 1.62-1.50 (m, 2H); 1.50-1.34 (m, 2H); 1.38 (m, 6H); 1.13 (d, / = 6 Hz, 3H); 0.98-0.76 (m, 4H).
Preparation of Examples BW and BX Scheme 61
Figure imgf000312_0001
I Cmpd. 75/EDC/HOBt/DIPEA/THF; Ii. TFA, 1M NaOH.
Example BW
Example BW was prepared in a similar fashion to Example BK using Compound 75 (0.27 mmol) and Compound 46 (0.24 mmol) to provide 0.154 g (86%) of Example BW as an amorphous white solid (mlz 733.3 (M+HT). Example.BX
Example BX was prepared in a similar fashion to Example AM using Example BW (0.21 mmol) to provide 0.091 g (98%) of the TFA salt of Example BX as an amorphous white solid, mlz 677.5 (M+H)+; 1H-NMR (CDCl3, 300 MHz): 8.83 (s, IH); 8.77 (s, IH); 7.84 (s, IH); 7.77 (s, IH); 7.27-7.00 (m, 10H); 6.62 (d, / = 9 Hz, IH); 6.44 (d, / = 6 Hz7 IH); 5.35 (d, / = 10 Hz, IH); 5.24 (s, 2H); 4.69 (AB d, / = 15 Hz, IH); 4.62 (AB d, } = 16 Hz, IH); 4.14 (br m, 2H); 3.96-3.78 (m, 2H); 3.51 (dd, / = 11, 4.5 Hz, IH); 3.38 (br s, IH); 2.82-2.58 (m, 4H); 2.41 (m, IH); 1.70-1.24 (m, 4H); 1.20- 0.88 (m, 2H); 0.88-0.54 (m, 2H). Preparation of Examples BY and BZ
Scheme 62 Boc
Figure imgf000313_0001
Figure imgf000313_0002
p BY (R1 = Boc, R2 = H) ^ BZ (R1 = R2 = H) I. Cmpd. 8/EDC/HOBt/DIPEA/THF; II. 4M HCϊ/dioxane.
Compound 118
Compound 118 was prepared in a similar fashion to Compound 104 except that Compound 115 (0.40 mmol) was used instead of Compound 102, which was reacted with Compound 9 (0.48 mmol) to ultimately provide 0.075 g (89%) of Compound 118 as a foamy white solid (m/z 443.4 (M-HH)+). Example BY
Example BY was prepared in a similar fashion to Example BM using Compound 118 (0.17 mmol) and Compound 8 (0.15 mmol) to produce 0.079 g (62%) of Example BY as an amorphous white solid (m/z 834.3 (M+H)+). Example BZ
Example BZ was prepared in a similar fashion to Example BQ using Example BY (0.095 mmol) to provide 0.082 g (99%) of the HCl salt of Example BZ as an amorphous white solid m/z 734.2 (M-HH)VH-NMR (OMSO-dβ, 300 MHz): 8.08 (s, IH); 7.86 (br m, 3H); 758 (d, /= 9 Hz, IH); 7.25-7.00 (m, HH); 6.32 (br s, IH); 5.16 (s, 2H); 4.99 (br m, 4H); 4.48 (AB d, / = 15 Hz, IH); 4.43 (AB dj= 15 Hz, IH); 4.02 (m, IH); 3.89 (m, IH); 3.63 (m, IH); 3.22 (hep, /= 7 Hz, IH); 2.87 (s, 3H); 2.76-2.56 (m, 4H); 1.58-1.15 (m, 10H); 1.29 (d, / = 7 Hz, 6H).
Preparation of Example CA Scheme 63
Figure imgf000315_0001
1. 4-morphoiinecarbony! chloride, DIPEA, DCM.
Example CA
Example R (0.11 mmol) was diluted in DCM (1 mL) and treated with 4- morpholinecarbonyl chloride (0.13 mmol) and DIPEA (0.16 mmol). After 2 h, volatiles were removed in vacuo and the residue was purified by column chromatography on SiO2 (0-20% MeOH/DCM) to afford 0.068 g (76%) of Example CA as an amorphous white solid m/z 819.1 (M+H)+; 1H-NMR (CDCh, 300 MHz): 8.82 (s, IH); 7.85 (s, IH); 7.27-7.07 (m, 12H); 6.94 (s, IH); 6.26 (br s, IH); 5.73 (d, / - 8 Hz, IH); 5.28 (AB d, / = 13 Hz, IH); 5.22 (AB d, / = 13 Hz, IH); 4.50 (AB d, / = 16 Hz, IH); 4.44 (AB d, / = 16 Hz, IH); 4.17 (m, IH); 3.98 (br s, IH) 3.76 (br s, IH); 3.68 (br s, IH); 3.60 (m, 4H); 3.40 (m, 2H), 3.32 (m, 4H); 2.97 (s, 3H); 2.87 (dd, / - 13, 5 Hz, 2H); 2.73, (m, 2H); 2.57 (m, 2H); 1.79 (m, 2H); 1.60-1.20 (m, 6H); 1.37 (d, / = 7 Hz, 6H). Preparation of Compound CB Scheme 64
Figure imgf000316_0001
CB I. morpholine, EDC, HOBt1 THF.
Example CB
Example AF (0.15 mmol) was diluted in THF (1 mL) and treated with morpholine (0.61 mmol), HOBt (0.18 mmol) and finally EDC (0.18 mmol). The reaction mixture was allowed to age overnight. The reaction mixture was then diluted in EtOAc and sat. Na2CO3. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with brine, dried over anhydrous MgSO4 and concentrated in vacuo. The resulting residue was purified via preparatory HPLC to provide 0.024 g (20%) of Example CB as an amorphous white solid, mlz 790.4 (M+H)+; 1H-NMR (CDCb, 300 MHz): 8.81 (s, IH); 7.84 (s, IH); 7.27-7.10 <m, 10H); 6.96 (s, IH); 6.78 (d, / = 8 Hz, IH); 6.67 (s, IH); 5.36 (d, / = 9 Hz, IH); 5.27 (AB d, / = 13 Hz, IH); 5.20 (AB dj- 13 Hz, IH); 4.59 (s, IH); 4.51 (s, 2H); 4.02 (m, IH); 3.80-3.30 (m, 10H); 2.98 (s, 3H); 2.90-2.45 (m, 6H); 1.52 (m, 2H); 1.39 (d, / = 7 Hz, 6H); 1.32 (m, 2H). Preparation of Compound CC Scheme 65
Figure imgf000317_0001
I. N-methylpiperazine, EDC, HOBt, DIPEA1THF.
Example CC
Example CC was prepared in a similar fashion to Example CB except that N-methylpiperazine (0.16 mmol) was reacted with Compound AF (0.10 mmol) instead of morpholme and DIPEA (0.19 mmol) was added to produce 0.009 g (11%) of Example CC as an amorphous white solid m/z 803.4 (M+H)+; 1H-NMR (CDCh 300 MHz): 8.80 (s, IH); 7.84 (s, IH); 7.27-7.10 (m, HH); 6.91 (s, IH); 6.78 (m, 2H); 5.27 (AB d, / = 13 Hz, IH); 5.21 (AB d, / = 13 Hz, IH); 4.59 (m, IH); 449 (AB d J = 16 Hz, 4.44 (AB d, / = 16 Hz, IH); 4.01 (m, IH); 3.90-3.40 (m, 4H); 3.27 (hep, / = 7 Hz/ IH); 3.10-2.90 (m, IH); 2.97 (s, 3H); 2.90-2.30 (m, HH); 1.60-1.25 (m, 6H); 1.37 (d, / = 7 Hz, 6H). Preparation of Example CD Scheme 66
Figure imgf000318_0001
Example CD
To a solution of Example R (30.5 mg, 0.043 mmol) in methanol (1.5 mL) was added formaldehyde (1 mL, 37% in H2O). After stirring for 10 minutes, NaBH(OAc)3 (49 mg, 0.23 mmol) was added and the resulting mixture was stirred for 10 h. The reaction was monitored with LC/MS. When LC/MS indicated the absence of starting material Example R, the reaction mixture was evaporated to dryness, and filtered through a cotton plug. The crude product was then purified through CombiFlash (10% MeOH/CHiCk) to give 29.7 mg of Example CD 1H- NMR (CDCb, 500 MHz): 8.78 (s, IH); 7.83 (s, IH); 7.12-7.22 (m, 10H); 6.85 (s, IH); 5.83 (d, IH, J = 8.5 Hz ), 5.23 (CIAB, 2H, J = 13.1 Hz); 4.49 (dAB/ 2H, J = 16.5 Hz); 4.29 (m, IH); 4.15 (m, IH); 3.75 (m, IH); 3.30 (m, IH); 2.93 (s, 3H); 2.87 (dd, IH, Jl= 5.5 Hz, J2 = 13.5 Hz); 2.72 (m, 2H); 2.66 (dd, Jl= 7.3 Hz, J2 = 13.3 Hz), 2.47 (br s, IH), 2.36 (br s, IH), 2.23 (s, 6H), 1.91 (m, 2H), 1.56 (m, 2H), 1.40 (m, 2H), 1.40 (d, 6H, J = 6.8 Hz). mlz 734 (M+H)+; 756 (M+Na)h; Preparation of Example CE Scheme 67
Figure imgf000319_0001
I.EDC, HOBt, IPr2NEt, THF II, a. HCI;/dioxane; b. CDI, IPr2NEt, Compound 9, CH2CI2
Compound 119
Compound 119 is commercially available from Aldrich, and was used as received. Compound 120
A mixture of Compound 119 (200 mg, 0.91 mmol), Compound 8 (373.7 mg, 0.91 mmol), EDC (212 mg, 1.37 mmol), HOBt (160.3 mg, 1.19 mmol) and iPnNEt (794.7 μL, 4.56 mmol) in THF was stirred for 10 h at room temperature. The mixture was then evaporated to a small volume and purified by CombiFlash (eluted with 1 to 10 % MeOH/CH-Cli). The fractions containing the target Compounds were collected and re-purified by CombiFlash (40-100% EtOAc/hexanes) to give 449 mg of Compound 120 as oil ( mlz 611.0 (M+H)+). Example CE
Compound 120 (449 mg, 0.74 mmol) was treated with HCl/dioxane (3 mL). The resulting mixture was evaporated to dryness and lyophilized to provide 373.6 mg of a white solid.
To a solution of the above white compound (52.5 mg, 0.096 mmol) in CH2CI2 (10 mL) was added Compound 9 (19.8 mg, 0.096 mmol), CDI (15.6 mg, 0.096 mmol) followed by iPrzNEt (33.4 μL, 0.192 mmol). The mixture was stirred for 20 h before it was evaporated to dryness. The mixture was added CHaCIi, then filtered through a cotton plug. The filtrate was evaporated to dryness and purified with CombiFlash. The fractions with Example CE was collected and re- purified on the TLC to give 15.1 mg of Example CE. Η-NMR (CDCb, 300 MHz): 8.79 <s, IH); 7.82 (s, IH); 7.09-7.27 (m, 10H), 6.94 (S/ IH); 6.25 (d, 2H, J = 8.7 Hz); 5.23 (s, 2H); 5.17 (br s, IH); 4.43 (dAB/ 2H, J = 16.5 Hz); 4.29 (m, IH); 4.13 (m, IH), 3.76 (m, 2H); 3.48 (m, IH); 3.29 (s, 3H); 3.25 (m, IH), 2.94 (s, 3H), 2.65-2.82 (m, 4H), 1.75 (m, 2H), 1.54 (m, 2H), 1.39 (d, 5H, J = 6.9 Hz). mix 707 (M+H)+; 729 (M+Na)+. Preparation of Example CF Scheme 68
Figure imgf000320_0001
Example .CF
Example CF was prepared using the same method as Example CE, except that Compound 9 was replaced with Compound 68. 1H-NMR (CDCb, 300 MHz): 8.79 (s, IH); 8.74 (s, IH), 7.81 (s, IH), 7.73 (s, IH); 7.12-7.27 (m, 10H); 6.15 (d, IH, J = 8.7 Hz), 5.39 (d, IH, J = 6.8 Hz); 5.21 (s, 2H), 5.06 (d, J = 9.1 Hz, IH); 4.64 (dAB, 2H, J = 15.5 Hz); 4.28 (m, IH); 4.134 (m, IH), 3.79 (m, IH), 3.70 (m, IH); 3.34 (m, IH); 3.28 (s, 3H); 2.87 (s, 3H); 2.72 (m, 4H); 1.57 (m, 2H); 1.50 (m, 2H). (m/z 665.2 (M+H)+; 687.3 (M+Na)+. Preparation of Compound CG Scheme 69
Figure imgf000321_0001
i. a, CDI, DtPEA, WIeCN; b. compound 9, MeCN. II. 1M LiOH, THF. IM. EDCI, HOBt, iPr2NEt, compound 8
Compound 121
Compound 121 is commercially available from Aldrich, and was used as received. Compound 122
To a suspension of Compound 121 (2.05 g, 11.3 mmol) in CH2CI2 (40 mL) was added. IPr2NEt (5.87 mL, 33.9 mmol) followed by CDI (1.86 g, 11.3 mmol). The resulting mixture was stirred at room temperature for 6 h, then Compound 9 (2.33g, 11.3 mmol) was added. The resulting mixture was stirred for another 10 h before it was evaporated to dryness. The mixture was re-dissolved in CHbCkand the solid was removed by filtration. The filtrate was evaporated to dryness and purified by CombiFlash (eluted with 20-80% EtOAc/hexanes) to give 3.2 g of Compound 207 as a pale yellow oil. mlz 298.0 (M+H)+. Compound 123
To a solution of Compound 122 (3.2g, 10.8 mmol) in THF (100 mL) was added freshly prepared IM LiOH (10.8 mmol). The biphasic reaction was stirred vigorously at room temperature for 16 h before being quenched with IM HCl. The pH of the mixture was adjusted to 2.5-3, and then evaporated to a small volume. The mixture was partitioned between CH2CI2 and brine (50 mL), the aqueous layer was separated and extracted with CH2CI2 twice. The combined CH2CI2 layers were dried over anhydrous Na2SO* and concentrated to give 3.37 g of Compound 123 a pale yellow oil that is used with further purification, miz 316.0 (M+H)+, 338 (M+Na)+; Example CG
Example CG was prepared following the same procedure for Example C instead that Compound 123 was used instead of Compound 7. 1H-NMR (CDCk, 500 MHz): 8.80 (s, IH); 7.83 (s, IH), 7.11-7.26 (m, 10H), 6.96 (s, IH); 7.12-7.27 <m, 10H); 6.52 (br s, IH), 6.40 (br s, IH), 5.23 (s, 2H), 5.20 (m, IH), 4.44 (dAB/ 2H, J = 15.5 Hz), 4.39 (m, IH), 4.11 (m, IH), 3.80 (m, IH), 3.61 (m, 2H), 3.28 (sep, IH, J = 7.0 Hz); 2.94 (s, 3H), 2.79 (dd, IH, Jl = 6.1 Hz, J2= 13.4 Hz); 2.71 (m, 3H), 1.93 (m, IH), 1.71 (m, IH), 1.54 (m, IH), 1.38 (d, 6H, J = 7.0 Hz) 1.37 (m, IH). (: )+; mlz 707.3
Figure imgf000322_0001
Preparation of Compound 100 Scheme 70
Figure imgf000322_0002
121 100
I. a. CDI, DIPEA, MeCN;
Compound 100 was prepared using the same method used to prepare Compound 122, except that Compound 9 was replaced with Compound 68. Preparation of Example CH
Scheme 71
Figure imgf000323_0001
I. EDCI/HOBt/iPr2NEt/THF; II. HCHO/NaBH(OAc)3/HOAc/CH3CN; III. Cmpd. 16/iPr2NEt/CH3CN
Compounds 124 and 125
To a solution of Compound 29 (135 mg, 0.43 mmol) and Compound 22 (116 mg, 0.43 mmol) in THF (5 mL) were added HOBt (70 mg, 0.52 mmol), EDC (94 μL, 0.52 mmol), and diisopropylethylamine (150 μL, 0.83 mmol). The mixture was stirred for 12 hours and concentrated. Purification by reverse HPLC gave Compound 124 (70 mg) and Compound 125 (120 mg). Compound 124: 1H-NMR (CDCl3) δ 7.2-7.1 (10 H, m), 7.0 (2 H, s), 6.45 (2 H, m), 6.15(2 H, m), 4.45 (4 H, s), 4.1 (2 H, m), 3.96 (2 H, m), 3.3 (2 H, m), 2.98 (6 H, s), 2.7 (4 H, m), 2.1 (2 H, m), 1.6-1.3 (16 H, m), 0.90 (12 H, m). m/z 859.3 (M+H)+ ; Compound 125: m/z 564.3 (M+H)+ Compound.126
To a solution of Compound 125 (120 mg, 0.21 mmol) in CHaCN (1 mL) was added 37% formaldehyde solution (17 μL, 0.23 mmol), followed by HOAc (24 μl, 0.42 mmol). The mixture was stirred for 2 hours., and NaBH(O Aφ (140 mg, 0.63 mrαol) was added. The mixture was stirred for 2 additional hours and diluted with EtOAc. The organic phase was washed with saturated Na2CO3 solution, water, and brine, and dried over Na2SO4. Concentration gave Compound 126, which was used in the next step without further purification, m/z 578.3 (JVMHQ+ Example CH
Example CH (26 mg) was prepared following the procedure used to prepare Example L, except that Compound 126 was used instead of Compound 22. Η-NMR (CDC13) 6 8.91 (1 H, m), 7.82 (1 H, m), 7.2-7.0 (11 H, m), 6.4 (1 H, m), 6.2 (1 H, m), 5.23-5.05 (2 H, m), 4.44 (2 H, s), 4.44 (1 H, m), 4.2 (1 H, m), 3.95 (1 H, m), 3.32 (1 H, m), 2.98 (3 H, s), 2.8-2.5 (7 H, m), 2.15 (1 H, m), 1.7-1.2 (10 H, m), 0.88 (6 H, m). m/z 719.3 (M+H)+
Preparation of Example CI Scheme 72
Figure imgf000325_0001
!. HCHO/NaBH(OAc)3/HOAc/CH3CN; II. Cmpd. 29/EDCf/HOBt/iPr2NEt/THF Compound 127
Compound 127 (110 mg) was prepared following the procedure used to prepare Compound 126, except that Compound 8 was used instead of Compound 125. m/z 424.4 (M+H)+ Example CI
Example CI (7 mg) was prepared following the procedure used to prepare Example C, except that Compounds 127 and 29 were used instead of Compounds 8 and 7. 1H-NMR (CDC13) δ 9.0 (1 H, s), 8.92 (1 H, s), 7.4-7.0 (11 H, m), 5.25 (2 H, m), 4.6-4.0 (5 H, m), 3.4 (1 H, m), 3.1-2.6 (10 H, m), 1.9 (1 H, m), 1.8 (10 H, m), 0.9 (6 H, m); m/z 719.2 (M+H)'
Preparation of Compound CT Scheme 73
Figure imgf000326_0001
1. a. TFAZCH2Ci2; b. Na2CO3; II. Cmpd. 16/iPr2NEt/CH3CN; ill. Cmpd. 29/EDC!/HOBt/iPr2NEt/THF
Compound ,128
To a solution of Compound 21 (100 mg) in dichϊoromethane (5 mL) was added TFA (1 mL). The mixture was stirred for 3 hours, and excess reagents were evaporated. The oil was diluted with EtOAc, and then was washed with saturated Na2CO3 solution (2x), water (2x), and brine, and dried over Na2SO4. Concentration gave Compound 128 (46 mg). m/z 267.1 (M+H)+ Compound 129
Compound 129 (44 mg) was prepared following the procedure for Compound 8, except that Compound 128 was used instead of Compound 22. m/z 408.10 (M+H)+ Example CT
Example CJ (55 mg) was prepared following the procedure for Example C, except that Compounds 129 and 29 were used instead of Compounds 8 and 7. 1H- NMR (CDC13) δ 8.81 (1 H, s), 7.85 (1 H, s), 7.2-7.0 (11 H, m), 6.4 (1 H, m), 6.12 (1 H, m), 5.44 (2 H, m), 5.26 (2 H, s), 4.85 (1 H, m), 4.70 (1 H, m), 4.4 (3 H, m), 4.06 (1 H, m), 3.25 (1 H, m), 2.98 (3 H, s), 2.78 (4 H, m), 2.21 (1 H, m), 1.38 (6 H, m), 0.88 (6 H, m); m/z 703.2 (M+H)+
Preparation of Compounds CK and CL
Scheme 74
Figure imgf000327_0001
Figure imgf000327_0002
I. Cmpd 8/EDC/HOBt; It. a. TFA; b. NaOH/THF
Example CK
Example CK (88 mg) was prepared following the procedure used to prepare Example C, except that Compound 49 was used instead of Compound 7. m/z 749.2 (M+H)+ Example CL
A mixture of Example CK (85 mg) and TFA (5 mL) was stirred for 3 hours. Excess TFA was evaporated and the mixture was dried under high vacuum. The mixture was dissolved in THF (5 mL)7 and 1.0 N sodium hydroxide solution was added until the pH was 11. The solution was stirred for 10 minutes, and extracted with EtOAc. The organic phase was washed with water, brine, and dried over Na2SO4.
Concentration and purification by flash column chromatography (EtOAc) gave Example CL (66 mg). 1H-NMR (CDC13) & 8.81 (1 H, s), 7.84 (1 H, s), 7.30-6.96 (11 H, m), 5.22 (2 H, s), 4.90 (1 H, m), 4.45 (1 H, m), 4.35-4.0 (4 H, m), 3.8 (1 H, m), 3.6 (1 H7 m), 3.21 (1 H, m), 2.95 (3 H, s), 2.8-2.6 (4 H, m), 2.0-1.4 (4 H, m), 1.25 (6H, m). m/z 693.2 (M+H)+.
Preparation of Example CM
Scheme 75
Figure imgf000328_0001
I. SOCI2/MeOH; II. a. CDi/iPr2NEt; b. Cmpd. 9; lll.a. NaOH/THF/H2O; b. HCi; IV. Cmpd. 8/EDC/HOBt;
Compound 130 Compound 130 is commercially available from (TCI), and was used as received. Compound 131
To the solution of Compound 130 (510 mg, 3 mmol) in methanol (12 mL) at 02C was added thionyi chloride (0.5 mL, 6.6 mmol), dropwise. The mixture was stirred at 0 ΩC for 30 minutes and brought to reflux for 3 hours. Concentration gave Compound 131 as a white solid. Compound 132
To a stirred solution of Compound 131 (3 mmol) and diisopropylethylamine (2 mL, 12 mmol) in dichloromethane (35 mL) was added CDI (486 mg, 3 mmol). The mixture was stirred for 12 hours. Compound 9 was added, and the mixture was stirred for 12 additional hours. Concentration and purification by flash column chromatography (CHiCb/iPrOH = 10/1) gave Compound 132 (414 mg). m/z 380.0 (M÷H)+ Compound 133
Compound 133 was prepared following the procedure for Compound 67, except that Compound 132 was used instead of Compound 66. m/z 364.0(M-H)- Example CM
Example CM (600 mg) was prepared following the procedure for Example C, except Compound 133 was used instead of Compound 7. 1H-NMR (CDC13) & 9.18 (1 H, s), 8.35 (1 H, s), 7.95 (1 H, s), 7.6 (1 H, m), 7.3-7.0 (11 H, m), 5.22 (2 H, m), 4.70 (1 H, m), 4.50 (2 H, m), 4.05 (1 H, m), 3.86 (3 H7 s), 3.80 (2 H, m), 3.55 (1 H, m), 3.10 (1 H, m), 2.90 (3 H, s), 2.70 (4 H, m), 1.45 (10 H, m); m/z 757.3 (M+H)+ Preparation of Examples, O , P, CN, and CO
Scheme 76
Figure imgf000330_0001
Figure imgf000330_0002
CO R = Me
I. Cmpd. 16/iPr2NEt; II. Cmpd. 13d or Cmpd. 49/EDC/HOBt; III. a. TFA; b. NaOH/THF Example O
Example O (17 mg) was prepared following the procedure for Example C, except Compounds 46 and 49 were used instead of Compounds 8 and 7. m/z 749.3 (M+H)^ Example CN
Example CN (22 mg) was prepared following the procedure used to prepare Example C, except Compounds 46 and 13e were used instead of Compounds 8 and 7. m/z 763.2 (M+H)+ Example P
Example P (12 mg) was prepared following the procedure used to prepare Example CL, except Example O was used instead of Example CK. 1H-NMR (CDCb) δ 8.76 (1 H, s), 7.79 (1 H, s), 7.25-6.9 (11 H, m), 6.51 (1 H, broad), 5.42 (1 H, m), 5.18 (2 H, m), 4.42 (2 H, m), 4.22 (1 H, m), 4.10 (1 H, m), 3.95 (1 H, m), 3.79 (1 H, m), 3.58 (1 H, m), 3.23 (1 H, m), 2.93 (3 H, s), 2.9-2.5 (4 H, m), 1.6-1.2 ( 10 H, m); m/z: 693.2 (M+H)+. Compound CO
Example CO (13 mg) was prepared following the procedure used to prepare Example CL, except Example CN was used instead of Compound CK. 1H-NMR (CDCb) & 8.85 (IH, m), 7.88 (1 H, m), 7.3-7.0 (11 H, m), 6.55 (1 H, m), 6.24 (1 H, m), 5.45 (1 H, m), 5.23 (2 H, m), 4.6 (2 H, m), 4.2 (1 H7 m), 4.0 (2 H, m), 3.7 (1 H, m), 3.5 (1 H, m), 3.02 (3 H, s), 2.70 (4 H, m), 1.6-1.0 (13 H, m); m/z: 707.3 (M+H)+. Preparation of Examples CF-CS Scheme 77
Figure imgf000331_0001
Figure imgf000331_0002
CQ R = Me
Figure imgf000331_0003
CS R = Me
I. Cmpd. 16/1Pr2NEt; II. Cmpd. 13d or 49/EDC/HOBt; 111. a. TFA; b. NaOH/THF Compound 134
Compound 134 was prepared using procedure described for Compound 76, except that CBZ-D-alaninol was used instead of CBZ-L-alaninol. Compound 135
Compound 135 was prepared following the procedure used to prepare Compound 8, except Compound 134 was used instead of Compound 22. Example CF
Example CP (12 mg) was prepared following the procedure used to prepare Example C, except Compounds 135 and 49 were used instead of Compounds 8 and 7. m/z 597.2 (M+H)+. Example CQ
Example CQ (11 mg) was prepared following the procedure used to prepare Example C, except Compounds 135 and 13d were used instead of Compounds 8 and 7. m/z 611.2 (M+H)+. Example CR
Example CR (7 mg) was prepared following the procedure used to prepare Example P, except that Example CP was used instead of Example O .1H-NMR (CDCl3) δ 8.82 (1 H, s), 7.88 (1 H, s), 7.02 (1 H, s), 6.92 (1 H, m), 5.28 (2 H, s), 5.10 (1 H, m), 4.5 (2 H, m), 4.15 (2 H, m), 3.88 (1 H, m), 3.8-3.5 (2 H, m), 3.35 (1 H, m), 3.0 (3 H, s), 1.5-1.0 (16 H, m); m/z: 541.1 (M+H)+. Example CS
Example CS (8 mg) was prepared following the procedure used to prepare Example CO, except that Example CQ was used instead of Example CN. 1H- NMR (CDCb) δ 8.83 (1 H, s), 7.88 (1 H, s), 6.98 (1 H7 s), 6.81 (1 H, m), 6.58 (1 H, m), 5.28 (2 H, s), 5.18 (1 H, m), 4.4-4.3 (2 H, m), 4.03 (1 H, m), 3.85 (1 H, m), 3.58 (2 H, m), 3.3 (1 H, m), 2.99 (3 H, s), 1.5-0.98 (19 H, m); m/z: 555.2 (M+H)+. Preparation of Examples CT-CV Scheme 78
Figure imgf000333_0001
138
Figure imgf000333_0002
CU X = CH2CH2; R = Bn CV X = CH2; R = Bn
I. PhCHO/NaBH4; II. Cmpd 16/JPr2NEt; il. Cmpd 13d/EDC/HOBt;
Compound 136
Compounds 136a-c are commercially available (Sigma- Aid rich). Compound 137
To a solution of Compound 136 (20 mmol) in methanol (25 mL) was added benzaldehyde (40 mmol) dropwise. The mixture was stirred for 2 hours and was cooled to 0 QC. Sodium borohydride (44 mmol) was added in portions. The mixture was warmed to 25 eC and stirred for 2 hours. Acetic acid (10 mL) was added and the mixture was stirred for 10 minutes. Methanol was removed and the mixture was partitioned between EtOAc and 3 N NaOH solution. The organic layer was separated and water phase was extracted with EtOAc (2x). The combined organic layers was washed with water, brine, and dried over NazSO^ Concentration gave Compound 137. Compound 138 Compound 138 was prepared following the procedure used to prepare Compound 8, except that Compound 137 was used Instead of Compound 22. Example CT
Example CT (70 mg) was prepared following the procedure used to prepare Example C, except that Compounds 29 and 138a was used instead of Compounds 7 and 8. .1H-NMR (CDCl3) δ 8.79 (1 H, s), 7.86 (1 H, s), 6.97 (1 H7 s), 6.49 (1 H, m), 6.15 (1 H, m), 5.28 (2 H, s), 5.20 (1 H, m), 4.44 (2 H, m), 4.05 (1 H, m), 3.25 (5 H, m), 3.0 (3 H, s), 2.24 (1 H, m), 1.8-1.45 (4 H, m), 1.38 (6 H, m), 0.97 (6 H, m); m/z: 525.2 (M+H)+. Example CU
Example CU (140 mg) was prepared following the procedure used to prepare Example C, except that Compounds 29 and 138b was used instead of Compounds 7 and 8. 1H-NMR (CDCk) δ 8.78 (1 H, s), 7.85 (1 H, m), 7.4-7.05 (10 H, m), 6.93 (1 H, s), 5.90 (1 H, m), 5.35 (2 H, s), 4.9-4.6 (2 H, m), 4.6-4.4 (4 H, m), 4.2 (1 H, m), 3.4-3.05 (5 H, m), 3.0 (3 H, s), 2.0 (1 H, m), 1.8-1.3 (10 H, m), 0.90 (6 H, m); m/z: 705.2 (M+H)+. Examle CV
Example CV (145 mg) was prepared following the procedure used to prepare Example C, except that Compounds 29 and 138c was used instead of Compounds 7 and 8. 1H-NMR (CDCb) δ 8.76 (1 H, m), 7.86 (1 H, m), 7.4-7.02 (10 H, m), 6.97 (1 H, m), 5.75 (1 H, m), 5.38 (2 H7 m), 4.95-4.3 (6 H, m), 4.15 (1 H, m), 3.4-3.0 (5 H, m), , 3.0 (3 H, s), 2.2-1.6 (3 H, m), 1.4 (6 H, m), 0.88 (6 H, m); m/z: 691.2(MH-H)+. Preparation of Example CW
Figure imgf000335_0001
CW
Example CW could be prepared, e.g. by reacting Compound 8 with a compound having the following structure:
Figure imgf000335_0002
where "LG" is a leaving group such as a halogen. Such compounds could be prepared by one-carbon degradation of the corresponding carboxylic acid or ester (e.g., Compounds 28 or 29) by known methods such as the Hunsdieker reaction or the Kochi reaction or similar methods. Preparation of Example CX
Scheme 79
Figure imgf000335_0003
I. a.TMSNCO/iPr2NEt/THF; b. MeOH Example R Example R (hydrochloride salt) was synthesized following the procedure described in WO 2008/010921 A2 (herein incorporated by reference in its entirety for all purposes) or as described above. Example CX
To a suspension of Example R (hydrochloride salt) (150 mg, 0.2 mmol) in THF (2 mL) was added diisopropylethylamine (70 *l, 0.4 mmol). The mixture was stirred until a clear solution was obtained. To this solution was added trimethylsilyl isocyanate (30 »1, 0.22 mmol) dropwise, and the mixture was stirred for 12 hours. The solvent was removed and the mixture was coevaporated twice with 5 mL of MeOH. Purification with preparative thin layer chromatography (preparative TLC) gave Example CX (86 mg). m/z: 749.2 (M+H)+. 1H NMR (CD3OD) δ 8.99 (s7 IH); 7.83 (s, IH); 7.72 (m, IH); 7.30-7.00 (m, HH); 5.22 (s, 2H); 4.54 (s, 2H); 4.19 (s, IH); 4.07 (m, IH); 3.75 (m, IH); 3.28 (m, IH); 3.30-2.90 (m, 2H); 2.97 (s, 3H); 2.71 (m, 4H); 1.79 (m, 2H); 1.50 (m, 4H); 1.38 (d, 6H, J=7 Hz). Preparation of Example CY
Scheme 80
Figure imgf000336_0001
i. diformyihydrazine/ pyrid!ne/Et3N/TMSCI/100 C Example CY
To a solution of Example R (hydrochloride salt) (269 mg, 0.36 mmol) in pyridine (3 mL) was added diformyihydrazine (95 mg, 1.1 mmol), followed by chlorotrimethylsilane (2.7 mL) and triethylamine (0.34 mL). The mixture was heated at 100 0C for 14 hours, and solvents were removed. The mixture was quenched with water, and extracted three times with EtOAc. The organic layer was dried over Na2SO4 and concentrated to give a white solid. Purification by HPLC and preparative TLC (5% MeOH in dichloromethane) gave Example CY (5 mg). m/z: 758.3 (M+H)+. 1H NMR (CD3OD) δ 8.98 (s, IH); 8.50 (s, 2H); 7.83 (s, IH); 7.30-7.00 (m, HH); 5.21 (S/ 2H); 4.54 (m, 2H); 4.11 (m, 4H); 3.76 (m, IH); 3.28 (m, IH); 2.95 (s, 3H); 2.69 (m, 4H); 2.04 (m, 2H); 1.70-1.20 (m, 10H). Preparation of Example CZ Scheme 81
Figure imgf000337_0001
I. Methyl 4-bromobutyrate/NaHCO3/DMF/60 C Example CZ
To a suspension of Example R (hydrochloride salt) (200 mg, 0.27 mmol) and sodium bicarbonate (92 mg, 1.1 mmol) in DMF (2 mL) was added a solution of methyl 4-bromobutyrate (74 »1, 0.54 mmol) in DMF (1 mL). The mixture was heated at 65 0C for 20 hours and the solvent was removed under reduced pressure. The mixture was quenched with water, and extracted with EtOAc. The organic layer was washed three times with water, twice with sodium carbonate solution, and once with brine, and dried over Na2SO4. Concentration followed by purification using HPLC gave Example CZ as a white solid (23 mg). m/z: 774.3 (M+H)+. 1H NMR (CD3OD) 58.99 (s, IH); 7.84 (s, IH); 7.30-7.00 (m, 11H); 5.22 (s, 2H); 4.55 (m, 2H); 4.09 (m, 2H); 3.90-3.60 (m, IH); 3.55-3.10 (m, 5H); 2.98 (s, 3H); 2.71 (m, 4H); 2.37 (m, 2H); 2.04 (m, 2H); 1.81 (m, 2H); 1.70-1.20 (m, 10H). Preparation of Example DA
Scheme 82
Figure imgf000338_0001
I. 2,5-dimethoxyTHF/NaOAc/HOAc/125 C
Example DA
To a suspension of Example R (hydrochloride salt) (250 mg, 0.34 mmol) in acetic acid (0.73 mL) was added sodium acetate (153 mg, 1.9 mmol), followed by 2,5-dimethoxyTHF (44 »1, 0.34 mmol). The mixture was heated at 125 0C for 90 minutes, and the solvent was removed under reduced pressure. The residue was quenched with saturated sodium bicarbonate solution and extracted with EtOAc. The organic layer was washed sequentially with saturated NaHCO3 solution, water, and brine, and dried over Na2SO4. Concentration and purification by HPLC gave a white solid, which was further purified by preparative TLC to give Example DA (25 mg). m/z: 756.3 (M+H)\ 1H NMR (CD3OD) o 8.96 (s, IH); 7.82 (s, IH); 7.30-7.00 (m, HH); 6.62 (s, 2H); 6.02 (s, 2H); 5.20 (s, 2H); 4.51 (s, 2H); 4.20-3.95 (m, 2H); 3.88 (m, 2H); 3.75 (n% IH); 3.26 (m, IH); 2.93 (s, 3H); 2.70 (m, 4H); 2.01 (m, 2H); 1.70-1.20 (m, 10H). Preparation of Example PB Scheme 83
Figure imgf000339_0001
1. NH3-H2O/formaldehyde/glyoxal/π-PrOH/80 C
Example DB
To Example R (220 mg, 0.34 mmol) in propanol (1.9 mL) was added aqueous ammonia (39 mg, 0.34 mmol, 28-30%). The mixture was stirred for 5 minutes. To the above mixture was added a solution of glyoxal (53 mg, 0.37 mmol, 40% wt) and formaldehyde (30 mg, 0.37 mmol, 37%wt) in propanol (3.7 mL) drop wise. The mixture was heated at 80 0C for 5 hours. The solvent was removed under reduced pressure, and the residue was diluted with EtOAc. The organic layer was washed with water and brine, and dried over Na2SO4. Concentration of the organic layer and purification by HPLC gave Example DB as a white powder (101 mg). m/z: 757.3 (M+HV.Η NMR (CD3OD) & 8.97 (s, IH); 7.82 (s, IH); 7.60 (s, IH); 7.30-7.00 (m, 12H); 6.96 (s, IH); 5.20 (s, 2H); 4.53 (m, 2H); 4.20-3.90 (m, 4H); 3.76 (m, IH); 3.28 (m, IH); 2.95 (s, 3H); 2.70 (m, 4H); 2.02 (m, 2H); 1.70-1.20 (m, 10H). Preparation of Example DC
Scheme 84
Figure imgf000340_0001
!. a. succinic anhydride/CHtøCtø b. Ac2OZNaOAc Example DC
To a solution of Example R (220 mg, 0.34 mmol) in dichloromethane (1.5 mL) was added succinic anhydride (41 mg, 0.41 mmol). The mixture was heated at 45 0C for 12 hours. The solvent was removed and a white solid was dried under high vacuum. To this solid was added sodium acetate (10 mg, 0.12 mmol), followed by acetic anhydride (1.5 mL). The mixture was heated at 85 0C for 1 hour, and the solvent was removed under reduced pressure. The residue was diluted with EtOAc, and was washed sequentially with water, saturated NaHCO3, water, and brine, and dried over Na2SO4. Concentration gave Example DC (190 mg). m/z: 788.2 (M+H)+. 1H NMR (CD3OD) δ 8.99 (s, IH); 7.84 (s, IH); 7.30-7.00 (m, HH); 5.22 (s, 2H); 4.70-4.40 (m, 2H); 4.20-3.90 (m, 2H); 3.75 (m, IH); 3.54 (m, IH); 3.42 (m, IH); 3.28 (m, IH); 2.98 (s, 3H); 2.67 (m, 8H); 2.00 (m, IH); 1.81 (m, IH); 1.704.20 (m, 10H). Preparation of Example DD
Scheme 85
Figure imgf000341_0001
I. CF3CH2OSO2CCl3ZNaHCO3ZDMF
Example DD
To a solution of Example R (220 mg, 0.34 mmol) in DMF (3 mL) was added sodium carbonate (100 mg), followed by 2,2,2-trifluoroethyl trichloromethanesulfonate (112 »1, 0.68 mmol). The mixture was stirred for 3 days and the solvent was removed under reduced pressure. The residue was diluted with EtOAc. The organic layer was sequentially washed twice with saturated sodium carbonate solution, once with water, and once with brine, and dried over Na2SO4. Concentration and purification by flash column chromatography (9% MeOH in dichloromethane) gave Example DD (109 mg). m/z: 788.2 (M+H)+. 1H NMR (CD3OD) δ 8.98 (s, IH); 7.82 (s, IH); 7.62 (d, IH, /-9 Hz); 7.30-7.00 (m, HH); 6.85 (d, IH, J=9 Hz); 5.20 (m, 2H); 4.54 (s, 2H); 4.23 (m, IH); 4.11 (m, IH); 3.77 (m, IH); 3.31 (m, 2H); 3.12 (q, 2H, /=10 Hz); 2.95 (m, 3H); 3.80-2.50 (m, 6H); 1.77 (m, 2H); 1.70-1.20 (m, 10H). "F NMR (CD3OD) • -73.28 (t, IH, /=10 Hz). Preparation of Example DE Scheme 86
Figure imgf000342_0001
I. a. <MeS)2C=NCN/EtOH; b. MeNH2/Ei0H Example DE
To a clear solution of dimethyl N-cyanodithioiminocarbonate (50 mg, 0.34 mmol) in ethanol (0.5 mL) was added slowly a solution of Example R (220 mg, 0.34 mmol) in ethanol (2.5 mL). The mixture was stirred for 12 hours. To the above mixture was added a solution of methylamine in EtOH (1.6 mL, 33%wt). The mixture was stirred for 6 hours, and solvents were removed under reduced pressure. Purification by HPLC gave Example DE (92 mg). m/z: 787.3 (M+H)+. 1H NMR (CD,OD) δ 8.98 (s, IH); 7.83 (s, IH); 7.30-7.00 (m, HH); 5.21 (s, 2H); 4.51 (s, 2H); 4.18 (m, IH); 4.09 (m, IH); 3.77 (m, IH); 3.28 (m, 2H); 3.16 (m, IH); 2.97 (s, 3H); 2.80 (s, 3H); 2.715 (m, 4H); 1.84 (m, IH); 1.70 (m, IH); 1.654.20 (m, 10H).
Preparation of Examples DF-DG Scheme 87
Figure imgf000343_0001
I. BrCH2CH2OH/Na2CO3/DMF/70 C; II. CDi/DMAP/THF/70 C Example DF
To a solution of Example R (220 mg, 0.34 mrαol) in DMF (1 mL) was added sodium carbonate (72 mg, 0.68 mmol), followed by a solution of 2-bromoethanol (24 »1, 0.34 mmol) in DMF (0.4 mL). The mixture was heated at 70 0C for 12 hours. Concentration under high vacuum gave Example DF. m/z: 750.2 Example DG
To a suspension of Example DF (0.34 mmol) in THF (3.4 mL) was added carbonyldiimidazole (CDI) (83 mg, 0.51 mmol), followed by DMAP (4 mg). The mixture was heated at 70 0C for 3 hours, and the solvent was removed. The residue was diluted with EtOAc, and was washed with water and brine, and dried over Na2SO4. Concentration and purification with preparative TLC gave Example DG (83 mg). m/z: 776.2 (M+H)+. 1H NMR (CD3OD) δ 8.98 (s, IH); 7.83 (s, IH); 7.67 (m, IH); 7.30-7.00 (m, HH); 6.87 (m, IH); 6.49 (m, IH); 5.21 (s, 2H); 4.70- 4.40 (m, 2H); 4.34 (t, 2H, /=8 Hz); 4.18 (m, IH); 4.06 (m, IH); 3.76 (m, IH); 3.60 (t, 2H, /=8 Hz); 3.24 (m, 3H); 2.97 (s, 3H); 2.71 (m, 4H); 1.86 (m, 2H); 1.70-1.20 (m, 10H).
Preparation of Example DH Scheme 88
Figure imgf000344_0001
. diformylhydrazine/ pyridine/Et3N/TMSCI/100 C
Example W
Example W was synthesized following the procedure described in WO2008/ 010921 A2, and as described above in Scheme 25. Example DH
Example DH (100 mg) was prepared following the procedure used to prepare example CY, except that Example W was used instead of Example R. 1H NMR (CD,OD): δ 8.97 (s, IH), 8.40 (s, 2H), 7.81 (s, IH), 7.15 (m, 10H), 5.20 (s, 2H), 4.54 (m, 2H), 4.20 (m, IH), 4.07 (m, IH), 3.87 (m, 3H), 3.24 (m, IH), 2.95 (s, 3H), 2.85 (m, IH), 2.60 (m, 3H), 1.81 (m, 2H), 1.60-1.43 (m, 4H), 1.33 (d, J=7.2 Hz, 6H). Mass Spectrum (m/e): (M+H)+ 758.2, (M-H)" 755.9. Preparation of Example DI Scheme 89
Figure imgf000345_0001
I. Methyl 4-bromobutyrate/NaHCO3/DMF/60 C Example DI
Example DI (28 mg) was prepared following the procedure used to prepare Example CZ, except that compound W (160 mg) was used instead of Example R. m/z: 774.2 (M+H)\ 1H NMR (CD?OD) b 8.97 (1 H, s), 7.81 (1 H, s), 7.24-7.02 (11 H, m), 5.20 (2 H, s), 4.54 (2 H, m), 4.18 (1 H, m), 4.0 (1 H, m), 3.75 (1 H, m ), 3.20 (4 H, m), 3.01 (1 H, m), 2.99 (3 H, s), 2.8-2.5 (4 H, m), 2.38 (2 H, m), 2.04 (2 H, m), 1.62-1.40 (6 H, m), 1.31 (6 H, m).
Preparation of Example DT Scheme 90
Figure imgf000346_0001
I. NH3-H2O/formaldehyde/glyoxa)/n-PrOH/80 C Example DT
Example DJ (44 mg) was prepared following the procedure used to prepare Example DB, except that Example W (160 mg) was used instead of Example R. m/z: 757.3 (M+H)\ 1H NMR (CD3OD) δ 8.97 (1 H, s), 7.83 (1 H, s), 7.50 (1 H, s), 7.25-7.04 (11 H, m), 6.99-6.96 (2 H, m), 5.20 (2 H, s), 4.52 (2 H, m), 4.20 (1 H, m), 4.03 (1 H, m), 3.78 (3 H, m), 3.22 (1 H, m), 2.95 (3 H, s), 2.9-2.4 (4 H, m), 1.8 (2 H, m), 1.7-1.4 (4 H, m), 1.31 (6 H, m).
Preparation of Examples DK-DL Scheme 91
Figure imgf000347_0001
I. BrCH2CH2θH/Na2CO3/DMF/70 C; Ii. CDUDMAPfT HF /70 C Example DK
Example DK was prepared following the procedure used to prepare Example DF7 except that Example W (160 mg) was used instead of Example R. Example DL
Example DL (28 mg) was prepared following the procedure used to prepare Example DG, except that Example DK was used instead of Example DF. m/z: 776.2 (M+H)+. 3H NMR (CD3OD) δ 8.97 (1 H, s), 7.81 (1 H, s), 7.25-7.05 (11 H, m), 5.20 (2 H, s), 4.55 (2 H, m), 4.31 (2 H, m), 4.2-4.0 (2 H, m), 3.75 (1 H, m), 3.44 (2 H, m), 3.3-3.0 (3 H, m), 2.98 (3 H, s), 2.8-2.4 (4 H, m), 1.7-1.4 (6 H, m), 1.32 (6 H, m). Preparation of Examples DM(a-c) Scheme 92
Figure imgf000348_0001
138b 138c
Figure imgf000348_0002
I. EDC/HOBt/DSPEA/THF; Ii. HCI/dioxane; HI. a. CDI/DIPEA; b. cmpd 9/DIPEA Compound 8
Compound 8 was synthesized following the procedure described in WO2008/010921 A2, and as described above. Compounds 138a /138b /138c
Compounds 138a, 138b, and 138c were obtained from Aldrich. Compound 139a
To a solution of acid 138a (266 mg, 1.0 mmol) and amine 8 (409 mg, 1.0 mmol) in THF (10 mL) were added HOBt (203 mg, 1.5 mmol), EDC (294 «1, 2.0 mmol), and diisopropylethylamine (0.835 mL, 4.0 mmol). The mixture was stirred for 12 hours and the solvents were removed. The residue was diluted with EtOAc. The organic phase was washed three times with saturated Na2CO3 solution, twice with water, and once with brine, and dried over Na2SO4. Concentration and purification by flash column chromatography (0%-10% MeOH in dichloromethane) gave Compound 139a (509 mg). m/z: 658.1 (M+H)\ Compound 139b
Compound 139b (543 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 138b was used instead of Compound 138a. m/z: 658.1 (M+H)\ Compound 139c
Compound 139c (587 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 138c was used instead of Compound 138a. m/z: 658.2 (M+H)+. Compound 140a
To Compound 139a (500 mg) was added 10 mL of HCl/dioxane solution (4N, 40 mmol). The mixture was stirred for 1 hour, and the solvents were removed. The residue was diluted with diethyl ether, and stirred for 1 hour. The diethyl ether layer was decanted. The solid was washed, with diethyl ether (2x) and dried under vacuum. The resulting Compound 140a was a brown powder (520 mg). m/z: 558.3 (M+H)\ Compound 140b
Compound 140b (476 mg) was prepared following the procedure used to prepare Compound 140a, except that Compound 139b was used instead of Compound 139a. m/z: 558.2 (M+H)\ Compound 140c
Compound 140c (536 mg) was prepared following the procedure used to prepare Compound 140a, except that Compound 139c was used instead of Compound 139a. m/z: 558.3 (M+H)+. Compound 9
Compound 9 was synthesized following the procedure described in WO2008/010921 A2. Example DM(a)
To the stirred solution of Compound 140a (520 mg, 0.75 mmol) and diisopropylethylamine (0.52 mL, 3.0 mmol) in dichloromethane (6 mL) was added CDI (122 mg, 0.75 mmol). The mixture was stirred for 12 hours. To this mixture was added a solution of Compound 9 (128 mg, 0.75 mmol) in dichloromethane (2 mL), and the mixture was stirred for 5 additional hours. The solvents were removed, and the residue was diluted with EtOAc. The organic layer was washed twice with water and once with brine, and dried over Na2SO4. Concentration and purification by HPLC gave Example DM(a) (270 mg). m/z: 754.3 (M+H)+. 1H NMR (CD3OD) 6 8.97 (s, IH); 8.41 (m, IH); 7.82 (s, IH); 7.70 (m, 2H); 7.30-7.00 (m, HH); 6.99 (s, IH); 5.21 (s, 2H); 4.56 (m, IH); 4.48 (s, 2H); 4.02 (m, IH); 3.72 (m, IH); 3.28 (m, IH); 3.15-2.90 (m, 2H); 2.93 (s, 3H); 2.68 (m, 4H); 1.60-1.30 (m, 10H). Example DMfb)
Example DM(b) (36 mg) was prepared following the procedure used to prepare Example DM(a), except that Compound 140b was used instead of Compound 140a. m/z: 754.3 (M+H)\ 1H NMR (CD3OD) δ 8.97 (s, IH); 8.38 (m, 2H); 7.83 (s, IH); 7.68 (m, IH); 7.33 (m, IH); 7.30-7.00 (m, 10H); 6.96 (s, IH); 5.21 (s, 2H); 4.45 (m, 3H); 4.01 (m, IH); 3.72 (m, IH); 3.28 (m, IH); 3.15-2.90 (m, 2H); 2.90 (s, 3H); 2.68 (m, 4H); 1.60-1.30 (m, 10H). Example DM(c)
Example DM(c) (283 mg) was prepared following the procedure used to prepare Example DM(a), except that Compound 140c was used instead of Compound 140a. m/z: 754.3 (M+H)\ 1H NMR (CD3OD) δ 8.97 (s, IH); 8.39 (d, 2H, /=6 Hz); 7.82 (s, IH); 7.27 (d, 2H, /=6 Hz); 7.30-7.00 (m, 10H); 6.94 (s, IH); 5.21 (s, 2H); 4.53 (m, IH); 4.45 (s, 2H); 4.03 (m, IH); 3.74 (m, IH); 3.32 (m, IH); 3.10-2.90 (m, 2H); 2.90 (s, 3H); 2.72 (m, 4H); 1.60-1.30 (m, 10H). Preparation of Example DN
Scheme 93
Figure imgf000351_0001
I. SOCI2/MeOH; II. a. CDI/iPr2NEt; b. cmpd 9; lll.a. NaOH/THF/H2O; b. HCI; iV. cmpd 8/EDC/HOBt;
Compound 141
Compound 141 was obtained from TCI. Compound 142
To a solution of Compound 141 (1.0 g, 6.4 mmol) in methanol (20 mL) at 0 0C was added thionyl chloride (1.0 mLy 14.2 mmol) dropwise. The mixture was stirred at 0 °C for 30 minutes and brought to reflux for 3 hours. Concentration gave Compound 142 as a white solid. Compound 143 Compound 143 (1.68 g) was prepared following the procedure used to prepare Example DM(a), except that Compound 142 was used instead of Compound 140a. m/z: 366.0 (M+H)\ Compound 144
To a solution of Compound 143 (1.68 g, 4.8 mmol) in MeOH/H2O (20 mL/20 mL) at 0 0C was added sodium hydroxide (229 mg, 5.74 mmol). The mixture was stirred for 1 hour and the solvents were removed under reduced pressure. Hydrochloric acid in dioxane (1.5 mL, 4 N7 6 mmol) was added, and the mixture was evaporated and dried under high vacuum. Compound 144 was obtained as a white solid (1.8 g). Example DN
Example DN (260 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 144 was used instead of Compound 138a. m/z: 743.2 (M+H)+. 1H NMR (CDCl3) δ 8.78 (1 H, s), 7.81 (1 H, s), 7.44 (1 H, s), 7.39 (1 H, s), 7.3-7.0 ( 10 H, m), 6.95 (2 H, m), 6.7 (1 H, br), 6.2 (1 H, m), 5.3 (1 H, m), 5.2 (2 H, m), 4.5-4.2 (5 H, m), 4.1 (1 H, m), 3.70 (1 H, m), 3.22 (1 H, m), 2.96 (3 H, s), 2.8-2.5 (4 H, m), 1.5-1.2 (10 H, m).
Preparation of .Example DO Scheme 94
Figure imgf000353_0001
Figure imgf000353_0002
I. EDC/HOBt; Compound, 46
Compound 46 was synthesized following the procedure described in WO2008/010921 A2. Example DO
Example DO {215 mg) was prepared following the procedure used to prepare Compound 139a, except that Compounds 144 and 46 were used instead of Compounds 8 and 138a. m/z: 743.2 (M+H)+. 1H NMR (CD3OD) 6 8.97 (s, IH); 7.82 (S/ IH); 7.45 (s, IH); 7.30-7.00 (m, 13H); 6.19 (s, IH); 5.20 (s, 2H); 4.60-4.40 (m, 2H); 4.21 (m, 2H); 4.09 (m, IH); 3.25 (m, IH); 2.93 (s, 3H); 2.90-2.50 (m, 5H); 1.70- 1.20 (m, 10H). Preparation of Examples DF-DT
Scheme 95
Figure imgf000354_0001
DP DQ DR
Figure imgf000354_0002
DS DT
I. RNH2/EDC/HOBt;
Example AF
Example AF was synthesized following the procedure described in WO2008/010921 A2, and as described above in Scheme 27. Example DP
Example DP (23 mg) was prepared following the procedure used to prepare Compound 139a, except that Example AF and 2-aminopyridine were used instead of Compounds 8 and 138a. m/z: 797.2 (M+H)+. 2H NMR (DMSO-dJ δ 10.45 (IH, s), 9.06 (1 H, s), 8.31 (1 H, m), 8.04 (1 H, m), 7.85 (1 H, m), 7.75 (1 H, m), 7.55 (1 H, m); 7.2-7.0 (13 H, m), 6.54 (1 H, m), 5.12 (2 H, s), 4.52 (1 H, m), 4.43 (2 H, s), 3.93 (1 H, m), 3.58 (1 H, m), 3.17 (1 H, m), 2.85 (3 H, s), 2.8-2.4 (6 H, m), 1.36 (4 H, m), 1.25 (6 H, m). Example DQ Example DQ (32 mg) was prepared following the procedure used to prepare Compound 139a, except that Example AF and 3-aminopyridine were used instead of Compounds 8 and 138a. m/z: 797.2 (MH-H)+. 1H NMR (DMSO-dό) b 10.39 (IH, s), 9.06 (1 H, s), 8.88 (1 H7 s), 8.36 (1 H, m), 8.18 (1 H, m), 7.S5 (1 H, s), 7.54 (2 H, m), 7.2-7.0 (12 H, m), 6.60 (1 H, m), 5.14 (2 H, s), 4.55 (1 H, m), 4.45 (2 H, s), 4.0-3.5 (2 H, m), 3.19 (1 H, m), 2.86 (3 H, s), 2.8-2.4 (6 H, m), 1.37 (4 H, m), 1.26 (6 H, m). Example DR
Example DR (30 mg) was prepared following the procedure used to prepare Compound 139a, except that Example AF and 4-aminopyridine were used instead of Compounds 8 and 138a. m/z: 797.3 (M+H)+. 1H NMR (DMSO-d6) δ 11.24 (1 H, s), 9.05 (1 H, s), 8.61 (2 H, d, J = 6.3 Hz), 7.96 (2 H, d, J = 6.3 Hz), 7.84 (1 H, s), 7.58 (1 H, m), 7.2-7.0 (12 H, m), 6.65 (1 H, m)7 5.14 (2 H, s), 4.6 (1 H, m), 4.46 (2 H, s), 3.9 (1 H, m), 3.4 (1 H, m), 3.20 (1 H, m), 2.87 (3 H, s), 2.7-2.4 (6 H, m), 1.37 (4 H, m), 1.25 (6 H, m). Example DS
Example DS (50 mg) was prepared following the procedure used to prepare Compound 139a, except that Example AF and 1-aminopyrrolidine were used instead of Compounds 8 and 138a. m/z: 789.2 (M+H)+. 1H NMR (DMSO-d6) & 9.06 (1 H, s), 8.63 (1 H7 s), 8.26 (1 H, s), 7.85 (1 H7 s)7 7.55 (1 H, m), 7.35 (1 H, m), 7.2-7.0 (10 H, m); 6.40 (1 H, m), 5.15 (2 H, s), 4.55-4.30 (3 H, m), 3.85 (1 H, m), 3.63 (1 H, m), 3.4-3.1 (5 H, m), 2.86 (3 H, s), 2.8-2.4 (6 H, m), 1.66 (4 H7 m), 1.4-1.2 (10 H, m). Example DT
Example DT (50 mg) was prepared following the procedure used to prepare Compound 139a7 except that Example AF and methanesulfonamide were used instead of Compounds 8 and 138a. m/z: 798.2 (M+H)\ 1H NMR (DMSO-d6) 6 11.65 (1 H, s), 9.10 (1 H, s), 7.88 (1 H, s), 7.50 (1 H, m), 7.2-7.0 (12 H, m), 6.6 (1 H7 m), 5.15 (2 H, s), 4.5-4.4 (3 H, m), 4.0-3.4 (2 H, m), 3.20 (1 H, m), 3.15 (3 H, s)7 2.85 (3 H, s), 2.7-2.4 (6 H, m)7 1.4-1.2 (10 H, m). Preparation of Examples DU(a-c) Scheme 96
Figure imgf000356_0001
I TMSI/EtOH/DCM, Il amino aicohoi/DCM, II! a NaOH/THF/H2O, b HCl, IV cmpd 8/EDC/HOBt/DfPEA/DMF
Compound 122
Compound 122 was synthesized following the procedure described in WO2008/ 010921 A2, and as described above in Scheme 69. Compound 145
To a solution of Compound 122 (1.0 g, 4 mmol) in dichloromethane (5 mL) was added ethyl alcohol (1.5 mL, 25.6 mmol), followed by iodotrimethylsilane (2 mL, 14.3 mmol). The mixture was stirred for 6 hours and the mixture was used directly for the next step, m/z: 453.9 (M+H)+. Compound 146a
To a solution of Compound 145 (1 mmol) in dichloromethane (2 mL) was added a solution of (R)-3-hydroxypyrrolidine (435 mg, 5 mmol) in dichloromethane (1 mL). The mixture was stirred for 12 hours and the solvents were removed under reduced pressure. Purification by flash column chromatography (0-20% MeOH in dichloromethane) gave Compound 146a (230 mg). m/z: 413.1 (M+H)\ Compound 146b
Compound 146b (200 mg) was prepared following the procedure used to prepare Compound 146a, except that compound (S)-3-hydroxy pyrrolidine was used instead of compound (R)-3-hydroxypyrrolidine. m/z: 413.1 (M+H)\ Compound 146c
Compound 146c (380 mg) was prepared following the procedure used to prepare Compound 146a, except that compound 4-hydroxypiperidine was used instead of compound (R) -3-hydroxy pyrrolidine, m/z: 427.1 (M +H)+. Compound 147a
Compound 147a (250 mg) was prepared following the procedure used to prepare Compound 144, except that Compound 146a was used instead of Compound 143. Compound 147b
Compound 147b (210 mg) was prepared following the procedure used to prepare Compound 144, except that Compound 146b was used instead of Compound 143. Compound ,147c
Compound 147c (400 mg) was prepared following the procedure used to prepare Compound 144, except that Compound 146c was used instead of Compound 143. Example DUfa)
Example DU{a) (250 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 147a was used instead of Compound 138a. m/z: 776.3 (M+H)+. 1H NMR (CD3OD) δ 8.97 (1 H, s), 7.81 (1 H, s), 7.25-7.05 (11 H, m), 5.19 (2 H, m), 4.54 (2 H, m), 4.25 (1 H, m), 4.2-4.1 (2 H, m), 3.75 {1 H7 in), 3.22 (1 H, m), 2.94 (3 H, s), 2.8-2.7 (6 H, m), 2.5-2.3 (4 H, m), 2.1-1.8 (2 H, m), 1.7-1.4 (6 H, m), 1.37 (6 H, m). Example Uϋ(b)
Example DU(b) (253 mg) was prepared following the procedure used to prepare Compound 139a, except that compound 147b was used instead of Compound 138a. m/z: 776.3 (M+H)". 1H NMR (CD3OD) δ 8.97 (1 H, s), 7.81 (1 H, s), 7.22-7.05 (11 H, m), 5.18 (2 H, m), 4.5 (2 H, m), 4.25 (1 H, m), 4.2-4.1 (2 H, m), 3.78 (1 H, m), 3.25 (1 H, m), 2.95 (3 H, s), 2.8-2.6 (6 H, m), 2.6-2.3 (4 H, m), 2.1-1.8 (2 H, m), 1.8-1.4 (6 H, m), 1.37 (6 H, m). Example DU(c)
Example DU(c) (450 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 147c was used instead of Compound 138a. m/z: 790.3 (M+H)+. 1H NMR (CD3OD) & 8.97 (1 H, s), 7.81 (1 H, s), 7.25-7.05 (11 H, m), 5.20 (2 H, m), 4.54 (2 H, m), 4.2-4.0 (2 H, m), 3.75 (1 H, m), 3.58 (1 H, m), 3.25 (1 H, m), 2.97 (3 H, s), 2.8-2.6 (6 H, m), 2.25 (2 H, m), 2.08 (2 H, m), 1.9-1.6 (4 H, m), 1.6-1.4 (6 H, m), 1.38 (6 H, m).
Preparation of Example DV
Scheme 97
Figure imgf000359_0001
I. SO3-pyridine/Et3N/DMSO Example DV
A mixture of Example DU(c) (230 mg, 0.29 mmol) and triethylamine (0.14 mL) in DMSO (1 mL) was stirred at 25 0C for 30 minutes, and then was cooled to 5-10 °C. Sulfur trioxide pyridine complex (0.17 g) was added to above reaction mixture and the mixture was stirred for 1 hour at 5-10 0C. The mixture was poured into ice water, and stirred for 20 minutes, and was extracted with EtOAc. The organic phase was washed twice with water, twice with saturated NaHCO3 solution, twice with water, and once with brine, and dried over Na2SO4. Concentration and purification by flash column chromatography (0-20% MeOH in dichloromethane) gave Example DV (67 mg). m/z: 788.3 (M+H)+. 1H NMR (CDCl1) δ 8.78 (1 H, s), 7.81 (1 H, s), 7.3-7.1 (10 H, m)7 6.90 (1 H7 s), 6.5 (1 H7 br), 5.35 (1 H, m), 5.22 (2 H, s), 4.4-4.0 (4 H, m), 3.78 (1 H, m), 3.23 (1 H, m), 2.93 (3 H, s)7 2.8-2.5 ( 8 H7 m), 2.4-2.2 (6 H, m), 2.0-1.4 (6 H, m), 1.32 (6 H, m). Preparation of Example DW Scheme 98
Figure imgf000360_0001
DW i. SO3-pyridine/Et3N/DMSO Example DW
Example DW (78 mg) was prepared following the procedure used to prepare Example DV, except that Example DU(a) was used instead of Example DU(c). m/z: 774.3 (M+H)\ 1H NMR (CDCl,) b 8.78 (1 H7 s), 7.82 (1 H, s), 7.3-7.0 (10 H, m), 6.89 (1 H, s), 6.55 (1 H, br), 5.40 (1 H, m), 5.21 (2 H, s), 4.5-4.2 (3 H, m), 4.15 (1 H, m), 3.78 (1 H, m), 3.23 (1 H, m), 3.1-2.9 (4 H, m), 2.9 (3 H, s), 2.8-2.5 (6 H, m), 2.40 (2 H, m), 1.90 (2 H, m), 1.55 (2 H, m), 1.38 (8 H, m).
Preparation of Examples DX(a-f) Scheme 99
Figure imgf000361_0001
I. amine/NaBH(OAc)3/AcOH/CH3CN, II. a. NaOH/EtOH/H2O; b. HQ; Il I. compound 8/EDC/HOBt/DiPEA
Compound 60
Compound 60 was synthesized following the procedure described in WO2008 /010921 A2, and as described above in Scheme 23. Compound 148 a
To a solution of Compound 60 (800 mg, 2 mmol) in CH1CN (8 ml) was added a solution of 1-acetylpiperazine (512 mg, 4 mmol) in CH,CN (1 mL), followed by HOAc (240 ui, 4 mmol) and NaBH(OAc)1 (1.33 g, 6 mmol). The lnixture was stirred for 12 hours and was diluted with EtOAc. The organic phase was washed with saturated Na2CO1 solution, water, and brine, and dried over Na2SO4. Concentration and purification by flash column chromatography (0-12% iPrOH in dichloromethane) gave Compound 148a (250 nig), m/z: 516.1 (M+H)". Compound 148b
Compound 148b (530 mg) was prepared following the procedure used to prepare Compound 148a, except that 1-ethylsulfonylpiperazine was used instead of 1-acetylpiperazine. m/z: 566.1 (M+H)+. Compound 148c
Compound 148c (384 mg) was prepared following the procedure used to prepare Compound 148a, except that 4-trifluoromethylpiperidine was used instead of 1-acetylpiperazine. m/z: 541.2 (M+H)\ Compound 148d
Compound 148d (342 mg) was prepared following the procedure used to prepare Compound 148a, except that 4, 4-difluoropiperidine was used instead of 1-acetylpiperazine. m/z: 509.1 (M+H)+. Compound 148e
Compound 148e (320 mg) was prepared following the procedure used to prepare Compound 148a, except that 4-fluoropiperidme was used instead of 1- acetylpiperazine. m/z: 491.1 (M+H)+. Compound 148f
Compound 148f (389 mg) was prepared following the procedure used to prepare Compound 148a, except that 3,3-difluoropiperidine was used instead of 1-acetylpiperazine. m/z: 509.1 (M+H)+. Example 149a
To a solution of Compound 148a (250 mg, 0.48 mmol) in ethyl alcohol (3 mL) was added 1.0 N sodium hydroxide solution (0.53 mL, 0.53 mmol). The mixture was stirred for 1 hour and the solvents were removed under reduced pressure. 4.0 N Hydrochloric acid in dioxane (0.13 mL, 0.52 mmol) was added, and the mixture was evaporated. Coevaporation with DMF (2x100 mL) gave Compound 149a, which was used without further purification in the next step. Example 149b
Compound 149b was prepared following the procedure used to prepare Compound 149a, except that Compound 148b was used instead of Compound 148a. Example 149c
Compound 149c was prepared following the procedure used to prepare Compound 149a, except that Compound 148c was used instead of Compound 148a. Example 149d
Compound 149d was prepared following the procedure used to prepare Compound 149a, except that Compound 148d was used instead of Compound 148a. Example 149e
Compound 149e was prepared following the procedure used to prepare Compound 149a, except that Compound 148e was used instead of Compound 148a. Example 149f
Compound 149f was prepared following the procedure used to prepare Compound 149a, except that Compound 148f was used instead of Compound 148a. Example QX(a)
Example DX (a) (90 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 149a was used instead of Compound 138a. m/z: 817.3 (M+H)\ 1H NMR (CDCl3) • 8.78 (1 H, s), 7.81 (1 H, s), 7.3-7.0 (10 H, m), 6.90 (1 H, s), 6.40 (1 H, m), 5.40 (1 H, m), 5.22 (2 H, s), 4.6-4.3 (2 H, m), 4.3-4.1 (2 H, m), 3.78 (1 H, m), 3.5-3.2 (5 H, m), 2.92 (3 H, s), 2.9-2.6 (4 H, m), 2.4-2.2 (6 H, m), 2.07 (3 H, s), 1.9 (2 H, m), 1.64.3 (10 H, m). Example DXfb)
Example DX(b) (150 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 149b was used instead of Compound 138a. m/z: 867.3 (M+H)+. 1H NMR (CDCl3) • 8.78 (1 H, s), 7.81 (1 H, s), 7.3-7.0 (10 H, m), 6.92 (1 H, s), 6.4 (1 H, br), 5.35 (1 H, br), 5.2 (2 H, s), 4.6-4.0 (4 H, m), 3.78 (1 H, m), 3.3-3.1 (5 H, m), 2.92 (5 H, m), 2.8-2.6 (4 H, m), 2.5-2.2 (6 H, m), 1.90 (2 H, m), 1.6-1.3 (13 H, m). Example DXf c)
Example DX{c) (427 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 149c was used instead of Compound 138a. m/z: 842.2 (M+H)\ 1H NMR (CDCl3) • 8.77 (1 H, s), 7.80 (1 H, s), 7.3-7.0 (10 H, m), 6.88 (1 H, s), 6.40 (1 H, br), 5.50 (1 H, br), 5.20 (2 H, m), 4.7-4.3 (2 H, m), 4.18 (2 H, m), 3.75 (1 H, m), 3.23 (1 H, m), 3.05-2.8 (4 H, m), 2.8-2.6 (4 H, m), 2.25 (2 H, m), 2.0-1.65 (6 H, m), 1.6-1.2 (14 H, m). Example OX(d)
Example DX(d) (390 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 149d was used instead of Compound 138a. m/z: 810.2 (M+H)+. 1H NMR (CDCl3) • 8.78 (1 H, s), 7.81 (1 H, s)7 7.4-7.0 (10 H, m), 6.89 (1 H, s), 6.40 (1 H, br), 5.40 (1 H, br), 5.22 (2 H, m), 4.6-4.3 (2 H, m), 4.22 (2 H, m), 3.78 (1 H, m), 3.24 (1 H, m), 3.0-2.6 (7 H, m), 2.5 -2.2 (6 H, m), 2.0-1.7 (6 H, m), 1.6-1.2 (10 H, m). Example DXf e)
Example DX(e) (160 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 149e was used instead of Compound 138a. m/z: 792.3 (M+H)\ 1H NMR (CDCl3) • 8.77 (1 H, s), 7.81 (1 H, s), 7.3-7.0 (10 H, m), 6.87 (1 H, s), 6.45 (1 H, br), 5.55 (1 H, br), 5.20 (2 H, m), 4.9-4.3 (3 H, m), 4.3-4.1 (2 H7 m)7 3.75 (1 H, m)7 3.25 (1 H, m)7 3.1-2.8 (5 H, m), 2.8-2.6 (4 H, m), 2.6-2.1 (6 H, m), 2.0-1.4 (8 H, m), 1.37 (6 H, m). Example DXffl
Example DX(f) (480 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 149f was used instead of Compound 138a. m/z: 810.2 (M+H)+. 1H NMR (CDCl,) * 8.77 (1 H, s), 7.80 (1 H, s), 7.3-7.0 (10 H, m), 6.93 (1 H, br), 6.84 (1 H, s), 6.40 (1 H, br), 5.50 (1 H, br), 5.20 (2 H7 m), 4.5-4.3 (2 H, m), 4.3-4.1 (2 H, m), 3.75 (1 H, m), 3.24 (1 H, m), 3.05-2.8 (5 H, m), 2.8-2.6 (4 H, m), 2.5-2.2 (6 H, m), 2.04.75 (4 H, m), 1.7-1.37 (10 H, m).
Preparation of Example DY
Scheme 100
BOCHN-V0
Figure imgf000366_0002
Figure imgf000366_0001
Figure imgf000366_0003
1 Boc2O/THF; H.NaOMe/MeOH, IK SO3-pyrιdιne/DMSO/Et3N,
IV. thiomorphohne/NaBH(OAc)3/HOAc, V 4-methylmorpholιne N-oxιde/OsO4,
VJ. HCI, VH. a CDI, b cmpd 9, VIII a NaOH, b HCI,
JX. EDC/HOBt/cmpd 8
Compound 150
Compound 150 was obtained from Aldrich. Compound 151
To a suspension of Compound 150 (25 g, 137 mmol) in THF (400 mL) was added triethylamine (21 mL, 151 mmol), followed by Boc2O (31.5 g, 144 mmol). The mixture was stirred for 48 hours, and the solvents were removed. The residue was diluted with EtOAc, and washed twice with saturated sodium carbonate solution, once with water, and once with brine, and dried over Na2SO4. Concentration gave Compound 151 (25 g). Compound 152
To a solution of Compound 151 (2.0 g, 10 mmol) in MeOH (20 mL) at 0 0C was added 4.4 N sodium methoxide solution in methanol (0.46 mL, 2 mmol). The mixture was stirred for 45 minutes, and quenched with saturated NH4Cl solution. The solvent was evaporated, and the residue was diluted with EtOAc. The organic phase was washed with saturated NH4Cl solution, water, and brine, and dried over Na2SO4. Concentration gave Compound 152 (2.6 g). Compound 153
Compound 153 (1.9 g) was prepared following the procedure used to prepare Example DV, except that Compound 152 was used instead of Example DlHc). Compound 154
Compound 154 (1.65 g) was prepared following the procedure used to prepare Compound 148a, except that Compound 153 and 4-thiomorpholine were used instead of Compound 60 andl-acetylpiperazine. Compound 155
To a solution of Compound 154 (1.55 g, 4.86 mmol) in acetone/water (270 mL/70 mL) was added 4-methylmorpholine N-oxide (1.25 g, 10 mmol), followed by OsO4/tBuOH solution (6.8 mL, 2.5%). The mixture was stirred for 12 hours and the solvents were removed under reduced pressure. Purification by flash column chromatography (60-100% EtAOc in hexanes) gave Compound 155 (1.44
S)- Compound 156 Compound 156 was prepared following the procedure used to prepare Compound 140a, except that Compound 155 was used instead of Compound 139a. Compound 157
Compound 157 (660 mg) was prepared following the procedure used to prepare Example DM(a), except that Compound 156 was used instead of Compound 140a. m/z: 447.0 (M+H)+. Compound 158
Compound 158 was prepared following the procedure used to prepare Compound 144, except that Compound 157 was used instead of Compound 143. m/z: 433.1 (M+H)+. Example DY
Example DY (350 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 158 was used instead of Compound 138a. m/z: 824.2 (M+H)+. 3H NMR (CDCl3) • 8.80 (1 H, s), 7.82 (1 H, s), 7.2-7.0 (10 H, m), 6.96 (1 H, s), 6.71 (1 H, br), 6.4 (1 H, br), 5.21 (2 H, m), 5.15 (1 H, br), 4.5-4.1 (4 H, m), 3.80 (1 H, m), 3.22 (1 H, m), 3.0-2.8 (11 H, m), 2.8-.2.6 (4 H, m), 2.47 (2 H, m), 2.0-1.7 (2 H, m), 1.6-1.3 (10 H, m).
Preparation of Examples DZ-EA
Scheme 101
Figure imgf000369_0001
Figure imgf000369_0002
I. NaCN/{NH4)2CO3/EtOH/H2O/90 C; M. EDC/HOBt/cmpd 8 Compounds 159/160
To a solution of Compound 60 (1.6 mmol) in EtOH/H2O (1.6 m.L/1.6 mL) was added ammonium carbonate (600 mg, 6.4 mmol), followed by sodium cyanide (158 nig). The mixture was heated at 90 0C for 16 hours and cooled to 25 0C. 1 N hydrochloric acid was added until pH = 3-4. The residue was diluted with EtOAc, and washed with water and brine. The organic phase was dried over Na2SO4 and concentrated to give Compounds 159 and 160, which were used without further purification in the next step. Examples DZ/EA
Examples DZ (80 mg) and EA (60 mg) were prepared following the procedure used to prepare Compound 139a, except that Compounds 159 and 160 were used instead of Compound 138a. Example DZ: m/z: 732.3 (M+H)+. 1H NMR (CDCl3) • 8.75 (1 H, m), 7.80 (1 H, m), 7.3-7.0 (10 H, m), 6.95 (1 H, m), 6.8 (1 H, br), 6.40 (1 H, br), 5.8 (1 H, br), 5.20 (2 H, m), 4.40 (2 H, m), 4.2-3.8 ( 3 H, m), 3.78 (1 H, m), 3.23 (1 H, m), 2.95 (3 H, m), 2.8-2.3 (6 H, m), 1.6-1.3 (10 H, m). Example EA: m/z: 775.2 (M+H)+. 1H NMR (CDCl3) • 8.81 (1 H, s), 8.02 (1 H, br), 7.9 (1 H, s), 7.85 (1 H, br), 7.3-7.0 (11 H, m), 6.3 (1 H, br), 5.4-5.1 (3 H, m), 4.6-4.3 (2 H, m), 4.2-3.8 (2 H, m), 3.8-3.4 (1 H, m), 3.3 (1 H, m), 3.1-2.9 (3 H, m), 2.8-2.4 (4 H, m), 2.15 (2 H, m), 1.7-1.2 (10 H, m).
Preparation of Example EB Scheme 102
Figure imgf000371_0001
Figure imgf000371_0002
I. morphoiine/NaBH{OAc)3/HOAc; IL HCI; III. a. CDI; b. cmpd 3b; IV. a. NaOH; b. HCi; V. EDC/HOBt/cmpd 8
Compound 161
Compound 161 (11 g) was prepared following the procedure used to prepare Compound 148a, except that Compounds 153 and morpholine were used instead of Compounds 60 and 1-acetylpiperazine. m/z: 303.0 (M÷H)+. Compound 162
Compottnd 162 (10.4 g) was prepared following the procedure used to prepare Compound 140a, except that Compound 161 was used instead of Compound 139a. m/z: 203.1 (M+H)+. Example 3b
Compound 3b was synthesized following the procedure described in WO2008/010921 A2, and as described above in Scheme 10. Example 163
Compound 163 (540 mg) was prepared following the procedure used to prepare Example DM{a), except that Compounds 162 and 36 were used instead of Compounds 140a and 9. m/z: 385.1 (M+H)τ. Example 164
Compound 164 (780 mg) was prepared following the procedure used to prepare Compound 144, except that Compound 163 was used instead of Compound 143. m/z: 371.0 (M+H)+. Example EB
Example EB (210 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 164 was used instead of Compound 138a. m/z: 762.2 (M+H)+. 1H NMR (DMSO-d6) • 9.06 (1 H, s), 7.85 (1 H, s), 7.7 (1 H, br), 7.2-7.0 (12 H, m), 6.55 (1 H, br), 6.20 (1 H, br), 5.18 (2 H, s), 4.23 (2 H, m), 4.15 -3.8 (2 H, m), 3.65 (1 H, m), 3.55 (4 H, m), 3.2 (1 H, m), 2.7-2.4 (6 H, m), 2.3-2.0 (6 H, m), 1.5-1.2 (10 H, m). Preparation of Compound 166 Scheme 103
Figure imgf000372_0001
!. NaOH/H2O; II. bis(4-nitrophenyl) carbonate/Et3N Compound 3
Compound 3 was synthesized following the procedure described in WO2008 /010921 A2. Compound 165
To a suspension of Compound 3 (2.65 g, 12.5 mmol) in water (10 inL) was added sodium hydroxide (1.5 g, 38 mmol). The mixture was heated at 90 0C for 12 hours and cooled to 25 0C. The mixture was extracted with EtOAc. The organic layer was washed with brine and dried over Na2SO4. Purification by flash column chromatography (50% EtOAc in hexanes) gave Compound 165 (810 mg). Compound 166
To a solution of Compound 165 (810 mg, 5.2 mmol) in DCM (12 mL) was added bis(4-nitrophenyl) carbonate (1.73 g, 5.7 mmol), followed by triethylamine (1.1 mL, 7.8 mmol). The mixture was stirred for 14 hours, and the solvents were removed. The residue was diluted with EtOAc7 and washed twice with saturated sodium carbonate, followed by water, and then brine, and was dried over Na2SO4. Concentration and purification by flash column chromatography (20% EtOAc in hexanes) gave Compound 166 (1.4 g).
Preparation of Example EC Scheme 104
Figure imgf000374_0001
168
Figure imgf000374_0002
I. a. NaOH; b. HCi; V. EDC/HOBt/cmpd 8; IH, a. HCI; b. NaOH; IV. cmpd 166/iPr2NEt
Compound 167
Compound 167 was prepared following the procedure used to prepare Compound 144, except that Compound 161 was used instead of Compound 143. Compound 168
Compound 168 (1.2 g) was prepared following the procedure used to prepare Compound 139a, except that Compound 167 was used instead of Compound 138a. m/z: 680.3 (M+H)+. Compound 169
To a solution of Compound 168 (1.2 g, 1.8 mmol) in MeOH (10 mL) was added 4 N hydrochloric acid (4.4 mL, 17.6 mmol). The mixture was stirred for 6 hours, and the solvents were removed. The residue was basified with 2 N sodium hydroxide solution (pH = 11), and extracted with EtOAc. The organic layer was washed with brine and dried over Na2SO4. Concentration gave Compound 169
(1-O g) Example EC
To a solution of Compound 169 (116 mg, 0.2 mmol) in CH3CN (2 mL) was added Compound 166 (71 mg, 0.22 mmol), followed by triethylamine (71 «L, 0.4 mmol). The mixture was stirred for 48 hours, and was diluted with EtOAc. The organic layer was washed "with saturated sodium carbonate solution, water, and brine, was dried over Na2SO4. Purification by flash column chromatography (0- 15% IPrOH in DCM) gave compound 1073 (130 mg). m/z: 763.3 (M+H)+. 1H NMR (CDCl3) • 8.75 (1 H, s), 7.78 (1 H, s), 7.67 (1 H, br), 7.3-7.0 (11 H, m), 6.22 (1 H, m), 5.24 (2 H, s), 5.16 (2 H, s), 5.10 (1 H, br), 4.28-4.10 (2 H, m), 3.8 (1 H, m), 3.6 (4 H, m), 3.32 (1 H, m), 2.9-2.6 (4 H, m), 2.4-2.1 (6 H, m), 1.8 (2 H, m), 1.6 (2 H, m), 1.4 (8 H, m).
Preparation of Compound 173 Scheme 105
Figure imgf000375_0001
170 171 172 173
Compound 170
Compound 170 was obtained from Aldrich. Compound 171 Hydrogen sulfide gas was passed through a solution of Compound 170 (1.8 mL, 20 mmol) in pyridine (100 niL) and triethylamine (4.4 mL) for 5 hours. The solution was purged with nitrogen for 10 minutes, and the solvents were removed. The residue was coevaporated three times with 10 mL of ethyl alcohol. Purification by flash column chromatography (10% iPrOH in DCM) gave Compound 171 (2.0 g). Compound 172
To a solution of Compound 171 (2 g, 17 mmol) in acetone (30 mL) was added 1,3-dichloroacetone (2.1 g, 17 mmol), followed by MgSO4 (2.0 g, 17 mmol). The mixture was refluxed for 12 hours and cooled to 25 0C. The mixture was filtered. Concentration gave Compound 172. m/z: 191.9 (MH-H)+. Compound 173
To a solution of 40% methylamine in water (36 mL) was added a solution of Compound 172 (17 mmol) in water (10 mL). The mixture was stirred for 1 hour, and concentrated under reduced pressure. Purification by flash column chromatography (10% MeOH in DCM) gave Compound 173. m/z: 187.0 (M+H)+. Preparation of Compound 177 Scheme 106
Figure imgf000376_0001
I. a. NaOH/EtOH/H2O; b. BnBr/DMF; II. SO3-pyridine; Ml. morpho!ine/NaBH(Oac)3/HOAc; IV. HCi
Compound 174 To a solution of Compound 151 (10.5 g, 50 mmol) in ethyl alcohol (160 mL) was added sodium hydroxide solution (2.1 g, 52.5 mmol, 30 mL). The mixture was stirred for 1 hour, and the solvent was removed under reduced pressure. The residue was coevaporated three times with 200 mL of ethyl alcohol. The white solid was dried at 60 0C for 2 hours under high vacuum. To this solid was added DMF (80 mL), followed by benzyl bromide (7.3 mL, 61 mmol). The mixture was stirred for 12 hours in darkness and diluted with EtOAc. The organic phase was washed five times with water followed once with brine, and "was then dried over Na2SO4. Concentration gave Compound 174 (15 g). Compound 175
Compound 175 was prepared following the procedure used to prepare Example DV, except that Compound 174 was used instead of Example DU(c). Compound 176
Compound 176 was prepared following the procedure used to prepare Compound 148a, except that Compound 175 and morpholine were used instead of Compound 60 and 1-acetylpiperazine. Compound 177
Compound 177 (3.4 g) was prepared following the procedure used to prepare example 140a, except that Compound 176 was used instead of Compound 139a. m/z: 279.1 (M+H)+. Preparation of Example ED
Scheme 107
Figure imgf000378_0001
I. a. CDi/D!PEA; b. cmpd 173; II. a. NaOH; b. HCI; HI. cmpd 8/EDC/HOBt
Compound 178
Compound 178 (300 mg) was prepared following the procedure used to prepare Example DM(a), except that Compounds 173 and 177 were used instead of Compounds 140a and 9. m/z: 491.3 (M+H)+. Compound 179
Compound 179 was prepared following the procedure used to prepare Compound 149a, except that Compound 178 was used instead of Compound 148a. Example ED
Example ED (370 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 179 was used instead of Compound 138a. m/z: 792.3 (M+H)+. 1H NMR (CD3OD) • 8.98 (1 H, s), 7.83 (1 H, s), 7.20-7.08 (11 H, m), 5.20 (2 H, m), 4.55 (2 H, m), 4.3-4.0 (4 H, m), 3.75 (3 H, m), 3.4 (2 H, m), 3.2-3.0 (4 H7 m), 2.99 (3 H, s), 2.70 (4 H, m), 2.1-1.8 (2 H, m), 1.7-1.4 (10
H, m).
Preparation of Example EE
Scheme 108
Figure imgf000379_0001
i. cmpd 9/EDC/HOBt; II. a. NaH/DMF; b. 2-morpholineethylbromide; ill. a. TFA/DCM; b. NaOH; IV1 a. triphosgene/DIPEA; b. cmpd 8/DiPEA
Compound 180
Compound 180 was obtained from Aldrich. Compound 181
Compound 181 (1.6 g) was prepared following the procedure used to prepare Compound 139a, except that Compounds 180 and 9 were used instead of Compounds 8 and 138a. m/z: 327.9 (M+H)τ. Compound 182
To a suspension of sodium hydride (52 mg, 60%, 1.3 mmol) in DMF (4 mL) was added a solution of Compound 181 (327 mg, 1 mmol) in DMF (1 mL). The mixture was stirred for 90 minutes, and a solution of 2-morpholineethyl bromide (212 mg, 1.1 mmol) in DMF (1 mL) was added dropwise. The mixture was stirred for 12 hours, and quenched with water. The aqueous phase was extracted three times with EtOAc. The combined organic phases were washed five times with water and once with brine, and dried over Na2SO4. The dried organic phases were concentrated and purified by flash column chromatography (0-10% MeOH in DCM) to give Compound 182 (267 mg). m/z: 441.1 (M+H)+. Compound 183
Compound 183 (175 mg) was prepared following the procedure used to prepare Compound 169, except that Compound 182 was used instead of Compound 168. m/z: 341.2 (M+H)+. Example EE
To a solution of triphosgene (56 mg, 0.19 mmol) in DCM (1 mL) at 0 0C was added a solution of Compound 8 (210 mg, 0.51 mmol) and DIPEA (194 •_) in DCM (1.8 mL). The mixture was stirred for 30 minutes, and a solution of Compound 183 (175 mg, 0.51 mmol) and DIPEA (194 -1) in DCM (1 mL) was added. The mixture was warmed to 25 °C and stirred for 12 hours. The mixture was diluted with EtOAc, and washed twice with saturated sodium carbonate, once with water, and once with brine, and was dried over Na2SO4. The dried organic phases were concentrated and purified by flash column chromatography (15% iPrOH in DCM) gave Example EE (150 mg). m/z: 776.3 (M+H)+. 1H NMR (CD3OD) • 8.97 (1 H, s), 7.82 (1 H, s), 7.25-7.05 (11 H, m), 5.21 (2 H, s), 4.6 (2 H, m), 4.3-4.1 (2 H, m), 3.95 (1 H, m), 3.75 (1 H, s), 3.47 (4 H, m), 3.3 (5 H, m), 3.06/2.94 (3 H, s), 2.7 (4 H, m), 2.30 (4 H, m), 1.64.2 (10 H, m).
Preparation of Examples EF-EH
Scheme 109
Figure imgf000381_0001
184 185 186
Figure imgf000381_0002
EF
Figure imgf000381_0003
EH
1. a. CDI/DSPEA; b. MeNH2; II. a. NaOH/THF/H2O; b. HCl; lll.cmpd 8/EDC/HOBt/DIPEA; IV. a. TFA/DCM; b. NaOH; V. NaBH(OAc)3/HOAc
Compound 184
Compound 184 was obtained from Aldrich. Compound 185
Compound 185 (291 mg) was prepared following the procedure used to prepare Example DM(a), except that Compound 184 and methylamine were used instead of Compounds 140a and 9. m/z: 289.9 (M+H)+. Compound 186 Compound 186 was prepared following the procedure used to prepare Compound 144, except that Compound 185 was used instead of Compound 143. m/z: 275.9 (M+H)÷. Example EF
Example EF (102 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 186 was used instead of Compound 138a. m/z: 667.1 (M+H)+. Example EG
Example EG (144 mg) was prepared following the procedure used to prepare Compound 169, except that Example EF was used instead of Compound 168 m/z: 567.2 (M+H)+. Compound 54
Compound 54 was synthesized following the procedure described in WO2008/010921 A2. Example EH
Example EH (25 mg) was prepared following the procedure used to prepare Compound 148a, except that Example EG and Compound 54 were used instead of Compound 60 and 1-acetylpiperazine. m/z: 637.3 (M-f-H)\ 1H NMR (CDCl3) • 9.00 (br s, IH); 7.94 (br s, IH); 7.72 (br s, IH); 7.40-7.00 (m, 10H); 5.49 (m, IH); 5.25 (s, 2H); 4.47 (m, IH); 4.30 (m, IH); 4.02 (br s, IH); 3.65 (m, 2H); 3.41 (m, 2H); 2.76 (m, 9H); 2.25-1.70 (m, 4H); 1.70-1.40 (m, 6H).
Preparation of Example EI-ET Scheme 110
Figure imgf000383_0001
I. a. CDt/DIPEA; b. cmpd 9; II. a. NaOH/EtOH; b. BnBr/DMF; III. SO3-pyridine/Et3N; IV. morphoHne/NaBH(OAc)3/AcOH/CH3CN; V. a. NaOH/EtOH/H2O; b. HCI; IV.cmpd 8/EDC/HOBt/DIPEA; VII. chiral column separation Compound 187
Compound 187 was obtained from Aldrich, Compound 188
Compound 188 (897 mg) was prepared following the procedure used to prepare Example DM(a), except that Compound 187 was used instead of Compound 140a. m/z: 298.0 (M+H)+. Compound 189
Compound 189 (1.24 g) was prepared following the procedure used to prepare Compound 174, except that Compound 188 was used instead of Compound 151. m/z: 406.1 (M+H)+. Compound 190
Compound 190 (712 mg) was prepared following the procedure used to prepare Example DV, except that Compound 189 was used instead of Example DU(c). m/z: 40.4.0 (M+H)\ Compound 191
Compound 191 (384 mg) was prepared following the procedure used to prepare Compound 148a, except that Compound 190 and morpholine were used instead of Compound 60 and 1-acetylpiperazine. m/z: 475.1 (M+H)+. Compound 192
Compound 192 (900 mg) was prepared following the procedure used to prepare Compound 149a, except that Compound 191 was used instead of Compound 148a. m/z: 385.0 (M÷H)\ Example EI
Example EI (151 mg) was prepared following the procedure used to prepare Compound 139a, except that Compound 192 was used instead of Compound 138a. m/z: 776.2 (M+H)+. 1H NMR (CD3OD) • 8.97 (1 H, s), 7.82 (1 H, s), 7.3-7.1 (11 H, m), 5.2 (2 H, s), 4.5 (2 H, m), 4.18 (2 H, m), 3.78 (1 H, m), 3.59 (4 H, m), 3.23 (1 H, m), 2.97 (3 H, s), 2.8-2.5 (4 H, m), 2.5-2.1 (6 H, m), 1.9-1.6 (2 H, m), 1.6-1.3 (10 H, m). Example ET
Example EI was purified with HPLC (chiral eel OD-H column by Chiral Technologies Inc, heptane/iPrOH = 70/30) to give Example EJ. m/z: 776.2 (M+H)+. 1H NMR (CDCl3) • 8.98 (s, IH); 7.90 (s, IH); 7.75 (m, IH); 7.40-7.00 (m, 15H), 6.55 (br s, IH); 5.92 (br s, IH); 7.75 (d, IH); 5.28, 5.19 (dAB, J=14 Hz, 2H); 4.70- 4.37 (m, 3H); 3.99 (m, 5H); 3.76 (br s, IH); 3.65-3.30 (m, 3H); 2.97 (m, 5H); 2.90-2.60 (m, 7H); 2.28 (br s, 2H); 1.91 (br s, 2H); 1.6-1.3 (m, 12H). Preparation of Example EK
Scheme 111
Figure imgf000385_0001
193 194
Figure imgf000385_0002
195 196
Figure imgf000385_0003
I. UAIH4, THF; II. PCS5, toluene; Ml. MeNH2In MeOH; IV.a. CDI/DIPEA; b. empd 169
Compound 193
Compound 193 was synthesized following the procedure from J. Med. Chem., 41(4), 1998, 602-617 (herein incorporated by reference in its entirety for all purposes). Compound 194
Compound 193 (1.4 g, 7 mmol) was dissolved in anhydrous THF (7 mL) and added drop wise over 1 hour into a 1 M LiAlH4 solution in THF stirring at 0 °C under nitrogen gas. The reaction mixture was then allowed to warm to room temperature and stirred for 1 hour, at which time HPLC showed that reaction was complete. The reaction mixture was cooled in an ice bath and methanol was slowly added. Aqueous potassium sodium tartarate solution was then added. The organic solution was extracted with ethyl acetate and then dried over anhydrous sodium sulfate and concentrated under reduced pressure to give Compound 194 (1 g, 91%), which was used in the next reaction without further purification. Compound 195
Compound 194 (1 g, 6.37 mmol) was dissolved in anhydrous toluene (6 mL). To the resulting solution was added PCl, (1.3 g, 6.37 mmol). After the reaction mixture was stirred for 1 hour, the reaction was complete. Solid sodium bicarbonate was added to the reaction mixture, which was then diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate solution, followed by saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield Compound 195 (0.91 g, 81%). Compound 196
Compound 195 (0.91 g, 5.2 mmol) was dissolved in 2 M methylamine in methanol (15 mL). The reaction mixture was stirred for 15 hours, then concentrated under reduced pressure. The resulting oil was dissolved in dilute aqueous HCl solution to give a solution with a pH of 2. The solution was then washed with ethyl acetate. The aqueous layer was concentrated under reduced pressure. The residue was purified by preparative HPLC to give Compound 196 (0.6 g, 56%). Example EK
Example EK (14 mg) was prepared following the procedure used to prepare Example DM(a), except that Compounds 169 and 196 were used instead of Compounds 140a and 9. 1H NMR (CD3OD): • 8.98 (S/ IH), 7.82 (s, IH), 7.55 (s, IH), 7.19 (m, 10H), 5.21 (m, 2H), 4.68 (m, 2H), 4.20 (m, IH), 4.15 (m, IH), 3.79 (m, IH), 3.64 (m, 4H), 3.25 (m, IH), 2.98 (s, 3H), 2.73 (m, 4H), 2.23-2.40 (m, 6H), 1.90- 1.70 (m, 2H), 1.51 (m, 4H), 1.36 (d, J=6.9 Hz, 6H). Mass Spectrum (m/e): (M+H)+ 776.3, (M-H)" 773.9 Preparation of Example EL
Scheme 112
Figure imgf000387_0001
i. a. 1 ,1-bis(methylthio)-2-nitroethylene/DMF; b. MeNH2/Me0H Example EL
Example W (71 mg, 0.1 mmol) and l,14ήs(methylthio)-2-nitroethylene (17 mg, 0.1 mmol) was dissolved in anhydrous DMF (2 mL). The resulting mixture was stirred at room temperature for 90 minutes, followed by another 16 hours at 400C. An additional 10% of l,l-bis(methylthio)-2-nitroethylene was added and the mixture was stirred at 60 0C for 8 hours. A solution of 2 M methylamine in methanol (1.2 mL, 2.4 mmol) was added and the mixture was stirred for 3 hours at room temperature. The mixture was diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product obtained was purified by flash silica gel column chromatography (3-10% MeOH in DCM). Final purification with Cls-reverse phase prep HPLC gave Example EL (55 mg, 68%). 1H NMR (CD3OD): • 8.97 (s, IH), 7.81 (S/ IH), 7.16 (m, 10H), 6.66 (s, IH), 5.20 (s, 2H), 4.54 (m, 2H), 4.17 (m, 2H), 3.80 (m, IH), 3.35 (s, 3H), 3.23 (m, IH), 3.00-2.80 (m, 9H), 2.63 (m, 3H), 1.60-1.43 (m, 6H), 1.33 (d, J=7.2 Hz, 6H). Mass Spectrum (m/e): (M+H)+ 806.3, (M-H)" 804.1. Preparation of Examples EM-EN
Scheme 113
Figure imgf000388_0001
122 197
Figure imgf000388_0002
i. TMS-i/EtOH; II, KCN/DMSO; III. NaOH/H2O/EtOH; IV. EDC,/HOBt/TEA/THF; V.a. HCi/MeOH; b. H2NSO2NH2
Compound 197
Compound 122 (460 mg, 1.5 mmol) was dissolved in anhydrous DCM. To the resulting solution was added EtOH (540 *L, 9.28 mmol), followed by TMS-I (663 »L, 4.6 mmol) drop wise. The mixture was stirred for 2 hours at room temperature. Additional TMS-I (200 #L) was added and the mixture was stirred for 1 hour. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOH and concentrated under reduced pressure. The residue was again dissolved in another portion of EtOH. The resulting oil was dissolved in anhydrous DMSO (5 mL). KCN was added, and the resulting mixture was stirred at room temperature for 16 hours. The mixture was diluted with ethyl acetate and "washed sequentially "with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified with flash silica gel column chromatography (EtOAc). The product (260 mg, 0.74 mmol) was dissolved in EtOH and stirred in an ice bath. NaOH (33 mg, 0.82 mmol) was dissolved in water and added to the EtOH solution in portions. The reaction mixture was acidified with 10% citric acid to a pH of 2-3 and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting Compound 197 (228 mg, 47%) was used in the next step without further purification. Example EM
Compound 197 (228 mg, 0.7 mmol) was dissolved in anhydrous THF (5 mL). EDC (202 mg, 1.05 mmol) and HOBt (162 mg, 1.05 mmol) were added to the solution and the resulting mixture was stirred for 30 minutes. Compound 8 (214 mg, 0.7 mmol) was added to the reaction mixture along with anhydrous DMF (3 mL) and TEA (294 »L, 2.11 mmol). The mixture was stirred for 90 minutes, then diluted with EtOAc and washed sequentially with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified with flash silica gel column chromatography (0-10% MeOH in DCM). Final purification with C18-reverse phase prep HPLC gave Example EM (291mg, 58%). 1H NMR (CD3OD): • 8.97 (s, IH), 7.83 (s, IH), 7.17 (m, 10H), 5.22 (s, 2H), 4.53 (s, 2H), 4.23 (m, IH), 4.06 (m, IH), 3.77 (m, IH), 3.27 (m, IH), 2.96 (s, 3H), 2.72 (m, 4H), 2.37 (m, 2H), 1.88 (m, 2H), 1.52 (m, 4H), 1.38 (d, J=7.2 Hz, 6H). Mass Spectrum (m/e): (M+H)1 716.2, (M-H)" 713.9. Example EN Example EM (120 mg, 0.168 mmol) was dissolved in anhydrous MeOH {5 mL) and concentrated under reduced pressure. This process was repeated twice with fresh portions of MeOH. The residue was dissolved in MeOH (5 mL) and stirred in an ice bath under nitrogen gas. HCl gas was bubbled into the MeOH solution for 5-10 minutes to saturate the solution. The reaction vessel was sealed and the reaction mixture was stirred at 0 °C for 8 hours. The reaction mixture was then concentrated under reduced pressure at room temperature. The residue was dissolved in EtOAc and washed twice with 10% aqueous sodium carbonate solution, followed by saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was dissolved in 2-methoxy ethanol (5 mL). Sulfamide (161 mg, 1.68 mmol) was added to the solution, which was stirred at 8O0C for 8 hours and then at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc and washed with saturated aqueous sodium bicarbonate solution, followed by saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude material was purified with flash silica gel column chromatography (0-10% MeOH in EXZM). Final purification with C1B-reverse phase prep HPLC gave Example EN (16 mg, 12%). 1H NMR (CD3OD): • 8.98 (s, IH), 7.83 (s, IH), 7.67 (m, IH), 7.16 (m, 10H), 6.82 (m, IH), 5.21 (s, 2H), 4.53 (m, 2H), 4.15 (m, 2H), 3.77 (m, IH), 3.28 (m, IH), 2.96 (s, 3H), 2.68 (m, 4H), 2.21 (m, 2H), 1.88 (m, 2H), 1.45 (m, 4H), 1.35 (d, J=7.2 Hz, 6H). Mass Spectrum (m/e): (M+H)" 812.1, (M-H)" 810.0. Preparation of Example EO Scheme 114
Figure imgf000391_0001
i. a. cmpd 169/CDI/DiPEA; b. cmpd 68 Compound 68
Compound 68 was synthesized following the procedure described in WO2008 /010921 A2. Example EO
Example EO (39 mg) was prepared following the procedure used to prepare Example DM(a), except that Compounds 68 and 169 were used instead of Compounds 140a and 9. 1H NMR (CD3OD): • 8.98 (s, IH), 8.93 (s, IH), 7.82 (s, 2H)x 7.19 (m, 10H), 5.21 (s, 2H), 4.60 (m, 2H), 4.20 (m, IH), 4.10 (m, IH), 3.77 (m, IH), 3.64 (m, 4H), 2.93 (s, 3H), 2.74 (m, 4H), 2.38-2.28 (m, 6H), 1.84-1.70 (m, 2H), 1.50 (m, 4H). Mass Spectrum (m/c): (M+H)+ 734.3, (M-H)" 731.9
Preparation of Example EF-EO Scheme 115
Figure imgf000392_0001
198 199
Figure imgf000392_0002
I. cmpd 46/EDC/HOBt/DIPEA; Ii. HCI/dioxane; TBSCI/pyridine; IV. a. CDi/DIPEA; b.crπpd 68; V. HCI/dioxane
Compound 198
Compound 198 was obtained from Aldrich. Compound 199
Compound 198 (205 mg, 1 mmol) was mixed with Compound 46 (446 mg, 1 mmol) and HOBt (230 mg, 1.5 mmol) in anhydrous DMF (5 mL). EDC (230mg, 1.2 mmol) was then added. The resulting mixture was stirred for 30 minutes. DIPEA (348 »L, 2 mmol) was added. The mixture was stirred for 2 hours, then diluted with EtOAc, washed sequentially with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude material was purified with flash silica gel column chromatography (0400% EtOAc in DCM) to give Compound 199 (345 mg, 58%). Compound 200
Compound 199 (345 mg, 0.58 mmol) was dissolved in a small amount of MeOH. A solution of 4 N HCl in dioxane (5 mL) was added. The resulting mixture was stirred for 1 hour and concentrated under reduced pressure. The residue was dissolved in EtOAc and washed sequentially with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was dissolved in anhydrous DCM (10 mL). Pyridine (163 »L, 2 mmol) and t-butyldimethylsilyl chloride (166 mg, 1.1 mmol) were added. The resulting mixture was stirred for 15 hours. More pyridine (163 •L) and TBS-Cl (60 mg) were added. The resulting mixture was stirred for another 24 hours. The mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc and washed sequentially with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude material was purified by flash silica gel column chromatography (0-5% MeOH in DCM) to give Compound 200 (248 mg, 69%). Example EP
Example EP was prepared following the procedure used to prepare Example DM(a), except that Compounds 200 and 68 were used instead of Compounds 140a and 9. Example EQ
To Example EP was added 4 N HCl in dioxane (4 mL). The mixture was stirred for 1 hour and the solvent was evaporated. The residue was diluted with EtOAc, and washed sequentially with saturated aqueous sodium carbonate, water, and brine. The organic layer was dried over Na2SO4, then concentrated. The residue was purified by flash column chromatography (10% iPrOH in DCM) to give Example EQ (35 mg). 1H NMR (CD3OD): δ 8.97 (s, IH), 8.89 (s, IH), 7.81 (s, 2H), 7.70 (m, IH), 7.19 (m, 10H), 6.92 (m, IH), 5.20 (s, 2H), 4.73 (m, 2H), 4.22 (m, IH), 4.13 (m, IH), 3.78 (m, IH), 3.56 (d, J=5.4Hz, 2H), 3.31 (m, IH), 2.94 (s, 3H), 2.67 (m, 4H), 1.45 (m, 4H). Mass Spectrum (m/e): (MH-H)+ 651.2, (M-H)" 648.8.
ICso Determinations for Human Liver Cytochrome P450
Materials and General Methods
Pooled (n > 15 donors) human hepatic microsomal fraction was obtained from BD-Gentest (Woburn, MA) who also supplied hydroxy-terfenadine, 4'- hydroxydiclofenac and NADPH regenerating system. Ritonavir was prepared from commercial Norvir® oral solution (Abbott Laboratories, Abbott Park, IL). Other reagents were from Sigma- Aldrich (St. Louis, MO) and included terfenadine, fexofenadine, BRL 15572, diclofenac and mefenamic acid.
Incubations were performed in duplicate in 50 mM potassium phosphate buffer, pH 7.4 with NADPH regenerating system used as described by the manufacturer. The final microsomal protein concentrations had previously been determined to be within the linear range for activity and resulted in less than 20% consumption of substrate over the course of the incubation. The final substrate concentrations used were equal to the apparent Km values for the activities determined under the same conditions. Inhibitors were dissolved in DMSO, and the final concentration of DMSO, from both substrate and inhibitor vehicles, was 1% (v/v). Incubations were performed at 370C with shaking and were initiated by addition of substrate. Aliquots were then removed at 0, 7 and 15 minutes. Samples were quenched by treatment with an acetonitrile, formic acid, water (94.8%/0.2%/5%, v/v/v) mixture containing internal standard. Precipitated protein was removed by centrifugation at 3000 rpm for 10 min and aliquots of the supernatant were then subjected to LC-MS analysis.
The LC-MS system consisted of a Waters Acquity UPLC, with a binary solvent manager and a refrigerated (8°C) sample organizer and sample manager, interfaced to a Micromass Quattro Premier tandem mass spectrometer operating in electrospray ionization mode. The column was a Waters Acquity UPLC BEH CiS 2.1 x 50 mm, 1.7 μm pore size. Mobile phases consisted of mixtures of acetonitrile, formic acid and water, the composition for mobile phase A being l%/0.2%/98.8% (v/v/v) and that for mobile phase B being 94.8%/0.2%/5% (v/v/v). The injection volumes were 5 μL and the flow rate was 0.8 mL/min. Concentrations of metabolites were determined by reference to standard curves generated with authentic analytes under the same conditions as the incubations.
IC50 values (the concentration of inhibitor reducing CYP3A activity by 50%) were calculated by non-linear regression using GraphPad Prism 4.0 software and a sigmoidal model.
CYP3A Inhibition Assay
The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using terfenadine oxidase, a well-characterized CYP3A-selective activity described in Ling, K.-H.J., et al Drug Metab. Dispos. 23, 631-636, (1995) and Jurima- Romet, et al Drug Metab, Dispos. 22, 849-857, (1994). The final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 3 μM, respectively. Metabolic reactions were terminated by treatment with seven volumes of quench solution containing 0.1 μM BRL 15572 as internal standard. A further 8 volumes of water were added before centrifugation and aliquots of the supernatant were removed for analysis. For LC-MS analysis chromatographic elution was achieved by a series of linear gradients starting at 20% B and holding for 0.1 minutes, then increasing to 80% B over 1.5 minutes, holding for 0.4 minutes and then returning to the starting conditions for 0.05 min. The system was allowed to re-equilibrate for at least 0.25 minutes prior to the next injection. The mass spectrometer was operated in positive ion mode and the following precursor ([M+H]+)/product ion pairs were monitored and quantified using MassLynx 4.0 (SP4, 525) software: hydroxy- terfenadine 488.7/452.4, fexofenadine 502.7/466.4 and BRL 15572 407.5/209.1. Terfenadine oxidase activity was determined from the sum of hydroxy- terfenadine and carboxy-terfenadine (fexofenadine) metabolites.
CYP2C9 Inhibition Assay
The potencies of the compounds as inhibitors of human hepatic CYP2C9 were assessed using diclofenac 4' -hydroxylase, an activity specific for this enzyme, as described in Leeman, T., et al Life Sd. 52, 29-34, (1992). The final concentrations of microsomal protein and diclofenac substrate were 0.08 mg/mL and 4 μM, respectively. Metabolic reactions were terminated by treatment with three volumes of quench solution containing 1 μM mefenamic acid as internal standard. After centrifugation a further 4 volumes of water were added. Aliquots of the supernatant were then subjected to LC-MS analysis.
For LC-MS analysis chromatographic elution was achieved by a series of linear gradients starting at 20% B and holding for 0.3 minutes, then increasing to 99% B over 1.2 minutes, holding for 0.5 minutes and then returning to the starting conditions for 0.25 min. The system was allowed to re-equilibrate for at least 0.25 minutes prior to the next injection. The mass spectrometer was operated in negative ion mode and the following precursor ([M-Hj-)/product ion pairs were monitored and quantified: 4'-hydroxy-didofenac 312.4/294.2 and mefenamic acid 242.4/224.2. Biological Assays Used for the Characterization of HIV Protease Inhibitors
HIV-I Protease Enzyme Assay (Ki)
The assay is based on the fluorimetric detection of synthetic hexapeptide substrate cleavage by HIV-I protease in a defined reaction buffer as initially described by M.V. Toth and G.R.Marshall, Int. T. Peptide Protein Res. 36, 544 (1990) (herein incorporated by reference in its entirety for all purposes).
The assay employed (2-aminobenzoyl)Thr-ϊle-Nle-(p-nitro)Phe-Gm-Arg as the substrate and recombinant HIV-I protease expressed in E. CoIi as the enzyme. Both of the reagents were supplied by Bachem California, Inc. (Torrance, CA; Cat. no. H-2992). The buffer for this reaction was 100 mM ammonium acetate, pH 5.3, 1 M sodium chloride, 1 mM ethylendiaminetetraacetic acid, 1 mM dithiothreitol, and 10% dimethylsulfoxide.
To determine the inhibition constant Ki, a series of solutions were prepared containing identical amount of the enzyme (1 to 2.5 nM) and the inhibitor to be tested at different concentrations in the reaction buffer. The solutions were subsequently transferred into a white 96-well plate (190 μl each) and preincubated for 15 min at 37 0C The substrate was solublized in 100% dimethylsulfoxide at a concentration of 800 μM and 10 μl of 800 μM substrate was added into each well to reach a final substrate concentration of 40 μM. The real-time reaction kinetics was measured at 37 0C using a Gemini 96-well plate fluorimeter (Molecular Devices, Sunnyvale, CA) at λ(Ex) = 330 nm and λ(Em) = 420 ran. Initial velocities of the reactions with different inhibitor concentrations were determined and the Ki value (in picomolar concentration units) was calculated by using EnzFitter program (Biosoft, Cambridge, U.K.) according to an algorithm for tight-binding competitive inhibition described by Ermolieff J., Lin X., and Tang J., Biochemistry 36, 12364 (1997). HIV-I Protease Enzyme Assay (IC50)
As for the Ki assay, above, the IC50 assay is based on the fluorimetric detection of synthetic hexapeptide substrate cleavage by HIV-I protease in a defined reaction buffer as initially described by M.V. Toth and G.R.Marshall, Int. T. Peptide Protein Res. 36, 544 (1990).
The assay employed (2-aminobenzoyl)Thr-Ile-Nle-(p-nitro)Phe-Gln-Arg as the substrate and recombinant HIV-I protease expressed in E.Coli as the enzyme. Both of the reagents were supplied by Bachem California, Inc. (Torrance, CA; Cat. nos. H-2992 and H-9040, respectively). The buffer for this reaction was 100 mM ammonium acetate, pH 5.5, 1 M sodium chloride, 1 mM ethylendiaminetetraacetic acid, and 1 mM dithiothreitol, and 10% dim ethylsulf oxide.
To determine the IC50 value, 170 μL of reaction buffer was transferred into the wells of a white 96- well microti ter plate. A series of 3-fold dilutions in DMSO of the inhibitor to be tested was prepared, and 10 μL of the resulting dilutions was transferred into the wells of the microtiter plate. 10 μL of a 20-50 nM enzyme stock solution in reaction buffer was added to each well of the 96-well plate to provide a final enzyme concentration of 1-2.5 nM. The plates were then preincubated for 10 minutes at 37QC. The substrate was solublized in 100% dimethylsulf oxide at a concentration of 400 μM and 10 μl of the 400 μM substrate was added into each well to reach a final substrate concentration of 20 μM. The real-time reaction kinetics were measured using a Gemini 96-well plate fluorimeter (Molecular Devices, Sunnyvale, CA) at A(Ex) = 330 nm and A(Em) = 420 nm. Initial velocities of the reactions with different inhibitor concentrations were determined and the ICso value (in nanomolar concentration units) was calculated by using GraphPad Prism™ software to fit nonlinear regression curves. Anti-HIV-1 Cell Culture Assay (EC50)
The assay is based on quantification of the HIV-I -associated cytopathic effect by a colorimetric detection of the viability of virus-infected cells in the presence or absence of tested inhibitors. HIV-1-induced cell death was determined using a metabolic substrate 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)- 2H-tetrazolium-5-carboxanilide (XTT) which is converted only by intact cells into a product with specific absorption characteristics as described by Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH and Boyd MR, T, Natl. Cancer Inst. 81, 577 (1989) (herein incorporated by reference in its entirety for all purposes).
MT2 cells (NIH AIDS reagent program, Cat # 237) maintained in RPMI- 1640 medium supplemented with 5% fetal bovine serum and antibiotics were infected with the wild-type HIV-I strain HIB (Advanced Biotechnologies, Columbia, MD) for 3 hours at 37 0C using the virus inoculum corresponding to a multiplicity of infection equal to 0.01. The infected cells in culture media were distributed into a 96-well plate (20,000 cells in 100 μl/well), and incubated in the presence of a set of solutions containing 5-fold serial dilutions of the tested inhibitor (100 μl/well) for 5 days at 37 0C. Samples with untreated infected and untreated mock-infected control cells were also distributed to the 96-well plate and incubated under the same conditions.
To determine the antiviral activity of the tested inhibitors, a substrate XTT solution (6 mL per assay plate) at a concentration of 2 mg/mL in a phosphate- buffered saline pH 7.4 was heated in water-bath for 5 min at 55 0C before 50 μl of N-methylphenazonium methasulfate (5 μg/mL) was added per 6 mL of XTT solution. After removing 100 μl media from each well on the assay plate, 100 μl of the XTT substrate solution was added to each well. The cells and the XTT solution were incubated at 37 0C for 45 to 60 min in a CO2 incubator. To inactivate the virus, 20 μl of 2% Triton X-100 was added to each well. Viability, as determined by the amount of XTT metabolites produced, was quantified spectrophotometrically by the absorbance at 450 nm (with subtraction of the background absorbance at 650 run). Data from the assay was expressed as the percentage absorbance relative to untreated control and the fifty percent effective concentration (ECso) was calculated as the concentration of compound that effected an increase in the percentage of XTT metabolite production in infected/ compound treated cells to 50% of that produced by uninfected, compound-free cells.
Anti-HIV-1 Cell Culture Assay (ECso) in presence of 40% Human Serum or Human Serum Proteins
This assay is almost identical to the Anti-HIV-1 Cell Culture Assay described above, except that the infection was made in the presence or absence of 40% human serum (Type AB Male Cambrex 14-498E) or human serum proteins (Human α-acid Glycoprotein, Sigma G-9885; Human Serum Albumin, Sigma A1653, 96-99%) at physiological concentration. The HIV-I -induced cell death was determined as described above, except that the infected cells distributed in the 96- well plate were incubated in 80% Human Serum (2X concentration) or in 2 mg/mL Human α-acid Glycoprotein + 70 mg/mL HSA (2X concentration) rather than in culture media. Cytotoxicity Cell Culture Assay (CCso)
The assay is based on the evaluation of cytotoxic effect of tested compounds using a metabolic substrate 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium- 5-carboxanilide (XTT) as described by Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH and Boyd MR, T. Natl. Cancer Inst. 81, 577 (1989). This assay is almost identical to the previous assay described (Anti-HIV-1 Cell Culture Assay), except that the cells were not infected. The compound induced cell death (or growth reduction) was determined as previously described.
MT-2 cells maintained in RPMI-1640 medium supplemented with 5% fetal bovine serum and antibiotics were distributed into a 96-well plate (20,000 cells in 100 μl/well) and incubated in the presence or absence of 5-fold serial dilutions of the tested inhibitor (100 μl/well) for 5 days at 37 0C. Controls included untreated infected cells and infected cells protected by 1 μM of P4405 (Podophyllotoxin, Sigma Cat # P4405).
To determine cytotoxicity, an XTT solution (6 mL per assay plate) at a concentration of 2 mg/mL in phosphate-buffered saline pH 7.4 was heated in the dark in a water-bath for 5 min at 55 0C before 50 μl of N-methylphenazonium methasulfate (5 μg/mL) was added per 6 mL of XTT solution. After removing 100 μL media from each well on the assay plate, 100 μL of the XTT substrate solution was added to each well. The cells and the XTT solution were incubated at 37 °C for 45 to 60 min in a CO2 incubator. To inactivate the virus, 20 μl of 2% Triton X- 100 was added to each well. Viability, as determined by the amount of XTT metabolites produced, is quantified spectrophotometrically by the absorbance at 450 nm (with subtraction of the background absorbance at 650 nm). Data from the assay is expressed as the percentage absorbance relative to untreated control, and the fifty percent cytotoxicity concentration (ECso) was calculated as the concentration of compound that effected an increase in the percentage of cell growth in compound treated cells to 50% of the cell growth provided by uninfected, compound -free cells.
Experimental data based on representative Examples A-EQ demonstrate that the compounds of Formula (IV) of the present invention can have a CYP450 3A4 inhibition activity in a range represented by an ICso from about 100 nM to about 4700 nM, and a CYP450 2C9 inhibition activity in a range represented by an ICso from about 100 nM to about 10,000 nM.
Experimental data based on representative Examples A-EQ demonstrate that the compounds of Formula (IV) of the present invention can have a protease inhibition activity in a range represented by HIV ECso from about 140 nM to greater than about 30000 nM.
Experimental data based on representative Examples P, S, and T have a CYP450 3A4 inhibition activity in a range represented by an IC50 from about 80- 150 nM, a CYP450 2C9 inhibition activity in a range represented by an ICso from about 1000-10,000 nM, and a protease inhibition activity in a range represented by HIV ECso greater than about 30,000 nM.

Claims

What is Claimed:
1. A compound of formula IV,
Figure imgf000403_0001
Formula IV or a pharmaceutically acceptable salt, solvate, and/or ester thereof, wherein, each L3 is independently an alkylene or substituted alkylene; each A is independently an aryl or substituted aryl;
X is heterocyclylalkyl;
Y is heterocyclylalkyl or alkyl;
G1 and G2 are independently CH or N, with the proviso that G1 and G2 are different;
G3 is -NR7- or -O-;
R1, R3, R5, and R7 are each independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyL and substituted arylalkyl;
R2 is independently selected from the group consisting of substituted alkyl, alkoxy alkyl, hydroxy alkyl, trialkylsiloxy alkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl substituted aminoalkyl, -alkylene-N(Ra)-C{O)- alkyl, -aIkylene-NRa-C(O)-N(Ra)2, -alkylene-NRa-C(=N-Rb)-N(Ra)2, -alkylene- C(=N-Rb)-N(Ra)2, -alkylene-C(O)-OH, -alkylene-C(O)-Oalkyl, and -alkylene-
Figure imgf000403_0002
R8 and R9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, and -CN; each Ra is independently selected from the group consisting of H, alkyl, and substituted alkyl; Rb is selected from the group consisting of H, alkyl, substituted alkyl, CN, and -
S(Oz)-alkyl; and each Rc is independently selected from the group consisting of H, alkyl, substituted alkyl, heterocyclyl, substituted heterocyclyl, -S (O2)- alkyl, -S(θ2)- aryl, and substituted -S(O2)-aryl.
2. The compound of claim 1, having the following formula:
HN-R
wherein Rd is selected from the group consisting of H, haloalkyl, -C(O)-N (Ra)2, - C<-N-Rb)-N<Ra)2, hydroxyalkyl,
Figure imgf000404_0001
-C(O)-alkyl
3. The compound of claim 1, having the following formula:
Figure imgf000404_0002
4. The compound of claim 3, wherein said Heterocyclyl is a substituted or unsubstituted heteroaryl.
5. The compound of claim 4, wherein said heteroaryl is selected from the group consisting of triazolyl, pyrrolyl, imidazolyl, pyridyl, pyrazolyl, and imidazolidin-dionyl.
6. The compound of claim 3, wherein said Heterocyclyl is a substituted or unsubstituted heterocycloalkyl.
7. The compound of claim 6, wherein said heterocycloalkyl is selected from the group consisting of pyrrolidinonyl, pyrrolidine-dionyl, oxazolidinonyl, pyrrolidinyl, piperidinyl, piperidinonyL piperazinyl, thiomorpholinyl, and morpholinyl.
8. The compound of claim 7, wherein said heterocycloalkyl is morpholinyl.
9. The compound of claim 1, having the following formula:
Figure imgf000405_0001
wherein Q is -OH or -N(Ra)2.
10. The compound of claim 9, wherein Q is -OH.
11. The compound of claim 9, wherein Q is -NHR1V and Ra is substituted or unsubstituted heterocyclyl or sulfonylalkyl.
12. The compound of claim 1, having the following formula:
Figure imgf000405_0002
wherein M is substituted alkyl.
13. The compound of claim 12, wherein said substituted alkyl is selected from hydroxyalkyi, substituted hydroxyalkyl, cyanoalkyl, substituted cyanoalkyl, and trialkylsiloxyalkyl.
14. The compound of claim I7 having the following formula:
Figure imgf000406_0001
15. The compound of claim 1, having the following formula:
Figure imgf000406_0002
16. The compound of claim 15, wherein R8 is H.
17. The compound of claim 15, wherein R2 is aminoalkyl or heterocyclylalkyl.
18. The compound of claim 1, selected from the group consisting of:
Figure imgf000407_0001
Figure imgf000408_0001
Figure imgf000409_0001
408
Figure imgf000410_0001
Figure imgf000411_0001
410
Figure imgf000412_0001
Figure imgf000413_0001
412
Figure imgf000414_0001
Figure imgf000415_0001
414
Figure imgf000416_0001
Figure imgf000417_0001
Figure imgf000418_0001
19. A compound which is:
Figure imgf000418_0002
or a pharmaceutically acceptable salt, ester, and/or solvate thereof.
20. A compound which is
Figure imgf000418_0003
or a pharmaceutically acceptable salt, ester, and/or solvate thereof.
21. A compound which is
Figure imgf000418_0004
or a pharmaceutically acceptable salt, ester, and/or solvate thereof.
22. A method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
23. The method of claim 22 wherein said administering comprises administering a therapeutically effective amount of a combination comprising said drug and the compound of Formula IV or a pharmaceutically acceptable salt, solvate, and/or ester of the compound of Formula IV.
24. The method of claim 22, wherein the drug metabolized by cytochrome P450 is an HIV protease inhibiting compound, an HIV non-nucleoside inhibitor of reverse transcriptase, an HIV nucleoside inhibitor of reverse transcriptase, HIV nucleotide inhibitor of reverse transcriptase, an HIV integrase inhibitor, a gp41 inhibitor, a CXCR4 inhibitor, a gρl20 inhibitor, a CCR5 inhibitor, capsid polymerization inhibitors, other drugs for treating HIV, an interferon, ribavirin analog, NS3 protease inhibitor, alpha-glucosidase 1 inhibitor, hepatoprotectant, non~nucleoside inhibitor of HCV, NS5a inhibitors, NS5b polymerase inhibitors, other drugs for treating HCV, or mixtures thereof.
25. The method of claim 23, wherein the drug and the compound or pharmaceutically acceptable salt, solvate, and/or ester thereof of claim 1 is administered as a single composition to the patient.
26. The method of claim 22, wherein said improving is increasing blood plasma levels of the drug which is metabolized by cytochrome P450 monooxygenase.
27. A method for inhibiting cytochrome P450 monooxygenase in a patient comprising administering to a patient in need thereof an amount of a compound of claim 1, or a pharmaceutically acceptable salt solvate, and/or ester thereof/ effective to inhibit cytochrome P450 monooxygenase.
28. A method for treating an HIV infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, In combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp!20 inhibitors, G 6PD and NADH-oxidase inhibitors, CCR5 inhibitors, other drugs for treating HIV, and mixtures thereof.
29. The method of claim 28, wherein:
(1) said HIV protease inhibitors are selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC- 114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DGl 7, PPL-100, DG35, and AG 1859; (2) said HIV non-nucleoside inhibitors of reverse transcriptase are selected from the group consisting of capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, TMC-120, TMC-278 (rilpivirene), BILR 355 BS, VRX 840773, UK-453061, and RDEA806;
(3) said HIV nucleoside inhibitors of reverse transcriptase are selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±-FTC), D-d4FC, phosphazide, fozivudine tidoxil, apricitibine (AVX754), amdoxovir, KP-1461, and fosalvudine tidoxil (formerly HDP 99.0003);
(4) said HIV nucleotide inhibitors of reverse transcriptase are selected from the group consisting of tenofovir disoproxil fumarate, GS-9131, and adefovir dipivoxil;
(5) said HIV integrase inhibitors are selected from the group consisting of curcumin, derivatives of curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5- dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurin tricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, L-870810, MK-0518 (raltegravir), elvitegravir, BMS- 538158, GSK364735C, BMS-707035, MK-2048, and BA 011;
(6) said gp41 inhibitor are selected from the group consisting of enfuvirtide, sifuvirtide, FB006M, and TRI-1144;
(7) said CXCR4 inhibitor is AMD-070;
(8) said entry inhibitor is SPOlA;
(9) said gp!20 inhibitor is BMS-488043 or BlockAide/ CR;
(10) said G6PD and NADH-oxidase inhibitor is immunitin; (11) said CCR5 inhibitors are selected from the group consisting of aplaviroc, vicriviroc, maraviroc, PRO-140, INCB15050, PF-232798 (Pfizer), and CCR5mAb004;
(12) said other drugs for treating HIV are selected from the group consisting of BAS-100, SPI-452, REP 9, SP-OlA, TNX-355, DES6, ODN-93, ODN- 112, VGV-I, PA-457 (bevirimat), Ampligen, HRG214, Cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007 A-221 HIV, DEBIO-025, BAY 50-4798, MDXOlO (ipilimumab), PBS 119, ALG 889, and PA-1050040 (PA-040).
30. A method for treating an HCV infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of interferons, ribavirin analogs, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, or mixtures thereof.
31. The method of claim 30, wherein:
(1) said interferons are selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infer gen), feron, reaferon, intermax alpha, r-IFN-beta, infer gen + actimmune, IFN-omega with DUROS, albuferon, locteron, Albuferon, Rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and Pegylated IFN- beta;
(2) said ribavirin analogs are selected from the group consisting of rebetol, copegus, and viramidine (taribavirin); (3) said NS5b polymerase inhibitors are selected from the group consisting of NM-283, valopicitabine, Rl 626, PSI-6130 (Rl 656), HCV-796, BILB 1941, XTL- 2125, MK-0608, NM-107, R7128 (R4048), VCH-759, PF-868554, and GSK625433;
(4) said NS3 protease inhibitor are selected from the group consisting of SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339, and ITMN- 191;
(5) said alpha-glucosidase 1 inhibitors are selected from the group consisting of MX-3253 (celgosivir) and UT-231B;
(6) said hepatoprotectants are selected from the group consisting of IDN- 6556, ME 3738, LB-84451, and MitoQ;
(7) said non-nucleoside inhibitors of HCV are selected from the group consisting of benzimidazole derivatives, benzo-l,2,4-thiadiazine derivatives, phenylalanine derivatives, A-831, and A-689; and
(8) said other drugs for treating HCV are selected from the group consisting of zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL- 6865, ANA 971, NOV-205, tarvacin, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, Bavituximab, Oglufanide, and VX-497 (merimepodib).
32. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and a pharmaceutically acceptable carrier or exipient.
33. The pharmaceutical composition of claim 32, further comprising at least one additional therapeutic agent metabolized by cytochrome P450.
34. The pharmaceutical composition of claim 33, wherein the at least one additional therapeutic agent is selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp!20 inhibitors, CCR5 inhibitors/ capsid polymerization inhibitors, interferons, ribavirin analogs, NS3 protease inhibitors, alpha- glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, other drugs for treating HCV, and combinations thereof.
35. The pharmaceutical composition of claim 34, wherein:
(1) said HIV protease inhibitors are selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-100, DG35, and AG 1859;
(2) said HIV non-nucleoside inhibitors of reverse transcriptase are selected from the group consisting of capravirine, emivirine, delaviridine, ef avirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, and TMC-120, TMC-278 (rilpivirene), efavirenz, BILR 355 BS, VRX 840773, UK-453061, and RDEA806;
(3) said HIV nucleoside inhibitors of reverse transcriptase are selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abaca vir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±-FTC), D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, apricitibine (AVX754), amdoxovir, KP-1461, and fosalvudine tidoxil (formerly HDP 99.0003), ; (4) said HIV nucleotide inhibitors of reverse transcriptase are selected from the group consisting of tenofovir disoproxil fumarate, GS-9131, and adefovir dipivoxil;
(5) said HIV integrase inhibitors are selected from the group consisting of curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5- dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyϊ ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, and L- 870810, MK-0518 (raltegravir), elvitegravir, BMS-538158, GSK364735C, BMS- 707035, MK-2048, and BA Oil;
(6) said gp41 inhibitor are selected from the group consisting of enfuvirtide, sifuvirtide, FB006M, and TRI-1144;
(7) said CXCR4 inhibitor is AMD-070;
(8) said entry inhibitor is SPOlA;
(9) said gpl20 inhibitor is BMS-488043 or BlockAide/ CR;
(10) said G6PD and NADH-oxidase inhibitor is immunitin;
(11) said CCR5 inhibitors are selected from the group consisting of aplaviroc, vicriviroc, maraviroc, PRO-140, INCB15050, PF-232798 (Pfizer), and CCR5mAb004;
(12) said other drugs for treating HIV are selected from the group consisting of BAS-100, SPI-452, REP 9, SP-OlA, TNX-355, DES6, ODN-93, ODN- 112, VGV-I, PA-457 (bevirimat), Ampligen, HRG214, Cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDXOlO (ipilimumab), PBS 119, ALG 889, and PA-1050040 (PA-040);
(13) said interferons are selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rlFN-alpha 2a, rlFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), feron, reaferon, intermax alpha, r-IFN-beta, infergen + actimmune, IFN-omega with DUROS, albuferon, locteroπ, Albuferon, Rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and Pegylated IFN- beta;
(14) said ribavirin analogs are selected from the group consisting of rebetol, copegus, and viramidine (taribavirin);
(15) said NS5b polymerase inhibitors are selected from the group consisting of NM-283, valopidtabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048), VCH-759, PF-868554, and GSK625433;
(16) said NS3 protease inhibitor are selected from the group consisting of SCH-503034 (SCH-T), VX-950 (telaprevir), BILN-2065, BMS-605339, and ITMN- 191;
(17) said alpha-glucosidase 1 inhibitors are selected from the group consisting of MX-3253 (celgosivir) and UT-231B;
(18) said hepatoprotectants are selected from the group consisting of IDN- 6556, ME 3738, LB-84451, and MitoQ;
(19) said non-nucleoside inhibitors of HCV are selected from the group consisting of benzimidazole derivatives, benzo-l,2,4-thiadiazine derivatives, phenylalanine derivatives, A-831, and A-689; and
(20) said other drugs for treating HCV are selected from the group consisting of zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL- 6865, ANA 971, NOV-205, tarvacin, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, Bavituximab, Oglufanide, and VX-497 (merimepodib).
36. A new pharmaceutical composition or use for the preparation of a medicament, comprising a compound of claim 1.
37. A compound of claim 1 as a therapeutic substance.
38. The use of a compound of claim 1 for the manufacture of a medicament for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, increasing the blood plasma level of a drug which is metabolized by cytochrome P450 monooxygenase, inhibiting cytochrome P450 monooxygenase, treating an HIV infection, or treating an HCV infection in a patient.
39. The use of claim 38, wherein said drug which is metabolized by cytochrome P450 monooxygenase is an HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gpl20 inhibitors, G6PD and NADH-oxidase inhibitors, CCR5 inhibitors, other drugs for treating HIV, an interferon, ribavirin analog, NS3 protease inhibitor, alpha-glucosidase 1 inhibitor, hep atop rotectant, non-nucleoside inhibitor of HCV, and other drugs for treating HCV, or mixtures thereof.
40. The use of claim 39, wherein said medicament is a combination of a compound of claim 1 and one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gpl20 inhibitors, G6PD and NADH- oxidase inhibitors, CCR5 inhibitors, other drugs for treating HIV, interferons, ribavirin analogs, NS5b polymerase inhibitors, NS3 protease inhibitors, alpha- glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV7 and other drugs for treating HCV, and mixtures thereof.
41. The use of claim 40, wherein:
(1) said HIV protease inhibitors are selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-IOO7 DG35, and AG 1859;
(2) said HIV non-nucleoside inhibitors of reverse transcriptase are selected from the group consisting of capravirine, emivirine, delaviridine, ef avirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, and TMC-120, TMC-278 (rilpivirene), efavirenz, BILR 355 BS, VRX 840773, UK-453061, and RDEA806;
(3) said HIV nucleoside inhibitors of reverse transcriptase are selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±-FTC), D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, apricitibine (AVX754), amdoxovir, KP-1461, and fosalvudine tidoxil (formerly HDP 99.0003), ;
(4) said HIV nucleotide inhibitors of reverse transcriptase are selected from the group consisting of tenofovir disoproxil fumarate, GS-9131, and adefovir dipivoxil;
(5) said HIV integrase inhibitors are selected from the group consisting of curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5- dicaffeoylquinic acid, derivatives of 3,5-dkaffeoyIquinic acid, aurin tricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, and L- 870810, MK-0518 (raltegravir), elvitegravir, BMS-538158, GSK364735C, BMS- 707035, MK-2048, and BA 011;
(6) said gp41 inhibitor are selected from the group consisting of enfuvirtide, sifuvirtide, FB006M, and TRI-1144;
(7) said CXCR4 inhibitor is AMD-070;
(8) said entry inhibitor is SPOlA;
(9) said gpl20 inhibitor is BMS-488043 or BlockAide/ CR;
(10) said G6PD and NADH-oxidase inhibitor is immunitin;
(11) said CCR5 inhibitors are selected from the group consisting of aplaviroc, vicriviroc, maraviroc, PRO-MO, INCB15050, PF-232798 (Pfizer), and CCR5mAbOO4;
(12) said other drugs for treating HIV are selected from the group consisting of BAS-100, SPI-452, REP 9, SP-OlA, TNX-355, DES6, ODN-93, ODN- 112, VGV-I, PA-457 (bevirimat), Ampligen, HRG214, Cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDXOlO (ipilimumab), PBS 119, ALG 889, and PA-1050040 (PA-040);
(13) said interferons are selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rlFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), feron, reaferon, intermax alpha, r-IFN-beta, infergen + actimmune, IFN-omega with DUROS, albuferon, locteron, Albuferon, Rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and Pegylated IFN- beta; (14) said ribavirin analogs are selected from the group consisting of rebetol, copegus, and viramidine (taribavirin);
(15) said NS5b polymerase inhibitors are selected from the group consisting of NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048), VCH-759, PF-868554, and GSK625433;
(16) said NS3 protease inhibitor are selected from the group consisting of SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339, and ITMN- 191;
(17) said alpha-glucosidase 1 inhibitors are selected from the group consisting of MX-3253 (celgosivir) and UT-231B;
(18) said hepatoprotectants are selected from the group consisting of IDN- 6556, ME 37387 LB-84451, and MitoQ;
(19) said non-nucleoside inhibitors of HCV are selected from the group consisting of benzimidazole derivatives, benzo-l,2,4-thiadiazine derivatives, phenylalanine derivatives, A-831, and A-689; and
(20) said other drugs for treating HCV are selected from the group consisting of zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL- 6865, ANA 971, NOV-205, tarvacin, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, Bavituximab, Oglufanide, and VX-497 (merimepodib).
PCT/US2008/054788 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics WO2008103949A1 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
EP16180589.0A EP3150586B1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
ES08743531.9T ES2525454T3 (en) 2007-02-23 2008-02-22 Modulators of the pharmacokinetic properties of therapeutic agents
EP19219599.8A EP3689353A1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
US12/528,185 US9891239B2 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
AU2008218186A AU2008218186C1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
PL16180589T PL3150586T3 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
CA2678907A CA2678907C (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
EP24169258.1A EP4403221A3 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
NZ579802A NZ579802A (en) 2007-02-23 2008-02-22 Compounds for improving the efficacy of other drugs
BRPI0807581-6A2A BRPI0807581A2 (en) 2007-02-23 2008-02-22 PHARMACKINETIC PROPERTY MODULATORS OF THERAPEUTIC PRODUCTS
UAA200909677A UA101312C2 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
AP2009004964A AP2986A (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
EP12167589.6A EP2487161B2 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
EA200901155A EA019893B1 (en) 2007-02-23 2008-02-22 Pharmaceutical composition and method for treating hiv infection
AP2013007042A AP3915A (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
EP08743531.9A EP2118082B1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
MX2009008935A MX2009008935A (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics.
KR1020157011742A KR101664154B1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
CN2008800132554A CN101679325B (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
JP2009551044A JP4881446B2 (en) 2007-02-23 2008-02-22 Modulation of pharmacokinetic properties of therapeutic agents
IL200550A IL200550A0 (en) 2007-02-23 2009-08-23 Modulators of pharmacokinetic properties of therapeutics
ZA2009/05882A ZA200905882B (en) 2007-02-23 2009-08-25 Modulator of pharmacokinetic properties of therapeutics
HK10104142.7A HK1137451A1 (en) 2007-02-23 2010-04-28 Modulators of pharmacokinetic properties of therapeutics
CY20201100220T CY1122761T1 (en) 2007-02-23 2020-03-13 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTIC AGENTS
LU00156C LUC00156I2 (en) 2007-02-23 2020-06-02
LTPA2020508C LTC3150586I2 (en) 2007-02-23 2020-06-04 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTIC AGENTS
CY2020011C CY2020011I1 (en) 2007-02-23 2020-06-05 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTIC AGENTS
NO2020011C NO2020011I1 (en) 2007-02-23 2020-06-05 Cobicistat or a pharmaceutically acceptable salt or solvate thereof, darunavir or a pharmaceutically acceptable salt or solvate thereof, in particular darunavir ethanolate and emtricitabine or a pharmaceutically acceptable salt or solvate thereof
FR20C1021C FR20C1021I1 (en) 2007-02-23 2020-06-17 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTIC AGENTS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90322807P 2007-02-23 2007-02-23
US60/903,228 2007-02-23
US95871607P 2007-07-06 2007-07-06
US60/958,716 2007-07-06

Publications (1)

Publication Number Publication Date
WO2008103949A1 true WO2008103949A1 (en) 2008-08-28

Family

ID=39522375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/054788 WO2008103949A1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics

Country Status (32)

Country Link
US (7) US9891239B2 (en)
EP (5) EP4403221A3 (en)
JP (9) JP4881446B2 (en)
KR (2) KR101577698B1 (en)
CN (2) CN103435570B (en)
AP (2) AP2986A (en)
AR (1) AR065439A1 (en)
AU (1) AU2008218186C1 (en)
BR (1) BRPI0807581A2 (en)
CA (1) CA2678907C (en)
CY (9) CY1118292T1 (en)
DK (2) DK3150586T3 (en)
EA (1) EA019893B1 (en)
ES (6) ES2602784T3 (en)
FI (1) FI2487161T4 (en)
FR (1) FR20C1021I1 (en)
HK (1) HK1137451A1 (en)
HR (5) HRP20161476T4 (en)
HU (6) HUE029866T2 (en)
IL (1) IL200550A0 (en)
LT (9) LT2487166T (en)
LU (1) LUC00156I2 (en)
MX (1) MX2009008935A (en)
NO (4) NO2017002I1 (en)
NZ (1) NZ579802A (en)
PL (3) PL3150586T3 (en)
PT (6) PT2487161T (en)
SG (2) SG10201705929QA (en)
SI (1) SI3150586T1 (en)
TW (1) TWI533868B (en)
WO (1) WO2008103949A1 (en)
ZA (1) ZA200905882B (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091197A2 (en) 2009-02-06 2010-08-12 Gilead Sciences, Inc. Tablets for combination therapy
US20100256366A1 (en) * 2009-04-03 2010-10-07 Richard Polniaszek Methods and intermediates for preparing pharmaceutical agents
WO2010151672A2 (en) * 2009-06-26 2010-12-29 Georgetown University Amino acid derived ureas
WO2012045007A1 (en) 2010-10-01 2012-04-05 Gilead Sciences, Inc. Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester
WO2012088153A1 (en) * 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
WO2012088156A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
WO2012088178A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
WO2012151165A1 (en) * 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts
WO2013004818A1 (en) 2011-07-07 2013-01-10 Janssen R&D Ireland Darunavir combination formulations
WO2013116715A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
WO2013116730A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
CN103694196A (en) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 Cytochrome P450 monooxygenase inhibitor intermediate, and preparation methods and application thereof
WO2014064409A1 (en) * 2012-10-23 2014-05-01 Cipla Limited Pharmaceutical antiretroviral composition
AU2015200637A1 (en) * 2009-02-06 2015-02-26 Gilead Sciences, Inc. Tablets for combination therapy
EP2296633B1 (en) 2008-05-02 2015-09-30 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
CN105198829A (en) * 2015-08-15 2015-12-30 浙江永宁药业股份有限公司 Cobicistat intermediate preparing method, intermediate and application thereof
US9296769B2 (en) 2011-08-16 2016-03-29 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
US9891239B2 (en) 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN109912530A (en) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 A kind of preparation method than his raw material impurity of department
US10426780B2 (en) 2010-01-27 2019-10-01 Viiv Healthcare Company Antiviral therapy
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US11628181B2 (en) 2014-12-26 2023-04-18 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014685B1 (en) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Phosphonate-containing antiviral compounds (variants) and pharmaceutical composition based thereon
UA88313C2 (en) 2004-07-27 2009-10-12 Гилиад Сайенсиз, Инк. Phosphonate analogs of hiv inhibitor compounds
EP2049506B2 (en) * 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US20080161246A1 (en) * 2006-08-31 2008-07-03 Abbott Laboratories Cytochrome P450 Oxidase Inhibitors and Uses Thereof
DK2487161T4 (en) 2007-02-23 2024-06-24 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
JP2011503231A (en) * 2007-11-20 2011-01-27 コンサート ファーマシューティカルズ インコーポレイテッド Peptides for treatment of HCV infection
CA2710679A1 (en) * 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
EA018308B1 (en) 2008-07-08 2013-07-30 Джилид Сайэнс, Инк. Salts of hiv inhibitor compounds
EA021377B9 (en) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Modulators of toll-like receptors
NL2005306C2 (en) * 2010-09-02 2012-03-05 Tersia Nederland B V CONNECTOR FOR MULTI-LAYER PIPES, WELDING DEVICE FOR CONNECTING THE CONNECTOR TO MULTI-LAYER PIPES, METHOD OF CONNECTING AND A COMPOSITION OBTAINED VIA THE METHOD.
ME01980B (en) * 2010-11-19 2015-05-20 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
EP2472320A2 (en) 2010-12-30 2012-07-04 Rohm and Haas Electronic Materials LLC Compositions comprising base-reactive component and processes for photolithography
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
ES2926068T3 (en) 2012-12-21 2022-10-21 Gilead Sciences Inc Polycyclic carbamoylpyridone compounds and their pharmaceutical use
WO2014105777A1 (en) 2012-12-26 2014-07-03 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
PT3252058T (en) 2013-07-12 2021-03-09 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (en) 2013-07-12 2018-07-21
EA031172B1 (en) 2013-10-07 2018-11-30 Бристол-Майерс Сквибб Холдингс Айэрланд Hiv treatment formulation of atazanavir and cobicistat
WO2015083066A1 (en) 2013-12-03 2015-06-11 Mylan Laboratories Ltd. Preparation of cobicistat intermediates
WO2015145324A1 (en) 2014-03-25 2015-10-01 Mylan Laboratories Ltd Process for the preparation of cobicistat
NO2717902T3 (en) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (en) 2014-06-20 2019-11-21 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
TWI806081B (en) 2014-07-11 2023-06-21 美商基利科學股份有限公司 Modulators of toll-like receptors for the treatment of hiv
US10258621B2 (en) * 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
UY36298A (en) 2014-09-16 2016-04-29 Gilead Science Inc SOLID FORMS OF A TOLL TYPE RECEIVER MODULATOR
TWI738321B (en) 2014-12-23 2021-09-01 美商基利科學股份有限公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
ES2837383T3 (en) 2015-04-02 2021-06-30 Gilead Sciences Inc Polycyclic carbamoylpyridone compounds and their pharmaceutical use
CN107513046B (en) * 2016-06-15 2019-12-13 江苏欧信制药有限公司 Synthesis method of Coxstat
WO2018026835A1 (en) * 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
US20190175511A1 (en) 2016-08-08 2019-06-13 Hetero Labs Limited A Multi-Class Anti-Retroviral Composition
WO2018029561A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions
KR101908853B1 (en) * 2017-05-17 2018-10-16 경북대학교 산학협력단 Composition for Inhibiting Cytochrome P450 Enzyme containing Acetylshikonin
PL3661937T3 (en) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
CA3089388A1 (en) * 2018-01-30 2019-08-08 Sun Biopharma, Inc. Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol
CN117105928B (en) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 Protease inhibitor and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1183026B1 (en) * 1999-06-04 2006-07-05 Abbott Laboratories Improved pharmaceutical formulations comprising ritonavir
US20060199851A1 (en) * 2005-03-02 2006-09-07 Kempf Dale J Novel compounds that are useful for improving pharmacokinetics
WO2008010921A2 (en) * 2006-07-07 2008-01-24 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US77295A (en) * 1868-04-28 theqdoee krausch
US181902A (en) * 1876-09-05 Improvement in bell toys
US115665A (en) * 1871-06-06 Improvement in folding-steps for carriages
US108617A (en) * 1870-10-25 Improvement in ore-pulverizers
US127689A (en) * 1872-06-11 Improvement in differential pulley-blocks
US191319A (en) * 1877-05-29 Improvement in stoves
US143314A (en) * 1873-09-30 Improvement in condenser-tube fastenings
US199851A (en) * 1878-01-29 Improvement in circular saws
US99902A (en) * 1870-02-15 1870-02-15 Improvement in adjustable dials for travelers watches
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3882114A (en) 1967-10-26 1975-05-06 Oreal N-(morpholinomethyl carbamyl) cysteamine and glycine
GB1241024A (en) 1968-10-29 1971-07-28 Boehringer Sohn Ingelheim Pharmaceutical tablet base and a process for its manufacture
FR2096292A5 (en) 1970-06-15 1972-02-11 Sumitomo Chemical Co
GB1339764A (en) 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
CH586568A5 (en) 1972-04-10 1977-04-15 Hoffmann La Roche
US3957774A (en) 1972-04-17 1976-05-18 L'oreal N-morpholinomethyl-n-'-substituted ethyl and propylureas
DE2845326C2 (en) 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Use of a specific microdisperse, amorphous, porous silica for the production of digoxin-containing tablets with a strongly accelerated release of active ingredient
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
HU186777B (en) 1981-07-09 1985-09-30 Magyar Tudomanyos Akademia Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them
US4603143A (en) 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en) 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
FR2631620B1 (en) 1988-05-19 1990-07-27 Rhone Poulenc Chimie NOVEL PRECIPITATED ABSORBENT SILICA AND COMPOSITION BASED ON SAILOR
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5362912A (en) 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
EP0428849A3 (en) 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JPH06127981A (en) 1992-03-03 1994-05-10 Fuainiteii Kk Composite laminated layer glass and window formed by using this glass
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DK0727419T3 (en) 1992-12-29 2002-06-10 Abbott Lab Intermediates for the preparation of compounds that inhibit retroviral protease
WO1995005808A1 (en) 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5763464A (en) 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
JP4064476B2 (en) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド Spherical agglomerated starch with silicon dioxide
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4494539B2 (en) 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． Free-flowing dry particles
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
FR2767071B1 (en) 1997-08-06 1999-09-10 Rhodia Chimie Sa COMPOSITION COMPRISING A LIQUID ABSORBED ON A PRECIPITATED SILICA BASE
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
FR2773994B1 (en) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis PRODUCTS FROM HUMAN IMMUNODEFICIENCY VIRUS INHIBITORS OF ANTI-PROTEASES FOR IMPROVED BIODAVAILABILITY, TROPISM TO AND / OR DELIVERY IN THE CENTRAL NERVOUS SYSTEM
JP4027535B2 (en) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Powder containing fat-soluble drug
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
OA12053A (en) 1999-10-06 2006-05-02 Tibotec Pharm Ltd HexahydrofuroÄ2,3-bÜfuran-3-yl-N-ä3-Ä(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)aminoÜ-1-benzyl-2-hydroxypropylücarbamate as retroviral protease inhibitor.
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
US20030035834A1 (en) 2000-05-26 2003-02-20 Pawan Seth Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
TWI290053B (en) 2000-09-19 2007-11-21 Daiichi Seiyaku Co Medicinal composition for preventing the generation of a disagreeable taste
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
DE10112651A1 (en) 2001-03-16 2002-09-19 Degussa Inhomogeneous silicas as carrier material
OA12596A (en) 2001-05-01 2006-06-08 Pfizer Prod Inc Method for manufacturing a low dose pharmaceuticalcomposition.
DE10126163A1 (en) 2001-05-30 2002-12-05 Degussa Solid, semi-solid or liquid pharmaceutical or cosmetic preparations, containing pyrogenic silicon dioxide of high tamped density as auxiliary to provide good flow properties
AU2002325192B2 (en) 2001-07-06 2008-05-22 Veloxis Pharmaceuticals, Inc. Controlled agglomeration
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
WO2003047551A1 (en) 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7285566B2 (en) 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
DE60315796T2 (en) 2002-01-17 2008-06-05 Merck & Co., Inc. HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE
US6926906B2 (en) 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
US6726448B2 (en) 2002-05-15 2004-04-27 General Electric Company Ceramic turbine shroud
PA8576201A1 (en) 2002-07-10 2004-05-26 Pfizer Prod Inc PHARMACEUTICAL COMPOSITION THAT HAS A DISTRIBUTION AND UNIFORM POWER OF FARMACO
DE10250711A1 (en) 2002-10-31 2004-05-19 Degussa Ag Pharmaceutical and cosmetic preparations
CA2470365C (en) 2002-11-20 2011-05-17 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
US7189416B2 (en) 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
JP2004184681A (en) 2002-12-03 2004-07-02 Konica Minolta Holdings Inc Heat developable photosensitive material
ATE398455T1 (en) 2003-01-14 2008-07-15 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR ANTIVIRAL COMBINATION THERAPY
EP1596835A1 (en) 2003-02-19 2005-11-23 H. Lundbeck A/S Method for preparation of an agglomerate using melt agglomeration
FR2851918B1 (en) 2003-03-06 2006-06-16 IMPREGNATED POWDER ENHANCING BIOAVAILABILITY AND / OR SOLUBILITY AND METHOD OF MANUFACTURE
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
JP4018664B2 (en) 2003-04-30 2007-12-05 第一三共株式会社 Stabilized solid preparation
DE10337198A1 (en) 2003-08-13 2005-03-17 Degussa Ag Carriers based on granules produced from pyrogenically prepared silicon dioxides
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
JP2005075826A (en) 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh Controlled release preparation comprising porous silica support
JP2005091988A (en) 2003-09-19 2005-04-07 Konica Minolta Medical & Graphic Inc Heat developable photosensitive material and method for forming image
US20070122482A1 (en) 2003-10-03 2007-05-31 Per Holm Method for preparing modified release pharmaceutical compositions
US20050096390A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20050095287A1 (en) 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
US7834043B2 (en) 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
WO2005084670A1 (en) 2004-03-01 2005-09-15 Lek Pharmaceuticals D.D. Pharmaceutical formulation
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050238675A1 (en) 2004-04-26 2005-10-27 Wenjie Li Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
BRPI0401742B8 (en) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda ritonavir analogue compound useful as retroviral protease inhibitor, ritonavir analogue compound preparation and ritonavir analogue compound pharmaceutical composition
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
JP4629104B2 (en) 2004-05-21 2011-02-09 日本たばこ産業株式会社 Concomitant drug containing 4-oxoquinoline derivative and anti-HIV agent
JP2006003701A (en) 2004-06-18 2006-01-05 Konica Minolta Medical & Graphic Inc Heat developable photosensitive material and image forming method
WO2006000229A2 (en) 2004-06-28 2006-01-05 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations
KR101229431B1 (en) * 2004-07-06 2013-02-04 아보트 러보러터리즈 Prodrugs of HIV protease inhibitors
AR045841A1 (en) 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie A SOLID PHARMACEUTICAL COMPOSITION THAT INCLUDES THE TIAZOLIL METHYL ESTER OF THE ACID [5S- (5R *, 8R *, 10R *, 11R *)] -10- HYDROXY-2-METHYL-5- (1-METHYTILE) -1- [2 - (1-METHYLE) -4-TIAZOLIL] -3,6-DIOXO-8,11-BIS (PHENYLMETIL) -2,4,7,12- TETRAAZATRIDECAN-13-OICO AND A PROCEDURE TO PREPARE IT.
EP2266579A1 (en) 2004-10-19 2010-12-29 Achillion Pharmaceuticals, Inc. Pharmaceutical composition comprising elvucitavine
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20070014854A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
BRPI0620578A2 (en) 2005-12-27 2011-12-06 Jubilant Organosys Ltd pharmaceutical composition that dissolves in the mouth and process for the preparation thereof
US20090233964A1 (en) 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP2308490A1 (en) 2005-12-30 2011-04-13 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
BRPI0706280A2 (en) 2006-01-05 2011-03-22 Lifecycle Pharma As disintegrating loadable tablet product and method for preparing a disintegrating loadable tablet
EP1990062A1 (en) 2006-02-20 2008-11-12 ASAHI BREWERIES, Ltd. Granules, tablets and method of producing the same
US20070287664A1 (en) 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
UY30535A1 (en) 2006-08-10 2008-03-31 Cipla Ltd COMPOSITION UNDERSTANDING ANTIRRETROVIRAL PHARMACOS AND AT LEAST AN INSOLUBLE WATER POLYMER, PREPARATION PROCESS AND APPLICATIONS.
US20080161246A1 (en) 2006-08-31 2008-07-03 Abbott Laboratories Cytochrome P450 Oxidase Inhibitors and Uses Thereof
EP2063862A2 (en) 2006-09-04 2009-06-03 Matrix Laboratories Ltd Pharmaceutical formulation for use in hiv therapy
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
LT2487166T (en) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
JP5547066B2 (en) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド Therapeutic compositions and uses thereof
CA2692331A1 (en) 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
KR20170072365A (en) 2007-12-27 2017-06-26 백스터 인터내셔널 인코포레이티드 Method and compositions for specifically detecting physiologically acceptable polymer molecules
SG190618A1 (en) * 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
SG10201706215UA (en) 2009-02-06 2017-08-30 Gilead Sciences Inc Tablets for combination therapy
EP2238979A1 (en) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
JP6127981B2 (en) 2012-01-10 2017-05-17 Jnc株式会社 Light emitting layer material and organic electroluminescent device using the same
KR20140119177A (en) 2012-02-03 2014-10-08 길리애드 사이언시즈, 인코포레이티드 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1183026B1 (en) * 1999-06-04 2006-07-05 Abbott Laboratories Improved pharmaceutical formulations comprising ritonavir
US20060199851A1 (en) * 2005-03-02 2006-09-07 Kempf Dale J Novel compounds that are useful for improving pharmacokinetics
WO2008010921A2 (en) * 2006-07-07 2008-01-24 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9891239B2 (en) 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2009242451C1 (en) * 2008-05-02 2017-05-18 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
EP2296633B1 (en) 2008-05-02 2015-09-30 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
EP3006032A1 (en) 2008-05-02 2016-04-13 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2010091197A2 (en) 2009-02-06 2010-08-12 Gilead Sciences, Inc. Tablets for combination therapy
EP2393485B1 (en) 2009-02-06 2015-07-29 Gilead Sciences, Inc. Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir
CN102307573A (en) * 2009-02-06 2012-01-04 吉里德科学公司 Tablets for combination therapy
WO2010091197A3 (en) * 2009-02-06 2011-06-03 Gilead Sciences, Inc. Tablets for combination therapy
AU2015200637B2 (en) * 2009-02-06 2016-12-08 Gilead Sciences, Inc. Tablets for combination therapy
CN102307573B (en) * 2009-02-06 2013-09-11 吉里德科学公司 Tablets for combination therapy
EA030123B1 (en) * 2009-02-06 2018-06-29 Джилид Сайэнс, Инк. Tablet for treating hiv and method of treating hiv using same
AU2015200637C1 (en) * 2009-02-06 2017-08-03 Gilead Sciences, Inc. Tablets for combination therapy
JP2012517432A (en) * 2009-02-06 2012-08-02 ギリアード サイエンシーズ， インコーポレイテッド Tablets for combination treatment
AP3250A (en) * 2009-02-06 2015-05-31 Gilead Sciences Inc Tablets for combination therapy
EA021313B1 (en) * 2009-02-06 2015-05-29 Джилид Сайэнс, Инк. Tablets for combination therapy
AU2010210598B2 (en) * 2009-02-06 2015-03-05 Gilead Sciences, Inc. Tablets for combination therapy
AU2015200637A1 (en) * 2009-02-06 2015-02-26 Gilead Sciences, Inc. Tablets for combination therapy
JP2014221845A (en) * 2009-02-06 2014-11-27 ギリアード サイエンシーズ， インコーポレイテッド Tablets for combination therapy
CN107382997A (en) * 2009-04-03 2017-11-24 吉利德科学公司 For preparing the method and intermediate of drug agents
US20100256366A1 (en) * 2009-04-03 2010-10-07 Richard Polniaszek Methods and intermediates for preparing pharmaceutical agents
CN107382997B (en) * 2009-04-03 2021-02-26 吉利德科学公司 Process and intermediates for the preparation of pharmaceutical agents
CN111217808A (en) * 2009-04-03 2020-06-02 吉利德科学公司 Process and intermediates for the preparation of pharmaceutical agents
KR101874557B1 (en) * 2009-04-03 2018-07-04 길리애드 사이언시즈, 인코포레이티드 Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved
WO2010115000A2 (en) 2009-04-03 2010-10-07 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
AP2887A (en) * 2009-04-03 2014-05-31 Gilead Sciences Inc Method of preparing an inhibitor of cytochrome P540 monooxygenase, and intermediates involved
US8853210B2 (en) 2009-04-03 2014-10-07 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
JP2014193897A (en) * 2009-04-03 2014-10-09 Gilead Sciences Inc Inhibitor of cytochrome p450 monooxygenase, and intermediate involved
JP2018008983A (en) * 2009-04-03 2018-01-18 ギリアード サイエンシーズ， インコーポレイテッド Inhibitor of cytochrome p450 monooxygenase and related intermediates
TWI464165B (en) * 2009-04-03 2014-12-11 Gilead Sciences Inc Methods and intermediates for preparing pharmaceutical agents
US8497396B2 (en) * 2009-04-03 2013-07-30 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
WO2010115000A3 (en) * 2009-04-03 2011-09-22 Gilead Sciences, Inc. Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved
JP2017122107A (en) * 2009-04-03 2017-07-13 ギリアード サイエンシーズ， インコーポレイテッド Inhibitor of cytochrome p450 monooxygenase, and intermediates involved
CN102438982B (en) * 2009-04-03 2015-05-06 吉里德科学公司 Methods and intermediates for preparing cytochrome P450 monooxygenase inhibitor
KR101728375B1 (en) * 2009-04-03 2017-04-19 길리애드 사이언시즈, 인코포레이티드 Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved
CN102438982A (en) * 2009-04-03 2012-05-02 吉里德科学公司 Methods and intermediates for preparing pharmaceutical agents
JP2012522797A (en) * 2009-04-03 2012-09-27 ギリアード サイエンシーズ， インコーポレイテッド Inhibitors of cytochrome P450 monooxygenase and intermediates related thereto
AU2010232559B2 (en) * 2009-04-03 2015-06-18 Gilead Sciences, Inc. Method of preparing an inhibitor of cytochrome P450 monooxygenase, and intermediates involved
US9428473B2 (en) 2009-04-03 2016-08-30 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
US9115100B2 (en) 2009-04-03 2015-08-25 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
CN104876888A (en) * 2009-04-03 2015-09-02 吉里德科学公司 Methods And Intermediates For Preparing Pharmaceutical Agents
JP2016128476A (en) * 2009-04-03 2016-07-14 ギリアード サイエンシーズ， インコーポレイテッド Inhibitor of cytochrome p450 monooxygenase, and intermediates involved therein
EP3009434A1 (en) 2009-04-03 2016-04-20 Gilead Sciences, Inc. Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved
EA022739B1 (en) * 2009-04-03 2016-02-29 Джилид Сайэнс, Инк. Method for preparing cytochrome p450 monooxygenase inhibitor and intermediates used in this method
WO2010151672A3 (en) * 2009-06-26 2011-05-12 Georgetown University Amino acid derived ureas
WO2010151672A2 (en) * 2009-06-26 2010-12-29 Georgetown University Amino acid derived ureas
US11234985B2 (en) 2010-01-27 2022-02-01 Viiv Healthcare Company Antiviral therapy
US10426780B2 (en) 2010-01-27 2019-10-01 Viiv Healthcare Company Antiviral therapy
WO2012045007A1 (en) 2010-10-01 2012-04-05 Gilead Sciences, Inc. Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester
US8987313B2 (en) 2010-12-21 2015-03-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450
WO2012088156A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
WO2012088153A1 (en) * 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
WO2012088178A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
JP2014513123A (en) * 2011-05-02 2014-05-29 ギリアード サイエンシーズ， インコーポレイテッド Amorphous solid salt
WO2012151165A1 (en) * 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts
AU2012250890B2 (en) * 2011-05-02 2015-05-28 Gilead Sciences, Inc. Amorphous solid salts
WO2013004818A1 (en) 2011-07-07 2013-01-10 Janssen R&D Ireland Darunavir combination formulations
US11654150B2 (en) 2011-07-07 2023-05-23 Janssen Sciences Ireland Uc Darunavir combination formulations
US9296769B2 (en) 2011-08-16 2016-03-29 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
WO2013116730A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
WO2013116715A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
US9346796B2 (en) 2012-02-03 2016-05-24 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
CN103694196A (en) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 Cytochrome P450 monooxygenase inhibitor intermediate, and preparation methods and application thereof
US20180250271A1 (en) * 2012-10-23 2018-09-06 Cipla Limited Pharmaceutical Antiretroviral Composition
US10420727B2 (en) 2012-10-23 2019-09-24 Cipla Limited Pharmaceutical antiretroviral composition
US10004721B2 (en) 2012-10-23 2018-06-26 Cipla Limited Pharmaceutical antiretroviral composition
AU2013336491B2 (en) * 2012-10-23 2018-08-02 Cipla Limited Pharmaceutical antiretroviral composition
WO2014064409A1 (en) * 2012-10-23 2014-05-01 Cipla Limited Pharmaceutical antiretroviral composition
US11628181B2 (en) 2014-12-26 2023-04-18 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN105198829A (en) * 2015-08-15 2015-12-30 浙江永宁药业股份有限公司 Cobicistat intermediate preparing method, intermediate and application thereof
CN105198829B (en) * 2015-08-15 2017-10-31 浙江永宁药业股份有限公司 A kind of Preparation Method And Their Intermediate and purposes than his intermediate of department
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11903959B2 (en) 2017-12-07 2024-02-20 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN109912530A (en) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 A kind of preparation method than his raw material impurity of department
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Also Published As

Publication number Publication date
KR101577698B1 (en) 2015-12-15
ZA200905882B (en) 2018-12-19
LT2487162T (en) 2016-11-10
JP6192776B2 (en) 2017-09-06
ES2603645T3 (en) 2017-02-28
AP2009004964A0 (en) 2009-10-31
CY2020011I2 (en) 2020-11-25
EP3150586B1 (en) 2020-01-08
SG183059A1 (en) 2012-08-30
IL200550A0 (en) 2010-05-17
HRP20161502T1 (en) 2016-12-16
US20140017199A1 (en) 2014-01-16
LTC2487162I2 (en) 2022-06-27
CY1118227T1 (en) 2017-06-28
CY2017003I1 (en) 2017-06-28
ES2779826T3 (en) 2020-08-20
PL3150586T3 (en) 2020-06-01
PT2118082E (en) 2014-12-12
SG10201705929QA (en) 2017-08-30
EP4403221A3 (en) 2024-10-09
MX2009008935A (en) 2009-11-02
LTC3150586I2 (en) 2022-05-10
HRP20161428T1 (en) 2016-12-16
BRPI0807581A2 (en) 2014-07-01
US20150139948A1 (en) 2015-05-21
AU2008218186B2 (en) 2014-01-23
AP2013007042A0 (en) 2013-08-31
EA200901155A1 (en) 2010-02-26
LT2487166T (en) 2016-11-10
LT2487161T (en) 2016-11-10
US20160069915A1 (en) 2016-03-10
CY2017002I1 (en) 2017-06-28
CY2017002I2 (en) 2017-06-28
US8486942B2 (en) 2013-07-16
KR20150056665A (en) 2015-05-26
NO2017002I2 (en) 2017-01-12
JP6147282B2 (en) 2017-06-14
PL2487162T3 (en) 2017-03-31
US9891239B2 (en) 2018-02-13
EA019893B1 (en) 2014-07-30
AU2008218186C1 (en) 2014-07-17
HUE031707T2 (en) 2017-07-28
CN103435570B (en) 2015-06-10
DK2487166T3 (en) 2017-02-20
CY2017001I2 (en) 2017-09-13
LT3150586T (en) 2020-03-10
PL2487161T3 (en) 2017-03-31
NO2020011I1 (en) 2020-06-05
JP2014088441A (en) 2014-05-15
AP2986A (en) 2014-09-30
DK3150586T3 (en) 2020-02-17
ES2602784T3 (en) 2017-02-22
CY1118292T1 (en) 2017-06-28
CY2017003I2 (en) 2017-06-28
CN101679325B (en) 2013-08-28
JP6147388B2 (en) 2017-06-14
LUC00156I1 (en) 2020-06-02
KR101664154B1 (en) 2016-10-10
HK1137451A1 (en) 2010-07-30
LTPA2016039I1 (en) 2017-01-10
JP2021001236A (en) 2021-01-07
AU2008218186A1 (en) 2008-08-28
EP2487161B2 (en) 2024-06-05
FI2487161T4 (en) 2024-06-06
PT2487162T (en) 2016-11-23
JP2011231132A (en) 2011-11-17
EP3150586A1 (en) 2017-04-05
LTPA2016038I1 (en) 2017-01-10
NO2017001I1 (en) 2017-01-12
PT2487161T (en) 2016-11-10
KR20090122261A (en) 2009-11-26
TWI533868B (en) 2016-05-21
AP3915A (en) 2016-11-29
ES2603617T3 (en) 2017-02-28
CY1118219T1 (en) 2017-06-28
NO2017002I1 (en) 2017-01-12
EP2487161A1 (en) 2012-08-15
JP2010519314A (en) 2010-06-03
LTPA2016040I1 (en) 2017-01-10
HUS1600054I1 (en) 2017-01-30
EP2487161B1 (en) 2016-08-10
HRP20161476T1 (en) 2016-12-16
US8148374B2 (en) 2012-04-03
CN103435570A (en) 2013-12-11
JP2016121193A (en) 2016-07-07
LTC2487163I2 (en) 2022-06-27
JP2016172773A (en) 2016-09-29
TW200904419A (en) 2009-02-01
LTC2487166I2 (en) 2021-10-11
ES2601820T3 (en) 2017-02-16
CY2017001I1 (en) 2017-09-13
PL2487161T5 (en) 2024-09-09
HUE029843T2 (en) 2017-04-28
EP3689353A1 (en) 2020-08-05
LT2487163T (en) 2016-10-25
CN101679325A (en) 2010-03-24
PT2487163T (en) 2016-11-21
LTPA2020508I1 (en) 2020-06-25
HUE029842T2 (en) 2017-04-28
CY1122761T1 (en) 2020-11-25
CA2678907A1 (en) 2008-08-28
HUS2000013I1 (en) 2020-06-29
US20120237478A1 (en) 2012-09-20
JP5554300B2 (en) 2014-07-23
CA2678907C (en) 2014-06-17
JP2015078241A (en) 2015-04-23
US20080207620A1 (en) 2008-08-28
FR20C1021I1 (en) 2020-07-31
SI3150586T1 (en) 2020-03-31
CY1118232T1 (en) 2017-06-28
CY2020011I1 (en) 2020-11-25
HRP20161371T1 (en) 2016-12-02
JP4881446B2 (en) 2012-02-22
NZ579802A (en) 2012-04-27
PT2487166T (en) 2016-10-17
ES2525454T3 (en) 2014-12-23
EP2118082B1 (en) 2014-10-01
HRP20200349T1 (en) 2020-06-12
NO2017003I1 (en) 2017-01-12
HRP20161476T4 (en) 2024-07-05
HUE029866T2 (en) 2017-03-28
US20170158647A1 (en) 2017-06-08
JP2019059790A (en) 2019-04-18
EP2118082A1 (en) 2009-11-18
US20100189687A1 (en) 2010-07-29
AR065439A1 (en) 2009-06-10
PT3150586T (en) 2020-03-31
LUC00156I2 (en) 2021-02-17
JP2017171695A (en) 2017-09-28
EP4403221A2 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
DK2487166T3 (en) Modulators of the pharmacokinetic properties of therapeutics
WO2008010921A2 (en) Modulators of pharmacokinetic properties of therapeutics
EP2170851A1 (en) Modulators of pharmacokinetic properties of therapeutics
DK2487163T3 (en) Modulators of Pharmacokinetic properties terapeutikas
AU2015204378B2 (en) Modulators of pharmacokinetic properties of therapeutics
AU2015234299B2 (en) Modulators of pharmacokinetic properties of therapeutics
AU2015258296B2 (en) Modulators of pharmacokinetic properties of therapeutics
AU2022204390A1 (en) Modulators of pharmacokinetic properties of therapeutics
AU2013204805C1 (en) Modulators of pharmacokinetic properties of therapeutics

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880013255.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08743531

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2678907

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 5324/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/008935

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009551044

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200550

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008743531

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 579802

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008218186

Country of ref document: AU

Ref document number: 1020097019921

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200901155

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2008218186

Country of ref document: AU

Date of ref document: 20080222

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12528185

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0807581

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090824

WWE Wipo information: entry into national phase

Ref document number: 1020157011742

Country of ref document: KR